2021-01-17 13:47:05 | INFO | fairseq_cli.generate | {'_name': None, 'common': {'_name': None, 'no_progress_bar': False, 'log_interval': 100, 'log_format': None, 'tensorboard_logdir': None, 'wandb_project': None, 'azureml_logging': False, 'seed': 1, 'cpu': False, 'tpu': False, 'bf16': False, 'memory_efficient_bf16': False, 'fp16': True, 'memory_efficient_fp16': False, 'fp16_no_flatten_grads': False, 'fp16_init_scale': 128, 'fp16_scale_window': None, 'fp16_scale_tolerance': 0.0, 'min_loss_scale': 0.0001, 'threshold_loss_scale': None, 'user_dir': None, 'empty_cache_freq': 0, 'all_gather_list_size': 16384, 'model_parallel_size': 1, 'quantization_config_path': None, 'profile': False, 'reset_logging': True}, 'common_eval': {'_name': None, 'path': './checkpoint_fr_underscore/checkpoint_last.pt', 'post_process': None, 'quiet': False, 'model_overrides': '{}', 'results_path': './out/fr_underscore_en'}, 'distributed_training': {'_name': None, 'distributed_world_size': 1, 'distributed_rank': 0, 'distributed_backend': 'nccl', 'distributed_init_method': None, 'distributed_port': -1, 'device_id': 0, 'distributed_no_spawn': False, 'ddp_backend': 'c10d', 'bucket_cap_mb': 25, 'fix_batches_to_gpus': False, 'find_unused_parameters': False, 'fast_stat_sync': False, 'heartbeat_timeout': -1, 'broadcast_buffers': False, 'distributed_wrapper': 'DDP', 'slowmo_momentum': None, 'slowmo_algorithm': 'LocalSGD', 'localsgd_frequency': 3, 'nprocs_per_node': 1, 'pipeline_model_parallel': False, 'pipeline_balance': None, 'pipeline_devices': None, 'pipeline_chunks': 0, 'pipeline_encoder_balance': None, 'pipeline_encoder_devices': None, 'pipeline_decoder_balance': None, 'pipeline_decoder_devices': None, 'pipeline_checkpoint': 'never', 'zero_sharding': 'none', 'tpu': False}, 'dataset': {'_name': None, 'num_workers': 1, 'skip_invalid_size_inputs_valid_test': False, 'max_tokens': 768, 'batch_size': None, 'required_batch_size_multiple': 8, 'required_seq_len_multiple': 1, 'dataset_impl': None, 'data_buffer_size': 10, 'train_subset': 'train', 'valid_subset': 'valid', 'validate_interval': 1, 'validate_interval_updates': 0, 'validate_after_updates': 0, 'fixed_validation_seed': None, 'disable_validation': False, 'max_tokens_valid': 768, 'batch_size_valid': None, 'curriculum': 0, 'gen_subset': 'test', 'num_shards': 1, 'shard_id': 0}, 'optimization': {'_name': None, 'max_epoch': 0, 'max_update': 0, 'stop_time_hours': 0.0, 'clip_norm': 0.0, 'sentence_avg': False, 'update_freq': [1], 'lr': [0.25], 'stop_min_lr': -1.0, 'use_bmuf': False}, 'checkpoint': {'_name': None, 'save_dir': 'checkpoints', 'restore_file': 'checkpoint_last.pt', 'finetune_from_model': None, 'reset_dataloader': False, 'reset_lr_scheduler': False, 'reset_meters': False, 'reset_optimizer': False, 'optimizer_overrides': '{}', 'save_interval': 1, 'save_interval_updates': 0, 'keep_interval_updates': -1, 'keep_last_epochs': -1, 'keep_best_checkpoints': -1, 'no_save': False, 'no_epoch_checkpoints': False, 'no_last_checkpoints': False, 'no_save_optimizer_state': False, 'best_checkpoint_metric': 'loss', 'maximize_best_checkpoint_metric': False, 'patience': -1, 'checkpoint_suffix': '', 'checkpoint_shard_count': 1, 'load_checkpoint_on_all_dp_ranks': False, 'model_parallel_size': 1, 'distributed_rank': 0}, 'bmuf': {'_name': None, 'block_lr': 1.0, 'block_momentum': 0.875, 'global_sync_iter': 50, 'warmup_iterations': 500, 'use_nbm': False, 'average_sync': False, 'distributed_world_size': 1}, 'generation': {'_name': None, 'beam': 5, 'nbest': 1, 'max_len_a': 0.0, 'max_len_b': 200, 'min_len': 1, 'match_source_len': False, 'unnormalized': False, 'no_early_stop': False, 'no_beamable_mm': False, 'lenpen': 1.0, 'unkpen': 0.0, 'replace_unk': None, 'sacrebleu': False, 'score_reference': False, 'prefix_size': 0, 'no_repeat_ngram_size': 0, 'sampling': False, 'sampling_topk': -1, 'sampling_topp': -1.0, 'constraints': None, 'temperature': 1.0, 'diverse_beam_groups': -1, 'diverse_beam_strength': 0.5, 'diversity_rate': -1.0, 'print_alignment': None, 'print_step': False, 'lm_path': None, 'lm_weight': 0.0, 'iter_decode_eos_penalty': 0.0, 'iter_decode_max_iter': 10, 'iter_decode_force_max_iter': False, 'iter_decode_with_beam': 1, 'iter_decode_with_external_reranker': False, 'retain_iter_history': False, 'retain_dropout': False, 'retain_dropout_modules': None, 'decoding_format': None, 'no_seed_provided': False}, 'eval_lm': {'_name': None, 'output_word_probs': False, 'output_word_stats': False, 'context_window': 0, 'softmax_batch': 9223372036854775807}, 'interactive': {'_name': None, 'buffer_size': 0, 'input': '-'}, 'model': None, 'task': Namespace(_name='translation_from_pretrained_bart', all_gather_list_size=16384, azureml_logging=False, batch_size=None, batch_size_valid=None, beam=5, best_checkpoint_metric='loss', bf16=False, bpe='sentencepiece', broadcast_buffers=False, bucket_cap_mb=25, checkpoint_shard_count=1, checkpoint_suffix='', constraints=None, cpu=False, criterion='cross_entropy', curriculum=0, data='./postprocessed/en_underscore', data_buffer_size=10, dataset_impl=None, ddp_backend='c10d', decoding_format=None, device_id=0, disable_validation=False, distributed_backend='nccl', distributed_init_method=None, distributed_no_spawn=False, distributed_port=-1, distributed_rank=0, distributed_world_size=1, distributed_wrapper='DDP', diverse_beam_groups=-1, diverse_beam_strength=0.5, diversity_rate=-1.0, empty_cache_freq=0, eos=2, eval_bleu=False, eval_bleu_args=None, eval_bleu_detok='space', eval_bleu_detok_args=None, eval_bleu_print_samples=False, eval_bleu_remove_bpe=None, eval_tokenized_bleu=False, fast_stat_sync=False, find_unused_parameters=False, finetune_from_model=None, fix_batches_to_gpus=False, fixed_validation_seed=None, force_anneal=None, fp16=True, fp16_init_scale=128, fp16_no_flatten_grads=False, fp16_scale_tolerance=0.0, fp16_scale_window=None, gen_subset='test', heartbeat_timeout=-1, iter_decode_eos_penalty=0.0, iter_decode_force_max_iter=False, iter_decode_max_iter=10, iter_decode_with_beam=1, iter_decode_with_external_reranker=False, keep_best_checkpoints=-1, keep_interval_updates=-1, keep_last_epochs=-1, langs='ar_AR,cs_CZ,de_DE,en_XX,es_XX,et_EE,fi_FI,fr_XX,gu_IN,hi_IN,it_IT,ja_XX,kk_KZ,ko_KR,lt_LT,lv_LV,my_MM,ne_NP,nl_XX,ro_RO,ru_RU,si_LK,tr_TR,vi_VN,zh_CN', left_pad_source='True', left_pad_target='False', lenpen=1, lm_path=None, lm_weight=0.0, load_alignments=False, load_checkpoint_on_all_dp_ranks=False, localsgd_frequency=3, log_format=None, log_interval=100, lr_scheduler='fixed', lr_shrink=0.1, match_source_len=False, max_len_a=0, max_len_b=200, max_source_positions=1024, max_target_positions=1024, max_tokens=768, max_tokens_valid=768, maximize_best_checkpoint_metric=False, memory_efficient_bf16=False, memory_efficient_fp16=False, min_len=1, min_loss_scale=0.0001, model_overrides='{}', model_parallel_size=1, nbest=1, no_beamable_mm=False, no_early_stop=False, no_epoch_checkpoints=False, no_last_checkpoints=False, no_progress_bar=False, no_repeat_ngram_size=0, no_save=False, no_save_optimizer_state=False, no_seed_provided=False, nprocs_per_node=1, num_batch_buckets=0, num_shards=1, num_workers=1, optimizer=None, optimizer_overrides='{}', pad=1, path='./checkpoint_fr_underscore/checkpoint_last.pt', patience=-1, pipeline_balance=None, pipeline_checkpoint='never', pipeline_chunks=0, pipeline_decoder_balance=None, pipeline_decoder_devices=None, pipeline_devices=None, pipeline_encoder_balance=None, pipeline_encoder_devices=None, pipeline_model_parallel=False, post_process=None, prefix_size=0, prepend_bos=False, print_alignment=None, print_step=False, profile=False, quantization_config_path=None, quiet=False, replace_unk=None, required_batch_size_multiple=8, required_seq_len_multiple=1, reset_dataloader=False, reset_logging=True, reset_lr_scheduler=False, reset_meters=False, reset_optimizer=False, restore_file='checkpoint_last.pt', results_path='./out/fr_underscore_en', retain_dropout=False, retain_dropout_modules=None, retain_iter_history=False, sacrebleu=False, sampling=False, sampling_topk=-1, sampling_topp=-1.0, save_dir='checkpoints', save_interval=1, save_interval_updates=0, score_reference=False, scoring='bleu', seed=1, sentencepiece_model='../models/mbart.cc25/sentence.bpe.model', shard_id=0, skip_invalid_size_inputs_valid_test=False, slowmo_algorithm='LocalSGD', slowmo_momentum=None, source_lang='src', target_lang='label', task='translation_from_pretrained_bart', temperature=1.0, tensorboard_logdir=None, threshold_loss_scale=None, tokenizer=None, tpu=False, train_subset='train', truncate_source=False, unk=3, unkpen=0, unnormalized=False, upsample_primary=1, user_dir=None, valid_subset='valid', validate_after_updates=0, validate_interval=1, validate_interval_updates=0, wandb_project=None, warmup_updates=0, zero_sharding='none'), 'criterion': {'_name': 'cross_entropy', 'sentence_avg': True}, 'optimizer': None, 'lr_scheduler': {'_name': 'fixed', 'force_anneal': None, 'lr_shrink': 0.1, 'warmup_updates': 0, 'lr': [0.25]}, 'scoring': {'_name': 'bleu', 'pad': 1, 'eos': 2, 'unk': 3}, 'bpe': {'_name': 'sentencepiece', 'sentencepiece_model': '../models/mbart.cc25/sentence.bpe.model'}, 'tokenizer': None}
2021-01-17 13:47:07 | INFO | fairseq.tasks.translation | [src] dictionary: 250001 types
2021-01-17 13:47:07 | INFO | fairseq.tasks.translation | [label] dictionary: 250001 types
2021-01-17 13:47:07 | INFO | fairseq_cli.generate | loading model(s) from ./checkpoint_fr_underscore/checkpoint_last.pt
2021-01-17 13:48:19 | INFO | fairseq.data.data_utils | loaded 2,024 examples from: ./postprocessed/en_underscore/test.src-label.src
2021-01-17 13:48:19 | INFO | fairseq.data.data_utils | loaded 2,024 examples from: ./postprocessed/en_underscore/test.src-label.label
2021-01-17 13:48:19 | INFO | fairseq.tasks.translation | ./postprocessed/en_underscore test src-label 2024 examples
S-228	Clinical comparisons were made between the 2 groups.<unk>
T-228	clinical
H-228	-0.42261606454849243	▁Clinic al
D-228	-0.42261606454849243	Clinical
P-228	-1.2246 -0.1077 -0.3157 -0.0425
S-664	We identified 12 556 patients from 45 practices.<unk>
T-664	patients
H-664	-0.7178012132644653	
D-664	-0.7178012132644653	
P-664	-1.3490 -0.0866
S-1528	Of 402 patients, 48 (12%) had EH.<unk>
T-1528	patients
H-1528	-0.17872993648052216	▁EH
D-1528	-0.17872993648052216	EH
P-1528	-0.2603 -0.1843 -0.0916
S-1451	A nested case-control study design was used.<unk>
T-1451	
H-1451	-1.0082650184631348	▁neste d ▁case - control
D-1451	-1.0082650184631348	nested case-control
P-1451	-3.5745 -0.2087 -0.5195 -0.2124 -0.1382 -2.2260 -0.1786
S-133	The basis for these differences requires further examination.<unk>
T-133	
H-133	-0.24755854904651642	
D-133	-0.24755854904651642	
P-133	-0.4717 -0.0234
S-1685	The young woman and her family adamantly refuse.<unk>
T-1685	
H-1685	-1.4635052680969238	
D-1685	-1.4635052680969238	
P-1685	-2.7193 -0.2077
S-1916	RESULTS: No adverse events occurred.<unk>
T-1916	adverse_events
H-1916	-1.0916892290115356	
D-1916	-1.0916892290115356	
P-1916	-2.0335 -0.1499
S-1497	SETTING: Single tertiary referral centre.<unk>
T-1497	
H-1497	-0.6535199284553528	▁tertia ry _ ▁refer ral ▁centre
D-1497	-0.6535199284553528	tertiary_ referral centre
P-1497	-1.8151 -0.5227 -0.7508 -0.4599 -0.0134 -1.1102 -0.4692 -0.0868
S-256	This was associated with lower NO production of EC.<unk>
T-256	
H-256	-1.6325525045394897	▁EC
D-256	-1.6325525045394897	EC
P-256	-4.3391 -0.4280 -0.1306
S-307	Recommendations based on a systematic review.<unk>
T-307	
H-307	-0.6094887852668762	
D-307	-0.6094887852668762	
P-307	-1.1534 -0.0656
S-1607	However, the molecular mechanism is still unclear.<unk>
T-1607	
H-1607	-0.7912637591362	▁molecular
D-1607	-0.7912637591362	molecular
P-1607	-0.2240 -2.0492 -0.1007
S-1496	DXA results were compared with Australian reference data.<unk>
T-1496	dxa
H-1496	-0.9025554060935974	▁d XA
D-1496	-0.9025554060935974	dXA
P-1496	-1.0592 -0.1988 -1.9818 -0.3704
S-18	No correlation to changes in FM was found.<unk>
T-18	correlation
H-18	-0.5570086240768433	▁FM
D-18	-0.5570086240768433	FM
P-18	-1.4071 -0.2095 -0.0545
S-1897	Playing it safe: exercise and cardiovascular health.<unk>
T-1897	exercise cardiovascular health
H-1897	-1.6396865844726562	▁exercise ▁cardiovascular ▁health
D-1897	-1.6396865844726562	exercise cardiovascular health
P-1897	-4.9714 -1.1224 -1.6780 -0.3353 -0.0913
S-1699	Results were similar for HF and PNA.<unk>
T-1699	hf pna
H-1699	-1.188214659690857	▁ HF
D-1699	-1.188214659690857	HF
P-1699	-1.0899 -0.4718 -3.0829 -0.1082
S-1066	Contemporary use of devices in heart failure.<unk>
T-1066	heart_failure
H-1066	-1.8177162408828735	▁devices _ ▁in _ heart _ ▁failure
D-1066	-1.8177162408828735	devices_ in_heart_ failure
P-1066	-5.2412 -2.1135 -1.2569 -2.3300 -1.4850 -0.8508 -2.7470 -0.1820 -0.1531
S-233	Liver disease in the adults was more advanced.<unk>
T-233	liver_disease
H-233	-0.9595580697059631	▁Live r ▁disease
D-233	-0.9595580697059631	Liver disease
P-233	-1.3323 -0.0457 -2.9645 -0.3047 -0.1506
S-1592	Renal artery stenosis - an update.<unk>
T-1592	renal_artery_stenosis
H-1592	-0.3130204677581787	▁Ren al ▁arter y ▁sten osis
D-1592	-0.3130204677581787	Renal artery stenosis
P-1592	-0.0309 -0.2230 -0.5641 -0.4435 -0.8277 -0.1717 -0.1451 -0.0982
S-190	The primary end point was inhospital mortality.<unk>
T-190	primary_end_point inhospital mortality
H-190	-0.9300407767295837	hospital _ ▁mortal ity
D-190	-0.9300407767295837	hospital_ mortality
P-190	-3.7501 -0.5108 -0.6592 -0.2977 -0.1929 -0.1695
S-1712	DESIGN: Retrospective cohort study.<unk>
T-1712	retrospective_cohort_study
H-1712	-0.8604776263237	▁Retro spec tive ▁co hor t
D-1712	-0.8604776263237	Retrospective cohort
P-1712	-5.2218 -0.0554 -0.0253 -0.1669 -0.1317 -0.5004 -0.6693 -0.1130
S-1279	Acute care surgery in heart transplant recipients.<unk>
T-1279	acute_care_surgery heart_transplant
H-1279	-1.2417408227920532	▁a cute _ ▁surgery ▁heart ▁transplant ▁recipient s
D-1279	-1.2417408227920532	acute_ surgery heart transplant recipients
P-1279	-3.2965 -0.0026 -0.3722 -5.4423 -0.5334 -0.8858 -1.3569 -0.2668 -0.1923 -0.0686
S-1788	The reality of heart failure in Latin America.<unk>
T-1788	heart_failure latin_america
H-1788	-1.3012561798095703	▁heart _ ▁failure ▁Latin ▁America
D-1788	-1.3012561798095703	heart_ failure Latin America
P-1788	-3.0014 -0.3454 -4.2438 -0.7504 -0.4153 -0.2106 -0.1419
S-811	DESIGN: Observational cohort study.<unk>
T-811	observational_cohort_study
H-811	-1.0108782052993774	
D-811	-1.0108782052993774	
P-811	-1.9216 -0.1001
S-1345	Periodic breathing with no heart beat.<unk>
T-1345	periodic_breathing heart_beat
H-1345	-1.4731554985046387	
D-1345	-1.4731554985046387	
P-1345	-2.8758 -0.0705
S-211	DESIGN: Retrospective cohort.<unk>
T-211	retrospective_cohort
H-211	-0.4433895945549011	▁Retro spec tive ▁co hor t
D-211	-0.4433895945549011	Retrospective cohort
P-211	-2.5901 -0.0528 -0.0183 -0.1236 -0.0813 -0.2986 -0.2587 -0.1237
S-241	Two final multivariate models were developed.<unk>
T-241	multivariate_models
H-241	-1.0522091388702393	
D-241	-1.0522091388702393	
P-241	-1.9353 -0.1691
S-346	He developed HF again 4 years later.<unk>
T-346	hf
H-346	-0.5825387835502625	▁ HF
D-346	-0.5825387835502625	HF
P-346	-1.2755 -0.3432 -0.4898 -0.2217
S-589	The 90-day mortality was 28%.<unk>
T-589	mortality
H-589	-0.4542475938796997	▁90- day _ ▁mortal ity
D-589	-0.4542475938796997	90-day_ mortality
P-589	-1.5938 -0.1875 -0.5376 -0.4404 -0.1893 -0.1421 -0.0890
S-796	SETTING: Patients' home environment.<unk>
T-796	patients
H-796	-1.1091489791870117	
D-796	-1.1091489791870117	
P-796	-2.1024 -0.1159
S-1944	Similar results were observed after 6 months.<unk>
T-1944	
H-1944	-0.21881425380706787	
D-1944	-0.21881425380706787	
P-1944	-0.4132 -0.0245
S-1982	Of these, 92 participants completed the trial.<unk>
T-1982	
H-1982	-0.7461135387420654	
D-1982	-0.7461135387420654	
P-1982	-1.4082 -0.0840
S-44	Trials were assessed for quality.<unk>
T-44	
H-44	-0.7817683815956116	
D-44	-0.7817683815956116	
P-44	-1.4482 -0.1154
S-1846	We will extract data in duplicate.<unk>
T-1846	
H-1846	-0.9559143781661987	
D-1846	-0.9559143781661987	
P-1846	-1.8152 -0.0966
S-1686	Should the doctors let her die?<unk>
T-1686	doctors
H-1686	-0.30042600631713867	▁doctor s
D-1686	-0.30042600631713867	doctors
P-1686	-0.3624 -0.1857 -0.6021 -0.0516
S-422	Heart rate was minimally altered.<unk>
T-422	heart_rate
H-422	-0.5862739682197571	▁Heart
D-422	-0.5862739682197571	Heart
P-422	-0.1802 -1.4211 -0.1575
S-1356	Nutrition in heart failure: an update.<unk>
T-1356	heart_failure
H-1356	-1.3006843328475952	▁Nutrition _ ▁in _ heart _ ▁failure
D-1356	-1.3006843328475952	Nutrition_ in_heart_ failure
P-1356	-3.2705 -1.5880 -0.7644 -1.4853 -1.3698 -0.3601 -2.4920 -0.2085 -0.1675
S-1620	SETTING: Northwest United States.<unk>
T-1620	united_states
H-1620	-0.9833974838256836	
D-1620	-0.9833974838256836	
P-1620	-1.9217 -0.0451
S-1683	She is going into heart failure.<unk>
T-1683	heart_failure
H-1683	-1.2800546884536743	▁heart _ ▁failure
D-1683	-1.2800546884536743	heart_ failure
P-1683	-1.8803 -0.9328 -3.3243 -0.1346 -0.1283
S-363	Therefore, the surgery was successful.<unk>
T-363	surgery
H-363	-0.5612342953681946	
D-363	-0.5612342953681946	
P-363	-1.0662 -0.0562
S-795	DESIGN: Cross-sectional.<unk>
T-795	
H-795	-0.752959132194519	▁Cross - sec tional
D-795	-0.752959132194519	Cross-sectional
P-795	-1.8243 -0.1427 -1.0590 -0.9559 -0.4146 -0.1213
S-798	INTERVENTIONS: Not applicable.<unk>
T-798	
H-798	-0.505672037601471	▁INTER VEN tions
D-798	-0.505672037601471	INTERVENtions
P-798	-0.5099 -0.8749 -0.9132 -0.1811 -0.0493
S-1595	It is predominantly unilateral.<unk>
T-1595	
H-1595	-0.6284202337265015	▁unilateral
D-1595	-0.6284202337265015	unilateral
P-1595	-1.3960 -0.3442 -0.1451
S-979	Heart failure in the young.<unk>
T-979	heart_failure
H-979	-1.1052942276000977	▁Heart _ ▁failure
D-979	-1.1052942276000977	Heart_ failure
P-979	-0.1488 -0.7180 -3.8462 -0.6501 -0.1634
S-1249	5, 43-47].<unk>
T-1249	
H-1249	-0.2739724814891815	
D-1249	-0.2739724814891815	
P-1249	-0.4737 -0.0743
S-1687	Is there any alternative?<unk>
T-1687	
H-1687	-0.4271320104598999	
D-1687	-0.4271320104598999	
P-1687	-0.8332 -0.0211
S-1246	(2012) Clin.<unk>
T-1246	
H-1246	-0.39043381810188293	▁c lin
D-1246	-0.39043381810188293	clin
P-1246	-0.8573 -0.0910 -0.5265 -0.0870
S-1247	Trans.<unk>
T-1247	
H-1247	-0.9213964343070984	▁trans
D-1247	-0.9213964343070984	trans
P-1247	-0.5259 -2.1189 -0.1193
S-1248	Sci.<unk>
T-1248	
H-1248	-1.0582120418548584	
D-1248	-1.0582120418548584	
P-1248	-1.8405 -0.2759
S-1763	Similar results were obtained for the secondary study end point.<unk>
T-1763	end_point
H-1763	-0.7148290872573853	
D-1763	-0.7148290872573853	
P-1763	-1.3760 -0.0537
S-1005	Intermediate frailty was defined as 1 to 2.<unk>
T-1005	frailty
H-1005	-0.7529750466346741	▁Inter media te _ fra il ty
D-1005	-0.7529750466346741	Intermediate_frailty
P-1005	-1.1533 -0.0593 -0.3307 -0.3728 -0.5869 -0.6275 -3.3601 -0.1673 -0.1189
S-1963	Further large-scale randomised studies are warranted.<unk>
T-1963	randomised
H-1963	-0.6988727450370789	
D-1963	-0.6988727450370789	
P-1963	-1.2784 -0.1193
S-222	These decreases are most likely due to better CHF treatments.<unk>
T-222	chf
H-222	-0.47613516449928284	▁CHF
D-222	-0.47613516449928284	CHF
P-222	-0.2757 -1.1002 -0.0526
S-205	We read the article by Dodson et al with interest.<unk>
T-205	dodson
H-205	-0.33028843998908997	▁do d son
D-205	-0.33028843998908997	dodson
P-205	-0.6583 -0.0380 -0.0344 -0.8588 -0.0620
S-392	A total of 8204 patients were included in the analyses.<unk>
T-392	patients
H-392	-0.4515573978424072	
D-392	-0.4515573978424072	
P-392	-0.8400 -0.0631
S-575	This exercise modality is a promising alternative for this population.<unk>
T-575	exercise
H-575	-0.7161740660667419	
D-575	-0.7161740660667419	
P-575	-1.3792 -0.0531
S-126	RESULTS: The mean age was 55 ± 15 years.<unk>
T-126	
H-126	-0.8195466995239258	
D-126	-0.8195466995239258	
P-126	-1.5039 -0.1352
S-1101	We evaluated temporal trends in HF after MI.<unk>
T-1101	hf mi
H-1101	-1.1360620260238647	▁ HF
D-1101	-1.1360620260238647	HF
P-1101	-2.2847 -0.3439 -1.5902 -0.3255
S-673	The rates and risk factors associated with CHF were evaluated.<unk>
T-673	chf
H-673	-1.0884970426559448	▁rates ▁CHF
D-673	-1.0884970426559448	rates CHF
P-673	-1.6387 -2.4295 -0.1754 -0.1104
S-1886	Heart failure affects nearly one million people in the UK.<unk>
T-1886	heart_failure
H-1886	-1.476119875907898	▁Heart _ pu issa nce
D-1886	-1.476119875907898	Heart_puissance
P-1886	-1.0955 -0.6968 -6.1433 -0.4169 -0.0184 -1.6554 -0.3066
S-825	Patients were followed up for 3.0 ± 1.8 years.<unk>
T-825	patients followed_up
H-825	-0.6215195059776306	
D-825	-0.6215195059776306	
P-825	-1.1608 -0.0822
S-1805	Assessing the link between air pollution and heart failure.<unk>
T-1805	air heart_failure
H-1805	-0.6553177237510681	▁air ▁pollution ▁heart _ ▁failure
D-1805	-0.6553177237510681	air pollution heart_ failure
P-1805	-0.0277 -1.1984 -0.4025 -0.7833 -1.8317 -0.1515 -0.1921
S-1296	The extracorporeal support was needed for three days.<unk>
T-1296	extracorporeal_support
H-1296	-0.35926374793052673	▁extra corp o real ▁support
D-1296	-0.35926374793052673	extracorporeal support
P-1296	-0.5344 -0.0262 -0.3193 -0.0920 -1.1917 -0.2368 -0.1145
S-247	This function is impaired in patients with cardiovascular disease.<unk>
T-247	patients cardiovascular_disease
H-247	-1.1510151624679565	▁cardiovascular ▁disease
D-247	-1.1510151624679565	cardiovascular disease
P-247	-1.9075 -2.4898 -0.1243 -0.0824
S-1073	Heart failure: a disease complex with challenging therapeutics.<unk>
T-1073	heart_failure disease therapeutics
H-1073	-1.2486460208892822	▁Heart _ ▁failure
D-1073	-1.2486460208892822	Heart_ failure
P-1073	-0.2609 -1.0625 -2.3176 -2.5017 -0.1005
S-1116	Secondary outcomes included markers of hemostasis.<unk>
T-1116	secondary_outcomes hemostasis
H-1116	-0.8861168026924133	▁hemos tas is
D-1116	-0.8861168026924133	hemostasis
P-1116	-3.1429 -0.9581 -0.1280 -0.1202 -0.0813
S-53	Remote ischemic conditioning for patients with heart failure?<unk>
T-53	remote_ischemic_conditioning patients heart_failure
H-53	-1.295680046081543	▁ ische mic ▁condition ing ▁heart _ ▁failure
D-53	-1.295680046081543	ischemic conditioning heart_ failure
P-53	-2.2082 -1.3859 -0.4821 -0.5040 -0.8036 -4.6463 -0.8929 -1.8106 -0.1282 -0.0950
S-1584	Heart rate variability in risk stratification of cardiac patients.<unk>
T-1584	heart_rate_variability risk_stratification cardiac patients
H-1584	-1.7264373302459717	▁Heart ▁rate _ vari able
D-1584	-1.7264373302459717	Heart rate_variable
P-1584	-0.2726 -3.2337 -1.0469 -0.8095 -2.6688 -3.7392 -0.3142
S-1619	DESIGN: Retrospective matched cohort study.<unk>
T-1619	retrospective_matched_cohort_study
H-1619	-0.9282328486442566	
D-1619	-0.9282328486442566	
P-1619	-1.7926 -0.0639
S-1754	We evaluated whether this finding has a prognostic meaning.<unk>
T-1754	prognostic
H-1754	-0.9914414286613464	
D-1754	-0.9914414286613464	
P-1754	-1.8823 -0.1006
S-749	Compliance with treatment had a more remarkable role.<unk>
T-749	compliance
H-749	-1.1340938806533813	
D-749	-1.1340938806533813	
P-749	-2.2380 -0.0302
S-312	We made policy recommendations on the basis of our systematic review.<unk>
T-312	policy
H-312	-0.9606292843818665	
D-312	-0.9606292843818665	
P-312	-1.8748 -0.0465
S-311	Data were, however, limited to 2-3 studies per outcome.<unk>
T-311	outcome
H-311	-0.2809060215950012	
D-311	-0.2809060215950012	
P-311	-0.5180 -0.0439
S-885	A total of 1483 patients were included in this study.<unk>
T-885	patients
H-885	-0.4047169089317322	
D-885	-0.4047169089317322	
P-885	-0.7638 -0.0456
S-1339	Sham-operated animals were used as a control group.<unk>
T-1339	
H-1339	-1.5846948623657227	▁Sham - opera tion _ animal
D-1339	-1.5846948623657227	Sham-operation_animal
P-1339	-0.9537 -2.6989 -0.0351 -2.3819 -1.0808 -3.8381 -1.3871 -0.3021
S-1399	A retrospective descriptive research design was used.<unk>
T-1399	
H-1399	-0.9273281097412109	▁retro spec tive ▁de script ive
D-1399	-0.9273281097412109	retrospective descriptive
P-1399	-2.1707 -0.0660 -0.0128 -1.5728 -0.4556 -0.0826 -2.9098 -0.1483
S-1125	These reasons were classified using a published taxonomy.<unk>
T-1125	
H-1125	-1.523284673690796	
D-1125	-1.523284673690796	
P-1125	-2.9293 -0.1173
S-364	However, this patient developed HF 4 years later.<unk>
T-364	patient hf
H-364	-0.795758068561554	▁ HF
D-364	-0.795758068561554	HF
P-364	-2.3165 -0.3226 -0.3175 -0.2263
S-1900	The benefits of exercise extend well beyond the cardiovascular system.<unk>
T-1900	exercise cardiovascular
H-1900	-1.4281644821166992	▁benefits ▁cardiovascular
D-1900	-1.4281644821166992	benefits cardiovascular
P-1900	-2.2091 -0.8495 -2.5928 -0.0613
S-1037	Now, reporting in Cell, Anand et al.<unk>
T-1037	reporting cell anand
H-1037	-0.7857218980789185	▁Cell ▁Anand
D-1037	-0.7857218980789185	Cell Anand
P-1037	-2.6661 -0.2216 -0.1500 -0.1052
S-1988	There were no study-related serious adverse events.<unk>
T-1988	adverse_events
H-1988	-0.7157770991325378	
D-1988	-0.7157770991325378	
P-1988	-1.3706 -0.0610
S-949	No major complications occurred during follow-up.<unk>
T-949	complications follow-up
H-949	-0.6382091045379639	
D-949	-0.6382091045379639	
P-949	-1.2364 -0.0400
S-957	Doxorubicin was injected i.p.<unk>
T-957	doxorubicin injected
H-957	-0.2999403476715088	▁do xor ubi cin
D-957	-0.2999403476715088	doxorubicin
P-957	-0.5710 -0.0577 -0.2272 -0.0672 -0.7485 -0.1280
S-1684	Her doctors urgently recommend blood transfusions.<unk>
T-1684	doctors blood_transfusions
H-1684	-1.287866234779358	▁doctor s ▁trans fusion s
D-1684	-1.287866234779358	doctors transfusions
P-1684	-1.5537 -1.7523 -3.9749 -0.0343 -0.9166 -0.5276 -0.2557
S-1534	Heart failure in patients treated with bisphosphonates.<unk>
T-1534	heart_failure patients bisphosphonates
H-1534	-0.9114578366279602	▁Heart _ ▁failure ▁bis phos phon ates
D-1534	-0.9114578366279602	Heart_ failure bisphosphonates
P-1534	-0.1614 -1.5950 -2.0892 -1.2991 -0.0427 -0.2748 -2.1835 -0.4173 -0.1401
S-1198	Diuretic use in heart failure and outcomes.<unk>
T-1198	diuretic heart_failure outcomes
H-1198	-1.3916904926300049	▁di ure tic _ utilisation ▁heart _ ▁failure
D-1198	-1.3916904926300049	diuretic_utilisation heart_ failure
P-1198	-0.7744 -0.0439 -3.5452 -3.1641 -1.8361 -1.2809 -0.5408 -2.2972 -0.2679 -0.1665
S-169	Caspase-3 gene expression increased in heart failure.<unk>
T-169	caspase-3 gene_expression heart_failure
H-169	-2.2413816452026367	▁cas pas e ▁heart _ ▁failure
D-169	-2.2413816452026367	caspase heart_ failure
P-169	-4.3636 -1.1471 -1.0193 -5.2273 -1.1890 -4.4876 -0.2836 -0.2136
S-712	Two Cox proportional hazards models were developed.<unk>
T-712	cox_proportional_hazards_models
H-712	-0.6603385806083679	▁co x ▁proportion al _ ▁hazard s
D-712	-0.6603385806083679	cox proportional_ hazards
P-712	-0.8327 -0.0107 -0.5620 -0.2743 -0.3939 -2.0374 -1.0174 -0.6100 -0.2047
S-1090	Acute right heart failure in pulmonary hypertension.<unk>
T-1090	acute_right_heart_failure pulmonary_hypertension
H-1090	-0.8896732330322266	▁right ▁heart _ ▁failure ▁pulmonar y ▁hyper tension
D-1090	-0.8896732330322266	right heart_ failure pulmonary hypertension
P-1090	-4.6180 -1.9554 -0.4544 -1.3776 -0.0056 -0.0661 -0.1937 -0.0007 -0.1506 -0.0746
S-1843	We will use American, Canadian and European HF guidelines as our reference.<unk>
T-1843	american hf
H-1843	-1.2221012115478516	▁ HF
D-1843	-1.2221012115478516	HF
P-1843	-1.8998 -1.4741 -1.4288 -0.0857
S-1889	Patients are likely to be older women with a history of hypertension.<unk>
T-1889	patients hypertension
H-1889	-0.7844218611717224	▁hyper tension
D-1889	-0.7844218611717224	hypertension
P-1889	-2.9401 -0.0066 -0.0915 -0.0995
S-1616	Besides, these genes can be targets to develop treatments.<unk>
T-1616	genes
H-1616	-0.5700356364250183	
D-1616	-0.5700356364250183	
P-1616	-1.0780 -0.0620
S-32	Literature was reassessed in April 2013, and additional studies were included.<unk>
T-32	
H-32	-1.4962825775146484	
D-32	-1.4962825775146484	
P-32	-2.8106 -0.1819
S-786	Internal reliability was assessed with Cronbach's α.<unk>
T-786	
H-786	-0.729953944683075	▁cro n bach
D-786	-0.729953944683075	cronbach
P-786	-2.0962 -0.0983 -0.1431 -1.2005 -0.1116
S-804	The third trial added little or no information to the first 2 trials.<unk>
T-804	
H-804	-0.754395067691803	
D-804	-0.754395067691803	
P-804	-1.4257 -0.0831
S-0	National trends in patient safety for four common conditions, 2005-2011.<unk>
T-0	patient conditions
H-0	-1.101835012435913	▁patient _ ▁safety ▁conditions
D-0	-1.101835012435913	patient_ safety conditions
P-0	-2.3530 -0.8133 -2.1807 -0.6764 -0.2664 -0.3211
S-1759	AT was identified in 1935 out of 2137 patients (90.54%).<unk>
T-1759	patients
H-1759	-0.8771992921829224	
D-1759	-0.8771992921829224	
P-1759	-1.6575 -0.0969
S-156	No trial of implanted monitoring devices met the inclusion criteria.<unk>
T-156	implanted
H-156	-0.8994987607002258	▁implant ed _ ▁monitoring ▁devices
D-156	-0.8994987607002258	implanted_ monitoring devices
P-156	-0.0030 -0.4583 -0.9723 -1.8997 -2.7586 -0.1357 -0.0689
S-1469	Few treatments have been investigated in clinical trials.<unk>
T-1469	clinical
H-1469	-0.9575870037078857	
D-1469	-0.9575870037078857	
P-1469	-1.8885 -0.0267
S-518	HR modulates Ea, and, therefore, afterload burden.<unk>
T-518	ea afterload
H-518	-2.1983697414398193	▁HR _ modul ates _ ▁Ea
D-518	-2.1983697414398193	HR_modulates_ Ea
P-518	-3.6902 -5.2093 -0.8135 -0.7330 -1.0964 -2.3405 -3.3797 -0.3243
S-778	There were no periprocedural deaths or strokes.<unk>
T-778	deaths strokes
H-778	-0.4582492709159851	▁per i pro ced ural ▁stroke s
D-778	-0.4582492709159851	periprocedural strokes
P-778	-0.7969 -0.8295 -0.1319 -0.1712 -0.0438 -1.9914 -0.0645 -0.0567 -0.0385
S-1594	The most common cause of RAS is atherosclerosis.<unk>
T-1594	ras atherosclerosis
H-1594	-1.0644561052322388	▁ RAS ▁at hero sc ler osis
D-1594	-1.0644561052322388	RAS atherosclerosis
P-1594	-1.0390 -0.0599 -1.7268 -0.7499 -3.0433 -2.4944 -0.2114 -0.1269 -0.1286
S-1000	Measuring frailty in heart failure: a community perspective.<unk>
T-1000	frailty heart_failure
H-1000	-1.471481442451477	▁fra il ty _ ▁in _ heart _ ▁failure ▁communauté
D-1000	-1.471481442451477	frailty_ in_heart_ failure communauté
P-1000	-4.7682 -1.6938 -2.9562 -1.1488 -0.3801 -1.1649 -1.3317 -0.3415 -1.1603 -1.2303 -1.3058 -0.1763
S-1932	PSSS did not impact the effect of exercise training on outcomes.<unk>
T-1932	psss exercise training outcomes
H-1932	-0.8083369135856628	▁PS SS
D-1932	-0.8083369135856628	PSSS
P-1932	-1.4101 -0.3045 -1.3276 -0.1911
S-1479	MicroRNAs in heart failure: new targets in disease management.<unk>
T-1479	micrornas heart_failure disease
H-1479	-0.8264257907867432	▁micro RNA s ▁heart _ ▁failure ▁disease ▁management
D-1479	-0.8264257907867432	microRNAs heart_ failure disease management
P-1479	-1.5128 -0.0027 -0.0547 -1.5711 -0.6187 -2.4688 -0.3775 -1.2252 -0.3111 -0.1217
S-612	Using exercise to improve quality of life for people with heart failure.<unk>
T-612	exercise quality_of_life heart_failure
H-612	-2.0919413566589355	
D-612	-2.0919413566589355	
P-612	-4.0803 -0.1036
S-1770	Hazard ratios were computed with Cox regression analysis.<unk>
T-1770	hazard_ratios cox_regression_analysis
H-1770	-0.6601875424385071	▁co x ▁re gression
D-1770	-0.6601875424385071	cox regression
P-1770	-0.8146 -0.0229 -1.3883 -0.5148 -0.9966 -0.2239
S-1033	Cardiology: Bromodomain inhibition halts heart failure.<unk>
T-1033	cardiology bromodomain halts heart_failure
H-1033	-1.27755606174469	▁Card i ology ▁implant ation ▁heart _ ▁failure
D-1033	-1.27755606174469	Cardiology implantation heart_ failure
P-1033	-0.2435 -0.5618 -1.1354 -5.3463 -0.3995 -0.9913 -1.3466 -2.4392 -0.2520 -0.0602
S-1885	Management of heart failure with preserved ejection fraction.<unk>
T-1885	heart_failure_with_preserved_ejection_fraction
H-1885	-1.1051167249679565	▁management _ de _ ▁heart _ ▁failure ▁e je ction _ fraction
D-1885	-1.1051167249679565	management_de_ heart_ failure ejection_fraction
P-1885	-1.6786 -1.3796 -1.9894 -0.1746 -1.2711 -0.3106 -3.2200 -2.4818 -0.5694 -0.0833 -1.7584 -0.0191 -0.2382 -0.2977
S-677	Median age of the entire cohort was 71 years old.<unk>
T-677	
H-677	-1.0815626382827759	▁Media n _ ▁age
D-677	-1.0815626382827759	Median_ age
P-677	-0.5626 -0.1637 -1.2828 -3.0287 -1.2809 -0.1706
S-1688	Composite quality measures for common inpatient medical conditions.<unk>
T-1688	inpatient medical conditions
H-1688	-0.6601441502571106	▁in patient _ ▁medical ▁conditions
D-1688	-0.6601441502571106	inpatient_ medical conditions
P-1688	-1.1264 -0.1014 -1.6187 -1.4608 -0.0424 -0.1202 -0.1512
S-1679	A young adult Jehovah's Witness with severe anemia.<unk>
T-1679	witness anemia
H-1679	-1.1620092391967773	▁Jehovah _ s _ ▁Wit ness ▁an emia
D-1679	-1.1620092391967773	Jehovah_s_ Witness anemia
P-1679	-0.4146 -1.9703 -1.6734 -0.5315 -0.1687 -1.7820 -4.4723 -0.2223 -0.2536 -0.1314
S-812	SETTING: Department of cardiology in a university hospital.<unk>
T-812	cardiology hospital
H-812	-0.9668381214141846	▁card i ology ▁university _ hospital
D-812	-0.9668381214141846	cardiology university_hospital
P-812	-2.8077 -1.3834 -0.8559 -0.3558 -1.6262 -0.3902 -0.2729 -0.0427
S-1078	However, treatment of HFpEF still poses significant challenges.<unk>
T-1078	hfpef
H-1078	-0.4386652112007141	▁ HF p EF
D-1078	-0.4386652112007141	HFpEF
P-1078	-0.8641 -0.3548 -0.0758 -1.0398 -0.2322 -0.0654
S-1309	Concurrent HF comprised 75% of incident HF cases.<unk>
T-1309	hf hf
H-1309	-1.2279694080352783	▁ HF
D-1309	-1.2279694080352783	HF
P-1309	-2.0489 -0.7733 -1.7879 -0.3018
S-1375	We examined several markers indicative of autonomic balance.<unk>
T-1375	autonomic_balance
H-1375	-0.49528735876083374	▁autonomi c ▁balance
D-1375	-0.49528735876083374	autonomic balance
P-1375	-1.2941 -0.4188 -0.5246 -0.1189 -0.1200
S-624	Impact of frailty on HF risk is not known.<unk>
T-624	frailty hf
H-624	-1.1228327751159668	▁impact _ de _ fra il ty ▁ HF
D-624	-1.1228327751159668	impact_de_frailty HF
P-624	-2.0015 -1.6758 -1.7348 -0.2002 -0.3669 -0.6798 -4.1053 -0.7176 -0.0487 -0.6440 -0.1766
S-1960	No patient was admitted to hospital for worsening heart failure.<unk>
T-1960	patient hospital heart_failure
H-1960	-1.4090512990951538	▁hospital _ de _ ▁worse ning _ ▁heart _ ▁failure
D-1960	-1.4090512990951538	hospital_de_ worsening_ heart_ failure
P-1960	-3.4237 -2.0004 -3.1867 -0.1625 -1.3399 -0.7428 -0.4951 -1.8948 -0.6740 -2.5535 -0.2627 -0.1724
S-702	ST2 was modestly associated with measures of functional capacity.<unk>
T-702	st2 functional_capacity
H-702	-1.2644518613815308	
D-702	-1.2644518613815308	
P-702	-2.4279 -0.1010
S-204	Heart failure and cognitive impairment: relationships with mortality.<unk>
T-204	heart_failure mortality
H-204	-0.37682580947875977	▁Heart _ ▁failure ▁cognitive ▁im pair ment ▁mortal ity
D-204	-0.37682580947875977	Heart_ failure cognitive impairment mortality
P-204	-0.1064 -0.4884 -0.9627 -1.1205 -0.1642 -0.0031 -0.0719 -0.8127 -0.1549 -0.1385 -0.1219
S-280	Severe LV fibrosis was found in ANS mice.<unk>
T-280	lv_fibrosis
H-280	-0.7517482042312622	▁LV _ ▁fibro sis
D-280	-0.7517482042312622	LV_ fibrosis
P-280	-0.0541 -1.2462 -0.1093 -0.6074 -2.4055 -0.0880
S-495	The median follow-up duration was 20.8 mo.<unk>
T-495	follow-up_duration
H-495	-0.6497856378555298	▁media n _ ▁follow - up
D-495	-0.6497856378555298	median_ follow-up
P-495	-0.7763 -0.2030 -0.8856 -1.9963 -0.1459 -0.0140 -1.0349 -0.1422
S-511	Dynamic and competitive collateral growth patterns were observed.<unk>
T-511	collateral_growth
H-511	-1.215161919593811	▁competitive ▁col lateral
D-511	-1.215161919593811	competitive collateral
P-511	-2.9371 -1.0387 -0.0162 -1.9695 -0.1143
S-325	Indices were correlated against CO with mixed linear models.<unk>
T-325	correlated mixed_linear_models
H-325	-1.0859205722808838	▁CO
D-325	-1.0859205722808838	CO
P-325	-0.9708 -2.0752 -0.2117
S-410	Similar results were found for heart failure hospitalization and cardiovascular death.<unk>
T-410	heart_failure hospitalization cardiovascular_death
H-410	-1.3941998481750488	▁heart _ ▁failure ▁hospital ization ▁cardiovascular ▁death
D-410	-1.3941998481750488	heart_ failure hospitalization cardiovascular death
P-410	-0.7775 -0.6849 -4.0194 -3.0540 -1.4791 -0.0346 -2.3183 -0.1141 -0.0660
S-1654	Key secondary outcomes include cognitive function and quality of life.<unk>
T-1654	secondary_outcomes quality_of_life
H-1654	-1.319562315940857	▁cognitive _ fon ction nel
D-1654	-1.319562315940857	cognitive_fonctionnel
P-1654	-0.9700 -1.6137 -2.8124 -0.1833 -1.3179 -2.1924 -0.1472
S-633	The role of vasopressin in congestive heart failure.<unk>
T-633	vasopressin congestive_heart_failure
H-633	-0.587559700012207	▁vaso press in ▁con ges tive ▁heart _ ▁failure
D-633	-0.587559700012207	vasopressin congestive heart_ failure
P-633	-0.1338 -0.1973 -0.8338 -0.5339 -0.1823 -0.1671 -1.9676 -0.8603 -1.4110 -0.1025 -0.0734
S-707	Ten-year experience with extended criteria cardiac transplantation.<unk>
T-707	extended_criteria_cardiac_transplantation
H-707	-1.0523604154586792	▁cardiac ▁transplant ation
D-707	-1.0523604154586792	cardiac transplantation
P-707	-2.0983 -2.8693 -0.0299 -0.1993 -0.0650
S-332	Mitral stenosis reversed by medical treatment for heart failure.<unk>
T-332	mitral_stenosis medical_treatment heart_failure
H-332	-1.3655489683151245	▁Mit ral _ ▁sten osis _ ▁rever sed ▁medical ▁treatment ▁heart _ ▁failure
D-332	-1.3655489683151245	Mitral_ stenosis_ reversed medical treatment heart_ failure
P-332	-1.5263 -0.0070 -1.2008 -2.1436 -0.6284 -4.6645 -0.1187 -1.1750 -0.8336 -2.9549 -0.5020 -0.5529 -3.7344 -0.3009 -0.1403
S-1211	However, the role of PDE2 in HF is poorly understood.<unk>
T-1211	pde2 hf
H-1211	-0.28094032406806946	▁p de 2 ▁ HF
D-1211	-0.28094032406806946	pde2 HF
P-1211	-0.9801 -0.1020 -0.1953 -0.3635 -0.1062 -0.1293 -0.0902
S-958	over 2 weeks to obtain a cumulative dose of 18 mg/kg.<unk>
T-958	
H-958	-1.0990698337554932	
D-958	-1.0990698337554932	
P-958	-2.1243 -0.0738
S-1837	Results from the 1:1 propensity score-matched analyses were similar.<unk>
T-1837	
H-1837	-0.26727622747421265	▁pro pens ity
D-1837	-0.26727622747421265	propensity
P-1837	-0.3381 -0.0169 -0.3584 -0.5007 -0.1223
S-1998	RESULTS: Fifty patients were enrolled at 10 centers.<unk>
T-1998	patients
H-1998	-1.0139024257659912	
D-1998	-1.0139024257659912	
P-1998	-1.9517 -0.0761
S-1634	RESULTS: There were 749 self-identified black patients (33%).<unk>
T-1634	patients
H-1634	-1.7195696830749512	▁black
D-1634	-1.7195696830749512	black
P-1634	-2.8267 -2.0826 -0.2494
S-1261	RESULTS: Twenty-seven studies with 1887 patients were included.<unk>
T-1261	patients
H-1261	-0.44515305757522583	
D-1261	-0.44515305757522583	
P-1261	-0.8171 -0.0732
S-134	Implications of metric choice for common applications of readmission metrics.<unk>
T-134	readmission
H-134	-1.0163874626159668	▁ metric _ ▁choice ▁read mission _ ▁metri cs
D-134	-1.0163874626159668	metric_ choice readmission_ metrics
P-134	-0.8295 -0.1908 -2.0502 -3.4787 -1.9132 -0.3042 -0.6191 -1.0143 -0.5601 -0.1232 -0.0970
S-261	This may be one mechanism how ET exerts beneficial effects in CHF.<unk>
T-261	chf
H-261	-2.2140932083129883	
D-261	-2.2140932083129883	
P-261	-4.2373 -0.1909
S-145	Careful consideration should be placed on readmission metric choice for these applications.<unk>
T-145	readmission
H-145	-0.6769234538078308	▁read mission ▁ metric
D-145	-0.6769234538078308	readmission metric
P-145	-1.2925 -0.1683 -1.8422 -0.0327 -0.6235 -0.1023
S-1726	We examined physician volume within strata of hospital volume and physician specialty.<unk>
T-1726	physician hospital physician
H-1726	-1.1026993989944458	▁physician _ ▁volume ▁hospital ▁physician _ special ty
D-1726	-1.1026993989944458	physician_ volume hospital physician_specialty
P-1726	-0.5758 -2.0342 -1.7348 -1.0519 -2.9428 -0.5478 -0.4203 -0.9789 -0.5525 -0.1880
S-1839	LIMITATION: Residual confounding and short follow-up.<unk>
T-1839	follow-up
H-1839	-1.02901029586792	▁Res idu al ▁con found ing
D-1839	-1.02901029586792	Residual confounding
P-1839	-5.0317 -0.4025 -0.1542 -1.4711 -0.1853 -0.0745 -0.8156 -0.0973
S-1758	Median follow-up was 3.01 (1.39-4.98) years.<unk>
T-1758	follow-up
H-1758	-0.5457367300987244	▁Media n _ ▁follow - up
D-1758	-0.5457367300987244	Median_ follow-up
P-1758	-0.4723 -0.2373 -1.7123 -1.2679 -0.1719 -0.0085 -0.3708 -0.1249
S-1238	Arrhythmia-related costs accounted for 45% of total expenditures.<unk>
T-1238	costs expenditures
H-1238	-0.8133829236030579	▁Ar rhythm ia - related ▁costs
D-1238	-0.8133829236030579	Arrhythmia-related costs
P-1238	-0.6719 -0.2840 -1.2032 -0.5274 -0.6767 -2.3140 -0.6561 -0.1739
S-403	Medication regimen and sST2 values were obtained during 10 months.<unk>
T-403	medication sst2
H-403	-0.6383032202720642	▁Medica tion
D-403	-0.6383032202720642	Medication
P-403	-0.2795 -0.0378 -2.0274 -0.2085
S-481	The objective of this study was to test its reliability in stable HF.<unk>
T-481	stable_hf
H-481	-1.3531866073608398	
D-481	-1.3531866073608398	
P-481	-2.6476 -0.0588
S-159	No beneficial effect on mortality was observed with STS HM.<unk>
T-159	mortality sts
H-159	-1.487131953239441	▁s ts _ HM
D-159	-1.487131953239441	sts_HM
P-159	-4.9634 -1.0264 -1.3794 -1.1546 -0.1913 -0.2076
S-150	STUDY DESIGN: Systematic review and network meta-analysis.<unk>
T-150	meta-analysis
H-150	-0.992181122303009	▁réseau _ meta - analys is
D-150	-0.992181122303009	réseau_meta-analysis
P-150	-3.3592 -1.5503 -2.1856 -0.5024 -0.0447 -0.0485 -0.1645 -0.0824
S-598	Surgical tactics included a brief hypothermic circulatory arrest.<unk>
T-598	surgical hypothermic_circulatory_arrest
H-598	-0.9400827884674072	▁sur g ical _ ▁tac tiques ▁circula tory _ ▁arrest
D-598	-0.9400827884674072	surgical_ tactiques circulatory_ arrest
P-598	-0.7195 -0.3037 -0.7700 -1.0171 -2.4572 -1.0809 -2.5081 -1.1532 -0.5154 -0.4293 -0.1786 -0.1481
S-616	Primary outcomes were improvements in functional capacity and quality of life.<unk>
T-616	primary_outcomes functional_capacity quality_of_life
H-616	-1.5439168214797974	
D-616	-1.5439168214797974	
P-616	-3.0182 -0.0696
S-64	We meta-analyzed mortality using random-effects models.<unk>
T-64	meta-analyzed mortality random-effects_models
H-64	-0.6359212398529053	▁mortal ity
D-64	-0.6359212398529053	mortality
P-64	-0.9200 -0.3028 -1.1382 -0.1826
S-194	Ejection fraction and sex were independently associated with BNP.<unk>
T-194	ejection_fraction bnp
H-194	-0.4652881324291229	▁e je ction _ fraction ▁b NP
D-194	-0.4652881324291229	ejection_fraction bNP
P-194	-1.4988 -0.6294 -0.0038 -0.5339 -0.0577 -0.4588 -0.4783 -0.2863 -0.2407
S-1009	Over a mean follow-up of 2.4 years, 63 patients died.<unk>
T-1009	follow-up patients
H-1009	-0.5955257415771484	
D-1009	-0.5955257415771484	
P-1009	-1.1389 -0.0521
S-1796	Chronic HF is the cause of death in 6.3% of cases.<unk>
T-1796	chronic_hf death
H-1796	-0.5490521788597107	▁Chro nic ▁ HF
D-1796	-0.5490521788597107	Chronic HF
P-1796	-0.3765 -0.1605 -1.8014 -0.0371 -0.7070 -0.2118
S-352	The etiology of the MR and MS was diagnosed as functional.<unk>
T-352	etiology diagnosed
H-352	-0.46433043479919434	▁MR ▁MS
D-352	-0.46433043479919434	MR MS
P-352	-0.9354 -0.5802 -0.2596 -0.0821
S-787	Among 849 patients, 200 (24%) had HFpEF.<unk>
T-787	patients hfpef
H-787	-1.0890238285064697	▁h p EF
D-787	-1.0890238285064697	hpEF
P-787	-3.4315 -0.0866 -1.5888 -0.1815 -0.1567
S-997	Cardiac amyloidosis, about an atypical case.<unk>
T-997	cardiac_amyloidosis
H-997	-0.34884288907051086	▁Card iac _ a my lo idos is
D-997	-0.34884288907051086	Cardiac_amyloidosis
P-997	-0.0729 -0.0165 -0.2402 -0.9170 -0.5492 -0.6590 -0.2948 -0.2980 -0.4059 -0.0350
S-507	Pigs were given antiarrhythmic medication to prevent sudden death.<unk>
T-507	antiarrhythmic medication death
H-507	-0.7502555847167969	▁Pig s ▁anti ar rhythm ic ▁medication
D-507	-0.7502555847167969	Pigs antiarrhythmic medication
P-507	-1.1515 -0.2322 -0.6493 -1.3048 -0.1416 -1.1101 -0.7002 -1.1755 -0.2871
S-1911	Robot-assisted training for heart failure patients - a small pilot study.<unk>
T-1911	training heart_failure patients
H-1911	-1.1393859386444092	▁Robot - assist ed _ training ▁heart _ ▁failure
D-1911	-1.1393859386444092	Robot-assisted_training heart_ failure
P-1911	-0.7153 -0.3402 -0.0011 -0.2164 -1.8771 -2.5387 -2.4849 -0.3025 -2.9156 -0.9024 -0.2390
S-550	Of the 6 patients, 5 experienced significant improvement in functional capacity and symptoms.<unk>
T-550	patients functional_capacity symptoms
H-550	-1.117669701576233	
D-550	-1.117669701576233	
P-550	-2.1554 -0.0799
S-219	Of the CHF patients, 778 (2.4%) were intubated.<unk>
T-219	chf patients intubated
H-219	-0.7926806807518005	▁CHF
D-219	-0.7926806807518005	CHF
P-219	-0.0395 -2.2131 -0.1254
S-266	The end point was survival from the time of inclusion through 4 years.<unk>
T-266	end_point
H-266	-0.8434234857559204	
D-266	-0.8434234857559204	
P-266	-1.6136 -0.0732
S-424	Heart rate was unchanged, and arterial pressure declined modestly.<unk>
T-424	heart_rate arterial_pressure
H-424	-0.9152499437332153	▁Heart ▁rate ▁arterial _ tension
D-424	-0.9152499437332153	Heart rate arterial_tension
P-424	-0.2621 -3.9949 -0.2335 -0.9548 -0.6764 -0.1589 -0.1261
S-1736	Very few of these patients were on standard therapy with beta blockade.<unk>
T-1736	patients therapy beta_blockade
H-1736	-1.3486453294754028	▁ therapy ▁beta _ block ade
D-1736	-1.3486453294754028	therapy beta_blockade
P-1736	-3.6825 -0.1835 -3.1939 -1.7493 -1.0534 -0.7305 -0.1226 -0.0736
S-840	Hgb level was not significantly correlated with baseline HRQoL.<unk>
T-840	hgb correlated baseline hrqol
H-840	-0.49344077706336975	▁h gb ▁h gb ▁base line ▁HR Qo L
D-840	-0.49344077706336975	hgb hgb baseline HRQoL
P-840	-0.0512 -0.0151 -1.2196 -0.2688 -1.2168 -0.2164 -1.5498 -0.0306 -0.6149 -0.1496 -0.0951
S-1914	Patients underwent testing of cardiac and inflammatory biomarkers.<unk>
T-1914	patients cardiac inflammatory biomarkers
H-1914	-1.003509521484375	▁cardiac _ ▁and _ ▁infla mma tory ▁bio mark ers
D-1914	-1.003509521484375	cardiac_ and_ inflammatory biomarkers
P-1914	-0.1675 -2.4238 -5.3677 -1.4429 -0.3260 -0.3419 -0.5150 -0.9745 -0.0034 -0.0999 -0.2157 -0.1638
S-1069	Most data have been collected in patients with systolic dysfunction.<unk>
T-1069	collected patients systolic_dysfunction
H-1069	-1.6472023725509644	▁sy sto lique _ ▁dys function
D-1069	-1.6472023725509644	systolique_ dysfunction
P-1069	-4.6724 -1.1672 -4.5848 -0.7884 -0.3240 -1.2864 -0.2886 -0.0658
S-1464	A preserved ejection fraction outcomes trial is beginning.<unk>
T-1464	preserved_ejection_fraction outcomes
H-1464	-1.0447092056274414	▁pres er ved ▁e je ction fraction
D-1464	-1.0447092056274414	preserved ejectionfraction
P-1464	-1.3346 -0.1587 -2.7037 -0.6197 -1.2179 -0.0329 -1.7898 -1.2241 -0.3210
S-1797	Decompensated HF is the main cause of cardiovascular hospitalization.<unk>
T-1797	decompensated_hf cardiovascular hospitalization
H-1797	-1.3007043600082397	▁ HF ▁cardiovascular ▁hospital ization
D-1797	-1.3007043600082397	HF cardiovascular hospitalization
P-1797	-1.9708 -0.2471 -2.0345 -3.6498 -0.9050 -0.1676 -0.1301
S-1471	Therapeutic implications of biomarkers in chronic heart failure.<unk>
T-1471	therapeutic biomarkers chronic_heart_failure
H-1471	-0.8176302909851074	▁bio mark ers ▁chronic _ heart _ ▁failure
D-1471	-0.8176302909851074	biomarkers chronic_heart_ failure
P-1471	-0.5239 -0.0047 -0.0600 -2.3455 -0.6342 -1.4855 -0.6958 -2.2108 -0.1372 -0.0785
S-461	Do outcomes for patients with heart failure vary by emergency department volume?<unk>
T-461	outcomes patients heart_failure emergency_department
H-461	-2.085514545440674	▁heart _ ▁failure ▁emergency ▁department
D-461	-2.085514545440674	heart_ failure emergency department
P-461	-4.7954 -1.1597 -4.1745 -0.5735 -2.4207 -1.2782 -0.1966
S-1255	VO2max increased (~24%) but did not reach statistical significance.<unk>
T-1255	vo2max significance
H-1255	-0.3586941659450531	▁VO 2 max
D-1255	-0.3586941659450531	VO2max
P-1255	-0.7468 -0.1631 -0.0136 -0.7499 -0.1200
S-1204	An estimated 5.1 million Americans aged 20 years and older have heart failure.<unk>
T-1204	heart_failure
H-1204	-1.5429328680038452	
D-1204	-1.5429328680038452	
P-1204	-3.0030 -0.0828
S-799	MAIN OUTCOME MEASURE: Time to complete the TUG test.<unk>
T-799	outcome tug_test
H-799	-0.9291304349899292	▁m AIN ▁o UTC OME _ me as ure ▁TU G
D-799	-0.9291304349899292	mAIN oUTCOME_measure TUG
P-799	-0.8477 -0.1690 -3.2931 -0.0048 -0.1700 -1.1367 -0.4813 -0.4034 -1.7297 -0.5230 -2.8082 -0.4360 -0.0758
S-608	The HR was also not elevated in subjects with a history of HF.<unk>
T-608	elevated hf
H-608	-0.46216535568237305	▁HR ▁ HF
D-608	-0.46216535568237305	HR HF
P-608	-0.4243 -1.2730 -0.0664 -0.3983 -0.1489
S-70	Further research is needed to study other potential predictors, particularly biomarkers.<unk>
T-70	biomarkers
H-70	-0.3877789378166199	▁bio mark ers
D-70	-0.3877789378166199	biomarkers
P-70	-1.7620 -0.0072 -0.0391 -0.0744 -0.0561
S-394	Forty-one patients developed ESRD (1.3/1000 patient-years).<unk>
T-394	patients esrd
H-394	-1.0539603233337402	▁ES RD
D-394	-1.0539603233337402	ESRD
P-394	-3.5262 -0.0658 -0.3595 -0.2643
S-591	Previously documented prognostic factors were also confirmed in this cohort.<unk>
T-591	prognostic
H-591	-0.8284985423088074	
D-591	-0.8284985423088074	
P-591	-1.5500 -0.1070
S-603	METHODS: We used data from four different US healthcare programmes.<unk>
T-603	healthcare
H-603	-1.514209508895874	
D-603	-1.514209508895874	
P-603	-2.9877 -0.0407
S-1028	Appropriately designed clinical trials will be needed to confirm these potential benefits.<unk>
T-1028	clinical
H-1028	-0.4995281994342804	
D-1028	-0.4995281994342804	
P-1028	-0.9640 -0.0350
S-1197	Our review of this newly introduced drug is based on our experience in Japan.<unk>
T-1197	drug japan
H-1197	-0.9546567797660828	
D-1197	-0.9546567797660828	
P-1197	-1.8357 -0.0736
S-746	Abnormal cardiac T2* values determined changes in treatment in most subjects.<unk>
T-746	cardiac
H-746	-0.73188316822052	▁ab normal ▁cardiac
D-746	-0.73188316822052	abnormal cardiac
P-746	-1.3401 -0.0116 -0.3235 -1.8822 -0.1020
S-800	Three trials were performed on the same day and by the same assessors.<unk>
T-800	
H-800	-0.6000474691390991	
D-800	-0.6000474691390991	
P-800	-1.1315 -0.0686
S-1923	Results can only be considered as preliminary and need further validation in larger studies.<unk>
T-1923	
H-1923	-0.4642024636268616	
D-1923	-0.4642024636268616	
P-1923	-0.8638 -0.0646
S-1854	We will explore why some interventions may succeed in one setting and fail in another.<unk>
T-1854	
H-1854	-0.6452615857124329	
D-1854	-0.6452615857124329	
P-1854	-1.2198 -0.0707
S-1206	Determination of risk and associated treatment strategies is the subject of this brief review.<unk>
T-1206	
H-1206	-0.7622107863426208	▁risk
D-1206	-0.7622107863426208	risk
P-1206	-1.4846 -0.7396 -0.0624
S-1299	Heart failure with preserved left ventricular ejection fraction.<unk>
T-1299	heart_failure_with_preserved_left_ventricular_ejection_fraction
H-1299	-0.737457275390625	▁Heart _ ▁failure ▁vent ri cular ▁e je ction fraction
D-1299	-0.737457275390625	Heart_ failure ventricular ejectionfraction
P-1299	-0.0706 -1.2077 -2.6597 -1.2407 -0.1437 -0.1796 -0.9916 -0.5109 -0.2182 -1.2238 -0.2433 -0.1596
S-1919	The quality of life assessment indicated better well-being in all participants.<unk>
T-1919	quality_of_life
H-1919	-1.6136517524719238	▁quality _ of _ ▁life
D-1919	-1.6136517524719238	quality_of_ life
P-1919	-2.6296 -0.2529 -2.7071 -0.1254 -3.4291 -1.9609 -0.1905
S-785	Covariate adjustment was made using Cox proportional hazards models.<unk>
T-785	covariate_adjustment cox_proportional_hazards_models
H-785	-0.5155720114707947	▁co x ▁proportion al _ ▁hazard s
D-785	-0.5155720114707947	cox proportional_ hazards
P-785	-0.4089 -0.3111 -0.1219 -0.2860 -0.5247 -0.9884 -0.9398 -0.8990 -0.1602
S-1195	Tolvaptan is a vasopressin type 2 receptor antagonist.<unk>
T-1195	tolvaptan vasopressin_type_2_receptor_antagonist
H-1195	-0.386371374130249	▁Tol va p tan ▁vaso press in ▁receptor
D-1195	-0.386371374130249	Tolvaptan vasopressin receptor
P-1195	-0.2075 -0.0158 -0.4498 -0.1020 -0.0476 -0.1268 -1.1334 -0.0094 -1.6417 -0.1298
S-645	Epidemiology and treatment of chronic heart failure; use of bisoprolol.<unk>
T-645	epidemiology chronic_heart_failure bisoprolol
H-645	-1.110478162765503	▁Epidemi ology ▁chronic _ heart _ ▁failure ▁bis o pro lol
D-645	-1.110478162765503	Epidemiology chronic_heart_ failure bisoprolol
P-645	-3.8673 -0.9329 -4.1500 -0.7465 -1.6217 -0.7179 -1.6627 -0.2431 -0.1189 -0.0247 -0.0508 -0.2058 -0.0940
S-437	Effectiveness and safety of spironolactone for systolic heart failure.<unk>
T-437	spironolactone systolic_heart_failure
H-437	-1.070117712020874	▁spi rono lac tone ▁sy sto lic _ ▁heart _ ▁failure
D-437	-1.070117712020874	spironolactone systolic_ heart_ failure
P-437	-2.5044 -0.0520 -0.1569 -0.0815 -1.5406 -0.2438 -3.2432 -0.9269 -1.8668 -1.2006 -1.7956 -0.1953 -0.1039
S-1034	Heart failure (HF) is the leading cause of mortality in modern society.<unk>
T-1034	heart_failure hf leading mortality society
H-1034	-1.190467119216919	▁Heart _ ▁failure ▁ HF ▁mortal ity
D-1034	-1.190467119216919	Heart_ failure HF mortality
P-1034	-0.4753 -0.2149 -2.8403 -3.0538 -0.0358 -3.0304 -0.1856 -0.6921 -0.1859
S-339	Functional MS has not been reported in patients with degenerative MR.<unk>
T-339	functional_ms reported patients degenerative_mr
H-339	-0.2871291935443878	▁Fun ction al ▁MS ▁de genera tive ▁MR
D-339	-0.2871291935443878	Functional MS degenerative MR
P-339	-0.6658 -0.0003 -0.0331 -0.1400 -1.4595 -0.2209 -0.0311 -0.0480 -0.2057 -0.0670
S-989	Key role of ERK1/2 molecular scaffolds in heart pathology.<unk>
T-989	molecular_scaffolds heart pathology
H-989	-0.929914116859436	▁e RK ▁molecular _ ▁sc af fold s ▁heart _ path ologie
D-989	-0.929914116859436	eRK molecular_ scaffolds heart_pathologie
P-989	-2.2880 -0.0148 -2.0834 -1.6614 -1.5288 -1.7416 -0.8078 -0.0898 -0.1920 -0.4290 -0.3578 -1.3997 -0.2788 -0.1459
S-1067	Devices have become a cornerstone of heart failure (HF) therapy.<unk>
T-1067	heart_failure hf therapy
H-1067	-1.7097431421279907	▁heart _ ▁failure HF ▁ therapy
D-1067	-1.7097431421279907	heart_ failureHF therapy
P-1067	-6.0322 -0.5527 -4.4654 -0.8739 -1.1691 -0.0466 -0.3440 -0.1940
S-581	LVET was measured from the reconstructed aortic pressure curve.<unk>
T-581	lvet aortic_pressure
H-581	-1.166680097579956	▁a or tic _ tension _ ▁cur ve
D-581	-1.166680097579956	aortic_tension_ curve
P-581	-2.7608 -0.4196 -2.3870 -0.2307 -2.9205 -1.2989 -1.0465 -0.0775 -0.1442 -0.3812
S-983	Cardiac symptoms in children are usually the result of congenital lesions.<unk>
T-983	cardiac symptoms congenital lesions
H-983	-0.7196833491325378	▁Card iac
D-983	-0.7196833491325378	Cardiac
P-983	-0.3358 -0.1847 -2.1835 -0.1748
S-1651	Nights spent in hospital will be counted as a coprimary outcome.<unk>
T-1651	hospital coprimary_outcome
H-1651	-1.0517699718475342	▁Night s ▁hospital ▁co prima ry ▁outcome
D-1651	-1.0517699718475342	Nights hospital coprimary outcome
P-1651	-0.6543 -0.0716 -5.1878 -0.4285 -0.0002 -0.8753 -1.8598 -0.1508 -0.2377
S-669	Trastuzumab-related cardiotoxicity among older patients with breast cancer.<unk>
T-669	cardiotoxicity patients breast_cancer
H-669	-0.5341745615005493	▁Tras tuz um ab - related _ ▁cardio toxic ity ▁breast ▁cancer
D-669	-0.5341745615005493	Trastuzumab-related_ cardiotoxicity breast cancer
P-669	-0.9658 -0.0055 -0.0570 -0.4940 -0.3030 -0.6958 -0.8994 -0.2111 -0.9491 -0.7669 -0.5086 -1.2105 -0.3112 -0.1007
S-1606	OBJECTIVES: Heart failure is a major public health problem worldwide.<unk>
T-1606	heart_failure public health
H-1606	-1.5767015218734741	▁Heart _ ▁failure ▁public _ ▁health
D-1606	-1.5767015218734741	Heart_ failure public_ health
P-1606	-1.4735 -0.6407 -5.4044 -0.3871 -0.2318 -1.9371 -2.3957 -0.1433
S-1414	We explored whether physician continuity further influences outcomes after discharge.<unk>
T-1414	physician outcomes discharge
H-1414	-0.7526176571846008	▁physician _ continu ity ▁dis charge
D-1414	-0.7526176571846008	physician_continuity discharge
P-1414	-0.0735 -0.8998 -0.7038 -0.5941 -3.3744 -0.0085 -0.2041 -0.1627
S-539	Postoperative normalization of albumin level is associated with improved survival.<unk>
T-539	postoperative albumin
H-539	-1.0171689987182617	▁Post operativ e _ ▁normal ization ▁album in
D-539	-1.0171689987182617	Postoperative_ normalization albumin
P-539	-3.2323 -0.0348 -0.5309 -1.6053 -1.0393 -0.8512 -0.7146 -0.7578 -1.2840 -0.1215
S-1276	In addition to prognosis, the pathophysiological origin is also discussed.<unk>
T-1276	prognosis pathophysiological
H-1276	-0.777906596660614	▁pat ho phy si ological
D-1276	-0.777906596660614	pathophysiological
P-1276	-3.1929 -0.2950 -0.0789 -0.1799 -0.4336 -1.2095 -0.0555
S-545	METHODS: From 2005 to 2011, 271 patients underwent LVAD implantation.<unk>
T-545	patients lvad implantation
H-545	-0.5251778960227966	▁implant ation
D-545	-0.5251778960227966	implantation
P-545	-1.5663 -0.0465 -0.4027 -0.0852
S-1821	Overall management of patients with heart failure requires the collaboration of professionals from multiple disciplines.<unk>
T-1821	patients heart_failure
H-1821	-1.8628692626953125	▁patients _ con tre _ la _ heart _ ▁failure
D-1821	-1.8628692626953125	patients_contre_la_heart_ failure
P-1821	-2.8179 -0.7013 -3.3762 -1.9940 -1.0606 -5.0198 -0.2434 -3.2514 -0.7031 -2.5985 -0.5086 -0.0797
S-1792	LA countries have reduced gross income and lower total expenditure on health per capita.<unk>
T-1792	income expenditure health
H-1792	-2.0931155681610107	▁gross _ ▁income ▁health ▁per ▁capita
D-1792	-2.0931155681610107	gross_ income health per capita
P-1792	-5.8413 -1.7858 -0.6550 -4.6435 -2.2937 -0.0576 -1.1226 -0.3455
S-1908	The AHA and the ESC advocate pre-participation screening of young athletes.<unk>
T-1908	aha esc
H-1908	-0.8413645029067993	▁ AHA ▁ESC
D-1908	-0.8413645029067993	AHA ESC
P-1908	-0.7670 -0.0208 -0.7048 -2.5211 -0.1931
S-709	There is a paucity of data examining long-term outcomes with this strategy.<unk>
T-709	paucity outcomes
H-709	-1.1862906217575073	
D-709	-1.1862906217575073	
P-709	-2.2824 -0.0902
S-1732	Our findings suggest that clinician expertise may play an important role in HF care.<unk>
T-1732	clinician hf
H-1732	-0.7183719277381897	▁clinic ian ▁expertise ▁ HF
D-1732	-0.7183719277381897	clinician expertise HF
P-1732	-1.7283 -0.8136 -1.0966 -0.1946 -0.0753 -1.0489 -0.0713
S-1072	In addition, stand-alone diagnostic devices are now also being developed for HF.<unk>
T-1072	diagnostic hf
H-1072	-0.892104983329773	▁stand - a lone _ Diagnos ▁devices ▁ HF
D-1072	-0.892104983329773	stand-alone_Diagnos devices HF
P-1072	-2.9780 -0.1493 -0.1390 -0.0170 -0.5030 -2.4711 -2.9856 -0.3127 -0.0846 -0.0818 -0.0910
S-1848	We will assess the impact of the intervention on adherence to the CPGs.<unk>
T-1848	cpgs
H-1848	-0.9267902374267578	▁c PG s
D-1848	-0.9267902374267578	cPGs
P-1848	-2.5146 -1.4434 -0.2114 -0.1822 -0.2824
S-75	Enrollment occurred from September 2010 to March 2013 across 26 sites in North America.<unk>
T-75	north_america
H-75	-0.7397881150245667	▁en roll ment
D-75	-0.7397881150245667	enrollment
P-75	-1.7446 -0.0027 -0.0612 -1.7765 -0.1140
S-1824	Hence, progress has yet to be made regarding appropriate referrals and patient circulation.<unk>
T-1824	patient circulation
H-1824	-1.095190405845642	
D-1824	-1.095190405845642	
P-1824	-2.0900 -0.1004
S-1965	Despite that, no major development has occurred in the therapy in recent years.<unk>
T-1965	therapy
H-1965	-0.4746226668357849	▁ therapy
D-1965	-0.4746226668357849	therapy
P-1965	-1.4367 -0.3031 -0.1018 -0.0569
S-1576	DESIGN: Prospective, non-randomized, two-center pilot project.<unk>
T-1576	prospective
H-1576	-0.9842683672904968	
D-1576	-0.9842683672904968	
P-1576	-1.8439 -0.1246
S-1881	RESULTS: There were no significant difference between two groups patients (P > 0.05).<unk>
T-1881	patients
H-1881	-0.43954724073410034	
D-1881	-0.43954724073410034	
P-1881	-0.8330 -0.0461
S-372	At this point, insignificant MS can be considered as not indicative for surgery.<unk>
T-372	surgery
H-372	-0.7306528687477112	▁ms
D-372	-0.7306528687477112	ms
P-372	-1.3301 -0.7928 -0.0690
S-675	Analyses included descriptive statistics and Cox proportional hazards models.<unk>
T-675	descriptive_statistics cox_proportional_hazards_models
H-675	-0.5935036540031433	▁co x ▁proportion al _ ▁hazard s
D-675	-0.5935036540031433	cox proportional_ hazards
P-675	-0.6410 -0.0043 -0.4101 -0.1534 -0.4387 -1.0903 -1.1616 -1.2152 -0.2268
S-913	Certain dialysis patients demonstrated compelling improvement after device implantation.<unk>
T-913	dialysis patients implantation
H-913	-0.15680073201656342	▁di al ysis ▁implant ation
D-913	-0.15680073201656342	dialysis implantation
P-913	-0.0939 -0.1564 -0.0630 -0.3876 -0.0371 -0.2520 -0.1075
S-1503	Psychometric testing of the Self-Care of Heart Failure Index Version 6.2.<unk>
T-1503	psychometric self-care_of_heart_failure_index_version_6.2
H-1503	-0.7509150505065918	▁psycho metric _ ▁testing ▁Self - Car e _ de _ ▁Heart _ ▁Fail ure
D-1503	-0.7509150505065918	psychometric_ testing Self-Care_de_ Heart_ Failure
P-1503	-1.3964 -0.0314 -2.7586 -1.3239 -1.3094 -0.0335 -0.6620 -0.0561 -0.1800 -2.0559 -0.0966 -0.2000 -0.4169 -0.1387 -0.1405 -1.6813 -0.2842
S-1537	The risk of heart failure was estimated by Cox proportional hazard analyses.<unk>
T-1537	heart_failure cox_proportional_hazard_analyses
H-1537	-1.2457743883132935	▁co x ▁proportion al _ ▁hazard
D-1537	-1.2457743883132935	cox proportional_ hazard
P-1537	-4.9100 -0.0045 -2.0204 -0.0604 -0.6104 -0.6670 -1.2269 -0.4666
S-253	Endothelial function was assessed by flow-mediated dilatation.<unk>
T-253	endothelial_function flow-mediated_dilatation
H-253	-0.7238266468048096	▁en dot heli al _ f ré que nce ▁flow - media ted ▁di la tation
D-253	-0.7238266468048096	endothelial_fréquence flow-mediated dilatation
P-253	-0.7038 -0.3906 -0.0848 -0.0174 -2.0340 -1.9161 -0.3242 -0.8900 -0.0712 -1.7324 -0.0748 -0.0513 -2.8585 -1.1203 -0.3080 -0.0116 -0.2880 -0.1519
S-975	In total, 17% of patients developed acute kidney injury postoperatively.<unk>
T-975	patients acute_kidney_injury postoperatively
H-975	-0.8617154359817505	▁a cute _ ▁ki dne y ▁injury
D-975	-0.8617154359817505	acute_ kidney injury
P-975	-1.1499 -0.0088 -0.4738 -3.1054 -0.9844 -0.1600 -1.0757 -0.6931 -0.1043
S-1465	Pharmacological treatment of acute heart failure: current treatment and new targets.<unk>
T-1465	pharmacological acute_heart_failure
H-1465	-1.2882639169692993	▁Pharma c ological ▁treatment ▁a cute _ heart _ ▁failure
D-1465	-1.2882639169692993	Pharmacological treatment acute_heart_ failure
P-1465	-3.6742 -0.0083 -0.5276 -4.7834 -0.7195 -0.0288 -0.1920 -2.2331 -0.7863 -2.0073 -0.3895 -0.1094
S-551	One patient died postoperatively secondary to multiorgan failure and sepsis.<unk>
T-551	patient postoperatively multiorgan_failure sepsis
H-551	-0.8882095217704773	▁multi organ _ ▁failure ▁se psis
D-551	-0.8882095217704773	multiorgan_ failure sepsis
P-551	-3.4034 -0.0038 -2.2753 -1.0718 -0.1073 -0.0014 -0.1067 -0.1361
S-567	Randomized trial of Nordic walking in patients with moderate to severe heart failure.<unk>
T-567	randomized walking patients severe_heart_failure
H-567	-2.3009274005889893	▁Nordic _ ▁walking
D-567	-2.3009274005889893	Nordic_ walking
P-567	-1.4891 -2.2269 -3.7740 -3.7654 -0.2493
S-1059	T1-mapping values were compared between the baseline and heart failure scans.<unk>
T-1059	t1-mapping baseline heart_failure
H-1059	-1.7387166023254395	
D-1059	-1.7387166023254395	
P-1059	-3.3490 -0.1284
S-2011	Survival projections are based on a modified Seattle Heart Failure Model.<unk>
T-2011	seattle_heart_failure_model
H-2011	-0.959078848361969	▁sur vi val ▁Seattle ▁Heart _ ▁Fail ure ▁Model
D-2011	-0.959078848361969	survival Seattle Heart_ Failure Model
P-2011	-2.2267 -0.0037 -0.5840 -3.2864 -1.4550 -1.3728 -0.0671 -0.0934 -1.1135 -0.2150 -0.1323
S-223	Hemodynamic phenotype of the failing Fontan in an adult population.<unk>
T-223	hemodynamic_phenotype fontan
H-223	-0.8184234499931335	▁Hem o dynamic _ ▁ph eno type ▁fail ing ▁Font an
D-223	-0.8184234499931335	Hemodynamic_ phenotype failing Fontan
P-223	-0.5757 -0.0289 -0.0242 -1.1038 -2.3233 -0.0541 -0.0429 -3.7372 -0.4233 -0.2915 -0.8797 -1.0751 -0.0799
S-358	In this patient there was no MS before the surgery by echocardiography.<unk>
T-358	patient surgery echocardiography
H-358	-0.49008795619010925	▁MS ▁surgery ▁e cho card i ography
D-358	-0.49008795619010925	MS surgery echocardiography
P-358	-0.2392 -1.6087 -0.9124 -0.1431 -0.2376 -0.8565 -0.2721 -0.1085 -0.0328
S-349	Coronary angiography revealed no significant lesions in the major branches.<unk>
T-349	coronary_angiography lesions
H-349	-0.8844751119613647	▁Corona ry _ ang i ography
D-349	-0.8844751119613647	Coronary_angiography
P-349	-0.0404 -0.5666 -0.6101 -0.6560 -4.1403 -0.2312 -0.7560 -0.0751
S-826	Univariate and multivariate analyses were used for factors predicting survival.<unk>
T-826	multivariate_analyses
H-826	-0.8419612646102905	
D-826	-0.8419612646102905	
P-826	-1.6033 -0.0806
S-1902	Individuals who exercise regularly extend their life expectancy by three to seven years.<unk>
T-1902	exercise life_expectancy
H-1902	-0.831546425819397	
D-1902	-0.831546425819397	
P-1902	-1.5851 -0.0780
S-772	Safe, effective off-pump sternal sparing approach for HeartMate II exchange.<unk>
T-772	sternal heartmate_ii
H-772	-0.7429759502410889	▁off - pump _ ster nal _ ▁spar ing ▁Heart Mate _ ▁II ▁exchange
D-772	-0.7429759502410889	off-pump_sternal_ sparing HeartMate_ II exchange
P-772	-0.2478 -0.0343 -0.0521 -3.1301 -2.2022 -0.0440 -0.3481 -0.2325 -0.0761 -1.5564 -0.4353 -1.9732 -0.9681 -0.2632 -0.1743 -0.1499
S-1263	Most adverse events observed in the studies were not severe and resolved without special treatment.<unk>
T-1263	adverse_events
H-1263	-0.6823577284812927	
D-1263	-0.6823577284812927	
P-1263	-1.3284 -0.0363
S-888	Furthermore, there was continuous relationship between QRS duration and extent of benefit.<unk>
T-888	qrs_duration
H-888	-0.9859399795532227	▁QR s
D-888	-0.9859399795532227	QRs
P-888	-0.7224 -1.9559 -1.0708 -0.1947
S-1640	There was no interaction between race and exercise training on outcomes (P > .5).<unk>
T-1640	exercise training outcomes
H-1640	-1.5208219289779663	
D-1640	-1.5208219289779663	
P-1640	-2.9704 -0.0713
S-1397	Using standardized nursing terminologies makes it possible to measure aspects of nursing care.<unk>
T-1397	nursing nursing
H-1397	-1.4473848342895508	▁nur sing
D-1397	-1.4473848342895508	nursing
P-1397	-2.5319 -0.7316 -2.3799 -0.1461
S-547	The patients were examined for new-onset severe AI requiring surgical intervention.<unk>
T-547	patients surgical
H-547	-1.584432601928711	▁implant ation
D-547	-1.584432601928711	implantation
P-547	-3.7897 -1.2004 -1.1383 -0.2095
S-1165	Over a median follow-up of 541 days, there were 150 events (37%).<unk>
T-1165	follow-up
H-1165	-0.8316433429718018	
D-1165	-0.8316433429718018	
P-1165	-1.6258 -0.0375
S-3	The analysis included a large study sample with more than 60,000 patients across 4372 hospitals.<unk>
T-3	patients hospitals
H-3	-0.7756041884422302	
D-3	-0.7756041884422302	
P-3	-1.4816 -0.0696
S-1006	The deficit index was defined as the proportion of deficits present out of 32 deficits.<unk>
T-1006	deficit_index
H-1006	-0.48384079337120056	▁deficit s
D-1006	-0.48384079337120056	deficits
P-1006	-0.1877 -1.2239 -0.3692 -0.1545
S-1696	We repeated this analysis using 2005-2008 performance on existing quality indicators, including mortality.<unk>
T-1696	mortality
H-1696	-1.2788742780685425	
D-1696	-1.2788742780685425	
P-1696	-2.4450 -0.1127
S-810	This study sought to examine the ability of GLS in predicting CV events in AF.<unk>
T-810	gls
H-810	-1.4281874895095825	▁g LS
D-810	-1.4281874895095825	gLS
P-810	-2.0267 -0.7535 -2.7981 -0.1344
S-370	According to the guideline, the MS at that time could be considered indicative for surgery.<unk>
T-370	surgery
H-370	-0.7541292309761047	▁MS
D-370	-0.7541292309761047	MS
P-370	-1.6404 -0.5509 -0.0711
S-1855	We will disseminate our findings through briefing reports, publications and presentations.<unk>
T-1855	
H-1855	-0.4981846213340759	
D-1855	-0.4981846213340759	
P-1855	-0.9362 -0.0602
S-1752	Prognostic value of indeterminable anaerobic threshold in heart failure.<unk>
T-1752	prognostic anaerobic_threshold heart_failure
H-1752	-1.2164589166641235	▁ana ero bic _ ▁thre s hold ▁heart _ ▁failure
D-1752	-1.2164589166641235	anaerobic_ threshold heart_ failure
P-1752	-3.0339 -1.3304 -1.1429 -2.3334 -0.8645 -0.1155 -0.4356 -0.8993 -0.8439 -3.3790 -0.1189 -0.1000
S-1486	Renin-angiotensin-aldosterone system inhibitors in heart failure.<unk>
T-1486	renin-angiotensin-aldosterone_system_inhibitors heart_failure
H-1486	-0.9520220160484314	▁re nin - angi oten sin - al do ster one
D-1486	-0.9520220160484314	renin-angiotensin-aldosterone
P-1486	-1.3873 -0.8102 -0.0744 -0.0352 -0.0845 -1.6555 -0.3192 -0.0811 -0.9355 -0.0341 -1.9659 -4.7888 -0.2045
S-1372	We hypothesized in CHF, unilateral renal DNx would improve cardiac autonomic balance.<unk>
T-1372	chf unilateral_renal_dnx cardiac autonomic_balance
H-1372	-0.6816959381103516	▁CHF ▁unilateral ▁renal ▁DN x ▁cardiac _ ▁autonomi c ▁balance
D-1372	-0.6816959381103516	CHF unilateral renal DNx cardiac_ autonomic balance
P-1372	-0.0477 -2.1605 -0.2066 -0.7136 -0.0203 -0.0827 -2.6599 -0.3725 -0.7669 -0.7882 -0.2416 -0.1197
S-1491	Skeletal muscle abnormalities and exercise capacity in adults with a Fontan circulation.<unk>
T-1491	skeletal_muscle exercise_capacity fontan_circulation
H-1491	-0.8579744100570679	▁s kelet al _ ▁muscle _ ▁ab normal ities ▁Font an _ ▁circulation
D-1491	-0.8579744100570679	skeletal_ muscle_ abnormalities Fontan_ circulation
P-1491	-3.3769 -0.0016 -0.0700 -0.8936 -0.6976 -0.5675 -0.1377 -0.0563 -1.0176 -4.0444 -0.6526 -0.8115 -0.1855 -0.2453 -0.1115
S-1014	Learning from recent trials and shaping the future of acute heart failure trials.<unk>
T-1014	acute_heart_failure
H-1014	-1.0931870937347412	▁a cute _ heart _ ▁failure
D-1014	-1.0931870937347412	acute_heart_ failure
P-1014	-1.4854 -0.0332 -0.3062 -3.1172 -0.6861 -2.3696 -0.6343 -0.1133
S-898	9/10 patients were Stage 3 chronic kidney disease (CKD) or worse.<unk>
T-898	patients chronic_kidney_disease ckd
H-898	-1.4475557804107666	▁chronic _ ▁ki dne y ▁disease CK D
D-898	-1.4475557804107666	chronic_ kidney diseaseCKD
P-898	-2.1436 -0.7213 -3.4061 -1.1949 -0.5249 -3.3048 -1.4024 -1.2243 -0.4113 -0.1418
S-362	Mitral regurgitation as well as HF symptoms disappeared after the surgery.<unk>
T-362	mitral_regurgitation hf symptoms surgery
H-362	-0.6038103699684143	▁Mit ral _ re gur gi tation ▁ HF
D-362	-0.6038103699684143	Mitral_regurgitation HF
P-362	-3.5845 -0.0100 -0.3760 -0.8458 -0.2419 -0.1466 -0.2099 -0.2716 -0.0350 -0.6787 -0.2419
S-1598	This progressive disease can lead to resistant hypertension and end stage kidney failure.<unk>
T-1598	disease lead hypertension kidney_failure
H-1598	-0.634284496307373	▁progressive ▁hyper tension ▁ki dne y _ ▁failure
D-1598	-0.634284496307373	progressive hypertension kidney_ failure
P-1598	-0.4782 -2.5919 -0.0010 -0.2642 -0.0799 -0.1342 -1.9770 -0.5484 -0.1622 -0.1058
S-1669	In this article, we describe current strategies for the treatment of end stage heart failure.<unk>
T-1669	end_stage_heart_failure
H-1669	-1.5848370790481567	
D-1669	-1.5848370790481567	
P-1669	-3.1350 -0.0346
S-147	CONTEXT: Readmission to hospital for heart failure is common after recent discharge.<unk>
T-147	readmission hospital heart_failure discharge
H-147	-1.150787353515625	▁hospital _ for _ heart _ ▁failure ▁dis charge
D-147	-1.150787353515625	hospital_for_heart_ failure discharge
P-147	-2.7006 -0.4951 -3.0784 -0.5862 -1.2371 -0.2973 -2.7051 -1.1554 -0.0109 -0.2843 -0.1083
S-1798	The prevalence of systolic HF varies from 64% to 69%.<unk>
T-1798	prevalence systolic_hf
H-1798	-1.2179254293441772	▁sy sto lic ▁ HF
D-1798	-1.2179254293441772	systolic HF
P-1798	-3.4701 -1.0340 -2.1647 -1.4847 -0.0410 -0.2099 -0.1211
S-143	Correlations among metrics were modest when measuring hospital longitudinal change.<unk>
T-143	correlations hospital longitudinal change
H-143	-0.952275812625885	
D-143	-0.952275812625885	
P-143	-1.8087 -0.0959
S-1580	MAIN OUTCOME MEASURE: 30-day all-cause readmissions.<unk>
T-1580	outcome all-cause_readmissions
H-1580	-1.2793818712234497	▁m AIN _ o UTC OME
D-1580	-1.2793818712234497	mAIN_oUTCOME
P-1580	-0.5609 -0.3786 -0.9070 -3.7517 -0.0129 -0.5308 -4.0081 -0.0851
S-1589	Abnormal HR variability predicts both sudden and non-sudden cardiac death.<unk>
T-1589	hr_variability cardiac_death
H-1589	-1.375418782234192	▁ab normal ▁HR _ ▁variabil ity ▁sud den ▁cardiac _ ▁death
D-1589	-1.375418782234192	abnormal HR_ variability sudden cardiac_ death
P-1589	-3.4095 -0.0200 -0.6506 -2.7810 -1.6072 -0.4094 -1.3739 -0.0102 -2.7441 -3.1910 -1.3034 -0.2042 -0.1758
S-1048	Importantly, no toxicity or effects on systemic blood pressure were observed.<unk>
T-1048	systemic_blood_pressure
H-1048	-1.082940697669983	▁ toxic ity
D-1048	-1.082940697669983	toxicity
P-1048	-0.1467 -0.1453 -0.4525 -4.4606 -0.2096
S-828	These groups were not significantly different in terms of medication and resting hemodynamics.<unk>
T-828	medication resting_hemodynamics
H-828	-0.6417272090911865	▁medication ▁rest ing _ hem o dynamic s
D-828	-0.6417272090911865	medication resting_hemodynamics
P-828	-1.2682 -1.7789 -0.2173 -0.2625 -2.2295 -0.2414 -0.0765 -0.0842 -0.2124 -0.0464
S-1720	Physician volume, specialty, and outcomes of care for patients with heart failure.<unk>
T-1720	physician outcomes patients heart_failure
H-1720	-1.417307734489441	▁Physic ian
D-1720	-1.417307734489441	Physician
P-1720	-0.9515 -0.4184 -3.9821 -0.3172
S-331	Lack of correlation of remaining indices may reflect postsystolic function.<unk>
T-331	correlation postsystolic_function
H-331	-1.700299620628357	▁indice s ▁posts y sto lic
D-331	-1.700299620628357	indices postsystolic
P-331	-4.7154 -0.2238 -0.4720 -0.5534 -2.2694 -3.8044 -1.4673 -0.0967
S-1782	Mice subjected to AAC demonstrated a progressive development of cardiac hypertrophy.<unk>
T-1782	aac cardiac_hypertrophy
H-1782	-0.954230010509491	▁a ac ▁cardiac _ ▁hyper trop hy
D-1782	-0.954230010509491	aac cardiac_ hypertrophy
P-1782	-0.8916 -1.8681 -1.9550 -2.4660 -0.8259 -0.0078 -0.1238 -0.2629 -0.1870
S-617	Secondary outcome measures related to patient satisfaction and sustainability of the intervention post study.<unk>
T-617	secondary_outcome patient post
H-617	-1.2476322650909424	▁patient _ ▁satisfaction
D-617	-1.2476322650909424	patient_ satisfaction
P-617	-2.1426 -1.6019 -0.5683 -1.7865 -0.1389
S-1582	This represented a net economic savings, even accounting for the added cost of the intervention.<unk>
T-1582	economic accounting cost
H-1582	-1.3535650968551636	▁économique s ▁coût
D-1582	-1.3535650968551636	économiques coût
P-1582	-1.2368 -2.6416 -2.1725 -0.6066 -0.1103
S-582	RESULTS: Overall ICU mortality (median stay, 5 days) was 17%.<unk>
T-582	icu mortality
H-582	-0.7516236901283264	▁ ICU _ ▁mortal ity
D-582	-0.7516236901283264	ICU_ mortality
P-582	-0.3389 -0.0319 -2.4583 -0.9320 -0.2586 -1.1010 -0.1406
S-2020	Nurses in all settings have an essential role in supporting patients in managing this disease.<unk>
T-2020	nurses patients disease
H-2020	-1.083170771598816	▁Nur ses ▁patients
D-2020	-1.083170771598816	Nurses patients
P-2020	-1.9031 -0.0263 -2.3087 -1.0920 -0.0857
S-905	We therefore studied our center's experience with CRT in dialysis-dependent patients.<unk>
T-905	crt patients
H-905	-0.6144111752510071	▁c RT ▁di al ysis - dependent ▁patients
D-905	-0.6144111752510071	cRT dialysis-dependent patients
P-905	-0.7185 -0.5121 -2.1106 -0.4280 -0.0685 -0.3191 -0.2777 -1.4314 -0.1828 -0.0956
S-217	The mean age of the CHF patients was 76 ± 14 years, and 57% were female.<unk>
T-217	chf patients
H-217	-0.6980608701705933	▁CHF
D-217	-0.6980608701705933	CHF
P-217	-0.8319 -1.2011 -0.0612
S-163	Where 'usual' care is less good, the impact of RM is likely to be greater.<unk>
T-163	rm
H-163	-1.8381307125091553	
D-163	-1.8381307125091553	
P-163	-3.5626 -0.1136
S-556	BACKGROUND: Few studies have focused on young and very young adults with HF.<unk>
T-556	hf
H-556	-0.7696701884269714	▁ HF
D-556	-0.7696701884269714	HF
P-556	-2.2477 -0.5051 -0.2840 -0.0418
S-529	Hypoalbuminemia has been recognized as a prognostic indicator in patients with heart failure.<unk>
T-529	hypoalbuminemia prognostic patients heart_failure
H-529	-0.8894473314285278	▁hypo album in emia
D-529	-0.8894473314285278	hypoalbuminemia
P-529	-1.5618 -0.3116 -0.5948 -0.1269 -2.5243 -0.2173
S-1461	First-in-class angiotensin receptor neprilysin inhibitor in heart failure.<unk>
T-1461	angiotensin_receptor_neprilysin_inhibitor heart_failure
H-1461	-0.900810956954956	▁ang io ten sin ▁receptor _ ▁nepri ly sin ▁inhibi tor ▁heart _ ▁failure
D-1461	-0.900810956954956	angiotensin receptor_ neprilysin inhibitor heart_ failure
P-1461	-0.2781 -1.7291 -0.2913 -1.1430 -0.5932 -1.6094 -0.8874 -0.2350 -1.0324 -1.8045 -0.0792 -0.3433 -0.6715 -3.5140 -0.1277 -0.0738
S-1079	Unfolded protein response regulates cardiac sodium current in systolic human heart failure.<unk>
T-1079	unfolded_protein_response cardiac_sodium systolic heart_failure
H-1079	-1.352190375328064	▁cardiac _ so dium _ ▁current ▁sy sto lic _ ▁human ▁heart _ ▁failure
D-1079	-1.352190375328064	cardiac_sodium_ current systolic_ human heart_ failure
P-1079	-5.2880 -1.2013 -0.1810 -0.0138 -0.4865 -1.7990 -1.7723 -0.0394 -2.0919 -1.0218 -2.5827 -0.9402 -0.8250 -2.8682 -0.2560 -0.2681
S-1566	Presence of diastolic dysfunction in patients with peripheral artery disease.<unk>
T-1566	diastolic_dysfunction patients peripheral_artery_disease
H-1566	-0.9280622005462646	▁dia sto lic ▁dys function ▁per i pher al ▁arter y _ ▁disease
D-1566	-0.9280622005462646	diastolic dysfunction peripheral artery_ disease
P-1566	-0.0481 -0.4563 -3.5147 -0.7299 -0.5606 -0.5658 -0.6571 -0.0441 -0.1951 -0.6024 -1.0400 -2.1602 -3.1064 -0.1665 -0.0738
S-1252	Western blot analysis, immunohistochemistry and electron microscopy were used.<unk>
T-1252	western_blot immunohistochemistry electron_microscopy
H-1252	-0.17425410449504852	▁immun oh isto che mist ry ▁electro n ▁micro s copy
D-1252	-0.17425410449504852	immunohistochemistry electron microscopy
P-1252	-0.4699 -0.0369 -0.3286 -0.0715 -0.2987 -0.1729 -0.0020 -0.0216 -0.2719 -0.2463 -0.1351 -0.1137 -0.0962
S-1741	However, limited evidence is available specifically on idiopathic dilated cardiomyopathy.<unk>
T-1741	evidence idiopathic_dilated_cardiomyopathy
H-1741	-0.43555405735969543	▁ idio pathi c ▁dil ated _ ▁cardio my o pathy
D-1741	-0.43555405735969543	idiopathic dilated_ cardiomyopathy
P-1741	-0.6471 -0.0174 -0.0130 -0.1130 -0.6263 -0.7024 -0.7538 -0.0737 -2.0862 -0.4070 -0.0213 -0.1415 -0.0593
S-67	Ischemic cardiomyopathy and male sex were not independent predictors of mortality.<unk>
T-67	ischemic_cardiomyopathy mortality
H-67	-0.5525228381156921	▁i sche mic _ ▁cardio my o pathy ▁male ▁sex ▁mortal ity
D-67	-0.5525228381156921	ischemic_ cardiomyopathy male sex mortality
P-67	-1.5786 -0.0029 -0.1769 -0.7508 -0.0966 -0.9657 -0.3935 -0.0181 -1.0025 -1.5612 -0.7292 -0.2133 -0.1005 -0.1455
S-350	The patient was diagnosed as hypertensive LV dysfunction with mild MR and significant MS.<unk>
T-350	patient diagnosed hypertensive_lv_dysfunction
H-350	-0.28078749775886536	▁hyper tensi ve ▁LV ▁dys function ▁MR ▁MS
D-350	-0.28078749775886536	hypertensive LV dysfunction MR MS
P-350	-0.0797 -0.2701 -0.1577 -0.4066 -0.2855 -0.2602 -0.7443 -0.4435 -0.0839 -0.0763
S-1036	At the molecular level, HF has been associated with chromatin hyperacetylation.<unk>
T-1036	hf chromatin_hyperacetylation
H-1036	-1.1009854078292847	▁ HF ▁chr omat in _ ▁hyper ace ti lation
D-1036	-1.1009854078292847	HF chromatin_ hyperacetilation
P-1036	-1.4904 -0.0716 -0.2926 -0.0513 -2.1711 -0.9266 -0.4166 -1.8020 -5.7390 -0.0126 -0.1638 -0.0742
S-1724	We divided physicians into quintiles according to their volume of patients with HF.<unk>
T-1724	physicians patients hf
H-1724	-0.8777744770050049	▁physician s ▁ HF
D-1724	-0.8777744770050049	physicians HF
P-1724	-2.0658 -0.0695 -2.6676 -0.1412 -0.2450 -0.0775
S-1701	Race influences the safety and efficacy of spironolactone in severe heart failure.<unk>
T-1701	spironolactone severe_heart_failure
H-1701	-1.2818108797073364	▁Race ▁ef fica cy ▁spi rono lac tone
D-1701	-1.2818108797073364	Race efficacy spironolactone
P-1701	-2.0612 -5.1684 -0.0033 -0.7615 -0.3354 -0.0818 -0.4225 -0.4689 -3.3136 -0.2016
S-1644	Conceptually, maintenance of sinus rhythm could prevent adverse outcomes related to AF.<unk>
T-1644	sinus_rhythm adverse_outcomes
H-1644	-0.7100418210029602	▁sinus ▁ rhythm ▁AF
D-1644	-0.7100418210029602	sinus rhythm AF
P-1644	-2.1572 -0.6564 -0.0913 -1.1724 -0.0911 -0.0917
S-875	This included significant amelioration of all the ingenuity pathway analysis noted above.<unk>
T-875	ingenuity_pathway_analysis
H-875	-0.6703133583068848	▁ingen u ity
D-875	-0.6703133583068848	ingenuity
P-875	-0.5464 -0.3515 -0.4380 -1.8510 -0.1647
S-568	BACKGROUND: Patients with heart failure are a growing population within cardiac rehabilitation.<unk>
T-568	patients heart_failure cardiac_rehabilitation
H-568	-1.3250949382781982	▁heart _ ▁failure ▁cardiac ▁rehabilita tion
D-568	-1.3250949382781982	heart_ failure cardiac rehabilitation
P-568	-3.7380 -0.6667 -3.7916 -0.6543 -1.4097 -0.0407 -0.2311 -0.0686
S-1795	The prognosis of C'D HF is worse than for other etiologies.<unk>
T-1795	prognosis hf etiologies
H-1795	-0.6893368363380432	▁c d ▁ HF
D-1795	-0.6893368363380432	cd HF
P-1795	-2.1590 -0.5047 -0.5681 -0.0854 -0.6961 -0.1226
S-1137	Myocardial infarction was elicited in adult male Wistar rats.<unk>
T-1137	myocardial_infarction
H-1137	-0.6637037992477417	▁My o card ial ▁in far ction ▁Wi star ▁rat s
D-1137	-0.6637037992477417	Myocardial infarction Wistar rats
P-1137	-0.1616 -0.0734 -0.0707 -0.1065 -0.2384 -2.0648 -0.0298 -3.8515 -1.2884 -0.3934 -0.0286 -0.1605 -0.1607
S-490	E/e'septal showed good diagnostic performance for detecting normal filling pressures.<unk>
T-490	septal diagnostic filling_pressures
H-490	-1.8724902868270874	
D-490	-1.8724902868270874	
P-490	-3.5944 -0.1506
S-39	Background: The benefits of anemia treatment in patients with heart disease are uncertain.<unk>
T-39	anemia patients heart_disease
H-39	-1.5280448198318481	▁an emia
D-39	-1.5280448198318481	anemia
P-39	-1.1251 -0.2131 -4.6510 -0.1229
S-468	Interventions to improve management of acute heart failure are required at low-volume sites.<unk>
T-468	acute_heart_failure
H-468	-1.109808087348938	▁a cute _ heart _ ▁failure
D-468	-1.109808087348938	acute_heart_ failure
P-468	-1.3569 -0.0437 -0.2426 -3.2977 -0.7728 -2.3987 -0.5700 -0.1961
S-1689	BACKGROUND: Public reporting on quality aims to help patients select better hospitals.<unk>
T-1689	public_reporting patients hospitals
H-1689	-1.8340198993682861	▁public ▁report ing
D-1689	-1.8340198993682861	public reporting
P-1689	-2.7684 -2.6820 -0.1471 -3.4548 -0.1179
S-1617	Effects of care management and telehealth: a longitudinal analysis using medicare data.<unk>
T-1617	telehealth longitudinal medicare
H-1617	-1.229985237121582	▁care _ management ▁tele health ▁medica re
D-1617	-1.229985237121582	care_management telehealth medicare
P-1617	-4.3759 -1.1467 -0.5227 -3.4016 -0.6526 -0.1130 -0.0066 -0.7399 -0.1110
S-299	Preoperative demographics, operative outcomes, and survival were analyzed.<unk>
T-299	preoperative operative outcomes
H-299	-0.771259605884552	
D-299	-0.771259605884552	
P-299	-1.4855 -0.0570
S-543	Treatment algorithms for de novo, post-LVAD AI have not been well defined.<unk>
T-543	post-lvad_ai
H-543	-1.190897822380066	▁algorithm s ▁post - L VAD ▁AI
D-543	-1.190897822380066	algorithms post-LVAD AI
P-543	-4.1088 -0.0790 -1.5391 -0.0062 -2.7968 -0.0910 -1.8198 -0.1461 -0.1312
S-1829	DESIGN: Population-based, retrospective, new-user cohort study.<unk>
T-1829	cohort_study
H-1829	-1.3685698509216309	▁Popula tion - based
D-1829	-1.3685698509216309	Population-based
P-1829	-4.2831 -0.0309 -0.3339 -0.6266 -2.8713 -0.0656
S-1232	Rhythm- and rate-control strategies are associated with similar efficacy outcomes.<unk>
T-1232	rate-control outcomes
H-1232	-1.1131601333618164	▁ Rhythm - ▁and ▁rate - control
D-1232	-1.1131601333618164	Rhythm- and rate-control
P-1232	-0.2726 -0.0509 -0.1161 -5.8524 -1.8793 -0.0750 -0.0215 -1.5413 -0.2095
S-1711	OBJECTIVES: To analyze the relationship between length of stay and rehospitalization.<unk>
T-1711	rehospitalization
H-1711	-1.189076542854309	
D-1711	-1.189076542854309	
P-1711	-2.3152 -0.0630
S-872	We found that 538 proteins significantly changed after TAC, which mapped to 53 pathways.<unk>
T-872	proteins tac
H-872	-1.3861021995544434	▁ TAC
D-872	-1.3861021995544434	TAC
P-872	-1.7964 -2.5991 -0.9684 -0.1805
S-361	However, the degree of MS early after surgery was not significant, with an MVA of 1.8 cm2.<unk>
T-361	surgery mva
H-361	-0.6216441988945007	▁MS ▁m va
D-361	-0.6216441988945007	MS mva
P-361	-0.8758 -0.8569 -0.6392 -0.6656 -0.0708
S-1769	Participants were divided into age-specific low, moderate, and high CRF categories.<unk>
T-1769	crf
H-1769	-0.5170444846153259	▁c RF
D-1769	-0.5170444846153259	cRF
P-1769	-1.4383 -0.2579 -0.3245 -0.0475
S-688	Mediterranean and DASH diet scores were calculated from food-frequency questionnaires.<unk>
T-688	dash
H-688	-0.7754198908805847	▁Mediterrane an ▁DAS h
D-688	-0.7754198908805847	Mediterranean DASh
P-688	-0.9121 -0.0238 -0.0862 -0.5207 -2.9009 -0.2088
S-1931	CONCLUSIONS: Poor social support and high barriers to exercise were associated with lower exercise time.<unk>
T-1931	exercise exercise
H-1931	-1.9477803707122803	▁social _ ▁support
D-1931	-1.9477803707122803	social_ support
P-1931	-0.9695 -1.9307 -1.7934 -4.8727 -0.1726
S-132	In patients with diabetes, lower EO-CFUs were associated with improved functional capacity.<unk>
T-132	patients diabetes eo-cfus functional_capacity
H-132	-0.926320493221283	▁diabetes ▁e - c FU s
D-132	-0.926320493221283	diabetes e-cFUs
P-132	-0.5890 -2.7307 -0.3109 -0.6309 -0.5553 -1.5989 -0.8391 -0.1557
S-377	Risk stratification for death and all-cause hospitalization in heart failure clinic outpatients.<unk>
T-377	risk_stratification death all-cause_hospitalization heart_failure clinic outpatients
H-377	-2.025158405303955	▁Risk ▁hospital ization ▁heart _ ▁failure
D-377	-2.025158405303955	Risk hospitalization heart_ failure
P-377	-3.9170 -4.2415 -1.3663 -0.3829 -0.4029 -3.7300 -1.9450 -0.2157
S-844	Cardiac-resynchronization therapy in heart failure with a narrow QRS complex.<unk>
T-844	cardiac-resynchronization_therapy heart_failure narrow_qrs_complex
H-844	-0.9138356447219849	▁Card iac - re syn chron ization _ therapy _ ▁in _ heart _ ▁failure ▁QR S
D-844	-0.9138356447219849	Cardiac-resynchronization_therapy_ in_heart_ failure QRS
P-844	-0.2840 -0.1717 -0.6400 -0.1296 -0.0347 -0.0001 -1.1085 -1.1227 -1.6361 -2.2022 -1.3055 -0.7746 -0.9302 -0.9046 -4.2317 -0.7593 -0.7389 -0.2635 -0.1248
S-1573	Hospital-to-Home: a hospital readmission reduction program for congestive heart failure.<unk>
T-1573	hospital-to-home hospital readmission congestive_heart_failure
H-1573	-0.9316856265068054	▁hospital _ ▁read mission _ re duction _ program ▁con ges tive _ heart _ ▁failure
D-1573	-0.9316856265068054	hospital_ readmission_reduction_program congestive_heart_ failure
P-1573	-0.1502 -0.5339 -2.8338 -0.0759 -0.0858 -0.9328 -0.0166 -1.8826 -2.6807 -0.5871 -0.4487 -0.1847 -0.4207 -2.1325 -1.1082 -2.0983 -0.4634 -0.1345
S-1636	Blacks had shorter 6-minute walk distance and lower peak VO2 at baseline.<unk>
T-1636	6-minute_walk_distance peak_vo2 baseline
H-1636	-1.5444546937942505	▁Black s ▁VO 2
D-1636	-1.5444546937942505	Blacks VO2
P-1636	-1.7789 -0.2280 -5.3485 -0.3059 -1.2216 -0.3838
S-191	Multivariate models were used to compute odds ratios while accounting for hospital clustering.<unk>
T-191	multivariate_models odds_ratios accounting hospital
H-191	-1.1269896030426025	▁odds ▁ratio s ▁hospital _ ▁cluster ing
D-191	-1.1269896030426025	odds ratios hospital_ clustering
P-191	-3.1429 -3.5064 -0.1519 -0.1468 -0.8728 -0.4956 -1.3602 -0.3130 -0.1533
S-497	HFrEF and HFpEF patients exhibited a similar distribution along the regression line.<unk>
T-497	hfref hfpef patients regression_line
H-497	-0.8325250148773193	▁h f f ▁ HF p f
D-497	-0.8325250148773193	hff HFpf
P-497	-0.2582 -0.7131 -1.5079 -1.2203 -0.1245 -0.1371 -1.4938 -1.8164 -0.2215
S-412	Nitroxyl (HNO): A novel approach for the acute treatment of heart failure.<unk>
T-412	nitroxyl hno acute heart_failure
H-412	-1.0906460285186768	▁ni tro x yl
D-412	-1.0906460285186768	nitroxyl
P-412	-1.9557 -0.0194 -0.0229 -0.2665 -4.1721 -0.1073
S-1412	Impact of physician continuity on death or urgent readmission after discharge among patients with heart failure.<unk>
T-1412	physician death readmission discharge patients heart_failure
H-1412	-1.4374297857284546	▁physician ▁continu ity ▁urgent _ ▁read mission _ de _ dis charge ▁patients ▁heart _ ▁failure
D-1412	-1.4374297857284546	physician continuity urgent_ readmission_de_discharge patients heart_ failure
P-1412	-0.3940 -0.8764 -0.1727 -5.5737 -0.9485 -1.7689 -0.0252 -2.9351 -3.6930 -0.2760 -0.1187 -0.0148 -1.2740 -2.6425 -1.2643 -3.3409 -0.3848 -0.1702
S-322	Heart block was induced, the pulmonary artery snared, and BiVP initiated.<unk>
T-322	heart_block pulmonary_artery bivp
H-322	-0.7001913189888	▁Heart _ block ▁pulmonar y ▁arter y _ ▁snar ed ▁Bi VP
D-322	-0.7001913189888	Heart_block pulmonary artery_ snared BiVP
P-322	-0.8172 -2.2706 -1.1127 -0.0183 -0.0722 -0.4454 -0.9736 -2.7533 -0.2192 -0.2232 -0.6522 -0.0046 -0.1472 -0.0931
S-1319	Feasibility was assessed in terms of recruitment, intervention compliance, and attrition.<unk>
T-1319	compliance attrition
H-1319	-0.8716375827789307	▁fe asi bility
D-1319	-0.8716375827789307	feasibility
P-1319	-0.9987 -0.0206 -0.2164 -3.0756 -0.0469
S-940	These results further implicate resistin as a link between inflammation, metabolism, and heart disease.<unk>
T-940	resistin inflammation metabolism heart_disease
H-940	-1.3361530303955078	▁ inflammation ▁metabolism ▁heart
D-940	-1.3361530303955078	inflammation metabolism heart
P-940	-1.1383 -0.3388 -1.8782 -2.0766 -2.2694 -0.3157
S-974	During 90 days of follow-up, there were 2,462 cardiovascular events and 617 deaths.<unk>
T-974	follow-up cardiovascular_events deaths
H-974	-1.4057823419570923	▁cardiovascular ▁events
D-974	-1.4057823419570923	cardiovascular events
P-974	-1.4541 -3.4920 -0.6205 -0.0565
S-588	The change in LVET between admission and follow-up measurement was not associated with outcome.<unk>
T-588	change lvet admission follow-up outcome
H-588	-1.026904582977295	▁change ▁L VET ▁follow - up
D-588	-1.026904582977295	change LVET follow-up
P-588	-0.9894 -2.4606 -0.3015 -3.5117 -0.0447 -0.0078 -0.6912 -0.2083
S-1605	Bioinformatic analysis of microarray data reveals several key genes related to heart failure.<unk>
T-1605	microarray genes heart_failure
H-1605	-1.3104898929595947	▁bio informati c
D-1605	-1.3104898929595947	bioinformatic
P-1605	-0.4898 -0.0338 -0.4050 -5.3687 -0.2551
S-1183	Identifying CAD as a cause of systolic HF has prognostic and treatment implications.<unk>
T-1183	cad systolic_hf prognostic
H-1183	-1.0734138488769531	▁CAD ▁cause _ de _ ▁sy sto lic _ ▁ HF
D-1183	-1.0734138488769531	CAD cause_de_ systolic_ HF
P-1183	-0.1879 -0.8285 -0.8343 -2.3960 -0.1454 -2.8412 -0.4875 -2.2910 -0.7415 -1.7833 -0.0164 -1.3248 -0.0766
S-1202	Herein, we review the current knowledge on diuretic use and outcomes in HF.<unk>
T-1202	diuretic outcomes hf
H-1202	-1.2497590780258179	▁di ure tic ▁ HF
D-1202	-1.2497590780258179	diuretic HF
P-1202	-1.1245 -0.4703 -2.8901 -3.9174 -0.1574 -0.1085 -0.0801
S-373	Therefore, the surgical indications need to be carefully evaluated in patients with functional MS.<unk>
T-373	surgical patients functional_ms
H-373	-1.150694489479065	▁sur g ical ▁MS
D-373	-1.150694489479065	surgical MS
P-373	-2.9195 -0.4154 -0.3443 -3.0349 -0.1206 -0.0694
S-813	PATIENTS: 196 persistent AF patients referred for echocardiographic examination.<unk>
T-813	patients patients echocardiographic
H-813	-1.4649453163146973	▁af ▁patients ▁e cho car dio graphic
D-813	-1.4649453163146973	af patients echocardiographic
P-813	-1.7424 -3.4187 -0.4647 -0.2282 -0.1671 -1.9751 -2.5321 -2.5674 -0.0888
S-161	Care packages generally improved health-related quality-of-life and were acceptable to patients.<unk>
T-161	quality-of-life patients
H-161	-1.1007763147354126	
D-161	-1.1007763147354126	
P-161	-2.0593 -0.1422
S-985	It is not appropriate to expand on the management of congenital heart lesions in this review.<unk>
T-985	congenital heart lesions
H-985	-0.7546117305755615	▁con geni tal _ ▁heart _ ▁les ions
D-985	-0.7546117305755615	congenital_ heart_ lesions
P-985	-1.5062 -0.0080 -0.1384 -0.9049 -2.1508 -1.0332 -1.4403 -0.2035 -0.1013 -0.0596
S-1349	PVF and its recovery had no effect on PB characteristics (period or amplitude).<unk>
T-1349	pvf pb
H-1349	-0.3656107187271118	▁PV f ▁ PB ▁amplitud e
D-1349	-0.3656107187271118	PVf PB amplitude
P-1349	-0.0708 -0.2175 -1.4066 -0.1321 -0.6157 -0.0557 -0.3163 -0.1100
S-401	It remains unclear whether sST2 concentrations identify benefit of BB therapy, however.<unk>
T-401	sst2 therapy
H-401	-1.0714927911758423	▁BB ▁ therapy
D-401	-1.0714927911758423	BB therapy
P-401	-3.0193 -1.8783 -0.1716 -0.1612 -0.1271
S-1143	Cardiac function was assessed by means of the pressure-volume conductance catheter system.<unk>
T-1143	cardiac_function catheter
H-1143	-0.9819770455360413	▁Card iac _ fon ction nel ▁pressure - volu me _ con duct ance ▁cat heter
D-1143	-0.9819770455360413	Cardiac_fonctionnel pressure-volume_conductance catheter
P-1143	-0.2046 -0.1367 -2.1202 -3.0557 -0.1464 -2.9303 -1.1104 -0.2935 -0.0676 -0.0781 -1.1550 -2.1212 -1.5598 -0.1388 -0.5655 -0.0119 -1.8872 -0.0926
S-353	As significant MS was associated with HF, surgical indication for MS was discussed.<unk>
T-353	hf surgical
H-353	-0.3435472249984741	▁MS ▁ HF ▁sur g ical ▁indica tion ▁MS
D-353	-0.3435472249984741	MS HF surgical indication MS
P-353	-0.6684 -1.8064 -0.0059 -0.1472 -0.0933 -0.2414 -0.1917 -0.0289 -0.4286 -0.0901 -0.0771
S-865	General use of beta-blockers (93%) and adherence in this study was high.<unk>
T-865	beta-blockers
H-865	-0.38117027282714844	▁beta - block ers
D-865	-0.38117027282714844	beta-blockers
P-865	-1.0514 -0.0786 -0.2847 -0.0795 -0.7076 -0.0852
S-1872	The primary safety end point was system- and procedure-related major adverse neurological and cardiovascular events.<unk>
T-1872	end_point neurological cardiovascular_events
H-1872	-1.828120231628418	▁safety _ ▁end ▁point
D-1872	-1.828120231628418	safety_ end point
P-1872	-2.4605 -1.5360 -2.3509 -0.8939 -3.5495 -0.1779
S-342	He had grade 4/6 holosystolic murmur and a third heart sound in the apex.<unk>
T-342	grade holosystolic_murmur third_heart_sound apex
H-342	-1.1125538349151611	▁holo sy sto lique _ ▁mur mur
D-342	-1.1125538349151611	holosystolique_ murmur
P-342	-0.1940 -0.4494 -1.6789 -1.9967 -1.0636 -1.0179 -0.0276 -3.4661 -0.1187
S-306	Should eligibility for heart transplantation be a requirement for left ventricular assist device use?<unk>
T-306	heart_transplantation left_ventricular_assist_device
H-306	-0.9521133303642273	▁e ligi bility ▁heart ▁implant ation ▁left ▁vent ri cular _ assist ▁device
D-306	-0.9521133303642273	eligibility heart implantation left ventricular_assist device
P-306	-2.7570 -0.0008 -0.3052 -2.1813 -2.1405 -0.0315 -0.6056 -0.2925 -0.2237 -0.2601 -0.7439 -0.2231 -3.6687 -0.7683 -0.0796
S-1157	Relationships between right ventricular function, body composition, and prognosis in advanced heart failure.<unk>
T-1157	right_ventricular_function prognosis heart_failure
H-1157	-1.1972548961639404	▁vent ri cular
D-1157	-1.1972548961639404	ventricular
P-1157	-0.5796 -0.2305 -0.2844 -4.7533 -0.1385
S-1039	The remodelling that precedes HF is induced by haemodynamic and neuronal stressors.<unk>
T-1039	remodelling hf haemodynamic neuronal_stressors
H-1039	-0.6236928105354309	▁remodel ling ▁ HF ▁ha emo dynamic ▁neuron al ▁stress ors
D-1039	-0.6236928105354309	remodelling HF haemodynamic neuronal stressors
P-1039	-1.3461 -0.9812 -0.7374 -0.0150 -0.0640 -0.2837 -0.1068 -1.5824 -0.0624 -2.1118 -0.4584 -0.2243 -0.1347
S-1557	Adjusted means were calculated for subclinical atherosclerosis using general linear models.<unk>
T-1557	subclinical atherosclerosis linear_models
H-1557	-1.3237489461898804	▁sub clin ical _ at hero sc ler osis
D-1557	-1.3237489461898804	subclinical_atherosclerosis
P-1557	-1.3049 -0.0866 -0.7829 -0.5332 -1.7520 -2.2351 -3.2819 -2.8234 -0.2837 -1.3468 -0.1308
S-1273	Exercise intolerance is a hallmark feature of chronic heart failure and is associated with poor prognosis.<unk>
T-1273	exercise_intolerance chronic_heart_failure prognosis
H-1273	-1.1918977499008179	▁Exerci se _ ▁in tolerance ▁chronic _ heart _ ▁failure
D-1273	-1.1918977499008179	Exercise_ intolerance chronic_heart_ failure
P-1273	-3.6836 -0.0734 -1.1746 -0.1662 -0.0247 -0.9978 -0.5909 -1.7645 -0.9261 -2.9446 -1.8338 -0.1226
S-538	In conclusion, preoperative hypoalbuminemia is associated with poor prognosis after LVAD surgery.<unk>
T-538	preoperative hypoalbuminemia prognosis lvad surgery
H-538	-0.5692300796508789	▁pre operativ e ▁hypo album in emia ▁l VAD
D-538	-0.5692300796508789	preoperative hypoalbuminemia lVAD
P-538	-0.3125 -0.0769 -0.0768 -1.2633 -0.4651 -0.6384 -0.4500 -2.1810 -0.0624 -0.5968 -0.1384
S-981	In children, where coronary disease is not the leading cause of heart failure, it is less common.<unk>
T-981	coronary_disease leading heart_failure
H-981	-1.137658953666687	▁corona ry _ ▁disease ▁heart _ ▁failure
D-981	-1.137658953666687	coronary_ disease heart_ failure
P-981	-0.8037 -0.5967 -1.0770 -3.1721 -2.1191 -0.2759 -1.9437 -0.1779 -0.0728
S-929	Recent clinical studies have connected elevated resistin levels with the development and severity of heart failure.<unk>
T-929	clinical connected elevated resistin heart_failure
H-929	-1.6768831014633179	
D-929	-1.6768831014633179	
P-929	-3.2525 -0.1013
S-1012	CONCLUSION: The deficit index and the biological phenotype equally predict mortality.<unk>
T-1012	deficit_index biological_phenotype mortality
H-1012	-0.62187260389328	▁deficit _ ▁index ▁bi ological _ ▁ph eno type ▁mortal ity
D-1012	-0.62187260389328	deficit_ index biological_ phenotype mortality
P-1012	-0.7081 -1.3578 -0.7017 -0.0322 -0.2922 -1.1006 -2.3805 -0.1857 -0.0449 -0.7376 -0.2816 -0.1153 -0.1461
S-1231	BACKGROUND: Atrial fibrillation (AF) is common in patients with heart failure.<unk>
T-1231	atrial_fibrillation patients heart_failure
H-1231	-0.9026931524276733	▁at rial _ ▁fi bril lation _ AF ▁heart _ ▁failure
D-1231	-0.9026931524276733	atrial_ fibrillation_AF heart_ failure
P-1231	-1.1706 -0.0324 -0.4423 -2.5532 -0.0297 -0.0105 -2.1380 -1.0508 -1.1560 -0.7190 -2.2072 -0.1737 -0.0516
S-1457	Fat, cachexia, and the right ventricle in heart failure: a web of complicity.<unk>
T-1457	cachexia right_ventricle heart_failure
H-1457	-1.0616122484207153	▁cache xia ▁vent ric le ▁heart _ ▁failure ▁complici ty
D-1457	-1.0616122484207153	cachexia ventricle heart_ failure complicity
P-1457	-3.3174 -0.1372 -0.9354 -3.4410 -0.2092 -0.6871 -0.7464 -1.4369 -0.5893 -0.6705 -0.4567 -0.1123
S-992	Specific signalling pathways activating either adaptive or maladaptive cardiac remodelling have been identified.<unk>
T-992	signalling_pathways cardiac_remodelling
H-992	-0.9524086117744446	▁signal ling _ path ways ▁mal adapt ive ▁cardiac ▁remodel ling
D-992	-0.9524086117744446	signalling_pathways maladaptive cardiac remodelling
P-992	-1.0404 -2.2445 -1.7216 -1.4205 -0.6494 -3.0506 -0.0198 -0.0102 -0.7833 -0.7541 -0.3626 -0.2174 -0.1067
S-884	All baseline ECGs were reviewed by a panel of 3 experienced electrocardiographers.<unk>
T-884	baseline ecgs electrocardiographers
H-884	-0.596084713935852	▁e CG s ▁electro car dio graph ers
D-884	-0.596084713935852	eCGs electrocardiographers
P-884	-2.5544 -0.1781 -0.9613 -0.4673 -0.0289 -1.2369 -0.0657 -0.1304 -0.2578 -0.0801
S-328	During AVD and VVD variations, CO was associated with free wall RS (P < 0.008).<unk>
T-328	avd vvd free_wall_rs
H-328	-1.1628830432891846	▁AV d ▁VVD ▁free ▁wall
D-328	-1.1628830432891846	AVd VVD free wall
P-328	-0.7183 -0.6982 -2.1297 -2.1915 -0.6941 -1.5997 -0.1088
S-1446	This appears to be a genuine effect that is not solely a consequence of heart rate variation.<unk>
T-1446	heart_rate
H-1446	-1.4241867065429688	
D-1446	-1.4241867065429688	
P-1446	-2.7376 -0.1108
S-388	Therefore, we examined incidence and predictors of ESRD in outpatients with HF.<unk>
T-388	incidence esrd outpatients hf
H-388	-0.7033449411392212	▁ES RD ▁out patient s ▁ HF
D-388	-0.7033449411392212	ESRD outpatients HF
P-388	-2.0465 -0.1005 -2.2454 -0.0451 -0.0335 -1.5327 -0.0092 -0.1836 -0.1335
S-1153	A left bundle branch block electrical activation sequence was simulated in all models.<unk>
T-1153	left_bundle_branch_block
H-1153	-1.1235870122909546	▁bran ch ▁block _ electric al _ activa tion _ se que nce
D-1153	-1.1235870122909546	branch block_electrical_activation_sequence
P-1153	-5.7675 -0.3061 -3.3654 -0.1424 -2.3189 -0.2188 -0.2482 -0.9856 -0.0435 -1.6578 -1.3320 -0.0347 -0.0008 -0.3302 -0.1018
S-1834	The risk for hHF was not higher with DPP-4 inhibitors than with the other study drugs.<unk>
T-1834	dpp-4_inhibitors drugs
H-1834	-0.8674008250236511	▁h HF ▁d p -4 ▁inhibi tors
D-1834	-0.8674008250236511	hHF dp-4 inhibitors
P-1834	-0.0202 -1.4222 -0.6062 -0.9770 -2.0022 -0.3400 -1.1673 -1.1822 -0.0893
S-718	CONCLUSIONS: ECCT is an acceptable alternative for advanced heart failure therapy in select patients.<unk>
T-718	ecct heart_failure therapy patients
H-718	-1.3533741235733032	▁EC CT ▁advanced _ heart _ ▁failure ▁ therapy
D-718	-1.3533741235733032	ECCT advanced_heart_ failure therapy
P-718	-0.4881 -1.9863 -3.2937 -0.5414 -2.0667 -0.3337 -3.4186 -2.1071 -0.0466 -0.5123 -0.0925
S-815	CV events were defined as CV death, non-fatal stroke and hospitalisation for heart failure.<unk>
T-815	death stroke hospitalisation heart_failure
H-815	-1.0649482011795044	▁CV ▁death _ non - fa tal ▁stroke ▁hospital isation ▁heart _ ▁failure
D-815	-1.0649482011795044	CV death_non-fatal stroke hospitalisation heart_ failure
P-815	-0.5494 -4.2945 -3.8842 -0.5707 -0.0184 -0.0135 -0.0435 -0.9178 -1.3525 -0.0114 -1.4675 -0.7898 -1.5092 -0.3337 -0.2181
S-248	Protective effects of exercise training (ET) on endothelial function have been demonstrated.<unk>
T-248	exercise training endothelial_function
H-248	-1.3640483617782593	▁ Protect ive _ effect s ▁é et ▁en dot heli al _ ▁function
D-248	-1.3640483617782593	Protective_effects éet endothelial_ function
P-248	-1.8988 -0.2380 -0.0080 -3.0011 -2.7785 -1.7616 -3.2388 -3.6852 -0.4524 -0.9132 -0.0622 -0.0163 -0.9963 -2.5291 -0.1313 -0.1140
S-714	Among the 454 patients who underwent heart transplant, 84 (18.5%) were ECCT.<unk>
T-714	patients heart_transplant ecct
H-714	-1.6906157732009888	▁heart _ ▁transplant
D-714	-1.6906157732009888	heart_ transplant
P-714	-4.0508 -1.9382 -0.8861 -1.5072 -0.0707
S-20	Prospectively, FFM decreased but FM increased, despite stable body weight in CC.<unk>
T-20	prospectively ffm stable
H-20	-1.162867784500122	▁F f f f f f f f f f f f f f _ f f f f f ▁figure _ f f f f
D-20	-1.162867784500122	Ffffffffffffff_fffff figure_ffff
P-20	-1.8514 -0.7627 -0.1878 -0.1218 -0.1097 -0.1219 -0.1630 -0.2219 -0.3088 -0.4396 -0.5825 -0.7400 -0.9210 -1.1129 -4.9669 -0.8446 -0.0883 -0.1307 -0.8036 -1.8813 -3.8663 -3.2564 -2.5938 -0.6583 -0.5387 -1.3995 -3.7180 -0.1689
S-908	No periprocedural or long-term complications were observed among dialysis patients.<unk>
T-908	complications dialysis patients
H-908	-0.665019154548645	▁per i pro ced ural ▁complica tions ▁di al ysis
D-908	-0.665019154548645	periprocedural complications dialysis
P-908	-1.6447 -0.8147 -0.0693 -0.1252 -0.0434 -3.6748 -0.1122 -0.4682 -0.1871 -0.1088 -0.6426 -0.0892
S-943	BACKGROUND: AF is a precipitating factor for clinical deterioration of HFPEF.<unk>
T-943	clinical hfpef
H-943	-1.084741473197937	▁precipit ation ▁h f f
D-943	-1.084741473197937	precipitation hff
P-943	-1.6730 -0.5948 -3.1154 -0.5162 -0.2475 -1.3512 -0.0951
S-84	Participating in a multihospital study to promote adoption of heart failure guidelines: lessons for nurse leaders.<unk>
T-84	heart_failure nurse
H-84	-1.5520801544189453	▁multi hospital ▁ adoption _ de _ heart _ ▁failure
D-84	-1.5520801544189453	multihospital adoption_de_heart_ failure
P-84	-1.5300 -0.0242 -4.5936 -0.1730 -1.9618 -1.8114 -0.5212 -1.3608 -0.6833 -3.1355 -2.5784 -0.2517
S-1003	METHODS: Southeastern Minnesota residents with HF were recruited from 2007 to 2011.<unk>
T-1003	minnesota hf
H-1003	-0.9450925588607788	▁South e a stern ▁Minnesota ▁ HF
D-1003	-0.9450925588607788	Southeastern Minnesota HF
P-1003	-5.2705 -0.0384 -0.4394 -0.0347 -0.5944 -1.3009 -0.0980 -0.5839 -0.1455
S-9	OBJECTIVES: Cardiac cachexia (CC) is associated with changes in body composition.<unk>
T-9	cardiac_cachexia
H-9	-0.5996630787849426	▁Card iac _ ca xia CC
D-9	-0.5996630787849426	Cardiac_caxiaCC
P-9	-0.3680 -0.0172 -0.3886 -0.4863 -0.5338 -1.2760 -1.6494 -0.0779
S-632	CONCLUSIONS: Frailty is independently associated with risk of HF in older adults.<unk>
T-632	frailty hf
H-632	-0.9357677102088928	▁Fra il ty ▁ HF
D-632	-0.9357677102088928	Frailty HF
P-632	-1.3037 -0.7620 -2.3549 -1.1949 -0.1366 -0.7126 -0.0857
S-254	The proteome of HDL particles was profiled by shotgun LC-MS/MS.<unk>
T-254	proteome hdl
H-254	-0.6838520765304565	▁prote ome _ de _ ▁HD L ▁parti cles ▁shot gun ▁ LC - MS
D-254	-0.6838520765304565	proteome_de_ HDL particles shotgun LC-MS
P-254	-0.9164 -1.5889 -1.1422 -1.0524 -0.2657 -0.8914 -1.5731 -0.5799 -0.1023 -0.1157 -0.1184 -1.9191 -0.0842 -0.0509 -0.0313 -0.9964 -0.1974
S-566	Fatal and nonfatal outcomes were discordant, with better survival despite higher hospitalization rates.<unk>
T-566	outcomes hospitalization
H-566	-1.2243624925613403	▁Fa tal _ non fa tal
D-566	-1.2243624925613403	Fatal_nonfatal
P-566	-4.0370 -0.0353 -1.6000 -0.6911 -0.0718 -0.2671 -2.9053 -0.1873
S-532	Preoperative clinical characteristics and laboratory variables associated with mortality were analyzed.<unk>
T-532	preoperative clinical mortality
H-532	-0.910515546798706	▁pre operativ e _ ▁clinic al
D-532	-0.910515546798706	preoperative_ clinical
P-532	-1.1479 -0.0094 -0.2090 -0.6996 -1.3428 -0.0607 -3.6906 -0.1241
S-1484	Here, we give an overview of these miRNAs and their role in cardiac pathogenesis.<unk>
T-1484	mirnas cardiac pathogenesis
H-1484	-0.7992118000984192	▁mi RNA s ▁cardiac
D-1484	-0.7992118000984192	miRNAs cardiac
P-1484	-1.2960 -0.0172 -0.0812 -0.1328 -3.2079 -0.0602
S-61	We conducted a meta-analysis to identify factors associated with mortality in ICD-HF patients.<unk>
T-61	meta-analysis mortality patients
H-61	-0.7878616452217102	▁mortal ity ▁i CD - HF
D-61	-0.7878616452217102	mortality iCD-HF
P-61	-3.1003 -0.4280 -0.8819 -0.1419 -0.1288 -0.0951 -1.2318 -0.2950
S-777	The patients were extubated within 3 to 6 hours, and blood loss and transfusion requirements were nominal.<unk>
T-777	patients extubated blood transfusion
H-777	-1.4215013980865479	▁trans fusion
D-777	-1.4215013980865479	transfusion
P-777	-4.5768 -0.0750 -0.8677 -0.1666
S-984	Most of these lesions, such as septal defects, are amenable to surgical intervention.<unk>
T-984	lesions septal surgical
H-984	-0.4321278929710388	▁sept al ▁defect s ▁sur g ical
D-984	-0.4321278929710388	septal defects surgical
P-984	-0.3113 -0.2185 -1.8048 -0.0857 -0.1152 -0.1325 -0.3653 -0.7910 -0.0649
S-730	Only 13% of patients had no discrepancy between the discharge and follow-up medication lists.<unk>
T-730	patients discharge follow-up medication
H-730	-0.8484914302825928	▁dis charge ▁medication
D-730	-0.8484914302825928	discharge medication
P-730	-1.6267 -0.0199 -2.1523 -0.3900 -0.0536
S-1030	Measuring heart failure care by 30-day readmission: Rethinking the quality of outcome measures.<unk>
T-1030	heart_failure readmission outcome
H-1030	-1.3778833150863647	▁heart _ ▁failure _ de _ ca pit aux
D-1030	-1.3778833150863647	heart_ failure_de_capitaux
P-1030	-0.6952 -0.3386 -3.9968 -0.6997 -2.6287 -0.3686 -2.6018 -1.2700 -1.3399 -1.0499 -0.1675
S-1042	However, the role of 'readers' (bromodomain proteins) was less well defined.<unk>
T-1042	bromodomain_proteins
H-1042	-0.8499528765678406	bro modo main ▁protein s
D-1042	-0.8499528765678406	bromodomain proteins
P-1042	-3.8145 -0.0403 -0.1427 -1.7547 -0.0377 -0.0971 -0.0626
S-1667	This patient population has a 1-year mortality rate of approximately 50% and requires special therapeutic interventions.<unk>
T-1667	patient mortality therapeutic
H-1667	-1.367921233177185	▁mortal ity
D-1667	-1.367921233177185	mortality
P-1667	-3.9856 -0.3144 -1.0650 -0.1066
S-315	We found that BTT and DT as implantation strategies tend to be no longer mutually exclusive.<unk>
T-315	btt dt implantation
H-315	-0.501638650894165	▁b t ▁ DT ▁implant ation
D-315	-0.501638650894165	bt DT implantation
P-315	-0.4770 -0.7038 -1.1564 -0.0772 -0.0065 -0.0398 -1.5090 -0.0433
S-1970	The treatment was safe, typical adverse event was hypotension, however without a need to interrupt the treatment.<unk>
T-1970	adverse_event hypotension
H-1970	-0.6568579077720642	▁hypo tension ▁interrupt
D-1970	-0.6568579077720642	hypotension interrupt
P-1970	-1.7270 -0.0125 -1.0220 -0.4608 -0.0620
S-948	Multiple procedures and pharmaceutically assisted success rate was 73% (n = 54).<unk>
T-948	pharmaceutically
H-948	-0.549260139465332	▁ pharma ce ut ically _ assist ed
D-948	-0.549260139465332	pharmaceutically_assisted
P-948	-0.2474 -0.0382 -0.3051 -1.3190 -0.4691 -1.4265 -0.1626 -0.3516 -1.0921 -0.0810
S-288	RESULTS: Over a mean follow-up of 10.4 years, 970 participants developed incident HF.<unk>
T-288	follow-up hf
H-288	-1.0616791248321533	▁incident ▁ HF
D-288	-1.0616791248321533	incident HF
P-288	-2.9953 -1.9444 -0.2051 -0.0896 -0.0739
S-1475	However, the use of biomarkers in the treatment of HF remains in its infancy.<unk>
T-1475	biomarkers hf
H-1475	-0.20997485518455505	▁bio mark ers ▁ HF
D-1475	-0.20997485518455505	biomarkers HF
P-1475	-0.1730 -0.0039 -0.0342 -0.7475 -0.1363 -0.3196 -0.0553
S-1498	RESULTS: Peak VO2 was 1.9±0.1 L/min (66±3% of predicted values).<unk>
T-1498	peak_vo2
H-1498	-0.9467809796333313	▁Peak ▁VO 2
D-1498	-0.9467809796333313	Peak VO2
P-1498	-1.3728 -2.1275 -0.2012 -0.8401 -0.1923
S-699	ST2 was analyzed in a subset of 910 patients with evaluable plasma samples.<unk>
T-699	st2 patients plasma
H-699	-1.5554734468460083	
D-699	-1.5554734468460083	
P-699	-3.0418 -0.0692
S-1575	In addition to indicating possible suboptimal care of patients with this condition, there are significant economic considerations.<unk>
T-1575	patients condition economic
H-1575	-0.7106116414070129	▁économique
D-1575	-0.7106116414070129	économique
P-1575	-1.6001 -0.4380 -0.0937
S-1690	However, individual quality measures are suboptimal in identifying superior and inferior hospitals based on outcome performance.<unk>
T-1690	hospitals outcome
H-1690	-1.3211857080459595	
D-1690	-1.3211857080459595	
P-1690	-2.5180 -0.1244
S-671	The rates and risk factors associated with trastuzumab-related CHF among older patients are unknown.<unk>
T-671	chf patients
H-671	-0.5918371677398682	▁tras tuz um ab - related ▁CHF
D-671	-0.5918371677398682	trastuzumab-related CHF
P-671	-1.6246 -0.0175 -0.3934 -1.0991 -0.2667 -1.4066 -0.1173 -0.2675 -0.1340
S-2000	At 6 months, 88% of patients continued on support, 4% received transplants, and 8% died.<unk>
T-2000	patients transplants
H-2000	-0.7546359300613403	▁implant s
D-2000	-0.7546359300613403	implants
P-2000	-2.6128 -0.1398 -0.2290 -0.0370
S-1903	Healthy individuals should engage in 150 minutes of moderate-intensity, aerobic exercise per week.<unk>
T-1903	healthy engage exercise
H-1903	-1.9396512508392334	
D-1903	-1.9396512508392334	
P-1903	-3.7468 -0.1325
S-1694	We ranked hospitals on the basis of their July 2005 to June 2008 performance on the composite.<unk>
T-1694	hospitals
H-1694	-0.46289053559303284	▁hospital s
D-1694	-0.46289053559303284	hospitals
P-1694	-0.9182 -0.2520 -0.6164 -0.0649
S-1955	FINDINGS: Between Oct 10, 2013, and March 27, 2015, we enrolled ten patients.<unk>
T-1955	patients
H-1955	-1.3987400531768799	▁financier s
D-1955	-1.3987400531768799	financiers
P-1955	-3.8249 -0.9274 -0.7785 -0.0641
S-1	The effects of more than a decade of national efforts dedicated to improve patient safety remain largely unclear.<unk>
T-1	patient
H-1	-1.1917108297348022	
D-1	-1.1917108297348022	
P-1	-2.3247 -0.0587
S-125	We recorded mortality, HF hospital admissions, transplant, and ventricular assist device.<unk>
T-125	mortality hf hospital admissions transplant ventricular_assist_device
H-125	-0.6536880731582642	▁ HF ▁hospital _ ad missions ▁vent ri cular _ assist ▁device
D-125	-0.6536880731582642	HF hospital_admissions ventricular_assist device
P-125	-2.3311 -0.0512 -1.0998 -2.4603 -0.7599 -0.0205 -0.3933 -0.0823 -0.1506 -0.3468 -0.0839 -1.0705 -0.1946 -0.1069
S-1182	Coronary artery disease (CAD) is a major cause of systolic heart failure (HF).<unk>
T-1182	coronary_artery_disease cad systolic_heart_failure hf
H-1182	-1.1437464952468872	▁Corona ry _ ▁arter y ▁disease ▁CAD ▁sy sto lic _ heart _ ▁failure HF
D-1182	-1.1437464952468872	Coronary_ artery disease CAD systolic_heart_ failureHF
P-1182	-0.2020 -0.1178 -1.3398 -0.3738 -0.1871 -2.8207 -2.0659 -2.0271 -0.0312 -2.5474 -0.5386 -1.7918 -0.6162 -2.8891 -1.5799 -0.2361 -0.0792
S-600	Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist.<unk>
T-600	heart_failure patients rheumatoid_arthritis tnf_antagonist
H-600	-0.8904238343238831	▁Heart _ ▁failure ▁rhe um ato id _ ar thri tis ▁T NF ▁anta gon ist
D-600	-0.8904238343238831	Heart_ failure rheumatoid_arthritis TNF antagonist
P-600	-0.1604 -1.0858 -2.6473 -3.4783 -0.1766 -0.6512 -1.2454 -0.2425 -1.8600 -0.2971 -1.4448 -0.4804 -0.0104 -0.5574 -0.0674 -1.0600 -0.4305 -0.1323
S-1593	Renal artery stenosis (RAS) is a common form of peripheral arterial disease.<unk>
T-1593	renal_artery_stenosis ras peripheral_arterial_disease
H-1593	-0.5647354125976562	▁Ren al ▁arter y _ ▁sten osis ▁ RAS ▁per i pher al _ ▁arterial
D-1593	-0.5647354125976562	Renal artery_ stenosis RAS peripheral_ arterial
P-1593	-0.0586 -0.0524 -0.7428 -0.2929 -1.2769 -0.5019 -0.0725 -1.4082 -0.0031 -0.3373 -0.2623 -0.0416 -0.0565 -0.7288 -0.9634 -2.6470 -0.1544
S-923	Wilcoxon matched-pairs signed-rank tests were used for pre-post comparisons.<unk>
T-923	wilcoxon_matched-pairs_signed-rank_tests
H-923	-0.4881322979927063	▁Wil co xon
D-923	-0.4881322979927063	Wilcoxon
P-923	-0.3643 -0.0066 -0.3369 -1.5411 -0.1917
S-293	Survival after left ventricular assist device with and without temporary right ventricular support.<unk>
T-293	left_ventricular_assist_device right_ventricular_support
H-293	-0.609297513961792	▁vent ri cular _ assist ▁device ▁right ▁vent ri cular _ support
D-293	-0.609297513961792	ventricular_assist device right ventricular_support
P-293	-0.1274 -0.0865 -0.1431 -1.1440 -0.0838 -1.7060 -1.9924 -0.0828 -0.0728 -0.1051 -1.3876 -1.2671 -0.2440 -0.0875
S-1554	Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study.<unk>
T-1554	psoriasis atherosclerosis cardiovascular_events rotterdam_study
H-1554	-0.6398147344589233	▁p sori asis ▁at hero sc ler osis ▁incident _ ▁cardiovascular ▁events ▁Rotterdam
D-1554	-0.6398147344589233	psoriasis atherosclerosis incident_ cardiovascular events Rotterdam
P-1554	-1.5788 -0.0875 -0.1557 -0.2346 -0.2098 -1.9021 -2.0436 -0.1032 -0.2041 -0.1100 -0.3731 -2.0303 -0.0810 -0.4353 -0.0482
S-1713	SETTING: Six thousand five hundred thirty-seven hospitals nationwide from January 1999 through September 2005.<unk>
T-1713	hospitals
H-1713	-0.944760262966156	▁hospital s
D-1713	-0.944760262966156	hospitals
P-1713	-2.3548 -0.7472 -0.6020 -0.0750
S-154	DATA EXTRACTION: Data were extracted and validity was assessed independently by two reviewers.<unk>
T-154	
H-154	-0.9500817060470581	
D-154	-0.9500817060470581	
P-154	-1.8679 -0.0323
S-1227	Eplerenone was effective in reducing the primary composite endpoint in all subgroups.<unk>
T-1227	eplerenone primary_composite_endpoint
H-1227	-1.0698695182800293	▁e pler en one
D-1227	-1.0698695182800293	eplerenone
P-1227	-0.6110 -0.0115 -0.2865 -4.2937 -1.0769 -0.1396
S-1280	Orthotopic heart transplantation (OHT) is the optimal treatment for end-stage heart failure.<unk>
T-1280	orthotopic_heart_transplantation oht end-stage_heart_failure
H-1280	-0.6837562918663025	▁Ort ho topic _ heart _ ▁transplant ation ▁o HT
D-1280	-0.6837562918663025	Orthotopic_heart_ transplantation oHT
P-1280	-0.4524 -0.0345 -0.0582 -1.0464 -1.4545 -1.6984 -0.2867 -0.0130 -0.1025 -0.4509 -2.5469 -0.0608
S-592	Right atrial myxoma complicated by pulmonary embolism and revealed by right heart failure.<unk>
T-592	right_atrial_myxoma pulmonary_embolism right_heart_failure
H-592	-0.6730093955993652	▁Right ▁at rial _ My xo ma ▁pulmonar y ▁e mbol ism ▁right ▁heart _ ▁failure
D-592	-0.6730093955993652	Right atrial_Myxoma pulmonary embolism right heart_ failure
P-592	-0.3396 -0.7806 -0.0276 -0.5517 -2.7637 -0.0508 -0.1375 -0.0020 -0.0380 -0.6943 -0.0004 -1.3274 -0.1456 -1.0370 -0.6963 -3.2660 -0.1749 -0.0808
S-1369	Unilateral renal denervation improves autonomic balance in conscious rabbits with chronic heart failure.<unk>
T-1369	unilateral_renal_denervation autonomic_balance chronic_heart_failure
H-1369	-1.0398821830749512	▁Uni lateral _ ▁renal _ ▁den er va tion ▁autonomi c _ ▁balance ▁ conscious ▁rabbi ts
D-1369	-1.0398821830749512	Unilateral_ renal_ denervation autonomic_ balance conscious rabbits
P-1369	-3.8760 -0.0235 -0.5607 -0.4547 -2.5772 -1.3920 -0.0461 -0.0909 -0.0413 -0.3817 -0.5596 -1.5303 -0.2711 -1.8407 -0.1127 -0.0287 -0.0149 -5.6654 -0.2904
S-594	Myxomas in the right atrium may rarely embolize to the pulmonary arterial vasculature.<unk>
T-594	myxomas right_atrium embolize pulmonary_arterial_vasculature
H-594	-0.7133055329322815	▁My xo mas ▁pulmonar y ▁arterial _ ▁vas cula ture
D-594	-0.7133055329322815	Myxomas pulmonary arterial_ vasculature
P-594	-1.3301 -0.0142 -0.3511 -0.3360 -0.0972 -2.4802 -1.8952 -1.0974 -0.3470 -0.1969 -0.3140 -0.1004
S-1203	The high-risk patient with heart failure with reduced ejection fraction: treatment options and challenges.<unk>
T-1203	patient heart_failure_with_reduced_ejection_fraction
H-1203	-1.1834930181503296	▁high - risk ▁patient ▁heart _ ▁failure ▁e je ction _ fraction
D-1203	-1.1834930181503296	high-risk patient heart_ failure ejection_fraction
P-1203	-2.7090 -0.0488 -0.0080 -2.0838 -2.0032 -0.7608 -3.5448 -2.3068 -0.9862 -0.0953 -1.5992 -0.0154 -0.2868 -0.1210
S-638	Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure.<unk>
T-638	nfat mir-25 transcription_factor hand2 heart_failure
H-638	-1.425919532775879	▁m r -25 ▁tran scription _ factor ▁Hand 2 ▁heart _ ▁failure
D-638	-1.425919532775879	mr-25 transcription_factor Hand2 heart_ failure
P-638	-3.2398 -4.5387 -0.8349 -0.0745 -0.0916 -1.4126 -2.3341 -0.0942 -0.7669 -1.7579 -1.2172 -2.9525 -0.2674 -0.3805
S-1429	Further, the expression of type I regulatory subunit (RI) was increased in HF.<unk>
T-1429	expression type_i_regulatory_subunit ri hf
H-1429	-2.2614409923553467	▁ HF
D-1429	-2.2614409923553467	HF
P-1429	-4.6731 -3.7323 -0.4826 -0.1578
S-1564	The results were similar when coronary heart disease, stroke, and heart failure were analyzed separately.<unk>
T-1564	coronary_heart_disease stroke heart_failure
H-1564	-0.9702175259590149	▁corona ry _ ▁heart ▁disease ▁stroke ▁heart _ ▁failure
D-1564	-0.9702175259590149	coronary_ heart disease stroke heart_ failure
P-1564	-0.1816 -0.2546 -0.9682 -1.7540 -3.9672 -0.1002 -0.1756 -0.7257 -2.3816 -0.1067 -0.0571
S-458	Moreover, VEGF inhibition counteracted the positive effects of B on cardiac function and remodeling.<unk>
T-458	vegf_inhibition cardiac_function remodeling
H-458	-0.8174679279327393	▁VE GF _ ▁inhibi tion ▁b ▁cardiac ▁remodel ing
D-458	-0.8174679279327393	VEGF_ inhibition b cardiac remodeling
P-458	-0.0841 -0.0362 -3.0604 -0.1295 -0.0149 -0.6164 -0.3859 -4.3517 -0.0816 -0.1703 -0.0610
S-400	We recently found changing doses of β-blocker (BB) may affect sST2 concentrations.<unk>
T-400	changing β-blocker sst2
H-400	-0.586948573589325	▁β - block er BB ▁s ST 2
D-400	-0.586948573589325	β-blockerBB sST2
P-400	-0.8069 -0.0522 -0.3162 -0.0776 -2.0333 -0.9361 -0.4138 -0.4492 -0.6594 -0.1249
S-720	Change in readmissions and follow-up visits as part of a heart failure readmission quality improvement initiative.<unk>
T-720	change readmissions follow-up heart_failure readmission
H-720	-1.5486963987350464	▁read missions ▁heart _ ▁failure
D-720	-1.5486963987350464	readmissions heart_ failure
P-720	-3.8684 -0.0178 -0.3510 -0.3531 -2.7978 -3.3105 -0.1423
S-1991	Neither intervention had a significant effect on quality of life as measured by the MLHF Questionnaire.<unk>
T-1991	quality_of_life mlhf_questionnaire
H-1991	-1.4615544080734253	▁ ML HF
D-1991	-1.4615544080734253	MLHF
P-1991	-1.6473 -2.4637 -1.7245 -1.3044 -0.1679
S-199	Pediatric heart failure (HF) is an important cause of morbidity and mortality in childhood.<unk>
T-199	heart_failure hf morbidity mortality
H-199	-0.6811429262161255	▁Pediatri c ▁heart _ ▁failure ▁ HF ▁morbi d ity ▁mortal ity
D-199	-0.6811429262161255	Pediatric heart_ failure HF morbidity mortality
P-199	-1.0454 -0.0083 -1.4630 -0.5434 -1.9283 -2.4463 -0.0229 -0.4958 -0.0444 -0.1627 -0.3635 -0.1240 -0.7432 -0.1447
S-938	Further, elevation in resistin correlated with decline in ejection fraction in these women.<unk>
T-938	elevation resistin correlated ejection_fraction
H-938	-0.753328263759613	▁resist in ▁e je ction _ fraction
D-938	-0.753328263759613	resistin ejection_fraction
P-938	-0.3641 -0.8641 -2.6638 -0.7955 -0.1448 -1.3670 -0.0157 -0.3882 -0.1767
S-732	Patients with heart failure were complex and often had diagnostic testing and medication changes at follow-up visits.<unk>
T-732	patients heart_failure diagnostic medication follow-up
H-732	-1.5966137647628784	▁Patient s ▁heart _ ▁failure ▁medication
D-732	-1.5966137647628784	Patients heart_ failure medication
P-732	-2.7161 -0.1921 -2.4015 -1.9029 -3.5970 -1.5828 -0.2298 -0.1507
S-711	Baseline characteristics and outcomes were compared between ECCT and standard criteria cardiac transplant recipients.<unk>
T-711	baseline outcomes ecct cardiac_transplant
H-711	-1.1041771173477173	▁EC CT ▁cardiac ▁transplant ation
D-711	-1.1041771173477173	ECCT cardiac transplantation
P-711	-0.6165 -1.3564 -0.4923 -1.6536 -2.8167 -0.6836 -0.1101
S-1884	CONCLUSION: The CPET guiding exercise rehabilitation is safe and effective for patients with CHF.<unk>
T-1884	cpet exercise_rehabilitation patients chf
H-1884	-0.7290506958961487	▁c PET _ gu iding _ ▁exercise _ ▁rehabilita tion ▁CHF
D-1884	-0.7290506958961487	cPET_guiding_ exercise_ rehabilitation CHF
P-1884	-0.3191 -1.5923 -2.2987 -1.2644 -0.0704 -0.1640 -1.9579 -0.2006 -0.9652 -0.0103 -0.4324 -0.1534 -0.0490
S-1121	Reasons for not prescribing guideline-recommended medications to adults with heart failure.<unk>
T-1121	prescribing medications heart_failure
H-1121	-2.0702555179595947	
D-1121	-2.0702555179595947	
P-1121	-4.0189 -0.1216
S-1074	Heart failure (HF) is the most common cause of cardiovascular hospitalization, especially among the elderly.<unk>
T-1074	heart_failure hf cardiovascular hospitalization
H-1074	-1.1914565563201904	▁Heart _ ▁failure ▁ HF ▁cardiovascular _ hospital ization
D-1074	-1.1914565563201904	Heart_ failure HF cardiovascular_hospitalization
P-1074	-0.5386 -0.3291 -3.3011 -2.7699 -0.0143 -0.8035 -2.6621 -0.1601 -0.9509 -1.4747 -0.1018
S-776	We have used this technique to exchange malfunctioning HeartMate II LVADs in 14 consecutive patients.<unk>
T-776	heartmate_ii lvads patients
H-776	-1.0892071723937988	▁mal function ing ▁Heart Mate _ ▁II ▁L VAD s
D-776	-1.0892071723937988	malfunctioning HeartMate_ II LVADs
P-776	-4.8950 -1.2735 -0.2723 -0.0716 -0.4857 -1.1826 -1.1087 -2.4333 -0.0111 -0.6495 -0.4069 -0.2801
S-599	The patient had an uneventful recovery and was asymptomatic after 6 months of follow-up.<unk>
T-599	patient asymptomatic follow-up
H-599	-1.0579413175582886	
D-599	-1.0579413175582886	
P-599	-2.0327 -0.0832
S-1381	Renal DNx also prevented the increase in circulating plasma NE seen in CHF-INV rabbits.<unk>
T-1381	renal_dnx plasma
H-1381	-0.6424583196640015	▁Ren al ▁DN x ▁circula tion _ ▁plasma ▁CHF - IN V ▁rabbi ts
D-1381	-0.6424583196640015	Renal DNx circulation_ plasma CHF-INV rabbits
P-1381	-0.1056 -0.0508 -1.8619 -0.0109 -0.1063 -3.9893 -0.7866 -0.8821 -0.4376 -0.0566 -0.5474 -0.8615 -0.0230 -0.0318 -0.2823 -0.2456
S-1525	However, clinical characteristics and outcomes of EH have not been well described in HFpEF.<unk>
T-1525	clinical outcomes hfpef
H-1525	-0.685344934463501	▁EH ▁h p EF
D-1525	-0.685344934463501	EH hpEF
P-1525	-0.3949 -2.9223 -0.0087 -0.5547 -0.1201 -0.1114
S-774	When dysfunction is due to pump failure or driveline injury, isolated pump replacement can be curative.<unk>
T-774	dysfunction pump driveline pump curative
H-774	-0.7824564576148987	▁dys function ▁pump _ ▁failure ▁drive line _ ▁injury
D-774	-0.7824564576148987	dysfunction pump_ failure driveline_ injury
P-774	-1.5940 -0.3372 -0.4494 -1.5525 -0.4159 -0.1228 -0.2210 -1.3306 -0.1431 -2.3536 -0.0868
S-1333	Given the lack of effective evidence-based therapies in these patients, FES warrants further investigation.<unk>
T-1333	evidence-based therapies patients fes
H-1333	-1.2201472520828247	
D-1333	-1.2201472520828247	
P-1333	-2.3833 -0.0570
S-1828	OBJECTIVE: To examine the associations of hHF with saxagliptin and sitagliptin.<unk>
T-1828	saxagliptin sitagliptin
H-1828	-0.45456480979919434	▁h HF ▁sax ag lip tin ▁si tag lip tin
D-1828	-0.45456480979919434	hHF saxagliptin sitagliptin
P-1828	-0.0043 -1.3579 -0.4267 -0.1782 -1.4588 -1.2130 -0.0437 -0.0003 -0.1194 -0.4460 -0.1673 -0.0392
S-171	No band of activated Caspase was found in the normal nor in the paced myocardium.<unk>
T-171	caspase myocardium
H-171	-0.9171181917190552	▁cas pas e ▁pace d _ My o car dium
D-171	-0.9171181917190552	caspase paced_Myocardium
P-171	-4.0688 -1.0641 -0.7870 -0.3825 -0.4899 -0.3388 -2.7153 -0.1050 -0.0054 -0.6566 -0.2929 -0.0991
S-1285	All but one of the seven ischemic/inflammatory abdominal problems occurred in the MT group.<unk>
T-1285	ischemic inflammatory abdominal
H-1285	-1.0764617919921875	▁ ische mic _ in flam ma tory _ ▁abdominal
D-1285	-1.0764617919921875	ischemic_inflammatory_ abdominal
P-1285	-1.2590 -2.1755 -0.7502 -0.4935 -0.2022 -0.7298 -0.5415 -1.4233 -0.2820 -1.1305 -3.6917 -0.2382
S-719	Age and renal dysfunction are important determinants of long-term survival and post-transplant morbidity.<unk>
T-719	renal_dysfunction morbidity
H-719	-0.879810094833374	▁renal _ ▁dys function ▁long - term _ trans plant _ ▁morbi d ity
D-719	-0.879810094833374	renal_ dysfunction long-term_transplant_ morbidity
P-719	-2.1274 -2.2238 -0.6710 -0.7188 -1.7291 -0.0293 -0.4519 -0.9485 -2.4625 -0.0963 -1.5754 -0.2435 -0.0881 -0.4981 -0.1095 -0.1038
S-62	METHODS: We searched in MedLine, EMBASE, and CINAHL in May 2012.<unk>
T-62	medline embase cinahl
H-62	-0.7112312316894531	▁Med Line ▁ EMBA se ▁c INA HL
D-62	-0.7112312316894531	MedLine EMBAse cINAHL
P-62	-0.6741 -0.1972 -0.5214 -0.0208 -3.7563 -0.5257 -0.5011 -0.6079 -0.2516 -0.0562
S-140	Correlations between the ACR and CMS metrics were highest (r = 0.67-0.84).<unk>
T-140	correlations acr cms
H-140	-0.5890076756477356	▁A CR ▁CMS
D-140	-0.5890076756477356	ACR CMS
P-140	-1.6497 -0.1966 -0.4558 -0.5552 -0.0877
S-1771	During a mean follow-up of 19.8±10.4 years, 153 HF deaths occurred.<unk>
T-1771	follow-up hf deaths
H-1771	-0.5862202048301697	▁ HF
D-1771	-0.5862202048301697	HF
P-1771	-1.1004 -0.2163 -0.8543 -0.1739
S-40	Purpose: To evaluate the benefits and harms of treatments for anemia in adults with heart disease.<unk>
T-40	anemia heart_disease
H-40	-1.6927237510681152	▁an emia
D-40	-1.6927237510681152	anemia
P-40	-2.6294 -0.2812 -3.7872 -0.0731
S-302	Survival to hospital discharge was not different between groups (95.2 versus 88.2%; p = 0.2).<unk>
T-302	hospital discharge
H-302	-0.8292325735092163	▁sur vi val _ ▁to _ hospital _ dis charge
D-302	-0.8292325735092163	survival_ to_hospital_discharge
P-302	-1.2290 -0.0062 -1.0967 -1.3487 -3.8989 -0.5064 -0.7932 -0.5179 -0.0734 -0.1158 -0.3084 -0.0562
S-2008	BACKGROUND: Heart failure disease management programs can influence medical resource use and quality-adjusted survival.<unk>
T-2008	heart_failure disease medical
H-2008	-1.503077745437622	▁Heart _ pu issa nce _ de _ corrupt ion
D-2008	-1.503077745437622	Heart_puissance_de_corruption
P-2008	-0.2818 -0.4188 -6.2188 -0.1927 -0.0350 -0.6429 -1.9884 -0.1643 -5.5671 -0.0800 -2.3809 -0.0662
S-252	HDL-bound malondialdehyde and HDL-induced NO production by EC were quantified.<unk>
T-252	malondialdehyde
H-252	-0.5864816308021545	▁HD L - bound ▁malo ndi alde hy de ▁HD L - indu ce ▁production ▁EC
D-252	-0.5864816308021545	HDL-bound malondialdehyde HDL-induce production EC
P-252	-0.1570 -0.7439 -0.1398 -0.0618 -1.5052 -0.1749 -0.2769 -0.7581 -0.0477 -0.0513 -0.6295 -0.1035 -0.0126 -3.3142 -1.1442 -1.1134 -0.1762 -0.1464
S-627	During a median follow up of 11.4 (7.1-11.7) years, 466 participants developed HF.<unk>
T-627	follow_up hf
H-627	-1.1390172243118286	▁ HF
D-627	-1.1390172243118286	HF
P-627	-3.0363 -1.1614 -0.2783 -0.0801
S-1021	Studies and subsequent meta-analyses are mixed on the absolute value of routine NP assessment of ED patients.<unk>
T-1021	meta-analyses patients
H-1021	-1.0182242393493652	▁ NP
D-1021	-1.0182242393493652	NP
P-1021	-1.0660 -0.0905 -2.7340 -0.1823
S-676	In total, 9,535 patients were included, of whom 2,203 (23.1%) received trastuzumab.<unk>
T-676	patients trastuzumab
H-676	-0.24889075756072998	▁tras tuz um ab
D-676	-0.24889075756072998	trastuzumab
P-676	-0.9050 -0.0379 -0.1457 -0.2461 -0.1101 -0.0487
S-531	We studied 272 consecutive patients undergoing LVAD implantation from 2000 to 2010 at our institution.<unk>
T-531	patients lvad implantation
H-531	-0.5533580183982849	▁implant ation
D-531	-0.5533580183982849	implantation
P-531	-1.2052 -0.0226 -0.8706 -0.1151
S-1454	Seventy-seven cases with pre-HCT germline DNA and 178 controls were genotyped.<unk>
T-1454	dna genotyped
H-1454	-0.6217359304428101	▁h CT ▁germ line _ DNA ▁geno type
D-1454	-0.6217359304428101	hCT germline_DNA genotype
P-1454	-0.4281 -1.3890 -0.2138 -0.2218 -1.0401 -0.3977 -0.0883 -0.0159 -2.3263 -0.0964
S-1468	The treatment aims are to stabilize the patient, improve clinical symptoms, and increase long-term survival rates.<unk>
T-1468	patient clinical symptoms
H-1468	-1.226593017578125	
D-1468	-1.226593017578125	
P-1468	-2.4078 -0.0454
S-1874	RESULTS: One hundred forty-six patients were randomized, 70 to control and 76 to treatment.<unk>
T-1874	patients randomized
H-1874	-0.805237352848053	
D-1874	-0.805237352848053	
P-1874	-1.5422 -0.0682
S-1189	Of the 124 patients in the derivation cohort, 27% had CAD, including 15% with severe CAD.<unk>
T-1189	patients cad cad
H-1189	-1.8931609392166138	▁CAD
D-1189	-1.8931609392166138	CAD
P-1189	-4.6641 -0.9140 -0.1014
S-729	Fifty-one percent of patients had blood work drawn, and 26% had a medication dose changed.<unk>
T-729	patients blood medication
H-729	-1.4402140378952026	
D-729	-1.4402140378952026	
P-729	-2.7998 -0.0807
S-123	We evaluated CPCs and functional capacity (peak VO2) every 6 months for up to 2 years.<unk>
T-123	cpcs functional_capacity peak_vo2
H-123	-1.1498172283172607	▁c PC s ▁VO 2
D-123	-1.1498172283172607	cPCs VO2
P-123	-0.2965 -0.8911 -0.1830 -4.5073 -1.2019 -0.6673 -0.3016
S-502	The bottleneck stent model for chronic myocardial ischemia and heart failure in pigs.<unk>
T-502	bottleneck_stent chronic_myocardial_ischemia heart_failure
H-502	-0.8206314444541931	▁bottle ne ck _ ▁sten t ▁chronic _ ▁my o card ial _ ische mia ▁heart _ ▁failure ▁pig s
D-502	-0.8206314444541931	bottleneck_ stent chronic_ myocardial_ischemia heart_ failure pigs
P-502	-0.3500 -0.0054 -0.3294 -1.6181 -0.8136 -0.0270 -3.2108 -0.5006 -3.0956 -0.2276 -0.1639 -0.0743 -0.2031 -4.4424 -0.3926 -0.1111 -0.9826 -1.0900 -0.0559 -0.0396 -0.2152 -0.1051
S-1656	Gastrointestinal bleeding in patients with ventricular assist devices: what every cardiac nurse should know.<unk>
T-1656	gastrointestinal_bleeding patients ventricular_assist_devices cardiac nurse
H-1656	-0.5437909960746765	▁Gastro inte stin al _ ▁ble ed ing ▁vent ri cular _ assist ▁devices ▁cardiac ▁nurse
D-1656	-0.5437909960746765	Gastrointestinal_ bleeding ventricular_assist devices cardiac nurse
P-1656	-0.0827 -0.0089 -0.4090 -0.3039 -1.0607 -0.4039 -0.3410 -0.1487 -0.0683 -0.0798 -0.1286 -0.2343 -0.0909 -3.3489 -0.0143 -2.6654 -0.2991 -0.0997
S-489	In conclusion, e' is useful for estimating LV filling pressure in stable severe systolic HF.<unk>
T-489	lv_filling_pressure stable severe_systolic_hf
H-489	-1.1042991876602173	▁LV ▁fill ing _ pu issa nce ▁ HF
D-489	-1.1042991876602173	LV filling_puissance HF
P-489	-0.3916 -2.1600 -0.2644 -0.9977 -3.0715 -0.0267 -0.0133 -3.5982 -1.2488 -0.2511 -0.1239
S-1899	Exercise is generally associated with a 50% reduction in adverse events from coronary artery disease (CAD).<unk>
T-1899	exercise adverse_events coronary_artery_disease cad
H-1899	-1.557565689086914	▁corona ry ▁arter y ▁disease CAD
D-1899	-1.557565689086914	coronary artery diseaseCAD
P-1899	-4.6389 -0.4250 -1.5007 -0.4500 -2.9950 -2.1949 -0.1678 -0.0882
S-146	Remote monitoring after recent hospital discharge in patients with heart failure: a systematic review and network meta-analysis.<unk>
T-146	remote_monitoring hospital discharge patients heart_failure meta-analysis
H-146	-1.4096237421035767	▁hospital _ dis charge ▁patients _ con tre _ heart _ ▁failure ▁réseau
D-146	-1.4096237421035767	hospital_discharge patients_contre_heart_ failure réseau
P-146	-2.9187 -0.6174 -0.0729 -0.0082 -2.1725 -0.3860 -2.8960 -2.4381 -0.3508 -2.9678 -0.4053 -3.8895 -1.2128 -0.7085 -0.1000
S-695	Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes.<unk>
T-695	st2 ambulatory patients heart_failure functional_capacity outcomes
H-695	-1.487544298171997	▁Solu ble _ ▁ST 2 ▁in ▁ambula tory ▁patients _ with _ ▁heart _ ▁failure
D-695	-1.487544298171997	Soluble_ ST2 in ambulatory patients_with_ heart_ failure
P-695	-2.8978 -0.0145 -2.2610 -1.9897 -0.1731 -3.1250 -0.7212 -0.4788 -1.9245 -0.7861 -4.4532 -0.3409 -1.7504 -0.3673 -2.8298 -0.9880 -0.1868
S-1809	Cardiac overexpression of Mammalian enabled (Mena) exacerbates heart failure in mice.<unk>
T-1809	cardiac_overexpression mammalian_enabled mena heart_failure
H-1809	-0.7314678430557251	▁Card iac ▁Mamma lian _ ▁enabled ▁men a ▁heart _ ▁failure ▁mi ce
D-1809	-0.7314678430557251	Cardiac Mammalian_ enabled mena heart_ failure mice
P-1809	-0.7025 -0.0741 -0.8081 -0.2897 -1.1984 -1.1498 -2.1415 -0.1134 -0.1439 -0.7193 -2.0916 -1.2653 -0.0274 -0.1363 -0.1106
S-771	Titin hypophosphorylation importantly contributed to the underlying myocardial DD.<unk>
T-771	titin_hypophosphorylation myocardial_dd
H-771	-0.5281361937522888	▁Tit in _ hy phos phor y lation ▁my o card ial ▁ DD
D-771	-0.5281361937522888	Titin_hyphosphorylation myocardial DD
P-771	-0.0291 -0.9330 -1.3087 -0.6728 -0.1666 -0.3540 -1.0502 -0.0109 -1.1973 -0.2236 -0.1949 -0.1186 -1.6273 -0.0104 -0.2396 -0.3132
S-907	Baseline and 6-month echocardiograms were assessed for evidence of reverse remodeling.<unk>
T-907	baseline echocardiograms evidence reverse_remodeling
H-907	-0.7960814237594604	▁e cho card i ogram s
D-907	-0.7960814237594604	echocardiograms
P-907	-0.5867 -0.1236 -0.2773 -0.4982 -0.0099 -0.4139 -4.3100 -0.1490
S-1999	The indications for LVAS support were bridge to transplantation (54%) or destination therapy (46%).<unk>
T-1999	lvas bridge_to_transplantation destination_therapy
H-1999	-1.012072205543518	▁l VAS ▁implant ation ▁destination _ therapy
D-1999	-1.012072205543518	lVAS implantation destination_therapy
P-1999	-1.6582 -0.0707 -4.0486 -0.0201 -1.6384 -0.8519 -0.4732 -0.2499 -0.0975
S-164	Investigation of apoptosis in a canine model of chronic heart failure induced by tachycardia.<unk>
T-164	apoptosis chronic_heart_failure tachycardia
H-164	-1.1793758869171143	▁apo pto sis ▁can ine _ model _ de _ ▁chronic _ ▁heart _ ▁failure ▁ta chy car dia
D-164	-1.1793758869171143	apoptosis canine_model_de_ chronic_ heart_ failure tachycardia
P-164	-4.5575 -0.0288 -0.8896 -0.0202 -0.0312 -2.2169 -1.1747 -1.3697 -1.7597 -0.2169 -2.6041 -0.3535 -2.3687 -0.6602 -2.9733 -1.0426 -0.1127 -0.0181 -1.0419 -1.1785 -0.1483
S-399	BACKGROUND: Concentrations of soluble (s)ST2 predict prognosis in heart failure.<unk>
T-399	st2 prognosis heart_failure
H-399	-1.641619086265564	
D-399	-1.641619086265564	
P-399	-3.2519 -0.0314
S-183	No benefit of RAS- or β-blocker uptitration was observed in HFpEF.<unk>
T-183	β-blocker uptitration hfpef
H-183	-0.5774070024490356	▁ RAS - ▁β - block er _ up tit ration ▁ HF p EF
D-183	-0.5774070024490356	RAS- β-blocker_uptitration HFpEF
P-183	-0.5968 -0.0149 -0.5606 -2.7016 -0.0446 -0.2384 -0.1309 -2.0466 -0.3779 -1.6847 -0.0334 -0.5732 -0.0633 -0.0149 -0.4386 -0.0988 -0.1968
S-1103	Framingham Heart Study criteria were used to define HF, which was further classified according to EF.<unk>
T-1103	framingham_heart_study hf ef
H-1103	-0.4443431794643402	▁Fram ing ham ▁Heart _ ▁Study ▁ HF ▁EF
D-1103	-0.4443431794643402	Framingham Heart_ Study HF EF
P-1103	-0.0422 -0.0733 -0.0409 -0.6850 -1.5359 -0.1340 -0.7414 -0.0522 -1.2682 -0.2291 -0.0855
S-35	This guideline grades the evidence and recommendations using the ACP's clinical practice guidelines grading system.<unk>
T-35	evidence acp clinical_practice_guidelines
H-35	-1.4355751276016235	▁a CP ▁clinic al _ pru den ti ence
D-35	-1.4355751276016235	aCP clinical_prudentience
P-35	-1.4189 -0.0620 -1.6693 -0.0392 -0.4591 -4.7472 -0.7913 -0.9950 -4.0302 -1.4312 -0.1480
S-1199	Diuretics are frequently administered to relieve congestive symptoms in patients with heart failure (HF).<unk>
T-1199	diuretics symptoms patients heart_failure hf
H-1199	-1.3458563089370728	▁di ure tics
D-1199	-1.3458563089370728	diuretics
P-1199	-0.4041 -0.1449 -1.7783 -4.2554 -0.1466
S-208	Rates of ED visits and of intubations for congestive heart failure declined from 1996 to 2008.<unk>
T-208	intubations congestive_heart_failure
H-208	-0.5169392824172974	▁ED ▁in tuba tions ▁con ges tive _ ▁heart _ ▁failure
D-208	-0.5169392824172974	ED intubations congestive_ heart_ failure
P-208	-0.3828 -0.0507 -0.0435 -0.0320 -0.5909 -0.1719 -0.1398 -0.8421 -1.6611 -0.9782 -1.4566 -0.2220 -0.1486
S-1648	The EAST will test whether an early, modern rhythm control therapy can reduce cardiovascular complications in AF.<unk>
T-1648	east rhythm_control_therapy cardiovascular complications
H-1648	-0.7418688535690308	▁e AST ▁ rhythm _ control ▁ therapy ▁cardiovascular ▁complica tions ▁AF
D-1648	-0.7418688535690308	eAST rhythm_control therapy cardiovascular complications AF
P-1648	-1.5882 -0.1670 -0.3814 -1.4322 -0.5522 -0.0525 -1.4423 -0.0566 -1.5349 -1.2699 -0.0363 -1.5812 -0.1175 -0.1738
S-1778	BACKGROUND: Cardiac hypertrophy is accompanied by significant alterations in energy metabolism.<unk>
T-1778	cardiac_hypertrophy energy_metabolism
H-1778	-0.5015328526496887	▁Card iac _ ▁hyper trop hy ▁énergétique
D-1778	-0.5015328526496887	Cardiac_ hypertrophy énergétique
P-1778	-0.5219 -0.1387 -0.4081 -0.3028 -0.0153 -0.0896 -1.8752 -1.0807 -0.0815
S-560	The youngest patients were less likely to have clinical and radiological signs of HF during hospitalization.<unk>
T-560	patients clinical radiological hf hospitalization
H-560	-0.8526803255081177	▁ HF
D-560	-0.8526803255081177	HF
P-560	-2.5104 -0.1610 -0.6206 -0.1187
S-959	Nicorandil (3 mg/kg/day) was given orally with or without doxorubicin treatment.<unk>
T-959	nicorandil orally doxorubicin
H-959	-0.2526077330112457	▁Nico rand il ▁do xor ubi cin
D-959	-0.2526077330112457	Nicorandil doxorubicin
P-959	-0.0067 -0.0381 -0.5287 -0.4571 -0.1507 -0.1605 -0.1159 -0.7579 -0.0579
S-621	Frailty and risk for heart failure in older adults: the health, aging, and body composition study.<unk>
T-621	frailty heart_failure health
H-621	-1.4483405351638794	▁Fra il ty _ de _ f ré que nce _ f ré que nce ▁heart _ ▁failure ▁ aging
D-621	-1.4483405351638794	Frailty_de_fréquence_fréquence heart_ failure aging
P-621	-3.5668 -0.0450 -1.9243 -3.4339 -1.6102 -0.3400 -3.8199 -0.0839 -0.1792 -0.0078 -1.4788 -4.6983 -0.0796 -0.0728 -0.0051 -2.1850 -0.3704 -3.1795 -1.9594 -0.8188 -1.8783 -0.1266
S-747	Heart T2* was confirmed to be highly predictive over 1 year for heart failure and arrhythmias.<unk>
T-747	heart heart_failure arrhythmias
H-747	-1.6956433057785034	▁Heart
D-747	-1.6956433057785034	Heart
P-747	-0.5241 -4.4350 -0.1278
S-1611	Interactors of the DEGs were retrieved with Osprey and then networks were constructed.<unk>
T-1611	degs osprey
H-1611	-0.756506621837616	▁DE G s ▁o spre y ▁network s
D-1611	-0.756506621837616	DEGs osprey networks
P-1611	-2.8915 -2.2559 -0.3951 -0.2080 -0.0118 -0.0763 -1.4099 -0.0934 -0.1836 -0.0396
S-843	In addition, the beneficial effects of HRQoL from exercise training were not modulated by baseline Hgb.<unk>
T-843	hrqol exercise training baseline hgb
H-843	-0.829531192779541	▁HR Qo L ▁h gb
D-843	-0.829531192779541	HRQoL hgb
P-843	-1.4179 -0.0661 -0.5919 -3.2893 -0.2200 -0.1760 -0.0455
S-1401	All top 10 NOC outcomes demonstrated statistically significant improvement in outcome ratings from admission to discharge.<unk>
T-1401	noc outcomes outcome admission discharge
H-1401	-1.0963966846466064	▁NO c
D-1401	-1.0963966846466064	NOc
P-1401	-0.9364 -1.1898 -2.0654 -0.1940
S-945	AF-free probability after catheter ablation and factors relating to maintenance of sinus rhythm were investigated.<unk>
T-945	catheter_ablation sinus_rhythm
H-945	-0.9242731332778931	▁AF - free ▁probabil ity ▁cat heter ▁ab lation ▁maintenance ▁sinus ▁ rhythm
D-945	-0.9242731332778931	AF-free probability catheter ablation maintenance sinus rhythm
P-945	-0.8252 -0.5336 -0.7002 -5.2337 -0.3270 -1.5615 -0.0204 -1.0780 -0.0118 -1.1689 -1.2461 -0.5462 -0.1408 -0.2878 -0.1828
S-982	It is, however, an important disease, accounting for 10% of paediatric cardiac transplants in children.<unk>
T-982	disease accounting cardiac_transplants
H-982	-1.2008640766143799	▁pa e dia tric ▁cardiac ▁transplant s
D-982	-1.2008640766143799	paediatric cardiac transplants
P-982	-2.1311 -0.0280 -3.7480 -0.3367 -1.8055 -1.2775 -0.1945 -1.1971 -0.0893
S-1400	Data were obtained from 268 inpatient records of patients discharged with HF during a 1-year period.<unk>
T-1400	inpatient patients discharged hf
H-1400	-0.5522245168685913	▁in patient ▁records ▁ HF
D-1400	-0.5522245168685913	inpatient records HF
P-1400	-0.0635 -0.1240 -1.5321 -1.3901 -0.2196 -0.4370 -0.0993
S-68	CONCLUSIONS: This meta-analysis identified strong reliable mortality predictors in ICD-HF patients.<unk>
T-68	meta-analysis mortality patients
H-68	-1.009724736213684	▁i CD - HF
D-68	-1.009724736213684	iCD-HF
P-68	-2.6589 -0.8660 -0.1429 -0.2579 -1.9034 -0.2292
S-5	However, there were no measurable overall improvements for patients admitted with pneumonia or surgical conditions.<unk>
T-5	patients pneumonia surgical conditions
H-5	-0.8726834654808044	▁pneu monia ▁conditions
D-5	-0.8726834654808044	pneumonia conditions
P-5	-0.0890 -0.9097 -3.1819 -0.1369 -0.0459
S-1223	Patients were receiving optimal therapy and most had been hospitalized for a cardiovascular reason within 180 days of inclusion.<unk>
T-1223	patients therapy hospitalized cardiovascular
H-1223	-1.368463397026062	▁cardiovascular
D-1223	-1.368463397026062	cardiovascular
P-1223	-3.1996 -0.7645 -0.1413
S-290	Interestingly, the simpler laboratory report model was statistically no different than the ARIC HF model.<unk>
T-290	report aric hf
H-290	-0.865769624710083	▁a RIC ▁ HF
D-290	-0.865769624710083	aRIC HF
P-290	-1.4215 -0.5300 -2.3716 -0.1214 -0.5921 -0.1579
S-848	All patients underwent device implantation and were randomly assigned to have CRT capability turned on or off.<unk>
T-848	patients implantation crt
H-848	-0.4468434751033783	▁implant ation ▁c RT
D-848	-0.4468434751033783	implantation cRT
P-848	-0.3559 -0.0221 -0.4075 -0.3702 -1.4416 -0.0838
S-1467	It is a life-threatening situation in which diagnosis and initiation of therapy are crucial.<unk>
T-1467	diagnosis therapy
H-1467	-0.8164164423942566	▁ therapy
D-1467	-0.8164164423942566	therapy
P-1467	-2.0282 -1.0648 -0.0701 -0.1026
S-1852	We will synthesise the results narratively and, if appropriate, will pool results for meta-analysis.<unk>
T-1852	meta-analysis
H-1852	-0.8134837746620178	
D-1852	-0.8134837746620178	
P-1852	-1.5606 -0.0664
S-792	Future studies should extend and replicate our findings, including the establishment of its responsiveness to clinical change.<unk>
T-792	clinical change
H-792	-1.2240606546401978	
D-792	-1.2240606546401978	
P-792	-2.4206 -0.0275
S-1008	The deficit index ranged from 0.02-0.75, with a mean (SD) of 0.25 (0.13).<unk>
T-1008	deficit_index
H-1008	-0.9031205177307129	▁deficit
D-1008	-0.9031205177307129	deficit
P-1008	-0.5111 -2.0783 -0.1199
S-1716	RESULTS: Medicare's post-acute care transfer policy led to immediate declines in length of stay.<unk>
T-1716	medicare policy
H-1716	-1.3001258373260498	▁Medica re ▁post - a cute _ care _ transfer _ policy
D-1716	-1.3001258373260498	Medicare post-acute_care_transfer_policy
P-1716	-0.1863 -0.0033 -3.8140 -0.0151 -0.0267 -0.0204 -0.6300 -4.2723 -1.3331 -1.5584 -3.0407 -0.4796 -2.5587 -0.2633
S-892	There may be some delayed benefit when the QRS is ≥160 ms, but this needs further investigation.<unk>
T-892	qrs
H-892	-1.1734262704849243	
D-892	-1.1734262704849243	
P-892	-2.2918 -0.0550
S-216	RESULTS: Of the 2,374,428 ED visits, 32,036 (1.3%) were for CHF.<unk>
T-216	chf
H-216	-1.03815495967865	▁ED ▁CHF
D-216	-1.03815495967865	ED CHF
P-216	-1.6642 -2.2657 -0.1558 -0.0669
S-692	Diet score components, vegetables, nuts, and whole grain intake, were inversely associated with mortality.<unk>
T-692	mortality
H-692	-2.23201584815979	▁vegetables ▁nu ts ▁grain ▁in take
D-692	-2.23201584815979	vegetables nuts grain intake
P-692	-5.5657 -2.2217 -0.0180 -4.2398 -1.7026 -0.7687 -3.1089 -0.2307
S-619	CONCLUSIONS: Anecdotal evidence of perceived benefit was expressed in participant satisfaction responses.<unk>
T-619	evidence
H-619	-1.0226999521255493	
D-619	-1.0226999521255493	
P-619	-1.9996 -0.0458
S-1508	Contrasting groups validity, internal consistency, and test-retest reliability were supported as well.<unk>
T-1508	
H-1508	-1.752363920211792	▁groupes _ ▁valid ity
D-1508	-1.752363920211792	groupes_ validity
P-1508	-3.6696 -1.4529 -1.4917 -0.5305 -3.2311 -0.1384
S-49	Data supporting iron use come mainly from 1 large trial, and long-term effects are unknown.<unk>
T-49	
H-49	-0.5974085330963135	▁ir on
D-49	-0.5974085330963135	iron
P-49	-0.6932 -0.0586 -1.5497 -0.0881
S-821	Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertension.<unk>
T-821	prognostic right_ventricular_contractile_reserve patients pulmonary_hypertension
H-821	-0.36169910430908203	▁vent ri cular _ contract ile _ ▁reserve ▁pulmonar y ▁hyper tension
D-821	-0.36169910430908203	ventricular_contractile_ reserve pulmonary hypertension
P-821	-0.1488 -0.1247 -0.1889 -0.3903 -0.5539 -0.8362 -0.2435 -0.4156 -0.7288 -0.1730 -1.0560 -0.0006 -0.1283 -0.0753
S-1439	Variability in QT intervals was expressed as the SD of all QT intervals (SDQT).<unk>
T-1439	qt_intervals sd_of_all_qt_intervals sdqt
H-1439	-1.1016719341278076	▁ QT _ ▁interval s ▁SD QT
D-1439	-1.1016719341278076	QT_ intervals SDQT
P-1439	-0.7343 -0.4372 -2.3624 -0.3331 -0.0809 -0.0620 -5.1330 -0.5945 -0.1777
S-1297	Seven days after the emergency cardiac catheterization the patient was extubated and transferred to our intermediate care.<unk>
T-1297	cardiac_catheterization patient extubated transferred
H-1297	-1.082955002784729	▁emergency _ ▁cardiac _ ▁cat heter ization
D-1297	-1.082955002784729	emergency_ cardiac_ catheterization
P-1297	-0.3446 -0.8565 -0.0723 -4.1611 -1.2954 -0.0180 -1.3024 -1.6405 -0.0557
S-245	Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties.<unk>
T-245	exercise training patients chronic_heart_failure high-density_lipoprotein
H-245	-2.0273358821868896	▁implant ation _ des _ chron _ heart _ ▁failure ▁implant ation _ de _ la _ tension _ ▁lipo prote in
D-245	-2.0273358821868896	implantation_des_chron_heart_ failure implantation_de_la_tension_ lipoprotein
P-245	-4.5368 -1.3928 -2.7698 -4.0622 -0.3110 -5.0497 -2.3501 -1.5734 -0.6134 -2.5921 -3.7870 -0.3347 -1.5169 -1.6686 -0.4651 -4.3070 -1.3521 -3.9063 -1.1726 -1.0737 -0.6538 -1.2251 -1.7926 -0.1494
S-931	Specifically, we explored whether resistin underlies acute anthracycline-induced cardiotoxicity.<unk>
T-931	resistin acute anthracycline-induced_cardiotoxicity
H-931	-0.7674546241760254	▁resist in ▁a cute ▁an thra cycli ne - indu ced ▁cardio toxic ity
D-931	-0.7674546241760254	resistin acute anthracycline-induced cardiotoxicity
P-931	-1.1482 -0.4128 -0.2516 -0.0196 -0.5532 -0.0577 -2.4611 -1.1777 -1.5670 -0.0033 -3.1803 -0.2762 -0.2709 -0.5822 -0.1747 -0.1428
S-1869	BAT results in centrally mediated reduction of sympathetic outflow and increased parasympathetic activity.<unk>
T-1869	bat sympathetic_outflow parasympathetic_activity
H-1869	-1.0112954378128052	▁BAT ▁sympa the tic _ ▁out flow ▁para sy mpa the tic ▁activity
D-1869	-1.0112954378128052	BAT sympathetic_ outflow parasympathetic activity
P-1869	-0.6800 -2.6445 -0.4187 -2.4561 -0.9608 -0.8147 -0.2153 -0.0933 -0.4554 -0.1707 -2.7619 -2.1127 -1.0292 -0.2012 -0.1547
S-1065	T1 mapping may be a useful technique for detecting early but clinically significant myocardial fibrosis.<unk>
T-1065	t1_mapping clinically myocardial_fibrosis
H-1065	-1.6540632247924805	
D-1065	-1.6540632247924805	
P-1065	-3.2484 -0.0597
S-1447	The effect of acute autonomic nervous system modulation on QTV appears to be limited in HF patients.<unk>
T-1447	acute autonomic_nervous_system qtv hf patients
H-1447	-0.8815663456916809	▁a cute _ ▁autonomi c _ ▁ner vous _ system _ ▁modul ation ▁Q TV ▁ HF
D-1447	-0.8815663456916809	acute_ autonomic_ nervous_system_ modulation QTV HF
P-1447	-0.4428 -0.0058 -0.2261 -1.5700 -0.2937 -0.3736 -2.8440 -4.0984 -1.6778 -0.4702 -1.6975 -0.9793 -0.0221 -0.1353 -0.1769 -1.0812 -0.1068 -0.4216 -0.1264
S-960	Heart rate and aortic blood flow were recorded 24 h after receiving the last dose of doxorubicin.<unk>
T-960	heart_rate aortic blood_flow doxorubicin
H-960	-0.567001223564148	▁Heart _ a or tic _ ▁blood _ ▁flow ▁do xor ubi cin
D-960	-0.567001223564148	Heart_aortic_ blood_ flow doxorubicin
P-960	-0.3512 -0.6435 -2.5028 -0.0879 -1.9815 -0.2123 -0.4814 -0.6450 -0.9045 -0.1948 -0.0561 -0.1875 -0.0652 -0.1240 -0.0676
S-327	During RVPO with BiVP, CO only correlated with RS synchrony and CS (P < 0.05).<unk>
T-327	rvpo bivp correlated rs_synchrony
H-327	-0.5763583779335022	▁ RV PO ▁Bi VP ▁RS ▁synchron y ▁CS
D-327	-0.5763583779335022	RVPO BiVP RS synchrony CS
P-327	-0.2859 -0.1381 -2.4078 -1.4345 -0.0311 -1.3808 -0.0576 -0.2519 -0.0235 -0.1545 -0.1743
S-903	Usefulness and consequences of cardiac resynchronization therapy in dialysis-dependent patients with heart failure.<unk>
T-903	cardiac_resynchronization_therapy patients heart_failure
H-903	-0.786207914352417	▁cardiac _ re syn chron ization _ therapy ▁di al ysis - dependent ▁patients ▁heart _ ▁failure
D-903	-0.786207914352417	cardiac_resynchronization_therapy dialysis-dependent patients heart_ failure
P-903	-0.2763 -1.4683 -0.9814 -0.0099 -0.0002 -1.1680 -1.8112 -0.4378 -0.1611 -0.0641 -0.0292 -0.6189 -0.1582 -1.4719 -1.2859 -1.1226 -3.6149 -0.1481 -0.1100
S-1933	However, for cardiovascular death or HF hospitalization, exercise training had a greater impact on patients with lower BTES.<unk>
T-1933	cardiovascular_death hf hospitalization exercise training patients btes
H-1933	-1.1723215579986572	▁cardiovascular _ ▁death ▁ HF ▁hospital isation ▁b tes
D-1933	-1.1723215579986572	cardiovascular_ death HF hospitalisation btes
P-1933	-1.1967 -2.1057 -1.3042 -1.1632 -0.0007 -3.1130 -1.3958 -1.9596 -0.4278 -0.1681 -0.0608
S-1500	Low skeletal muscle mass correlated with poorer VO2 max (r=0.67, p=0.004).<unk>
T-1500	skeletal_muscle correlated vo2_max
H-1500	-1.106979250907898	▁skelet al _ ▁muscle _ ▁mass ▁VO 2
D-1500	-1.106979250907898	skeletal_ muscle_ mass VO2
P-1500	-0.5413 -0.4398 -1.0465 -1.5010 -1.2064 -1.9252 -3.8108 -0.1421 -0.3886 -0.0680
S-526	Because Ees is unaltered, improved ventricular-arterial coupling is responsible for increased SV.<unk>
T-526	ees ventricular-arterial_coupling
H-526	-0.3719136416912079	▁vent ri cular - arte rial ▁coup ling ▁SV
D-526	-0.3719136416912079	ventricular-arterial coupling SV
P-526	-0.0229 -0.1194 -0.1040 -0.4995 -0.0564 -0.1341 -0.3232 -2.5185 -0.0490 -0.1117 -0.1522
S-77	Within each strategy, participants were randomized in a double-blind, 2:1 ratio to active treatment or placebo.<unk>
T-77	randomized double-blind active placebo
H-77	-1.1605548858642578	▁double - blind ▁active
D-77	-1.1605548858642578	double-blind active
P-77	-2.5707 -0.0201 -0.0027 -0.8056 -3.4003 -0.1639
S-1213	RESULTS: Myocardial PDE2 expression and activity were ~2-fold higher in advanced human HF.<unk>
T-1213	myocardial pde2 expression activity hf
H-1213	-0.8589681386947632	▁My o card ial _ p de 2 ▁expression ▁ HF
D-1213	-0.8589681386947632	Myocardial_pde2 expression HF
P-1213	-1.4461 -0.0738 -0.0759 -0.0413 -1.2464 -1.7335 -0.4352 -0.4200 -0.2450 -2.6081 -2.5110 -0.1740 -0.1562
S-986	There is a small subgroup of children that have diastolic failure from cardiomyopathic restriction to flow.<unk>
T-986	diastolic_failure cardiomyopathic
H-986	-0.9077460169792175	▁dia sto lic _ ▁failure ▁cardio my o pathi c ▁restriction
D-986	-0.9077460169792175	diastolic_ failure cardiomyopathic restriction
P-986	-1.1031 -0.2246 -2.8433 -0.8999 -1.2069 -0.3459 -2.1989 -0.7019 -0.0136 -0.1796 -0.5341 -1.4926 -0.0564
S-1850	We will include clinical outcomes such as hospitalisations, readmissions and mortality, if data is available.<unk>
T-1850	clinical outcomes hospitalisations readmissions mortality
H-1850	-0.5572170615196228	▁hospital isation s ▁read missions ▁mortal ity
D-1850	-0.5572170615196228	hospitalisations readmissions mortality
P-1850	-2.9757 -0.0110 -0.1331 -1.2888 -0.0468 -0.1202 -0.2438 -0.1452 -0.0503
S-1925	BACKGROUND: Psychosocial factors may influence adherence with exercise training for heart failure (HF) patients.<unk>
T-1925	psychosocial exercise training heart_failure hf patients
H-1925	-1.4422866106033325	▁psycho social ▁factors
D-1925	-1.4422866106033325	psychosocial factors
P-1925	-0.8300 -0.0087 -2.0729 -4.2230 -0.0769
S-1436	The aim of the present study was to investigate the role of autonomic nervous system activity on QTV.<unk>
T-1436	autonomic_nervous_system activity qtv
H-1436	-0.7808306217193604	▁autonomi c _ ▁ner vous _ system _ ▁activity ▁Q TV
D-1436	-0.7808306217193604	autonomic_ nervous_system_ activity QTV
P-1436	-0.6980 -0.1185 -0.3440 -2.2155 -2.3195 -1.2337 -0.5646 -0.7196 -1.5577 -0.0985 -0.1601 -0.0629 -0.0583
S-2004	There were no pump exchanges, pump malfunctions, pump thrombosis, or hemolysis events.<unk>
T-2004	pump pump pump_thrombosis hemolysis
H-2004	-0.8833412528038025	▁pump _ change s ▁pump ▁ thro mbo sis ▁hem ol ysis
D-2004	-0.8833412528038025	pump_changes pump thrombosis hemolysis
P-2004	-0.0491 -1.3114 -3.1844 -0.0931 -0.8023 -2.6581 -0.3060 -0.3273 -2.2887 -0.5336 -0.0579 -0.0660 -0.6489 -0.0403
S-883	For this substudy, we excluded patients in atrial fibrillation and those with a previous pacemaker.<unk>
T-883	patients atrial_fibrillation pacemaker
H-883	-0.6473515629768372	▁at rial _ ▁fi bril lation ▁pace maker
D-883	-0.6473515629768372	atrial_ fibrillation pacemaker
P-883	-1.8562 -0.0794 -0.6262 -2.2461 -0.0432 -0.0289 -1.2005 -0.1442 -0.2015 -0.0474
S-1768	Measures included body mass index and CRF quantified as duration of maximal treadmill exercise testing.<unk>
T-1768	body_mass_index crf exercise
H-1768	-0.6514504551887512	▁body _ ▁index ▁c RF ▁tre ad m ill
D-1768	-0.6514504551887512	body_ index cRF treadmill
P-1768	-0.8087 -0.8491 -1.5269 -0.1539 -0.0367 -0.4218 -0.0233 -0.0962 -0.4117 -2.7142 -0.1234
S-1426	In this study, human myocardial tissue was used to examine the state of PKA subunits.<unk>
T-1426	myocardial_tissue pka
H-1426	-0.7925094366073608	▁human _ mé o card ial _ ▁tissu e ▁p KA
D-1426	-0.7925094366073608	human_méocardial_ tissue pKA
P-1426	-2.0650 -0.5047 -3.5867 -0.1294 -0.1093 -0.0373 -0.5244 -0.8214 -0.2361 -0.5033 -0.7993 -0.8901 -0.0956
S-1791	A systematic search of the electronic databases and the World Health Organization website was undertaken for HF in LA.<unk>
T-1791	world_health_organization hf
H-1791	-1.0117077827453613	▁electronic ▁database s ▁World _ ▁Health ▁Organization ▁ HF
D-1791	-1.0117077827453613	electronic databases World_ Health Organization HF
P-1791	-3.4366 -3.4510 -0.0269 -0.4460 -0.1958 -1.4184 -0.5764 -0.7176 -0.0854 -0.6422 -0.1327
S-1321	RESULTS: Attrition was 30% but with 100% compliance to exercise and injections in patients who completed the study.<unk>
T-1321	attrition compliance exercise injections patients
H-1321	-0.8901984691619873	▁implant ions
D-1321	-0.8901984691619873	implantions
P-1321	-3.1838 -0.1241 -0.2130 -0.0400
S-626	RESULTS: Mean age of participants was 74 ± 3 years; 48% were men and 59% were white.<unk>
T-626	
H-626	-0.9370092153549194	
D-626	-0.9370092153549194	
P-626	-1.8119 -0.0622
S-1219	This may constitute an important defense mechanism during cardiac stress, for example, by antagonizing excessive β-AR drive.<unk>
T-1219	cardiac_stress β-ar drive
H-1219	-1.450143575668335	▁cardiac _ stress ▁β - AR
D-1219	-1.450143575668335	cardiac_stress β-AR
P-1219	-2.9470 -2.4421 -2.2040 -2.0328 -0.0443 -0.1790 -1.6232 -0.1287
S-1681	This month's "Ethics Rounds" presents a case in which these 2 complexities overlapped.<unk>
T-1681	ethics_rounds
H-1681	-0.4983636140823364	▁e thi cs _ ▁Round s
D-1681	-0.4983636140823364	ethics_ Rounds
P-1681	-0.9110 -0.0281 -0.2569 -1.8332 -0.2268 -0.0883 -0.5893 -0.0532
S-1928	Higher PSSS indicated higher levels of social support, whereas higher BTES indicated more barriers to exercise.<unk>
T-1928	psss btes exercise
H-1928	-0.9889481067657471	▁PS SS ▁social _ support ▁b tes ▁barrier s
D-1928	-0.9889481067657471	PSSS social_support btes barriers
P-1928	-3.1424 -1.1620 -0.3303 -1.3871 -1.6941 -0.3447 -0.2812 -1.0116 -0.0308 -1.3363 -0.1579
S-650	The effectiveness of bisoprolol in reducing mortality has also also been documented in a number of studies.<unk>
T-650	bisoprolol mortality
H-650	-1.1012616157531738	bis o pro lol
D-650	-1.1012616157531738	bisoprolol
P-650	-2.5142 -0.1840 -0.1457 -0.7609 -2.9017 -0.1011
S-623	BACKGROUND: Frailty is common in the elderly and is associated with adverse health outcomes.<unk>
T-623	frailty health outcomes
H-623	-0.9162127375602722	▁Fra il ty ▁el der ly ▁advers e
D-623	-0.9162127375602722	Frailty elderly adverse
P-623	-0.6619 -0.8424 -3.1637 -0.3956 -0.1375 -0.5107 -0.5623 -0.0475 -2.7892 -0.0513
S-221	CONCLUSION: The rates of annual ED visits for CHF and intubation rates declined from 1996 to 2008.<unk>
T-221	chf intubation
H-221	-0.7862130999565125	▁ED ▁visit s ▁CHF ▁in tub ation
D-221	-0.7862130999565125	ED visits CHF intubation
P-221	-1.9796 -3.6476 -0.0784 -0.0323 -0.0027 -0.0131 -0.0293 -1.2168 -0.0761
S-1422	Research is needed to explore whether physician continuity is important for other conditions and in settings other than recent hospital discharge.<unk>
T-1422	physician conditions hospital discharge
H-1422	-0.6825670599937439	▁physician _ continu ity ▁conditions
D-1422	-0.6825670599937439	physician_continuity conditions
P-1422	-0.2841 -0.7492 -0.6193 -0.2730 -0.2495 -2.5060 -0.0968
S-1714	PARTICIPANTS: Medicare fee-for-service beneficiaries associated with 2,101,481 hospitalizations.<unk>
T-1714	medicare hospitalizations
H-1714	-0.4508683681488037	▁Medica re ▁fee - for - service
D-1714	-0.4508683681488037	Medicare fee-for-service
P-1714	-0.0478 -0.0041 -1.2383 -0.2930 -0.0679 -0.0876 -0.0177 -2.1698 -0.1316
S-1368	However, clinical and therapeutic implications are indistinct and need to be elucidated in further studies.<unk>
T-1368	clinical therapeutic
H-1368	-0.4674091041088104	▁clinic al ▁ therapeut ic
D-1368	-0.4674091041088104	clinical therapeutic
P-1368	-1.1338 -0.0303 -0.9221 -0.0123 -0.5325 -0.5804 -0.0605
S-1315	Increased attention to these high-risk patients is needed given the lack of improvement in their long-term prognosis.<unk>
T-1315	patients prognosis
H-1315	-1.0762118101119995	
D-1315	-1.0762118101119995	
P-1315	-2.1159 -0.0365
S-1983	Exercise attendance was 84% (SD, 14%) and diet adherence was 99% (SD, 1%).<unk>
T-1983	exercise
H-1983	-0.896880030632019	SD ▁die t _ ad her ence SD
D-1983	-0.896880030632019	SD diet_adherenceSD
P-1983	-3.7422 -1.8307 -0.0379 -1.7329 -0.7700 -0.1248 -0.0104 -0.3241 -0.3023 -0.0936
S-1862	RESULTS: The sample (n = 25) was predominately male (76%) with an average age of 62 years.<unk>
T-1862	
H-1862	-0.6925497651100159	
D-1862	-0.6925497651100159	
P-1862	-1.3415 -0.0436
S-2013	The model can be used to evaluate parallel-group and single-cohort study designs and hypothetical programs.<unk>
T-2013	
H-2013	-0.7775164246559143	▁parallel - group ▁co hor t
D-2013	-0.7775164246559143	parallel-group cohort
P-2013	-2.4407 -0.0738 -0.0228 -2.5108 -0.0364 -0.1711 -0.8507 -0.1137
S-1382	These results suggest renal DNx improves cardiac autonomic balance in CHF by a reduction of sympathetic tone.<unk>
T-1382	renal_dnx cardiac autonomic_balance chf sympathetic_tone
H-1382	-0.4497668445110321	▁renal ▁DN x ▁cardiac _ ▁autonomi c ▁balance ▁CHF ▁sympa the tic ▁tone
D-1382	-0.4497668445110321	renal DNx cardiac_ autonomic balance CHF sympathetic tone
P-1382	-0.0394 -0.9894 -0.0181 -0.0421 -1.8308 -0.1091 -0.3719 -0.3607 -0.0225 -0.0238 -0.3653 -2.0247 -0.1743 -0.2806 -0.0937
S-29	Treatment of anemia in patients with heart disease: a clinical practice guideline from the American College of Physicians.<unk>
T-29	anemia patients heart_disease clinical_practice_guideline american_college_of_physicians
H-29	-1.2895649671554565	▁an emia ▁patients _ con tre _ heart _ ▁disease ▁clinic al _ prac ti line ▁American ▁College _ of _ ▁Physic ians
D-29	-1.2895649671554565	anemia patients_contre_heart_ disease clinical_practiline American College_of_ Physicians
P-29	-1.2122 -0.0328 -3.4308 -0.6460 -2.6059 -2.0403 -0.9044 -2.2596 -0.9057 -3.3080 -3.3713 -0.0148 -0.1282 -1.8497 -1.2486 -2.0726 -3.0452 -0.6982 -0.0501 -1.4466 -0.0752 -0.6337 -0.0410 -0.1770 -0.0410
S-386	Incidence and predictors of end-stage renal disease in outpatients with systolic heart failure.<unk>
T-386	incidence end-stage_renal_disease outpatients systolic_heart_failure
H-386	-0.8241746425628662	▁end - s tage ▁renal ▁disease ▁out patient s ▁sy sto lic _ ▁heart _ ▁failure
D-386	-0.8241746425628662	end-stage renal disease outpatients systolic_ heart_ failure
P-386	-0.2531 -0.1041 -0.3001 -0.0015 -0.2890 -1.0618 -2.0775 -0.0110 -0.0307 -0.5625 -0.0843 -4.8476 -0.9698 -1.2286 -1.4795 -1.3060 -0.1425 -0.0854
S-1135	The parasympathetic neurotransmission can be improved by acetylcholinesterase inhibition.<unk>
T-1135	parasympathetic_neurotransmission acetylcholinesterase_inhibition
H-1135	-0.45331010222435	▁para sy mpa the tic _ ▁neuro trans mission ▁a ce tyl cho line ster ase ▁inhibi tion
D-1135	-0.45331010222435	parasympathetic_ neurotransmission acetylcholinesterase inhibition
P-1135	-0.0237 -0.1483 -0.0443 -1.1460 -1.2509 -0.8787 -0.1007 -0.0009 -0.0606 -0.1065 -0.0235 -0.1231 -1.6542 -0.1590 -0.1744 -2.2889 -0.6331 -0.0300 -0.1600 -0.0592
S-515	Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients.<unk>
T-515	heart_rate_reduction ivabradine left_ventricle heart_failure patients
H-515	-1.1462293863296509	▁heart _ re duction ▁i va bra dine ▁left ▁vent ric le ▁heart _ ▁failure
D-515	-1.1462293863296509	heart_reduction ivabradine left ventricle heart_ failure
P-515	-1.6264 -1.6794 -1.1240 -0.0118 -0.0687 -0.0458 -1.4170 -0.0484 -1.8611 -0.8060 -4.6232 -0.9869 -0.7938 -0.9554 -2.2111 -0.9789 -0.2479
S-2018	Heart Failure: Pathophysiology, Diagnosis, Medical Treatment Guidelines, and Nursing Management.<unk>
T-2018	heart_failure pathophysiology diagnosis medical_treatment nursing
H-2018	-0.4353622794151306	▁Heart _ ▁Fail ure ▁Path o phy si ology ▁Medical ▁Treatment _ ▁Guide lines ▁Nur sing ▁Management
D-2018	-0.4353622794151306	Heart_ Failure Pathophysiology Medical Treatment_ Guidelines Nursing Management
P-2018	-0.1111 -0.8070 -0.0925 -0.0346 -2.3047 -0.1686 -0.0023 -0.2262 -0.3187 -0.5944 -0.1098 -1.8099 -0.7359 -0.1545 -0.0824 -0.0995 -0.4882 -0.0825 -0.0491
S-198	Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines.<unk>
T-198	diagnosis medical heart_failure canadian_cardiovascular_society
H-198	-1.214070200920105	▁medical _ management _ of _ heart _ ▁failure ▁Canadian _ ▁Card io vas cular _ ▁Society
D-198	-1.214070200920105	medical_management_of_heart_ failure Canadian_ Cardiovascular_ Society
P-198	-2.3276 -1.8641 -0.4570 -0.9589 -3.3428 -0.3994 -0.7232 -0.3735 -2.1952 -2.8434 -0.4232 -2.7114 -0.5852 -0.6413 -0.2355 -1.1197 -0.7310 -1.0066 -0.1285
S-13	Biomarkers of neurohormonal stimulation, inflammation, and endothelial dysfunction were measured.<unk>
T-13	biomarkers neurohormonal_stimulation inflammation endothelial_dysfunction
H-13	-0.17200729250907898	▁bio mark ers ▁neuro hormon al ▁stimul ation ▁ inflammation ▁en dot heli al ▁dys function
D-13	-0.17200729250907898	biomarkers neurohormonal stimulation inflammation endothelial dysfunction
P-13	-0.5410 -0.0047 -0.0182 -0.3536 -0.0821 -0.1479 -0.2349 -0.0203 -0.0521 -0.0089 -0.0786 -0.6745 -0.0528 -0.0167 -0.2039 -0.4065 -0.1179 -0.0815
S-426	Echocardiographic predictors of reverse remodeling after cardiac resynchronization therapy and subsequent events.<unk>
T-426	echocardiographic reverse_remodeling cardiac_resynchronization_therapy
H-426	-0.6430808901786804	▁e cho car dio graphic ▁rever se ▁remodel ing ▁cardiac _ re syn chron ization
D-426	-0.6430808901786804	echocardiographic reverse remodeling cardiac_resynchronization
P-426	-0.5810 -0.1856 -0.0872 -1.0268 -0.6895 -2.8798 -0.0079 -0.3546 -0.1035 -0.0364 -1.0711 -1.1541 -0.0009 -0.0001 -0.8709 -1.8165 -0.0665
S-634	Neurohormonal abnormalities contribute to the pathophysiology of congestive heart failure (CHF).<unk>
T-634	neurohormonal pathophysiology congestive_heart_failure chf
H-634	-0.6065922379493713	▁Neuro hormon al ▁ab normal ities ▁pat ho phy si ology ▁con ges tive _ heart _ ▁failure CH f
D-634	-0.6065922379493713	Neurohormonal abnormalities pathophysiology congestive_heart_ failureCHf
P-634	-0.5883 -0.0494 -0.0376 -1.0806 -0.0392 -0.8431 -2.0974 -0.0293 -0.0194 -0.2603 -0.7903 -0.6936 -0.1404 -0.1793 -0.4118 -2.7122 -0.5681 -1.5374 -0.7010 -0.3689 -0.1217 -0.0757
S-1485	In addition, we provide brief insight into the potential of miRNAs as novel therapeutic targets for heart failure.<unk>
T-1485	mirnas therapeutic heart_failure
H-1485	-1.0573630332946777	▁mi RNA s
D-1485	-1.0573630332946777	miRNAs
P-1485	-2.2418 -0.0175 -0.0719 -2.8657 -0.0900
S-1164	The extent of RV dysfunction correlated with greater antecedent weight loss and a lower fat/lean body mass ratio.<unk>
T-1164	rv_dysfunction correlated lean_body_mass
H-1164	-1.234887957572937	▁ RV _ ▁dys function
D-1164	-1.234887957572937	RV_ dysfunction
P-1164	-0.3793 -0.1602 -1.6272 -1.2466 -1.0388 -3.9074 -0.2847
S-2023	Such an understanding can ultimately reduce morbidity and mortality and optimize quality of life in patients with HF.<unk>
T-2023	morbidity mortality quality_of_life patients hf
H-2023	-0.8108853697776794	▁morbi d ity ▁ HF
D-2023	-0.8108853697776794	morbidity HF
P-2023	-0.3614 -0.0961 -0.2936 -3.6395 -1.0042 -0.1799 -0.1015
S-1274	This review provides an update on cardiopulmonary exercise variables, proven to be prognostically important in heart failure.<unk>
T-1274	cardiopulmonary exercise prognostically heart_failure
H-1274	-1.4793493747711182	▁cardio pul mon ary _ ré que nce
D-1274	-1.4793493747711182	cardiopulmonary_réquence
P-1274	-0.3925 -0.1205 -3.7950 -1.0740 -1.8500 -3.0843 -1.2419 -0.0445 -3.1100 -0.0806
S-1670	Potent inhibition of L-type Ca2+ currents by a Rad variant associated with congestive heart failure.<unk>
T-1670	rad_variant congestive_heart_failure
H-1670	-1.4630671739578247	▁l - type _ ca 2 _ ▁current s ▁Rad ▁con ges tive _ ▁heart _ ▁failure
D-1670	-1.4630671739578247	l-type_ca2_ currents Rad congestive_ heart_ failure
P-1670	-4.1060 -0.4512 -0.0638 -1.5488 -0.0450 -0.5784 -4.3438 -4.4947 -0.1669 -0.4447 -2.1410 -0.2440 -0.1619 -0.7018 -2.5956 -1.7029 -3.6358 -0.2451 -0.1269
S-565	Clinical and radiological signs of HF were less common, yet quality of life was more significantly impaired.<unk>
T-565	clinical radiological hf quality_of_life
H-565	-0.9141882061958313	▁radi ological ▁ HF
D-565	-0.9141882061958313	radiological HF
P-565	-0.5393 -0.6179 -3.1825 -0.0609 -0.9792 -0.1053
S-1091	The right ventricle (RV) is integral to normal cardiac function, but receives little attention in the medical literature.<unk>
T-1091	right_ventricle rv cardiac_function medical
H-1091	-1.3180909156799316	▁vent ric le ▁ RV ▁cardiac
D-1091	-1.3180909156799316	ventricle RV cardiac
P-1091	-0.3728 -2.6064 -0.2648 -2.9935 -0.4481 -0.7141 -3.0372 -0.1078
S-1682	An 18-year-old Jehovah's Witness with sickle cell disease has life-threatening anemia.<unk>
T-1682	witness sickle_cell_disease anemia
H-1682	-0.8012272715568542	▁Jehovah _ s _ ▁Wit ness ▁sick le _ cell _ ▁disease ▁an emia
D-1682	-0.8012272715568542	Jehovah_s_ Witness sickle_cell_ disease anemia
P-1682	-0.1021 -2.1566 -1.3439 -1.3468 -0.3916 -0.9049 -0.0977 -0.1338 -0.2691 -1.4416 -1.1189 -1.6337 -1.2552 -0.0430 -0.3399 -0.2408
S-1057	Animals were scanned twice with a 1.5-T MRI scanner, once at baseline and once at heart failure.<unk>
T-1057	mri_scanner baseline heart_failure
H-1057	-1.830838918685913	▁m ri ▁scanner ▁heart
D-1057	-1.830838918685913	mri scanner heart
P-1057	-1.9500 -3.0369 -2.0485 -0.8886 -2.8591 -0.2021
S-209	OBJECTIVE: Many advances have been made recently in the treatment of congestive heart failure (CHF).<unk>
T-209	congestive_heart_failure chf
H-209	-0.849949061870575	▁con ges tive _ heart _ ▁failure CH f
D-209	-0.849949061870575	congestive_heart_ failureCHf
P-209	-2.0176 -0.1186 -0.0372 -0.4826 -2.1179 -0.4318 -2.2115 -1.4094 -0.4215 -0.0669 -0.0344
S-1721	BACKGROUND: There is an urgent need to improve outcomes and reduce costs for patients with heart failure (HF).<unk>
T-1721	outcomes costs patients heart_failure hf
H-1721	-2.1206986904144287	
D-1721	-2.1206986904144287	
P-1721	-4.2164 -0.0250
S-99	This study reports the quantitative analysis of a new chromatin subproteome in the normal and diseased mouse heart.<unk>
T-99	chromatin_subproteome diseased heart
H-99	-1.019953966140747	▁chr omat in _ sub prote ome ▁mouse ▁heart
D-99	-1.019953966140747	chromatin_subproteome mouse heart
P-99	-1.0749 -0.0400 -1.6541 -0.4861 -0.3879 -0.1432 -1.0292 -3.2661 -2.9490 -0.1017 -0.0872
S-1493	A muscle-wasting syndrome exists in acquired heart failure but has not been assessed in Fontan subjects.<unk>
T-1493	syndrome heart_failure fontan
H-1493	-0.7072176933288574	▁muscle - was ting _ ▁syndrome ▁acquire d _ heart _ ▁failure ▁Font an
D-1493	-0.7072176933288574	muscle-wasting_ syndrome acquired_heart_ failure Fontan
P-1493	-0.6869 -0.1503 -1.5933 -0.5656 -2.5951 -0.5764 -0.2670 -0.0455 -0.1757 -1.6150 -0.7374 -1.8192 -0.1090 -0.1848 -0.1223 -0.0719
S-684	Mediterranean and DASH diet scores and mortality in women with heart failure: The Women's Health Initiative.<unk>
T-684	dash mortality heart_failure health
H-684	-1.057141661643982	▁Mediterrane an ▁DAS h _ die t _ ▁score s ▁mortal ity ▁women ▁heart _ ▁failure ▁Women s _ Health ▁Initiative
D-684	-1.057141661643982	Mediterranean DASh_diet_ scores mortality women heart_ failure Womens_Health Initiative
P-684	-1.7683 -0.0171 -0.0900 -0.7392 -3.0640 -1.5279 -0.1650 -1.4145 -1.0502 -0.0467 -0.8870 -0.0872 -2.0214 -1.6179 -0.2477 -4.3658 -0.8885 -1.2471 -0.5008 -1.2405 -1.0647 -0.1328 -0.1300
S-118	The differential effect of LVEF on long-term mortality is significantly attenuated in the older age group.<unk>
T-118	differential_effect lvef mortality
H-118	-0.6330411434173584	▁LV EF ▁long - term _ ▁mortal ity
D-118	-0.6330411434173584	LVEF long-term_ mortality
P-118	-0.6641 -0.3615 -0.9345 -0.1379 -1.0105 -0.4561 -1.6645 -0.3017 -0.6494 -0.1502
S-291	CONCLUSIONS: cTnT and NT-proBNP have significant value in HF risk prediction.<unk>
T-291	ctnt nt-probnp hf
H-291	-0.4379097819328308	▁c t n t ▁NT - pro b NP ▁ HF
D-291	-0.4379097819328308	ctnt NT-probNP HF
P-291	-0.7134 -0.1181 -0.6436 -0.2063 -0.3415 -0.0350 -0.0108 -0.8149 -0.1705 -0.4180 -0.1387 -1.9133 -0.1687
S-195	Inhospital mortality was 2.7%, and patients above the median BNP level had higher mortality than those below.<unk>
T-195	inhospital mortality patients bnp mortality
H-195	-0.4750806987285614	▁in hospital _ ▁mortal ity ▁b NP
D-195	-0.4750806987285614	inhospital_ mortality bNP
P-195	-0.4259 -0.0333 -1.6716 -0.1636 -0.1468 -0.1605 -0.4346 -1.1409 -0.0985
S-1626	No relationship was found between the Health Buddy Program and ED use or number of hospital days for participants who were hospitalized.<unk>
T-1626	health_buddy_program hospital hospitalized
H-1626	-1.2752892971038818	▁Health ▁Budd y _ program ▁ED ▁hospital ized
D-1626	-1.2752892971038818	Health Buddy_program ED hospitalized
P-1626	-1.4159 -0.1918 -0.0579 -3.1157 -1.7640 -0.1563 -1.0707 -4.6109 -0.2675 -0.1022
S-936	We also examined resistin levels in anthracycline-treated breast cancer patients with and without cardiotoxicity.<unk>
T-936	resistin breast_cancer patients cardiotoxicity
H-936	-0.7418692708015442	▁resist in ▁an thra cycli ne - tre ated ▁breast ▁cancer ▁cardio toxic ity
D-936	-0.7418692708015442	resistin anthracycline-treated breast cancer cardiotoxicity
P-936	-1.6944 -0.5919 -1.4208 -0.0073 -2.1352 -0.4938 -0.7719 -0.0124 -2.4055 -0.0250 -1.0398 -0.3817 -0.0685 -0.5117 -0.2086 -0.1015
S-1622	INTERVENTION: The Health Buddy Program, which integrates a content-driven telehealth system with care management.<unk>
T-1622	health_buddy_program telehealth
H-1622	-1.0011953115463257	▁Health ▁Budd y _ program ▁content - driv en ▁tele health _ system ▁care ▁management
D-1622	-1.0011953115463257	Health Buddy_program content-driven telehealth_system care management
P-1622	-0.9701 -0.4499 -0.0396 -4.3455 -1.5715 -1.1472 -0.0263 -0.0061 -0.0891 -0.5875 -0.5878 -3.6548 -0.5559 -1.2801 -1.2438 -0.3704 -0.0946
S-1287	Mortality was 24 per cent with five deaths occurring within 30 days of ACS consultation and/or operation.<unk>
T-1287	mortality deaths acs consultation operation
H-1287	-0.7424924969673157	▁Mor t ality ▁a CS
D-1287	-0.7424924969673157	Mortality aCS
P-1287	-1.0214 -0.0144 -0.0359 -1.2662 -1.3986 -1.3726 -0.0884
S-1740	BACKGROUND: Contemporary therapeutic options have led to substantial improvement in survival of patients with heart failure.<unk>
T-1740	therapeutic patients heart_failure
H-1740	-1.5040644407272339	▁ therapeut ic
D-1740	-1.5040644407272339	therapeutic
P-1740	-2.9829 -0.3603 -0.5888 -3.5172 -0.0711
S-586	Dobutamine requirement, higher furosemide dose, and higher oxygen flow were associated with unfavorable outcome.<unk>
T-586	dobutamine furosemide outcome
H-586	-0.7376914620399475	▁do bu tamine ▁fur os em ide ▁oxygen
D-586	-0.7376914620399475	dobutamine furosemide oxygen
P-586	-0.5109 -0.3823 -0.0653 -0.8785 -0.6673 -0.0843 -0.0269 -3.0588 -1.6213 -0.0813
S-130	CONCLUSIONS: We noted differential relations between CPCs and outcomes in patients with vs without diabetes.<unk>
T-130	cpcs outcomes patients diabetes
H-130	-0.62991863489151	▁c PC s ▁diabetes
D-130	-0.62991863489151	cPCs diabetes
P-130	-0.6007 -0.8242 -0.3961 -1.6102 -0.1651 -0.1833
S-727	Frequency of 7-day follow-up visits increased from 19.6% to 46.9% (P < .01).<unk>
T-727	follow-up
H-727	-1.0140584707260132	▁fréquence
D-727	-1.0140584707260132	fréquence
P-727	-1.3276 -1.6810 -0.0336
S-1284	Patients undergoing MT were more likely to require consultation for abdominal problems (88 vs 27%; P = 0.004).<unk>
T-1284	patients consultation abdominal
H-1284	-1.638720989227295	▁Patient s ▁consultation ▁abdominal
D-1284	-1.638720989227295	Patients consultation abdominal
P-1284	-4.5092 -0.1250 -1.8868 -0.9158 -2.3015 -0.0940
S-1661	This article describes the possible causes of, the array of diagnostic procedures for, and treatments for this complication.<unk>
T-1661	diagnostic complication
H-1661	-0.7130954265594482	▁complica tion
D-1661	-0.7130954265594482	complication
P-1661	-2.5588 -0.1844 -0.0597 -0.0495
S-2001	Thirty-day mortality was 2% and 6-month survival 92%, which exceeded the 88% performance goal.<unk>
T-2001	mortality
H-2001	-1.3388664722442627	
D-2001	-1.3388664722442627	
P-2001	-2.5788 -0.0990
S-850	RESULTS: On March 13, 2013, the study was stopped for futility on the recommendation of the data and safety monitoring board.<unk>
T-850	
H-850	-1.5366190671920776	▁fut ility
D-850	-1.5366190671920776	futility
P-850	-1.0724 -0.1219 -4.8765 -0.0757
S-1092	The etiologic causes of acute RV failure often differ from those encountered in left ventricular dysfunction.<unk>
T-1092	etiologic acute_rv_failure left_ventricular_dysfunction
H-1092	-1.0290195941925049	▁a cute ▁ RV _ ▁failure ▁left ▁vent ri cular _ ▁dys function
D-1092	-1.0290195941925049	acute RV_ failure left ventricular_ dysfunction
P-1092	-3.2955 -0.0122 -0.5249 -0.2549 -3.0379 -3.4725 -0.1980 -0.9356 -0.4853 -0.4352 -1.6596 -0.2395 -0.4048 -0.3015 -0.1778
S-576	Left ventricular ejection time in acute heart failure complicating precapillary pulmonary hypertension.<unk>
T-576	left_ventricular_ejection_time acute_heart_failure precapillary_pulmonary_hypertension
H-576	-0.6418856978416443	▁vent ri cular ▁e je ction ▁a cute _ ▁heart _ ▁failure ▁pre cap illa ry _ ▁pulmonar y ▁hyper tension
D-576	-0.6418856978416443	ventricular ejection acute_ heart_ failure precapillary_ pulmonary hypertension
P-576	-0.0603 -0.2165 -0.0905 -2.5853 -0.3924 -0.0093 -3.2995 -0.0338 -0.8451 -2.3416 -0.7066 -1.3547 -0.1016 -0.4632 -0.0042 -0.3735 -0.5930 -0.3429 -0.1145 -0.4037 -0.0003 -0.2407 -0.1899
S-541	Surgical correction of aortic valve insufficiency after left ventricular assist device implantation.<unk>
T-541	surgical aortic_valve_insufficiency left_ventricular_assist_device implantation
H-541	-0.5237141251564026	▁a or tic ▁val ve ▁insu ffi cie ncy ▁vent ri cular ▁implant ation
D-541	-0.5237141251564026	aortic valve insufficiency ventricular implantation
P-541	-0.4627 -0.0323 -1.4350 -0.4207 -0.0713 -2.0223 -0.0327 -1.5641 -0.0318 -0.4873 -0.1019 -0.0332 -1.3773 -0.0200 -0.2290 -0.0578
S-750	Impact of ejection fraction on the clinical response to cardiac resynchronization therapy in mild heart failure.<unk>
T-750	ejection_fraction clinical cardiac_resynchronization_therapy mild_heart_failure
H-750	-0.6657581925392151	▁e je ction _ fraction ▁cardiac _ ▁re syn chron ization _ therapy ▁mild _ heart _ ▁failure
D-750	-0.6657581925392151	ejection_fraction cardiac_ resynchronization_therapy mild_heart_ failure
P-750	-0.6588 -0.2296 -0.0041 -1.2652 -0.0015 -0.2682 -1.0165 -0.9636 -0.0155 -0.0007 -1.1024 -1.0516 -0.1994 -0.8914 -0.6876 -1.4455 -1.0307 -2.2570 -0.1183 -0.1077
S-318	Effects of biventricular pacing on left heart twist and strain in a porcine model of right heart failure.<unk>
T-318	biventricular_pacing left_heart_twist strain right_heart_failure
H-318	-0.822309136390686	▁bi ven tri cular _ pa cing ▁left _ ▁heart _ ▁twist ▁por cine _ model _ de _ ▁right _ ▁heart _ ▁failure
D-318	-0.822309136390686	biventricular_pacing left_ heart_ twist porcine_model_de_ right_ heart_ failure
P-318	-0.3526 -0.1413 -0.0560 -0.8558 -1.4079 -0.4260 -0.2429 -2.4330 -1.2767 -1.2082 -0.6964 -0.2400 -0.8852 -0.2334 -1.6604 -1.4257 -0.8162 -1.9529 -0.2040 -0.6280 -0.5218 -0.9538 -0.3181 -2.1373 -0.1583 -0.1481
S-761	They contribute to myocardial diastolic dysfunction (DD) through collagen deposition or titin modification.<unk>
T-761	myocardial_diastolic_dysfunction dd collagen_deposition titin
H-761	-0.5290905833244324	▁my o card ial _ ▁dia sto lic _ ▁dys function ▁ DD ▁collage n _ de position ▁titi n ▁modification
D-761	-0.5290905833244324	myocardial_ diastolic_ dysfunction DD collagen_deposition titin modification
P-761	-0.3186 -0.1092 -0.0747 -0.0384 -0.1330 -1.9073 -0.6033 -3.0086 -1.0058 -0.1817 -0.8026 -2.3095 -0.0071 -0.0286 -0.0502 -0.5246 -0.0355 -0.0627 -0.0271 -0.0627 -0.6914 -0.1248 -0.0618
S-832	Stress Doppler echocardiography may be a useful tool for prognostic assessment in pulmonary hypertension patients.<unk>
T-832	stress_doppler_echocardiography prognostic pulmonary_hypertension patients
H-832	-0.46984121203422546	▁Stress ▁do pp ler ▁e cho card i ography ▁pulmonar y ▁hyper tension
D-832	-0.46984121203422546	Stress doppler echocardiography pulmonary hypertension
P-832	-0.2103 -1.3963 -0.0354 -0.3418 -0.8407 -0.7483 -0.3679 -1.0885 -0.3845 -0.0611 -0.0761 -0.8635 -0.0052 -0.5246 -0.1036
S-329	CO correlated with septal wall CS during AVD variation and free wall CS during VVD variation (P < 0.008).<unk>
T-329	correlated septal wall avd free_wall_cs vvd
H-329	-0.8982305526733398	▁sept al ▁wall _ ▁CS ▁av d ▁free ▁wall _ ▁CS ▁VVD
D-329	-0.8982305526733398	septal wall_ CS avd free wall_ CS VVD
P-329	-1.5937 -0.2066 -0.7555 -1.9981 -1.3754 -0.3925 -0.2346 -1.1646 -0.9567 -1.6160 -1.4450 -0.2346 -0.4335 -0.1685
S-418	Neither inhibition of protein kinase A nor soluble guanylate cyclase altered this contractile response.<unk>
T-418	protein_kinase_a guanylate_cyclase contractile_response
H-418	-0.9561847448348999	▁inhibi tion ▁protein _ ▁kina se ▁solu ble ▁gua ny late _ ▁cy cla se ▁contract ile
D-418	-0.9561847448348999	inhibition protein_ kinase soluble guanylate_ cyclase contractile
P-418	-0.7719 -0.0191 -1.6769 -2.5204 -0.0988 -0.1003 -2.6641 -0.0255 -0.7269 -0.2976 -4.0941 -1.1336 -0.6966 -0.1076 -1.0941 -0.0303 -0.2896 -1.6706 -0.1495
S-1162	Subjects were followed up for adverse events (defined as death, transplantation, or circulatory assist device).<unk>
T-1162	followed_up adverse_events death transplantation circulatory_assist_device
H-1162	-0.7369489073753357	▁implant ation ▁circula tory _ assist ▁device
D-1162	-0.7369489073753357	implantation circulatory_assist device
P-1162	-4.1666 -0.0214 -0.0702 -0.2372 -0.1668 -0.1014 -1.6443 -0.1602 -0.0646
S-351	Both systolic and diastolic mitral leaflet motions were restricted without any clear organic lesion.<unk>
T-351	systolic diastolic_mitral_leaflet_motions organic lesion
H-351	-1.2298043966293335	▁sy sto lic _ de _ ▁dia sto lic _ met ral ▁le a flet
D-351	-1.2298043966293335	systolic_de_ diastolic_metral leaflet
P-351	-0.6350 -0.0655 -1.1630 -2.3065 -3.6836 -0.2983 -2.1157 -0.4469 -1.6051 -0.8389 -2.8034 -0.0227 -2.3982 -0.1635 -0.0077 -2.2254 -0.1272
S-119	Changes in circulating progenitor cells are associated with outcome in heart failure patients: a longitudinal study.<unk>
T-119	circulating_progenitor_cells outcome heart_failure patients longitudinal
H-119	-0.8962922096252441	▁circula tion _ pro gen itor _ cell s ▁heart _ ▁failure
D-119	-0.8962922096252441	circulation_progenitor_cells heart_ failure
P-119	-0.3807 -2.5293 -0.2599 -0.3429 -0.6270 -0.2643 -1.6733 -0.7431 -0.1228 -0.8832 -0.5669 -3.2391 -0.7823 -0.1332
S-1115	Primary outcome was sympathetic activity as measured by (123)I-MIBG myocardial washout.<unk>
T-1115	primary_outcome sympathetic_activity myocardial_washout
H-1115	-1.7181295156478882	▁m g ▁my o card ial
D-1115	-1.7181295156478882	mg myocardial
P-1115	-1.8755 -2.2493 -4.3705 -1.2469 -0.4909 -0.0334 -3.1095 -0.3691
S-215	We used the Student t test, calculated 95% confidence intervals (CIs), and performed regression analyses.<unk>
T-215	student_t_test confidence_intervals cis regression_analyses
H-215	-1.527764916419983	▁c s ▁re gression
D-215	-1.527764916419983	cs regression
P-215	-4.7525 -0.9961 -2.5860 -0.0520 -0.7104 -0.0696
S-597	The left pulmonary artery was completed occluded and the right pulmonary artery was partially obstructed.<unk>
T-597	left_pulmonary_artery right_pulmonary_artery
H-597	-0.5982683300971985	▁pulmonar y ▁arter y
D-597	-0.5982683300971985	pulmonary artery
P-597	-0.8146 -0.1308 -0.5196 -0.7667 -1.2419 -0.1161
S-1951	METHODS: We did this proof-of-principle cohort study at one centre in Canada.<unk>
T-1951	proof-of-principle_cohort_study canada
H-1951	-1.0754064321517944	
D-1951	-1.0754064321517944	
P-1951	-2.0851 -0.0657
S-1937	This study assessed the impact of HR reduction with beta blockers on exercise capacity in recent onset HFrEF.<unk>
T-1937	hr_reduction beta_blockers exercise_capacity hfref
H-1937	-0.7948564887046814	▁HR _ re duction ▁beta _ block ers ▁exercise _ capaci tation ▁h Fr EF
D-1937	-0.7948564887046814	HR_reduction beta_blockers exercise_capacitation hFrEF
P-1937	-0.3222 -2.4387 -0.7444 -0.0074 -1.0457 -1.0324 -0.6947 -0.0178 -0.6030 -0.8142 -0.7357 -3.3013 -0.1655 -0.5019 -0.9325 -0.0906 -0.0647
S-946	LV strain and strain rate were assessed by echocardiography at baseline and over 12 months after ablation.<unk>
T-946	lv_strain strain echocardiography baseline ablation
H-946	-0.7671887278556824	▁LV ▁e cho card i ography ▁ab lation
D-946	-0.7671887278556824	LV echocardiography ablation
P-946	-0.2487 -3.8769 -0.2731 -0.3952 -0.8118 -0.4885 -1.2919 -0.0287 -0.1478 -0.1093
S-121	We evaluated the association between serial measurements of CPCs and functional capacity and outcomes in heart failure (HF).<unk>
T-121	cpcs functional_capacity outcomes heart_failure hf
H-121	-1.1446866989135742	▁c PC s ▁functional _ ▁capacity ▁heart _ ▁failure HF
D-121	-1.1446866989135742	cPCs functional_ capacity heart_ failureHF
P-121	-0.2254 -0.5957 -0.3341 -0.8849 -3.0141 -3.0942 -0.4663 -0.3941 -3.4940 -0.9546 -0.1610 -0.1178
S-6	Some events, such as pressure ulcers in surgical patients, actually increased despite considerable national attention to these problems.<unk>
T-6	pressure_ulcers surgical patients
H-6	-0.6480972170829773	▁pressure _ ▁ul cer s ▁sur g ical
D-6	-0.6480972170829773	pressure_ ulcers surgical
P-6	-1.2400 -0.7477 -0.0908 -0.3143 -0.5751 -0.7179 -0.1335 -0.2603 -2.2436 -0.1578
S-1527	We compared clinical, laboratory, echocardiographic, invasive hemodynamic, and outcome data among groups.<unk>
T-1527	clinical echocardiographic invasive hemodynamic outcome
H-1527	-0.3664095997810364	▁e cho car dio graphic ▁invasi ve _ hem o dynamic
D-1527	-0.3664095997810364	echocardiographic invasive_hemodynamic
P-1527	-0.3114 -0.1385 -0.1143 -1.1106 -0.3761 -0.0899 -0.1601 -0.5866 -1.4176 -0.1144 -0.0177 -0.2769 -0.0492
S-1341	Here, we found that CHF atrial explants produced less c-Kit+ cells than sham explants.<unk>
T-1341	chf atrial_explants cells explants
H-1341	-0.49594375491142273	▁CHF ▁at rial _ ▁ex plant s ▁c - K it _ cell s ▁sham ▁ex plant s
D-1341	-0.49594375491142273	CHF atrial_ explants c-Kit_cells sham explants
P-1341	-0.0099 -1.4490 -0.1487 -1.8886 -0.9579 -0.0639 -0.4700 -0.2367 -0.2187 -0.2815 -0.0083 -1.3521 -0.3868 -0.2731 -0.2294 -1.4638 -0.0068 -0.1886 -0.2201 -0.0650
S-886	Of these, 1175 had left bundle-branch block (LBBB) and 308 had non-LBBB.<unk>
T-886	left_bundle-branch_block lbbb
H-886	-0.5591430068016052	▁bund le - bran ch _ block LB BB LB BB
D-886	-0.5591430068016052	bundle-branch_blockLBBBLBBB
P-886	-0.0380 -0.0441 -0.1279 -0.0120 -0.1584 -1.6172 -2.0035 -0.4349 -0.1872 -1.1513 -0.3125 -1.1037 -0.0782
S-1811	We have previously demonstrated that cardiac Mena deletion produced cardiac dysfunction with conduction abnormalities and hypertrophy.<unk>
T-1811	cardiac mena_deletion cardiac_dysfunction hypertrophy
H-1811	-0.4439539909362793	▁cardiac _ ▁Men a ▁dele tion ▁cardiac _ ▁dys function ▁hyper trop hy
D-1811	-0.4439539909362793	cardiac_ Mena deletion cardiac_ dysfunction hypertrophy
P-1811	-0.0286 -1.9072 -0.8818 -0.1980 -0.3923 -0.0308 -0.0741 -1.2549 -0.6487 -0.6961 -0.1126 -0.0045 -0.1334 -0.2176 -0.0787
S-902	PD appears to be a viable option in refractory, end-stage congestive heart failure (CHF).<unk>
T-902	pd congestive_heart_failure chf
H-902	-0.9238557815551758	▁PD ▁re frac tory ▁end - s tage _ con ges tive _ heart _ ▁failure CH f
D-902	-0.9238557815551758	PD refractory end-stage_congestive_heart_ failureCHf
P-902	-2.5640 -2.4524 -0.0235 -0.5468 -2.9350 -0.0577 -0.1383 -0.0006 -0.5325 -0.1979 -0.6296 -0.0883 -0.7716 -2.4341 -0.8624 -2.2923 -1.2876 -0.3946 -0.1684 -0.0993
S-649	However, during the past decades several studies have demonstrated that beta blockers decrease mortality in patients with heart failure.<unk>
T-649	beta_blockers mortality patients heart_failure
H-649	-1.8169488906860352	
D-649	-1.8169488906860352	
P-649	-3.5791 -0.0548
S-1233	We compared the economic impact of the 2 treatment strategies in patients with AF and heart failure from the province of Québec, Canada.<unk>
T-1233	economic patients heart_failure québec canada
H-1233	-1.7528623342514038	▁économique
D-1233	-1.7528623342514038	économique
P-1233	-0.4201 -4.7479 -0.0906
S-682	Among patients treated with trastuzumab, those with cardiac comorbidities and older age may be at higher risk.<unk>
T-682	patients trastuzumab cardiac comorbidities
H-682	-0.7442228198051453	▁tras tuz um ab ▁cardiac
D-682	-0.7442228198051453	trastuzumab cardiac
P-682	-0.7628 -0.0081 -0.0329 -0.1641 -0.0181 -4.1594 -0.0641
S-279	This phenotype was reproducible, and there were few perioperative or early deaths in the experimental procedures.<unk>
T-279	phenotype perioperative deaths
H-279	-0.7819499969482422	
D-279	-0.7819499969482422	
P-279	-1.4995 -0.0644
S-369	At the time of second HF 4 years after valve plasty, MS was significant with an MVA of 1.2 cm2.<unk>
T-369	hf valve_plasty mva
H-369	-0.5885595679283142	▁ HF ▁val ve ▁plast y ▁MS ▁m VA
D-369	-0.5885595679283142	HF valve plasty MS mVA
P-369	-0.8731 -0.0394 -1.3962 -0.0540 -0.9622 -0.7773 -0.9384 -0.0825 -0.6212 -0.6341 -0.0957
S-662	Multivariable hierarchical regression models were adjusted for demographics, insurance status, and comorbidities.<unk>
T-662	regression_models comorbidities
H-662	-1.043824553489685	▁multi vari able _ multi vari able _ re gression s ▁insurance _ status ▁como rbi di ties
D-662	-1.043824553489685	multivariable_multivariable_regressions insurance_status comorbidities
P-662	-2.9669 -0.0018 -0.0233 -0.8482 -3.7734 -0.0018 -0.0258 -0.3017 -2.5568 -0.0679 -3.7015 -1.0433 -2.3824 -0.4960 -0.6588 -0.0013 -0.3632 -1.4075 -0.1552 -0.1000
S-1893	The duration and extent of the symptoms are relevant and it is useful to classify patients according to the NYHA functional assessment.<unk>
T-1893	symptoms patients nyha
H-1893	-1.1460124254226685	
D-1893	-1.1460124254226685	
P-1893	-2.2237 -0.0683
S-701	The median baseline ST2 level was 23.7 ng/mL (interquartile range, 18.6-31.8).<unk>
T-701	baseline st2 interquartile_range
H-701	-1.3567249774932861	▁figure
D-701	-1.3567249774932861	figure
P-701	-2.8513 -1.0874 -0.1314
S-927	Human resistin in chemotherapy-induced heart failure in humanized male mice and in women treated for breast cancer.<unk>
T-927	resistin heart_failure breast_cancer
H-927	-0.668106734752655	▁Human ▁resist in ▁che mo therapy _ indu ced ▁heart _ ▁failure ▁human ized ▁male ▁mi ce ▁breast ▁cancer
D-927	-0.668106734752655	Human resistin chemotherapy_induced heart_ failure humanized male mice breast cancer
P-927	-1.2673 -2.1655 -0.2756 -0.4469 -0.0731 -0.0361 -0.9193 -0.0008 -1.3759 -0.1237 -0.5729 -0.5501 -2.1725 -0.5767 -0.3364 -1.2152 -0.0442 -0.2409 -1.2037 -0.2784 -0.1552
S-849	The primary efficacy outcome was the composite of death from any cause or first hospitalization for worsening heart failure.<unk>
T-849	outcome death hospitalization heart_failure
H-849	-1.6619576215744019	
D-849	-1.6619576215744019	
P-849	-3.1674 -0.1565
S-1402	Findings from this study provide insight on the possible contribution of nursing to outcomes of hospitalized older adults with HF.<unk>
T-1402	nursing outcomes hospitalized hf
H-1402	-1.619152307510376	
D-1402	-1.619152307510376	
P-1402	-3.1954 -0.0429
S-1071	Besides therapeutic functions, devices can have add-on diagnostic features such as early detection of fluid overload.<unk>
T-1071	therapeutic diagnostic fluid_overload
H-1071	-1.0867143869400024	▁ therapeut ic
D-1071	-1.0867143869400024	therapeutic
P-1071	-0.6139 -0.0128 -0.2307 -4.4566 -0.1195
S-1395	Nursing-sensitive outcome change scores for hospitalized older adults with heart failure: a preliminary descriptive study.<unk>
T-1395	outcome change hospitalized heart_failure
H-1395	-1.301627516746521	▁Nur sing - sensitiv e ▁outcome _ change ▁score s ▁hospital ized _ ▁older ▁adults ▁heart _ ▁failure
D-1395	-1.301627516746521	Nursing-sensitive outcome_change scores hospitalized_ older adults heart_ failure
P-1395	-0.7016 -0.1927 -0.2515 -0.0185 -0.2480 -4.2510 -2.0766 -0.9716 -4.7526 -0.0755 -1.2159 -0.6564 -1.5305 -2.2424 -2.1844 -0.6862 -0.5293 -3.1614 -0.1290 -0.1576
S-793	Within-day test-retest reliability of the Timed Up & Go test in patients with advanced chronic organ failure.<unk>
T-793	patients chronic_organ_failure
H-793	-1.6078153848648071	▁temps _ up _ go
D-793	-1.6078153848648071	temps_up_go
P-793	-1.7437 -2.4760 -0.7656 -1.3168 -1.6753 -3.0350 -0.2424
S-1637	Over a median follow-up of 2.5 years, black race was associated with increased risk for all outcomes except mortality.<unk>
T-1637	follow-up outcomes mortality
H-1637	-1.482730746269226	▁black _ race
D-1637	-1.482730746269226	black_race
P-1637	-0.3438 -1.9580 -2.1199 -2.8106 -0.1814
S-553	Various transcatheter approaches to these difficult problems are also available and offer less invasive alternatives to conventional surgery.<unk>
T-553	transcatheter invasive surgery
H-553	-0.4088209569454193	▁trans cat heter
D-553	-0.4088209569454193	transcatheter
P-553	-0.0227 -0.1514 -0.0191 -1.7725 -0.0784
S-748	The choice of chelation regimens known to remove heart iron efficiently was not sufficient by itself to influence the risk.<unk>
T-748	chelation heart_iron
H-748	-1.2302104234695435	▁che lation ▁heart _ ▁ir on
D-748	-1.2302104234695435	chelation heart_ iron
P-748	-1.7508 -0.0151 -5.2761 -0.7784 -0.0980 -0.0982 -1.7063 -0.1187
S-1926	We aimed to describe the association between social support and barriers to participation with exercise adherence and clinical outcomes.<unk>
T-1926	exercise clinical outcomes
H-1926	-1.5162074565887451	▁social ▁support ▁barrier s
D-1926	-1.5162074565887451	social support barriers
P-1926	-0.3715 -2.1648 -3.0316 -0.0281 -3.3962 -0.1052
S-1257	Effectiveness of Chinese herbal medicine as an adjunctive treatment for dilated cardiomyopathy in patients with heart failure.<unk>
T-1257	medicine dilated_cardiomyopathy patients heart_failure
H-1257	-0.8944962620735168	▁Chinese _ ▁herbal ▁medicine ▁dil ated _ ▁cardio my o pathy ▁heart _ ▁failure
D-1257	-0.8944962620735168	Chinese_ herbal medicine dilated_ cardiomyopathy heart_ failure
P-1257	-1.1893 -1.4843 -0.9479 -1.1765 -0.3475 -0.7146 -0.2470 -0.2730 -3.0769 -0.5872 -0.0339 -0.7789 -0.8355 -2.2740 -0.1983 -0.1471
S-1856	Patient perceptions of implantable cardioverter-defibrillator deactivation discussions: A qualitative study.<unk>
T-1856	patient implantable_cardioverter-defibrillator
H-1856	-0.5849063396453857	▁implant able ▁implant able ▁implant able ▁cardio ver ter - de _ de fi br illa tor _ de _ activa tion
D-1856	-0.5849063396453857	implantable implantable implantable cardioverter-de_defibrillator_de_activation
P-1856	-0.0003 -0.0161 -0.6785 -0.0248 -1.8220 -0.0312 -1.5611 -0.1446 -0.0243 -0.7092 -0.0055 -1.3596 -1.7959 -3.2056 -0.6966 -0.0099 -0.1393 -0.1380 -0.0438 -0.8725 -0.0771 -0.0508 -0.4813 -0.1501
S-167	We evaluated protein levels of these genes by Western blot and DNA fragmentation by TUNEL method from autopsy samples.<unk>
T-167	protein genes western_blot dna_fragmentation tunel
H-167	-0.981968879699707	▁protein es ▁Western ▁blot ▁DNA _ ▁fragment ation ▁TU NEL ▁auto psy
D-167	-0.981968879699707	proteines Western blot DNA_ fragmentation TUNEL autopsy
P-167	-1.2066 -3.7253 -1.9951 -0.1884 -1.5279 -2.4400 -0.2149 -0.0173 -0.7106 -0.9257 -0.1870 -0.0178 -0.4868 -0.1042
S-1480	Heart failure is the leading cause of mortality in Western society and represents the fastest growing subclass of cardiovascular diseases.<unk>
T-1480	heart_failure leading mortality western society cardiovascular_diseases
H-1480	-1.5706321001052856	▁Heart _ pu issa nce
D-1480	-1.5706321001052856	Heart_puissance
P-1480	-1.2053 -0.3425 -5.0515 -0.2538 -0.0215 -3.9487 -0.1711
S-917	In HFPEF animal models, dietary sodium restriction improves ventricular and vascular stiffness and function.<unk>
T-917	hfpef sodium ventricular vascular_stiffness
H-917	-0.7546189427375793	▁H FP EF ▁dieta ry _ so dium ▁restriction ▁vent ri cular ▁vas cular ▁sti ff ness
D-917	-0.7546189427375793	HFPEF dietary_sodium restriction ventricular vascular stiffness
P-917	-1.7806 -0.0682 -1.5744 -2.6003 -0.1250 -0.7487 -0.1728 -0.0240 -0.8899 -0.0021 -0.0956 -0.1963 -1.0388 -0.3800 -1.5644 -0.6931 -1.6177 -0.6743 -0.0917
S-1532	Despite these differences, EH and CH had similarly elevated cardiac filling pressures and equivalent adverse outcomes.<unk>
T-1532	elevated cardiac_filling_pressures adverse_outcomes
H-1532	-1.1173614263534546	▁EH ▁cardiac ▁fill ing _ tension s
D-1532	-1.1173614263534546	EH cardiac filling_tensions
P-1532	-0.3562 -0.7662 -5.2110 -0.2818 -2.1653 -0.8200 -0.1307 -0.2321 -0.0929
S-1146	Mechanistic insight into prolonged electromechanical delay in dyssynchronous heart failure: a computational study.<unk>
T-1146	electromechanical_delay dyssynchronous_heart_failure
H-1146	-0.8102699518203735	▁electro me chan ical _ de lay ▁dys syn chron ous _ heart _ ▁failure
D-1146	-0.8102699518203735	electromechanical_delay dyssynchronous_heart_ failure
P-1146	-2.0147 -0.0058 -0.5228 -1.0491 -0.7631 -0.0537 -0.4125 -0.2477 -0.0028 -0.0003 -1.7469 -0.9687 -1.7942 -0.8995 -1.4673 -1.5525 -0.2729
S-165	Participation of apoptosis during the development of pacing-induced dilated cardiomyopathy is not fully understood.<unk>
T-165	apoptosis pacing-induced_dilated_cardiomyopathy
H-165	-0.7968317270278931	▁apo pto sis ▁pa cing - indu ced _ ▁dil ated _ ▁cardio my o pathy
D-165	-0.7968317270278931	apoptosis pacing-induced_ dilated_ cardiomyopathy
P-165	-1.3104 -0.0416 -1.1918 -0.3099 -2.0107 -0.3012 -0.0030 -2.4264 -0.4050 -1.5508 -1.2263 -0.6173 -0.2559 -1.9693 -0.4924 -0.0447 -0.0886 -0.0976
S-1370	A hallmark of chronic heart failure (CHF) is an increased sympathetic tone resulting in autonomic imbalance.<unk>
T-1370	chronic_heart_failure chf sympathetic_tone autonomic_imbalance
H-1370	-0.8212283849716187	▁chronic _ heart _ ▁failure CH f ▁sympa the tic _ ▁tone ▁autonomi c _ ▁im balance
D-1370	-0.8212283849716187	chronic_heart_ failureCHf sympathetic_ tone autonomic_ imbalance
P-1370	-1.9038 -0.8937 -2.3503 -0.6419 -1.8861 -1.7388 -0.1554 -0.6288 -0.1975 -1.2939 -1.4352 -0.1177 -0.0044 -0.3249 -1.3495 -0.2946 -0.0112 -0.2624 -0.1132
S-596	The right atrium mass presented with prolapse through the tricuspid valve causing a stenotic physiology.<unk>
T-596	right_atrium prolapse tricuspid_valve stenotic_physiology
H-596	-0.6088399291038513	▁right ▁at rium _ ▁mass ▁pro lapse ▁tri cus pid ▁val ve ▁ste no tic _ ▁physio log y
D-596	-0.6088399291038513	right atrium_ mass prolapse tricuspid valve stenotic_ physiology
P-596	-2.2595 -0.9531 -0.0207 -1.7299 -1.9988 -0.3641 -0.0467 -0.9072 -0.1236 -0.1475 -0.1559 -0.4310 -0.0010 -0.1034 -1.1232 -0.4525 -0.4324 -0.4469 -0.6399 -0.3726 -0.0756
S-571	The primary outcome, measured after 12 weeks, was functional capacity assessed by a 6-minute walk test (6MWT).<unk>
T-571	primary_outcome functional_capacity 6-minute_walk_test 6mwt
H-571	-1.3614537715911865	▁m t
D-571	-1.3614537715911865	mt
P-571	-4.9515 -0.0575 -0.2879 -0.1489
S-224	Fontan failure can occur even with normal systolic ventricular function and often in the context of significant liver disease.<unk>
T-224	fontan_failure systolic_ventricular_function liver_disease
H-224	-1.0957516431808472	▁Font an _ f ré que nce ▁vent ri cular ▁ liver
D-224	-1.0957516431808472	Fontan_fréquence ventricular liver
P-224	-0.2761 -1.2465 -0.9169 -4.7758 -0.2483 -0.2356 -0.0135 -1.8434 -0.3590 -0.1584 -1.6240 -0.6438 -2.9204 -0.0788
S-1431	Western blots with site-specific monoclonal antibodies showed increased Ser83 phosphorylation in HF.<unk>
T-1431	western_blots monoclonal_antibodies ser83 phosphorylation hf
H-1431	-0.6380024552345276	▁Western ▁blot s ▁mono clo nal _ anti bo dies ▁Ser 83 ▁ phos phor y lation ▁ HF
D-1431	-0.6380024552345276	Western blots monoclonal_antibodies Ser83 phosphorylation HF
P-1431	-0.2018 -0.7642 -0.1001 -1.5226 -0.0108 -0.3709 -1.4975 -0.2301 -0.1381 -2.3082 -0.4251 -0.5796 -0.0889 -0.0595 -0.7740 -2.9274 -0.0222 -0.9929 -0.0071 -0.1943 -0.1825
S-1292	INVESTIGATIONS: The cardiac catheterization showed a thrombotic obstruction of the right coronary artery.<unk>
T-1292	cardiac_catheterization thrombotic_obstruction right_coronary_artery
H-1292	-0.726459801197052	▁cardiac _ ▁cat heter ization ▁ thro mbo tic _ ▁ob struct ion ▁right ▁corona ry ▁arter y
D-1292	-0.726459801197052	cardiac_ catheterization thrombotic_ obstruction right coronary artery
P-1292	-0.2511 -2.5325 -0.5277 -0.0086 -1.1496 -0.3166 -0.0478 -0.1075 -3.4677 -0.9080 -0.7229 -0.0152 -0.0180 -1.3916 -0.4662 -0.8573 -0.3300 -1.0428 -0.2624 -0.1056
S-528	Relation of preoperative serum albumin levels to survival in patients undergoing left ventricular assist device implantation.<unk>
T-528	preoperative serum_albumin patients left_ventricular_assist_device implantation
H-528	-0.7709077596664429	▁pre operativ e ▁se rum ▁album in ▁vent ri cular ▁implant ation
D-528	-0.7709077596664429	preoperative serum albumin ventricular implantation
P-528	-1.1699 -0.1312 -0.0965 -1.2548 -0.1804 -1.5047 -0.1844 -3.2979 -0.1714 -0.1385 -2.1200 -0.0275 -0.3768 -0.1389
S-1992	Fully Magnetically Levitated Left Ventricular Assist System for Treating Advanced HF: A Multicenter Study.<unk>
T-1992	fully_magnetically_levitated_left_ventricular_assist_system hf
H-1992	-0.6107920408248901	▁magnet ically _ ▁Lev itate d ▁Le ft ▁Vent ri cular ▁Assist ▁ HF
D-1992	-0.6107920408248901	magnetically_ Levitated Left Ventricular Assist HF
P-1992	-1.0007 -0.4283 -0.9160 -0.0912 -0.9316 -0.2546 -0.7805 -0.0116 -1.3159 -0.2598 -0.2434 -0.8495 -1.8454 -0.3158 -0.3704 -0.1580
S-614	The challenge is to deliver cost-effective, participatory, population-specific health interventions that result in measurable benefits.<unk>
T-614	health
H-614	-0.8521913886070251	▁coût - effect ive
D-614	-0.8521913886070251	coût-effective
P-614	-1.7099 -0.0361 -0.0315 -0.0151 -3.2106 -0.1099
S-851	At study closure, the 809 patients who had undergone randomization had been followed for a mean of 19.4 months.<unk>
T-851	patients randomization
H-851	-0.8650408983230591	▁ closure
D-851	-0.8650408983230591	closure
P-851	-2.2992 -0.0230 -1.0484 -0.0895
S-1662	It is critical to develop an understanding of this topic so cardiac nurses can partner with other subspecialty groups to manage this population.<unk>
T-1662	cardiac nurses
H-1662	-0.8249599933624268	▁cardiac ▁nurse s
D-1662	-0.8249599933624268	cardiac nurses
P-1662	-0.3074 -3.1184 -0.0728 -0.5840 -0.0422
S-1282	In total, 28 consultations were required in 21 patients (9%) and 16 procedures were performed in 11 patients (5%).<unk>
T-1282	consultations patients patients
H-1282	-0.3220478892326355	▁consultation s
D-1282	-0.3220478892326355	consultations
P-1282	-0.0468 -0.0483 -1.1428 -0.0503
S-50	Conclusion: Higher transfusion thresholds do not consistently improve mortality rates, but large trials are needed.<unk>
T-50	transfusion mortality
H-50	-1.2183648347854614	▁trans fusion _ ▁thre s hold s
D-50	-1.2183648347854614	transfusion_ thresholds
P-50	-0.2278 -0.3785 -2.5764 -3.1371 -0.1401 -0.7552 -0.1125 -3.4957 -0.1420
S-1539	The absolute risk of heart failure was 4.4% in the exposed group and 3.7% in the control group (P < 0.01).<unk>
T-1539	heart_failure
H-1539	-1.6143840551376343	▁risk _ de _ heart _ ▁failure
D-1539	-1.6143840551376343	risk_de_heart_ failure
P-1539	-3.7396 -1.1752 -1.6999 -0.1914 -1.5881 -1.1628 -4.2998 -0.5600 -0.1126
S-383	The concordance c statistics in the UM/VA/VA-RT cohorts were 0.71/0.68/0.74.<unk>
T-383	c_statistics
H-383	-1.1767680644989014	▁UM / VA - RT
D-383	-1.1767680644989014	UM/VA-RT
P-383	-1.4059 -1.9853 -0.9761 -2.3612 -1.0290 -0.3220 -0.1580
S-1875	The major adverse neurological and cardiovascular event-free rate was 97.2% (lower 95% confidence bound 91.4%).<unk>
T-1875	neurological cardiovascular bound
H-1875	-1.5372909307479858	▁advers e ▁neurologi cal
D-1875	-1.5372909307479858	adverse neurological
P-1875	-3.5746 -0.0378 -0.2157 -0.1304 -5.1695 -0.0957
S-1050	Importantly, the targets of BETs in the mouse TAC model were also found to be relevant in human HF.<unk>
T-1050	bets tac hf
H-1050	-0.7953997254371643	▁ BET s ▁mouse ▁ TAC
D-1050	-0.7953997254371643	BETs mouse TAC
P-1050	-1.1395 -0.1096 -0.6124 -0.3901 -0.3214 -0.0121 -3.6231 -0.1550
S-1972	Czech Republic significantly contributed to this study and all study sites should be congratulated and thanked for their high-quality work provided.<unk>
T-1972	czech_republic
H-1972	-0.6771945357322693	▁Czech ▁Republic
D-1972	-0.6771945357322693	Czech Republic
P-1972	-0.4556 -1.0751 -0.9491 -0.2289
S-414	Its clinical usefulness is limited by chemical instability and cogeneration of nitrite which itself has vascular effects.<unk>
T-414	clinical nitrite vascular
H-414	-0.5860258340835571	▁chemical ▁in st ability ▁nit rite ▁vas cular
D-414	-0.5860258340835571	chemical instability nitrite vascular
P-414	-1.9073 -0.0512 -0.0818 -0.0476 -1.0793 -0.5589 -0.1534 -0.0389 -1.8762 -0.0656
S-858	METHODS: All patients in the MADIT-CRT study who received a device (N = 1,790) were identified.<unk>
T-858	patients madit-crt
H-858	-0.582028865814209	▁MAD it - c RT
D-858	-0.582028865814209	MADit-cRT
P-858	-0.2246 -1.0529 -0.0691 -0.8041 -0.3046 -1.5689 -0.0498
S-1106	Over the 5-year follow-up period, 715 patients developed HF, 475 of whom developed it during the first week.<unk>
T-1106	follow-up patients hf
H-1106	-0.6612433791160583	▁ HF
D-1106	-0.6612433791160583	HF
P-1106	-1.8195 -0.1754 -0.5868 -0.0633
S-76	INTERVENTIONS: Participants were randomized in an open, 1:1 allocation ratio to the dopamine or nesiritide strategy.<unk>
T-76	randomized dopamine nesiritide
H-76	-0.9237492680549622	▁dop amine ▁nesi riti de
D-76	-0.9237492680549622	dopamine nesiritide
P-76	-3.8969 -0.2251 -0.3590 -0.0278 -0.1822 -1.7209 -0.0544
S-1290	Extracorporeal membrane oxygenation as bridge to recovery in infarction-related refractory right heart failure.<unk>
T-1290	extracorporeal_membrane_oxygenation refractory_right_heart_failure
H-1290	-0.8752342462539673	▁extra corp o real ▁membran e _ ▁oxygen ation ▁in far ction _ related _ ▁re frac tory _ ▁right ▁heart _ ▁failure
D-1290	-0.8752342462539673	extracorporeal membrane_ oxygenation infarction_related_ refractory_ right heart_ failure
P-1290	-1.5083 -0.0064 -0.2532 -0.0507 -0.0742 -0.1502 -0.5546 -1.4577 -0.0114 -0.1355 -1.7457 -0.0099 -0.7081 -0.3131 -1.4301 -1.3452 -0.0117 -1.7458 -0.8683 -3.1455 -1.6625 -1.3720 -2.9282 -0.1775 -0.2150
S-136	DATA SOURCES: 2000-2009 California Office of Statewide Health Planning and Development Patient Discharge Data Nonpublic file.<unk>
T-136	california_office_of_statewide_health_planning_and_development_patient_discharge_data_nonpublic_file
H-136	-1.1165580749511719	▁California ▁office _ de _ ▁State _ wide _ ▁Health _ plan ning _ de _ ▁Development ▁Patient _ dis charge
D-136	-1.1165580749511719	California office_de_ State_wide_ Health_planning_de_ Development Patient_discharge
P-136	-2.9583 -0.1966 -0.4895 -2.2339 -0.1134 -3.7032 -0.7253 -2.3701 -0.0913 -1.5881 -2.0273 -1.7522 -0.0497 -1.1686 -2.9709 -0.1159 -0.5121 -0.1687 -1.1006 -0.0109 -0.0054 -1.2395 -0.0893
S-368	Because functional MS is dynamic and proportional to LV dilatation, the degree of functional MS can potentially vary considerably.<unk>
T-368	functional_ms lv_dilatation functional_ms
H-368	-1.4955172538757324	▁LV _ di la tation
D-368	-1.4955172538757324	LV_dilatation
P-368	-4.0630 -2.9692 -0.7444 -0.0682 -0.0032 -2.4664 -0.1542
S-838	Treatment group effects on HRQoL were estimated using linear mixed models according to the intention-to-treat principle.<unk>
T-838	hrqol linear_mixed_models intention-to-treat
H-838	-1.0784038305282593	▁HR Qo L
D-838	-1.0784038305282593	HRQoL
P-838	-3.6381 -0.0202 -0.5831 -1.0457 -0.1050
S-648	Because of their negative inotropic effect, beta blockers were neglected for a long time from the treatment of heart failure.<unk>
T-648	inotropic_effect beta_blockers heart_failure
H-648	-1.0310590267181396	▁in o tropi c
D-648	-1.0310590267181396	inotropic
P-648	-0.6420 -0.3692 -0.0438 -0.3477 -4.6419 -0.1418
S-1954	Patients had clinical and echocardiography evaluations at baseline and months 1 and 3 after shunt implantation.<unk>
T-1954	patients clinical echocardiography baseline shunt implantation
H-1954	-0.262691855430603	▁e cho card i ography ▁shu nt ▁implant ation
D-1954	-0.262691855430603	echocardiography shunt implantation
P-1954	-0.4204 -0.0698 -0.3023 -0.7432 -0.3257 -0.7680 -0.0588 -0.0043 -0.0157 -0.1015 -0.0799
S-1779	Whether these changes in energy metabolism precede and contribute to the development of heart failure in the hypertrophied heart is not clear.<unk>
T-1779	energy_metabolism heart_failure hypertrophied heart
H-1779	-1.011460781097412	▁ énergie _ ▁metabolism ▁hyper trop hi ed ▁heart
D-1779	-1.011460781097412	énergie_ metabolism hypertrophied heart
P-1779	-3.9109 -0.4093 -1.6386 -0.1920 -3.1519 -0.0542 -0.0252 -0.6499 -0.7801 -0.1378 -0.1760
S-2012	Projections of resource use and quality of life are modeled using relationships with time-varying Seattle Heart Failure Model scores.<unk>
T-2012	quality_of_life seattle_heart_failure_model
H-2012	-0.899392306804657	▁temps - var ying ▁Seattle ▁Heart _ ▁Fail ure
D-2012	-0.899392306804657	temps-varying Seattle Heart_ Failure
P-2012	-5.6838 -0.9344 -0.4519 -0.2309 -0.0436 -0.7947 -0.7692 -0.5446 -0.0429 -0.2341 -0.1633
S-1652	Usual care will consist of anticoagulation, therapy of underlying heart disease, and rate control as an initial approach.<unk>
T-1652	anticoagulation therapy heart_disease rate_control
H-1652	-0.8570669293403625	▁antico ag ulation ▁ therapy _ de _ ▁under ly ing ▁heart _ control
D-1652	-0.8570669293403625	anticoagulation therapy_de_ underlying heart_control
P-1652	-1.5991 -0.7432 -0.0185 -1.8267 -0.0158 -2.3272 -1.3817 -0.3481 -0.8989 -0.0900 -0.1028 -0.4742 -1.0713 -2.3165 -0.3907 -0.1084
S-212	SETTING: consecutive patients seen by ED physicians in 4 suburban hospitals in New Jersey and New York from 1996 to 2008.<unk>
T-212	patients physicians hospitals new_jersey new_york
H-212	-1.1986846923828125	▁ED ▁physician s ▁subur ban ▁hospital s ▁New ▁Jersey
D-212	-1.1986846923828125	ED physicians suburban hospitals New Jersey
P-212	-3.3953 -2.7634 -0.0846 -0.7986 -0.0250 -1.6749 -0.2656 -1.2471 -0.0943 -2.7361 -0.1005
S-2021	This article describes the pathophysiology of HF, diagnosis, medical management, and nursing interventions.<unk>
T-2021	pathophysiology hf diagnosis medical nursing
H-2021	-0.5134025812149048	▁pat ho phy si ology ▁ HF ▁medical ▁management
D-2021	-0.5134025812149048	pathophysiology HF medical management
P-2021	-1.5137 -0.1512 -0.0398 -0.2979 -0.6383 -0.3859 -0.0711 -0.5966 -0.2906 -1.6043 -0.0579
S-1350	This occurred despite a profound change in Paco2, cerebral blood flow, and perfusion of the carotid bodies.<unk>
T-1350	change paco2 cerebral blood_flow perfusion carotid
H-1350	-0.5231642723083496	▁Paco 2 ▁cerebral _ ▁blood _ ▁flow ▁caro tid ▁bo dies
D-1350	-0.5231642723083496	Paco2 cerebral_ blood_ flow carotid bodies
P-1350	-0.9798 -0.3352 -0.0470 -1.8268 -0.7819 -0.6672 -0.6799 -0.2173 -0.0606 -0.5686 -0.4288 -0.1347 -0.0735
S-1388	Comparison of baseline characteristics, duration of mechanical cardiac support, and renal function was made between the three groups.<unk>
T-1388	baseline mechanical_cardiac_support renal_function
H-1388	-1.3547395467758179	▁mechanic al _ ▁cardiac _ ▁support ▁renal e
D-1388	-1.3547395467758179	mechanical_ cardiac_ support renale
P-1388	-2.4263 -0.0383 -0.3649 -1.9043 -2.9102 -1.2455 -0.0128 -3.7448 -0.8100 -0.0903
S-1423	Human heart failure is accompanied by altered protein kinase A subunit expression and post-translational state.<unk>
T-1423	heart_failure protein_kinase_a expression
H-1423	-1.2914996147155762	▁heart _ pu issa nce ▁protein _ ▁kina se
D-1423	-1.2914996147155762	heart_puissance protein_ kinase
P-1423	-1.8032 -1.1733 -5.2970 -0.1082 -0.0360 -1.2173 -2.7128 -0.1554 -0.0496 -1.4765 -0.1771
S-1390	The patients in the ECMO group were significantly younger and smaller than the patients in the VAD and ECMO+VAD groups.<unk>
T-1390	patients ecmo patients vad ecmo vad
H-1390	-1.2488948106765747	▁EC mo ▁ VAD
D-1390	-1.2488948106765747	ECmo VAD
P-1390	-0.9211 -0.4885 -1.8410 -0.4073 -3.4498 -0.3857
S-1558	Using Cox regression, the hazards of cardiovascular events for psoriasis, as a time-dependent variable, were calculated.<unk>
T-1558	cox_regression cardiovascular_events psoriasis
H-1558	-0.7679974436759949	▁co x ▁re gression ▁cardiovascular ▁events ▁psoriasis
D-1558	-0.7679974436759949	cox regression cardiovascular events psoriasis
P-1558	-0.6432 -0.0066 -1.8380 -0.0793 -1.0122 -2.0689 -0.3012 -0.8407 -0.1219
S-1568	We investigated 120 consecutive patients with PAD, defined by an ankle-brachial index ≤ 0.9.<unk>
T-1568	patients pad ankle-brachial_index
H-1568	-0.46231240034103394	▁ PAD ▁an kle - bra chi al ▁index
D-1568	-0.46231240034103394	PAD ankle-brachial index
P-1568	-1.9745 -0.0516 -0.6738 -0.0786 -0.2582 -1.0927 -0.1974 -0.1963 -0.0298 -0.3614 -0.1711
S-160	Reductions were also observed in all-cause hospitalisations for TM interventions but not for STS interventions.<unk>
T-160	all-cause_hospitalisations sts
H-160	-1.260057806968689	
D-160	-1.260057806968689	
P-160	-2.4425 -0.0777
S-525	CONCLUSIONS: Isolated HR reduction by ivabradine improves TAC, thus reducing Ea.<unk>
T-525	hr_reduction ivabradine tac ea
H-525	-0.94167560338974	▁HR ▁i va bra dine ▁ TAC
D-525	-0.94167560338974	HR ivabradine TAC
P-525	-2.7103 -1.8523 -0.1337 -1.2664 -0.0497 -1.0118 -0.0122 -1.2446 -0.1942
S-1845	We will include prospective studies evaluating implementation interventions aimed at improving uptake of class I CPG recommendations in HF.<unk>
T-1845	prospective_studies cpg hf
H-1845	-1.1068090200424194	▁c p ▁recommendations ▁ HF
D-1845	-1.1068090200424194	cp recommendations HF
P-1845	-1.2949 -1.1492 -4.2373 -0.7794 -0.0411 -0.1409 -0.1049
S-1075	It has a higher mortality and morbidity than several cancers and consumes a significant portion of the health-care budget.<unk>
T-1075	mortality morbidity health-care budget
H-1075	-0.5014623403549194	▁mortal ity ▁cancer s ▁health - care ▁budget
D-1075	-0.5014623403549194	mortality cancers health-care budget
P-1075	-0.5812 -0.3468 -1.4094 -0.1904 -1.7846 -0.0705 -0.2863 -0.0498 -0.1724 -0.1232
S-1513	We aimed to characterize and quantify the various forms of NT-proBNP in the circulation of HF patients.<unk>
T-1513	nt-probnp circulation hf patients
H-1513	-0.5593157410621643	▁NT - pro B NP ▁circulation ▁ HF
D-1513	-0.5593157410621643	NT-proBNP circulation HF
P-1513	-0.8403 -0.0964 -0.0307 -0.8842 -0.0900 -0.5073 -1.5495 -0.0875 -1.2523 -0.2550
S-1070	Data in patients with preserved systolic function are scarce, but interesting therapeutic concepts are evolving.<unk>
T-1070	patients systolic_function therapeutic
H-1070	-1.3193532228469849	▁patients ▁pres er ved _ syn chron _ ▁function ▁ therapeut ic
D-1070	-1.3193532228469849	patients preserved_synchron_ function therapeutic
P-1070	-3.2845 -3.1502 -0.0200 -1.1400 -0.9158 -0.9747 -1.1998 -2.0198 -3.5034 -0.4763 -0.0215 -0.6932 -0.9694 -0.1023
S-259	A correlation between changes in HDL-induced NO production and flow-mediated dilatation improvement by ET was evident.<unk>
T-259	correlation flow-mediated_dilatation
H-259	-0.7884879112243652	▁HD L - indu ced _ ▁NO ▁production ▁flow - media te _ di la tation ▁ET
D-259	-0.7884879112243652	HDL-induced_ NO production flow-mediate_dilatation ET
P-259	-1.0680 -1.2079 -0.4314 -0.0018 -0.8223 -2.2970 -0.7535 -0.0066 -0.2806 -0.0761 -0.1002 -3.5507 -0.5010 -1.5254 -0.0722 -0.0089 -2.0686 -0.0928 -0.1164
S-271	Furthermore, the optimal cutoff level of NT-proBNP used to predict 4-year survival had high sensitivity.<unk>
T-271	nt-probnp sensitivity
H-271	-0.7069870829582214	▁NT - pro B NP
D-271	-0.7069870829582214	NT-proBNP
P-271	-1.9437 -0.0703 -0.0693 -1.1188 -0.1465 -1.4019 -0.1983
S-58	However, patients with AHF are highly heterogeneous, and appropriate risk stratification is essential in conducting studies in this area.<unk>
T-58	patients ahf risk_stratification
H-58	-0.9509655833244324	▁a HF
D-58	-0.9509655833244324	aHF
P-58	-2.1530 -0.1792 -1.2958 -0.1759
S-267	RESULTS: The mean age of the patients in this study was 71.1 ± 10.3 years; 50 of these patients were female.<unk>
T-267	patients patients
H-267	-0.9046180844306946	
D-267	-0.9046180844306946	
P-267	-1.7495 -0.0597
S-1002	Each method has strengths and limitations, but their utility has never been evaluated in the same community HF cohort.<unk>
T-1002	hf
H-1002	-0.8610119819641113	▁ HF
D-1002	-0.8610119819641113	HF
P-1002	-2.3739 -0.4916 -0.5249 -0.0537
S-65	RESULTS: Of 10,420 studies reviewed, 72 studies evaluating 63 predictors on 257,692 ICD patients proved eligible.<unk>
T-65	icd patients
H-65	-0.7720322608947754	▁i CD
D-65	-0.7720322608947754	iCD
P-65	-0.9846 -0.9547 -1.0447 -0.1041
S-144	CONCLUSIONS: Different approaches to computing readmissions can produce different hospital rankings and impact pay-for-performance.<unk>
T-144	readmissions hospital
H-144	-0.6398311853408813	▁computing _ ▁read missions ▁hospital ▁ranking s ▁pay - for - per form ance
D-144	-0.6398311853408813	computing_ readmissions hospital rankings pay-for-performance
P-144	-2.7005 -1.3502 -2.5615 -0.0382 -0.4033 -1.9764 -0.2199 -0.0561 -0.0233 -0.1525 -0.1431 -0.0144 -0.1211 -0.0211 -0.3166 -0.1392
S-1124	Reasons for nontreatment were identified from clinic notes and from interviews with 62 primary care clinicians caring for these patients.<unk>
T-1124	clinic clinicians patients
H-1124	-0.668388843536377	▁Reason s _ non tre at ment
D-1124	-0.668388843536377	Reasons_nontreatment
P-1124	-1.7960 -0.0950 -0.8054 -1.1397 -0.0023 -0.2476 -0.0292 -1.8421 -0.0582
S-700	Correlations and Cox models were used to assess the relationship among ST2, functional capacity, and long-term outcomes.<unk>
T-700	correlations cox_models st2 functional_capacity outcomes
H-700	-0.9772718548774719	▁co x
D-700	-0.9772718548774719	cox
P-700	-0.5663 -0.0060 -3.2371 -0.0998
S-1272	Exercise intolerance in heart failure: update on exercise parameters for diagnosis, prognosis and therapeutic interventions.<unk>
T-1272	exercise_intolerance heart_failure exercise diagnosis prognosis therapeutic
H-1272	-1.0674526691436768	▁Exerci se ▁in tolerance _ ▁in tolerance ▁heart _ ▁failure
D-1272	-1.0674526691436768	Exercise intolerance_ intolerance heart_ failure
P-1272	-2.1443 -0.4404 -0.2321 -0.0089 -1.6449 -0.4574 -0.9719 -2.8900 -0.5709 -2.2640 -1.0675 -0.1171
S-1560	Psoriasis patients were significantly younger, smoked more, and had higher diastolic blood pressure and body mass index levels.<unk>
T-1560	psoriasis patients diastolic_blood_pressure body_mass_index
H-1560	-0.9902517795562744	▁p sori asis
D-1560	-0.9902517795562744	psoriasis
P-1560	-0.9962 -0.0304 -0.6154 -3.1742 -0.1351
S-1365	Both BNP and NT-proBNP have proven to be reliable diagnostic and prognostic biomarkers in patients with heart failure.<unk>
T-1365	bnp nt-probnp diagnostic prognostic biomarkers patients heart_failure
H-1365	-0.960604727268219	▁b NP ▁NT - pro B NP
D-1365	-0.960604727268219	bNP NT-proBNP
P-1365	-0.1525 -0.1827 -3.3000 -0.0457 -0.0057 -0.8912 -0.0587 -3.8611 -0.1478
S-366	There have been reports demonstrating development of functional MS following ring annuloplasty for ischemic MR with LV dilatation.<unk>
T-366	functional_ms ring_annuloplasty ischemic_mr lv_dilatation
H-366	-0.3455159068107605	▁functional ▁MS ▁ring _ ▁ann ulo plast y ▁ ische mic ▁MR ▁LV ▁di la tation
D-366	-0.3455159068107605	functional MS ring_ annuloplasty ischemic MR LV dilatation
P-366	-0.9280 -0.1631 -0.2101 -0.9529 -0.7029 -0.2864 -0.0295 -0.2429 -0.6355 -0.2565 -0.1032 -0.0418 -0.0435 -1.2398 -0.0318 -0.0024 -0.2912 -0.0578
S-1194	Experience of a vasopressin receptor antagonist, tolvaptan, under the unique indication in Japanese heart failure patients.<unk>
T-1194	vasopressin_receptor_antagonist tolvaptan heart_failure patients
H-1194	-0.7028928995132446	▁vaso press in _ ▁receptor _ ▁anta gon ist ▁to lv ap tan ▁Japanese ▁heart _ ▁failure
D-1194	-0.7028928995132446	vasopressin_ receptor_ antagonist tolvaptan Japanese heart_ failure
P-1194	-0.0277 -0.0721 -0.8434 -0.7822 -0.1447 -0.6928 -0.2533 -0.0962 -2.7765 -0.4840 -0.5021 -0.0795 -0.0161 -1.2661 -2.2498 -0.6382 -1.8667 -0.4906 -0.0729
S-15	An inverse correlation was observed between pro-adrenomedullin (MR-proADM) and FFM.<unk>
T-15	inverse_correlation pro-adrenomedullin mr-proadm ffm
H-15	-0.4146953225135803	▁pro - ad re nom edu llin MR - pro AD m ▁F FM
D-15	-0.4146953225135803	pro-adrenomedullinMR-proADm FFM
P-15	-1.1419 -0.0256 -0.0083 -0.0362 -0.3270 -1.9496 -0.3407 -0.0969 -0.0254 -0.0089 -0.2808 -0.2534 -1.2086 -0.7947 -0.0813 -0.0559
S-398	Soluble concentrations of the interleukin receptor family member ST2 and beta-blocker therapy in chronic heart failure.<unk>
T-398	interleukin_receptor st2 beta-blocker therapy chronic_heart_failure
H-398	-1.0602993965148926	▁inter le u kin _ ▁receptor _ family _ ▁member ▁ST 2 ▁beta - block er ▁ therapy
D-398	-1.0602993965148926	interleukin_ receptor_family_ member ST2 beta-blocker therapy
P-398	-0.0058 -0.3604 -0.6322 -4.3103 -1.4443 -0.2871 -1.8995 -0.6850 -0.6258 -3.0842 -1.0025 -0.0432 -0.0928 -0.0317 -0.0562 -0.0366 -2.3815 -0.0279 -4.0722 -0.1266
S-2005	New York Heart Association classification, 6-min walk test, and quality-of-life scores showed progressive and sustained improvement.<unk>
T-2005	new_york_heart_association_classification 6-min_walk_test quality-of-life
H-2005	-1.7198294401168823	▁Heart _ association
D-2005	-1.7198294401168823	Heart_association
P-2005	-2.9411 -1.1997 -1.7097 -2.5259 -0.2228
S-1383	Comparative effects of ventricular assist device and extracorporeal membrane oxygenation on renal function in pediatric heart failure.<unk>
T-1383	ventricular_assist_device extracorporeal_membrane_oxygenation renal_function heart_failure
H-1383	-0.5486024022102356	▁vent ri cular _ assist ▁device ▁extra corp o real ▁membran e _ ▁oxygen ation ▁pediatr ic ▁heart _ ▁failure
D-1383	-0.5486024022102356	ventricular_assist device extracorporeal membrane_ oxygenation pediatric heart_ failure
P-1383	-0.0015 -0.0610 -0.1259 -0.7061 -0.0920 -1.5225 -0.2753 -0.0112 -0.1847 -0.0753 -0.3970 -0.1029 -1.3012 -0.4383 -0.0277 -0.2886 -0.2826 -1.8091 -1.1481 -2.9749 -0.1252 -0.1183
S-1765	Cardiorespiratory fitness, body mass index, and heart failure mortality in men: Cooper Center Longitudinal Study.<unk>
T-1765	cardiorespiratory_fitness body_mass_index heart_failure mortality cooper_center_longitudinal_study
H-1765	-1.2280205488204956	▁Card i ore spira tory _ ▁fitness ▁body _ ▁mass ▁index ▁heart _ ▁failure _ ▁mortal ity
D-1765	-1.2280205488204956	Cardiorespiratory_ fitness body_ mass index heart_ failure_ mortality
P-1765	-0.1988 -0.6372 -4.3107 -0.2000 -0.5852 -1.0388 -0.3334 -1.6588 -0.5519 -1.5014 -0.3703 -0.3677 -0.4312 -5.1875 -1.7038 -2.0812 -0.1875 -1.8731 -0.1139
S-806	CONCLUSIONS: The TUG test is reliable in patients with advanced COPD, CHF, or CRF after 2 trials.<unk>
T-806	tug_test patients copd chf crf
H-806	-1.637571096420288	▁TU G _ test ▁patients ▁advanced ▁COP d ▁CHF ▁c RF
D-806	-1.637571096420288	TUG_test patients advanced COPd CHF cRF
P-806	-1.2408 -2.2106 -4.2457 -2.4755 -4.3696 -3.3433 -0.7857 -1.7677 -0.0343 -0.4193 -0.0301 -0.3185 -0.0472
S-1898	Regular physical activity controls acquired cardiovascular risk factors such as obesity, diabetes mellitus, hypertension and hyperlipidaemia.<unk>
T-1898	physical activity cardiovascular obesity diabetes_mellitus hypertension hyperlipidaemia
H-1898	-0.757533848285675	▁cardiovascular e ▁diabetes ▁mell itus ▁hyper tension ▁hyper li pida emia
D-1898	-0.757533848285675	cardiovasculare diabetes mellitus hypertension hyperlipidaemia
P-1898	-1.0204 -5.7906 -1.8857 -0.1349 -0.1419 -0.0058 -0.0058 -0.0821 -0.0525 -0.3000 -0.1154 -0.2450 -0.0680
S-419	Unlike isoproterenol, CXL-1020 was equally effective in myocytes from normal or failing hearts.<unk>
T-419	isoproterenol cxl-1020 myocytes hearts
H-419	-1.3032118082046509	▁iso prot eren ol ▁c XL -10 20 ▁my o cy tes
D-419	-1.3032118082046509	isoproterenol cXL-1020 myocytes
P-419	-0.4525 -0.5798 -3.5538 -0.1966 -1.4635 -0.2969 -3.4385 -0.4496 -3.1776 -0.0819 -0.1822 -0.0502 -4.1396 -0.1824
S-1445	In conclusion, patients with HF and spontaneous VT have larger fluctuations in beat-to-beat QT intervals.<unk>
T-1445	patients hf spontaneous_vt qt_intervals
H-1445	-0.5626040697097778	▁ HF ▁spontane ous ▁ VT ▁beat - to - beat ▁ QT
D-1445	-0.5626040697097778	HF spontaneous VT beat-to-beat QT
P-1445	-0.6982 -0.0785 -5.0663 -0.2934 -0.1845 -0.0164 -0.5640 -0.0574 -0.2855 -0.0399 -0.0530 -0.1989 -0.1107 -0.5246 -0.2677
S-725	RESULTS: The average age of patients with heart failure was 79.9 years in 2011, with 45.9% having systolic heart failure.<unk>
T-725	patients heart_failure systolic_heart_failure
H-725	-2.3563601970672607	▁heart _ ▁failure
D-725	-2.3563601970672607	heart_ failure
P-725	-5.1294 -1.3125 -3.0101 -2.2248 -0.1050
S-305	However biventricular dysfunction does not have a favorable outcome at 1 year when compared with patients requiring isolated HeartMate II.<unk>
T-305	biventricular_dysfunction outcome patients heartmate_ii
H-305	-1.254881501197815	▁bi ven tri cular _ ▁dys function
D-305	-1.254881501197815	biventricular_ dysfunction
P-305	-0.2038 -0.3523 -0.1460 -2.8018 -1.5345 -0.7014 -2.0254 -3.3408 -0.1879
S-356	His HF symptom as well as cardiac murmurs disappeared with a reduction in blood pressure to 140/80 mm Hg.<unk>
T-356	hf symptom cardiac_murmurs blood_pressure
H-356	-0.843877911567688	▁ HF ▁cardiac _ ▁mur mur s ▁blood _ tension ▁h g
D-356	-0.843877911567688	HF cardiac_ murmurs blood_tension hg
P-356	-0.7367 -0.0364 -1.0157 -2.3698 -0.7992 -0.0471 -0.5008 -2.9008 -1.0355 -1.1646 -0.6581 -0.0120 -0.2918 -0.2459
S-376	Functional MS can potentially be reversed by medical treatment and thus requires careful evaluation of the surgical indications.<unk>
T-376	functional_ms medical_treatment surgical
H-376	-0.4857277572154999	▁Fun ction al ▁MS
D-376	-0.4857277572154999	Functional MS
P-376	-0.3355 -0.0003 -0.0252 -0.1753 -2.2720 -0.1060
S-203	This work does not include Recommendations for advanced management involving ventricular assist devices, or other device therapies.<unk>
T-203	ventricular_assist_devices therapies
H-203	-0.3758365213871002	▁vent ri cular _ assist ▁devices ▁device ▁ therapie s
D-203	-0.3758365213871002	ventricular_assist devices device therapies
P-203	-0.2506 -0.0853 -0.1338 -0.6832 -0.1045 -2.1503 -0.4303 -0.4494 -0.0284 -0.0246 -0.1043 -0.0654
S-1394	CONCLUSIONS: On the basis of these data, we demonstrate that renal dysfunction improves early after mechanical cardiac support.<unk>
T-1394	renal_dysfunction mechanical_cardiac_support
H-1394	-1.4166860580444336	▁renal _ ▁dys function
D-1394	-1.4166860580444336	renal_ dysfunction
P-1394	-1.1727 -1.6896 -1.3764 -0.8126 -3.4013 -0.0475
S-1956	The device was successfully implanted in all patients; no device-related or procedural adverse events occurred during follow-up.<unk>
T-1956	implanted patients adverse_events follow-up
H-1956	-0.8685307502746582	▁implant ation
D-1956	-0.8685307502746582	implantation
P-1956	-0.1255 -1.7455 -1.5019 -0.1012
S-1746	There was a trend toward enrollment of older patients with less severe left ventricular dilatation and dysfunction during the years.<unk>
T-1746	patients left_ventricular_dilatation dysfunction
H-1746	-0.6348896026611328	▁vent ri cular _ di la tation ▁dys function
D-1746	-0.6348896026611328	ventricular_dilatation dysfunction
P-1746	-1.2370 -0.2365 -0.2841 -0.6169 -2.0494 -0.3172 -0.0373 -1.4424 -0.4818 -0.2224 -0.0588
S-1351	It is concluded that PB in patients with HF could be produced by primary oscillations originating from the central pattern generator.<unk>
T-1351	pb patients hf
H-1351	-1.456632137298584	PB ▁ PB ▁ HF
D-1351	-1.456632137298584	PB PB HF
P-1351	-0.9005 -1.3628 -0.2559 -1.4254 -1.6580 -4.3654 -0.2285
S-38	(Grade: strong recommendation; moderate-quality evidence) Treatment of anemia in patients with heart disease: a systematic review.<unk>
T-38	grade evidence anemia patients heart_disease
H-38	-1.7091100215911865	▁implant ation ▁an emia ▁patients _ with _ heart _ de _ ca pit ence
D-38	-1.7091100215911865	implantation anemia patients_with_heart_de_capitence
P-38	-5.6873 -0.0750 -1.1570 -0.1863 -1.6080 -0.5327 -4.4662 -0.3614 -1.3141 -1.3416 -2.3058 -0.7982 -4.3533 -0.1957 -4.3392 -0.2347 -0.0986
S-548	RESULTS: During follow-up, 6 CF LVAD patients developed new, severe AI that was accompanied by heart failure.<unk>
T-548	follow-up lvad patients heart_failure
H-548	-1.7269591093063354	▁CF ▁l VAD
D-548	-1.7269591093063354	CF lVAD
P-548	-0.0766 -3.6393 -0.0747 -4.7342 -0.1099
S-1396	Nursing has a social mandate to ensure effective practice within its domain and to be accountable for the outcomes of nursing care.<unk>
T-1396	nursing mandate accountable outcomes nursing
H-1396	-0.6569255590438843	▁social ▁mandat e
D-1396	-0.6569255590438843	social mandate
P-1396	-0.7401 -0.0794 -0.2391 -2.0117 -0.2144
S-1294	TREATMENT AND CLINICAL COURSE: The patient became again hemodynamically unstable and a CPR was required.<unk>
T-1294	clinical patient hemodynamically cpr
H-1294	-0.8390990495681763	▁TRE at ment ▁hem o dynamic ally _ ▁uns table ▁c PR
D-1294	-0.8390990495681763	TREatment hemodynamically_ unstable cPR
P-1294	-5.1241 -1.3760 -0.1572 -1.9052 -0.0908 -0.1353 -0.9117 -0.5341 -0.5795 -0.0051 -0.5267 -0.2538 -0.1114 -0.0362
S-1506	We then used exploratory factor analysis to determine the presence of separate scale dimensions, followed by CFA in a separate sub-sample.<unk>
T-1506	exploratory_factor_analysis cfa
H-1506	-1.1769022941589355	▁c fa
D-1506	-1.1769022941589355	cfa
P-1506	-3.0360 -1.1235 -0.4100 -0.1381
S-1237	Baseline characteristics were similar in rhythm-control (n = 149) and rate-control (n = 155) groups.<unk>
T-1237	baseline rhythm-control rate-control
H-1237	-0.2938847839832306	▁ rhythm - control ▁rate - control
D-1237	-0.2938847839832306	rhythm-control rate-control
P-1237	-0.2128 -0.4263 -0.2554 -0.0148 -0.9107 -0.1505 -0.0182 -0.5246 -0.1314
S-2019	Heart failure (HF) is a debilitating chronic disease and is expected to increase in upcoming years due to demographic changes.<unk>
T-2019	heart_failure hf chronic disease
H-2019	-0.9839670062065125	▁Heart _ ▁failure ▁ HF ▁de bilitat ing ▁chronic ▁disease ▁demo graphic
D-2019	-0.9839670062065125	Heart_ failure HF debilitating chronic disease demographic
P-2019	-0.3642 -0.4819 -3.0206 -2.4843 -0.0349 -3.2431 -0.0012 -0.0773 -1.2373 -1.2634 -0.5284 -0.2447 -0.6643 -0.1300
S-555	OBJECTIVES: This study sought to determine the characteristics and outcomes of young adults with heart failure (HF).<unk>
T-555	outcomes heart_failure hf
H-555	-1.6090906858444214	
D-555	-1.6090906858444214	
P-555	-3.1715 -0.0467
S-43	Data Extraction: Data on study design, population characteristics, hemoglobin levels, and health outcomes were extracted.<unk>
T-43	hemoglobin health outcomes
H-43	-1.451297402381897	▁hem o glob in
D-43	-1.451297402381897	hemoglobin
P-43	-5.4730 -0.0662 -0.1274 -0.9521 -2.0214 -0.0677
S-1790	The HF epidemiology and the adequacy of relevant health service provision related to HF in LA are not well delineated.<unk>
T-1790	hf epidemiology health hf
H-1790	-1.1688449382781982	▁ HF _ ▁epidemi ology ▁health ▁service ▁ HF
D-1790	-1.1688449382781982	HF_ epidemiology health service HF
P-1790	-0.2614 -0.0853 -3.4282 -0.8529 -1.2411 -2.2118 -0.4582 -1.9604 -0.2528 -1.8261 -0.2792
S-1113	Second, we assessed whether that response correlates with levels of various serum factors that serve as markers for coagulability.<unk>
T-1113	correlates coagulability
H-1113	-1.4035614728927612	
D-1113	-1.4035614728927612	
P-1113	-2.7456 -0.0615
S-1719	CONCLUSION: A 1-day reduction in hospital length of stay was not consistently associated with a higher rate of rehospitalization.<unk>
T-1719	hospital rehospitalization
H-1719	-0.7807488441467285	▁hospital _ ▁length _ de _ ▁stay ▁re hospital ization
D-1719	-0.7807488441467285	hospital_ length_de_ stay rehospitalization
P-1719	-2.6980 -1.4492 -1.0823 -0.4827 -0.8758 -0.1836 -0.5133 -0.6127 -0.1364 -1.0977 -0.1362 -0.1010
S-1905	Sudden cardiac death in athletes under 35 is rare with.estimates ranging from 1 in 50,000 to 1 in 200,000.<unk>
T-1905	cardiac_death
H-1905	-1.1515427827835083	▁sud den _ ▁cardiac e
D-1905	-1.1515427827835083	sudden_ cardiace
P-1905	-1.2738 -0.0192 -0.2442 -0.4285 -5.0022 -0.9283 -0.1646
S-1692	To assess how well the composite measure predicts future high and low performers, and explains variance in future hospital mortality.<unk>
T-1692	hospital mortality
H-1692	-1.3643826246261597	
D-1692	-1.3643826246261597	
P-1692	-2.6635 -0.0652
S-683	Further studies need to confirm the role that the frequency of administration plays in the development of trastuzumab-related CHF.<unk>
T-683	administration chf
H-683	-0.39112740755081177	▁administration ▁tras tuz um ab - related ▁CHF
D-683	-0.39112740755081177	administration trastuzumab-related CHF
P-683	-1.4742 -0.4660 -0.0096 -0.1419 -0.4617 -0.9228 -0.1944 -0.0350 -0.1416 -0.0642
S-272	However, especially in the case of long-term survival, additional prospective, large, and multicenter studies are required to confirm our results.<unk>
T-272	prospective
H-272	-0.8023179769515991	▁long - term _ ▁survival
D-272	-0.8023179769515991	long-term_ survival
P-272	-0.3338 -0.2373 -0.8813 -1.1717 -2.2842 -0.6350 -0.0730
S-142	Between 47 and 75 percent of hospitals in an extreme decile according to one metric remained when using a different metric.<unk>
T-142	hospitals
H-142	-0.9996296167373657	▁hospital s
D-142	-0.9996296167373657	hospitals
P-142	-2.2963 -0.3179 -1.2483 -0.1360
S-1476	This is partly a result of shortcomings in research studies and a dearth of biomarker-guided clinical trials.<unk>
T-1476	clinical
H-1476	-0.35549694299697876	▁bio mark er - guide d ▁clinic al ▁trial s
D-1476	-0.35549694299697876	biomarker-guided clinical trials
P-1476	-0.2163 -0.0094 -0.0265 -0.3813 -0.0056 -0.2605 -1.2800 -0.0907 -1.7782 -0.0338 -0.0856 -0.0980
S-1131	The structure of medical records should be improved to facilitate documentation of contextual reasons for not providing guideline-recommended care.<unk>
T-1131	medical
H-1131	-1.3620178699493408	▁structure _ de _ ju rid iques
D-1131	-1.3620178699493408	structure_de_juridiques
P-1131	-1.2146 -0.8944 -1.7701 -0.1513 -3.1880 -1.1464 -0.4154 -3.3360 -0.1419
S-1979	INTERVENTIONS: Twenty weeks of diet, exercise, or both; attention control consisted of telephone calls every 2 weeks.<unk>
T-1979	exercise
H-1979	-1.429563045501709	
D-1979	-1.429563045501709	
P-1979	-2.8018 -0.0573
S-454	Moreover, B treatment was associated with increased cardiac angiogenesis and in vivo coronary perfusion and reduced cardiac fibrosis.<unk>
T-454	cardiac_angiogenesis in_vivo_coronary_perfusion cardiac_fibrosis
H-454	-0.5438054203987122	▁cardiac _ ▁ang io gene sis ▁in ▁vivo ▁corona ry _ per fusion ▁cardiac _ ▁fibro sis
D-454	-0.5438054203987122	cardiac_ angiogenesis in vivo coronary_perfusion cardiac_ fibrosis
P-454	-0.3084 -1.4358 -1.5886 -0.7706 -0.2431 -1.5903 -0.4672 -0.0402 -1.2195 -0.2784 -0.2573 -0.1469 -0.0107 -0.0391 -1.3195 -0.1305 -0.2869 -0.1623 -0.0370
S-1300	Half of patients with heart failure (HF) have a preserved left ventricular ejection fraction (HFpEF).<unk>
T-1300	patients heart_failure hf preserved_left_ventricular_ejection_fraction hfpef
H-1300	-0.9630301594734192	▁heart _ ▁failure ▁ HF ▁vent ri cular _ ▁e je ction _ fraction HF p EF
D-1300	-0.9630301594734192	heart_ failure HF ventricular_ ejection_fractionHFpEF
P-1300	-2.4840 -0.6425 -3.8267 -2.6343 -0.0335 -1.7762 -0.2062 -0.4696 -0.8029 -1.6504 -0.8235 -0.1821 -1.2045 -0.1552 -0.8875 -0.0262 -0.1647 -0.2287 -0.0990
S-1510	Circulating fragments of N-terminal pro-B-type natriuretic peptides in plasma of heart failure patients.<unk>
T-1510	n-terminal_pro-b-type_natriuretic_peptides plasma heart_failure patients
H-1510	-1.1838452816009521	▁Circula tion _ pro - B - type ▁na tri ure _ pe pti des ▁heart _ ▁failure
D-1510	-1.1838452816009521	Circulation_pro-B-type natriure_peptides heart_ failure
P-1510	-0.4667 -0.8943 -3.8554 -1.9313 -0.0542 -1.7691 -0.5636 -0.3078 -0.3097 -0.0151 -0.1485 -4.9287 -1.1625 -0.5847 -0.2063 -2.5042 -0.7257 -1.9121 -1.1232 -0.2138
S-1141	Pyridostigmine reduced the myocyte diameter and collagen density of the surviving left ventricle.<unk>
T-1141	pyridostigmine myocyte collagen left_ventricle
H-1141	-0.45698103308677673	▁Pyr ido stig mine ▁my o cy te ▁collage n _ ▁den s ity ▁sur vi ving ▁left ▁vent ric le
D-1141	-0.45698103308677673	Pyridostigmine myocyte collagen_ density surviving left ventricle
P-1141	-0.0051 -0.1173 -0.0006 -0.0688 -1.1886 -0.0596 -0.0484 -0.0881 -0.3607 -0.0584 -0.3174 -1.4092 -0.1983 -0.3467 -1.9853 -0.0035 -0.7216 -0.9397 -0.2334 -1.7906 -0.3840 -0.1120 -0.0732
S-506	Ejection fraction (EF), infarct size, collateral growth, and myocardial perfusion were assessed.<unk>
T-506	ejection_fraction ef infarct collateral_growth myocardial_perfusion
H-506	-0.4443773627281189	▁e je ction _ fraction ▁ef ▁col lateral _ ▁growth ▁my o card ial _ per fusion
D-506	-0.4443773627281189	ejection_fraction ef collateral_ growth myocardial_perfusion
P-506	-0.8790 -0.4907 -0.0096 -0.7050 -0.0081 -2.1446 -1.0033 -0.0073 -0.8902 -0.7566 -0.4228 -0.1651 -0.1715 -0.1045 -0.2577 -0.1173 -0.0159 -0.1696 -0.1243
S-1133	Heart failure (HF) is characterized by elevated sympathetic activity and reduced parasympathetic control of the heart.<unk>
T-1133	heart_failure hf elevated sympathetic_activity parasympathetic_control heart
H-1133	-1.2058749198913574	▁Heart _ ▁failure ▁h f ▁sympa the tic _ ▁activity ▁para sy mpa the tic _ control _ de _ heart
D-1133	-1.2058749198913574	Heart_ failure hf sympathetic_ activity parasympathetic_control_de_heart
P-1133	-0.2461 -0.5098 -2.1999 -2.3318 -1.1937 -2.0042 -0.4085 -2.1535 -1.8671 -1.4778 -0.2085 -0.1553 -0.0553 -2.1240 -1.8376 -0.8727 -0.0496 -1.6180 -2.4201 -0.3532 -3.2579 -0.2483 -0.1422
S-1230	Atrial fibrillation and congestive heart failure: a cost analysis of rhythm-control vs. rate-control strategies.<unk>
T-1230	atrial_fibrillation congestive_heart_failure cost rhythm-control rate-control
H-1230	-0.5115747451782227	▁at rial _ ▁fi bril lation ▁con ges tive ▁heart _ ▁failure ▁ rhythm - control ▁rate - control
D-1230	-0.5115747451782227	atrial_ fibrillation congestive heart_ failure rhythm-control rate-control
P-1230	-1.4339 -0.0168 -0.7824 -2.6027 -0.0125 -0.0052 -0.8031 -0.2821 -0.0380 -0.7623 -0.6597 -1.0005 -0.1348 -0.1636 -0.0949 -0.0059 -0.7176 -0.0990 -0.0043 -1.0550 -0.0687
S-1657	Patients with end-stage heart failure are increasingly being treated with implantation of a long-term ventricular assist device.<unk>
T-1657	patients end-stage_heart_failure implantation ventricular_assist_device
H-1657	-0.6419627666473389	▁end - s tage _ heart _ ▁failure ▁implant ation ▁long - term ▁vent ri cular _ assist ▁device
D-1657	-0.6419627666473389	end-stage_heart_ failure implantation long-term ventricular_assist device
P-1657	-2.5388 -0.1263 -0.5773 -0.0012 -0.8870 -1.8209 -1.1403 -2.1874 -0.0127 -0.0111 -0.1110 -0.0749 -0.4380 -0.4807 -0.3669 -0.1936 -0.4777 -0.0833 -1.5328 -0.2529 -0.1665
S-471	In the setting of increased ATP demand, XO-mediated ROS can decrease mitochondrial respiration and contractile function.<unk>
T-471	atp xo-mediated_ros mitochondrial_respiration contractile_function
H-471	-0.41796544194221497	▁ATP ▁ XO - media ted ▁ ROS ▁mito cho ndri al _ ▁respira tion ▁contract ile
D-471	-0.41796544194221497	ATP XO-mediated ROS mitochondrial_ respiration contractile
P-471	-0.1018 -2.7937 -0.4741 -0.0479 -0.1326 -0.5436 -0.0557 -0.1456 -0.4586 -0.4064 -0.3408 -0.0891 -0.3856 -0.7847 -0.0146 -0.0500 -0.0397 -0.9167 -0.1602
S-1406	These 2 receptors have opposing actions on adenylyl cyclase because of differential G-protein coupling.<unk>
T-1406	receptors adenylyl_cyclase g-protein_coupling
H-1406	-0.6211525797843933	▁a den yl yl _ ▁cy cla se ▁g - prote in ▁coup ling
D-1406	-0.6211525797843933	adenylyl_ cyclase g-protein coupling
P-1406	-0.2947 -0.0133 -0.1463 -1.3026 -1.5106 -0.1017 -0.0086 -0.7109 -1.6532 -0.1385 -0.2069 -0.9134 -0.4609 -2.0834 -0.2720 -0.1213
S-59	Predictors of mortality in patients with an implantable cardiac defibrillator: a systematic review and meta-analysis.<unk>
T-59	mortality patients implantable_cardiac_defibrillator meta-analysis
H-59	-0.45527809858322144	▁implant able _ ▁cardiac _ de _ fi br illa tor
D-59	-0.45527809858322144	implantable_ cardiac_de_fibrillator
P-59	-0.0860 -0.0497 -0.4636 -0.3739 -0.7637 -0.0471 -1.5654 -1.5162 -0.4285 -0.0093 -0.1079 -0.4180 -0.0894
S-1975	Exercise intolerance is the primary symptom of chronic HFPEF and a major determinant of reduced quality of life (QOL).<unk>
T-1975	exercise_intolerance symptom chronic_hfpef quality_of_life qol
H-1975	-1.0083513259887695	▁Exerci se _ ▁in tolerance ▁h f f
D-1975	-1.0083513259887695	Exercise_ intolerance hff
P-1975	-2.7873 -0.0585 -0.8177 -0.1798 -0.0065 -0.8796 -0.5302 -0.2096 -4.4870 -0.1274
S-877	CONCLUSIONS: This study elucidates the signaling pathways significantly changed in pressure-overload-induced heart failure.<unk>
T-877	signaling_pathways pressure-overload-induced_heart_failure
H-877	-1.1477833986282349	▁signal ing _ path ways ▁pressure - over load - indu ced ▁heart _ ▁failure
D-877	-1.1477833986282349	signaling_pathways pressure-overload-induced heart_ failure
P-877	-4.1435 -0.6276 -0.9844 -0.6781 -0.5550 -0.6169 -0.2240 -0.1492 -0.3716 -0.5713 -0.0094 -4.4851 -0.3671 -1.5156 -3.8013 -0.1975 -0.2147
S-1434	Autonomic modulation of repolarization instability in patients with heart failure prone to ventricular tachycardia.<unk>
T-1434	repolarization patients heart_failure ventricular_tachycardia
H-1434	-1.012269139289856	▁implant ation ▁in st ability ▁heart _ ▁failure ▁vent ri cular _ ta chy car dia
D-1434	-1.012269139289856	implantation instability heart_ failure ventricular_tachycardia
P-1434	-3.0114 -0.0513 -2.1046 -0.5771 -0.2827 -1.1459 -1.1108 -1.9833 -0.0222 -0.2225 -0.1948 -1.4958 -3.0380 -0.2608 -0.0120 -1.3745 -1.2333 -0.0997
S-1184	Whether all patients with systolic HF of unclear etiology should undergo coronary angiography has been controversial.<unk>
T-1184	patients systolic_hf etiology coronary_angiography
H-1184	-0.7773923277854919	▁sy sto lic ▁ HF ▁un clear ▁et i ology ▁corona ry _ ▁ang i ography
D-1184	-0.7773923277854919	systolic HF unclear etiology coronary_ angiography
P-1184	-1.9008 -0.1091 -1.7446 -0.6799 -0.0026 -3.1339 -0.0066 -0.9250 -0.0564 -0.4704 -0.0049 -0.7834 -1.4284 -1.4946 -0.6152 -0.1298 -0.4164 -0.0913
S-1509	This evidence provides a new understanding of the structure of the SCHFI v.6.2 and supports its use in clinical practice and research.<unk>
T-1509	evidence schfi_v.6.2 clinical
H-1509	-0.934332013130188	▁structure ▁ SCH FI
D-1509	-0.934332013130188	structure SCHFI
P-1509	-1.5670 -0.7296 -0.1292 -2.1661 -0.9661 -0.0479
S-1781	The rates of energy substrate metabolism were assessed in isolated working hearts obtained 1, 2, and 3 weeks after AAC.<unk>
T-1781	energy_substrate_metabolism hearts aac
H-1781	-0.845488429069519	▁energie _ ▁substrat e _ ▁metabolism
D-1781	-0.845488429069519	energie_ substrate_ metabolism
P-1781	-3.5416 -0.7170 -0.1700 -0.4037 -0.5653 -0.2053 -1.0583 -0.1029
S-630	Results were comparable across age, sex, and race, and in sub-groups based on diabetes mellitus or cardiovascular disease at baseline.<unk>
T-630	diabetes_mellitus cardiovascular_disease baseline
H-630	-1.2867776155471802	▁diabetes ▁mell itus ▁cardiovascular ▁disease
D-630	-1.2867776155471802	diabetes mellitus cardiovascular disease
P-630	-3.9357 -0.5874 -0.1151 -0.1866 -3.9099 -0.1876 -0.0852
S-1134	Experimental evidence suggests that the increase in parasympathetic function can be a therapeutic alternative to slow HF evolution.<unk>
T-1134	evidence parasympathetic therapeutic hf
H-1134	-0.9373468160629272	▁para sy mpa the tic _ function ▁ therapeut ic _ alternativ e ▁ HF
D-1134	-0.9373468160629272	parasympathetic_function therapeutic_alternative HF
P-1134	-1.5638 -0.6068 -0.1646 -1.1250 -1.5300 -1.3680 -2.8204 -0.8209 -0.1046 -0.4675 -0.9790 -1.3677 -0.7022 -1.2142 -0.0590 -0.9479 -0.0931
S-237	An ability to identify patients with HFpEF who are at increased risk for adverse outcomes can facilitate their more careful management.<unk>
T-237	patients hfpef adverse_outcomes
H-237	-0.48814213275909424	▁ HF p EF
D-237	-0.48814213275909424	HFpEF
P-237	-1.0613 -0.1292 -0.0533 -0.2592 -1.2814 -0.1443
S-1603	Surgical revascularization is considered only if catheter-based revascularization is unsuitable or unsuccessful.<unk>
T-1603	surgical revascularization revascularization
H-1603	-0.6156197786331177	▁sur g ical _ re vas cular ization ▁cat heter - based ▁re vas cular ization
D-1603	-0.6156197786331177	surgical_revascularization catheter-based revascularization
P-1603	-0.7507 -0.8258 -2.5440 -1.2011 -0.5798 -0.3620 -0.5265 -0.7668 -0.1456 -0.0034 -0.0333 -0.1176 -1.1211 -0.3083 -0.5318 -0.9990 -0.1725 -0.0920
S-607	The HR for the TNF antagonists compared with nbDMARD was 0.85 (95% CI 0.63 to 1.14).<unk>
T-607	tnf_antagonists nbdmard
H-607	-0.6101043820381165	▁HR ▁t NF _ ▁anta gon ists ▁n b DM ARD
D-607	-0.6101043820381165	HR tNF_ antagonists nbDMARD
P-607	-0.3012 -0.9404 -0.2265 -3.2497 -0.3339 -0.0413 -0.9646 -0.2453 -0.0181 -1.1555 -0.1203 -0.2529 -0.0817
S-1563	The risk of incident CVD was not increased in psoriasis (adjusted hazard ratio 0.73, 95% confidence interval 0.50-1.06).<unk>
T-1563	cvd psoriasis hazard_ratio confidence_interval
H-1563	-1.2520815134048462	▁incident ▁CV d ▁psoriasis
D-1563	-1.2520815134048462	incident CVd psoriasis
P-1563	-4.3015 -1.7414 -0.8067 -0.1533 -0.3470 -0.1626
S-1572	The prevalence of high BNP levels in patients with PAD suggests that routine BNP measurements might be useful to detect HF.<unk>
T-1572	prevalence bnp patients pad bnp hf
H-1572	-1.3902463912963867	▁b NP ▁ PAD ▁b NP
D-1572	-1.3902463912963867	bNP PAD bNP
P-1572	-1.0418 -0.3022 -3.9748 -0.4489 -1.8372 -0.3997 -3.0142 -0.1031
S-96	Morpholino-based knockdown of nucleolin nearly abolished protein expression but surprisingly had little impact on gross morphological development.<unk>
T-96	morpholino-based nucleolin protein_expression
H-96	-0.8373979330062866	▁Mor pho lino - based ▁knock down ▁nucleo lin ▁protein ▁expression ▁ morph ological
D-96	-0.8373979330062866	Morpholino-based knockdown nucleolin protein expression morphological
P-96	-0.3633 -0.1085 -0.4355 -0.6924 -0.7706 -1.1667 -0.0979 -2.4763 -2.1089 -1.2552 -0.6920 -1.5733 -0.0454 -0.2245 -1.3134 -0.0745
S-1185	We sought to derive and validate a clinical prediction rule to exclude CAD as a cause of systolic HF.<unk>
T-1185	clinical rule cad systolic_hf
H-1185	-0.9466805458068848	▁clinic al _ ▁predict ion _ ▁rule ▁CAD ▁sy sto lic ▁ HF
D-1185	-0.9466805458068848	clinical_ prediction_ rule CAD systolic HF
P-1185	-0.5811 -0.0249 -0.8348 -1.2871 -0.0114 -2.0945 -0.3984 -0.0987 -4.1390 -0.5995 -1.8007 -2.0402 -0.0201 -0.1819 -0.0878
S-1556	In this study, embedded within the population-based Rotterdam Study, we aimed to assess the association between psoriasis and cardiovascular outcomes.<unk>
T-1556	rotterdam_study psoriasis cardiovascular outcomes
H-1556	-1.0366586446762085	▁population - based ▁Rotterdam
D-1556	-1.0366586446762085	population-based Rotterdam
P-1556	-2.1392 -0.0194 -0.0242 -0.0305 -3.8900 -0.1166
S-207	Subsequently, the authors analyzed the association of cognitive impairment with 6-month mortality or readmission.<unk>
T-207	mortality readmission
H-207	-0.7913289666175842	▁cognitive ▁im pair ment
D-207	-0.7913289666175842	cognitive impairment
P-207	-0.8270 -0.8462 -0.1760 -0.0974 -2.7110 -0.0903
S-1631	We aimed to investigate the association between race and outcomes and to explore interactions with exercise training in patients with ambulatory HF.<unk>
T-1631	outcomes exercise training patients ambulatory hf
H-1631	-1.5936394929885864	▁race ▁ HF
D-1631	-1.5936394929885864	race HF
P-1631	-2.0048 -4.2464 -1.3542 -0.2084 -0.1544
S-841	Baseline Hgb did not moderate the beneficial effect of exercise training on KCCQ overall or subscales relative to usual care.<unk>
T-841	baseline hgb exercise training kccq
H-841	-1.0538413524627686	▁h gb ▁k cc q
D-841	-1.0538413524627686	hgb kccq
P-841	-0.7697 -0.0761 -3.3849 -0.0804 -1.9731 -0.9424 -0.1502
S-1359	This review provides an overview of the sonographic, histological, and functional abnormalities of different gastrointestinal regions.<unk>
T-1359	sonographic histological gastrointestinal
H-1359	-1.279021143913269	▁sono graphic ▁implant ations ▁gastro inte stin al
D-1359	-1.279021143913269	sonographic implantations gastrointestinal
P-1359	-1.4843 -1.4586 -5.4645 -1.4036 -0.9946 -0.0528 -0.5028 -0.3020 -1.0660 -0.0611
S-1286	Complications occurred after five ACS procedures (31%) in two patients undergoing MT and three patients undergoing VAD.<unk>
T-1286	complications acs patients patients vad
H-1286	-1.0930471420288086	▁a CS ▁patients ▁ VAD
D-1286	-1.0930471420288086	aCS patients VAD
P-1286	-0.4585 -0.3532 -4.8816 -1.5745 -0.1309 -0.1315 -0.1211
S-1577	SETTING: General hospital and cardiac specialty hospital, both located in a community of 150,000 population in predominantly rural South Dakota.<unk>
T-1577	hospital cardiac hospital south_dakota
H-1577	-1.045419454574585	▁hospital ▁cardiac _ special ty _ hospital
D-1577	-1.045419454574585	hospital cardiac_specialty_hospital
P-1577	-2.3475 -1.7971 -1.8568 -0.3170 -0.2154 -0.6356 -0.1400 -2.0233 -0.0760
S-1277	Different mechanisms underlie these exercise variables with an important contribution of haemodynamic, pulmonary and peripheral abnormalities.<unk>
T-1277	exercise haemodynamic pulmonary
H-1277	-0.20239078998565674	▁ha emo dynamic ▁pulmonar y ▁per i pher al ▁ab normal ities
D-1277	-0.20239078998565674	haemodynamic pulmonary peripheral abnormalities
P-1277	-0.3141 -0.3519 -0.0531 -0.0248 -0.0651 -0.2004 -0.5713 -0.0593 -0.1066 -0.1814 -0.0369 -0.6709 -0.1161 -0.0815
S-1392	In the ECMO group, the improvement in eGFR continued until day 28 after which there was a steady decline in eGFR.<unk>
T-1392	ecmo egfr egfr
H-1392	-1.0105013847351074	▁EC mo ▁e G FR
D-1392	-1.0105013847351074	ECmo eGFR
P-1392	-0.6848 -0.5651 -1.1891 -1.5011 -0.9145 -2.0293 -0.1897
S-1159	BACKGROUND: Previous studies investigating HF-related cachexia have not examined the impact of RV function on body composition.<unk>
T-1159	cachexia rv_function
H-1159	-0.7393885850906372	▁ HF - related ▁cache xia ▁ RV
D-1159	-0.7393885850906372	HF-related cachexia RV
P-1159	-0.4581 -0.1748 -0.3004 -1.6085 -1.3073 -0.3223 -0.1383 -0.0651 -2.9132 -0.1058
S-1191	A prediction rule of having ≥1 independent predictor identified 97% of the patients with CAD and 100% of the patients with severe CAD.<unk>
T-1191	rule patients cad patients cad
H-1191	-1.677212119102478	
D-1191	-1.677212119102478	
P-1191	-3.2895 -0.0650
S-1188	The diagnostic performance of the defined prediction rule was prospectively validated in a separate cohort recruited from 2 institutions.<unk>
T-1188	diagnostic rule prospectively
H-1188	-1.4157848358154297	▁predict ion _ ▁rule
D-1188	-1.4157848358154297	prediction_ rule
P-1188	-5.9393 -0.0267 -0.9709 -1.0429 -0.4014 -0.1135
S-1018	We describe lessons learned from recent trials in acute HF and outline strategies to improve the potential for success in future trials.<unk>
T-1018	acute_hf
H-1018	-0.49820050597190857	▁a cute ▁ HF
D-1018	-0.49820050597190857	acute HF
P-1018	-1.1049 -0.0087 -1.5026 -0.0534 -0.2329 -0.0867
S-1487	Heart failure (HF) is a very common condition that, despite advances in treatment, carries significant morbidity and mortality.<unk>
T-1487	heart_failure hf condition morbidity mortality
H-1487	-1.1105226278305054	▁Heart _ pu issa nce ▁ HF
D-1487	-1.1105226278305054	Heart_puissance HF
P-1487	-0.5857 -0.4374 -4.7660 -0.5713 -0.0168 -2.6861 -0.0831 -0.7385 -0.1097
S-775	We have developed a quick, safe pump-exchange technique that avoids a redo sternotomy and cardiopulmonary bypass.<unk>
T-775	redo_sternotomy cardiopulmonary_bypass
H-775	-0.9981350302696228	▁pump - ex change ▁technique ▁redo ▁ster no to my ▁cardio pul mon ary _ ▁by pass
D-775	-0.9981350302696228	pump-exchange technique redo sternotomy cardiopulmonary_ bypass
P-775	-5.0669 -0.0863 -0.1512 -0.0015 -0.5568 -0.0990 -0.8103 -0.0426 -0.4140 -2.0097 -0.0912 -0.1966 -4.3637 -1.3296 -1.4101 -1.8249 -0.0026 -0.3723 -0.1353
S-371	After aggressive medical treatment for HF, the HF symptom disappeared and the MS was reversed to an MVA of 1.7 cm2.<unk>
T-371	medical_treatment hf hf symptom mva
H-371	-1.073307991027832	▁ HF ▁ HF ▁MS ▁m VA
D-371	-1.073307991027832	HF HF MS mVA
P-371	-2.2910 -0.5519 -3.3904 -0.4314 -1.1285 -0.2660 -0.8764 -0.6157 -0.1086
S-1868	BACKGROUND: Increased sympathetic and decreased parasympathetic activity contribute to HF symptoms and disease progression.<unk>
T-1868	sympathetic parasympathetic_activity hf symptoms disease
H-1868	-0.9097737073898315	▁sympa the tic ▁para sy mpa the tic ▁ HF
D-1868	-0.9097737073898315	sympathetic parasympathetic HF
P-1868	-0.6963 -0.3181 -1.0166 -0.5796 -0.8183 -0.1499 -1.5220 -1.4518 -2.1467 -0.0684 -2.0854 -0.0642
S-354	The possibility of MS to improve after medical treatment for HF was considered because functional MS is highly dynamic and can potentially respond to medical treatment.<unk>
T-354	medical_treatment hf functional_ms medical_treatment
H-354	-1.0854237079620361	▁MS ▁ HF
D-354	-1.0854237079620361	MS HF
P-354	-0.6601 -2.5378 -0.1736 -1.9732 -0.0825
S-283	This might be a novel and useful mouse HF model to study the transition from compensated LV hypertrophy to HF in HHD.<unk>
T-283	hf transition compensated_lv_hypertrophy hf hhd
H-283	-0.7600226998329163	▁mouse ▁ HF ▁transition ▁compensa ted ▁LV _ ▁hyper trop hy ▁ HF ▁h HD
D-283	-0.7600226998329163	mouse HF transition compensated LV_ hypertrophy HF hHD
P-283	-2.3823 -1.0296 -0.1601 -1.9505 -1.1287 -1.7923 -1.0639 -0.9146 -0.3674 -0.0161 -0.1813 -0.8408 -0.0259 -0.1574 -0.5210 -0.2546 -0.1338
S-503	A large animal model of chronic myocardial ischemia and heart failure is crucial for the development of novel therapeutic approaches.<unk>
T-503	chronic_myocardial_ischemia heart_failure therapeutic
H-503	-1.2624411582946777	▁chronic _ My o card ial _ ▁ ische mia ▁heart _ ▁failure ▁ therapeut ic
D-503	-1.2624411582946777	chronic_Myocardial_ ischemia heart_ failure therapeutic
P-503	-5.2502 -0.3129 -4.8869 -0.3464 -0.1170 -0.0701 -0.1454 -5.0416 -1.1151 -0.5637 -0.2063 -0.8474 -1.1754 -1.4255 -0.0224 -0.5213 -0.5815 -0.0949
S-445	Spironolactone was independently associated with a 3.5-fold increased risk of hyperkalemia but not with acute kidney injury.<unk>
T-445	spironolactone hyperkalemia acute_kidney_injury
H-445	-0.5497760772705078	▁Spir ono lac tone ▁hyper kal emia ▁a cute _ ▁ki dne y ▁injury
D-445	-0.5497760772705078	Spironolactone hyperkalemia acute_ kidney injury
P-445	-0.1679 -0.2735 -0.2218 -0.3579 -0.1782 -1.0046 -0.4800 -0.2272 -0.0120 -0.2261 -3.8088 -0.6476 -0.1592 -0.8287 -0.1083 -0.0947
S-1529	Compared with CH, patients with EH had lower systolic blood pressure and less renal impairment despite similar rates of hypertension.<unk>
T-1529	patients systolic_blood_pressure renal_impairment hypertension
H-1529	-1.7780065536499023	▁EH ▁renal ▁im pair ment
D-1529	-1.7780065536499023	EH renal impairment
P-1529	-0.5229 -6.3282 -0.6157 -0.0041 -0.0590 -4.7390 -0.1772
S-1895	Estimating the jugular venous pressure and the presence of peripheral oedema allows assessment of the patient's volume status.<unk>
T-1895	jugular_venous_pressure peripheral_oedema patient
H-1895	-0.5047681927680969	▁jugu lar _ ve nous _ tension ▁per i pher al _ ▁oed ema ▁volume
D-1895	-0.5047681927680969	jugular_venous_tension peripheral_ oedema volume
P-1895	-0.0048 -0.1737 -0.2844 -1.1870 -2.4992 -0.6464 -0.7075 -0.0774 -0.2212 -0.0163 -0.0764 -0.7314 -1.0541 -0.0903 -0.2976 -0.4324 -0.0812
S-1023	Natriuretic peptide levels, like other biomarkers, can now be measured at the point of care (POC).<unk>
T-1023	natriuretic_peptide biomarkers point_of_care poc
H-1023	-0.7108857035636902	▁na tri ure tic _ pe pti de ▁bio mark ers ▁point _ of _ care
D-1023	-0.7108857035636902	natriuretic_peptide biomarkers point_of_care
P-1023	-0.2456 -0.0021 -0.0728 -3.9514 -1.2507 -0.4160 -0.2294 -0.2222 -0.3998 -0.0064 -0.0929 -0.2333 -0.2253 -1.6722 -0.1142 -2.6002 -0.9918 -0.0696
S-1384	BACKGROUND: Effects of mechanical cardiac support on renal function in children with end-stage heart failure are unknown.<unk>
T-1384	mechanical_cardiac_support renal_function end-stage_heart_failure
H-1384	-1.1831454038619995	▁mechanic al _ ▁cardiac _ ▁support ▁renal _ ▁function ▁end - s tage _ heart _ ▁failure
D-1384	-1.1831454038619995	mechanical_ cardiac_ support renal_ function end-stage_heart_ failure
P-1384	-1.2911 -0.0302 -0.5849 -2.2268 -2.2013 -1.5076 -0.3159 -2.3479 -3.8007 -1.9234 -0.0756 -0.1675 -0.0012 -0.2697 -1.9414 -0.8136 -2.7057 -0.1574 -0.1177
S-1352	Do anticoagulants or antiplatelet drugs have a role in treating heart failure in the absence of atrial fibrillation?<unk>
T-1352	anticoagulants antiplatelet_drugs heart_failure atrial_fibrillation
H-1352	-0.8149952292442322	▁antico a gul ants ▁anti plate let ▁drugs ▁heart _ ▁failure ▁at rial _ ▁fi bril lation
D-1352	-0.8149952292442322	anticoagulants antiplatelet drugs heart_ failure atrial_ fibrillation
P-1352	-1.1436 -0.3520 -0.1863 -0.0109 -0.1144 -2.1480 -0.3209 -0.8966 -1.9953 -1.1285 -2.6839 -0.0974 -0.0981 -0.4708 -3.4786 -0.0067 -0.0107 -0.2483 -0.0939
S-333	It is reported that functional mitral stenosis frequently develops after ring annuloplasty for ischemic mitral regurgitation.<unk>
T-333	reported functional_mitral_stenosis ring_annuloplasty ischemic_mitral_regurgitation
H-333	-0.5610038042068481	▁functional _ met ral _ ▁sten osis ▁ring _ ▁ann ulo plast y ▁ ische mic _ ▁mit ral _ re gur gi tation
D-333	-0.5610038042068481	functional_metral_ stenosis ring_ annuloplasty ischemic_ mitral_regurgitation
P-333	-0.7687 -1.3148 -2.9057 -0.0241 -1.2565 -0.2049 -0.0128 -0.0602 -1.0088 -0.5932 -0.2781 -0.0779 -0.1418 -0.5448 -0.1158 -0.0830 -0.6252 -2.6005 -0.0205 -0.6248 -0.8915 -0.0040 -0.0190 -0.0051 -0.3362 -0.0681
S-434	During follow-up, there were 134 deaths, 18 heart transplantations/LV assist device implantations, and 93 heart failure admissions.<unk>
T-434	follow-up deaths heart_transplantations lv_assist_device_implantations heart_failure admissions
H-434	-0.8561429381370544	▁heart ▁implant ations LV _ assist ▁device ▁implant ations ▁heart _ ▁failure
D-434	-0.8561429381370544	heart implantationsLV_assist device implantations heart_ failure
P-434	-1.8580 -0.8347 -0.0269 -1.0261 -1.0910 -0.0930 -2.9819 -0.1674 -0.0184 -0.3083 -0.6829 -2.4641 -0.3253 -0.1080
S-21	Diagnosis of heart failure with preserved ejection fraction: role of clinical Doppler echocardiography.<unk>
T-21	diagnosis heart_failure_with_preserved_ejection_fraction clinical doppler_echocardiography
H-21	-0.9619748592376709	▁heart _ pu issa nce _ fraction ▁clinic al ▁do pp ler _ ▁e cho card i ography
D-21	-0.9619748592376709	heart_puissance_fraction clinical doppler_ echocardiography
P-21	-1.7360 -0.6097 -5.3839 -0.1792 -0.0786 -2.2428 -2.9705 -0.5858 -0.0328 -0.8712 -0.0087 -0.8236 -0.9242 -0.5672 -0.2871 -0.1810 -1.0409 -0.2922 -0.2782 -0.1460
S-7	This study suggests that national patient safety initiatives have led to real progress in some areas but have not created across-the-board improvements.<unk>
T-7	patient
H-7	-1.592157244682312	▁patient _ ▁safety
D-7	-1.592157244682312	patient_ safety
P-7	-2.7403 -0.6086 -2.7584 -1.7163 -0.1372
S-1473	As a result, the focus of research investigations and clinical care has shifted to measurement and modification of maladaptive molecular processes.<unk>
T-1473	clinical
H-1473	-0.8455565571784973	▁mal adapt ive _ ▁molecular es
D-1473	-0.8455565571784973	maladaptive_ moleculares
P-1473	-2.7891 -0.0413 -0.0074 -0.6676 -0.2651 -2.8420 -0.0943 -0.0576
S-2009	Because projecting long-term costs and survival is challenging, a consistent and valid approach to extrapolating short-term outcomes would be valuable.<unk>
T-2009	costs outcomes
H-2009	-1.3928382396697998	▁long - term
D-2009	-1.3928382396697998	long-term
P-2009	-1.4431 -0.0500 -0.4007 -4.9407 -0.1296
S-1104	Both early-onset (0-7 days after MI) and late-onset (8 days to 5 years after MI) HF were examined.<unk>
T-1104	mi mi hf
H-1104	-1.637961745262146	▁MI ▁ HF
D-1104	-1.637961745262146	MI HF
P-1104	-4.2193 -3.3157 -0.3743 -0.1430 -0.1375
S-1151	The goal of this study was to determine the individual and combined contributions of HF-induced remodeling aspects to EMD prolongation.<unk>
T-1151	remodeling emd
H-1151	-0.40414685010910034	▁ HF - indu ced ▁remodel ing ▁EM d ▁prolong ation
D-1151	-0.40414685010910034	HF-induced remodeling EMd prolongation
P-1151	-0.2595 -0.1641 -0.4187 -0.0023 -1.6608 -0.3590 -0.0916 -0.5318 -0.5076 -1.0729 -0.0292 -0.0768 -0.0795
S-694	These data provide support for the concept that dietary recommendations developed for other cardiovascular conditions or general populations may also be appropriate in patients with HF.<unk>
T-694	cardiovascular conditions patients hf
H-694	-0.8236683011054993	▁cardiovascular ▁conditions ▁ HF
D-694	-0.8236683011054993	cardiovascular conditions HF
P-694	-2.8552 -0.1847 -1.7051 -0.0369 -0.0901 -0.0700
S-620	Secondary outcomes were met in relation to sustainability with commissioning of hospital- and community-based programmes on completion of the study.<unk>
T-620	secondary_outcomes
H-620	-0.7264217734336853	▁sustain ability ▁commission ing ▁hospital - ▁community - based ▁programme s
D-620	-0.7264217734336853	sustainability commissioning hospital- community-based programmes
P-620	-0.1343 -0.4351 -0.5093 -0.2470 -0.1086 -0.2747 -6.5906 -0.0629 -0.0426 -0.4895 -0.0597 -0.3755 -0.1136
S-85	Many multisite studies in practice settings focus on improving processes of care, adopting evidence-based practices, and improving patient outcomes.<unk>
T-85	evidence-based patient outcomes
H-85	-1.8334872722625732	
D-85	-1.8334872722625732	
P-85	-3.5886 -0.0783
S-303	However, 1-year survival was significantly greater in patients who required isolated HeartMate II LVAD (87% versus 77%; p = 0.03).<unk>
T-303	patients heartmate_ii lvad
H-303	-1.2921730279922485	▁Heart Mate _ ▁II ▁L VAD
D-303	-1.2921730279922485	HeartMate_ II LVAD
P-303	-4.2698 -0.7534 -1.3552 -0.9742 -2.7860 -0.0134 -0.0852 -0.1002
S-536	Furthermore, the impact of normalization of albumin levels during LVAD support on postoperative survival was analyzed in both groups.<unk>
T-536	albumin lvad postoperative
H-536	-1.9242826700210571	▁l VAD _ support ▁post operativ e
D-536	-1.9242826700210571	lVAD_support postoperative
P-536	-5.2685 -0.2491 -3.6478 -3.3801 -1.6941 -0.0655 -0.3024 -2.4059 -0.3053
S-994	A notable example is the Raf-MEK1/2-ERK1/2 signalling pathway that can control both adaptive and maladaptive remodelling.<unk>
T-994	signalling_pathway remodelling
H-994	-1.296034336090088	▁Raf - MEK - MEK - er k 1/2 ▁signal ling _ path way ▁adapt ive _ mal adapt ive ▁remodel ling
D-994	-1.296034336090088	Raf-MEK-MEK-erk1/2 signalling_pathway adaptive_maladaptive remodelling
P-994	-0.0702 -0.1377 -0.0109 -5.3500 -0.6473 -5.0853 -1.4411 -0.2569 -5.9858 -0.4390 -1.5290 -1.1008 -1.2504 -0.4458 -2.1628 -0.0077 -1.5160 -3.1111 -0.0711 -0.0210 -0.0500 -0.1553 -0.1675 -0.0920
S-1906	Hereditary and congenital abnormalities of the heart are the most common cause of nontraumatic death during sport in young athletes.<unk>
T-1906	hereditary congenital heart death
H-1906	-0.8808521032333374	▁her edit ary _ con geni tal _ ▁ab normal ities ▁heart ▁non trau matic _ ▁death
D-1906	-0.8808521032333374	hereditary_congenital_ abnormalities heart nontraumatic_ death
P-1906	-3.5438 -0.1403 -1.1075 -2.5372 -0.0700 -0.0065 -0.0426 -0.7306 -0.3211 -0.1848 -1.1974 -0.8776 -1.3677 -0.0131 -0.3155 -1.0597 -1.6964 -1.3199 -0.2045
S-1830	SETTING: 18 health insurance and health system data partners in the U.S. Food and Drug Administration's Mini-Sentinel program.<unk>
T-1830	health health u.s. drug administration
H-1830	-1.48081374168396	▁health _ ▁insurance _ de _ health _ system _ de _ dis tribution ▁u e s ▁Food _ de _ ▁Drug ▁Administration
D-1830	-1.48081374168396	health_ insurance_de_health_system_de_distribution ues Food_de_ Drug Administration
P-1830	-0.2500 -1.2900 -1.2840 -3.6675 -3.8972 -0.1080 -1.9536 -0.9369 -0.9119 -1.1888 -2.9320 -0.1709 -4.9845 -0.4472 -1.2418 -0.4130 -3.4077 -0.5503 -1.0041 -3.2373 -0.1170 -0.7744 -0.1685 -1.9233 -0.1602
S-1544	CONCLUSIONS: Bisphosphonate users were at increased risk of heart failure compared to age- and gender-matched control subjects.<unk>
T-1544	bisphosphonate heart_failure
H-1544	-1.534371256828308	bis phos phon ate ▁heart _ ▁failure
D-1544	-1.534371256828308	bisphosphonate heart_ failure
P-1544	-1.5575 -0.1454 -0.5656 -2.5754 -2.9163 -1.4294 -3.5992 -0.9788 -0.0419
S-808	Global left ventricular longitudinal systolic strain as a major predictor of cardiovascular events in patients with atrial fibrillation.<unk>
T-808	global_left_ventricular_longitudinal_systolic_strain cardiovascular_events patients atrial_fibrillation
H-808	-0.961804211139679	▁vent ri cular _ ▁longitud in al _ ▁sy sto lic _ ▁strain ▁cardiovascular ▁events ▁at rial _ ▁fi bril lation
D-808	-0.961804211139679	ventricular_ longitudinal_ systolic_ strain cardiovascular events atrial_ fibrillation
P-808	-0.1232 -0.1191 -0.0989 -0.4893 -1.2784 -0.1179 -0.0989 -0.3794 -3.6906 -0.1361 -1.1927 -3.1433 -1.2950 -0.3280 -3.9803 -0.6478 -0.0935 -0.5954 -3.7872 -0.0235 -0.0298 -0.3156 -0.1576
S-469	Xanthine oxidase inhibition preserves left ventricular systolic but not diastolic function in cardiac volume overload.<unk>
T-469	xanthine_oxidase_inhibition left_ventricular systolic diastolic_function cardiac_volume_overload
H-469	-1.1820553541183472	▁Xan thi ne _ ▁oxid ase _ ▁inhibi tion ▁vent ri cular _ syn chron e _ syn chron e _ syn chron e _ syn chron e _ syn chron e
D-469	-1.1820553541183472	Xanthine_ oxidase_ inhibition ventricular_synchrone_synchrone_synchrone_synchrone_synchrone
P-469	-0.0012 -0.0358 -0.3232 -1.5059 -1.5924 -3.6949 -1.5860 -0.2764 -0.0323 -0.0686 -0.3929 -0.5012 -0.8260 -0.4761 -1.7870 -3.0779 -0.8020 -0.6218 -0.5245 -1.5033 -0.8814 -1.7199 -0.3880 -1.5073 -0.9039 -2.5768 -0.3221 -1.4889 -0.9178 -3.1403 -0.2878 -1.5527 -4.6359 -0.2378
S-1521	Immunodetection of NT-proBNP was significantly improved with the use of antibodies that did not target these terminal regions.<unk>
T-1521	immunodetection nt-probnp antibodies terminal
H-1521	-0.39635512232780457	▁immun o det ection ▁NT - pro B NP ▁anti bo dies
D-1521	-0.39635512232780457	immunodetection NT-proBNP antibodies
P-1521	-0.3091 -0.0472 -0.1074 -0.0496 -0.9925 -0.0440 -0.0084 -0.7962 -0.0816 -0.0672 -0.0435 -2.1821 -0.7274 -0.0928
S-895	We examined the impact of PD on clinical status hospitalizations, and complications of therapy in severe end-stage HF.<unk>
T-895	pd clinical hospitalizations complications therapy end-stage_hf
H-895	-1.6369211673736572	▁PD ▁complica tions ▁ therapy
D-895	-1.6369211673736572	PD complications therapy
P-895	-1.3471 -5.3162 -0.0281 -1.3418 -0.0642 -3.2679 -0.0931
S-439	We studied the effectiveness and safety of spironolactone in adults with newly diagnosed systolic heart failure in clinical practice.<unk>
T-439	spironolactone diagnosed systolic_heart_failure clinical
H-439	-1.0396595001220703	▁spi rono lac tone ▁sy sto lic _ heart _ ▁failure
D-439	-1.0396595001220703	spironolactone systolic_heart_ failure
P-439	-2.7917 -0.0537 -0.2574 -0.1608 -1.2863 -0.3310 -3.4409 -0.4476 -1.9210 -0.7064 -1.4107 -0.6557 -0.0524
S-574	CONCLUSIONS: Nordic walking was superior to standard cardiac rehabilitation care in improving functional capacity and other important outcomes in patients with heart failure.<unk>
T-574	walking cardiac_rehabilitation functional_capacity outcomes patients heart_failure
H-574	-1.4771478176116943	▁Nordic _ ▁walking ▁cardiac ▁rehabilita tion
D-574	-1.4771478176116943	Nordic_ walking cardiac rehabilitation
P-574	-0.6045 -1.2858 -3.1407 -1.1911 -0.8444 -0.0136 -4.6571 -0.0800
S-544	In the present report, we have described 6 patients who underwent aortic valve surgery for new-onset post-LVAD AI.<unk>
T-544	report patients aortic_valve surgery post-lvad_ai
H-544	-0.7474930286407471	▁a or tic _ ▁val ve ▁surgery ▁new - ons et _ ▁post - L VAD
D-544	-0.7474930286407471	aortic_ valve surgery new-onset_ post-LVAD
P-544	-0.2881 -0.0221 -2.0603 -1.1758 -0.4909 -0.0396 -0.7262 -4.1670 -0.0745 -0.0281 -0.0513 -1.6307 -1.0377 -0.0072 -1.0360 -0.0257 -0.5164 -0.0774
S-658	Practice-level variation in use of recommended medications among outpatients with heart failure: Insights from the NCDR PINNACLE program.<unk>
T-658	medications outpatients heart_failure ncdr_pinnacle
H-658	-1.3865913152694702	▁medication s ▁heart _ ▁failure ▁NC DR ▁PIN NA CLE
D-658	-1.3865913152694702	medications heart_ failure NCDR PINNACLE
P-658	-3.9075 -0.0776 -4.0133 -1.2544 -3.5331 -0.0299 -0.1113 -1.5616 -0.6666 -0.7453 -0.6274 -0.1112
S-980	Heart failure is an enormous clinical burden in adult medicine, largely because of the prevalence of atheromatous coronary disease.<unk>
T-980	heart_failure clinical medicine prevalence coronary_disease
H-980	-1.1270055770874023	▁Heart _ ▁failure ▁medicine ▁a ther omat ous _ ▁corona ry ▁disease
D-980	-1.1270055770874023	Heart_ failure medicine atheromatous_ coronary disease
P-980	-0.5050 -0.8029 -2.2343 -4.0740 -0.0299 -0.0018 -0.0481 -3.2461 -0.3365 -0.2639 -1.2052 -2.7437 -0.1831 -0.1035
S-1891	Clinical symptoms and signs in HFpEF are often nonspecific although the primary symptoms are breathlessness, fatigue and fluid retention.<unk>
T-1891	clinical symptoms hfpef symptoms breathlessness fluid_retention
H-1891	-1.0699985027313232	▁ HF p f
D-1891	-1.0699985027313232	HFpf
P-1891	-1.2700 -0.7875 -0.3084 -1.1406 -2.7480 -0.1656
S-1892	There is still no single diagnostic test for HFpEF and the cornerstone in the assessment remains a thorough medical history and physical examination.<unk>
T-1892	diagnostic hfpef medical_history physical_examination
H-1892	-0.6816284656524658	▁ HF p EF
D-1892	-0.6816284656524658	HFpEF
P-1892	-1.0199 -0.4387 -0.2606 -0.5132 -1.7775 -0.0800
S-527	Therefore, unloading of the heart may contribute to the beneficial effect of isolated HR reduction in patients with systolic heart failure.<unk>
T-527	heart hr_reduction patients systolic_heart_failure
H-527	-1.3968558311462402	▁un load ing _ de _ heart
D-527	-1.3968558311462402	unloading_de_heart
P-527	-1.1507 -0.0132 -0.0408 -1.8035 -1.9957 -0.5086 -2.0018 -4.8218 -0.2356
S-1612	The overlapping part of the network was selected out using Cytoscape, for which functional enrichment analysis was applied with DAVID tools.<unk>
T-1612	cytoscape functional_enrichment_analysis david
H-1612	-0.717680037021637	▁réseau ▁Cy to scape ▁functional _ ▁en rich ment ▁DA VID
D-1612	-0.717680037021637	réseau Cytoscape functional_ enrichment DAVID
P-1612	-1.8937 -0.3446 -0.0377 -0.1456 -1.0088 -0.9748 -1.1912 -0.0013 -0.0630 -3.1818 -0.0020 -0.4126 -0.0728
S-928	Resistin is a circulating mediator of insulin resistance mainly expressed in human monocytes and responsive to inflammatory stimuli.<unk>
T-928	resistin insulin_resistance monocytes inflammatory
H-928	-0.49621400237083435	▁circula tion _ media tor _ de _ ▁insulin _ ▁resist ance ▁human ▁mono cy tes ▁infla mma tory ▁stimul i
D-928	-0.49621400237083435	circulation_mediator_de_ insulin_ resistance human monocytes inflammatory stimuli
P-928	-0.5505 -2.2000 -0.3456 -0.8865 -0.2533 -0.1190 -1.3097 -0.0977 -0.5468 -1.0982 -0.6550 -0.0308 -1.1403 -0.3219 -0.0121 -0.0172 -0.2477 -0.2656 -0.4676 -0.3701 -0.1537 -0.1838 -0.1398
S-1635	Blacks were younger with significantly more hypertension and diabetes, less ischemic etiology, and lower socioeconomic status versus whites.<unk>
T-1635	hypertension diabetes ischemic etiology
H-1635	-0.6138084530830383	▁hyper tension ▁diabetes ▁ ische mic _ ▁et i ology ▁socio economic ▁status
D-1635	-0.6138084530830383	hypertension diabetes ischemic_ etiology socioeconomic status
P-1635	-0.6690 -0.0023 -0.3107 -0.1360 -0.1025 -0.0986 -1.2701 -0.5782 -0.1944 -1.3550 -0.2974 -0.2464 -2.8577 -0.9975 -0.0913
S-262	Determination of a predictive cutoff value of NT-proBNP testing for long-term survival in ED patients with acute heart failure.<unk>
T-262	nt-probnp patients acute_heart_failure
H-262	-0.949956476688385	▁NT - pro B NP
D-262	-0.949956476688385	NT-proBNP
P-262	-1.3602 -0.0548 -0.0185 -0.9021 -0.0491 -4.1294 -0.1356
S-281	Oxidative stress was enhanced and small GTPase Rac1 activity was upregulated in the hearts of ANS mice.<unk>
T-281	oxidative_stress gtpase rac1 activity hearts
H-281	-0.787598729133606	▁o xi da tive _ stress ▁GT Pas e _ ▁Rac 1 ▁heart s ▁ ANS _ mi ce
D-281	-0.787598729133606	oxidative_stress GTPase_ Rac1 hearts ANS_mice
P-281	-0.5931 -0.0723 -0.1889 -0.0221 -2.4291 -1.0611 -1.9195 -0.1382 -0.1457 -0.5521 -0.1472 -0.2765 -1.6302 -0.0799 -3.7425 -0.4350 -2.1040 -0.4165 -0.3544 -0.1175 -0.1138
S-1789	Heart failure (HF) data in Latin America (LA) were reviewed to guide health service planning in the prevention and treatment of HF.<unk>
T-1789	heart_failure hf latin_america health hf
H-1789	-1.4262012243270874	▁Heart _ f ré que nce _ de _ f ré que nce ▁ HF
D-1789	-1.4262012243270874	Heart_fréquence_de_fréquence HF
P-1789	-0.8488 -0.3050 -5.3354 -2.4879 -0.1207 -0.0317 -2.0671 -3.8031 -0.1799 -2.9004 -0.1862 -0.0716 -0.0085 -3.4854 -0.9315 -1.3487 -0.1335
S-1459	We first propose fundamental definitions of the distinctive components of the right heart circulation and provide consensus on a universal definition of right heart failure.<unk>
T-1459	right_heart_circulation right_heart_failure
H-1459	-2.4034087657928467	▁right ▁heart _ ▁circulation
D-1459	-2.4034087657928467	right heart_ circulation
P-1459	-6.4871 -3.2378 -0.5991 -2.5008 -1.5131 -0.0825
S-1494	We sought to investigate whether adults with the Fontan circulation exhibit reduced skeletal muscle mass and/or metabolic abnormalities.<unk>
T-1494	fontan_circulation skeletal_muscle metabolic
H-1494	-0.8657349348068237	▁Font an _ ▁circulation ▁skelet al _ ▁muscle _ ▁mass ▁metabol ic
D-1494	-0.8657349348068237	Fontan_ circulation skeletal_ muscle_ mass metabolic
P-1494	-0.6066 -1.0747 -1.2700 -0.6145 -1.0262 -0.4194 -0.4932 -1.8670 -1.8167 -1.1142 -0.0087 -0.1806 -1.5719 -0.0567
S-1709	These hypothesis-generating findings suggest that safety and efficacy of mineralocorticoid receptor antagonists may differ by race.<unk>
T-1709	mineralocorticoid_receptor_antagonists
H-1709	-1.4902057647705078	▁mineral o cor tico id ▁receptor
D-1709	-1.4902057647705078	mineralocorticoid receptor
P-1709	-4.1649 -0.0739 -0.1986 -2.0874 -1.2546 -1.2698 -2.7631 -0.1094
S-232	In conclusion, adult patients with failing Fontan circulation had a lower SVR index and similar cardiac index compared with the pediatric cohort.<unk>
T-232	patients fontan_circulation svr cardiac_index
H-232	-0.9433937668800354	▁Font an ▁circulation ▁s VR ▁cardiac ▁index ▁pediatr ic ▁co hor t
D-232	-0.9433937668800354	Fontan circulation sVR cardiac index pediatric cohort
P-232	-3.6932 -0.9490 -1.8428 -1.5892 -0.0417 -1.0734 -1.9929 -0.0730 -0.4193 -1.2517 -0.0164 -0.0361 -0.1892 -0.0397
S-755	The time to death or first HF hospitalization was significantly prolonged with CRT (hazard ratio, 0.26; P=0.012).<unk>
T-755	death hf hospitalization crt hazard_ratio
H-755	-1.1895928382873535	▁ HF ▁c RT haz ard
D-755	-1.1895928382873535	HF cRThazard
P-755	-1.9108 -0.2890 -2.9018 -1.4010 -1.6807 -0.0152 -1.1670 -0.1513
S-1820	In addition to palliative care of patients in the terminal phase, accurate recognition of advanced disease is vital in the determination of therapeutic options.<unk>
T-1820	palliative_care patients terminal disease therapeutic
H-1820	-1.1871663331985474	▁palli ative _ de _ ▁patients
D-1820	-1.1871663331985474	palliative_de_ patients
P-1820	-0.0359 -0.0904 -1.4658 -2.4272 -0.3692 -1.8427 -3.1822 -0.0839
S-1710	Does reducing length of stay increase rehospitalization of medicare fee-for-service beneficiaries discharged to skilled nursing facilities?<unk>
T-1710	rehospitalization medicare discharged nursing
H-1710	-0.7795252799987793	▁re hospital ization ▁medica re ▁fee - for - service _ ▁beneficiar ies ▁skille d _ nur sing
D-1710	-0.7795252799987793	rehospitalization medicare fee-for-service_ beneficiaries skilled_nursing
P-1710	-3.3739 -0.0056 -0.1912 -0.0105 -0.0027 -0.1062 -1.7103 -0.4776 -0.0981 -0.0042 -2.3100 -2.6923 -0.0910 -0.1391 -0.0123 -0.3064 -0.5517 -0.5086 -2.8887 -0.1102
S-297	The purpose of this study was to determine the 1-year survival in patients requiring isolated LVAD and patients requiring biventricular support.<unk>
T-297	patients lvad patients biventricular_support
H-297	-0.8712734580039978	▁l VAD ▁bi ven tri cular
D-297	-0.8712734580039978	lVAD biventricular
P-297	-3.6392 -0.2296 -1.2184 -0.1092 -0.0128 -0.3630 -1.2845 -0.1135
S-158	Exclusion of one trial that provided better-than-usual support to the control group rendered each of the above comparisons statistically significant.<unk>
T-158	
H-158	-0.7284471988677979	
D-158	-0.7284471988677979	
P-158	-1.3885 -0.0683
S-86	While specific research questions may be the focus, it is the implementation issues and strategies that reveal how individuals and organizations are profoundly transformed.<unk>
T-86	
H-86	-0.724277913570404	
D-86	-0.724277913570404	
P-86	-1.4113 -0.0373
S-1757	Primary study end point was a composite of cardiovascular death and urgent cardiac transplant, and secondary end point was all-cause death.<unk>
T-1757	end_point cardiovascular_death cardiac_transplant secondary_end_point death
H-1757	-1.0501904487609863	▁cardiovascular _ ▁death ▁urgent _ ▁cardiac ▁transplant
D-1757	-1.0501904487609863	cardiovascular_ death urgent_ cardiac transplant
P-1757	-1.7620 -1.8782 -2.3230 -0.2347 -0.5388 -0.0794 -1.6216 -0.9134 -0.1008
S-26	Hence, the diagnosis of clinical (prognostic) diastolic dysfunction leading to HFPEF is of critical importance.<unk>
T-26	diagnosis clinical prognostic diastolic_dysfunction leading hfpef
H-26	-0.7250015139579773	▁clinic al _ prog nosti c ▁dia sto lic _ ▁dys function ▁H FP EF
D-26	-0.7250015139579773	clinical_prognostic diastolic_ dysfunction HFPEF
P-26	-2.5683 -0.0355 -0.7773 -0.1945 -0.0998 -0.0172 -1.6765 -0.6563 -3.4005 -0.5667 -0.1766 -0.3805 -1.0877 -0.2066 -0.3016 -0.1022 -0.0773
S-1076	HF with preserved ejection fraction (HFpEF) is commoner among women who may have underlying hypertension.<unk>
T-1076	hf_with_preserved_ejection_fraction hfpef hypertension
H-1076	-0.7971969246864319	▁ HF ▁h p f ▁hyper tension
D-1076	-0.7971969246864319	HF hpf hypertension
P-1076	-2.4336 -0.0168 -2.6144 -1.0019 -0.5524 -0.2476 -0.0050 -0.1679 -0.1350
S-101	Risk factors and outcomes associated with the development of myocardial ischemic events in patients who receive cardiac resynchronization therapy.<unk>
T-101	outcomes myocardial_ischemic_events patients cardiac_resynchronization_therapy
H-101	-0.7719151973724365	▁my o card ial _ ische mic ▁events ▁cardiac ▁re syn chron ization ▁ therapy
D-101	-0.7719151973724365	myocardial_ischemic events cardiac resynchronization therapy
P-101	-3.2636 -0.2898 -0.0652 -0.0578 -0.3988 -2.9577 -0.2297 -0.8916 -0.0332 -2.0325 -0.0009 -0.0001 -0.7915 -1.8980 -0.0267 -0.0700 -0.1155
S-1132	Increase in parasympathetic tone by pyridostigmine prevents ventricular dysfunction during the onset of heart failure.<unk>
T-1132	parasympathetic_tone pyridostigmine ventricular_dysfunction heart_failure
H-1132	-0.7010244727134705	▁para sy mpa the tic ▁tone ▁py rido stig mine ▁vent ri cular _ ▁dys function ▁heart _ ▁failure
D-1132	-0.7010244727134705	parasympathetic tone pyridostigmine ventricular_ dysfunction heart_ failure
P-1132	-0.1640 -0.7444 -0.0369 -1.8455 -1.2450 -0.3937 -0.7011 -0.0673 -0.0012 -0.2518 -0.0014 -0.1947 -0.5392 -1.8585 -0.2422 -0.3779 -1.2703 -1.1858 -3.3382 -0.1619 -0.1005
S-1515	NT-proBNP was enriched from HF patient plasma by use of immunoprecipitation followed by mass spectrometric analysis.<unk>
T-1515	nt-probnp hf patient plasma immunoprecipitation mass_spectrometric_analysis
H-1515	-0.5988211631774902	▁NT - pro B NP ▁ HF ▁patient _ ▁plasma ▁immun o preci pit ation ▁mass ▁spec tro metric
D-1515	-0.5988211631774902	NT-proBNP HF patient_ plasma immunoprecipitation mass spectrometric
P-1515	-0.7440 -0.2192 -0.0402 -0.6339 -0.0514 -0.8634 -0.0814 -2.8060 -1.3505 -0.9755 -0.0022 -0.2225 -0.2898 -0.0110 -0.0297 -0.1658 -1.7220 -0.0255 -0.2524 -1.8536 -0.2353
S-459	CONCLUSIONS: β-Blockade promotes cardiac angiogenesis in heart failure via activation of VEGF signaling pathway.<unk>
T-459	β-blockade cardiac_angiogenesis heart_failure vegf_signaling_pathway
H-459	-1.0555174350738525	▁β - Block ade ▁cardiac _ ▁ang io gene sis ▁heart _ ▁failure ▁VE GF ▁signal ing _ path way
D-459	-1.0555174350738525	β-Blockade cardiac_ angiogenesis heart_ failure VEGF signaling_pathway
P-459	-1.7706 -0.1592 -0.1194 -2.2104 -0.2560 -2.6797 -1.1720 -2.1667 -0.9823 -2.7910 -0.1622 -1.1312 -2.7921 -0.0438 -0.0128 -0.4745 -1.0327 -1.5212 -0.8654 -0.2756 -0.4824 -0.1199
S-1873	The primary efficacy end points were changes in NYHA functional class, quality-of-life score, and 6-minute hall walk distance.<unk>
T-1873	end_points nyha_functional_class quality-of-life 6-minute_hall_walk
H-1873	-1.161108136177063	▁ef fica cy _ ▁end ▁points ▁NY HA _ ▁functional ▁class ▁quality - of - life
D-1873	-1.161108136177063	efficacy_ end points NYHA_ functional class quality-of-life
P-1873	-4.1854 -0.0030 -0.2525 -2.7547 -2.6451 -0.4286 -0.2349 -0.2363 -2.3088 -1.3814 -1.4264 -0.9130 -0.1571 -0.0148 -0.1786 -0.1157 -3.4029 -0.2608
S-90	Chromatin-associated proteins alter chromatin structure by changing their association with DNA, thereby altering the gene expression profile.<unk>
T-90	chromatin-associated_proteins chromatin_structure changing dna gene_expression_profile
H-90	-0.7628134489059448	▁chr mat in _ as soci ated ▁protein s ▁chr omat in _ ▁structure ▁DNA ▁gene ▁expression
D-90	-0.7628134489059448	chrmatin_associated proteins chromatin_ structure DNA gene expression
P-90	-0.7276 -0.0338 -0.6218 -1.8105 -0.1805 -0.0010 -1.2232 -1.3632 -0.0536 -0.3951 -0.0778 -1.9393 -1.0333 -3.0322 -0.2308 -1.0343 -0.1090 -0.5462 -0.0803
S-238	We studied the patients having heart failure (HF) using data from the Heart Failure Adherence and Retention Trial (HART).<unk>
T-238	patients heart_failure hf heart_failure_adherence_and_retention_trial hart
H-238	-0.881666362285614	▁heart _ ▁failure ▁ HF ▁Heart _ ▁Fail ure _ ad her ence _ re tention _ tri al HAR T
D-238	-0.881666362285614	heart_ failure HF Heart_ Failure_adherence_retention_trialHART
P-238	-1.9669 -0.5259 -3.4574 -2.9248 -0.0194 -0.8375 -0.3045 -0.4724 -0.1422 -1.6012 -0.3624 -0.0726 -0.0024 -2.9161 -2.7362 -0.0150 -0.2030 -0.3377 -0.0483 -0.1234 -1.0143 -0.1211 -0.0737
S-1110	Differential effects of nonselective versus selective beta-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure.<unk>
T-1110	selective_beta-blockers cardiac_sympathetic_activity hemostasis patients heart_failure
H-1110	-1.203432321548462	▁non sel ective ▁beta - block ers ▁cardiac _ syn chron e _ ▁activity ▁hemos tas is ▁heart _ ▁failure
D-1110	-1.203432321548462	nonselective beta-blockers cardiac_synchrone_ activity hemostasis heart_ failure
P-1110	-5.8072 -0.0041 -0.2086 -1.9262 -0.0423 -0.1333 -0.0686 -0.0524 -1.0154 -3.2849 -0.3749 -3.0054 -1.1386 -2.4481 -0.9168 -0.1542 -0.4368 -1.0638 -1.0536 -3.1302 -0.1451 -0.0651
S-578	Major right ventricle overload leads to decreased stroke volume, which shortens left ventricular ejection time (LVET).<unk>
T-578	right_ventricle leads stroke_volume shortens left_ventricular_ejection_time lvet
H-578	-1.008421540260315	▁vent ric le _ over load ▁stroke ▁vent ri cular _ ▁e je ction _ ▁time ▁l VET
D-578	-1.008421540260315	ventricle_overload stroke ventricular_ ejection_ time lVET
P-578	-0.0493 -4.1529 -0.5335 -1.7325 -1.6771 -0.0497 -0.1294 -0.5954 -0.3196 -0.1834 -1.3516 -0.6880 -1.0624 -0.1045 -2.0505 -2.6918 -2.2823 -0.2597 -0.1545 -0.1003
S-1338	METHODS AND RESULTS: Myocardial infarction was created by left anterior descending coronary artery occlusion.<unk>
T-1338	myocardial_infarction left_anterior_descending_coronary_artery_occlusion
H-1338	-0.610795259475708	▁My o card ial ▁in far ction ▁left _ ▁anterior ▁descend ing ▁corona ry ▁arter y ▁oc clusi on
D-1338	-0.610795259475708	Myocardial infarction left_ anterior descending coronary artery occlusion
P-1338	-1.9707 -0.1341 -0.0918 -0.0648 -0.3504 -2.0911 -0.0113 -1.7334 -0.8821 -2.0687 -0.4390 -0.1063 -0.0640 -0.4566 -0.3456 -1.4158 -0.0096 -0.0180 -0.2545 -0.2288 -0.0902
S-1424	β-Adrenergic receptor blockade reduces total mortality and all-cause hospitalizations in patients with heart failure (HF).<unk>
T-1424	β-adrenergic_receptor_blockade mortality all-cause_hospitalizations patients heart_failure hf
H-1424	-1.1717356443405151	▁ad r energi c _ ▁receptor _ block ade
D-1424	-1.1717356443405151	adrenergic_ receptor_blockade
P-1424	-1.6641 -0.0476 -0.5382 -0.1365 -1.3746 -0.2248 -1.9941 -1.5873 -0.5247 -4.5812 -0.2160
S-609	But, it was elevated prior to 2002 (HR 2.17, 95% CI 0.45 to 10.50, test for interaction p=0.036).<unk>
T-609	elevated
H-609	-1.0177555084228516	
D-609	-1.0177555084228516	
P-609	-1.9313 -0.1043
S-1581	RESULTS: A statistically significant 42 percent relative reduction in 30-day readmission rate was documented for those patients participating in the pilot program.<unk>
T-1581	readmission patients
H-1581	-1.3518319129943848	
D-1581	-1.3518319129943848	
P-1581	-2.6056 -0.0981
S-1559	A total of 262 psoriasis (24% systemic/UV treatment) and 8,009 reference subjects were followed up for a mean of 11 years.<unk>
T-1559	psoriasis systemic followed_up
H-1559	-1.2349740266799927	▁psoriasis
D-1559	-1.2349740266799927	psoriasis
P-1559	-0.3227 -3.3087 -0.0735
S-991	While certain stimuli mediate a beneficial adaptation to stress conditions, others result in maladaptive remodelling, ultimately leading to heart failure.<unk>
T-991	conditions remodelling leading heart_failure
H-991	-0.5996412038803101	▁stress ▁conditions ▁mal adapt ive ▁remodel ling ▁heart
D-991	-0.5996412038803101	stress conditions maladaptive remodelling heart
P-991	-2.2775 -0.0686 -0.1056 -0.0138 -0.0113 -0.6414 -0.2876 -0.1598 -2.3484 -0.0823
S-513	The mortality was 32 and 37% in the LCX and LAD models but very (71%) high in the two-vessel disease model.<unk>
T-513	mortality lcx lad disease
H-513	-0.7007268071174622	▁mortal ity ▁ LC x ▁ LAD ▁two - ves sel _ ▁disease
D-513	-0.7007268071174622	mortality LCx LAD two-vessel_ disease
P-513	-1.7135 -0.1638 -0.2922 -0.0071 -0.2253 -0.2608 -0.0077 -3.3329 -0.0240 -0.0580 -0.0089 -0.7363 -2.8767 -0.6624 -0.1415
S-141	Rates calculated using the PPR and either ACR or CMS metrics were moderately correlated (r = 0.50-0.67).<unk>
T-141	ppr acr cms correlated
H-141	-0.6092955470085144	▁p PR ▁a CR ▁CMS
D-141	-0.6092955470085144	pPR aCR CMS
P-141	-0.8437 -1.0634 -0.2013 -0.7634 -0.4029 -0.8847 -0.1056
S-51	Intravenous iron may help to alleviate symptoms in patients with heart failure and iron deficiency and also warrants further study.<unk>
T-51	intravenous symptoms patients heart_failure
H-51	-0.9116482138633728	▁Intra ven ous ▁ir on ▁heart _ ▁failure ▁ir on ▁de fici en cy
D-51	-0.9116482138633728	Intravenous iron heart_ failure iron deficiency
P-51	-0.3161 -0.0118 -2.6709 -1.0958 -0.1234 -2.6449 -0.7056 -2.3683 -0.0169 -0.0651 -3.5273 -0.0550 -0.3047 -0.3894 -0.1785 -0.1129
S-1160	We hypothesized that RV dysfunction is linked to weight loss, abnormal body composition, and worsened prognosis in advanced HF.<unk>
T-1160	rv_dysfunction prognosis hf
H-1160	-1.2418816089630127	▁ RV _ ▁dys function
D-1160	-1.2418816089630127	RV_ dysfunction
P-1160	-0.4739 -0.1181 -1.8446 -0.7545 -0.8564 -4.3779 -0.2677
S-584	The LVET at entry (237 milliseconds) had 73% sensitivity and 89% specificity for identifying death in the ICU.<unk>
T-584	lvet sensitivity specificity death icu
H-584	-1.8284757137298584	▁l VET
D-584	-1.8284757137298584	lVET
P-584	-1.9315 -1.3118 -3.8825 -0.1881
S-1613	RESULTS: A total of 293 and 133 DEGs were obtained for non-ischemic and ischemic heart failure, respectively.<unk>
T-1613	degs ischemic_heart_failure
H-1613	-1.842091679573059	▁ ische mic ▁heart _ ▁failure
D-1613	-1.842091679573059	ischemic heart_ failure
P-1613	-3.5453 -2.3454 -0.6254 -5.2025 -1.1431 -1.7126 -0.0969 -0.0655
S-1179	Because this patient population is symptomatic on exertion, therapeutic treatments targeting abnormal exercise hemodynamic status may prove useful.<unk>
T-1179	patient symptomatic therapeutic exercise hemodynamic
H-1179	-1.6375170946121216	▁ex er tion ▁ therapeut ic
D-1179	-1.6375170946121216	exertion therapeutic
P-1179	-4.8809 -0.0058 -0.0194 -2.8784 -0.0431 -0.4010 -4.8157 -0.0559
S-1912	OBJECTIVE: The objective of this study was assess robot-assisted gait therapy with the Lokomat® system in heart failure patients.<unk>
T-1912	gait therapy lokomat heart_failure patients
H-1912	-0.762902021408081	▁robot - assist ed ▁ga it ▁ therapy ▁Lok omat _ system ▁heart _ ▁failure
D-1912	-0.762902021408081	robot-assisted gait therapy Lokomat_system heart_ failure
P-1912	-1.2004 -0.1872 -0.0020 -0.1125 -1.7269 -0.0896 -1.0342 -0.0200 -0.0955 -0.0385 -2.5679 -1.8831 -1.5974 -0.5910 -1.1916 -0.5392 -0.0924
S-210	We hypothesize that this should have resulted in fewer CHF patients presenting to the emergency department (ED) and fewer being intubated.<unk>
T-210	chf patients emergency_department intubated
H-210	-1.069864273071289	▁CHF ▁patients ▁emergency ▁department ED ▁in tuba ted
D-210	-1.069864273071289	CHF patients emergency departmentED intubated
P-210	-0.0871 -5.2212 -0.3989 -2.3465 -0.6010 -0.1271 -0.0247 -1.5037 -0.2997 -0.0887
S-1363	SUMMARY: The gut and its role for inflammation and dietary interventions in heart failure patients are a crucial target of further heart failure research.<unk>
T-1363	gut inflammation heart_failure patients heart_failure
H-1363	-1.179180383682251	▁gut ▁ inflammation ▁dieta ry ▁intervention s ▁heart _ ▁failure
D-1363	-1.179180383682251	gut inflammation dietary interventions heart_ failure
P-1363	-1.6397 -0.1545 -0.0381 -4.7168 -0.1769 -3.4018 -0.0878 -0.2062 -1.0011 -1.4882 -1.1005 -0.1386
S-462	Background—Heart failure is a common Emergency Department (ED) presentation but whether ED volume influences patient outcomes is unknown.<unk>
T-462	heart_failure emergency_department patient outcomes
H-462	-0.8432645201683044	▁he art _ ▁failure ▁Emer gen cy _ ▁Department ED ▁ED ▁volume
D-462	-0.8432645201683044	heart_ failure Emergency_ DepartmentED ED volume
P-462	-2.3795 -0.1136 -0.7250 -1.0233 -0.9377 -0.0356 -0.0163 -0.6406 -1.2478 -1.3217 -0.2003 -1.3524 -1.6935 -0.1184
S-1578	PARTICIPANTS: All patients admitted between June 7, 2010 and June 6, 2011 with a diagnosis of congestive heart failure.<unk>
T-1578	patients diagnosis congestive_heart_failure
H-1578	-1.0997068881988525	▁con ges tive _ heart _ ▁failure
D-1578	-1.0997068881988525	congestive_heart_ failure
P-1578	-2.6288 -0.1873 -0.0942 -0.6005 -2.7347 -1.0215 -2.4342 -0.1408 -0.0553
S-1250	We hypothesized that an improved mitochondrial structure may facilitate the reversal of detrimental alterations in sarcomeric microstructure.<unk>
T-1250	mitochondrial_structure sarcomeric_microstructure
H-1250	-0.7338541150093079	▁mito cho ndri al ▁structure
D-1250	-0.7338541150093079	mitochondrial structure
P-1250	-0.3986 -0.9348 -0.1163 -0.0374 -0.7290 -2.8529 -0.0679
S-258	In healthy individuals, ET had no effect on HDL function, whereas ET of CHF-NYHA-IIIb significantly improved HDL function.<unk>
T-258	healthy hdl chf-nyha-iiib hdl
H-258	-1.342029333114624	▁ET ▁HD L _ fon cti onnement ▁CHF - NY HA - III b
D-258	-1.342029333114624	ET HDL_fonctionnement CHF-NYHA-IIIb
P-258	-4.3879 -5.2382 -1.1884 -2.1203 -2.1186 -0.2342 -0.5163 -0.8652 -0.1717 -0.4386 -0.4740 -0.3456 -0.1465 -0.1553 -3.0080 -0.0637
S-1413	BACKGROUND: Early physician follow-up after discharge is associated with lower rates of death and readmission among patients with heart failure.<unk>
T-1413	physician follow-up discharge death readmission patients heart_failure
H-1413	-1.294725775718689	▁physician _ ▁follow - up _ de _ dis charge
D-1413	-1.294725775718689	physician_ follow-up_de_discharge
P-1413	-1.0888 -1.9714 -3.6817 -0.0624 -0.0048 -1.1146 -2.6360 -0.2294 -0.0359 -0.0087 -4.6309 -0.0720
S-635	Successful approaches to improving the prognosis of patients with CHF are based largely on therapeutic interruption of activated neurohormonal systems.<unk>
T-635	prognosis patients chf therapeutic neurohormonal_systems
H-635	-0.9097937345504761	▁CHF ▁ therapeut ic ▁interrupt ion _ de _ activa ted _ ▁neuro hormon al ▁systems
D-635	-0.9097937345504761	CHF therapeutic interruption_de_activated_ neurohormonal systems
P-635	-3.1376 -2.0299 -0.0550 -0.3354 -0.8794 -0.0193 -1.9915 -1.8231 -0.3468 -0.7453 -1.1050 -0.4113 -0.6608 -0.3055 -0.0975 -2.1468 -0.2304 -0.0557
S-180	Patients who received uptitration were significantly younger, with a higher heart rate and better renal function, and received spironolactone more often.<unk>
T-180	patients uptitration heart_rate renal_function spironolactone
H-180	-2.1682288646698	▁implant ation
D-180	-2.1682288646698	implantation
P-180	-3.7616 -0.9411 -3.7286 -0.2416
S-1481	An increasing body of evidence indicates an important role for microRNAs (miRNAs) in the pathogenesis and progression of heart failure.<unk>
T-1481	evidence micrornas mirnas pathogenesis heart_failure
H-1481	-1.001770257949829	▁micro RNA s _ mi RNA s
D-1481	-1.001770257949829	microRNAs_miRNAs
P-1481	-1.5799 -0.0046 -0.0328 -2.9251 -0.2382 -0.0078 -0.0199 -4.0739 -0.1337
S-1859	AIM: To determine patient awareness, preferences and timing of implantable cardioverter-defibrillator deactivation discussions.<unk>
T-1859	patient implantable_cardioverter-defibrillator
H-1859	-0.823181688785553	▁implant able _ ▁cardio ver ter - de _ de _ activa tion
D-1859	-0.823181688785553	implantable_ cardioverter-de_de_activation
P-1859	-0.1958 -0.0277 -1.2051 -2.6061 -0.1023 -0.0288 -0.5940 -0.0068 -1.1898 -2.6455 -1.3866 -1.6870 -0.0357 -0.5323 -0.1042
S-577	BACKGROUND: Novel noninvasive tools may improve the management of patients with pulmonary hypertension (PH) experiencing heart failure.<unk>
T-577	noninvasive patients pulmonary_hypertension heart_failure
H-577	-1.1234216690063477	▁pulmonar y _ ▁hyper tension PH ▁heart _ ▁failure
D-577	-1.1234216690063477	pulmonary_ hypertensionPH heart_ failure
P-577	-3.9373 -0.0726 -1.2594 -1.1496 -0.0026 -1.2395 -2.0614 -1.1610 -1.3113 -0.1092 -0.0537
S-122	METHODS: We included 156 consecutive consenting ambulatory HF patients (left ventricular ejection fraction < 40%).<unk>
T-122	ambulatory hf patients left_ventricular_ejection_fraction
H-122	-0.839077889919281	▁ambula tory ▁ HF ▁vent ri cular ▁e je ction fraction
D-122	-0.839077889919281	ambulatory HF ventricular ejectionfraction
P-122	-3.8969 -0.4215 -0.5153 -0.0790 -1.3064 -0.2203 -0.4579 -0.9843 -0.4356 -0.1071 -2.0984 -0.3083 -0.0769
S-1941	Beta-blocker dose after 12 months was comparable in patients with resting HR<70 versus ≥70 bpm (P value=0.631).<unk>
T-1941	beta-blocker patients resting_hr bpm p_value
H-1941	-0.8796850442886353	▁Beta - block er
D-1941	-0.8796850442886353	Beta-blocker
P-1941	-0.2187 -0.0237 -0.0518 -0.0855 -4.7797 -0.1186
S-1435	QT variability (QTV) signifies repolarization lability, and increased QTV is a risk predictor for sudden cardiac death.<unk>
T-1435	qt_variability qtv repolarization qtv cardiac_death
H-1435	-1.280219316482544	▁ QT _ ▁variabil ity ▁Q TV ▁repo lar ization _ la bility ▁Q TV ▁risk
D-1435	-1.280219316482544	QT_ variability QTV repolarization_lability QTV risk
P-1435	-1.6535 -0.1174 -3.1223 -3.2574 -0.4693 -0.7056 -0.7035 -5.5786 -0.3436 -0.2282 -0.3966 -0.2396 -0.0262 -0.1130 -0.5209 -1.6066 -3.7601 -0.2017
S-668	Addressing practice-level differences may be an important component of improving quality of care for patients with heart failure and reduced ejection fraction.<unk>
T-668	patients heart_failure_and_reduced_ejection_fraction
H-668	-1.4339637756347656	▁implant ation ▁heart _ ▁failure ▁e je ction _ fraction
D-668	-1.4339637756347656	implantation heart_ failure ejection_fraction
P-668	-3.7484 -0.8633 -6.2550 -0.8675 -2.1472 -1.1701 -1.0051 -0.0397 -0.8183 -0.0240 -0.1240 -0.1450
S-914	Compared with matched controls, dialysis patients were at increased risk for adverse events and worsened echocardiographic outcomes.<unk>
T-914	dialysis patients adverse_events echocardiographic outcomes
H-914	-0.8339537382125854	▁di al ysis
D-914	-0.8339537382125854	dialysis
P-914	-0.4799 -0.3348 -0.0958 -3.1764 -0.0829
S-641	In line, mutant mice overexpressing Hand2 in otherwise healthy heart muscle cells developed a phenotype of pathological hypertrophy.<unk>
T-641	hand2 healthy heart_muscle cells phenotype pathological hypertrophy
H-641	-1.0972106456756592	▁mu tant _ mi ce _ ▁over express ing ▁Hand ▁heart _ ▁muscle s ▁path ological _ ▁hyper trop hy
D-641	-1.0972106456756592	mutant_mice_ overexpressing Hand heart_ muscles pathological_ hypertrophy
P-641	-0.1111 -0.0602 -1.7762 -0.4425 -0.1678 -4.9777 -1.1617 -0.3538 -0.0853 -0.2687 -5.5938 -0.4841 -3.4157 -1.2278 -1.2327 -0.3921 -1.6306 -0.3800 -0.0014 -0.0456 -0.2147 -0.1153
S-1373	The present study used conscious, chronically instrumented New Zealand White rabbits undergoing renal DNx prior to pacing-induced CHF.<unk>
T-1373	new_zealand renal_dnx pacing-induced_chf
H-1373	-0.7368915677070618	▁implant ed ▁New ▁Zealand ▁White ▁rabbi ts ▁renal ▁DN x ▁pa cing - indu ced ▁CHF
D-1373	-0.7368915677070618	implanted New Zealand White rabbits renal DNx pacing-induced CHF
P-1373	-5.8537 -1.9700 -1.7044 -0.0277 -1.4999 -0.4022 -0.0290 -0.0373 -0.0167 -0.0056 -0.3002 -0.3227 -0.1856 -0.0002 -0.4600 -0.0065 -0.2183 -0.2240
S-1647	Furthermore, catheter ablation and new antiarrhythmic drugs have enhanced the potential effectiveness and safety of rhythm control therapy.<unk>
T-1647	catheter_ablation antiarrhythmic_drugs rhythm_control_therapy
H-1647	-0.40975630283355713	▁cat heter ▁ab lation ▁anti ar rhythm ic ▁drugs ▁ rhythm _ control ▁ therapy
D-1647	-0.40975630283355713	catheter ablation antiarrhythmic drugs rhythm_control therapy
P-1647	-0.3968 -0.0108 -0.3407 -0.0029 -0.0256 -1.4876 -1.0052 -0.5475 -0.2224 -0.1914 -0.4704 -1.2760 -0.0262 -0.6438 -0.0272 -0.1295 -0.1617
S-1029	It is also important that processes of care delivery are redesigned to take full advantage of the faster turnaround times provided by POC technology.<unk>
T-1029	advantage poc
H-1029	-2.015751838684082	▁technologies
D-1029	-2.015751838684082	technologies
P-1029	-5.6243 -0.2902 -0.1328
S-185	RAS-blocker uptitration independently predicts clinical outcome in patients with HFrEF but not in those with HFpEF.<unk>
T-185	ras-blocker uptitration clinical outcome patients hfref hfpef
H-185	-0.5820196866989136	RAS - block er ▁h Fr EF ▁ HF p EF
D-185	-0.5820196866989136	RAS-blocker hFrEF HFpEF
P-185	-0.2695 -0.1096 -0.2716 -0.1257 -1.8924 -1.5662 -1.0493 -1.0629 -0.2157 -0.0488 -0.6593 -0.1702 -0.1250
S-652	Cardiac failure is a major cause of death in patients with type 2 diabetes, but the molecular mechanism that links diabetes to heart failure remains unclear.<unk>
T-652	cardiac_failure death patients type_2_diabetes diabetes heart_failure
H-652	-1.2097331285476685	▁Card iac _ ▁failure ▁diabetes ▁heart _ ▁failure
D-652	-1.2097331285476685	Cardiac_ failure diabetes heart_ failure
P-652	-1.4136 -0.0543 -0.5749 -2.7912 -0.9412 -3.7460 -0.6151 -1.6857 -0.1865 -0.0889
S-1957	Transoesophageal echocardiography at 1 month showed that all shunts were patent, with no thrombosis or migration.<unk>
T-1957	transoesophageal_echocardiography shunts thrombosis
H-1957	-0.773915708065033	▁trans o es op hage al _ ▁e cho card i ography ▁shu nts ▁ thro mbo sis ▁migration
D-1957	-0.773915708065033	transoesophageal_ echocardiography shunts thrombosis migration
P-1957	-0.1192 -0.2207 -0.6354 -3.5936 -0.0598 -0.9256 -0.4091 -1.2888 -0.1048 -0.1866 -0.8358 -0.3174 -2.3995 -0.0795 -0.9101 -0.4353 -0.1619 -3.2591 -0.0302 -0.1920 -0.0878
S-579	Our arterial tonometry study tested the hypothesis that LVET carries prognostic value in patients with precapillary PH with heart failure.<unk>
T-579	arterial_tonometry lvet prognostic patients precapillary_ph heart_failure
H-579	-1.0247702598571777	▁arterial _ ▁ton ometr y ▁l VET ▁pre cap illa ry _ ▁PH ▁heart _ ▁failure
D-579	-1.0247702598571777	arterial_ tonometry lVET precapillary_ PH heart_ failure
P-579	-0.3016 -0.6662 -1.4969 -0.0628 -0.1699 -5.0333 -1.0714 -0.8621 -0.7020 -0.0081 -0.4172 -0.6904 -1.0109 -2.2871 -1.1949 -2.0835 -0.1966 -0.1911
S-1964	Study PARADIGM-HF - a paradigm shift in the treatment of chronic heart failure Chronic heart failure is a crucial problem of current cardiology.<unk>
T-1964	paradigm-hf shift chronic_heart_failure chronic_heart_failure cardiology
H-1964	-1.526004672050476	▁para DIG m - HF ▁chronic _ ▁heart _ ▁failure ▁card i ology
D-1964	-1.526004672050476	paraDIGm-HF chronic_ heart_ failure cardiology
P-1964	-6.3032 -0.1237 -0.2965 -0.2444 -0.0831 -5.7835 -0.7176 -2.4473 -0.8974 -1.5331 -3.1551 -0.3794 -0.5029 -0.2787 -0.1443
S-833	Hemoglobin, exercise training, and health status in patients with chronic heart failure (from the HF-ACTION randomized controlled trial).<unk>
T-833	hemoglobin exercise training health patients chronic_heart_failure hf-action randomized
H-833	-1.1356072425842285	▁Hem o glob in ▁health ▁status ▁patients ▁ HF - ac tion
D-833	-1.1356072425842285	Hemoglobin health status patients HF-action
P-833	-0.1753 -0.0193 -0.0050 -0.5366 -3.2304 -1.6104 -1.8129 -4.2695 -0.7304 -0.3554 -1.2886 -0.8535 -0.8890 -0.1221
S-770	CONCLUSIONS: Obese ZSF1 rats developed heart failure with preserved ejection fraction during a 20-week time span.<unk>
T-770	obese zsf1 heart_failure_with_preserved_ejection_fraction
H-770	-1.126692295074463	▁Z SF 1 ▁rat s ▁heart _ ▁failure ▁pres er ved ▁e je ction _ fraction
D-770	-1.126692295074463	ZSF1 rats heart_ failure preserved ejection_fraction
P-770	-0.9147 -0.5712 -3.7883 -2.0004 -0.1431 -1.3818 -1.1081 -4.2517 -1.3409 -0.0287 -1.5993 -0.4474 -0.9145 -0.0733 -1.0088 -0.0302 -0.5036 -0.1743
S-8	Cross-talk between the heart and adipose tissue in cachectic heart failure patients with respect to alterations in body composition: a prospective study.<unk>
T-8	cross-talk heart adipose_tissue cachectic_heart_failure patients prospective_study
H-8	-0.9917158484458923	▁heart ▁adi pose _ ▁tissu e ▁cache ctic ▁heart _ ▁failure
D-8	-0.9917158484458923	heart adipose_ tissue cachectic heart_ failure
P-8	-2.6365 -1.5063 -0.1888 -0.5503 -1.4755 -0.1098 -0.0290 -1.1457 -1.2325 -0.2274 -1.5834 -2.0639 -0.1433
S-88	Systems proteomics of cardiac chromatin identifies nucleolin as a regulator of growth and cellular plasticity in cardiomyocytes.<unk>
T-88	systems_proteomics cardiac_chromatin nucleolin cellular_plasticity cardiomyocytes
H-88	-0.8897202610969543	▁Systems _ protec o mics ▁cardiac ▁chr omat in ▁nucleo lin ▁regulator _ de _ ▁growth ▁cardio my o cy tes
D-88	-0.8897202610969543	Systems_protecomics cardiac chromatin nucleolin regulator_de_ growth cardiomyocytes
P-88	-2.2596 -0.3637 -1.6012 -1.6270 -0.0020 -1.1274 -1.0764 -0.0141 -0.8505 -0.5222 -0.5363 -3.1720 -1.2403 -1.4553 -0.1536 -1.3411 -1.2295 -0.6449 -0.7082 -0.0911 -0.1828 -0.2004 -0.0639
S-1546	Reversal of cardiac dysfunction and subcellular alterations by metoprolol in heart failure due to myocardial infarction.<unk>
T-1546	cardiac_dysfunction subcellular metoprolol heart_failure myocardial_infarction
H-1546	-0.35977521538734436	▁cardiac _ ▁dys function ▁sub cel lular ▁altera tions ▁met o pro lol ▁heart _ ▁failure ▁my o card ial ▁in far ction
D-1546	-0.35977521538734436	cardiac_ dysfunction subcellular alterations metoprolol heart_ failure myocardial infarction
P-1546	-0.0524 -1.1882 -0.4425 -0.6964 -0.3389 -0.2782 -0.0428 -2.3289 -0.0124 -0.1038 -0.0590 -0.0088 -0.0859 -0.3317 -0.5098 -0.8520 -0.2213 -0.1513 -0.2194 -0.1020 -0.3090 -0.2385 -0.0604 -0.2603 -0.1006
S-1054	Multiacquisition T1-mapping MRI during tidal respiration for quantification of myocardial T1 in swine with heart failure.<unk>
T-1054	t1-mapping mri tidal_respiration myocardial_t1 heart_failure
H-1054	-0.8593277931213379	▁m RI ▁tid al _ ▁respira tion ▁my o card ial _ ▁T 1 ▁s win e ▁heart _ ▁failure
D-1054	-0.8593277931213379	mRI tidal_ respiration myocardial_ T1 swine heart_ failure
P-1054	-0.2243 -1.7627 -5.1216 -0.0313 -0.9905 -0.4976 -0.0091 -0.1784 -0.1426 -0.0433 -0.0050 -2.4470 -1.0047 -0.0550 -0.6049 -0.0485 -0.1216 -2.2293 -1.1710 -1.7275 -0.3001 -0.1893
S-764	Myocardial collagen, collagen cross-linking, titin isoforms, and phosphorylation were also determined.<unk>
T-764	myocardial_collagen collagen_cross-linking titin isoforms phosphorylation
H-764	-0.41542407870292664	▁My o card ial ▁collage n ▁collage n _ ▁cross - link ing ▁titi n ▁ phos phor y lation
D-764	-0.41542407870292664	Myocardial collagen collagen_ cross-linking titin phosphorylation
P-764	-0.5946 -0.0281 -0.0329 -0.0683 -0.4404 -0.1507 -1.4670 -0.0506 -2.5038 -1.1192 -0.0050 -0.0017 -0.0464 -0.0242 -0.0627 -1.2292 -0.0066 -0.1615 -0.9202 -0.0119 -0.1598 -0.0546
S-744	Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.<unk>
T-744	heart_magnetic_resonance_imaging chelation compliance heart_disease patients thalassaemia_major
H-744	-0.9949273467063904	▁heart _ ▁magnetic _ ▁res on ance _ ▁imagin g ▁che lation _ ▁choice s ▁heart _ ▁disease ▁tha lassa emia
D-744	-0.9949273467063904	heart_ magnetic_ resonance_ imaging chelation_ choices heart_ disease thalassaemia
P-744	-0.3356 -0.6773 -0.7461 -2.2249 -1.9407 -0.1662 -0.0991 -0.5059 -0.9637 -0.0941 -0.5887 -0.0030 -1.6601 -2.3858 -0.0151 -3.0816 -1.2034 -4.0372 -0.1280 -0.5556 -0.6084 -0.8081 -0.0545
S-28	LV diastolic dysfunction and filling pressures can be assessed non-invasively using Doppler echocardiography.<unk>
T-28	lv_diastolic_dysfunction filling_pressures non-invasively doppler_echocardiography
H-28	-0.7223880290985107	▁LV ▁dia sto lic _ ▁dys function ▁fill ing _ tension s ▁do pp ler _ ▁e cho card i ography
D-28	-0.7223880290985107	LV diastolic_ dysfunction filling_tensions doppler_ echocardiography
P-28	-0.1225 -2.1762 -0.5569 -3.2941 -1.2760 -0.2598 -0.4818 -0.8842 -0.0884 -0.6697 -0.8394 -0.1553 -0.7885 -0.0145 -0.8968 -0.8918 -0.9171 -0.3516 -0.2221 -0.9556 -0.3167 -0.2516 -0.2046
S-733	Cardiac magnetic resonance postcontrast T1 time is associated with outcome in patients with heart failure and preserved ejection fraction.<unk>
T-733	cardiac_magnetic_resonance_postcontrast_t1_time outcome patients heart_failure preserved_ejection_fraction
H-733	-0.8292053937911987	▁Card iac _ ▁magnetic _ ▁res on ance _ ▁post contra st ▁heart _ ▁failure ▁e je ction _ fraction
D-733	-0.8292053937911987	Cardiac_ magnetic_ resonance_ postcontrast heart_ failure ejection_fraction
P-733	-0.1073 -0.0610 -0.2780 -0.8887 -1.8225 -2.1517 -0.1212 -0.0503 -1.2021 -0.5735 -0.0082 -0.0698 -4.4180 -0.4043 -2.9021 -1.3373 -0.3878 -0.0340 -1.1881 -0.0113 -0.1493 -0.0758
S-2015	RESULTS: The model demonstrated acceptable internal and external validity in replicating resource use, costs, and survival estimates from 3 clinical trials.<unk>
T-2015	costs clinical
H-2015	-1.9044653177261353	
D-2015	-1.9044653177261353	
P-2015	-3.7349 -0.0740
S-94	Our study identified 321 proteins in this subproteome, demonstrating it to have modest conservation (37%) with that revealed using strong acid.<unk>
T-94	proteins subproteome
H-94	-1.2435417175292969	▁protein s
D-94	-1.2435417175292969	proteins
P-94	-3.0502 -0.1303 -1.7586 -0.0351
S-861	RESULTS: Inappropriate therapy occurred in 253 (14%) of 1,790 patients during a follow-up period of 3.4 ± 1.1 years.<unk>
T-861	therapy patients follow-up
H-861	-0.25875550508499146	▁in appropria te ▁ therapy
D-861	-0.25875550508499146	inappropriate therapy
P-861	-0.7370 -0.0853 -0.0829 -0.4829 -0.0389 -0.3153 -0.0689
S-1645	Rhythm control therapy has been only moderately effective in published trials, and its potential benefit was offset by side effects of repeated interventions.<unk>
T-1645	rhythm_control_therapy
H-1645	-0.43278634548187256	▁ Rhythm _ control ▁ therapy
D-1645	-0.43278634548187256	Rhythm_control therapy
P-1645	-0.0718 -0.0627 -0.5509 -0.0583 -1.1449 -0.0397 -1.4114 -0.1226
S-200	This article presents guidelines for the recognition, diagnosis, and early medical management of HF in infancy, childhood, and adolescence.<unk>
T-200	diagnosis medical hf
H-200	-1.3256583213806152	▁ HF ▁in fan cy ▁adolesce nce
D-200	-1.3256583213806152	HF infancy adolescence
P-200	-2.0508 -3.2501 -2.6482 -0.4507 -0.1435 -3.1215 -0.0077 -0.1683 -0.0901
S-1417	A familiar physician was defined as one who had seen the patient at least twice in the year before the index admission or once during the index admission.<unk>
T-1417	physician patient admission admission
H-1417	-0.8858711123466492	▁familiar ▁physician ▁index ▁ad mission
D-1417	-0.8858711123466492	familiar physician index admission
P-1417	-2.0207 -1.0819 -0.1723 -1.1414 -0.0129 -1.5642 -0.2076
S-1514	METHODS: Plasma samples were collected from HF patients (n = 20) at rest and stored at -80 °C.<unk>
T-1514	plasma collected hf patients
H-1514	-0.9825712442398071	▁Plas ma ▁ HF
D-1514	-0.9825712442398071	Plasma HF
P-1514	-0.5986 -0.2301 -2.5965 -0.1736 -2.2357 -0.0610
S-1767	METHODS AND RESULTS: A total of 44 674 men without a history of cardiovascular disease underwent a baseline examination between 1971 and 2010.<unk>
T-1767	cardiovascular_disease baseline
H-1767	-1.6690791845321655	
D-1767	-1.6690791845321655	
P-1767	-3.2822 -0.0560
S-1697	RESULTS: The composite (vs. Hospital Compare) explained 68% (vs. 39%) of variation in future AMI mortality rates.<unk>
T-1697	hospital_compare ami mortality
H-1697	-0.9092957377433777	▁ AMI ▁mortal ity
D-1697	-0.9092957377433777	AMI mortality
P-1697	-1.6629 -0.4630 -2.3100 -0.1090 -0.7823 -0.1287
S-726	Thirty-day all-cause readmissions decreased from 27.5% to 19.1% after our quality improvement initiative (P = .024).<unk>
T-726	all-cause_readmissions
H-726	-1.0298207998275757	
D-726	-1.0298207998275757	
P-726	-2.0303 -0.0293
S-1939	Patients participated in a quality of care programme aiming to achieve guideline-recommended target doses for beta-blocker therapy.<unk>
T-1939	patients beta-blocker therapy
H-1939	-2.3583226203918457	
D-1939	-2.3583226203918457	
P-1939	-4.4152 -0.3015
S-1288	In summary, this is one of the largest series of ACS problems in patients undergoing OHT bridged to transplant with MT or VAD.<unk>
T-1288	acs patients oht transplant vad
H-1288	-1.0702985525131226	▁a CS ▁o HT ▁ bridge d ▁transplant ▁MT ▁ VAD
D-1288	-1.0702985525131226	aCS oHT bridged transplant MT VAD
P-1288	-0.3773 -0.8255 -4.3162 -0.3037 -1.6111 -0.0113 -0.2521 -2.4122 -3.2287 -0.3809 -0.0065 -0.0984 -0.0900
S-1555	Psoriasis has been suggested to be an independent risk factor for cardiovascular disease (CVD); however, available studies have shown inconsistent results.<unk>
T-1555	psoriasis cardiovascular_disease cvd
H-1555	-0.8631772398948669	▁p sori asis ▁cardiovascular ▁disease CV d
D-1555	-0.8631772398948669	psoriasis cardiovascular diseaseCVd
P-1555	-1.9519 -0.0854 -0.1947 -0.5147 -3.7941 -0.5722 -0.4172 -0.1689 -0.0693
S-487	Using a cutoff of 8, negative predictive value of E/e'septal was 89% and negative likelihood ratio of 0.15.<unk>
T-487	septal likelihood_ratio
H-487	-1.3820692300796509	▁e sept al
D-487	-1.3820692300796509	eseptal
P-487	-2.9675 -3.1127 -0.2181 -0.4432 -0.1689
S-139	PRINCIPAL FINDINGS: Average hospital rates for HF patients and the CMS metric were generally higher than for other conditions and metrics.<unk>
T-139	principal hospital hf patients cms conditions
H-139	-1.6619770526885986	▁ HF ▁conditions
D-139	-1.6619770526885986	HF conditions
P-139	-3.1502 -1.4802 -2.4058 -1.1459 -0.1278
S-1838	Results were also similar in subgroups of patients with and without prior cardiovascular disease and in a subgroup defined by the 2 highest DRS deciles.<unk>
T-1838	patients cardiovascular_disease drs
H-1838	-1.5972460508346558	▁cardiovascular ▁disease ▁d RS
D-1838	-1.5972460508346558	cardiovascular disease dRS
P-1838	-2.9964 -4.1054 -0.4976 -0.5307 -1.3987 -0.0547
S-1217	Importantly, PDE2-overexpressing cardiomyocytes showed marked protection from norepinephrine-induced hypertrophic responses.<unk>
T-1217	cardiomyocytes hypertrophic
H-1217	-0.7097960114479065	▁p de _ over express ing ▁cardio my o cy tes ▁no re pine ph rine - indu ced ▁hyper trop hic
D-1217	-0.7097960114479065	pde_overexpressing cardiomyocytes norepinephrine-induced hypertrophic
P-1217	-2.9658 -0.0638 -1.5742 -0.2870 -0.5246 -0.0675 -0.0562 -0.7951 -0.3954 -0.3596 -0.2209 -0.2001 -0.0178 -0.2760 -3.0065 -0.1535 -0.7560 -0.0022 -3.4188 -0.0885 -0.0022 -0.3054 -1.3703 -0.1275
S-622	OBJECTIVE: The aim of this study was to assess the association between frailty and risk for heart failure (HF) in older adults.<unk>
T-622	frailty heart_failure hf
H-622	-1.3215936422348022	▁association _ de _ fra il ty _ de _ f ré que nce _ de _ f ré que nce ▁heart _ ▁failure
D-622	-1.3215936422348022	association_de_frailty_de_fréquence_de_fréquence heart_ failure
P-622	-3.3342 -1.7264 -2.0483 -0.1540 -0.3892 -0.2306 -2.9855 -3.4911 -2.2592 -0.1842 -2.7760 -0.0547 -0.0914 -0.0080 -1.2929 -2.3963 -0.1456 -2.5812 -0.0337 -0.0744 -0.0049 -3.8270 -0.3430 -2.7052 -1.1638 -0.0604
S-1940	At baseline, 6 and 12 months, 36%, 70% and 62% of patients, respectively, had a resting HR<70 bpm.<unk>
T-1940	baseline patients resting_hr bpm
H-1940	-1.3320949077606201	
D-1940	-1.3320949077606201	
P-1940	-2.6237 -0.0405
S-1535	OBJECTIVES: The aim of this study was to investigate the occurrence of heart failure in patients treated with bisphosphonates.<unk>
T-1535	heart_failure patients bisphosphonates
H-1535	-1.2271950244903564	▁heart _ ▁failure ▁bis phos phon ates
D-1535	-1.2271950244903564	heart_ failure bisphosphonates
P-1535	-4.2435 -1.1876 -2.7761 -1.4410 -0.0447 -0.3164 -0.7877 -0.1721 -0.0756
S-1871	They were randomly assigned to receive ongoing GDMT alone (control group) or ongoing GDMT plus BAT (treatment group) for 6 months.<unk>
T-1871	gdmt gdmt bat
H-1871	-0.864182710647583	▁GD MT ▁BAT
D-1871	-0.864182710647583	GDMT BAT
P-1871	-0.7528 -0.1056 -3.2172 -0.1983 -0.0470
S-179	Patients with a RAS- and β-blocker dose increase of ≥10% of the recommended target dose were compared with patients without uptitration.<unk>
T-179	patients β-blocker patients uptitration
H-179	-1.008534550666809	▁ RAS - ▁β - block er
D-179	-1.008534550666809	RAS- β-blocker
P-179	-0.1389 -0.0043 -0.2980 -5.0603 -0.0462 -0.1733 -0.1431 -3.0287 -0.1841
S-170	Compared to the control group, expression of Bax and Bcl-2 proteins and their ratio were increased in dogs only after 4 weeks of pacing.<unk>
T-170	expression bax bcl-2 proteins pacing
H-170	-0.4966288208961487	▁Bax ▁b cl -2 ▁protein s
D-170	-0.4966288208961487	Bax bcl-2 proteins
P-170	-0.6036 -0.1846 -0.0473 -1.0495 -0.8375 -0.1360 -1.0015 -0.1130
S-1483	To date, many miRNAs (and their targets) that play a role in diverse aspects of cardiac remodeling and heart failure development have been identified.<unk>
T-1483	mirnas cardiac_remodeling heart_failure
H-1483	-0.34127721190452576	▁mi RNA s ▁cardiac ▁remodel ing ▁heart _ ▁failure
D-1483	-0.34127721190452576	miRNAs cardiac remodeling heart_ failure
P-1483	-0.7258 -0.0019 -0.0315 -0.0432 -0.3146 -0.0691 -0.4304 -0.6763 -1.2630 -0.1668 -0.0315
S-1545	However, users of alendronate showed a dose-dependent reduction in this risk, suggesting that alendronate may reduce the risk of heart failure.<unk>
T-1545	alendronate alendronate heart_failure
H-1545	-2.3624837398529053	▁ale ndr onate
D-1545	-2.3624837398529053	alendronate
P-1545	-4.8046 -0.3893 -3.0748 -3.4302 -0.1135
S-1804	This novel finding could partly explain the reported greater risk of heart failure linked to the CLCNKA SNP, but requires confirmation on other populations.<unk>
T-1804	reported heart_failure clcnka snp
H-1804	-2.4159529209136963	
D-1804	-2.4159529209136963	
P-1804	-4.7382 -0.0937
S-1362	The regulation of feeding is discussed, as are nutritional strategies with potentially anti-inflammatory effects in the treatment of CHF.<unk>
T-1362	regulation anti-inflammatory chf
H-1362	-0.7449506521224976	▁regula tion _ de _ ▁feed ing ▁nutrition al ▁anti - in flam ma tory ▁effects ▁CHF
D-1362	-0.7449506521224976	regulation_de_ feeding nutritional anti-inflammatory effects CHF
P-1362	-1.6542 -0.0105 -0.1926 -1.6699 -0.0821 -1.9866 -0.0781 -0.7614 -0.3667 -0.6797 -0.0275 -0.5368 -0.0396 -0.8263 -1.3040 -3.2646 -0.5090 -0.1024 -0.0621
S-25	In the general population, the presence of even mild clinical diastolic dysfunction has been associated with pronounced increases in all cause mortality.<unk>
T-25	clinical diastolic_dysfunction mortality
H-25	-1.0277754068374634	▁clinic al _ dis fon cti onnement ▁cause _ ▁mortal ity
D-25	-1.0277754068374634	clinical_disfonctionnement cause_ mortality
P-25	-1.6061 -0.0117 -0.4155 -2.7429 -3.2855 -1.2050 -1.7937 -1.5047 -0.1618 -0.1621 -0.3636 -0.0668 -0.0417
S-993	Paradoxically, however, in a number of cases, the transduction pathways involved in such opposing responses engage the same signalling proteins.<unk>
T-993	transduction_pathways engage signalling_proteins
H-993	-0.8610665798187256	▁trans duction _ path ways
D-993	-0.8610665798187256	transduction_pathways
P-993	-0.0274 -0.2066 -0.9865 -0.5812 -0.7138 -3.4346 -0.0773
S-602	We studied the risk of new or recurrent HF among a group of patients receiving these agents to treat rheumatoid arthritis (RA).<unk>
T-602	hf patients rheumatoid_arthritis ra
H-602	-1.3117707967758179	▁ HF ▁ HF ▁rhe um ato id _ ar thri tis RA
D-602	-1.3117707967758179	HF HF rheumatoid_arthritisRA
P-602	-1.7484 -0.2580 -3.1409 -0.2833 -4.5259 -0.3589 -0.6524 -2.1788 -0.4658 -1.3082 -0.2971 -1.0305 -3.0842 -0.1912 -0.1530
S-1516	Customized homogeneous sandwich AlphaLISA® immunoassays were developed and validated to quantify 6 fragments of NT-proBNP.<unk>
T-1516	alphalisa immunoassays nt-probnp
H-1516	-0.5978441834449768	▁sandwich ▁Alpha LIS a ▁immun o assa ys ▁NT - pro B NP
D-1516	-0.5978441834449768	sandwich AlphaLISa immunoassays NT-proBNP
P-1516	-2.6354 -1.2013 -0.2241 -1.2359 -0.9025 -0.1534 -0.1667 -1.2977 -0.0819 -0.0298 -0.0059 -0.6917 -0.0069 -0.2548 -0.0798
S-460	β-Blocker-induced enhancement of cardiac angiogenesis is essential for the favorable effects of this therapy on cardiac function and remodeling.<unk>
T-460	cardiac_angiogenesis therapy cardiac_function remodeling
H-460	-0.8761000633239746	Block er - indu ced ▁cardiac _ ▁ang io gene sis ▁ therapy ▁cardiac _ function ▁remodel ing
D-460	-0.8761000633239746	Blocker-induced cardiac_ angiogenesis therapy cardiac_function remodeling
P-460	-1.1489 -0.0365 -1.4938 -0.0026 -1.9517 -1.6283 -1.1439 -1.0761 -0.9915 -0.2349 -0.7366 -1.2495 -0.0503 -0.1407 -1.1700 -3.9808 -0.2432 -0.0524 -0.1201 -0.0704
S-226	Twenty-seven symptomatic adult Fontan (SAF) patients who underwent catheterization from 2001 to 2011 constituted our study group.<unk>
T-226	symptomatic_adult_fontan saf patients catheterization
H-226	-1.9986578226089478	▁figure
D-226	-1.9986578226089478	figure
P-226	-3.8220 -2.0175 -0.1565
S-63	Two reviewers selected citations that included ambulatory ICD patients and addressed the association between any predictor and mortality using multivariable regression.<unk>
T-63	ambulatory icd patients mortality multivariable_regression
H-63	-0.5629839301109314	▁ambula tory ▁I CD ▁patients ▁predict or ▁mortal ity ▁multi vari able ▁re gression
D-63	-0.5629839301109314	ambulatory ICD patients predictor mortality multivariable regression
P-63	-0.0605 -0.1638 -1.1221 -0.0599 -3.1446 -0.7700 -0.0417 -1.3707 -0.1269 -0.1274 -0.0005 -0.0154 -1.7005 -0.0149 -0.1648 -0.1242
S-1328	We sought to investigate the effects of FES on the above parameters in patients with preserved ejection fraction (HFpEF).<unk>
T-1328	fes patients preserved_ejection_fraction hfpef
H-1328	-0.8526435494422913	▁F es ▁pres er ved _ ▁e je ction _ fraction HF p EF
D-1328	-0.8526435494422913	Fes preserved_ ejection_fractionHFpEF
P-1328	-2.2877 -0.2960 -2.7457 -0.0301 -1.8478 -0.5878 -1.7982 -2.4516 -0.1339 -0.4945 -0.0480 -0.4679 -0.0073 -0.2232 -0.1217 -0.1007
S-955	Despite of its known cardiotoxicity, doxorubicin is still a highly effective anti-neoplastic agent in the treatment of several cancers.<unk>
T-955	cardiotoxicity doxorubicin anti-neoplastic_agent
H-955	-0.29538416862487793	▁cardio toxic ity ▁do xor ubi cin ▁anti - neo plast ic ▁agent ▁cancer s
D-955	-0.29538416862487793	cardiotoxicity doxorubicin anti-neoplastic agent cancers
P-955	-0.0268 -0.2347 -0.9806 -0.0428 -0.0148 -0.0415 -0.0231 -0.0987 -0.0573 -0.1574 -0.0699 -0.2749 -1.5778 -0.8295 -0.3764 -0.1488 -0.0665
S-1289	With similar incidence in MT and VAD groups, ACS consultations and operations are infrequent with high mortality and morbidity.<unk>
T-1289	incidence vad acs consultations operations mortality morbidity
H-1289	-0.9417144060134888	▁MT ▁ VAD ▁a CS ▁mortal ity ▁morbi d ity
D-1289	-0.9417144060134888	MT VAD aCS mortality morbidity
P-1289	-3.0808 -0.6757 -0.0574 -1.6842 -0.5125 -4.0433 -0.3415 -0.2391 -0.0476 -0.3540 -0.1515 -0.1130
S-1421	INTERPRETATION: Early physician follow-up after discharge and physician continuity were both associated with better outcomes among patients with heart failure.<unk>
T-1421	physician follow-up discharge physician outcomes patients heart_failure
H-1421	-0.9819496273994446	▁physician _ ▁follow - up _ ▁after _ dis charge ▁physician _ ▁continu ity ▁patients ▁heart _ ▁failure
D-1421	-0.9819496273994446	physician_ follow-up_ after_discharge physician_ continuity patients heart_ failure
P-1421	-0.2870 -1.0598 -2.9392 -0.0563 -0.0062 -0.9818 -1.7170 -0.6367 -0.0553 -0.0069 -0.0182 -1.1949 -1.0178 -0.1230 -1.7783 -3.3429 -1.1389 -3.1005 -0.1117 -0.0665
S-1354	Patients in sinus rhythm may benefit from antiplatelet agents or anticoagulants, but much work remains to establish efficacy and safety.<unk>
T-1354	patients sinus_rhythm antiplatelet_agents anticoagulants
H-1354	-0.48761531710624695	▁sinus ▁ rhythm ▁anti plate let ▁agents ▁antico a gul ants ▁ef fica cy
D-1354	-0.48761531710624695	sinus rhythm antiplatelet agents anticoagulants efficacy
P-1354	-2.0692 -0.7686 -0.0947 -0.0627 -0.8266 -0.9195 -0.2570 -0.5472 -0.3356 -0.2064 -0.0325 -0.3274 -0.0019 -0.5780 -0.6623 -0.1122
S-1011	Both measures predicted death equally (C-statistics: 0.687 for biological phenotype and 0.700 for deficit index).<unk>
T-1011	death c-statistics biological_phenotype deficit_index
H-1011	-0.4591895043849945	▁c - stat istic s ▁bi ological _ ▁ph eno type ▁deficit
D-1011	-0.4591895043849945	c-statistics biological_ phenotype deficit
P-1011	-0.5622 -0.6654 -0.0031 -0.0330 -0.0202 -0.1448 -0.2473 -1.9396 -1.1745 -0.0371 -0.0290 -0.0366 -1.3769 -0.1590
S-22	In developed countries, at least 38–54% of patients with heart failure show preserved left ventricular (LV) ejection fraction.<unk>
T-22	patients heart_failure left_ventricular ejection_fraction
H-22	-1.4239672422409058	▁vent ri cular ▁e je ction _ fraction
D-22	-1.4239672422409058	ventricular ejection_fraction
P-22	-5.9964 -0.6852 -0.2936 -4.8565 -0.3913 -0.0299 -1.3747 -0.0060 -0.3926 -0.2135
S-966	Interestingly, nicorandil did not interfere with cytotoxic effect of doxorubicin against the growth of solid Ehrlich carcinoma.<unk>
T-966	nicorandil cytotoxic doxorubicin ehrlich_carcinoma
H-966	-0.3952764868736267	▁nic oran dil ▁cy to toxic ▁effect ▁do xor ubi cin ▁solid ▁Eh r lich ▁car cino ma
D-966	-0.3952764868736267	nicorandil cytotoxic effect doxorubicin solid Ehrlich carcinoma
P-966	-0.3263 -0.0257 -0.2675 -0.3979 -0.0278 -0.0396 -2.1752 -0.0826 -0.0217 -0.0296 -0.0187 -1.8943 -0.1573 -0.0179 -0.5564 -1.2273 -0.0632 -0.2722 -0.2241 -0.0803
S-1858	Few studies have reported the patient's perspective on the timing of implantable cardioverter-defibrillator deactivation discussions.<unk>
T-1858	reported patient implantable_cardioverter-defibrillator
H-1858	-0.56341952085495	▁implant able ▁implant able _ ▁cardio ver ter - de _ fi br illa tor _ de _ activa tion
D-1858	-0.56341952085495	implantable implantable_ cardioverter-de_fibrillator_de_activation
P-1858	-0.0067 -0.0204 -1.6234 -0.0315 -0.7874 -1.9803 -0.1125 -0.0164 -0.7201 -0.0066 -1.1570 -3.5672 -0.7681 -0.0073 -0.1397 -0.2077 -0.0351 -0.7897 -0.0343 -0.0262 -0.2897 -0.0679
S-1371	Renal denervation (DNx) in CHF patients has resulted in symptomatic improvement, but the protective mechanisms remain unclear.<unk>
T-1371	renal_denervation dnx chf patients symptomatic
H-1371	-0.7816212177276611	▁Ren al _ den er va tion ▁d x ▁CHF
D-1371	-0.7816212177276611	Renal_denervation dx CHF
P-1371	-0.3457 -0.2772 -0.3646 -2.0485 -0.2566 -0.4157 -0.1105 -3.0481 -0.0797 -0.4224 -1.8756 -0.1350
S-24	LV diastolic dysfunction, either alone or in combination with other factors (figure 1), is the major underlying mechanism of HFPEF.<unk>
T-24	lv_diastolic_dysfunction combination figure hfpef
H-24	-1.002715826034546	▁LV _ ▁dia sto lic _ ▁dys function ▁h f f
D-24	-1.002715826034546	LV_ diastolic_ dysfunction hff
P-24	-0.1583 -2.1569 -2.2422 -0.7308 -3.5331 -0.3695 -0.1488 -0.5143 -0.5467 -1.0936 -0.2653 -1.1600 -0.1159
S-1019	Measurement of natriuretic peptides at the point of care in the emergency and ambulatory setting: current status and future perspectives.<unk>
T-1019	natriuretic_peptides point_of_care ambulatory
H-1019	-0.9029357433319092	▁na tri ure _ pe pti des ▁point _ de _ care ▁ambula tory
D-1019	-0.9029357433319092	natriure_peptides point_de_care ambulatory
P-1019	-0.0373 -0.0093 -0.1457 -3.8682 -1.5304 -0.1808 -0.2199 -2.5175 -0.1223 -1.4511 -0.0545 -2.0018 -0.9804 -0.3238 -0.9363 -0.0678
S-593	Myxomas are the most common type of cardiac benign tumors and most of them are located in the left atrium, followed by the right atrium.<unk>
T-593	myxomas cardiac benign_tumors left_atrium right_atrium
H-593	-0.6470087170600891	▁My xo mas ▁cardiac ▁benign ▁tumor s
D-593	-0.6470087170600891	Myxomas cardiac benign tumors
P-593	-2.5841 -0.0081 -0.1050 -0.3603 -0.6986 -0.1656 -0.0459 -1.7682 -0.0873
S-1077	Significant progress has been achieved in the development of lifesaving drugs for HF with reduced ejection fraction (HFrEF).<unk>
T-1077	drugs hf_with_reduced_ejection_fraction hfref
H-1077	-1.2023481130599976	▁life sa ving ▁drugs ▁ HF ▁h r EF
D-1077	-1.2023481130599976	lifesaving drugs HF hrEF
P-1077	-2.9346 -1.0009 -1.5760 -1.1082 -1.2914 -0.0222 -2.9959 -0.5079 -1.1854 -0.5316 -0.0718
S-766	At 20 weeks, the lean ZSF1 group was hypertensive, whereas both obese ZSF1 groups were hypertensive and diabetic.<unk>
T-766	zsf1 hypertensive obese zsf1 hypertensive diabetic
H-766	-0.796518087387085	▁lean ▁Z SF 1 ▁hyper tensi ve ▁obes e ▁Z SF 1 ▁hyper tensi ve ▁diabet ic
D-766	-0.796518087387085	lean ZSF1 hypertensive obese ZSF1 hypertensive diabetic
P-766	-0.1715 -1.5128 -0.1600 -2.0511 -3.2764 -0.3258 -0.3220 -0.5252 -0.0595 -0.7439 -0.1161 -0.9400 -3.0691 -0.2661 -0.6315 -0.1184 -0.5806 -0.1895 -0.0743
S-1659	Gastrointestinal bleeding is not uncommon and is reported to occur in 13% to 44% of patients treated with ventricular assist devices.<unk>
T-1659	gastrointestinal_bleeding reported patients ventricular_assist_devices
H-1659	-0.4358147382736206	▁Gastro inte stin al _ ▁ble ed ing ▁vent ri cular _ assist ▁devices
D-1659	-0.4358147382736206	Gastrointestinal_ bleeding ventricular_assist devices
P-1659	-0.2171 -0.0184 -0.5184 -0.2211 -1.3310 -0.4394 -0.4618 -0.3142 -0.0230 -0.0631 -0.1085 -0.2755 -0.1204 -2.7042 -0.0760 -0.0810
S-444	Crude rates of severe hyperkalemia and acute kidney injury during spironolactone use were similar to that seen in clinical trials.<unk>
T-444	hyperkalemia acute_kidney_injury spironolactone clinical
H-444	-0.5481365323066711	▁hyper kal emia ▁a cute _ ▁ki dne y ▁injury ▁spi rono lac tone
D-444	-0.5481365323066711	hyperkalemia acute_ kidney injury spironolactone
P-444	-2.2300 -0.3592 -0.0991 -0.8887 -0.0041 -0.2542 -2.0578 -0.4745 -0.1735 -1.2702 -0.0094 -0.0156 -0.2053 -0.0971 -0.5708 -0.0607
S-1949	BACKGROUND: In patients with heart failure, interventions to reduce elevated left atrial pressure improve symptoms and reduce the risk of hospital admission.<unk>
T-1949	patients heart_failure elevated left_atrial_pressure symptoms hospital admission
H-1949	-1.49198317527771	▁heart _ pu issa nce ▁figure ▁hospital _ ad mission
D-1949	-1.49198317527771	heart_puissance figure hospital_admission
P-1949	-1.5955 -0.9690 -5.8140 -0.0994 -0.0129 -5.3647 -2.1271 -1.3124 -0.3601 -0.0135 -0.1686 -0.0664
S-1366	Recently, the diagnostic roles of BNP and NT-proBNP in patients with coronary artery disease (CAD) have been investigated.<unk>
T-1366	diagnostic bnp nt-probnp patients coronary_artery_disease cad
H-1366	-0.785443127155304	▁b NP ▁NT - pro B NP ▁corona ry _ ▁arter y _ de _ ca pit aux
D-1366	-0.785443127155304	bNP NT-proBNP coronary_ artery_de_capitaux
P-1366	-0.2525 -0.3563 -1.2190 -0.0226 -0.0052 -0.4334 -0.0501 -0.3844 -0.5433 -0.8727 -0.9304 -0.4619 -0.8759 -2.5936 -0.2778 -1.8666 -1.4697 -2.5978 -0.4274 -0.0685
S-1220	Thus, activating myocardial PDE2 may represent a novel intracellular antiadrenergic therapeutic strategy in HF.<unk>
T-1220	myocardial pde2 intracellular antiadrenergic therapeutic hf
H-1220	-0.7039478421211243	▁my o card ial ▁p de 2 ▁intra cel lular _ anti ad r energi c ▁ therapeut ic ▁ HF
D-1220	-0.7039478421211243	myocardial pde2 intracellular_antiadrenergic therapeutic HF
P-1220	-3.2044 -0.2253 -0.0562 -0.0544 -2.3626 -0.2242 -0.7478 -1.0180 -0.6392 -0.0573 -1.1039 -0.0933 -0.4033 -0.2304 -0.6218 -0.3734 -0.7931 -0.1782 -0.6032 -2.2271 -0.6929 -0.1222 -0.1585
S-235	Comparison of predictors of heart failure-related hospitalization or death in patients with versus without preserved left ventricular ejection fraction.<unk>
T-235	heart hospitalization death patients preserved_left_ventricular_ejection_fraction
H-235	-1.3669683933258057	▁vent ri cular _ é je ction _ fraction
D-235	-1.3669683933258057	ventricular_éjection_fraction
P-235	-5.7846 -0.5426 -0.4888 -1.6597 -1.6385 -1.6072 -0.1337 -2.4522 -0.0314 -0.3157 -0.3822
S-590	CONCLUSIONS: Shortened LVET at ICU admission was a prognostic factor in patients with precapillary PH with heart failure.<unk>
T-590	shortened lvet icu admission prognostic patients precapillary_ph heart_failure
H-590	-1.134974718093872	▁ ICU _ ad mission ▁pre cap illa ry _ PH ▁heart _ ▁failure
D-590	-1.134974718093872	ICU_admission precapillary_PH heart_ failure
P-590	-1.7329 -0.4517 -4.1231 -0.8713 -0.0209 -0.4685 -0.5961 -0.0194 -0.6279 -1.2535 -1.6217 -2.2948 -1.5605 -2.0388 -0.3234 -0.1552
S-1810	Mammalian enabled (Mena) is a key regulator of cytoskeletal actin dynamics, which has been implicated in heart failure (HF).<unk>
T-1810	mammalian_enabled mena cytoskeletal_actin_dynamics heart_failure hf
H-1810	-1.0177738666534424	▁Mamma lian _ ▁enabled ▁Men a ▁cy tos kelet al _ act in _ ▁dynamic s ▁heart _ ▁failure HF
D-1810	-1.0177738666534424	Mammalian_ enabled Mena cytoskeletal_actin_ dynamics heart_ failureHF
P-1810	-1.0365 -0.2319 -0.9420 -1.7421 -2.2134 -0.0138 -4.1525 -0.8860 -0.0799 -0.0341 -0.3350 -1.5139 -1.5876 -0.5236 -1.0350 -0.0105 -0.1058 -0.3488 -4.1324 -1.2383 -0.1202 -0.1079
S-893	Reduced hospitalizations in severe, refractory congestive heart failure with peritoneal dialysis: a consecutive case series.<unk>
T-893	hospitalizations refractory_congestive_heart_failure peritoneal_dialysis
H-893	-0.6296002864837646	▁re frac tory _ con ges tive _ heart _ ▁failure ▁per ito ne al _ di al ysis
D-893	-0.6296002864837646	refractory_congestive_heart_ failure peritoneal_dialysis
P-893	-0.7786 -0.0405 -2.2537 -0.4745 -0.1895 -1.7571 -0.1286 -0.2388 -1.9598 -0.5642 -1.4369 -0.0790 -0.3550 -0.2379 -0.1211 -0.1980 -1.8344 -0.1395 -0.0609 -0.2606 -0.1130
S-916	BACKGROUND: Heart failure with preserved ejection fraction (HFPEF) involves failure of cardiovascular reserve in multiple domains.<unk>
T-916	heart_failure_with_preserved_ejection_fraction hfpef cardiovascular_reserve
H-916	-0.9381178617477417	▁Heart _ ▁failure ▁h f f f ▁cardiovascular _ ▁reserve
D-916	-0.9381178617477417	Heart_ failure hfff cardiovascular_ reserve
P-916	-0.3955 -0.6870 -3.6579 -1.7318 -0.4492 -0.2291 -1.2289 -1.6013 -0.3566 -0.5785 -0.2838 -0.0578
S-23	The prevalence of heart failure with preserved ejection fraction (HFPEF) is steadily increasing and its prognosis is poor.<unk>
T-23	prevalence heart_failure_with_preserved_ejection_fraction hfpef prognosis
H-23	-1.0152509212493896	▁heart _ pu issa nce ▁h f f
D-23	-1.0152509212493896	heart_puissance hff
P-23	-1.0788 -0.4530 -4.4651 -0.1071 -0.0026 -1.9527 -0.4043 -0.2027 -1.4047 -0.0814
S-337	Functional mitral stenosis (MS) frequently develops after ring annuloplasty for ischemic mitral regurgitation (MR).<unk>
T-337	functional_mitral_stenosis ring_annuloplasty ischemic_mitral_regurgitation
H-337	-0.5791822075843811	▁Fun ction al _ met ral _ ▁sten osis ▁m ▁ring ▁ann ulo plast y ▁ ische mic _ ▁mit ral _ re gur gi tation MR
D-337	-0.5791822075843811	Functional_metral_ stenosis m ring annuloplasty ischemic_ mitral_regurgitationMR
P-337	-1.0368 -0.0005 -0.1085 -0.6352 -3.5323 -0.0218 -0.7024 -0.6357 -0.0325 -0.8432 -1.6971 -1.2989 -0.2513 -0.0248 -0.0837 -0.4635 -0.0867 -0.0879 -0.5926 -3.0553 -0.0135 -0.4596 -0.7283 -0.0074 -0.0200 -0.0047 -0.0705 -0.2181 -0.0832
S-1966	In this regard, first results of studies with ARNI inhibitors (angiotensin-receptor neprilysin inhibitors) may be considered hopeful.<unk>
T-1966	arni_inhibitors angiotensin-receptor_neprilysin_inhibitors
H-1966	-0.6180717945098877	▁AR NI ▁inhibi tors angi oten sin - recept or _ ▁nepri ly sin ▁inhibi tors
D-1966	-0.6180717945098877	ARNI inhibitorsangiotensin-receptor_ neprilysin inhibitors
P-1966	-1.6178 -0.3847 -1.1353 -0.7583 -0.3006 -0.1718 -1.9392 -0.8258 -0.0305 -0.2224 -0.2720 -0.9234 -0.1763 -0.5274 -0.6424 -1.0142 -0.1264 -0.0568
S-651	Myocardial loss of IRS1 and IRS2 causes heart failure and is controlled by p38alpha MAPK during insulin resistance.<unk>
T-651	myocardial irs1 irs2 heart_failure p38alpha mapk insulin_resistance
H-651	-0.8253456950187683	▁My o card ial ▁loss ▁I RS 1 ▁i RS 2 ▁heart _ ▁failure ▁MA PK ▁insulin _ ▁resist ance
D-651	-0.8253456950187683	Myocardial loss IRS1 iRS2 heart_ failure MAPK insulin_ resistance
P-651	-2.2256 -0.0339 -0.0322 -0.0130 -1.1259 -0.9256 -0.0447 -1.7624 -1.0742 -0.2761 -0.5811 -0.8075 -1.5033 -1.6696 -3.1186 -0.0433 -0.0401 -1.6465 -0.9557 -0.0028 -0.1366 -0.1391
S-236	Heart failure with preserved ejection fraction (HFpEF) is recognized as a major cause of cardiovascular morbidity and mortality.<unk>
T-236	heart_failure_with_preserved_ejection_fraction hfpef cardiovascular_morbidity mortality
H-236	-0.6326397657394409	▁Heart _ per er ved _ ▁e je ction _ fraction HF p EF ▁cardiovascular _ ▁morbi d ity ▁mortal ity
D-236	-0.6326397657394409	Heart_pererved_ ejection_fractionHFpEF cardiovascular_ morbidity mortality
P-236	-0.2059 -0.2949 -5.5470 -1.0571 -0.6987 -0.2611 -1.6784 -1.0480 -0.0198 -0.2865 -0.0214 -1.1245 -0.0167 -0.3363 -0.1480 -0.9428 -0.2232 -0.0668 -0.1727 -0.1018 -0.1339 -0.0797 -0.0855
S-1851	We will identify the common elements of successful and failing interventions, and examine the context in which they were applied, using the Process Redesign contextual framework.<unk>
T-1851	
H-1851	-1.2178075313568115	
D-1851	-1.2178075313568115	
P-1851	-2.3880 -0.0476
S-573	No significant differences were found for peak aerobic capacity, left-hand grip strength, body weight, waist circumference, or symptoms of anxiety.<unk>
T-573	symptoms
H-573	-0.8474465012550354	▁pe ak _ ▁aero bic _ ▁capacity ▁left - hand _ ▁grip _ ▁strength ▁body _ weight ▁wa ist _ ▁circum ferenc e ▁anxiety
D-573	-0.8474465012550354	peak_ aerobic_ capacity left-hand_ grip_ strength body_weight waist_ circumference anxiety
P-573	-5.2019 -0.0681 -0.1897 -1.1686 -0.2329 -2.3030 -2.6290 -1.1189 -0.0839 -0.0472 -0.3962 -0.5108 -1.0560 -1.4682 -1.0557 -0.8338 -0.7954 -1.0505 -0.2099 -0.5454 -0.1678 -0.0520 -0.1241 -0.4976 -0.1290 -0.0977
S-713	The first to identify clinical variables contributing to survival between the 2 groups, and the second to determine the additional risk associated with assignment to ECCT.<unk>
T-713	clinical ecct
H-713	-1.4656500816345215	
D-713	-1.4656500816345215	
P-713	-2.8626 -0.0687
S-1883	However, there were nosignificant changes in control group (P>0.05) and their changes were smaller than those in exercise group (P < 0.01).<unk>
T-1883	nosignificant exercise
H-1883	-0.7507634162902832	
D-1883	-0.7507634162902832	
P-1883	-1.4592 -0.0424
S-1512	Moreover, there is yet to be established a common consensus regarding the circulating forms of NT-proBNP being used in current assays.<unk>
T-1512	nt-probnp
H-1512	-0.6173911094665527	▁circula ting _ ▁form s ▁NT - pro B NP
D-1512	-0.6173911094665527	circulating_ forms NT-proBNP
P-1512	-0.5471 -1.9826 -1.4500 -0.9014 -0.0334 -1.3762 -0.0432 -0.0120 -0.5818 -0.0539 -0.3247 -0.1023
S-1348	The 8- to 9-s PVF was incidentally produced during the ascending phase of a PB cycle, followed by another 12-s recovery period of low BP.<unk>
T-1348	pvf pb bp
H-1348	-0.8753902316093445	▁PV f ▁ PB
D-1348	-0.8753902316093445	PVf PB
P-1348	-0.4139 -0.1930 -0.5598 -0.0607 -3.8863 -0.1386
S-881	The interaction between these 2 simple ECG parameters and their effect on CRT has not been systematically assessed in a large-scale clinical trial.<unk>
T-881	ecg crt clinical
H-881	-0.923422634601593	▁e CG ▁c RT
D-881	-0.923422634601593	eCG cRT
P-881	-1.2039 -0.1057 -3.2141 -0.4641 -0.4822 -0.0705
S-407	Patients with high sST2 treated with low-dose BB had the highest cardiovascular event rate (2.08 events) and the highest cumulative hazard.<unk>
T-407	patients sst2 cardiovascular_event
H-407	-2.147610664367676	▁s st 2 ▁figure ▁cardiovascular ▁event
D-407	-2.147610664367676	sst2 figure cardiovascular event
P-407	-0.3052 -2.5502 -2.5456 -5.6073 -1.0123 -3.4746 -1.5698 -0.1157
S-690	For a median of 4.6 years of follow-up, 1385 of 3215 (43.1%) participants who experienced a HF hospitalization died.<unk>
T-690	follow-up hf hospitalization
H-690	-0.7581204175949097	▁ HF
D-690	-0.7581204175949097	HF
P-690	-0.7759 -0.1348 -2.0560 -0.0657
S-1985	The combination of exercise + diet was additive (complementary) for peak VO2 (joint effect, 2.5 mL/kg/min).<unk>
T-1985	combination exercise peak_vo2 joint
H-1985	-1.950783371925354	▁figure ▁VO 2 jo int
D-1985	-1.950783371925354	figure VO2joint
P-1985	-5.2401 -6.0748 -0.3342 -0.9391 -0.0119 -0.9563 -0.0991
S-447	Our findings suggest that the benefits of spironolactone in clinical practice may be reduced compared with other guideline-recommended medications.<unk>
T-447	spironolactone clinical medications
H-447	-1.2581976652145386	▁benefits ▁spi rono lac tone
D-447	-1.2581976652145386	benefits spironolactone
P-447	-3.1081 -2.9687 -0.0584 -0.3055 -0.2916 -2.0068 -0.0683
S-48	Limitations: Few trials have examined transfusions in patients with heart disease, and observational studies are potentially confounded by indication.<unk>
T-48	transfusions patients heart_disease
H-48	-0.7422019839286804	▁trans fusion s ▁heart ▁disease
D-48	-0.7422019839286804	transfusions heart disease
P-48	-0.1237 -0.0268 -0.0894 -1.6091 -3.0592 -0.2298 -0.0574
S-681	In this large cohort of older breast cancer patients, the rates of trastuzumb-related CHF are higher than those reported in clinical trials.<unk>
T-681	breast_cancer patients chf reported clinical
H-681	-0.9336470365524292	▁breast ▁cancer ▁patients ▁tras tuz um b - related ▁CHF
D-681	-0.9336470365524292	breast cancer patients trastuzumb-related CHF
P-681	-2.3001 -2.1135 -4.2606 -0.5264 -0.0040 -0.0668 -0.0568 -0.6954 -0.2489 -0.1560 -0.7177 -0.0576
S-779	Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction.<unk>
T-779	kansas_city_cardiomyopathy_questionnaire patients heart_failure reduced_ejection_fraction
H-779	-0.8850109577178955	▁Kansas ▁City ▁Card i om yo pathy _ ▁Question naire ▁heart _ ▁failure ▁e je ction _ fraction
D-779	-0.8850109577178955	Kansas City Cardiomyopathy_ Questionnaire heart_ failure ejection_fraction
P-779	-0.0688 -0.5916 -1.3411 -0.1633 -0.0297 -3.4677 -0.1851 -4.1535 -1.6475 -0.0009 -0.7856 -0.4536 -1.9105 -0.6438 -0.3865 -0.0121 -1.6241 -0.0046 -0.1085 -0.1216
S-479	Usefulness of tissue Doppler imaging for assessing left ventricular filling pressure in patients with stable severe systolic heart failure.<unk>
T-479	tissue_doppler left_ventricular_filling_pressure patients stable severe_systolic_heart_failure
H-479	-1.0519081354141235	▁tissu e ▁do pp ler _ ▁imagin g ▁left ▁vent ri cular _ ▁fill ing _ pu issa nce
D-479	-1.0519081354141235	tissue doppler_ imaging left ventricular_ filling_puissance
P-479	-2.8590 -0.6988 -0.6802 -0.0092 -0.5503 -2.7186 -0.4260 -0.0445 -0.2797 -0.1708 -0.5808 -0.1594 -1.8376 -1.2695 -0.3870 -0.9282 -4.0343 -0.0490 -0.0325 -4.1789 -0.1959
S-273	A novel heart failure mice model of hypertensive heart disease by angiotensin II infusion, nephrectomy, and salt loading.<unk>
T-273	heart_failure hypertensive_heart_disease angiotensin_ii infusion nephrectomy salt_loading
H-273	-0.6075907349586487	▁heart _ ▁failure _ mi ce ▁hyper tensi ve ▁heart _ ▁disease ▁ang io ten sin _ ▁II ▁in fusion ▁nep hr ecto my ▁salt
D-273	-0.6075907349586487	heart_ failure_mice hypertensive heart_ disease angiotensin_ II infusion nephrectomy salt
P-273	-0.1654 -0.5316 -1.4588 -0.7807 -0.6621 -0.0132 -0.2247 -0.7396 -0.5758 -2.2306 -0.5727 -3.3081 -0.0045 -0.2691 -0.1776 -0.4135 -1.4230 -0.4388 -0.0035 -0.0034 -0.0695 -0.0967 -0.1463 -0.9991 -0.0013 -1.0015 -0.0940
S-1218	CONCLUSIONS: PDE2 is markedly up-regulated in failing hearts and desensitizes against acute β-AR stimulation.<unk>
T-1218	pde2 hearts acute β-ar
H-1218	-0.5939251184463501	▁p de 2 ▁fail ing ▁heart s ▁a cute ▁β - AR
D-1218	-0.5939251184463501	pde2 failing hearts acute β-AR
P-1218	-1.7354 -0.0560 -1.0242 -0.5977 -0.2662 -0.3770 -0.0675 -1.5123 -0.0194 -0.5277 -0.0074 -0.1289 -1.7199 -0.2754
S-148	Remote monitoring (RM) strategies have the potential to deliver specialised care and management and may be one way to meet the growing needs of the heart failure population.<unk>
T-148	remote_monitoring rm heart_failure
H-148	-1.5793663263320923	▁Remote _ monitor ing _ RM
D-148	-1.5793663263320923	Remote_monitoring_RM
P-148	-1.0941 -1.8245 -0.9684 -2.8217 -1.9053 -0.6813 -3.2156 -0.1241
S-1470	This review summarizes the principles of pharmacologic treatment, the underlying clinical trials, and new pharmacologic targets.<unk>
T-1470	pharmacologic clinical pharmacologic
H-1470	-0.6107486486434937	▁ pharma c ologic
D-1470	-0.6107486486434937	pharmacologic
P-1470	-0.1042 -0.0372 -0.0439 -0.1118 -3.3080 -0.0593
S-646	The prevalence of chronic heart failure in Hungary is 1.6% in the adult population, but it occurs in 15-20% of subjects over 80 years of age.<unk>
T-646	prevalence chronic_heart_failure hungary
H-646	-2.3458120822906494	▁chronic _ de _ ca pit aux _ de _ ca pit aux
D-646	-2.3458120822906494	chronic_de_capitaux_de_capitaux
P-646	-4.8943 -0.7715 -6.8375 -0.1220 -3.3710 -0.6633 -2.9338 -1.0586 -5.3976 -0.1056 -3.6404 -0.2437 -1.0570 -3.7166 -0.3743
S-397	A low eGFR, age <60 years, need of diuretics, and uncontrolled hypertension identify patients with an increased risk for ESRD.<unk>
T-397	egfr diuretics hypertension patients esrd
H-397	-0.4964856207370758	▁e G FR ▁di ure tics ▁hyper tension ▁ES RD
D-397	-0.4964856207370758	eGFR diuretics hypertension ESRD
P-397	-0.1563 -1.0963 -0.5199 -1.3845 -0.0880 -1.6398 -0.5526 -0.0015 -0.3134 -0.0151 -0.1044 -0.0862
S-1168	CONCLUSIONS: RV dysfunction and cardiac cachexia often coexist, have additive adverse impact, and might be mechanistically interrelated.<unk>
T-1168	rv_dysfunction cardiac_cachexia
H-1168	-0.78270423412323	▁ RV ▁dys function ▁cardiac _ ▁cache xia
D-1168	-0.78270423412323	RV dysfunction cardiac_ cachexia
P-1168	-0.5521 -0.1880 -0.9199 -0.6145 -0.0821 -1.2745 -2.4592 -0.5211 -1.0674 -0.1483
S-105	Time-dependent analysis was performed to identify the effect of IE on the risk for subsequent heart failure (HF) or death in CRT-D recipients.<unk>
T-105	heart_failure hf death crt-d
H-105	-1.7084758281707764	▁temps - dependent ▁i e ▁heart _ ▁failure ▁h c RT - d
D-105	-1.7084758281707764	temps-dependent ie heart_ failure hcRT-d
P-105	-2.0810 -1.9802 -0.1265 -4.4220 -3.6777 -3.4627 -0.8128 -2.9496 -1.3599 -2.2356 -0.8023 -0.1673 -0.7338 -0.5889 -0.2269
S-1664	Because of its age-dependent increase in incidence and prevalence, heart failure is one of the leading causes of death and hospitalisation among the elderly.<unk>
T-1664	incidence prevalence heart_failure leading death hospitalisation
H-1664	-1.6450047492980957	▁age - dependent
D-1664	-1.6450047492980957	age-dependent
P-1664	-3.5103 -0.2264 -0.2399 -4.0819 -0.1665
S-846	Mechanical dyssynchrony also occurs in patients with a narrow QRS complex, which suggests the potential usefulness of CRT in such patients.<unk>
T-846	patients narrow_qrs_complex crt patients
H-846	-0.5984902381896973	▁Mechanic al _ syn chron y ▁QR S _ ▁complex ▁c RT
D-846	-0.5984902381896973	Mechanical_synchrony QRS_ complex cRT
P-846	-0.1653 -0.0160 -0.2791 -0.4988 -0.0001 -0.4256 -1.8526 -1.4916 -2.0658 -0.2879 -0.5124 -0.2323 -0.3849 -0.1665
S-34	The target audience for this guideline includes all clinicians, and the target patient population is anemic or iron-deficient adult patients with heart disease.<unk>
T-34	clinicians patient anemic patients heart_disease
H-34	-1.3972886800765991	▁clinic ians ▁a ne mic ▁ir on - d eficient ▁adult ▁patients ▁heart
D-34	-1.3972886800765991	clinicians anemic iron-deficient adult patients heart
P-34	-4.9911 -0.9045 -1.5189 -0.0172 -0.6944 -0.9169 -0.0398 -0.1177 -0.0846 -0.4089 -2.5493 -2.7791 -3.2254 -2.6250 -0.0865
S-1561	The adjusted carotid intima-media thickness was 1.02±0.18 mm for psoriasis and 1.02±0.16 mm for reference subjects.<unk>
T-1561	carotid_intima-media_thickness psoriasis
H-1561	-0.5791993141174316	▁caro tid _ ▁intim a - media _ ▁thi ck ness ▁psoriasis
D-1561	-0.5791993141174316	carotid_ intima-media_ thickness psoriasis
P-1561	-0.3795 -0.1191 -0.8207 -0.8608 -0.0853 -0.1189 -0.0444 -0.7758 -2.4862 -0.2912 -1.8605 -0.0261 -0.1350 -0.1053
S-1565	Psoriasis patients with predominantly mild disease from the general population are as likely to develop atherosclerosis and cardiovascular events as subjects without psoriasis.<unk>
T-1565	psoriasis patients disease atherosclerosis cardiovascular_events psoriasis
H-1565	-0.8754673600196838	▁p sori asis ▁patients ▁at hero sc ler osis ▁cardiovascular ▁events ▁psoriasis
D-1565	-0.8754673600196838	psoriasis patients atherosclerosis cardiovascular events psoriasis
P-1565	-2.9819 -0.0084 -0.1487 -2.7582 -1.9054 -0.0832 -1.5149 -0.9921 -0.0491 -0.1916 -1.1435 -0.1617 -0.2405 -0.0774
S-510	Complete coronary occlusion was necessary for significant collateral growth, which mostly had occurred already during the first wk after the stent occlusion.<unk>
T-510	coronary_occlusion collateral_growth stent
H-510	-0.31343165040016174	▁corona ry ▁oc clusi on ▁col lateral _ ▁growth ▁sten t ▁oc clusi on
D-510	-0.31343165040016174	coronary occlusion collateral_ growth stent occlusion
P-510	-0.3296 -0.6577 -0.2398 -0.1929 -0.3060 -0.3233 -0.0044 -1.4049 -0.8402 -0.1110 -0.0178 -0.2261 -0.0364 -0.1577 -0.1053 -0.0617
S-1947	However, despite aggressive dose uptitration, many patients did not achieve this target as they had little HR reduction with beta-blocker therapy.<unk>
T-1947	uptitration patients hr_reduction beta-blocker therapy
H-1947	-0.9751542806625366	▁aggressiv e ▁dose _ up tit ration ▁HR ▁re duction ▁beta - block er
D-1947	-0.9751542806625366	aggressive dose_uptitration HR reduction beta-blocker
P-1947	-3.6136 -0.0882 -1.6248 -1.4587 -0.4948 -0.4847 -0.0168 -0.7071 -3.6708 -0.0135 -0.7024 -0.0201 -0.1270 -0.0555 -2.4220 -0.1024
S-678	Among trastuzumab users, the rate of CHF was 29.4% compared with 18.9% in nontrastuzumab users (P < .001).<unk>
T-678	trastuzumab chf nontrastuzumab_users
H-678	-0.45858460664749146	▁tras tuz um ab ▁CHF ▁non tras tuz um ab
D-678	-0.45858460664749146	trastuzumab CHF nontrastuzumab
P-678	-0.4016 -0.0074 -0.0812 -0.2888 -0.3701 -2.0120 -0.0999 -0.0137 -0.0367 -0.3676 -1.7646 -0.0596
S-1026	Point-of-care systems could be used to assess NP levels in the ED and community outpatient settings to monitor the risk of acute heart failure.<unk>
T-1026	point-of-care outpatient acute_heart_failure
H-1026	-1.3796815872192383	▁point - of - care s ▁ NP ▁ NP
D-1026	-1.3796815872192383	point-of-cares NP NP
P-1026	-1.0374 -0.3232 -0.0405 -0.0262 -0.1189 -3.6892 -1.1159 -0.0144 -4.1424 -0.2044 -5.3069 -0.5370
S-129	Higher EO-CFUs were associated with reduced mortality (hazard ratio, 0.25; 95% confidence interval, 0.09-0.69).<unk>
T-129	eo-cfus mortality hazard_ratio confidence_interval
H-129	-1.3941599130630493	▁ EO - c FU s
D-129	-1.3941599130630493	EO-cFUs
P-129	-2.2100 -0.0909 -0.0930 -1.3950 -1.6388 -1.5869 -3.9434 -0.1952
S-1443	Compared with baseline, isoprenaline infusion increased SDQT in HNorm subjects (P = 0.02) but not in HF patients.<unk>
T-1443	baseline isoprenaline infusion sdqt hf patients
H-1443	-0.34320318698883057	▁iso pren a line ▁in fusion ▁SD QT ▁h Nor m ▁ HF
D-1443	-0.34320318698883057	isoprenaline infusion SDQT hNorm HF
P-1443	-0.6109 -0.0353 -0.3356 -0.0788 -0.8564 -0.0600 -0.0159 -0.7106 -0.1187 -0.9650 -0.0065 -0.7323 -0.0417 -0.4857 -0.0944
S-1150	However, the contributions of the four major HF remodeling aspects in extending EMD in the dyssynchronous failing heart remain unknown.<unk>
T-1150	hf remodeling emd dyssynchronous_failing_heart
H-1150	-0.5763088464736938	▁ HF ▁remodel ing ▁EM d ▁dys syn chron ous _ ▁fail ing ▁heart
D-1150	-0.5763088464736938	HF remodeling EMd dyssynchronous_ failing heart
P-1150	-0.2192 -0.0650 -1.9313 -0.0165 -0.4326 -0.2884 -0.0215 -0.0014 -0.0005 -3.3336 -0.6336 -0.6786 -0.1200 -1.1762 -0.1597 -0.1429
S-355	Consequently, surgery was not performed and aggressive medical treatment for HF and hypertension with vasodilators and diuretics was started.<unk>
T-355	surgery medical_treatment hf hypertension vasodilators diuretics
H-355	-0.581775963306427	▁surgery ▁ HF ▁hyper tension ▁vaso dila tors ▁di ure tics
D-355	-0.581775963306427	surgery HF hypertension vasodilators diuretics
P-355	-2.2911 -1.4492 -0.0239 -0.2408 -0.0032 -0.1243 -0.0308 -1.4993 -0.4958 -0.1073 -1.0172 -0.2181 -0.0621
S-1466	Acute heart failure (AHF) is defined as the rapid onset of, or changes in, the symptoms and signs of heart failure (HF).<unk>
T-1466	acute_heart_failure ahf symptoms heart_failure hf
H-1466	-1.141266107559204	▁a cute _ ▁heart _ ▁failure ▁a HF
D-1466	-1.141266107559204	acute_ heart_ failure aHF
P-1466	-0.5426 -0.1335 -0.3212 -2.0704 -0.4621 -2.3680 -3.1518 -0.5202 -1.7335 -0.1093
S-1734	Major clinical trials designed to analyze clinical outcomes using an aldosterone antagonist have been done in two groups with heart failure.<unk>
T-1734	clinical clinical outcomes aldosterone_antagonist heart_failure
H-1734	-0.8707935810089111	▁al do ster one _ ▁anta gon ist ▁heart _ ▁failure
D-1734	-0.8707935810089111	aldosterone_ antagonist heart_ failure
P-1734	-1.6445 -0.3824 -0.0965 -2.4502 -0.6637 -0.0829 -0.0643 -2.0747 -0.2068 -1.1359 -2.3961 -0.0857 -0.0366
S-449	BACKGROUND: Impaired angiogenesis in the post-myocardial infarction heart contributes to the progression to heart failure.<unk>
T-449	angiogenesis post-myocardial_infarction heart heart_failure
H-449	-0.8989943861961365	▁ang io gene sis ▁post - my o card ial _ ▁in far ction ▁heart
D-449	-0.8989943861961365	angiogenesis post-myocardial_ infarction heart
P-449	-0.3327 -3.0781 -0.3623 -2.0090 -0.2366 -0.0157 -1.9449 -0.4517 -0.2861 -0.2031 -1.1136 -0.3398 -1.8684 -0.1179 -0.4680 -2.3374 -0.1176
S-520	Ea, total arterial compliance (TAC), and end-systolic elastance (Ees) were calculated at baseline and after 8 months of treatment.<unk>
T-520	ea total_arterial_compliance tac end-systolic_elastance ees baseline
H-520	-0.8772343993186951	▁arterial _ comp te ▁ TAC ▁end - sy sto lic _ ▁elastan ce ▁e es
D-520	-0.8772343993186951	arterial_compte TAC end-systolic_ elastance ees
P-520	-1.0432 -1.5783 -1.4816 -2.1978 -1.0449 -0.0065 -0.3409 -0.0238 -1.3607 -0.4529 -3.2697 -1.1769 -0.0308 -0.5445 -0.6992 -0.0035 -0.4147 -0.1204
S-1098	Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction: a community study.<unk>
T-1098	heart_failure preserved_ejection_fraction myocardial_infarction
H-1098	-0.6390259861946106	▁heart _ ▁failure ▁e je ction _ fraction ▁my o card ial ▁in far ction
D-1098	-0.6390259861946106	heart_ failure ejection_fraction myocardial infarction
P-1098	-0.7493 -0.6404 -2.2495 -0.2639 -0.2115 -0.0187 -1.5488 -0.0191 -1.8755 -0.2168 -0.3030 -0.1601 -0.8614 -0.7790 -0.0842 -0.7379 -0.1444
S-978	Renal dysfunction was associated with all-cause mortality but not with cardiovascular events during the first 3 postoperative months after primary isolated CABG.<unk>
T-978	renal_dysfunction all-cause_mortality cardiovascular_events postoperative cabg
H-978	-1.1101503372192383	▁Ren al _ ▁dys function ▁cardiovascular e
D-978	-1.1101503372192383	Renal_ dysfunction cardiovasculare
P-978	-0.1596 -0.1568 -0.3204 -0.9512 -0.4577 -1.3888 -3.5044 -2.9422 -0.1103
S-304	CONCLUSIONS: Biventricular support using a HeartMate II LVAD and CentriMag RVAD resulted in limited mortality at hospital discharge.<unk>
T-304	biventricular_support heartmate_ii lvad centrimag rvad mortality hospital discharge
H-304	-0.8398367762565613	▁bi ven tri cular ▁support ▁Heart Mate _ ▁II ▁l VAD ▁Centri Mag _ r VAD
D-304	-0.8398367762565613	biventricular support HeartMate_ II lVAD CentriMag_rVAD
P-304	-1.6024 -0.1274 -0.0484 -1.4485 -1.8266 -0.5291 -0.3040 -1.1698 -0.9921 -1.3663 -0.0140 -0.0500 -0.4829 -1.4668 -1.5113 -0.1069 -1.8816 -0.1886
S-1448	Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation.<unk>
T-1448	genetic congestive_heart_failure haematopoietic_cell_transplantation
H-1448	-0.6220716834068298	▁an thra cycli ne ▁con ges tive ▁heart _ ▁failure ▁ha e mato po ie tique _ cell ▁transplant ation
D-1448	-0.6220716834068298	anthracycline congestive heart_ failure haematopoietique_cell transplantation
P-1448	-0.2597 -0.0538 -1.8647 -0.1241 -1.8078 -0.0691 -0.0438 -1.0511 -1.4148 -0.8689 -0.0278 -0.0314 -0.0348 -0.8584 -0.1972 -1.8976 -2.1581 -0.5273 -0.1320 -0.0119 -0.1736 -0.0778
S-1181	A simple validated clinical tool to predict the absence of coronary artery disease in patients with systolic heart failure of unclear etiology.<unk>
T-1181	clinical coronary_artery_disease patients systolic_heart_failure etiology
H-1181	-0.9940862655639648	▁corona ry _ ▁arter y ▁disease ▁sy sto lic _ heart _ ▁failure
D-1181	-0.9940862655639648	coronary_ artery disease systolic_heart_ failure
P-1181	-0.9184 -0.3761 -1.6053 -0.7349 -0.2874 -1.8540 -0.3169 -0.0877 -2.7418 -0.6817 -1.9457 -0.7702 -1.0210 -1.4820 -0.0882
S-1890	Other cardiovascular risk factors, such as diabetes mellitus, atrial fibrillation and coronary artery disease are prevalent in the HFpEF population.<unk>
T-1890	cardiovascular diabetes_mellitus atrial_fibrillation coronary_artery_disease hfpef
H-1890	-0.7490565776824951	▁diabetes ▁mell itus ▁at rial _ ▁fi bril lation ▁corona ry _ ▁arter y ▁disease ▁ HF p EF
D-1890	-0.7490565776824951	diabetes mellitus atrial_ fibrillation coronary_ artery disease HFpEF
P-1890	-2.8382 -0.4189 -0.1037 -0.0381 -0.0067 -0.4533 -1.5685 -0.0041 -0.0029 -0.0672 -0.5773 -1.5395 -0.4647 -1.0682 -5.0666 -0.8326 -0.0347 -0.0263 -0.1345 -0.3906 -0.0934
S-969	Renal dysfunction is related to long-term mortality and myocardial infarction after coronary artery bypass grafting (CABG).<unk>
T-969	renal_dysfunction mortality myocardial_infarction coronary_artery_bypass_grafting cabg
H-969	-0.6833387613296509	▁Ren al _ ▁dys function ▁long - term ▁mortal ity ▁my o card ial ▁in far ction ▁corona ry ▁arter y _ ▁by pass ▁graf ting CA BG
D-969	-0.6833387613296509	Renal_ dysfunction long-term mortality myocardial infarction coronary artery_ bypass graftingCABG
P-969	-0.0934 -0.1088 -0.6013 -1.1527 -0.3522 -3.6085 -0.0549 -0.3253 -1.6499 -0.2481 -0.8660 -0.0678 -0.0452 -0.0365 -0.2313 -0.3438 -0.0125 -0.1101 -0.5461 -0.6590 -1.1318 -0.8942 -1.9806 -0.0140 -0.0587 -3.0072 -1.9043 -0.0355 -0.2494 -0.1111
S-1953	Shunt implants were done after transseptal catheterisation with transoesophageal echocardiographic guidance under general anaesthesia.<unk>
T-1953	shunt implants transseptal_catheterisation transoesophageal_echocardiographic general_anaesthesia
H-1953	-0.6258506178855896	▁Shu nt ▁implant s ▁trans sept al ▁cat heter isation ▁trans o es op hage al ▁e cho car dio graphic ▁ana es the sia
D-1953	-0.6258506178855896	Shunt implants transseptal catheterisation transoesophageal echocardiographic anaesthesia
P-1953	-0.2784 -0.0333 -0.0086 -0.0818 -0.0055 -0.0540 -0.6980 -1.2758 -0.0022 -0.0472 -0.0009 -2.7894 -0.3006 -1.4068 -0.0147 -0.9150 -0.8581 -0.0638 -0.0739 -0.8927 -2.6666 -2.9654 -0.0156 -0.1546 -0.9022 -0.3141 -0.0789
S-1995	OBJECTIVES: The aim of this single-arm, prospective, multicenter study was to evaluate the performance and safety of this LVAS.<unk>
T-1995	prospective lvas
H-1995	-1.266021728515625	▁l VAS
D-1995	-1.266021728515625	lVAS
P-1995	-4.5694 -0.2680 -0.1341 -0.0927
S-260	CONCLUSIONS: These results demonstrate that HDL function is impaired in CHF and that ET improved the HDL-mediated vascular effects.<unk>
T-260	hdl chf vascular
H-260	-0.9186699390411377	▁HD L _ fon cti onnement ▁CHF ▁ET ▁HD L - media ted _ ▁vas cular ▁effects
D-260	-0.9186699390411377	HDL_fonctionnement CHF ET HDL-mediated_ vascular effects
P-260	-1.0242 -0.9782 -1.8670 -1.2581 -0.2404 -0.5384 -0.2201 -3.6537 -0.5356 -0.9968 -0.1688 -0.0857 -2.0126 -0.3758 -1.3118 -0.0332 -1.9699 -0.1283 -0.0561
S-1774	Within men matched for the same number of HF risk factors, fit men had significantly lower HF mortality than unfit men (P≤0.02).<unk>
T-1774	hf hf mortality
H-1774	-1.1889302730560303	▁ HF ▁ HF
D-1774	-1.1889302730560303	HF HF
P-1774	-0.3628 -0.0601 -2.4062 -0.1229 -4.0470 -0.1347
S-1853	Discussion and dissemination In this review, we will assess the impact of implementation strategies and contextual factors on physician adherence to HF CPGs.<unk>
T-1853	physician hf cpgs
H-1853	-0.8056403398513794	▁physician ▁ad her ence ▁ HF ▁c PG s
D-1853	-0.8056403398513794	physician adherence HF cPGs
P-1853	-4.2997 -0.4574 -0.1589 -0.0034 -0.5484 -0.0227 -2.6609 -0.2066 -0.0882 -0.1428 -0.2730
S-522	RESULTS: At baseline Ea, TAC, HR, and Ees did not differ significantly between ivabradine- and placebo-treated patients.<unk>
T-522	baseline ea tac ees patients
H-522	-0.7593820095062256	▁ TAC ▁e es ▁i va bra dine - ▁place bo - tre ated
D-522	-0.7593820095062256	TAC ees ivabradine- placebo-treated
P-522	-2.0454 -0.0638 -3.5758 -0.0292 -0.0326 -0.0165 -0.4334 -0.0091 -1.1988 -1.7562 -0.0033 -0.0123 -0.0096 -1.7018 -1.1821 -0.0802
S-1256	These initial results warrant further rigorous investigation, since the use of ERC (or pure epicatechin) may represent a safe and novel means of improving muscle function.<unk>
T-1256	warrant erc epicatechin muscle
H-1256	-1.0941123962402344	▁ ERC ▁ ERC ▁epi cate chin
D-1256	-1.0941123962402344	ERC ERC epicatechin
P-1256	-0.5021 -0.0912 -2.2020 -0.2368 -4.2393 -0.0061 -0.5743 -1.8626 -0.1327
S-736	METHODS AND RESULTS: Patients with suspected HFPEF (n=100) were enrolled in this prospective, observational study.<unk>
T-736	patients hfpef prospective
H-736	-0.5392992496490479	▁h f f
D-736	-0.5392992496490479	hff
P-736	-0.6935 -0.1997 -0.2300 -1.5066 -0.0666
S-1628	CONCLUSION: Care management coupled with content-driven telehealth technology has potential to improve health outcomes in high-cost Medicare beneficiaries.<unk>
T-1628	telehealth health outcomes medicare
H-1628	-1.3569616079330444	▁Care _ management ▁content - driv en ▁tele health ▁technologie
D-1628	-1.3569616079330444	Care_management content-driven telehealth technologie
P-1628	-1.5022 -2.1449 -0.2293 -4.2776 -0.0130 -0.0102 -0.0261 -1.7796 -0.5258 -2.3309 -3.3475 -0.0966
S-78	The dopamine (n = 122) and nesiritide (n = 119) groups were independently compared with the pooled placebo group (n = 119).<unk>
T-78	dopamine nesiritide placebo
H-78	-0.30852383375167847	▁dop amine ▁nesi riti de
D-78	-0.30852383375167847	dopamine nesiritide
P-78	-0.0097 -0.0196 -0.1301 -0.0145 -0.0694 -1.8566 -0.0597
S-1127	Clinician interviews identified twice as many reasons for nonprescribing as chart review (mean 1.6 vs. 0.8 reasons per patient, P<0.001).<unk>
T-1127	clinician nonprescribing patient
H-1127	-1.2669841051101685	▁clinic ian
D-1127	-1.2669841051101685	clinician
P-1127	-2.0412 -0.4342 -2.5145 -0.0781
S-1128	In these interviews, biomedical reasons for nonprescribing were cited in 50%-70% of patients, and contextual reasons in 64%-70%.<unk>
T-1128	biomedical nonprescribing patients
H-1128	-0.4463304579257965	▁bio medic al ▁reasons _ for _ non pre scribi ng
D-1128	-0.4463304579257965	biomedical reasons_for_nonprescribing
P-1128	-0.0246 -0.0155 -0.0038 -0.4050 -1.4942 -1.6357 -0.5007 -0.2098 -0.0017 -0.0684 -0.4253 -0.9399 -0.0777
S-1639	The hazard associated with black race was largely caused by increased HF hospitalization (HR 1.58, 95% CI 1.27-1.96), given similar cardiovascular mortality.<unk>
T-1639	hf hospitalization cardiovascular_mortality
H-1639	-0.6847417950630188	▁black _ race ▁ HF ▁cardiovascular ▁mortal ity
D-1639	-0.6847417950630188	black_race HF cardiovascular mortality
P-1639	-0.6433 -1.7298 -1.0512 -0.6902 -0.0169 -1.2615 -0.9610 -0.1535 -0.1519 -0.1881
S-1393	Improvement in eGFR in the VAD group and the ECMO+VAD group was much higher than in the ECMO group in the first 7 days.<unk>
T-1393	egfr vad ecmo vad ecmo
H-1393	-1.2906235456466675	▁e G FR ▁ VAD ▁EC mo _ VAD
D-1393	-1.2906235456466675	eGFR VAD ECmo_VAD
P-1393	-0.0948 -1.2304 -0.6703 -0.2574 -0.1657 -0.8511 -1.3743 -1.7209 -5.4400 -2.1123 -0.2796
S-41	Data Sources: MEDLINE, EMBASE, and Cochrane databases; clinical trial registries; reference lists; and technical advisors.<unk>
T-41	medline embase cochrane clinical
H-41	-0.7987244725227356	▁MED LINE ▁ EMBA SE ▁co ch rane ▁clinic al _ tri es
D-41	-0.7987244725227356	MEDLINE EMBASE cochrane clinical_tries
P-41	-0.2765 -0.9503 -0.3416 -0.0009 -1.1286 -0.2688 -0.0426 -0.0026 -3.4617 -0.0536 -0.2458 -2.9024 -0.4009 -1.8033 -0.1013
S-1764	CONCLUSIONS: The inability to identify AT most often occurs in patients with severe HF, and it has an independent prognostic role in HF.<unk>
T-1764	patients severe_hf prognostic hf
H-1764	-0.9975268840789795	▁in ability ▁ HF
D-1764	-0.9975268840789795	inability HF
P-1764	-1.3224 -1.5232 -1.1896 -0.3634 -1.4557 -0.1308
S-1142	Pyridostigmine also increased vascular endothelial growth factor protein in the left ventricle, suggesting myocardial angiogenesis.<unk>
T-1142	pyridostigmine vascular_endothelial_growth_factor protein left_ventricle myocardial_angiogenesis
H-1142	-0.8449081182479858	▁Pyr ido stig mine ▁vas cular _ en dot heli al _ ▁growth _ factor _ ▁protein ▁left ▁vent ric le ▁my o card ial _ ang io gene sis
D-1142	-0.8449081182479858	Pyridostigmine vascular_endothelial_ growth_factor_ protein left ventricle myocardial_angiogenesis
P-1142	-0.0718 -0.1830 -0.0001 -0.2159 -0.0657 -0.0315 -0.8516 -0.9668 -1.5242 -0.0677 -0.0187 -1.7450 -1.1130 -1.7400 -1.0774 -1.2127 -1.7255 -0.3465 -1.0187 -3.9909 -0.4025 -1.2142 -0.1006 -0.2998 -0.1212 -0.3615 -2.5671 -2.6035 -0.2719 -0.9003 -0.1457 -0.0820
S-1775	CONCLUSIONS: Higher baseline CRF is associated with lower HF mortality risk in men, regardless of the number of HF risk factors present.<unk>
T-1775	baseline crf hf mortality hf
H-1775	-0.8343703150749207	▁base line ▁c RF ▁ HF ▁mortal ity
D-1775	-0.8343703150749207	baseline cRF HF mortality
P-1775	-0.6382 -0.1492 -1.2754 -0.3005 -0.2240 -0.3799 -2.1259 -0.1041 -3.0563 -0.0901
S-1904	Recent studies have demonstrated that even lower volumes of exercise below these recommendations confer health benefits, which is highly relevant to individuals with established cardiac disease including heart failure.<unk>
T-1904	exercise health cardiac_disease heart_failure
H-1904	-1.8465274572372437	
D-1904	-1.8465274572372437	
P-1904	-3.6600 -0.0331
S-1921	CONCLUSIONS: Robot-assisted gait therapy with the Lokomat® System is feasible in heart failure patients and was safe in this trial.<unk>
T-1921	gait therapy lokomat heart_failure patients
H-1921	-0.7436664700508118	▁Robot - assist ed _ ▁ga it ▁ therapy ▁Lok omat _ system ▁heart _ ▁failure
D-1921	-0.7436664700508118	Robot-assisted_ gait therapy Lokomat_system heart_ failure
P-1921	-0.4172 -0.1471 -0.0022 -0.1858 -1.2470 -1.4315 -0.0842 -1.2551 -0.0203 -0.1178 -0.0808 -2.5303 -2.6062 -0.4114 -0.4829 -1.6773 -0.6050 -0.0838
S-769	The latter occurred specifically at the S3991 site of the elastic N2Bus segment and at the S12884 site of the PEVK segment.<unk>
T-769	s3991 n2bus s12884 pevk
H-769	-1.1436097621917725	▁elastic _ n 2 bus _ ▁segment ▁PE V K
D-769	-1.1436097621917725	elastic_n2bus_ segment PEVK
P-769	-1.1701 -0.9663 -1.1970 -0.3660 -1.0538 -3.5652 -0.7040 -0.6290 -2.0389 -1.5343 -0.3488 -0.1499
S-92	The present study tests the fundamental hypothesis that cardiac growth and plasticity in the setting of disease recapitulates conserved developmental chromatin remodeling events.<unk>
T-92	tests cardiac_growth disease chromatin remodeling
H-92	-0.7316882014274597	▁cardiac _ ▁growth _ ▁plastic ity ▁disease ▁recap it ulat es ▁chr omat in ▁remodel ing
D-92	-0.7316882014274597	cardiac_ growth_ plasticity disease recapitulates chromatin remodeling
P-92	-0.1083 -2.1096 -2.6724 -1.3070 -1.5318 -0.2619 -0.4903 -1.3187 -0.0080 -0.0034 -0.1227 -0.4472 -0.0169 -1.5808 -0.1996 -0.0801 -0.8606 -0.0511
S-1433	Therefore, failing myocardium displays altered expression and post-translational modification of PKA subunits that may impact downstream signaling.<unk>
T-1433	myocardium expression pka downstream_signaling
H-1433	-1.0593246221542358	▁my o car dium ▁display s ▁p KA
D-1433	-1.0593246221542358	myocardium displays pKA
P-1433	-0.9652 -0.0559 -0.0115 -0.1522 -3.7366 -0.5573 -2.2181 -0.8898 -1.8360 -0.1707
S-416	METHODS AND RESULTS: CXL-1020 converts solely to HNO and inactive CXL-1051 with a t1/2 of 2 minutes.<unk>
T-416	cxl-1020 hno cxl-1051 t1
H-416	-0.6461372375488281	▁c XL -10 20 ▁convert s ▁h no ▁in active ▁c XL -10 51
D-416	-0.6461372375488281	cXL-1020 converts hno inactive cXL-1051
P-416	-1.5922 -0.6265 -1.5537 -0.7808 -1.0661 -0.3757 -0.2895 -0.4680 -0.0775 -0.0056 -0.7503 -0.2317 -1.2588 -0.5814 -0.5591 -0.1211
S-93	We used quantitative proteomics to identify chromatin-associated proteins extracted via detergent and to quantify changes in their abundance during disease.<unk>
T-93	proteomics chromatin-associated_proteins disease
H-93	-0.623779833316803	▁prote o mics ▁chr omat in - as soci ated ▁protein s ▁detergent
D-93	-0.623779833316803	proteomics chromatin-associated proteins detergent
P-93	-1.4541 -0.7656 -0.0023 -0.2319 -0.0149 -0.7199 -0.5894 -0.0600 -0.0005 -1.1219 -1.9142 -0.0461 -0.5640 -1.7794 -0.0925
S-213	OBJECTIVE: PROTOCOL: We classified patients as having CHF based on International Classification of Diseases, Ninth Revision, codes.<unk>
T-213	patients chf international_classification_of_diseases
H-213	-1.3559343814849854	▁CHF ▁code s
D-213	-1.3559343814849854	CHF codes
P-213	-1.0259 -5.4457 -0.0463 -0.2127 -0.0490
S-1742	We thus examined changes in prognosis of a large idiopathic dilated cardiomyopathy cohort systematically followed during the past 30 years.<unk>
T-1742	prognosis idiopathic_dilated_cardiomyopathy
H-1742	-0.6194554567337036	▁ idio pathi c _ ▁dil ated _ ▁cardio my o pathy
D-1742	-0.6194554567337036	idiopathic_ dilated_ cardiomyopathy
P-1742	-0.6066 -0.1998 -0.0871 -0.2827 -0.6651 -0.7161 -0.8571 -0.1988 -0.2601 -3.2850 -0.7946 -0.0563 -0.5573 -0.1059
S-867	Inappropriate therapy due to atrial fibrillation was associated with a 50% lower rate in patients receiving carvedilol compared with those receiving metoprolol.<unk>
T-867	therapy atrial_fibrillation patients carvedilol metoprolol
H-867	-0.5575554370880127	▁ therapy ▁at rial _ ▁fi bril lation ▁car vedi lol ▁met o pro lol
D-867	-0.5575554370880127	therapy atrial_ fibrillation carvedilol metoprolol
P-867	-3.7977 -0.4175 -0.4984 -0.0763 -0.6909 -2.3702 -0.0453 -0.0130 -0.6101 -0.1672 -0.0542 -0.3213 -0.0798 -0.0059 -0.0337 -0.2320 -0.0649
S-1163	RESULTS: Subjects with RV dysfunction (51%) had lower body mass index, lower fat mass index, and were more likely to display cachexia (19%).<unk>
T-1163	rv_dysfunction body_mass_index fat_mass cachexia
H-1163	-1.014092206954956	▁ RV _ ▁dys function ▁body _ ▁mass ▁index ▁figure ▁cache xia
D-1163	-1.014092206954956	RV_ dysfunction body_ mass index figure cachexia
P-1163	-0.1969 -0.1682 -1.5258 -0.4647 -0.6373 -4.2640 -0.4174 -1.4408 -0.4768 -3.4220 -0.5484 -0.2077 -0.3385 -0.0890
S-300	RESULTS: A total of 139 patients required HeartMate II insertion; 34 (24%) required biventricular support at the time of HeartMate II implantation.<unk>
T-300	patients heartmate_ii biventricular_support heartmate_ii implantation
H-300	-0.6770092844963074	▁Heart Mate _ ▁II ▁implant ation
D-300	-0.6770092844963074	HeartMate_ II implantation
P-300	-1.5488 -0.6219 -1.2313 -0.7721 -0.8304 -0.0340 -0.2532 -0.1243
S-1016	As a result, pharmacologic management for acute HF has changed little in recent years, and adverse event rates remain higher than in chronic HF.<unk>
T-1016	pharmacologic acute_hf adverse_event chronic_hf
H-1016	-0.5068752765655518	▁ pharma c ologic ▁management ▁a cute ▁ HF
D-1016	-0.5068752765655518	pharmacologic management acute HF
P-1016	-0.4630 -0.0285 -0.0173 -0.1395 -0.9335 -0.4847 -0.0109 -0.9898 -0.0192 -2.4147 -0.0746
S-611	CONCLUSIONS: TNF antagonists were not associated with a risk of HF hospital admissions compared with nbDMARDs in this RA population.<unk>
T-611	tnf_antagonists hf hospital admissions nbdmards ra
H-611	-0.7127610445022583	▁t NF _ ▁anta gon ists ▁ HF ▁hospital ▁ad missions ▁n b DM ARD s ▁RA
D-611	-0.7127610445022583	tNF_ antagonists HF hospital admissions nbDMARDs RA
P-611	-0.7885 -0.1032 -3.8334 -0.1121 -0.1413 -0.8456 -0.3635 -0.0607 -3.3681 -2.5652 -0.1105 -0.2732 -0.0163 -0.3312 -0.0124 -0.0576 -0.1945 -0.2774 -0.0878
S-954	Nicorandil ameliorates mitochondrial dysfunction in doxorubicin-induced heart failure in rats: possible mechanism of cardioprotection.<unk>
T-954	nicorandil mitochondrial_dysfunction heart_failure cardioprotection
H-954	-0.6450389623641968	▁Nico rand il ▁mito cho ndri al ▁dys function ▁do xor ubi cin - indu ced ▁heart _ ▁failure ▁cardio protec tion
D-954	-0.6450389623641968	Nicorandil mitochondrial dysfunction doxorubicin-induced heart_ failure cardioprotection
P-954	-0.0224 -1.1033 -1.5652 -0.2833 -1.9757 -0.2461 -0.0722 -0.4157 -0.1843 -0.0315 -0.0237 -0.0445 -0.1455 -0.3518 -0.0024 -2.2729 -0.3694 -1.0009 -2.4256 -2.5085 -0.0192 -0.0052 -0.3396 -0.0719
S-367	This patient showed that functional MS could develop even in a patient with successful valve plasty for degenerative MR, if the LV is dilated by another disease.<unk>
T-367	patient functional_ms patient valve_plasty degenerative_mr dilated disease
H-367	-0.4187420606613159	▁functional ▁MS ▁val ve ▁plast y ▁de genera tive ▁MR ▁LV
D-367	-0.4187420606613159	functional MS valve plasty degenerative MR LV
P-367	-0.5467 -0.0501 -0.8941 -0.0069 -0.4572 -0.3508 -1.2766 -0.1430 -0.0180 -0.2134 -0.3621 -1.0629 -0.0616
S-1105	Changes in patient presentation were noted, including fewer ST-segment-elevation MIs, lower Killip class, and more comorbid conditions.<unk>
T-1105	patient st-segment-elevation_mis killip_class comorbid conditions
H-1105	-0.5259977579116821	▁st - seg ment - elevat ion ▁Kill ip ▁conditions
D-1105	-0.5259977579116821	st-segment-elevation Killip conditions
P-1105	-2.6348 -0.1933 -0.0113 -0.0262 -0.1685 -0.0104 -0.0171 -2.9620 -0.0837 -0.0236 -0.0997 -0.0816
S-1993	BACKGROUND: The HeartMate 3 left ventricular assist system (LVAS) is intended to provide long-term support to patients with advanced heart failure.<unk>
T-1993	heartmate left_ventricular_assist_system lvas patients heart_failure
H-1993	-1.0520621538162231	▁Heart Mate ▁left _ vent ri cular _ assist _ system ▁l VAS
D-1993	-1.0520621538162231	HeartMate left_ventricular_assist_system lVAS
P-1993	-0.2468 -0.8044 -2.5558 -0.9434 -0.8982 -0.6752 -0.4857 -0.4503 -0.1334 -3.2844 -0.8801 -1.2454 -0.0389 -3.0312 -0.1079
S-1860	DESIGN: Grounded theory was used to collect and analyze interview data from 25 heart failure patients with an implantable cardioverter-defibrillator.<unk>
T-1860	collect heart_failure patients implantable_cardioverter-defibrillator
H-1860	-0.555851936340332	▁implant able _ ▁cardio ver ter - de fi br illa tor
D-1860	-0.555851936340332	implantable_ cardioverter-defibrillator
P-1860	-0.3559 -0.0374 -0.7297 -2.8949 -0.0771 -0.0234 -0.6259 -0.0050 -2.0968 -0.2602 -0.0076 -0.0762 -0.5166 -0.0753
S-17	The latter correlated inversely to baseline NT-proBNP, MR-proANP, and MR-proADM (p<0.05).<unk>
T-17	correlated baseline nt-probnp mr-proanp mr-proadm
H-17	-0.38899391889572144	▁base line ▁NT - pro B NP ▁MR - pro AN p ▁MR - pro AD m
D-17	-0.38899391889572144	baseline NT-proBNP MR-proANp MR-proADm
P-17	-1.3361 -0.8085 -0.0860 -0.0160 -0.0239 -0.9147 -0.0921 -0.0254 -0.0285 -0.0249 -1.3479 -0.9311 -0.0381 -0.0196 -0.0334 -1.2482 -0.2281 -0.1106 -0.0779
S-517	BACKGROUND: The effective arterial elastance (Ea) represents resistive and pulsatile afterload of the heart derived from the pressure volume relation.<unk>
T-517	arterial_elastance ea pulsatile_afterload heart pressure_volume_relation
H-517	-0.9296860694885254	▁arterial _ ▁elastan ce ▁pulsa tile _ ▁after load ▁heart ▁pressure
D-517	-0.9296860694885254	arterial_ elastance pulsatile_ afterload heart pressure
P-517	-0.4967 -1.4385 -0.2640 -0.3002 -0.8038 -0.0791 -0.8556 -3.0823 -0.0171 -2.7228 -0.1681 -1.7946 -0.0630
S-1099	Major changes have recently occurred in the epidemiology of myocardial infarction (MI) that could possibly affect outcomes such as heart failure (HF).<unk>
T-1099	epidemiology myocardial_infarction mi outcomes heart_failure hf
H-1099	-0.8920947313308716	▁epidemi ologie ▁my o card ial _ ▁in far ction ▁m ▁heart _ ▁failure HF
D-1099	-0.8920947313308716	epidemiologie myocardial_ infarction m heart_ failureHF
P-1099	-0.5774 -1.3388 -1.4857 -0.0975 -0.1782 -0.0513 -1.4066 -0.2424 -0.9495 -0.0263 -1.5932 -2.2691 -0.8156 -3.0922 -0.8512 -0.1105 -0.0801
S-585	Other prognostic factors at admission were higher serum levels of brain natriuretic peptide (BNP) and creatinine and lower natremia.<unk>
T-585	prognostic admission brain_natriuretic_peptide bnp creatinine natremia
H-585	-0.8679269552230835	▁brain _ ▁na tri ure tic _ pe pti de ▁b NP ▁creati nine ▁na trem ia
D-585	-0.8679269552230835	brain_ natriuretic_peptide bNP creatinine natremia
P-585	-3.5881 -1.2733 -0.2754 -0.0055 -0.1128 -5.1321 -0.5117 -0.2736 -0.4579 -0.4081 -0.3412 -0.1898 -0.0376 -0.1750 -0.1720 -0.0351 -3.2137 -0.2009 -0.0867
S-1663	Management of end stage heart failure Heart failure is a major public health problem, with a patient population of at least 10 million in Europe and approximately 5 million in North America.<unk>
T-1663	end_stage_heart_failure heart_failure public health patient europe north_america
H-1663	-1.4748728275299072	▁management _ de _ ▁end _ heart _ ▁failure _ ▁Heart _ ▁failure ▁public _ ▁health
D-1663	-1.4748728275299072	management_de_ end_heart_ failure_ Heart_ failure public_ health
P-1663	-3.3677 -0.8515 -1.0474 -0.1554 -0.5462 -0.1976 -2.9463 -0.3313 -3.3931 -2.6888 -1.3146 -0.6633 -2.9097 -1.1282 -0.3885 -1.6503 -2.8676 -0.1002
S-1597	Even though the majority of patients with RAS are asymptomatic, it can clinically present with hypertension, nephropathy and congestive heart failure.<unk>
T-1597	patients ras asymptomatic clinically hypertension nephropathy congestive_heart_failure
H-1597	-0.43608522415161133	▁ RAS ▁hyper tension ▁nep hro pathy ▁con ges tive ▁heart _ ▁failure
D-1597	-0.43608522415161133	RAS hypertension nephropathy congestive heart_ failure
P-1597	-1.2425 -0.0240 -0.1183 -0.0008 -0.7447 -0.0146 -0.0710 -0.0772 -0.1581 -0.1149 -1.4215 -1.4167 -0.8772 -0.1615 -0.0983
S-1430	Isoelectric focusing of RIα demonstrated up to three variants, consistent with reports that Ser77 and Ser83 are in vivo phosphorylation sites.<unk>
T-1430	isoelectric_focusing riα ser77 ser83 in_vivo phosphorylation
H-1430	-1.3394827842712402	▁Iso electric _ ▁focus ing ▁RI α ▁ser 77 ▁ser 83 ▁ phos phor y lation
D-1430	-1.3394827842712402	Isoelectric_ focusing RIα ser77 ser83 phosphorylation
P-1430	-2.0037 -0.2727 -2.6427 -0.9127 -0.0654 -2.0735 -0.7904 -2.0741 -2.0898 -3.9701 -1.0774 -1.3932 -0.1702 -0.8470 -2.1154 -0.0478 -1.3970 -0.1675
S-1504	The Self-Care of Heart Failure Index Version 6.2 (SCHFI v.6.2) is widely used, but its psychometric profile is still questioned.<unk>
T-1504	self-care_of_heart_failure_index_version_6.2 schfi_v.6.2 psychometric
H-1504	-0.5571739673614502	▁Self - Car e _ of _ ▁Heart _ ▁Fail ure ▁ SCH FI ▁psycho metric ▁profile
D-1504	-0.5571739673614502	Self-Care_of_ Heart_ Failure SCHFI psychometric profile
P-1504	-0.3063 -0.0281 -0.6045 -0.0291 -0.2820 -1.6907 -0.5439 -0.2017 -0.2081 -0.1657 -0.1271 -3.0256 -1.0267 -1.7426 -0.0857 -0.0111 -0.2568 -0.1622 -0.0884
S-1440	The ratio of the SDQT to SD of RR intervals (SDRR) was calculated as an index of QTV normalized to heart rate variability.<unk>
T-1440	sdqt sd_of_rr_intervals sdrr qtv heart_rate_variability
H-1440	-1.160143256187439	▁SD QT ▁SD ▁ RR ▁index ▁Q TV ▁heart _ ▁variabil ity
D-1440	-1.160143256187439	SDQT SD RR index QTV heart_ variability
P-1440	-0.0358 -0.3246 -0.7445 -3.0951 -0.2885 -3.6710 -0.3222 -0.3470 -0.1871 -0.9749 -5.3700 -0.3695 -0.2528 -0.2588
S-1935	Heart rate reduction and exercise performance in recent onset heart failure with reduced ejection fraction: arguments for beta-blocker hypo-response.<unk>
T-1935	heart_rate_reduction exercise heart_failure_with_reduced_ejection_fraction beta-blocker
H-1935	-1.0327447652816772	▁Heart _ re duction _ de _ ▁exercise _ ▁performance ▁heart _ ▁failure ▁e je ction _ fraction ▁beta - block er ▁hypo - respons e
D-1935	-1.0327447652816772	Heart_reduction_de_ exercise_ performance heart_ failure ejection_fraction beta-blocker hypo-response
P-1935	-0.5885 -1.0454 -0.8019 -0.0222 -3.5218 -4.3242 -0.3909 -2.3510 -2.7139 -0.6533 -2.3451 -0.4346 -3.3551 -3.0793 -0.2384 -0.0200 -1.1258 -0.0056 -0.1602 -0.0231 -0.1756 -0.0487 -0.9203 -0.1459 -0.0000 -0.1205 -0.1933 -0.1123
S-1818	Future of advanced heart failure and mechanical support devices: A Cardiology-Cardiovascular Surgery Consensus Report Heart failure is a progressive disease.<unk>
T-1818	heart_failure cardiology-cardiovascular_surgery_consensus_report heart_failure disease
H-1818	-0.9692245721817017	▁heart _ ▁failure ▁mechanic al _ support ▁devices ▁Card i ology - car dio vas cular _ sur ger y
D-1818	-0.9692245721817017	heart_ failure mechanical_support devices Cardiology-cardiovascular_surgery
P-1818	-1.2198 -0.7853 -2.6671 -2.0838 -0.0084 -1.9649 -0.8663 -0.8736 -0.1132 -0.1563 -0.5982 -0.7932 -0.9784 -1.6889 -0.4718 -0.2451 -0.6378 -0.1003 -0.2214 -0.1605 -4.5512 -0.1377
S-1271	Newly diagnosed patients with HF under drug treatment have an affected profile of PAF biosynthetic enzymes and especially lyso-PAF-AT.<unk>
T-1271	diagnosed patients hf drug_treatment paf biosynthetic_enzymes lyso-paf-at
H-1271	-0.5145527124404907	▁ HF ▁PA f ▁bio syn the tic ▁enzym es ▁lys o - PA f - AT
D-1271	-0.5145527124404907	HF PAf biosynthetic enzymes lyso-PAf-AT
P-1271	-0.6251 -0.0191 -4.1548 -0.5430 -0.2547 -0.0015 -0.4658 -1.7199 -0.5247 -0.0478 -0.0194 -0.0270 -0.0222 -0.2173 -0.3410 -0.1987 -0.0612 -0.3583 -0.1750
S-1842	We will conduct a systematic review to identify implementation strategies that improve physician adherence to class I recommendations, those with clear evidence that benefits outweigh the risks.<unk>
T-1842	physician evidence
H-1842	-0.7020293474197388	▁physician ▁ad her ence
D-1842	-0.7020293474197388	physician adherence
P-1842	-1.1329 -0.4180 -0.1297 -0.0098 -2.4307 -0.0912
S-87	Utilizing voluntary testimonies and conversations with participating nurses, the benefits of involvement in a multisite study extend beyond meeting Magnet(®) research requirements.<unk>
T-87	nurses magnet
H-87	-1.2792869806289673	▁volunt ary ▁testimoni es ▁nurse s ▁multi site
D-87	-1.2792869806289673	voluntary testimonies nurses multisite
P-87	-4.5751 -0.9102 -2.1149 -0.0484 -0.6802 -0.0134 -0.9029 -0.0984 -3.3569 -0.0925
S-1981	RESULTS: Of the 100 enrolled participants, 26 participants were randomized to exercise; 24 to diet; 25 to exercise + diet; 25 to control.<unk>
T-1981	randomized exercise exercise
H-1981	-1.3855781555175781	
D-1981	-1.3855781555175781	
P-1981	-2.7248 -0.0464
S-1695	We then estimated the odds of future (July to December 2009) 30-day, risk-adjusted mortality at the worst versus best quintile of hospitals.<unk>
T-1695	mortality hospitals
H-1695	-0.8260419368743896	▁risk - ad just ed _ ▁mortal ity
D-1695	-0.8260419368743896	risk-adjusted_ mortality
P-1695	-4.3339 -0.0935 -0.0109 -0.0023 -0.0897 -1.3389 -0.1923 -0.1954 -1.8057 -0.1980
S-1236	RESULTS: In all, 304 patients were included, aged 68 ± 9 years; 86% male; ejection fraction, 26% ± 6%.<unk>
T-1236	patients ejection_fraction
H-1236	-0.8398939371109009	▁e je ction _ fraction
D-1236	-0.8398939371109009	ejection_fraction
P-1236	-3.0042 -1.5764 -0.0623 -0.8393 -0.0066 -0.2626 -0.1279
S-1314	CONCLUSIONS: Despite encouraging declines in the incidence of HF complicating AMI, it remains a common problem with high mortality.<unk>
T-1314	incidence hf ami mortality
H-1314	-0.9180527329444885	▁ HF ▁complicat ing ▁ AMI
D-1314	-0.9180527329444885	HF complicating AMI
P-1314	-1.1608 -0.1308 -3.4456 -0.1293 -0.1305 -0.0212 -2.2405 -0.0857
S-1731	CONCLUSIONS: Physician volume is associated with lower mortality for HF, particularly in low-volume institutions and among noncardiologist physicians.<unk>
T-1731	physician mortality hf physicians
H-1731	-0.8804348111152649	▁Physic ian _ volu me ▁ HF ▁non car dio logist ▁physician s
D-1731	-0.8804348111152649	Physician_volume HF noncardiologist physicians
P-1731	-0.2872 -0.2781 -0.8096 -2.6319 -0.2100 -2.0124 -0.1260 -3.1446 -0.0168 -0.8016 -0.3661 -2.1929 -0.0367 -0.2320 -0.0608
S-406	Those with low sST2/low-dose BB, or high sST2/high-dose BB had intermediate outcomes (0.92 and 1.19 events).<unk>
T-406	sst2 sst2 outcomes
H-406	-1.1056464910507202	▁s st 2/ low - dos e ▁BB
D-406	-1.1056464910507202	sst2/low-dose BB
P-406	-0.4323 -1.9534 -3.0275 -2.0230 -0.0177 -1.4193 -0.1988 -0.3236 -1.5136 -0.1474
S-817	Multivariate analysis showed worsening GLS (HR 1.121; 95% CI 1.023 to 1.228, p=0.014) was independently associated with increased CV events.<unk>
T-817	multivariate_analysis gls
H-817	-1.5366606712341309	▁gr s
D-817	-1.5366606712341309	grs
P-817	-1.7558 -2.5145 -1.6064 -0.2699
S-214	For each year of the study, we determined CHF visit rates (as a percentage of total ED visits) and calculated the percentage of CHF patients intubated.<unk>
T-214	chf chf patients intubated
H-214	-1.783412218093872	▁CHF
D-214	-1.783412218093872	CHF
P-214	-0.5425 -4.7134 -0.0944
S-483	Mean age was 56 ± 11 years and mean LV ejection fraction was 28 ± 8%; 48% had PCWP of >15 mm Hg.<unk>
T-483	lv_ejection_fraction pcwp
H-483	-0.6593300700187683	▁LV ▁e je ction _ fraction ▁PC WP ▁h g
D-483	-0.6593300700187683	LV ejection_fraction PCWP hg
P-483	-0.9885 -3.5952 -0.6950 -0.0477 -1.2554 -0.0099 -0.5387 -0.1760 -0.3828 -0.0354 -0.0956 -0.0918
S-740	Patients with T1 times below the median (<388.3 ms) were at greater risk of cardiac events than the rest of the group (P<0.01).<unk>
T-740	patients t1_times cardiac_events
H-740	-1.6762876510620117	
D-740	-1.6762876510620117	
P-740	-3.2477 -0.1049
S-100	Validation studies in the complementary model system of zebrafish examine the role of Nucleolin to orchestrate genomic reprogramming events shared between development and disease.<unk>
T-100	nucleolin genomic_reprogramming disease
H-100	-0.7263297438621521	▁zebra fish ▁nu cle olin ▁genom ic _ ▁re programm ing ▁disease
D-100	-0.7263297438621521	zebrafish nucleolin genomic_ reprogramming disease
P-100	-3.2280 -0.1808 -0.6468 -0.0018 -0.1762 -0.2190 -0.3594 -0.9296 -1.2249 -0.0276 -0.3074 -2.6106 -0.1550 -0.1016
S-1391	There was a steady improvement in eGFR in the VAD group and the ECMO+VAD group until day 7 after which there was a decline in renal function.<unk>
T-1391	egfr vad ecmo vad renal_function
H-1391	-1.154684066772461	▁e G FR ▁ VAD ▁EC mo _ VAD ▁renal e
D-1391	-1.154684066772461	eGFR VAD ECmo_VAD renale
P-1391	-0.0932 -1.2524 -0.7881 -0.4028 -0.0437 -1.1989 -1.4862 -2.4012 -1.6828 -2.1583 -2.4861 -0.8286 -0.1887
S-737	Confirmatory diagnostic tests, cardiac magnetic resonance imaging including T1 mapping, and invasive hemodynamic assessments were performed at baseline.<unk>
T-737	diagnostic tests cardiac_magnetic_resonance_imaging t1_mapping invasive_hemodynamic_assessments baseline
H-737	-0.6311987042427063	▁cardiac _ ▁magnetic _ ▁res on ance _ ▁imagin g ▁invasi ve _ hem o dynamic ▁assessment s
D-737	-0.6311987042427063	cardiac_ magnetic_ resonance_ imaging invasive_hemodynamic assessments
P-737	-0.0805 -1.1328 -0.8673 -1.2983 -1.8187 -0.1256 -0.1042 -1.2271 -0.4218 -0.0483 -1.3742 -0.3078 -0.1863 -1.6812 -0.1420 -0.0549 -1.1051 -0.3141 -0.2818 -0.0517
S-868	(MADIT-CRT: Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy; NCT00180271).<unk>
T-868	madit-crt multicenter_automatic_defibrillator_implantation_with_cardiac_resynchronization_therapy
H-868	-0.4061780571937561	▁m ADI t - c RT ▁multi center _ automat ic _ de ib rilla tor ▁implant ation ▁Card iac _ re syn chron ization ▁Therapy
D-868	-0.4061780571937561	mADIt-cRT multicenter_automatic_deibrillator implantation Cardiac_resynchronization Therapy
P-868	-0.4150 -0.3100 -0.1900 -0.0484 -0.3878 -0.1968 -0.8176 -0.0105 -0.4093 -0.2177 -0.1093 -0.6179 -1.0358 -1.0965 -0.3777 -0.0760 -0.1347 -0.0223 -0.1983 -0.0534 -0.5235 -0.2887 -0.0025 -0.0001 -1.1254 -2.0728 -0.5784 -0.0567
S-486	AUCs of E/eseptal and E/emean did not vary with s'septal, QRS width, or resynchronization.<unk>
T-486	aucs septal qrs resynchronization
H-486	-1.8937861919403076	▁a UC s ▁e e sept al ▁e ▁e ▁e ▁e ▁e ▁e ▁e sept al ▁QR s _ width ▁re syn chron ization
D-486	-1.8937861919403076	aUCs eeseptal e e e e e e eseptal QRs_width resynchronization
P-486	-3.5291 -0.0309 -0.2835 -0.4791 -4.9088 -0.2245 -0.2588 -0.6780 -3.3447 -3.8860 -4.1418 -4.2685 -4.4470 -4.5898 -6.3523 -1.4393 -0.7744 -2.0516 -1.8919 -0.1361 -0.0914 -0.0024 -0.0000 -1.0160 -0.2433 -0.1694
S-1200	Despite their widespread use, prospective data on the potential of diuretics to modulate HF-related morbidity and mortality are scarce.<unk>
T-1200	prospective diuretics morbidity mortality
H-1200	-0.7160232067108154	▁di ure tics ▁ HF - related _ ▁morbi d ity ▁mortal ity
D-1200	-0.7160232067108154	diuretics HF-related_ morbidity mortality
P-1200	-0.4495 -0.1365 -1.2847 -1.6714 -0.0794 -1.5649 -0.8242 -1.5667 -2.3963 -0.0756 -0.2346 -0.2622 -0.0782 -0.0671 -0.0490
S-1808	Physicians and professionals in public health should be aware that the air pollution experienced in most urban and industrial areas can aggravate cardiovascular health and lead to hospitalisation and death.<unk>
T-1808	physicians public health air cardiovascular health lead hospitalisation death
H-1808	-1.1509648561477661	▁public _ ▁health ▁air ▁pollution
D-1808	-1.1509648561477661	public_ health air pollution
P-1808	-1.8402 -0.7526 -1.7962 -0.0376 -0.3799 -3.0966 -0.1537
S-731	CONCLUSIONS: Our hospital's 30-day readmission rate for patients with heart failure decreased in parallel with an increase in 7-day follow-up visits.<unk>
T-731	hospital readmission patients heart_failure follow-up
H-731	-1.7071728706359863	▁hospital _ s ▁30- day _ ▁read mission _ ▁rate ▁heart _ ▁failure
D-731	-1.7071728706359863	hospital_s 30-day_ readmission_ rate heart_ failure
P-731	-3.0786 -2.3867 -3.6745 -4.7078 -0.0864 -0.2490 -1.5949 -0.0273 -0.8981 -1.4527 -3.4837 -0.3801 -2.5125 -0.9727 -0.1028
S-1658	As the use of these devices has grown, health care providers have been faced with managing clinically significant gastrointestinal bleeding in this population.<unk>
T-1658	health_care clinically gastrointestinal_bleeding
H-1658	-1.4246907234191895	▁implant ation ▁gastro inte stin al
D-1658	-1.4246907234191895	implantation gastrointestinal
P-1658	-2.4108 -1.6329 -2.1272 -0.0441 -0.6664 -0.2172 -4.2319 -0.0670
S-857	BACKGROUND: The impact of carvedilol and metoprolol on inappropriate therapy in heart failure patients with devices has not yet been investigated.<unk>
T-857	carvedilol metoprolol therapy heart_failure patients
H-857	-0.3466399013996124	▁car vedi lol ▁met o pro lol ▁in appropria te ▁ therapy ▁heart _ ▁failure ▁devices
D-857	-0.3466399013996124	carvedilol metoprolol inappropriate therapy heart_ failure devices
P-857	-0.5240 -0.0813 -0.0470 -0.4030 -0.1090 -0.0080 -0.0993 -0.8268 -0.0708 -0.0444 -0.5684 -0.0184 -0.4425 -1.0662 -1.3204 -0.4472 -0.0884 -0.0744
S-326	RESULTS: During IVC occlusion, CO correlated with twist, apical rotation, RS, RS synchrony, and CS (P < 0.05).<unk>
T-326	ivc_occlusion correlated rs rs_synchrony
H-326	-0.23265743255615234	▁IV c ▁oc clusi on ▁twist ▁ap ical ▁ro tation ▁RS ▁synchron y ▁CS
D-326	-0.23265743255615234	IVc occlusion twist apical rotation RS synchrony CS
P-326	-0.0406 -0.9736 -0.0285 -0.0329 -0.2527 -0.8848 -0.7798 -0.0712 -0.0921 -0.0015 -0.0384 -0.0510 -0.1003 -0.1545 -0.1289 -0.0918
S-973	Logistic regression models were used to estimate the risk for the primary outcome and the secondary outcome of death from any cause, while adjusting for confounders.<unk>
T-973	logistic_regression primary_outcome secondary_outcome death
H-973	-0.9839818477630615	▁Log istic _ re gression
D-973	-0.9839818477630615	Logistic_regression
P-973	-0.1934 -0.0317 -1.2530 -0.7813 -0.0101 -4.5249 -0.0934
S-378	BACKGROUND: Most heart failure (HF) risk stratification models were developed for inpatient use, and available outpatient models use a complex set of variables.<unk>
T-378	heart_failure hf risk_stratification inpatient outpatient
H-378	-1.2540724277496338	▁heart _ ▁failure ▁ HF ▁in patient _ utilisation ▁out patient
D-378	-1.2540724277496338	heart_ failure HF inpatient_utilisation outpatient
P-378	-0.2966 -0.5554 -4.0059 -2.6951 -0.0066 -2.2891 -0.0419 -2.5292 -1.8967 -0.4180 -0.0293 -1.4691 -0.0702
S-1301	Morbidity and mortality in HFpEF are similar to values observed in patients with HF and reduced EF, yet no effective treatment has been identified.<unk>
T-1301	morbidity mortality hfpef patients hf reduced_ef
H-1301	-0.6519075632095337	▁Morbi d ity _ de _ ▁mortal ity ▁ HF p EF
D-1301	-0.6519075632095337	Morbidity_de_ mortality HFpEF
P-1301	-0.1183 -0.0257 -0.2433 -2.4344 -1.5443 -0.0937 -0.1800 -0.1239 -0.4878 -0.0121 -0.1089 -0.1637 -3.4874 -0.1032
S-1574	OBJECTIVE: To decrease the 30-day readmission rate following hospital stay for congestive heart failure, which in the United States approaches 30 percent nationally.<unk>
T-1574	readmission hospital congestive_heart_failure united_states
H-1574	-1.1604984998703003	▁con ges tive _ heart _ ▁failure
D-1574	-1.1604984998703003	congestive_heart_ failure
P-1574	-5.8763 -0.2837 -0.0514 -0.3468 -1.5970 -0.4938 -1.5607 -0.1833 -0.0516
S-1045	Similar results were achieved through knockdown of the BET bromodomain-containing protein 4 (BRD4), which is highly expressed in cardiac tissues.<unk>
T-1045	bet bromodomain-containing_protein_4 brd4 cardiac
H-1045	-0.8370667099952698	▁ BET ▁bro modo main - conta ining ▁protein BR d 4 ▁cardiac
D-1045	-0.8370667099952698	BET bromodomain-containing proteinBRd4 cardiac
P-1045	-0.9187 -0.0153 -2.6435 -0.0304 -0.3373 -0.4618 -0.3826 -0.1754 -1.2219 -0.8450 -0.1353 -1.8662 -0.0634 -3.3518 -0.1074
S-1474	Accumulating evidence shows that molecular biomarkers provide a window into the pathophysiology of chronic HF and therefore have important therapeutic implications.<unk>
T-1474	evidence biomarkers pathophysiology chronic_hf therapeutic
H-1474	-0.5088085532188416	▁molecular ▁bio mark ers ▁pat ho phy si ology ▁chronic ▁ HF
D-1474	-0.5088085532188416	molecular biomarkers pathophysiology chronic HF
P-1474	-0.7261 -0.5950 -0.0075 -0.0321 -0.8732 -0.0647 -0.0541 -0.2951 -0.5553 -1.7141 -0.2610 -0.0139 -1.8342 -0.0970
S-56	Comments on "the role of the emergency department in acute heart failure clinical trials-Enriching patient identification and enrollment" by Collins et al.<unk>
T-56	emergency_department acute_heart_failure clinical patient collins
H-56	-1.1629661321640015	▁emergency ▁department ▁a cute _ heart _ ▁failure ▁clinic al _ ▁trial s ▁en rich ing ▁patient
D-56	-1.1629661321640015	emergency department acute_heart_ failure clinical_ trials enriching patient
P-56	-0.7821 -2.7389 -0.1013 -0.0041 -0.1133 -2.4210 -0.4957 -3.3180 -2.4410 -0.0564 -1.6959 -2.9111 -0.0219 -2.2892 -0.2744 -0.0785 -1.0496 -1.2231 -0.0810
S-46	Moderate-strength evidence from 3 trials of intravenous iron found improved short-term exercise tolerance and quality of life in patients with heart failure.<unk>
T-46	evidence intravenous exercise_tolerance quality_of_life patients heart_failure
H-46	-1.785875916481018	▁intra ven ous _ ▁ir on
D-46	-1.785875916481018	intravenous_ iron
P-46	-4.5094 -0.0300 -3.4090 -1.6777 -0.6847 -0.0522 -3.8486 -0.0754
S-1723	METHODS AND RESULTS: We used Medicare inpatient data in 2009 to examine all HF admissions to acute care hospitals in the United States.<unk>
T-1723	medicare inpatient hf admissions acute hospitals united_states
H-1723	-0.6763893365859985	▁Medica re ▁in patient ▁ HF ▁ad missions ▁a cute _ care ▁hospital s
D-1723	-0.6763893365859985	Medicare inpatient HF admissions acute_care hospitals
P-1723	-0.0301 -0.0018 -0.1541 -0.0277 -1.8928 -0.3313 -2.7878 -0.0333 -0.2732 -0.0762 -0.4558 -2.7260 -0.7051 -0.1068 -1.0614 -0.1588
S-1909	The ECG has the ability to detect congenital accessory pathways and ion channelopathies, and is frequently abnormal in individuals with cardiomyopathy.<unk>
T-1909	ecg congenital accessory ion_channelopathies cardiomyopathy
H-1909	-0.5737109780311584	▁e CG ▁con geni tal _ accesso ry _ ▁path ways ▁ion _ ▁channel o pathi es ▁cardio my o pathy
D-1909	-0.5737109780311584	eCG congenital_accessory_ pathways ion_ channelopathies cardiomyopathy
P-1909	-0.6008 -0.2927 -3.6611 -0.0027 -0.1777 -1.2102 -1.0976 -0.1000 -0.4539 -1.6715 -0.0981 -0.0585 -0.5895 -1.2526 -0.5103 -0.0723 -0.0098 -0.0695 -0.8653 -0.1390 -0.0543 -0.1179 -0.0900
S-275	This study aimed to develop a novel mouse HF model of HHD by combining salt loading and uninephrectomy with ANG II infusion.<unk>
T-275	hf hhd salt_loading uninephrectomy ang_ii_infusion
H-275	-0.6890002489089966	▁mouse ▁ HF ▁h h ▁h h ▁h h ▁salt _ ▁load ing ▁un ine ph r ecto my ▁ANG _ ▁II ▁in fusion
D-275	-0.6890002489089966	mouse HF hh hh hh salt_ loading uninephrectomy ANG_ II infusion
P-275	-0.5103 -1.3018 -0.0153 -0.1703 -0.7633 -0.2475 -0.7857 -0.9527 -0.8969 -4.0660 -2.1365 -0.1182 -0.0267 -0.1100 -0.0488 -2.0483 -0.2860 -0.0907 -1.6051 -0.0553 -0.8888 -0.4385 -0.0073 -0.0071 -0.2420 -0.0950
S-335	We report the case of a 57-year-old man who had a history of successful mitral valve plasty for degenerative mitral regurgitation.<unk>
T-335	report mitral_valve_plasty degenerative_mitral_regurgitation
H-335	-0.6022718548774719	▁mit ral ▁val ve ▁plast y ▁de genera tive ▁mit ral _ re gur gi tation
D-335	-0.6022718548774719	mitral valve plasty degenerative mitral_regurgitation
P-335	-3.0677 -0.0107 -1.6116 -0.1356 -0.1958 -0.2979 -0.5775 -0.1439 -0.0302 -3.0078 -0.0304 -0.7777 -0.7376 -0.0050 -0.0171 -0.0065 -0.1345 -0.0535
S-52	Erythropoiesis-stimulating agents do not seem to benefit patients with mild to moderate anemia and heart disease and may be associated with serious harms.<unk>
T-52	erythropoiesis-stimulating_agents patients anemia heart_disease
H-52	-1.0324876308441162	▁Er y thro po ies is - stimul ation ▁agents ▁an emia ▁heart
D-52	-1.0324876308441162	Erythropoiesis-stimulation agents anemia heart
P-52	-2.8299 -0.0944 -2.0375 -2.3425 -1.3986 -0.1500 -0.4352 -0.0546 -1.3000 -0.6459 -1.8247 -0.0519 -0.2893 -1.9486 -0.0843
S-1739	Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management.<unk>
T-1739	patients idiopathic_dilated_cardiomyopathy tuscany evidence-based
H-1739	-0.538257896900177	▁ idio pathi c _ ▁dil ated _ ▁cardio my o pathy ▁tu sca ny ▁evidence - based ▁management
D-1739	-0.538257896900177	idiopathic_ dilated_ cardiomyopathy tuscany evidence-based management
P-1739	-1.2695 -0.1944 -0.0773 -0.1459 -0.4634 -1.2081 -0.8165 -0.1520 -0.3531 -3.1742 -0.6501 -0.0465 -0.8970 -0.0010 -0.0345 -1.5876 -0.0179 -0.0112 -0.0354 -0.1193 -0.0485
S-1235	In-trial resource utilization and unit costs were estimated from Québec Health Insurance Board databases supplemented by disease-specific costs from the Ontario Case Costing Initiative.<unk>
T-1235	costs québec_health_insurance_board costs ontario_case_costing_initiative
H-1235	-0.7788891196250916	▁in - t rial ▁resource _ ▁utiliza tion ▁Québec ▁Health ▁Insurance ▁Board ▁disease - specific ▁costs ▁Ontario ▁Case ▁Cost ing
D-1235	-0.7788891196250916	in-trial resource_ utilization Québec Health Insurance Board disease-specific costs Ontario Case Costing
P-1235	-0.0875 -0.7833 -0.0952 -0.0085 -3.1503 -2.4534 -0.4680 -0.0040 -2.5178 -0.8457 -0.4998 -0.3447 -2.5223 -0.0409 -0.0347 -0.6250 -0.1420 -0.2511 -0.5828 -0.3170 -1.3095 -0.0522
S-176	Benefits in HF with preserved ejection fraction (pEF), as well as uptitration after a hospitalization, remain uncertain.<unk>
T-176	hf_with_preserved_ejection_fraction pef uptitration hospitalization
H-176	-0.6495484113693237	▁ HF ▁pres er ved ▁e je ction _ fraction ▁p EF ▁hospital isation
D-176	-0.6495484113693237	HF preserved ejection_fraction pEF hospitalisation
P-176	-0.8906 -0.0604 -1.8369 -0.0195 -1.1665 -0.2167 -1.8507 -0.2324 -0.6881 -0.0206 -0.6062 -0.1060 -0.4609 -1.8681 -0.2441 -0.1250
S-1244	HF (heart failure) and T2D (Type 2 diabetes) associate with detrimental alterations in SkM (skeletal muscle) structure/function.<unk>
T-1244	hf heart_failure t2d type_2_diabetes skm skeletal_muscle
H-1244	-0.7657254934310913	HF heart _ ▁failure ▁T 2 d ▁diabetes ▁Sk m ▁s kelet al ▁muscle
D-1244	-0.7657254934310913	HFheart_ failure T2d diabetes Skm skeletal muscle
P-1244	-1.5780 -1.2151 -0.7263 -0.3421 -1.9697 -0.0153 -0.6518 -0.9251 -0.1352 -0.1406 -2.4829 -0.0103 -0.0548 -1.0145 -0.8836 -0.1064
S-1971	Dual RAS and neprilysin inhibition might thus after long time become a change in stable chronic heart failure with systolic dysfunction treatment "paradigm".<unk>
T-1971	ras neprilysin_inhibition change stable chronic_heart_failure systolic_dysfunction
H-1971	-1.201307773590088	▁ RAS ▁ RAS ▁nepri ly sin _ ▁inhibi tion ▁chronic _ ▁heart _ ▁failure ▁sy sto lic _ ▁dys function
D-1971	-1.201307773590088	RAS RAS neprilysin_ inhibition chronic_ heart_ failure systolic_ dysfunction
P-1971	-0.6116 -0.0083 -2.9154 -0.1279 -2.9516 -0.2706 -0.5770 -2.1508 -0.0280 -0.0140 -3.6604 -0.9305 -1.8483 -0.8561 -2.6066 -0.5353 -0.2332 -4.7686 -0.7204 -0.2362 -0.2132 -1.0908 -0.2750
S-1058	A T1-mapping sequence was performed during tidal respiration before and 5 minutes after the administration of a gadolinium-chelate contrast agent.<unk>
T-1058	t1-mapping tidal_respiration administration gadolinium-chelate_contrast_agent
H-1058	-0.9369016289710999	▁tid al _ ▁respira tion ▁ gado lini um - che late _ ▁contrast ▁agent
D-1058	-0.9369016289710999	tidal_ respiration gadolinium-chelate_ contrast agent
P-1058	-5.0674 -0.0640 -0.9290 -1.0704 -0.0170 -0.2030 -0.0910 -0.4919 -0.3872 -0.4334 -0.0743 -3.6320 -0.3064 -2.4779 -0.3333 -0.2206 -0.1284
S-1140	In conscious HF rats, pyridostigmine reduced the basal heart rate, increased vagal, and reduced sympathetic control of heart rate.<unk>
T-1140	hf pyridostigmine basal_heart_rate sympathetic_control_of_heart_rate
H-1140	-0.8732879161834717	▁ HF ▁ HF ▁py rido stig mine ▁bas al ▁heart _ ▁rate ▁va gal ▁sympa the tic _ control _ de _ ▁heart _ ▁rate
D-1140	-0.8732879161834717	HF HF pyridostigmine basal heart_ rate vagal sympathetic_control_de_ heart_ rate
P-1140	-0.7320 -0.4852 -2.4632 -0.6692 -5.4273 -0.0149 -0.0006 -0.1732 -0.0142 -0.0515 -1.4245 -1.9566 -0.6101 -0.0068 -0.0028 -0.0577 -0.2480 -0.9320 -1.3427 -0.0712 -0.7616 -2.5151 -0.1673 -0.8797 -1.7839 -1.2188 -0.2456 -0.1964
S-1253	We report severe perturbations in components of the DAPC (dystrophin-associated protein complex) as well as sarcomeric microstructure at baseline.<unk>
T-1253	report dapc dystrophin-associated_protein_complex sarcomeric_microstructure baseline
H-1253	-0.7990285754203796	▁DAP c dys trop hin - as soci ated _ ▁protein ▁complex ▁sar come ric ▁micro structure
D-1253	-0.7990285754203796	DAPcdystrophin-associated_ protein complex sarcomeric microstructure
P-1253	-0.5653 -1.2403 -2.7202 -0.0120 -0.5551 -0.3224 -0.0731 -0.0007 -1.6483 -1.0867 -1.1333 -1.0308 -0.0097 -0.7825 -2.5784 -1.0577 -0.1268 -0.1762 -0.0621
S-1915	A cardiopulmonary exercise test, a quality of life score and an evaluation of the muscular strength by measuring the peak quadriceps force was performed.<unk>
T-1915	cardiopulmonary_exercise_test quality_of_life muscular peak_quadriceps_force
H-1915	-1.2877416610717773	▁cardio pul mon ary _ ré que nce _ de _ ▁life ▁score ▁muscular _ ▁strength ▁pe ak ▁quadri cep s ▁force
D-1915	-1.2877416610717773	cardiopulmonary_réquence_de_ life score muscular_ strength peak quadriceps force
P-1915	-0.0407 -0.0668 -2.0553 -1.2428 -1.8256 -5.9939 -0.6793 -0.0092 -2.5726 -3.3261 -0.0354 -0.9275 -3.8981 -0.1312 -1.9091 -2.2752 -0.1809 -0.1001 -1.9529 -0.0115 -0.0756 -1.2628 -0.1878 -0.1455
S-71	Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial.<unk>
T-71	dopamine nesiritide acute_heart_failure renal_dysfunction rose acute_heart_failure randomized
H-71	-0.7979706525802612	▁dop amine ▁nesi riti de ▁a cute _ heart _ ▁failure ▁renal ▁dys function ▁a cute _ heart _ ▁failure
D-71	-0.7979706525802612	dopamine nesiritide acute_heart_ failure renal dysfunction acute_heart_ failure
P-71	-1.7704 -0.0757 -1.7474 -0.0380 -0.0567 -0.1390 -0.0095 -0.9521 -2.0077 -0.3861 -1.7091 -0.4438 -0.7024 -0.3107 -0.8488 -0.0883 -0.0979 -1.9691 -0.2295 -2.6839 -1.1873 -0.1018
S-941	Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction.<unk>
T-941	outcomes catheter_ablation atrial_fibrillation patients heart_failure_with_preserved_ejection_fraction
H-941	-0.7049779295921326	▁cat heter ▁ab lation ▁at rial _ ▁fi bril lation ▁heart _ ▁failure ▁e je ction _ fraction
D-941	-0.7049779295921326	catheter ablation atrial_ fibrillation heart_ failure ejection_fraction
P-941	-1.1803 -0.1292 -1.2980 -0.0053 -1.3696 -0.2193 -0.5422 -2.3178 -0.0533 -0.0027 -0.4118 -0.6483 -1.9502 -1.7627 -0.6224 -0.0728 -1.2081 -0.0138 -0.1753 -0.1164
S-759	Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model.<unk>
T-759	myocardial titin_hypophosphorylation heart_failure_with_preserved_ejection_fraction metabolic
H-759	-0.6510115265846252	▁My o card ial ▁titi n ▁hypo phos phor y lation ▁heart _ ▁failure ▁rat ▁metabol ic ▁risk
D-759	-0.6510115265846252	Myocardial titin hypophosphorylation heart_ failure rat metabolic risk
P-759	-0.6289 -0.0340 -0.0278 -0.0648 -2.3176 -0.1294 -0.3192 -0.3130 -0.5414 -1.0322 -0.0056 -0.0627 -0.6577 -2.0414 -2.3087 -0.1799 -0.0895 -1.4659 -0.6287 -0.1718
S-953	However, the current study was a single-arm analysis; therefore, larger randomized control studies are needed to verify the benefit of AF ablation in this cohort.<unk>
T-953	randomized af_ablation
H-953	-1.1351256370544434	▁AF ▁ab lation
D-953	-1.1351256370544434	AF ablation
P-953	-4.5408 -0.7901 -0.0181 -0.2214 -0.1052
S-909	Heterogenous improvement in ejection fraction (+3.1 ± 9.2%) was noted and 2 patients derived absolute improvements of 8% and 22%, respectively.<unk>
T-909	ejection_fraction patients
H-909	-1.1750560998916626	▁e je ction _ fraction
D-909	-1.1750560998916626	ejection_fraction
P-909	-3.4469 -2.7978 -0.1759 -0.9433 -0.0073 -0.7388 -0.1155
S-317	However, evidence gaps, limitations in economic models, and the lack of Canadian data point to the importance of mandatory, systematic monitoring of LVAD use and outcomes.<unk>
T-317	evidence economic lvad outcomes
H-317	-1.2137285470962524	▁économique ▁models ▁l VAD
D-317	-1.2137285470962524	économique models lVAD
P-317	-0.1561 -2.6937 -3.3055 -0.0968 -0.9510 -0.0793
S-428	We hypothesized that combining parameters would be more robust and sought to develop a multiparametric echocardiographic score for predicting CRT response.<unk>
T-428	echocardiographic crt
H-428	-0.8228192329406738	▁e cho car dio graphic ▁score ▁c RT
D-428	-0.8228192329406738	echocardiographic score cRT
P-428	-3.0166 -0.6695 -0.1535 -1.0429 -0.6835 -1.1654 -0.7144 -0.2725 -0.3585 -0.1514
S-724	We quantified the change in 30-day readmission rate after the initiative, frequency of 7-day follow-up visits, and events at follow-up visits.<unk>
T-724	change readmission follow-up follow-up
H-724	-1.8572579622268677	
D-724	-1.8572579622268677	
P-724	-3.6219 -0.0927
S-1100	Data describing trends in HF after MI are scarce and conflicting and do not distinguish between preserved and reduced ejection fraction (EF).<unk>
T-1100	hf mi reduced_ejection_fraction ef
H-1100	-1.276463508605957	▁ HF ▁ HF ▁ HF ▁ HF ▁mis ▁pres er ved ▁e je ction _ fraction EF
D-1100	-1.276463508605957	HF HF HF HF mis preserved ejection_fractionEF
P-1100	-1.5395 -0.0511 -2.4397 -0.0629 -2.8782 -0.1047 -3.2679 -0.1828 -4.8678 -3.4029 -0.0132 -1.1954 -0.8081 -1.5006 -0.1169 -1.0155 -0.1817 -1.2055 -0.2784 -0.4165
S-298	METHODS: All patients who underwent HeartMate II LVAD alone or in conjunction with a temporary CentriMag RVAD were examined from 2006 to 2011.<unk>
T-298	patients heartmate_ii lvad centrimag rvad
H-298	-0.5909314155578613	▁Heart Mate _ ▁II ▁l VAD ▁temporar y ▁Centri Mag ▁R VAD
D-298	-0.5909314155578613	HeartMate_ II lVAD temporary CentriMag RVAD
P-298	-0.8481 -0.2175 -1.1163 -1.1076 -1.8231 -0.0106 -0.5015 -0.0697 -0.1413 -0.5255 -1.4918 -0.0044 -0.3166 -0.0991
S-791	CONCLUSIONS: Among patients with HFpEF, the KCCQ seems to be a valid and reliable measure of health status and offers excellent prognostic ability.<unk>
T-791	patients hfpef kccq health prognostic
H-791	-0.6735399961471558	▁ HF p EF ▁k cc q
D-791	-0.6735399961471558	HFpEF kccq
P-791	-0.7788 -0.1296 -0.0749 -0.4268 -0.3940 -0.1464 -0.8859 -3.1414 -0.0841
S-1334	Chronic heart failure is associated with transforming growth factor beta-dependent yield and functional decline in atrial explant-derived c-Kit+ cells.<unk>
T-1334	chronic_heart_failure yield atrial cells
H-1334	-0.7507538795471191	▁Chro nic _ heart _ ▁failure ▁transform ing ▁growth ▁factor _ ▁beta - dependent _ ▁yi eld ▁at rial ▁ex plant - der i ved ▁c - K it _ cell s
D-1334	-0.7507538795471191	Chronic_heart_ failure transforming growth factor_ beta-dependent_ yield atrial explant-derived c-Kit_cells
P-1334	-0.1241 -0.1064 -0.8043 -1.7947 -0.9944 -2.0538 -1.1321 -0.0435 -0.4681 -2.3570 -1.4847 -0.9469 -0.0093 -0.0992 -2.0780 -2.3917 -0.0005 -2.7855 -0.0185 -1.4173 -0.0043 -0.1014 -0.0745 -0.1198 -0.2325 -0.0168 -0.1349 -0.8169 -0.0078 -2.2153 -0.3789 -0.0723 -0.1348 -0.1055
S-1623	MEASUREMENTS: Mortality, inpatient admissions, hospital days, and emergency department (ED) visits during the 2-year study period were measured.<unk>
T-1623	mortality inpatient admissions hospital emergency_department
H-1623	-0.6675792336463928	▁Mor t ality ▁in patient _ ad missions ▁hospital _ ▁days ▁emergency ▁department _ ED
D-1623	-0.6675792336463928	Mortality inpatient_admissions hospital_ days emergency department_ED
P-1623	-0.9721 -0.0169 -0.1514 -0.3840 -0.1655 -1.6802 -0.2829 -0.0196 -0.2412 -1.0860 -0.7061 -0.2260 -1.9046 -0.9209 -2.1138 -0.4002 -0.0774
S-1093	Thus, RV failure frequently requires diagnostic procedures and management strategies that differ from those routinely used in the management of intrinsic left ventricular dysfunction.<unk>
T-1093	rv_failure diagnostic left_ventricular_dysfunction
H-1093	-1.0659193992614746	▁ RV ▁vent ri cular ▁dys function
D-1093	-1.0659193992614746	RV ventricular dysfunction
P-1093	-0.1130 -0.1199 -6.9233 -0.1592 -0.2398 -1.2208 -0.4330 -0.2273 -0.1568
S-441	We excluded patients with baseline serum creatinine level of >2.5 mg/dl or a serum potassium level of >5.0 mEq/L.<unk>
T-441	patients baseline serum_creatinine serum_potassium
H-441	-0.8839288353919983	▁base line ▁se rum _ ▁creati nine ▁figure ▁se rum _ ▁po tas s ium
D-441	-0.8839288353919983	baseline serum_ creatinine figure serum_ potassium
P-441	-2.1286 -0.4527 -1.3730 -0.3710 -0.9386 -1.1400 -0.8318 -2.9211 -0.1661 -0.1217 -0.9346 -1.1603 -0.7211 -0.5629 -0.0478 -1.0459 -0.1095
S-899	After PD initiation, average weight loss was almost 7 kg (p = 0.016) with improvement in diuretic response, peripheral edema, and functional class.<unk>
T-899	pd diuretic peripheral_edema functional_class
H-899	-0.7485944628715515	▁PD _ ▁initiat ion ▁di ure tic _ ▁response ▁per i pher al ▁ed ema ▁functional
D-899	-0.7485944628715515	PD_ initiation diuretic_ response peripheral edema functional
P-899	-0.3940 -3.2834 -1.8665 -0.0101 -0.9634 -0.1021 -1.7717 -2.2157 -1.0455 -0.0760 -0.2392 -0.0270 -0.0572 -0.2379 -0.0045 -0.1457 -0.9505 -0.0844
S-834	Anemia is common in patients with chronic heart failure (HF), with a prevalence ranging from 10% to 56%, and may be a risk factor for poor outcomes.<unk>
T-834	anemia patients chronic_heart_failure hf prevalence outcomes
H-834	-1.3023276329040527	▁an emia ▁chronic _ heart _ ▁failure HF
D-834	-1.3023276329040527	anemia chronic_heart_ failureHF
P-834	-1.0349 -0.0084 -4.0080 -0.5371 -2.0457 -0.6391 -2.9856 -0.5095 -1.1748 -0.0803
S-1170	Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.<unk>
T-1170	if-channel_inhibition hemodynamic exercise_tolerance heart_failure_with_preserved_ejection_fraction randomized
H-1170	-0.9193958640098572	▁If - chan nel _ ▁inhibi tion ▁hem o dynamic ▁status ▁ tolerance ▁heart _ ▁failure ▁pres er ved ▁e je ction _ fraction
D-1170	-0.9193958640098572	If-channel_ inhibition hemodynamic status tolerance heart_ failure preserved ejection_fraction
P-1170	-3.4872 -0.1020 -0.2293 -0.0153 -1.7446 -0.6227 -0.0358 -0.9964 -0.1067 -0.0628 -1.8699 -2.3626 -0.1445 -0.0972 -0.6730 -3.7739 -2.6469 -0.0941 -1.8466 -0.2842 -0.3653 -0.0276 -1.9491 -0.0048 -0.2700 -0.0916
S-1777	Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy.<unk>
T-1777	cardiac insulin-resistance mitochondrial_energy_production systolic_heart_failure pressure-overload_hypertrophy
H-1777	-0.6277676224708557	▁Card iac _ ▁insulin - re si stance ▁mito cho ndri al _ énergie ▁production ▁sy sto lic ▁heart _ ▁failure ▁pressure - over load ▁hyper trop hy
D-1777	-0.6277676224708557	Cardiac_ insulin-resistance mitochondrial_énergie production systolic heart_ failure pressure-overload hypertrophy
P-1777	-0.1645 -0.0140 -1.8248 -1.0862 -0.1202 -0.0399 -0.1290 -0.0000 -0.0252 -0.6218 -0.1087 -0.0309 -1.2579 -0.6426 -4.6556 -0.1320 -0.0255 -2.7696 -0.9625 -0.5881 -2.3399 -0.0543 -0.3367 -0.2161 -0.2552 -0.1258 -0.0006 -0.0435 -0.1671 -0.0949
S-427	BACKGROUND: Studies of echocardiographic predictors of response after cardiac resynchronization therapy (CRT) have largely involved single parameters.<unk>
T-427	echocardiographic cardiac_resynchronization_therapy crt
H-427	-0.637563169002533	▁e cho car dio graphic ▁predict ors ▁cardiac _ re syn chron ization _ therapy ▁c RT
D-427	-0.637563169002533	echocardiographic predictors cardiac_resynchronization_therapy cRT
P-427	-0.0282 -0.1578 -0.0591 -0.6966 -0.4017 -2.2961 -0.2258 -2.7973 -0.8732 -0.8822 -0.0064 -0.0003 -1.1309 -0.7328 -0.7751 -0.7453 -0.1172 -0.1500 -0.0377
S-1519	The apparent circulating NT-proBNP concentration was increased with antibodies targeting nonglycosylated and nonterminal epitopes (P < 0.05).<unk>
T-1519	nt-probnp antibodies nonterminal_epitopes
H-1519	-0.4573945701122284	▁circula ting ▁NT - pro B NP ▁anti bo dies ▁non gly cos yla ted ▁non termin al ▁e pito pes
D-1519	-0.4573945701122284	circulating NT-proBNP antibodies nonglycosylated nonterminal epitopes
P-1519	-0.3737 -1.4920 -0.0064 -0.0206 -0.0100 -0.3284 -0.0616 -0.0242 -0.0672 -2.0151 -1.7656 -0.3151 -0.0415 -0.2750 -1.2640 -1.7330 -0.0799 -0.0077 -0.1762 -0.0674 -0.1703 -0.1317 -0.0936
S-615	METHODOLOGY: A mixed-methods study was undertaken to assess the benefits of participation in a structured exercise programme for patients with heart failure.<unk>
T-615	mixed-methods_study exercise patients heart_failure
H-615	-1.9274548292160034	▁implant ation ▁structure d _ ré que nce _ ré que nce
D-615	-1.9274548292160034	implantation structured_réquence_réquence
P-615	-3.4976 -0.8979 -5.0374 -0.4837 -0.3958 -3.1618 -1.2205 -0.0702 -1.4137 -5.2136 -0.7274 -0.0367 -4.6481 -0.1800
S-1946	CONCLUSIONS: In recent onset HFrEF, exercise performance was better when resting HR was controlled <70 bpm with beta-blocker therapy.<unk>
T-1946	hfref exercise resting_hr bpm beta-blocker therapy
H-1946	-1.839098572731018	▁h f ▁h f ▁h f ▁h f ▁h f ▁h f ▁h f ▁h f ▁h f ▁h f ▁h f ▁h f ▁h f ▁h f ▁h f ▁h z ▁h z ▁bp m ▁beta - block er ▁ therapy
D-1946	-1.839098572731018	hf hf hf hf hf hf hf hf hf hf hf hf hf hf hf hz hz bpm beta-blocker therapy
P-1946	-0.2909 -0.5525 -2.1673 -0.4323 -2.9076 -0.2464 -2.8125 -0.1774 -2.7506 -0.2229 -2.7180 -0.3550 -2.7694 -0.5511 -2.8226 -0.8165 -2.9326 -1.1518 -2.9607 -1.4911 -3.1217 -1.8392 -3.2547 -2.1684 -3.4810 -2.4614 -3.5957 -2.7417 -3.5607 -2.9802 -3.7655 -2.1289 -4.6064 -2.1460 -4.9406 -0.1060 -0.8883 -0.0534 -0.0790 -0.0281 -1.5296 -0.0292 -0.1533 -0.1320
S-1386	METHODS: We performed a single center retrospective observational study in children with end-stage heart failure supported on pediatric mechanical cardiac support.<unk>
T-1386	end-stage_heart_failure mechanical_cardiac_support
H-1386	-1.2329612970352173	▁vent - s tage _ heart _ ▁failure ▁pediatr ic ▁mechanic al _ ▁cardiac ▁support
D-1386	-1.2329612970352173	vent-stage_heart_ failure pediatric mechanical_ cardiac support
P-1386	-6.1323 -2.7714 -0.4345 -0.0043 -0.7039 -2.0859 -0.7879 -2.5839 -0.0616 -0.5076 -1.1704 -0.0321 -0.3807 -0.1707 -2.7339 -0.3039 -0.0950
S-606	RESULTS: We compared 8656 new users of a nbDMARD with 11 587 new users of a TNF antagonist with similar baseline covariates.<unk>
T-606	nbdmard tnf_antagonist baseline covariates
H-606	-0.6276736259460449	▁n b DM ARD ▁T NF _ ▁anta gon ist ▁base line
D-606	-0.6276736259460449	nbDMARD TNF_ antagonist baseline
P-606	-0.2025 -0.0779 -1.4529 -0.1454 -1.2460 -0.1310 -1.6548 -0.1462 -0.0906 -1.4770 -0.5958 -0.2279 -1.2614 -0.0782
S-934	Hum-Retn mice showed increased cardiac mRNA levels of inflammatory and cell adhesion genes compared with Retn(-/-) mice.<unk>
T-934	cardiac_mrna inflammatory cell_adhesion_genes retn
H-934	-0.6692912578582764	▁Hum - re t n ▁cardiac ▁m RNA ▁infla mma tory ▁cell _ ▁a dhe sion _ ▁gene s ▁Ret n
D-934	-0.6692912578582764	Hum-retn cardiac mRNA inflammatory cell_ adhesion_ genes Retn
P-934	-0.9863 -0.2857 -0.7959 -0.0421 -0.0330 -1.2904 -0.0200 -0.0025 -3.3037 -0.1615 -0.7057 -1.5059 -0.3726 -0.6135 -0.0009 -0.0294 -1.7451 -1.5175 -0.0423 -0.3183 -0.0166 -1.5196 -0.0853
S-1266	Baseline and 6-Week follow-up levels of PAF and activity of its metabolic enzymes in patients with heart failure and healthy volunteers--a pilot study.<unk>
T-1266	baseline follow-up paf activity metabolic enzymes patients heart_failure healthy
H-1266	-0.9059310555458069	▁PA f ▁metabol ic _ ▁enzym es ▁heart _ ▁failure
D-1266	-0.9059310555458069	PAf metabolic_ enzymes heart_ failure
P-1266	-1.4531 -0.2384 -0.4897 -0.2715 -1.5790 -1.4151 -0.0322 -1.0000 -0.7487 -2.4702 -0.9773 -0.1960
S-91	Little is known about the global changes in chromatin subproteomes that accompany heart failure, and the mechanisms by which these proteins alter chromatin structure.<unk>
T-91	chromatin_subproteomes heart_failure proteins chromatin_structure
H-91	-0.9986844062805176	▁chr omat in _ sub prote om es ▁heart _ ▁failure
D-91	-0.9986844062805176	chromatin_subproteomes heart_ failure
P-91	-2.1298 -0.0395 -1.0025 -0.7525 -0.5738 -0.2117 -0.1186 -0.0994 -0.1638 -0.6191 -4.0192 -3.1294 -0.1235
S-1896	Patients with heart failure should be referred to heart failure nurses and have follow-up with local cardiology services as these have both been shown to reduce mortality.<unk>
T-1896	patients heart_failure heart_failure nurses follow-up cardiology mortality
H-1896	-0.7951444983482361	▁heart _ ▁failure ▁nurse s ▁card i ology ▁services ▁mortal ity
D-1896	-0.7951444983482361	heart_ failure nurses cardiology services mortality
P-1896	-1.4731 -0.7577 -1.5962 -1.2468 -0.0251 -0.9226 -0.3582 -0.6896 -0.6071 -2.3144 -0.1325 -0.0796 -0.1339
S-1138	After 4 wk of pyridostigmine administration, per os, methylatropine and propranolol were used to evaluate the cardiac sympathovagal balance.<unk>
T-1138	pyridostigmine administration methylatropine propranolol cardiac sympathovagal_balance
H-1138	-0.541935384273529	▁py rido stig mine ▁administration ▁met hy la tropi ne ▁propra no lol ▁cardiac _ ▁sympa t hova gal _ ▁balance
D-1138	-0.541935384273529	pyridostigmine administration methylatropine propranolol cardiac_ sympathovagal_ balance
P-1138	-0.3359 -0.0275 -0.0005 -0.0621 -1.8674 -0.1601 -0.0078 -0.1624 -0.0222 -1.0070 -0.0134 -0.0061 -0.0314 -0.0368 -0.5938 -5.5076 -0.1157 -0.7556 -0.0736 -1.3083 -0.1643 -0.1416 -0.0633
S-970	We aimed to investigate the association between preoperative renal dysfunction and early risk of stroke, myocardial infarction, or heart failure after CABG.<unk>
T-970	preoperative renal_dysfunction stroke myocardial_infarction heart_failure cabg
H-970	-0.5338643193244934	▁pre operativ e ▁renal ▁dys function ▁stroke ▁my o card ial ▁in far ction ▁heart _ ▁failure ▁CA BG
D-970	-0.5338643193244934	preoperative renal dysfunction stroke myocardial infarction heart_ failure CABG
P-970	-0.7418 -0.0520 -0.0828 -0.1520 -0.5493 -0.2875 -1.2691 -2.0504 -0.1245 -0.0774 -0.1095 -0.4433 -1.3023 -0.0441 -0.6675 -1.2292 -0.7864 -1.0654 -0.0320 -0.0622 -0.0826
S-1427	As expected, total myosin binding protein-C phosphorylation and Ser23/24 troponin I phosphorylation significantly decreased in HF.<unk>
T-1427	myosin protein-c phosphorylation troponin_i phosphorylation hf
H-1427	-0.5865902304649353	▁my os in _ binding _ ▁protein - C ▁ phos phor y lation ▁Ser 23 /24 ▁trop onin ▁ phos phor y lation ▁ HF
D-1427	-0.5865902304649353	myosin_binding_ protein-C phosphorylation Ser23/24 troponin phosphorylation HF
P-1427	-1.4164 -0.1425 -0.9631 -1.6281 -0.0945 -0.7155 -1.0805 -0.1947 -1.2165 -0.2000 -0.0128 -0.4164 -2.3054 -0.0156 -1.1220 -0.5364 -0.0937 -0.0086 -0.0979 -1.5786 -0.0554 -0.1627 -1.4858 -0.0182 -0.5829 -0.0076 -0.1023 -0.1705
S-670	The use of trastuzumab in the adjuvant setting improves outcomes but is associated with cardiotoxicity manifested as congestive heart failure (CHF).<unk>
T-670	trastuzumab adjuvant outcomes cardiotoxicity congestive_heart_failure chf
H-670	-0.5756531953811646	▁tras tuz um ab ▁cardio toxic ity ▁con ges tive _ ▁heart _ ▁failure CH f
D-670	-0.5756531953811646	trastuzumab cardiotoxicity congestive_ heart_ failureCHf
P-670	-0.2192 -0.0158 -0.0441 -0.2081 -0.2125 -0.3162 -0.4539 -0.1761 -0.0752 -0.2009 -0.7748 -2.1218 -0.8356 -2.5652 -1.5142 -0.4837 -0.0833 -0.0612
S-1207	Phosphodiesterase-2 is up-regulated in human failing hearts and blunts beta-adrenergic responses in cardiomyocytes.<unk>
T-1207	phosphodiesterase-2 hearts beta-adrenergic_responses cardiomyocytes
H-1207	-0.6802100539207458	▁Pho s pho dies tera se -2 ▁fail ing ▁heart s ▁blu nts ▁beta - ad r energi c ▁cardio my o cy tes
D-1207	-0.6802100539207458	Phosphodiesterase-2 failing hearts blunts beta-adrenergic cardiomyocytes
P-1207	-0.3916 -0.2581 -2.5527 -2.8143 -0.0342 -0.1129 -2.4246 -5.2227 -0.2625 -0.2932 -0.1160 -0.0385 -0.0117 -0.0695 -0.0138 -0.0319 -0.0976 -0.5385 -0.3487 -0.5354 -0.6861 -0.2905 -0.1019 -0.1500 -0.1585 -0.1301
S-391	Cox hazard models for time to ESRD, to death, and the composite end point of ESRD or death were constructed and predictors of ESRD identified.<unk>
T-391	cox_hazard_models esrd death composite_end_point esrd death esrd
H-391	-1.3106502294540405	▁co x ▁hazard _ modellen ▁temps ▁ES RD ▁death ▁ES RD
D-391	-1.3106502294540405	cox hazard_modellen temps ESRD death ESRD
P-391	-1.3176 -0.0005 -0.8706 -2.6366 -2.0397 -1.4079 -0.6587 -0.1608 -4.5346 -1.8150 -0.2369 -1.1527 -0.2069
S-557	METHODS: Patients were categorized into 5 age groups: 20 to 39, 40 to 49, 50 to 59, 60 to 69, and ≥70 years.<unk>
T-557	patients
H-557	-0.9092990756034851	
D-557	-0.9092990756034851	
P-557	-1.7816 -0.0370
S-1864	Most patients (n = 17, 68%) said they would consider deactivation, six (24%) were undecided and two (8%) were adamant they would never turn it off.<unk>
T-1864	patients
H-1864	-0.5135729908943176	▁de activa tion
D-1864	-0.5135729908943176	deactivation
P-1864	-2.0259 -0.0613 -0.0244 -0.4043 -0.0520
S-1729	Finally, costs were higher for the high-volume physicians ($8982 versus $8731; P=0.002, a difference that was consistent across hospital volume groups).<unk>
T-1729	costs physicians hospital
H-1729	-1.621962308883667	▁costs
D-1729	-1.621962308883667	costs
P-1729	-1.2837 -3.5126 -0.0695
S-1361	This review highlights the current knowledge of nutritional abnormalities that may occur in CHF, including fat, carbohydrates, proteins, water, and micronutrients.<unk>
T-1361	chf proteins
H-1361	-0.7644555568695068	▁nutrition al ▁ab normal ities ▁CHF ▁fat ▁car bo hydrat es ▁protein s ▁water
D-1361	-0.7644555568695068	nutritional abnormalities CHF fat carbohydrates proteins water
P-1361	-4.5972 -0.0562 -1.8963 -0.0231 -0.3292 -0.3475 -0.8917 -0.1925 -0.0064 -0.1945 -0.0474 -0.3195 -0.0351 -0.6870 -2.5493 -0.0584
S-932	Remarkably, doxorubicin (25mg/kg ip) led to a 4-fold induction of serum resistin levels in Hum-Retn mice.<unk>
T-932	doxorubicin resistin
H-932	-0.6755908131599426	▁do xor ubi cin ▁se rum _ ▁resist in ▁Hum - re t n ▁mi ce
D-932	-0.6755908131599426	doxorubicin serum_ resistin Hum-retn mice
P-932	-0.0046 -0.0384 -0.0666 -0.0137 -4.1348 -0.5020 -0.4930 -1.0569 -1.2017 -1.0165 -0.0659 -1.0278 -0.3539 -0.0691 -1.5372 -0.2514 -0.2186 -0.1085
S-321	MATERIALS AND METHODS: In nine pigs, the inferior vena cava (IVC) was snared to decrease CO and establish a control model.<unk>
T-321	inferior_vena_cava ivc
H-321	-1.049943447113037	▁pig s ▁inferior ▁ve na _ ca va IV c ▁CO
D-321	-1.049943447113037	pigs inferior vena_cavaIVc CO
P-321	-4.4540 -0.0604 -0.1884 -1.2356 -0.1536 -0.7838 -0.0415 -0.0488 -1.9498 -0.5698 -2.8453 -1.2175 -0.1006
S-359	Direct observation at the time of surgery also confirmed no findings of rheumatic or other causes of MS. After the surgery, MVA was reduced but only modestly.<unk>
T-359	surgery rheumatic surgery mva
H-359	-1.4208338260650635	▁m va
D-359	-1.4208338260650635	mva
P-359	-4.1635 -0.4814 -0.8898 -0.1486
S-728	Eighty-one percent of 7-day visits occurred in the University of Connecticut Heart Failure Center with a cardiologist or heart failure nurse practitioner.<unk>
T-728	university_of_connecticut_heart_failure_center heart_failure nurse_practitioner
H-728	-0.6097332835197449	▁University _ de _ ▁Connect i cut ▁Heart _ ▁Fail ure ▁Center ▁cardio logist ▁heart _ ▁failure ▁nurse _ prac ti tioner
D-728	-0.6097332835197449	University_de_ Connecticut Heart_ Failure Center cardiologist heart_ failure nurse_practitioner
P-728	-1.1691 -0.7565 -2.5387 -0.3412 -2.0233 -0.1106 -0.0725 -0.3983 -0.3213 -0.1165 -0.0993 -1.2239 -0.0195 -0.0228 -0.3855 -0.1523 -1.5590 -0.5933 -1.6457 -0.7276 -0.0084 -0.0466 -0.2150 -0.0867
S-472	Thus, we tested the hypothesis that XO inhibition improves cardiomyocyte bioenergetics and LV function in chronic ACF in the rat.<unk>
T-472	xo_inhibition cardiomyocyte_bioenergetics lv_function chronic_acf
H-472	-0.48541486263275146	▁ XO ▁inhibi tion ▁cardio my o cy te _ ▁bio ener ge tics ▁LV ▁chronic ▁A CF ▁rat
D-472	-0.48541486263275146	XO inhibition cardiomyocyte_ bioenergetics LV chronic ACF rat
P-472	-0.9503 -0.0163 -1.1587 -0.0374 -0.0202 -0.5699 -0.7016 -0.3890 -0.6059 -0.3066 -0.0879 -0.0150 -0.5375 -1.4145 -0.1158 -2.0730 -0.6766 -0.1119 -0.1521 -0.1779 -0.0755
S-1753	BACKGROUND: In patients with heart failure (HF), during maximal cardiopulmonary exercise test, anaerobic threshold (AT) is not always identified.<unk>
T-1753	patients heart_failure hf cardiopulmonary_exercise_test anaerobic_threshold
H-1753	-1.1010730266571045	▁heart _ ▁failure ▁ HF ▁cardio pul mon ary _ exercice ▁ana ero bic _ ▁thre s hold
D-1753	-1.1010730266571045	heart_ failure HF cardiopulmonary_exercice anaerobic_ threshold
P-1753	-1.3671 -0.5569 -3.8482 -2.7475 -0.0015 -0.4066 -0.0671 -3.4076 -0.7211 -1.1107 -3.5293 -1.0876 -0.0603 -0.2492 -1.2495 -0.4501 -0.0426 -0.3172 -0.7513 -0.0501
S-1084	UPR effectors, protein kinase R-like ER kinase (PERK), calreticulin, and CHOP, were increased in human HF tissues.<unk>
T-1084	upr protein_kinase_r-like_er_kinase perk calreticulin chop hf
H-1084	-0.7143458724021912	▁u PR ▁protein ▁kina se ▁ER ▁kina se per k ▁cal ret icul in ▁CHO p ▁ HF
D-1084	-0.7143458724021912	uPR protein kinase ER kinaseperk calreticulin CHOp HF
P-1084	-0.5899 -0.0035 -2.4395 -0.9363 -0.0345 -2.7722 -2.3363 -0.0145 -1.5343 -0.9405 -0.0105 -0.3316 -0.0074 -0.4447 -0.0184 -0.5054 -0.8033 -0.0269 -0.4408 -0.0964
S-1120	Therefore, carvedilol may reduce the risk of thromboembolic events in patients with heart failure, irrespective of β2-receptor haplotype status.<unk>
T-1120	carvedilol thromboembolic_events patients heart_failure β2-receptor_haplotype
H-1120	-0.7225562930107117	▁car vedi lol ▁ thro mbo e mbol ic ▁events ▁heart _ ▁failure ▁β 2- recept or _ ha plo type
D-1120	-0.7225562930107117	carvedilol thromboembolic events heart_ failure β2-receptor_haplotype
P-1120	-0.4113 -0.0994 -0.3116 -0.8300 -0.1214 -0.5842 -1.5714 -0.0314 -2.1191 -3.3215 -1.0136 -1.5303 -2.0042 -0.0654 -0.2971 -0.0360 -0.1564 -0.6467 -0.4782 -0.0362 -0.2714 -0.5921 -0.0900
S-1144	HF rats treated with pyridostigmine exhibited a higher stroke volume, ejection fraction, cardiac output, and contractility of the left ventricle.<unk>
T-1144	hf pyridostigmine stroke_volume ejection_fraction cardiac_output contractility left_ventricle
H-1144	-0.9468843340873718	▁ HF ▁ HF ▁py rido stig mine ▁stroke _ ▁volume ▁e je ction _ fraction ▁cardiac _ ▁output ▁contract ility ▁vent ric le
D-1144	-0.9468843340873718	HF HF pyridostigmine stroke_ volume ejection_fraction cardiac_ output contractility ventricle
P-1144	-1.6059 -0.0346 -2.9921 -0.2529 -5.4716 -0.0230 -0.0011 -0.2923 -0.8563 -2.2097 -1.6323 -0.3592 -0.2109 -0.0113 -0.5473 -0.0012 -0.0260 -2.7620 -0.1499 -0.5600 -0.3072 -1.2264 -2.3114 -0.5159 -0.1901 -0.0684
S-1324	Echocardiographic measures, N-terminal pro-brain natriuretic peptide, and inflammatory markers were mostly unchanged.<unk>
T-1324	echocardiographic n-terminal_pro-brain_natriuretic_peptide inflammatory
H-1324	-0.8254621028900146	▁e car dio graphic ▁measure s ▁pro - bra in _ ▁na tri ure tic _ pe pti de ▁infla mma tory ▁marker s
D-1324	-0.8254621028900146	ecardiographic measures pro-brain_ natriuretic_peptide inflammatory markers
P-1324	-0.8507 -1.7768 -0.2187 -0.3036 -4.1008 -0.0442 -4.2359 -0.0413 -0.3699 -0.1406 -0.9658 -0.5065 -0.0029 -0.0681 -3.7695 -1.1152 -0.2609 -0.1088 -0.2319 -0.0163 -0.1755 -0.9073 -1.0111 -0.0172 -0.1191 -0.1035
S-152	STUDY SELECTION: All randomised-controlled trials (RCTs) or observational cohort studies with a contemporaneous control group were included.<unk>
T-152	randomised-controlled_trials rcts observational_cohort_studies contemporaneous_control_group
H-152	-0.5365386605262756	▁random ised - control led ▁trial s RC t s
D-152	-0.5365386605262756	randomised-controlled trialsRCts
P-152	-1.2958 -0.4728 -0.1592 -0.0046 -0.6919 -1.1234 -0.0513 -0.2502 -0.8952 -0.4729 -0.9585 -0.0626
S-438	Aldosterone receptor antagonists have been shown in randomized trials to reduce morbidity and mortality in adults with symptomatic systolic heart failure.<unk>
T-438	aldosterone_receptor_antagonists randomized morbidity mortality symptomatic_systolic_heart_failure
H-438	-0.8885103464126587	▁al do ster one _ ▁receptor _ ▁anta gon ists
D-438	-0.8885103464126587	aldosterone_ receptor_ antagonists
P-438	-0.5431 -0.2064 -0.0400 -1.6434 -0.9280 -0.1738 -1.0007 -0.2506 -0.1097 -1.7786 -3.9120 -0.0759
S-613	Abstract In the current economic climate within the NHS, behavioural-change interventions in chronic disease such as exercise programmes will be time-limited within acute hospital facilities.<unk>
T-613	economic nhs chronic disease exercise acute hospital
H-613	-1.2555463314056396	▁économique _ ▁climate ▁NH s ▁behaviour al - change ▁implant s ▁chronic _ ▁disease
D-613	-1.2555463314056396	économique_ climate NHs behavioural-change implants chronic_ disease
P-613	-0.4126 -2.8620 -1.8828 -0.2163 -1.0692 -2.1193 -0.0497 -0.0601 -0.0010 -4.3410 -0.7006 -0.4081 -1.3241 -2.1062 -2.3582 -0.1775
S-912	In conclusion, at our center, the dialysis-dependent patients with HF who underwent CRT implantation did so safely and no serious complications were observed.<unk>
T-912	patients hf crt implantation complications
H-912	-0.3630301356315613	▁di al ysis - dependent ▁ HF ▁c RT ▁implant ation
D-912	-0.3630301356315613	dialysis-dependent HF cRT implantation
P-912	-0.2562 -0.0770 -0.0459 -0.1019 -0.1750 -2.6287 -0.0180 -0.8598 -0.0988 -0.0305 -0.0457 -0.3356 -0.0461
S-1389	RESULTS: During the study period, there were 23 patients in the VAD group, 16 patients in the ECMO+VAD group, and 37 patients in the ECMO group.<unk>
T-1389	patients vad patients ecmo vad patients ecmo
H-1389	-1.443613052368164	▁ VAD ▁EC mo + VAD
D-1389	-1.443613052368164	VAD ECmo+VAD
P-1389	-0.6888 -0.1479 -2.4367 -0.9764 -4.4231 -0.0936 -2.6524 -0.1301
S-687	METHODS AND RESULTS: Women's Health Initiative participants were followed up from the date of HF hospitalization through the date of death or last participant contact before August 2009.<unk>
T-687	health followed_up hf hospitalization death contact
H-687	-1.1496481895446777	▁Women _ s _ ▁Health ▁Initiative ▁ HF
D-687	-1.1496481895446777	Women_s_ Health Initiative HF
P-687	-2.6709 -1.7344 -0.5604 -0.3857 -1.7290 -2.1891 -0.3521 -0.0860 -1.6290 -0.1599
S-1452	Cases (post-HCT CHF) were identified from 2950 patients who underwent HCT between 1988 and 2007 at City of Hope and had survived ≥1 year.<unk>
T-1452	chf patients hct city_of_hope
H-1452	-0.8202771544456482	▁h ct ▁h ct ▁City _ of _ ▁Hope
D-1452	-0.8202771544456482	hct hct City_of_ Hope
P-1452	-0.4202 -1.1162 -1.4844 -0.6574 -3.7890 -0.1929 -0.6150 -0.1298 -0.3064 -0.2614 -0.0504
S-1094	In this summary, the structure and function of the RV will be reviewed, concentrating on the pathophysiologic mechanisms behind the development of RV dysfunction.<unk>
T-1094	rv pathophysiologic rv_dysfunction
H-1094	-0.8943904042243958	▁ RV
D-1094	-0.8943904042243958	RV
P-1094	-0.4329 -0.4681 -2.4957 -0.1809
S-1918	Peak oxygen consumption (range: –3% to + 61%) increased in three, and oxygen pulse (range: –7% to + 44%) in four of five patients.<unk>
T-1918	peak_oxygen_consumption pulse patients
H-1918	-0.9289553165435791	▁oxygen _ pu issa nce
D-1918	-0.9289553165435791	oxygen_puissance
P-1918	-1.3734 -1.3518 -2.5184 -0.1931 -0.0115 -0.9929 -0.0616
S-816	RESULTS: There were 19 CV deaths, 12 non-fatal stroke and 28 hospitalisations for heart failure during an average follow-up of 21 ± 10 months.<unk>
T-816	deaths stroke hospitalisations heart_failure follow-up
H-816	-0.907727837562561	▁CV _ ▁death s ▁non - fa tal _ ▁stroke ▁hospital isation s ▁heart _ ▁failure
D-816	-0.907727837562561	CV_ deaths non-fatal_ stroke hospitalisations heart_ failure
P-816	-0.5107 -3.6832 -3.0345 -0.0882 -0.9650 -0.0114 -0.0227 -0.0834 -1.2636 -0.2045 -1.4941 -0.0132 -0.1555 -1.2657 -0.4780 -2.7419 -0.2344 -0.0892
S-1907	In middle-aged recreational athletes more than 90% of sudden cardiac deaths occur in males and more than 90% are caused by atherosclerotic CAD.<unk>
T-1907	cardiac_deaths atherosclerotic_cad
H-1907	-0.5510364770889282	▁middle - a ged _ ▁recrea tional _ ▁ath letes ▁sud den _ ▁cardiac ▁death s ▁a ther os cle ro tic ▁CAD
D-1907	-0.5510364770889282	middle-aged_ recreational_ athletes sudden_ cardiac deaths atherosclerotic CAD
P-1907	-2.7216 -0.1115 -0.0845 -0.0180 -0.4575 -0.9309 -0.3303 -1.5837 -2.0925 -0.0049 -0.0374 -0.0090 -0.3276 -0.0822 -1.7914 -0.0988 -1.9297 -0.0038 -0.1745 -0.0909 -0.0638 -0.5767 -0.0621 -0.0917 -0.1010
S-1477	In this review, we summarize the potential therapeutic implications of promising biomarkers that uniquely capture the molecular dysfunction that occurs in chronic HF.<unk>
T-1477	therapeutic biomarkers molecular_dysfunction chronic_hf
H-1477	-0.47112685441970825	▁bio mark ers ▁molecular ▁dys function ▁chronic ▁ HF
D-1477	-0.47112685441970825	biomarkers molecular dysfunction chronic HF
P-1477	-2.5103 -0.0168 -0.0591 -0.1289 -0.4504 -0.2478 -1.1359 -0.4649 -0.0123 -0.0925 -0.0637
S-1806	Ambient air pollution is a well-recognised risk factor for cardiovascular health, and it has been shown to be an important trigger of acute myocardial infarction.<unk>
T-1806	air cardiovascular health acute_myocardial_infarction
H-1806	-0.9025076031684875	▁Ambient ▁air ▁pollution ▁cardiovascular _ ▁health ▁a cute _ My o card ial ▁in far ction
D-1806	-0.9025076031684875	Ambient air pollution cardiovascular_ health acute_Myocardial infarction
P-1806	-1.2757 -0.8540 -0.7260 -0.4112 -2.2453 -1.2578 -1.2583 -0.0421 -0.1494 -5.0854 -0.7686 -0.3905 -0.1130 -0.6075 -0.6247 -0.1224 -0.1802 -0.1329
S-1655	CONCLUSION: EAST will determine whether rhythm control therapy, when applied early after the initial diagnosis of AF, can prevent cardiovascular complications associated with AF.<unk>
T-1655	east rhythm_control_therapy diagnosis cardiovascular complications
H-1655	-0.5320401787757874	▁e AST ▁ rhythm _ control ▁ therapy ▁AF ▁cardiovascular ▁complica tions ▁AF
D-1655	-0.5320401787757874	eAST rhythm_control therapy AF cardiovascular complications AF
P-1655	-2.1256 -0.2818 -0.0332 -0.2028 -0.5429 -0.0434 -0.7303 -0.0307 -1.2892 -0.3127 -0.4215 -0.0218 -1.7815 -0.0858 -0.0773
S-1089	Because the effect is not entirely specific to the SCN5A transcript, the UPR may play an important role in downregulation of multiple cardiac genes in HF.<unk>
T-1089	scn5a upr downregulation cardiac genes hf
H-1089	-1.0451395511627197	▁s CN 5 a ▁tran script ▁u PR ▁down regul ation _ de _ multi _ ▁cardiac ▁gene s ▁ HF
D-1089	-1.0451395511627197	sCN5a transcript uPR downregulation_de_multi_ cardiac genes HF
P-1089	-1.9727 -0.5408 -0.9531 -0.3164 -0.9641 -0.0420 -0.0333 -0.1453 -3.9360 -0.2764 -0.0046 -2.5398 -2.3528 -0.4584 -0.8453 -2.9891 -0.4252 -4.7031 -0.0214 -0.2569 -0.0153 -0.1281 -0.1181
S-379	We hypothesized that routinely collected clinical data could predict the 6-month risk of death and all-cause medical hospitalization in HF clinic outpatients.<unk>
T-379	collected clinical death medical hospitalization hf clinic outpatients
H-379	-1.6601598262786865	▁ HF
D-379	-1.6601598262786865	HF
P-379	-3.5293 -1.3374 -1.5513 -0.2226
S-1192	In the prospective validation cohort of 143 patients, the prediction rule had 98% sensitivity and 18% specificity for CAD but 100% sensitivity for severe CAD.<unk>
T-1192	prospective patients rule sensitivity specificity cad sensitivity cad
H-1192	-1.3132214546203613	▁ sensitiv ity ▁CAD ▁ sensitiv ity
D-1192	-1.3132214546203613	sensitivity CAD sensitivity
P-1192	-4.0246 -1.1381 -0.2206 -1.5583 -2.1269 -0.0161 -0.0829 -2.5598 -0.0919
S-540	Attention to albumin levels by correcting nutrition, inflammation, and hepatic function could be an effective way to improve prognosis in patients evaluated for LVAD implantation.<unk>
T-540	albumin inflammation hepatic prognosis patients lvad implantation
H-540	-0.36182060837745667	▁album in ▁ inflammation ▁he pati c ▁implant ation
D-540	-0.36182060837745667	albumin inflammation hepatic implantation
P-540	-0.2281 -0.1876 -1.4591 -0.0855 -0.0458 -0.0641 -0.1235 -1.3216 -0.0181 -0.2741 -0.1725
S-496	TAPSE vs. PASP relationship showed a downward regression line shift in nonsurvivors who were more frequently presenting with higher PASP and lower TAPSE.<unk>
T-496	tapse pasp downward regression_line shift pasp tapse
H-496	-1.800984263420105	▁pas p ▁figure
D-496	-1.800984263420105	pasp figure
P-496	-3.8591 -1.1884 -2.7008 -1.1757 -0.0810
S-814	MAIN OUTCOME MEASURES: The risk of GLS measured by index beat method for CV events was assessed by Cox proportional hazards analyses.<unk>
T-814	outcome gls beat cox_proportional_hazards_analyses
H-814	-1.182576298713684	▁m AIN ▁m AIN ▁m AIN _ ▁o UTC OME _ me a su ures ▁g LS ▁index _ ▁beat ▁CV ▁co x ▁proportion al _ ▁hazard s
D-814	-1.182576298713684	mAIN mAIN mAIN_ oUTCOME_measuures gLS index_ beat CV cox proportional_ hazards
P-814	-2.5189 -0.0070 -2.5494 -0.0342 -2.6011 -0.0882 -2.4948 -2.9378 -0.0172 -0.0468 -3.1404 -0.5956 -1.2786 -0.4706 -2.6795 -2.2591 -0.6637 -0.1377 -0.5068 -0.2156 -3.2836 -4.0503 -0.0017 -0.0818 -0.0213 -1.6138 -0.3128 -0.0511 -0.5609 -0.2571
S-1817	These findings indicate that hearts with increased levels of Mena fare worse when subjected to cardiac injury and suggest that Mena contributes to HF pathophysiology.<unk>
T-1817	hearts mena cardiac_injury mena hf pathophysiology
H-1817	-0.8101526498794556	▁heart s ▁Men a ▁cardiac ▁injury ▁ HF
D-1817	-0.8101526498794556	hearts Mena cardiac injury HF
P-1817	-0.7529 -0.1266 -1.6468 -0.2020 -0.5775 -2.4551 -0.8863 -0.1899 -1.1180 -0.1464
S-1102	All residents of Olmsted County, Minnesota (n = 2,596) who had a first-ever MI diagnosed in 1990-2010 and no prior HF were followed-up through 2012.<unk>
T-1102	olmsted_county minnesota mi diagnosed hf followed-up
H-1102	-0.5059321522712708	▁Ol m sted ▁County ▁Minnesota ▁MI ▁ HF
D-1102	-0.5059321522712708	Olmsted County Minnesota MI HF
P-1102	-0.5623 -0.0060 -0.1533 -0.0803 -1.6182 -1.0079 -1.2632 -0.0734 -0.1943 -0.1007
S-1340	CHF-developed infarcted animals were selected on the basis of left ventricle end-diastolic pressure ≥ 20 mm Hg and scar size ≥ 30%.<unk>
T-1340	infarcted left_ventricle_end-diastolic_pressure
H-1340	-0.9399677515029907	▁CHF ▁in far ction ▁animals ▁left ▁vent ric le _ ▁end - dia sto lic _ tension ▁h g ▁scar
D-1340	-0.9399677515029907	CHF infarction animals left ventricle_ end-diastolic_tension hg scar
P-1340	-0.0413 -0.8412 -0.0570 -2.1672 -2.2817 -0.6577 -0.0564 -2.6543 -1.0294 -0.9967 -1.0697 -0.3600 -1.2978 -0.5820 -2.1742 -1.5395 -1.6432 -0.1849 -0.0126 -0.0464 -0.9207 -0.0652
S-1615	CONCLUSIONS: Genes differentially expressed in non-ischemic and ischemic heart failure can be biomarkers to distinguish the two types of heart failure.<unk>
T-1615	genes ischemic_heart_failure biomarkers heart_failure
H-1615	-1.1941606998443604	▁bio mark ers ▁heart _ ▁failure
D-1615	-1.1941606998443604	biomarkers heart_ failure
P-1615	-4.1856 -0.0246 -0.0509 -1.9327 -1.3392 -1.7385 -0.1973 -0.0844
S-10	Lipolysis and increased energy expenditure caused by A- and B natriuretic peptides (NPs) have been suggested to play a role in CC.<unk>
T-10	lipolysis expenditure b_natriuretic_peptides nps
H-10	-0.8606840968132019	▁Li poly sis ▁energie _ ▁ex pendi ture ▁na tri ure tic ▁pe pti des NP s ▁CC
D-10	-0.8606840968132019	Lipolysis energie_ expenditure natriuretic peptidesNPs CC
P-10	-0.8547 -0.0218 -0.9167 -2.5424 -1.7477 -0.1321 -0.0014 -0.0776 -2.3106 -0.0096 -0.1775 -3.9046 -1.7132 -0.4201 -0.1443 -1.2068 -0.0046 -0.7872 -0.1309 -0.1098
S-184	In conclusion, uptitration of neurohumoral blockers after an HF hospitalization is more frequently performed in younger patients with low co-morbidity burden.<unk>
T-184	uptitration neurohumoral_blockers hf hospitalization patients co-morbidity
H-184	-0.618891179561615	▁neuro hu moral ▁block ers ▁ HF ▁co - mor bid ity
D-184	-0.618891179561615	neurohumoral blockers HF co-morbidity
P-184	-0.2658 -0.2811 -0.0244 -2.3642 -0.0585 -0.2948 -0.0052 -2.2278 -0.0310 -0.1226 -0.2248 -0.0957 -2.5955 -0.0729
S-784	Predictive validity of the KCCQ Overall Summary scores was assessed with Kaplan-Meier curves for death and all-cause hospitalization.<unk>
T-784	kccq kaplan-meier_curves death all-cause_hospitalization
H-784	-0.9255437254905701	▁k cc q ▁Ka plan - me ier ▁cur ves
D-784	-0.9255437254905701	kccq Kaplan-meier curves
P-784	-1.1171 -0.0759 -1.5029 -2.4888 -0.0672 -0.0513 -1.0185 -0.0808 -0.3011 -0.3660 -3.8030 -0.2340
S-294	BACKGROUND: Right ventricular (RV) failure after the insertion of a left ventricular assist device (LVAD) historically results in poor outcomes.<unk>
T-294	right_ventricular rv left_ventricular_assist_device lvad outcomes
H-294	-0.6771360039710999	▁Right ▁vent ri cular ▁ RV ▁ insertion ▁left ▁vent ri cular _ assist ▁device ▁l VAD
D-294	-0.6771360039710999	Right ventricular RV insertion left ventricular_assist device lVAD
P-294	-1.8845 -0.1167 -0.0909 -0.2286 -1.4961 -0.9019 -1.9602 -0.0207 -0.3167 -0.3747 -0.1515 -0.2452 -1.1697 -0.1139 -2.3265 -1.1134 -0.0201 -0.2378 -0.0964
S-1308	We assessed the temporal incidence of and adjusted odds ratio/hazard ratio for death associated with HF concurrent with AMI admission and within 1 year after discharge.<unk>
T-1308	incidence adjusted_odds_ratio hazard_ratio death hf ami admission discharge
H-1308	-1.0055733919143677	▁odds _ haz ard ▁ratio ▁ HF ▁ AMI
D-1308	-1.0055733919143677	odds_hazard ratio HF AMI
P-1308	-4.1609 -2.6576 -0.0282 -0.0214 -0.7238 -0.6038 -0.1857 -1.2092 -0.1804 -1.1444 -0.1457
S-1316	Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: a double-blind randomized controlled feasibility study.<unk>
T-1316	testosterone_therapy exercise_rehabilitation patients chronic_heart_failure testosterone double-blind randomized
H-1316	-1.4459761381149292	▁Test o ster one _ therapy _ active _ rehabilit tion ▁male ▁patients ▁chronic _ heart _ ▁failure ▁testosteron e
D-1316	-1.4459761381149292	Testosterone_therapy_active_rehabilittion male patients chronic_heart_ failure testosterone
P-1316	-1.9990 -0.0713 -0.0151 -1.5514 -2.3912 -0.2340 -3.3769 -4.1376 -1.1935 -1.1622 -0.4560 -2.4576 -2.0425 -3.5689 -0.3600 -1.4894 -0.6590 -3.0353 -0.2159 -0.0115 -1.2736 -0.1096
S-689	Cox proportional hazards models adjusted for demographics, health behaviors, and health status were used to calculate hazard ratios and 95% confidence intervals (CI).<unk>
T-689	cox_proportional_hazards_models health health hazard_ratios confidence_intervals
H-689	-0.8812933564186096	▁co x ▁proportion al _ ▁hazard s
D-689	-0.8812933564186096	cox proportional_ hazards
P-689	-0.5860 -0.0024 -0.2623 -0.0310 -0.4804 -1.1838 -0.1758 -5.0558 -0.1541
S-1718	Individuals hospitalized for AMI without major complications, heart failure, or kidney infection or UTI with major complications had no increase in 30-day rehospitalization.<unk>
T-1718	hospitalized ami complications heart_failure kidney_infection uti complications rehospitalization
H-1718	-0.5525363087654114	▁ AMI ▁heart ▁failure ▁ki dne y ▁infection ▁ UTI
D-1718	-0.5525363087654114	AMI heart failure kidney infection UTI
P-1718	-1.5104 -0.0203 -1.6700 -1.3936 -0.3881 -0.0437 -0.0563 -0.3647 -0.4254 -0.0028 -0.6410 -0.1141
S-705	However, ST2 did not add significantly to reclassification of risk as assessed by changes in the C statistic, net reclassification improvement, and integrated discrimination improvement.<unk>
T-705	st2 c_statistic net_reclassification_improvement integrated_discrimination_improvement
H-705	-1.2341361045837402	▁ST 2 ▁re class ification _ de _ risk ▁c ▁statistic ▁discrimina tion
D-705	-1.2341361045837402	ST2 reclassification_de_risk c statistic discrimination
P-705	-3.8853 -0.4041 -4.2494 -0.0733 -0.0223 -1.0670 -1.4603 -0.2697 -0.3097 -0.4975 -1.9297 -2.9544 -0.0341 -1.1556 -0.1998
S-1599	Screening patients for RAS with either Doppler ultrasonography, computed tomographic angiography, or magnetic resonance angiography is preferred.<unk>
T-1599	patients ras doppler_ultrasonography tomographic_angiography magnetic_resonance_angiography
H-1599	-0.47219839692115784	▁ RAS ▁do pp ler _ ▁ultra son ography ▁to mo graphic ▁ang i ography ▁magnetic _ ▁res on ance _ ▁ang i ography
D-1599	-0.47219839692115784	RAS doppler_ ultrasonography tomographic angiography magnetic_ resonance_ angiography
P-1599	-0.9189 -0.0044 -0.4194 -0.0186 -0.3774 -1.0318 -0.1411 -0.0109 -0.2307 -0.3937 -0.0375 -0.2981 -1.4283 -0.3189 -0.1716 -0.0117 -1.0628 -2.5483 -0.0641 -0.1688 -0.5440 -1.2174 -0.2976 -0.1123 -0.3409 -0.1079
S-107	Treatment with CRT-D did not have a significant effect on IE risk compared with defibrillator-only therapy (HR 0.87, p = 0.51).<unk>
T-107	crt-d therapy
H-107	-0.5583906173706055	▁c RT - d ▁IE ▁de fi br illa tor - on ly ▁ therapy
D-107	-0.5583906173706055	cRT-d IE defibrillator-only therapy
P-107	-0.4883 -0.1721 -0.0838 -0.7567 -0.6909 -3.9839 -0.8460 -0.5845 -0.0254 -0.0774 -0.2845 -0.1353 -0.4614 -0.2457 -0.0456 -0.4865 -0.1246
S-1819	A considerable number of patients eventually reach an advanced or terminal phase, in spite of developments in diagnostic procedure, alternative treatments that can slow progression, management, and follow-up.<unk>
T-1819	patients terminal diagnostic follow-up
H-1819	-1.4745346307754517	
D-1819	-1.4745346307754517	
P-1819	-2.8810 -0.0681
S-316	We conclude that evidence is sufficient to support LVAD use, regardless of transplantation eligibility status, as long as patients are carefully selected and program infrastructure and budget are adequate.<unk>
T-316	evidence lvad transplantation patients budget
H-316	-1.0110671520233154	▁l VAD ▁implant ation _ ▁e ligi bility
D-316	-1.0110671520233154	lVAD implantation_ eligibility
P-316	-2.1725 -0.1385 -2.3992 -0.0263 -0.6439 -1.5965 -0.0017 -0.3852 -2.6589 -0.0880
S-530	We aimed to investigate the association of hypoalbuminemia with postoperative mortality in patients undergoing left ventricular assist device (LVAD) implantation.<unk>
T-530	hypoalbuminemia postoperative mortality patients left_ventricular_assist_device lvad implantation
H-530	-0.5195841193199158	▁hypo album in emia ▁post operativ e ▁mortal ity ▁left ▁vent ri cular ▁implant ation
D-530	-0.5195841193199158	hypoalbuminemia postoperative mortality left ventricular implantation
P-530	-0.0410 -0.2491 -0.4229 -0.2113 -0.6545 -0.1386 -0.2283 -0.5374 -0.0885 -0.2041 -0.3371 -0.3154 -0.1930 -4.4195 -0.0454 -0.5868 -0.1600
S-110	Age-dependent effect of left ventricular ejection fraction on long-term mortality in patients with heart failure (from the Heart Failure Survey in ISrael).<unk>
T-110	left_ventricular_ejection_fraction mortality patients heart_failure heart_failure_survey israel
H-110	-1.079564094543457	▁vent ri cular _ é je ction _ fraction ▁long - term _ ▁mortal ity ▁heart _ ▁Fail ure
D-110	-1.079564094543457	ventricular_éjection_fraction long-term_ mortality heart_ Failure
P-110	-3.3347 -0.4540 -0.5021 -1.8959 -1.6895 -0.8913 -0.0640 -2.3127 -0.1259 -2.7337 -0.0487 -0.6196 -0.9800 -2.1471 -0.0833 -1.0541 -0.6547 -0.8166 -0.0979 -1.9703 -0.1948
S-1596	The pathophysiologic mechanism stems from renal underperfusion resulting in the activation of the renin- angiotensin-aldosterone pathway.<unk>
T-1596	pathophysiologic renal_underperfusion renin-_angiotensin-aldosterone_pathway
H-1596	-0.7235642075538635	▁renal _ ▁under per fusion ▁re nin - ▁ang io ten sin - al do ster one
D-1596	-0.7235642075538635	renal_ underperfusion renin- angiotensin-aldosterone
P-1596	-2.2290 -1.1600 -1.5108 -0.0201 -0.1210 -0.0298 -0.3480 -0.0440 -0.4375 -0.7338 -0.1194 -0.8794 -1.1017 -0.0939 -1.6375 -0.0361 -1.9663 -1.1081 -0.1713
S-860	Secondary endpoints were inappropriate therapy due to atrial fibrillation and atrial tachyarrhythmias, also evaluated as ATP or shock therapy.<unk>
T-860	secondary_endpoints therapy atrial_fibrillation atrial_tachyarrhythmias atp shock_therapy
H-860	-0.7270793318748474	▁at rial _ ▁fi bril lation ▁at rial _ ta chy ar rhythm ias ▁ATP ▁shock ▁ therapy
D-860	-0.7270793318748474	atrial_ fibrillation atrial_tachyarrhythmias ATP shock therapy
P-860	-1.8924 -0.0122 -0.8013 -2.3500 -0.0082 -0.0097 -0.1141 -0.0184 -0.6337 -4.9018 -0.7538 -0.4575 -0.2195 -1.4948 -0.0590 -0.0889 -0.5011 -0.0117 -0.1469 -0.0666
S-1293	After percutaneous coronary revascularization a hemodynamically stable situation could be achieved and the patient was admitted to the intensive care unit (ICU).<unk>
T-1293	percutaneous coronary_revascularization hemodynamically stable patient intensive_care_unit icu
H-1293	-0.6934977769851685	▁per cuta ne _ ▁corona ry _ re vas cular ization ▁hem o dynamic ally
D-1293	-0.6934977769851685	percutane_ coronary_revascularization hemodynamically
P-1293	-0.2210 -0.0029 -0.0689 -2.7572 -0.6190 -1.0469 -0.6662 -0.9268 -0.2109 -0.3220 -0.9074 -0.2461 -0.0320 -0.0290 -0.7316 -2.9381 -0.0635
S-965	Moreover, nicorandil provided a significant cardioprotection via inhibition of apoptotic signaling pathway, DNA fragmentation and mitochondrial ultrastructural changes.<unk>
T-965	nicorandil cardioprotection apoptotic_signaling_pathway dna_fragmentation mitochondrial
H-965	-0.4326881766319275	▁nic oran dil ▁cardio protec tion ▁apo pto tic ▁signal ing ▁path way ▁DNA _ ▁fragment ation ▁mito cho ndri al _ ▁ultra struct ural ▁changes
D-965	-0.4326881766319275	nicorandil cardioprotection apoptotic signaling pathway DNA_ fragmentation mitochondrial_ ultrastructural changes
P-965	-0.4550 -0.0189 -0.1870 -0.2329 -0.0113 -0.0042 -0.2184 -0.0063 -0.7207 -0.4263 -0.5789 -0.8346 -0.1434 -0.0811 -3.3422 -0.1931 -0.0162 -0.0149 -0.4708 -0.0458 -0.0513 -0.3615 -2.0071 -0.0282 -0.0104 -1.4336 -0.1574 -0.0636
S-760	BACKGROUND: Obesity and diabetes mellitus are important metabolic risk factors and frequent comorbidities in heart failure with preserved ejection fraction.<unk>
T-760	obesity diabetes_mellitus metabolic comorbidities heart_failure_with_preserved_ejection_fraction
H-760	-1.027803897857666	▁diabetes _ ▁mell itus ▁metabol ic _ risk ▁conditions ▁heart _ ▁failure ▁e je ction _ fraction
D-760	-1.027803897857666	diabetes_ mellitus metabolic_risk conditions heart_ failure ejection_fraction
P-760	-1.4101 -2.4330 -0.1808 -0.1668 -0.7927 -0.0776 -1.5623 -0.6802 -3.4520 -0.7811 -0.5208 -4.1726 -1.9338 -0.3022 -0.0419 -0.8094 -0.0087 -0.0791 -0.1233
S-869	Global proteomics and pathway analysis of pressure-overload-induced heart failure and its attenuation by mitochondrial-targeted peptides.<unk>
T-869	proteomics pressure-overload-induced_heart_failure mitochondrial-targeted_peptides
H-869	-0.40794554352760315	▁prote o mics ▁pressure - over load - indu ced ▁heart _ ▁failure ▁mito cho ndri al - tar get ed ▁pe pti des
D-869	-0.40794554352760315	proteomics pressure-overload-induced heart_ failure mitochondrial-targeted peptides
P-869	-1.6191 -0.3583 -0.0013 -0.3320 -0.0878 -0.0541 -0.0901 -0.4851 -0.0109 -1.7777 -0.1518 -1.3872 -2.1432 -0.0005 -0.6472 -0.1723 -0.0267 -0.1147 -0.0490 -0.0300 -0.0651 -0.5720 -0.0658 -0.0969 -0.1419 -0.1260
S-450	The inhibition of vascular endothelial growth factor (VEGF) signaling has been shown to be crucial for the transition from compensatory hypertrophy to cardiac failure.<unk>
T-450	vascular_endothelial_growth_factor vegf transition compensatory_hypertrophy cardiac_failure
H-450	-0.8132127523422241	▁inhibi tion ▁vas cular _ en dot heli al _ ▁growth _ factor VE GF ▁transition ▁compensa tory _ ▁hyper trop hy ▁cardiac
D-450	-0.8132127523422241	inhibition vascular_endothelial_ growth_factorVEGF transition compensatory_ hypertrophy cardiac
P-450	-1.9029 -0.0151 -0.7645 -0.0367 -0.5167 -0.7376 -2.1043 -0.0985 -0.0184 -0.7847 -1.3905 -2.0543 -2.0630 -2.0259 -0.1252 -0.3923 -0.2256 -0.4292 -0.7895 -0.3306 -0.0016 -0.0503 -0.0343 -3.3704 -0.0683
S-103	The present study population comprised 1,045 patients with IC enrolled in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy.<unk>
T-103	patients ic multicenter_automatic_defibrillator_implantation_trial-cardiac_resynchronization_therapy
H-103	-0.465121865272522	▁IC ▁multi center _ automat ic _ de ib rilla tor ▁implant ation _ tri al - Card iac _ re syn chron ization ▁Therapy
D-103	-0.465121865272522	IC multicenter_automatic_deibrillator implantation_trial-Cardiac_resynchronization Therapy
P-103	-1.6147 -0.5096 -0.0194 -0.2147 -0.3163 -0.1758 -0.1956 -1.0263 -1.8713 -0.5602 -0.1419 -0.2661 -0.0209 -0.9197 -0.4155 -0.0809 -0.5478 -0.2409 -0.5545 -0.6248 -0.5052 -0.0009 -0.0000 -0.4858 -0.9979 -0.1511 -0.1005
S-320	Accordingly, we used speckle tracking echocardiography (STE) to analyze BiVP during acute right ventricular pressure overload (RVPO).<unk>
T-320	speckle_tracking_echocardiography ste bivp acute right_ventricular_pressure_overload rvpo
H-320	-0.7615349292755127	▁spec kle _ track ing ▁e cho card i ography ▁ste ▁bi VP ▁vent ri cular _ tension RV PO
D-320	-0.7615349292755127	speckle_tracking echocardiography ste biVP ventricular_tensionRVPO
P-320	-1.8952 -0.0953 -1.6724 -0.1128 -0.1186 -1.3172 -0.0914 -0.0961 -0.6987 -0.1835 -1.8041 -0.7696 -0.1002 -2.5763 -0.1199 -0.2169 -1.1088 -1.1318 -1.4069 -0.9928 -0.1246 -0.1206
S-1174	Cardiopulmonary exercise testing with echocardiographic assessment of myocardial function and left ventricular filling were undertaken at rest and after exercise.<unk>
T-1174	cardiopulmonary_exercise_testing echocardiographic myocardial_function left_ventricular_filling exercise
H-1174	-0.7165251970291138	▁Card io pul mon ary ▁e cho car dio graphic ▁assessment ▁my o card ial _ f ré que nce ▁vent ri cular ▁fill ing
D-1174	-0.7165251970291138	Cardiopulmonary echocardiographic assessment myocardial_fréquence ventricular filling
P-1174	-0.2009 -1.0148 -0.1420 -1.5848 -0.8494 -2.8855 -0.0481 -0.0086 -0.1729 -0.9281 -3.3484 -0.7596 -0.0642 -0.0410 -0.0356 -1.4848 -3.3220 -0.0796 -0.2229 -0.1202 -0.1769 -0.0936 -0.0654 -1.4356 -0.0330 -0.1834 -0.0449
S-1627	The Health Buddy Program was most strongly associated with fewer admissions for individuals with chronic obstructive pulmonary disease and mortality for those with congestive heart failure.<unk>
T-1627	health_buddy_program admissions chronic_obstructive_pulmonary_disease mortality congestive_heart_failure
H-1627	-0.9561794996261597	▁Health ▁Budd y _ program ▁chronic _ ▁ob struct ive _ ▁pulmonar y ▁disease ▁mortal ity ▁con ges tive _ ▁heart _ ▁failure
D-1627	-0.9561794996261597	Health Buddy_program chronic_ obstructive_ pulmonary disease mortality congestive_ heart_ failure
P-1627	-0.9999 -0.5087 -0.0240 -4.3973 -1.8875 -1.9397 -0.8429 -1.5471 -0.0743 -0.1025 -0.7261 -0.1602 -0.1423 -2.8004 -1.4764 -0.1254 -0.1111 -0.0505 -0.0390 -0.3243 -2.9953 -0.9095 -1.5075 -0.1184 -0.0942
S-1587	Various measures of HR dynamics, such as time-domain, spectral, and non-linear measures of HR variability have been used in risk stratification.<unk>
T-1587	hr_variability risk_stratification
H-1587	-0.8061688542366028	▁HR _ dynamic s ▁temps - doma in ▁HR ▁variabil ity ▁risk
D-1587	-0.8061688542366028	HR_dynamics temps-domain HR variability risk
P-1587	-0.2460 -2.7494 -0.8418 -0.0335 -1.0821 -0.0868 -0.0009 -0.0488 -1.6360 -1.6052 -0.6020 -0.7433 -1.4316 -0.1790
S-1313	Occurrence of HF within 90 days of the index AMI was associated with an adjusted hazard ratio of 2.7 for 1-year mortality in 90-day survivors.<unk>
T-1313	hf ami hazard_ratio mortality
H-1313	-0.9538984894752502	▁ HF ▁index ▁ AMI
D-1313	-0.9538984894752502	HF index AMI
P-1313	-1.7686 -0.2642 -0.0569 -0.4821 -0.0548 -3.8020 -0.2487
S-114	Among the study patients, 30% had preserved LVEF and 20%, 25%, and 25%, had mild, moderate, and severe reductions in LVEF, respectively.<unk>
T-114	patients preserved_lvef lvef
H-114	-0.3917995095252991	▁LV EF
D-114	-0.3917995095252991	LVEF
P-114	-0.8318 -0.2271 -0.4606 -0.0478
S-1088	CONCLUSIONS: UPR can be initiated by Na+ channel mRNA splice variants and is involved in the reduction of cardiac Na+ current during human HF.<unk>
T-1088	upr mrna_splice cardiac hf
H-1088	-0.9825290441513062	▁u PR ▁na + ▁channel ▁m RNA ▁sp lice ▁cardiac _ na + ▁current ▁ HF
D-1088	-0.9825290441513062	uPR na+ channel mRNA splice cardiac_na+ current HF
P-1088	-0.0718 -0.1810 -2.0948 -3.9292 -0.1000 -0.1640 -0.1295 -0.0908 -0.0266 -2.4420 -1.4453 -2.4369 -1.4211 -1.6659 -1.1404 -0.0494 -0.1710 -0.1258
S-1201	Diuretic efficacy may be limited by adverse neurohormonal activation and by "congestion-like" symptoms that may occur in the absence of fluid overload.<unk>
T-1201	diuretic neurohormonal symptoms fluid_overload
H-1201	-0.6366472244262695	▁di ure tic _ ▁ef fica cy ▁neuro hormon al _ activa tion ▁con gestion - like ▁fluid _ over load
D-1201	-0.6366472244262695	diuretic_ efficacy neurohormonal_activation congestion-like fluid_overload
P-1201	-0.5311 -0.0405 -3.3836 -1.1071 -0.1643 -0.0015 -0.5980 -0.7342 -0.3505 -0.1796 -0.4436 -0.7797 -0.0286 -2.3095 -0.0015 -0.4083 -0.2587 -0.8229 -0.6495 -1.5118 -0.1209 -0.1357 -0.0819
S-173	Our results are not in favour of apoptosis in the pathogenesis of heart failure in this model and may be it could be attributed to activation of other systems.<unk>
T-173	apoptosis pathogenesis heart_failure
H-173	-0.7931321263313293	▁apo pto sis ▁path ogen es is _ de _ ▁heart _ ▁failure
D-173	-0.7931321263313293	apoptosis pathogenesis_de_ heart_ failure
P-173	-0.9630 -0.0340 -1.3142 -1.5772 -0.2631 -0.0779 -0.6677 -0.7902 -1.4251 -0.2342 -1.1478 -0.6897 -1.4837 -1.1050 -0.1242
S-1052	Moreover, BETs were found to function, in part, by promoting transcriptional pause release (and thereby re-activating transcription) during pathological stress.<unk>
T-1052	bets transcriptional_pause_release pathological
H-1052	-0.9023069739341736	▁ BET s ▁tran scription al _ ▁pause _ release ▁tran scription
D-1052	-0.9023069739341736	BETs transcriptional_ pause_release transcription
P-1052	-0.8270 -0.0173 -2.2319 -1.3071 -0.1267 -1.0285 -0.5318 -1.1481 -0.2762 -0.9458 -0.2455 -0.0898 -3.7113 -0.1452
S-278	At 6 wk after the procedures, only ANS mice showed significant decreases in LV fractional shortening and increases in lung weight with a high incidence.<unk>
T-278	lv_fractional_shortening lung incidence
H-278	-0.9638338685035706	▁implant _ fraction al _ short en ing ▁lung _ weight
D-278	-0.9638338685035706	implant_fractional_shortening lung_weight
P-278	-3.6722 -3.1189 -0.9128 -0.1089 -0.1213 -1.8776 -0.0753 -0.5466 -0.1034 -0.9525 -0.6971 -0.2600 -0.0832
S-188	We sought to evaluate the relationship between sex, EF, and BNP in HF patients and determine prognostic significance of BNP as it relates to sex and EF.<unk>
T-188	ef bnp hf patients prognostic significance bnp ef
H-188	-1.4633642435073853	▁sex ▁EF ▁b NP ▁ HF ▁b NP
D-188	-1.4633642435073853	sex EF bNP HF bNP
P-188	-4.3738 -2.6470 -0.3179 -0.2293 -1.5037 -0.0983 -1.6219 -0.4730 -3.1514 -0.2173
S-1942	However, with similar dose uptitration, the former versus the latter had a significantly larger HR reduction (17±22 versus 4±15 bpm; P value=0.027).<unk>
T-1942	uptitration hr_reduction bpm p_value
H-1942	-1.0890791416168213	▁dose _ up tit ration ▁HR
D-1942	-1.0890791416168213	dose_uptitration HR
P-1942	-3.0041 -1.7565 -0.3779 -0.6233 -0.0173 -0.7262 -2.1304 -0.0769
S-1910	Screening with a 12-lead ECG in older athletes is of limited value given the overwhelming contribution of atherosclerotic CAD to sudden cardiac death.<unk>
T-1910	ecg atherosclerotic_cad cardiac_death
H-1910	-0.4958840608596802	▁e CG ▁a ther os cle ro tic ▁CAD ▁sud den ▁cardiac ▁death
D-1910	-0.4958840608596802	eCG atherosclerotic CAD sudden cardiac death
P-1910	-0.9226 -0.4511 -0.7304 -0.0038 -0.2663 -0.0684 -0.0599 -0.6121 -0.6424 -0.0784 -0.0180 -0.8659 -2.4929 -0.1119 -0.1143
S-446	Within a diverse community-based cohort with incident systolic heart failure, use of spironolactone was not independently associated with risks of hospitalization or death.<unk>
T-446	systolic_heart_failure spironolactone hospitalization death
H-446	-0.9332907795906067	▁incident _ syn chron _ heart _ ▁failure ▁spi rono lac tone ▁hospital ization
D-446	-0.9332907795906067	incident_synchron_heart_ failure spironolactone hospitalization
P-446	-2.6421 -0.9443 -0.9016 -1.1291 -1.4318 -1.8978 -0.6053 -1.3699 -0.1230 -0.0182 -0.1783 -0.1806 -0.6634 -1.1141 -1.6290 -0.1043
S-1087	PERK inhibition prevented the loss of full-length SCN5A and Kv4.3 mRNA levels resulting from expressing Na+ channel mRNA splice variants.<unk>
T-1087	perk scn5a kv4.3 mrna mrna_splice
H-1087	-1.1718500852584839	▁PER K ▁m RNA ▁m RNA ▁sp lice
D-1087	-1.1718500852584839	PERK mRNA mRNA splice
P-1087	-2.5008 -0.6175 -3.3840 -0.1227 -3.9721 -0.1996 -0.1581 -0.0154 -0.6127 -0.1355
S-1673	In this study, we have investigated the potential dysfunction of a naturally occurring Rad variant (Q66P) that has been associated with congestive heart failure in humans.<unk>
T-1673	dysfunction rad_variant q66p congestive_heart_failure
H-1673	-1.2111061811447144	▁dys function ▁rad _ variant ▁con ges tive _ ▁heart _ ▁failure
D-1673	-1.2111061811447144	dysfunction rad_variant congestive_ heart_ failure
P-1673	-2.7012 -0.3196 -0.8958 -3.4188 -1.2690 -3.6672 -0.2674 -0.0438 -0.2177 -1.8428 -0.5568 -1.1600 -0.5228 -0.0725
S-1614	Two networks were established and then functional enrichment analysis revealed that "regulation of programmed cell death" was most significantly over-represented in common DEGs.<unk>
T-1614	functional_enrichment_analysis regulation cell_death degs
H-1614	-0.8150924444198608	▁implant ation ▁programme d _ cell _ ▁death ▁DE G s
D-1614	-0.8150924444198608	implantation programmed_cell_ death DEGs
P-1614	-4.2827 -0.0125 -2.2685 -0.1023 -0.2005 -0.7112 -0.2644 -0.4263 -1.1988 -0.8384 -0.0548 -0.1266 -0.1093
S-1812	Moreover, elevated Mena expression correlates with HF in human and animal models, yet the precise role of Mena in cardiac pathophysiology is unclear.<unk>
T-1812	elevated mena_expression correlates hf mena cardiac pathophysiology
H-1812	-0.8471662402153015	▁Men a ▁expression ▁ HF ▁ HF ▁cardiac _ pat ho phy si ology
D-1812	-0.8471662402153015	Mena expression HF HF cardiac_pathophysiology
P-1812	-0.5935 -0.1725 -0.9630 -0.2870 -0.0163 -2.3167 -0.3024 -4.6030 -0.8700 -1.7940 -0.2735 -0.0512 -0.2849 -0.6865 -0.2022 -0.1380
S-1751	The benefits of controlled randomized trials can be replicated in the real world, emphasizing the importance of tailored follow-up and long-term continuity of care.<unk>
T-1751	randomized follow-up
H-1751	-1.0377637147903442	▁control led _ ▁random ized ▁trial s
D-1751	-1.0377637147903442	controlled_ randomized trials
P-1751	-3.4860 -0.2752 -0.2213 -0.7473 -1.3873 -1.7228 -0.0234 -1.3963 -0.0803
S-1358	RECENT FINDINGS: Apart from these perturbations, increasing evidence points to alterations in intestinal morphology, permeability, and absorption function in patients with CHF.<unk>
T-1358	evidence intestinal patients chf
H-1358	-0.8253907561302185	▁REC ENT _ ▁FIN DING s ▁intestinal ▁ morph ologie ▁per me ability ▁ab sor p tion _ ▁function ▁CHF
D-1358	-0.8253907561302185	RECENT_ FINDINGs intestinal morphologie permeability absorption_ function CHF
P-1358	-1.6998 -0.1981 -0.5646 -0.5220 -0.1845 -0.8094 -5.3758 -0.7782 -0.0132 -0.8252 -1.7540 -0.0073 -0.2798 -0.1632 -0.0080 -0.4267 -0.0336 -0.7191 -2.5379 -1.0244 -0.1630 -0.0709
S-1024	We have reviewed the current status of NP measurement together with the potential contribution of POC measurement of NPs to clinical care delivery in the emergency and other settings.<unk>
T-1024	poc nps clinical
H-1024	-1.490140438079834	▁ NP
D-1024	-1.490140438079834	NP
P-1024	-0.5495 -0.0318 -5.2115 -0.1678
S-679	Trastuzumab users were more likely to develop CHF than nontrastuzumab users (hazard ratio [HR], 1.95; 95% CI, 1.75 to 2.17).<unk>
T-679	trastuzumab chf nontrastuzumab_users hazard_ratio
H-679	-1.0795382261276245	▁Tras tuz um ab ▁CHF
D-679	-1.0795382261276245	Trastuzumab CHF
P-679	-1.8714 -0.0110 -0.0808 -0.5949 -0.3049 -4.5774 -0.1164
S-1353	Patients with atrial fibrillation (AF) and heart failure (HF) are at risk for stroke, and progress in anticoagulation has led to new options for these patients.<unk>
T-1353	patients atrial_fibrillation heart_failure hf stroke anticoagulation patients
H-1353	-0.9234405159950256	▁at rial _ fi bril lation AF ▁heart _ ▁failure ▁ HF ▁progress _ ▁in _ ▁antico ag ulation
D-1353	-0.9234405159950256	atrial_fibrillationAF heart_ failure HF progress_ in_ anticoagulation
P-1353	-0.6785 -0.0540 -0.7146 -3.0208 -0.0186 -0.0037 -1.5177 -0.7229 -0.5351 -0.9489 -1.9207 -0.0012 -1.7078 -1.8606 -0.5893 -1.0441 -2.0396 -0.9926 -0.0126 -0.9347 -0.0744
S-234	Our data suggest that Fontan failure is a distinct circulatory derangement with hemodynamic features similar to portal hypertension, albeit with limited ability to augment cardiac output.<unk>
T-234	fontan_failure circulatory hemodynamic portal_hypertension cardiac_output
H-234	-0.48736944794654846	▁Font an _ ▁failure ▁circula tory _ de rang ement ▁hem o dynamic ▁portal _ ▁hyper tension ▁aug ment ▁cardiac ▁output
D-234	-0.48736944794654846	Fontan_ failure circulatory_derangement hemodynamic portal_ hypertension augment cardiac output
P-234	-0.4770 -0.2583 -0.6720 -1.3872 -0.2819 -0.4016 -0.2222 -0.1082 -0.1531 -0.0137 -0.6455 -0.0464 -0.0107 -0.4278 -0.3263 -0.4180 -0.0007 -2.0111 -0.0108 -0.5133 -2.6354 -0.1466 -0.0417
S-433	Combination of these into an echocardiographic score allowed prediction of LV reverse remodeling with a sensitivity of 84% and a specificity of 79%.<unk>
T-433	combination echocardiographic lv_reverse_remodeling sensitivity specificity
H-433	-0.40322360396385193	▁e cho car dio graphic ▁score ▁LV ▁rever se ▁remodel ing
D-433	-0.40322360396385193	echocardiographic score LV reverse remodeling
P-433	-0.0401 -0.1144 -0.1184 -0.6438 -0.8160 -0.3931 -0.0470 -0.7729 -0.0151 -1.1140 -0.1909 -0.8054 -0.1707
S-112	We sought to evaluate the differential effect of LVEF on long-term mortality after hospitalization for acute decompensated HF in a real-world setting.<unk>
T-112	differential_effect lvef mortality hospitalization acute decompensated_hf
H-112	-0.575924813747406	▁LV EF ▁long - term ▁mortal ity ▁a cute _ de com pensa ted ▁ HF
D-112	-0.575924813747406	LVEF long-term mortality acute_decompensated HF
P-112	-0.4677 -0.5079 -1.1867 -0.0652 -0.4094 -2.2490 -0.2036 -1.3498 -0.0411 -0.1754 -0.0706 -0.2588 -0.0074 -2.2006 -0.8238 -0.0386 -0.1171 -0.1938
S-508	The occlusion time of the bottleneck stent and the timing of myocardial infarction could be modulated by the duration of antiplatelet medication.<unk>
T-508	bottleneck_stent myocardial_infarction antiplatelet_medication
H-508	-0.4630008041858673	▁bottle ne ck ▁sten t ▁tim ing ▁my o card ial ▁in far ction ▁anti plate let ▁medication
D-508	-0.4630008041858673	bottleneck stent timing myocardial infarction antiplatelet medication
P-508	-0.5122 -0.0188 -0.3388 -0.4171 -0.0243 -1.3996 -0.0156 -2.2040 -0.3144 -0.2682 -0.0815 -0.3572 -0.6811 -0.0113 -0.0385 -0.7131 -0.5111 -1.0628 -0.1603 -0.1301
S-282	After the addition of salt loading and uninephrectomy to the ANG II infusion mouse model, cardiac function was significantly impaired, and mice developed HF.<unk>
T-282	salt_loading uninephrectomy ang_ii_infusion cardiac_function hf
H-282	-0.7556089758872986	▁salt _ ▁load ing ▁un ine ph r ecto my ▁ANG _ ▁II ▁in fusion ▁cardiac _ fon cti onnement ▁ HF
D-282	-0.7556089758872986	salt_ loading uninephrectomy ANG_ II infusion cardiac_fonctionnement HF
P-282	-0.2144 -3.0473 -0.3070 -0.0178 -0.3620 -0.0611 -0.9176 -0.0774 -0.0351 -1.3667 -0.1311 -0.9435 -0.5186 -0.0062 -0.0251 -1.6542 -2.5365 -2.0863 -0.5456 -0.6788 -2.3530 -0.1250 -0.0701 -0.0541
S-296	For patients requiring biventricular support, we have used a hybrid system consisting of a HeartMate II LVAD and CentriMag right ventricular assist device (RVAD).<unk>
T-296	patients biventricular_support heartmate_ii lvad centrimag right_ventricular_assist_device rvad
H-296	-0.5498176217079163	▁bi ven tri cular ▁support ▁Heart Mate _ ▁II ▁l VAD ▁Centri Mag ▁vent ri cular _ assist ▁device r VAD
D-296	-0.5498176217079163	biventricular support HeartMate_ II lVAD CentriMag ventricular_assist devicerVAD
P-296	-0.6990 -0.0909 -0.0313 -0.8600 -1.6070 -1.0032 -0.2451 -1.7770 -0.6955 -1.1479 -0.0089 -0.0328 -0.1280 -0.4414 -0.0312 -0.0879 -0.3729 -0.0990 -0.9251 -2.0483 -0.0378 -0.1621 -0.1135
S-521	Blood pressure was measured by arm cuff; stroke volume (SV), ejection fraction, and end-diastolic volume were assessed by echocardiography.<unk>
T-521	blood_pressure arm_cuff stroke_volume ejection_fraction end-diastolic_volume echocardiography
H-521	-0.881914496421814	▁Blood _ tension ▁arm _ ▁cu ff ▁stroke _ pu issa nce ▁e je ction _ fraction ▁end - dia sto lic _ ▁volume ▁e cho card i ography
D-521	-0.881914496421814	Blood_tension arm_ cuff stroke_puissance ejection_fraction end-diastolic_ volume echocardiography
P-521	-0.2567 -1.7247 -0.8679 -2.6670 -0.6854 -0.5603 -0.0662 -0.0185 -1.6038 -2.9720 -1.0046 -0.0123 -1.9641 -0.1606 -0.0119 -0.4521 -0.0043 -1.1087 -0.0540 -3.3447 -1.1510 -3.6491 -1.5116 -0.4140 -0.0418 -0.0456 -0.0785 -0.3326 -0.3062 -0.1585 -0.1109
S-1060	The percentage of fibrosis of heart failure myocardial tissue was compared with similar left ventricular tissue from control animals using trichrome blue histologic analysis.<unk>
T-1060	fibrosis heart_failure myocardial_tissue left_ventricular trichrome_blue_histologic_analysis
H-1060	-0.7504477500915527	▁fibro sis _ de _ ▁heart _ ▁failure _ My o card ial _ ▁tissu e ▁left ▁vent ri cular _ ▁tissu e ▁tri ch rom e ▁blue ▁his t ologic
D-1060	-0.7504477500915527	fibrosis_de_ heart_ failure_Myocardial_ tissue left ventricular_ tissue trichrome blue histologic
P-1060	-0.0039 -0.2433 -1.5253 -1.5821 -0.2554 -0.8567 -0.2626 -1.4348 -1.2297 -3.3524 -0.2152 -0.0698 -0.0527 -0.9804 -1.4865 -0.3278 -1.3200 -1.0201 -0.1700 -0.1285 -1.2556 -2.8832 -0.1937 -1.2395 -0.0036 -0.0234 -0.0391 -0.2813 -0.7753 -0.0343 -0.1032 -1.2797 -0.1358
S-781	We evaluated the Kansas City Cardiomyopathy Questionnaire (KCCQ), a validated measure of HF with reduced EF, in patients with HFpEF.<unk>
T-781	kansas_city_cardiomyopathy_questionnaire kccq hf_with_reduced_ef patients hfpef
H-781	-0.8264739513397217	▁Kansas ▁City ▁Card i om yo pathy ▁k cc q ▁ HF ▁h p EF
D-781	-0.8264739513397217	Kansas City Cardiomyopathy kccq HF hpEF
P-781	-0.0115 -0.7414 -2.8938 -0.2865 -0.0301 -3.2978 -0.2784 -1.4273 -0.1799 -0.6586 -0.3182 -0.1751 -2.8783 -0.0643 -0.3498 -0.3807 -0.0784
S-1642	Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial.<unk>
T-1642	outcomes patients atrial_fibrillation early_treatment_of_atrial_fibrillation_for_stroke_prevention_trial
H-1642	-1.0528619289398193	▁implant ation ▁implant ation ▁at rial _ f ré que nce ▁implant ation ▁at rial _ ▁fi bril lation ▁Stro ke _ ▁pre vention
D-1642	-1.0528619289398193	implantation implantation atrial_fréquence implantation atrial_ fibrillation Stroke_ prevention
P-1642	-1.7025 -0.8267 -3.3060 -0.3688 -1.2756 -0.0711 -0.5206 -2.4279 -1.1968 -1.3265 -0.0157 -3.2277 -0.2057 -2.9585 -0.2559 -0.4503 -3.1664 -0.0413 -0.0205 -0.2359 -0.3355 -1.0598 -0.5219 -0.0070 -1.7883 -0.0614
S-491	Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis.<unk>
T-491	tricuspid_annular_plane_systolic_excursion pulmonary_arterial_systolic_pressure heart_failure right_ventricular_contractile_function prognosis
H-491	-1.1281956434249878	▁ann ular ▁plane _ syn chron e _ excursion ▁pulmonar y _ ▁arterial _ ▁sy sto lic _ tension ▁heart _ ▁failure ▁vent ri cular _ contract ile
D-491	-1.1281956434249878	annular plane_synchrone_excursion pulmonary_ arterial_ systolic_tension heart_ failure ventricular_contractile
P-491	-4.1406 -0.0022 -0.2763 -0.3689 -1.3256 -3.1525 -3.3761 -1.3919 -1.2014 -0.0015 -0.0248 -1.7541 -0.8091 -0.3506 -2.0614 -0.0891 -3.0197 -0.6063 -0.6520 -0.4470 -0.7961 -4.7131 -0.9327 -0.0946 -0.1372 -0.3951 -0.4879 -0.0770 -0.9215 -0.2397
S-1728	In contrast, patients cared for by high-volume physicians had higher readmission rates (25.8% versus 21.5%; P<0001); this relationship was similar across hospital volume groups.<unk>
T-1728	patients physicians readmission hospital
H-1728	-1.2281566858291626	▁high - volu me ▁physician s
D-1728	-1.2281566858291626	high-volume physicians
P-1728	-5.0980 -0.0496 -0.0205 -0.0068 -2.0735 -0.0552 -2.4184 -0.1033
S-564	CONCLUSIONS: Beyond divergent etiology and comorbidities, younger patients exhibited striking differences in presentation and outcomes compared with older counterparts.<unk>
T-564	etiology comorbidities patients outcomes
H-564	-1.3612964153289795	
D-564	-1.3612964153289795	
P-564	-2.6890 -0.0336
S-1934	Given that exercise training improves outcomes in HF patients, assessment of perceived barriers may facilitate individualized approaches to implement exercise training therapy in clinical practice.<unk>
T-1934	exercise training outcomes hf patients exercise training therapy clinical
H-1934	-1.227541446685791	▁ HF
D-1934	-1.227541446685791	HF
P-1934	-1.9408 -0.0684 -2.7808 -0.1201
S-95	Of these proteins, 176 exhibited altered expression during cardiac hypertrophy and failure; we conducted extensive functional characterization of one of these proteins, Nucleolin.<unk>
T-95	proteins expression cardiac_hypertrophy proteins nucleolin
H-95	-0.9270064830780029	▁cardiac ▁hyper trop hy ▁nu cle olin
D-95	-0.9270064830780029	cardiac hypertrophy nucleolin
P-95	-0.6958 -2.2577 -0.0170 -0.0721 -4.5203 -0.0061 -0.3475 -0.2933 -0.1332
S-768	The underlying myocardial DD was obvious from high muscle strip stiffness, which was largely (±80%) attributable to titin hypophosphorylation.<unk>
T-768	myocardial_dd muscle titin_hypophosphorylation
H-768	-0.6835154294967651	▁my o card ial ▁ DD ▁muscle _ ▁strip _ ▁sti ff ness ▁titi n ▁hypo phos phor y lation
D-768	-0.6835154294967651	myocardial DD muscle_ strip_ stiffness titin hypophosphorylation
P-768	-1.6954 -0.1152 -0.0446 -0.0166 -1.0390 -0.0136 -2.6602 -1.0377 -1.5163 -0.4314 -0.3352 -0.5979 -3.0057 -0.0684 -0.1141 -0.1096 -0.0498 -0.2336 -1.6014 -0.0187 -0.2099 -0.1231
S-1158	OBJECTIVES: This study sought to examine the relationships between right ventricular (RV) function, body composition, and prognosis in patients with advanced heart failure (HF).<unk>
T-1158	right_ventricular rv prognosis patients heart_failure hf
H-1158	-1.3324706554412842	▁vent ri cular ▁ RV
D-1158	-1.3324706554412842	ventricular RV
P-1158	-2.8690 -0.1207 -0.1228 -2.4992 -0.1702 -3.4674 -0.0781
S-1969	Beneficial effect of ARNI was consistent also for total and cardiovascular mortality, for hospitalization for heart failure and in other pre-specified subgroup analyses, including quality of life.<unk>
T-1969	arni cardiovascular_mortality hospitalization heart_failure quality_of_life
H-1969	-1.02679443359375	▁AR NI ▁cardiovascular ▁mortal ity ▁hospital ization _ for _ heart _ ▁failure ▁quality _ of _ ▁life
D-1969	-1.02679443359375	ARNI cardiovascular mortality hospitalization_for_heart_ failure quality_of_ life
P-1969	-3.9049 -1.0626 -0.1532 -1.2092 -0.0907 -0.0913 -0.6080 -0.7565 -2.8178 -0.4996 -1.1789 -0.6641 -1.7669 -0.8839 -0.4161 -0.3166 -0.2986 -3.4418 -0.2165 -0.1585
S-340	However, functional MS could develop even in patients with a history of successful valve plasty and annular size reduction for degenerative MR if the LV were dilated by another disease.<unk>
T-340	functional_ms patients valve_plasty degenerative_mr dilated disease
H-340	-0.4701274335384369	▁functional ▁MS ▁val ve ▁plast y ▁ann ular ▁size _ ▁re duction ▁de genera tive ▁MR ▁LV ▁dil ated ▁disease
D-340	-0.4701274335384369	functional MS valve plasty annular size_ reduction degenerative MR LV dilated disease
P-340	-0.3344 -0.0887 -1.1336 -0.0113 -0.2917 -0.2638 -0.0224 -0.0004 -2.1168 -0.5091 -0.9324 -0.0008 -0.7498 -0.2394 -0.0139 -0.4794 -0.1682 -1.3422 -0.0345 -1.3989 -0.1664 -0.0448
S-131	Higher EO-CFUs and lower CD34+VEGFR2+ cells were associated with improved functional capacity and reduced mortality in nondiabetic patients.<unk>
T-131	eo-cfus cells functional_capacity mortality nondiabetic patients
H-131	-1.4103115797042847	▁ EO - c FU s ▁CD 34 _ ve g FR 2 _ cell s
D-131	-1.4103115797042847	EO-cFUs CD34_vegFR2_cells
P-131	-1.6114 -0.0217 -0.0724 -0.9436 -0.7421 -0.6991 -0.4916 -0.3954 -4.0774 -1.3575 -1.0373 -1.5009 -2.3279 -4.8979 -0.6691 -0.1407 -4.2312 -0.1687
S-842	In conclusion, in the HF-ACTION cohort, there was no correlation with baseline Hgb and baseline HRQoL as measured by the KCCQ.<unk>
T-842	hf-action correlation baseline hgb baseline hrqol kccq
H-842	-0.4033791124820709	▁ HF - ac tion ▁h gb ▁base line ▁HR Qo L ▁k cc q
D-842	-0.4033791124820709	HF-action hgb baseline HRQoL kccq
P-842	-0.3568 -0.0887 -0.0666 -1.7795 -0.5606 -0.6774 -0.0657 -0.2891 -0.0211 -1.1919 -0.0173 -0.2882 -0.4157 -0.2607 -0.6163 -0.1026 -0.0591
S-1001	BACKGROUND: Frailty, an important prognostic indicator in heart failure (HF), may be defined as a biological phenotype or an accumulation of deficits.<unk>
T-1001	frailty prognostic heart_failure hf biological_phenotype
H-1001	-0.90981125831604	▁Fra il ty ▁heart _ ▁failure ▁h ▁bi ological ▁ph eno type ▁accumula tion _ de _ ▁deficit s
D-1001	-0.90981125831604	Frailty heart_ failure h biological phenotype accumulation_de_ deficits
P-1001	-1.9766 -0.2414 -1.2533 -1.7780 -0.5634 -1.5806 -1.6732 -1.3466 -0.1499 -4.0271 -0.0212 -0.0084 -0.4905 -0.0305 -1.2131 -1.2250 -0.8670 -0.3583 -0.0283 -0.2068 -0.0669
S-375	This case report demonstrates that functional MS could develop even in a patient with a history of successful valve plasty for degenerative MR, if the LV is dilated by another disease.<unk>
T-375	report functional_ms patient valve_plasty degenerative_mr dilated disease
H-375	-0.5170997381210327	▁functional ▁MS ▁val ve ▁plast y ▁de genera tive ▁MR ▁LV
D-375	-0.5170997381210327	functional MS valve plasty degenerative MR LV
P-375	-0.4637 -0.0980 -1.7217 -0.0081 -0.5090 -0.3353 -1.3760 -0.2845 -0.0133 -0.2434 -0.1906 -1.4238 -0.0549
S-1750	CONCLUSIONS: Evidence-based treatment has led to dramatic improvement in the prognosis of idiopathic dilated cardiomyopathy during the past 3 decades.<unk>
T-1750	evidence-based prognosis idiopathic_dilated_cardiomyopathy
H-1750	-0.716496467590332	▁ idio pathi c _ ▁dil ated _ ▁cardio my o pathy
D-1750	-0.716496467590332	idiopathic_ dilated_ cardiomyopathy
P-1750	-1.6643 -2.2085 -0.1948 -0.2103 -0.7090 -1.1107 -0.9213 -0.1917 -0.2959 -1.9297 -0.3404 -0.0340 -0.1678 -0.0523
S-1035	It is a consequence of pathological remodelling of the heart, which involves cardiac hypertrophy (a robust predictor of subsequent HF and death), fibrosis and inflammation.<unk>
T-1035	pathological remodelling heart cardiac_hypertrophy hf death fibrosis inflammation
H-1035	-0.24579979479312897	▁path ological ▁remodel ling ▁heart ▁cardiac ▁hyper trop hy ▁ HF ▁fibro sis ▁ inflammation
D-1035	-0.24579979479312897	pathological remodelling heart cardiac hypertrophy HF fibrosis inflammation
P-1035	-1.2779 -0.2208 -0.0594 -0.7079 -0.9109 -0.0290 -0.1324 -0.0027 -0.0135 -0.1318 -0.0147 -0.0345 -0.2329 -0.0784 -0.0032 -0.2367 -0.0917
S-1917	The combined training resulted in an improvement in peak work rate (range: 6% to 36%) and peak quadriceps force (range: 3% to 80%) in all participants.<unk>
T-1917	combined_training peak_work_rate peak_quadriceps_force
H-1917	-1.554426670074463	▁pe ak _ pu issa nce ▁figure
D-1917	-1.554426670074463	peak_puissance figure
P-1917	-4.5209 -0.0524 -0.7360 -4.9002 -0.2879 -0.0247 -2.0210 -1.3116 -0.1351
S-1756	We excluded 921 patients who did not perform a maximal exercise, based on lack of achievement of anaerobic metabolism (peak respiratory quotient ≤1.05).<unk>
T-1756	patients exercise anaerobic_metabolism peak_respiratory_quotient
H-1756	-1.8732014894485474	
D-1756	-1.8732014894485474	
P-1756	-3.6718 -0.0746
S-2014	Simulations consist of 10,000 pairs of virtual cohorts used to generate estimates of resource use, costs, survival, and incremental cost-effectiveness ratios from user inputs.<unk>
T-2014	costs
H-2014	-1.281351089477539	▁virtual ▁co hor ts ▁coût - effect ive
D-2014	-1.281351089477539	virtual cohorts coût-effective
P-2014	-4.7109 -0.6070 -0.0273 -0.0718 -3.2981 -0.4371 -0.1122 -0.0623 -3.3845 -0.1022
S-192	RESULTS: There were 47,025 patients with reduced (37% female), 13,950 with borderline (48% female), and 38,955 with preserved (65% female) EF.<unk>
T-192	patients ef
H-192	-1.7574076652526855	
D-192	-1.7574076652526855	
P-192	-3.4419 -0.0730
S-177	This study assesses the impact of RAS- and β-blocker uptitrations in patients with HFrEF versus HFpEF during and immediately after a hospital admission.<unk>
T-177	β-blocker uptitrations patients hfref hfpef hospital admission
H-177	-0.6429919004440308	▁ RAS - ▁β - block er ▁h Fr EF ▁ HF p f ▁hospital ▁ad mission
D-177	-0.6429919004440308	RAS- β-blocker hFrEF HFpf hospital admission
P-177	-0.2320 -0.0051 -0.3408 -2.8852 -0.0193 -0.2318 -0.0432 -1.3180 -0.6888 -1.5643 -1.2465 -0.1792 -0.0918 -2.0823 -0.1986 -0.7254 -0.0385 -0.1832 -0.1430
S-1604	The American College of Cardiology/American Heart Association guidelines on evaluation and management of patients with RAS provide the framework for determining individualized assessment and treatment plans for patients with RAS.<unk>
T-1604	american_college_of_cardiology american_heart_association patients ras patients ras
H-1604	-0.6912358999252319	▁American ▁College _ of _ ▁Card i ology _ American _ ▁Heart ▁Association ▁ RAS
D-1604	-0.6912358999252319	American College_of_ Cardiology_American_ Heart Association RAS
P-1604	-2.4135 -0.0955 -0.1035 -1.4739 -0.1696 -0.8033 -0.4870 -0.2588 -1.7320 -0.0550 -0.6670 -0.2553 -0.8947 -1.5093 -0.0683 -0.6527 -0.1114
S-265	METHODS: NT-proBNP levels were measured in plasma obtained from 99 patients with dyspnea and left ventricular dysfunction upon admission to the ED.<unk>
T-265	nt-probnp plasma patients dyspnea left_ventricular_dysfunction admission
H-265	-0.6106970310211182	▁NT - pro B NP ▁plasma ▁dys pne a ▁left ▁vent ri cular _ ▁dys function ▁ED
D-265	-0.6106970310211182	NT-proBNP plasma dyspnea left ventricular_ dysfunction ED
P-265	-1.6184 -0.0550 -0.0056 -0.8133 -0.0449 -1.2811 -0.7376 -0.2768 -0.7057 -0.6505 -0.9306 -0.4475 -0.5531 -1.7141 -0.2958 -0.6401 -0.5745 -0.1595 -0.0993
S-1857	BACKGROUND: There is a class I recommendation for implantable cardioverter-defibrillator deactivation discussions to occur between physicians and heart failure patients.<unk>
T-1857	implantable_cardioverter-defibrillator physicians heart_failure patients
H-1857	-0.7895532250404358	▁implant able ▁implant able ▁cardio ver ter - de _ de fi br illa tor _ de _ activa tion
D-1857	-0.7895532250404358	implantable implantable cardioverter-de_defibrillator_de_activation
P-1857	-0.0010 -0.0136 -1.2872 -0.0234 -1.5520 -0.1075 -0.0219 -0.5977 -0.0057 -1.7943 -1.4301 -4.1955 -1.2354 -0.0104 -0.1437 -0.2270 -0.0362 -0.9459 -0.1548 -0.0640 -3.3904 -0.1323
S-120	BACKGROUND: Circulating progenitor cells (CPCs) are involved in the process of endothelial repair and are a prognostic factor in cardiovascular diseases.<unk>
T-120	circulating_progenitor_cells cpcs endothelial prognostic cardiovascular_diseases
H-120	-0.5071839690208435	▁Circula tion _ pro gen itor ▁cell s ▁c PC s ▁en dot heli al _ ▁repair ▁cardiovascular
D-120	-0.5071839690208435	Circulation_progenitor cells cPCs endothelial_ repair cardiovascular
P-120	-0.1596 -1.4259 -0.3431 -0.2399 -0.5093 -0.0651 -0.7927 -0.0221 -0.2347 -0.1966 -0.2195 -0.0935 -0.5987 -0.0367 -0.0098 -1.5023 -0.0649 -0.2164 -3.3544 -0.0583
S-476	However, the improvement in contractile function is not paralleled by any attenuation in LV dilatation, LV end-diastolic pressure/wall stress, and lung weight.<unk>
T-476	contractile_function lv_dilatation lv_end-diastolic_pressure wall_stress lung
H-476	-0.9560136198997498	▁contract ile _ function ▁LV _ di la tation ▁LV ▁end - dia sto lic _ tension wall _ ▁stress ▁lung _ weight
D-476	-0.9560136198997498	contractile_function LV_dilatation LV end-diastolic_tensionwall_ stress lung_weight
P-476	-0.0388 -0.0746 -1.5617 -1.4986 -0.2904 -1.9007 -0.9119 -0.0833 -0.0126 -2.6607 -1.6948 -0.0326 -1.7191 -0.7581 -3.2178 -0.4977 -0.7295 -1.2821 -0.3199 -1.2683 -0.0097 -2.3516 -0.6697 -0.2108 -0.1052
S-478	However, LV remodeling and diastolic properties are not improved, which may explain the failure of XO inhibition to improve symptoms and hospitalizations in patients with severe heart failure.<unk>
T-478	lv_remodeling diastolic xo_inhibition symptoms hospitalizations patients severe_heart_failure
H-478	-0.8434510827064514	▁LV ▁remodel ing ▁dia sto lic ▁properties ▁ XO
D-478	-0.8434510827064514	LV remodeling diastolic properties XO
P-478	-0.0215 -0.4723 -0.0293 -1.2132 -0.3351 -1.1103 -1.0678 -0.2324 -0.0470 -4.5808 -0.1683
S-1802	A total of 569 individuals aged 55-85 and Caucasian were genotyped for SNP rs10927887 in the Ka renal chloride channel gene (CLCNKA).<unk>
T-1802	genotyped snp rs10927887 ka_renal_chloride_channel_gene clcnka
H-1802	-1.1121597290039062	▁Cau ca sian ▁s NP ▁rs 109 27 887 ▁Ka ▁renal _ ▁chlor ide _ ▁channel _ ▁gene CL CN KA
D-1802	-1.1121597290039062	Caucasian sNP rs10927887 Ka renal_ chloride_ channel_ geneCLCNKA
P-1802	-4.4528 -0.0038 -0.1984 -2.7360 -0.0151 -1.5091 -0.3264 -1.7513 -0.3362 -2.1875 -0.2918 -0.8154 -0.9302 -0.1430 -2.4466 -0.4408 -0.9202 -3.6920 -1.3150 -0.4862 -0.2117 -0.2420 -0.1284
S-1385	The objective of this study was to investigate the impact of ventricular assist device (VAD) and extracorporeal membrane oxygenation (ECMO) on renal function in children.<unk>
T-1385	ventricular_assist_device vad extracorporeal_membrane_oxygenation ecmo renal_function
H-1385	-0.5007933974266052	▁vent ri cular _ assist ▁device VAD ▁extra corp o real _ ▁membran e _ ▁oxygen ation ▁e mo ▁renal
D-1385	-0.5007933974266052	ventricular_assist deviceVAD extracorporeal_ membrane_ oxygenation emo renal
P-1385	-0.0034 -0.0449 -0.1062 -0.6285 -0.1077 -1.2527 -1.7646 -0.0257 -0.0119 -0.2506 -0.0991 -0.8582 -0.1982 -0.1574 -0.1931 -0.3613 -0.0188 -0.9799 -0.8627 -0.0278 -2.9174 -0.1471
S-999	However, after cardiac magnetic resonance, the typical amyloidotic pattern is found and the final diagnosis of multiple myeloma is made at osteomedullary biopsy.<unk>
T-999	cardiac_magnetic_resonance amyloidotic diagnosis multiple_myeloma osteomedullary_biopsy
H-999	-0.6338120698928833	▁cardiac ▁magnetic _ ▁res on ance ▁a my lo ido tic _ ▁pattern _ de _ multi ▁mye loma ▁osteo me dulla ry ▁bio psy
D-999	-0.6338120698928833	cardiac magnetic_ resonance amyloidotic_ pattern_de_multi myeloma osteomedullary biopsy
P-999	-0.0082 -0.4738 -2.2456 -0.4827 -0.0247 -0.0115 -0.0323 -0.1221 -0.2264 -0.1917 -1.8766 -2.3038 -0.5725 -3.8785 -1.1855 -0.3536 -0.5672 -1.1874 -0.1020 -0.0247 -0.0315 -0.1114 -0.7748 -0.0536 -0.0221 -0.2107 -0.0380
S-1303	Diagnosis of HFpEF is frequently challenging and relies upon careful clinical evaluation, echo-Doppler cardiography, and invasive haemodynamic assessment.<unk>
T-1303	diagnosis hfpef clinical echo-doppler_cardiography invasive_haemodynamic_assessment
H-1303	-0.3663647472858429	▁ HF p EF ▁e cho - D opp ler _ card i ography ▁invasi ve ▁ha emo dynamic ▁assessment
D-1303	-0.3663647472858429	HFpEF echo-Doppler_cardiography invasive haemodynamic assessment
P-1303	-0.5269 -0.2913 -0.0734 -0.3417 -1.8354 -0.0588 -0.0263 -0.6173 -0.0012 -0.2083 -0.9879 -0.7899 -0.1661 -0.2581 -0.0715 -0.1804 -0.1957 -0.6049 -0.0282 -0.6287 -0.1051 -0.0629
S-1068	Implantable cardioverter-defibrillators (ICDs) decrease mortality, and cardiac resynchronization therapy (CRT) improves symptoms and mortality.<unk>
T-1068	implantable_cardioverter-defibrillators icds mortality cardiac_resynchronization_therapy crt symptoms mortality
H-1068	-0.6721344590187073	▁implant able ▁implant able ▁implant able _ de _ de _ fi br illa tors IC d s ▁cardiac ▁re syn chron ization ▁ therapy ▁c RT ▁mortal ity
D-1068	-0.6721344590187073	implantable implantable implantable_de_de_fibrillatorsICds cardiac resynchronization therapy cRT mortality
P-1068	-0.0184 -0.0181 -0.4363 -0.0349 -1.5600 -0.0515 -0.7070 -0.1986 -1.5145 -2.1024 -2.1287 -1.7881 -0.5512 -0.0163 -2.0717 -0.7097 -0.3215 -0.0620 -0.0746 -1.4960 -0.0020 -0.0003 -0.7917 -2.1496 -0.0239 -0.7987 -0.1212 -0.6111 -0.2220 -0.1701 -0.0839
S-448	Vascular endothelial growth factor blockade prevents the beneficial effects of beta-blocker therapy on cardiac function, angiogenesis, and remodeling in heart failure.<unk>
T-448	vascular_endothelial_growth_factor_blockade beta-blocker therapy cardiac_function angiogenesis remodeling heart_failure
H-448	-0.7435164451599121	▁Vas cular _ en dot heli al _ ▁growth _ factor _ block ade ▁beta - block er ▁ therapy ▁cardiac ▁ang io gene sis ▁remodel ing ▁heart _ ▁failure
D-448	-0.7435164451599121	Vascular_endothelial_ growth_factor_blockade beta-blocker therapy cardiac angiogenesis remodeling heart_ failure
P-448	-0.0700 -0.0199 -0.3575 -0.7705 -1.9966 -0.1035 -0.0151 -0.4126 -2.4806 -0.6502 -1.2503 -0.9226 -1.0835 -0.9687 -0.5598 -0.0110 -0.0917 -0.0459 -0.5015 -0.0129 -0.0506 -5.3063 -0.4268 -0.0535 -0.5643 -0.3958 -0.0183 -0.1105 -0.8453 -3.5381 -0.0947 -0.0639
S-915	Low-sodium DASH diet improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with preserved ejection fraction.<unk>
T-915	dash diastolic_function ventricular-arterial_coupling hypertensive_heart_failure_with_preserved_ejection_fraction
H-915	-0.894664466381073	▁low - so dium ▁DAS h ▁die t ▁vent ri cular - arte rial ▁coup ling ▁hyper tensi ve _ heart _ ▁failure ▁e je ction ▁ fraction
D-915	-0.894664466381073	low-sodium DASh diet ventricular-arterial coupling hypertensive_heart_ failure ejection fraction
P-915	-4.9605 -0.1334 -0.0610 -0.0294 -0.1441 -0.9743 -2.9486 -0.0875 -1.2386 -0.0408 -0.0607 -0.4248 -0.1724 -0.2489 -0.0476 -2.1827 -0.0189 -0.6858 -0.5930 -1.1761 -1.6577 -1.0419 -3.5722 -1.9713 -0.2264 -0.0211 -1.8032 -0.0001 -0.1469 -0.1702
S-314	Neither BTT nor DT currently meet traditional cost-effectiveness limits in models using historical data, although BTT is standard practice for a limited number of patients in many regions.<unk>
T-314	btt dt btt patients
H-314	-0.9251933693885803	▁b t ▁ DT ▁coût - effect ive ness
D-314	-0.9251933693885803	bt DT coût-effectiveness
P-314	-0.2076 -0.9102 -1.1665 -0.0485 -1.3970 -0.1385 -0.1953 -0.0884 -3.3990 -2.5733 -0.0528
S-1800	Overall, in the scenario of lower total expenditure on health per capita and lower gross national income per capita, new strategies are essential for prevention and treatment of HF in LA.<unk>
T-1800	expenditure health income hf
H-1800	-1.089971899986267	▁ex pendi ture ▁health _ per ▁capita ▁gross _ national _ ▁income ▁ HF
D-1800	-1.089971899986267	expenditure health_per capita gross_national_ income HF
P-1800	-5.2279 -0.0057 -0.0542 -1.9169 -1.9880 -0.2477 -0.1268 -2.0429 -0.3962 -0.9766 -0.9592 -0.4062 -1.5079 -0.6473 -0.7562 -0.1798
S-1600	Adequate blood pressure control, goal-directed lipid-lowering therapy, smoking cessation, and other preventive measures form the foundation of management of patients with RAS.<unk>
T-1600	blood_pressure therapy patients ras
H-1600	-0.5658650398254395	▁blood ▁pressure _ control ▁lipid - lo wering ▁ therapy ▁smoking _ ▁ces s ation ▁ RAS
D-1600	-0.5658650398254395	blood pressure_control lipid-lowering therapy smoking_ cessation RAS
P-1600	-0.5916 -3.6607 -1.6305 -0.0251 -0.2414 -0.0666 -0.1127 -0.0245 -0.5503 -0.0593 -0.0222 -1.0162 -0.9649 -0.0166 -0.0344 -1.5337 -0.0315 -0.0609 -0.1084
S-196	After adjusting for over 20 clinical variables, the ability of BNP to predict inhospital mortality was similar among all subgroups (P for heterogeneity = .47).<unk>
T-196	clinical bnp inhospital mortality
H-196	-0.4885960519313812	▁b NP ▁in hospital _ ▁mortal ity
D-196	-0.4885960519313812	bNP inhospital_ mortality
P-196	-0.2094 -1.1979 -0.3132 -0.1985 -0.9737 -0.5714 -0.2013 -0.6810 -0.0509
S-1442	SDQT increased significantly in the HFVT(+) and HFVT(-) groups compared with the HNorm group during fixed-rate atrial pacing (P = 0.008).<unk>
T-1442	sdqt atrial_pacing
H-1442	-0.665581226348877	▁SD QT ▁ HF VT ▁h Nor m ▁figure ▁fixed - rate _ at rial _ pa cing
D-1442	-0.665581226348877	SDQT HFVT hNorm figure fixed-rate_atrial_pacing
P-1442	-0.0487 -0.7116 -0.2733 -0.0663 -0.7813 -0.3033 -2.0375 -0.0032 -2.4220 -1.1770 -0.0349 -0.0809 -0.2402 -1.6451 -0.1248 -1.4591 -0.3282 -1.0748 -0.3968 -0.1025
S-108	Time-dependent analysis showed that the development of IEs among CRT-D recipients was associated with more than twofold (p = 0.01) increased risk for subsequent heart failure or death.<unk>
T-108	ies crt-d heart_failure death
H-108	-1.2303332090377808	▁c RT - d
D-108	-1.2303332090377808	cRT-d
P-108	-2.0737 -0.2417 -0.0906 -0.8459 -3.9330 -0.1971
S-952	CONCLUSIONS: Our results suggest that AF can be effectively and safely treated with a composite of repeat procedures and pharmaceuticals in patients with HFPEF.<unk>
T-952	pharmaceuticals patients hfpef
H-952	-0.6596691608428955	▁af ▁ pharma ce u tical s ▁h FP EF
D-952	-0.6596691608428955	af pharmaceuticals hFPEF
P-952	-0.9969 -3.1246 -0.1184 -0.1009 -0.4081 -0.8548 -0.0450 -0.2532 -0.8303 -0.9957 -0.1071 -0.0808
S-1007	RESULTS: Among 223 patients (mean age 71 ± 14, 61% male), 21% were frail and 48% intermediate frail according to the biological phenotype.<unk>
T-1007	patients frail frail biological_phenotype
H-1007	-1.5828015804290771	
D-1007	-1.5828015804290771	
P-1007	-3.1231 -0.0425
S-738	Sixty-one patients with confirmed HFPEF entered a longitudinal outcome-monitoring phase (mean, 22.9±5.0 months), during which 16 had a cardiac event.<unk>
T-738	patients hfpef longitudinal cardiac_event
H-738	-0.8781730532646179	▁h f f
D-738	-0.8781730532646179	hff
P-738	-0.2694 -0.2275 -0.2001 -3.6172 -0.0768
S-1722	Physician volume is associated with better outcomes for patients undergoing procedures, but its association with outcomes for medically managed diseases, such as HF, is not well understood.<unk>
T-1722	physician outcomes patients outcomes medically diseases hf
H-1722	-0.9792641997337341	▁Physic ian ▁volume ▁ HF
D-1722	-0.9792641997337341	Physician volume HF
P-1722	-0.0474 -0.1100 -1.5813 -3.9031 -0.6300 -0.5012 -0.0819
S-1063	CONCLUSION: The proposed T1-mapping technique can quantify diffuse myocardial changes associated with heart failure without the use of a contrast agent and without breath-holding.<unk>
T-1063	t1-mapping myocardial heart_failure
H-1063	-0.9988872408866882	▁diffuse _ My o card ial _ ▁changes ▁heart _ ▁failure ▁contrast ▁agent ▁breath - hold ing
D-1063	-0.9988872408866882	diffuse_Myocardial_ changes heart_ failure contrast agent breath-holding
P-1063	-3.9038 -1.1278 -3.5916 -0.4036 -0.1870 -0.0471 -2.7951 -0.8801 -0.4419 -0.8466 -3.7314 -0.2002 -0.3347 -0.0460 -0.0449 -0.0212 -0.0485 -0.1862 -0.1411
S-1224	BACKGROUND: Underuse of eplerenone in patients with HF-REF may be due to fear of inducing hyperkalemia or WRF in high-risk patients.<unk>
T-1224	eplerenone patients hf-ref hyperkalemia patients
H-1224	-0.5104007124900818	▁e pler en one ▁ HF - re f ▁hyper kal emia ▁W RF
D-1224	-0.5104007124900818	eplerenone HF-ref hyperkalemia WRF
P-1224	-0.1353 -0.1136 -0.3890 -4.0693 -0.1920 -0.0593 -0.0874 -0.5168 -0.3555 -0.9128 -0.5754 -0.1759 -0.0858 -0.0698 -0.3377 -0.0908
S-827	Of 124 patients, 66 were below the median exercise-induced PASP increase of 30 mm Hg (low PASP), and 58 patients were above the median (high PASP).<unk>
T-827	patients exercise-induced_pasp pasp patients pasp
H-827	-1.6370205879211426	▁h g ▁pas p
D-827	-1.6370205879211426	hg pasp
P-827	-4.5399 -0.1811 -4.0153 -0.2270 -0.7758 -0.0831
S-149	OBJECTIVE: To determine whether RM strategies improve outcomes for adults who have been recently discharged (<28 days) following an unplanned admission due to heart failure.<unk>
T-149	rm outcomes discharged admission heart_failure
H-149	-1.5451103448867798	▁RM
D-149	-1.5451103448867798	RM
P-149	-1.0341 -3.5365 -0.0647
S-887	In patients with LBBB receiving implantable cardioverter defibrillator-CRT, there was a reduction in the primary outcome and in each individual component of the primary outcome.<unk>
T-887	patients lbbb implantable primary_outcome primary_outcome
H-887	-0.56612229347229	▁implant able ▁implant able _ ▁cardio ver ter _ de _ fi br illa tor - C RT
D-887	-0.56612229347229	implantable implantable_ cardioverter_de_fibrillator-CRT
P-887	-0.1961 -0.0164 -1.4057 -0.0195 -0.4708 -2.0784 -0.1021 -0.0376 -0.1089 -0.0339 -1.3897 -2.1499 -0.8051 -0.0079 -0.0941 -0.5536 -1.1902 -0.2098 -0.3891 -0.0636
S-880	BACKGROUND: The impact of QRS morphology and duration on the effectiveness of cardiac resynchronization therapy (CRT) has been usually assessed separately.<unk>
T-880	qrs_morphology cardiac_resynchronization_therapy crt
H-880	-0.48285818099975586	▁QR s ▁ morph ologie ▁cardiac _ re syn chron ization _ therapy ▁c RT
D-880	-0.48285818099975586	QRs morphologie cardiac_resynchronization_therapy cRT
P-880	-0.1045 -0.4486 -0.2785 -0.0133 -1.2025 -0.5845 -1.0175 -0.7198 -0.0220 -0.0004 -1.2709 -0.8671 -0.6911 -0.7740 -0.0567 -0.1019 -0.0551
S-639	Although aberrant reactivation of embryonic gene programs is intricately linked to pathological heart disease, the transcription factors driving these gene programs remain ill-defined.<unk>
T-639	gene pathological heart_disease transcription_factors driving gene
H-639	-1.30978262424469	▁re activa tion ▁em bry o nic _ ▁gene ▁programs ▁path ological _ ▁heart ▁disease ▁tran scription ▁factors
D-639	-1.30978262424469	reactivation embryonic_ gene programs pathological_ heart disease transcription factors
P-639	-6.7122 -0.0465 -0.0224 -0.0802 -0.0330 -0.1169 -2.1327 -1.8012 -1.6680 -2.5062 -0.0657 -0.3430 -1.5132 -1.0568 -4.7915 -0.9904 -0.0109 -0.6842 -1.4395 -0.1811
S-807	Values of standard error of measurement and MDC may be used in daily clinical practice with these populations to define what is expected and what represents true change in repeated measures.<unk>
T-807	standard_error_of_measurement mdc clinical change
H-807	-0.9650509357452393	▁m DC
D-807	-0.9650509357452393	mDC
P-807	-0.4840 -1.4221 -1.7207 -0.2334
S-409	Patients with low sST2/low-dose BB or high sST2/high-dose BB had intermediate odds ratios for cardiovascular events (P=0.18 and 0.02).<unk>
T-409	patients sst2 sst2 odds_ratios cardiovascular_events
H-409	-1.2575631141662598	▁s st 2/ low - dos e ▁BB ▁s st 2/ high - dos e ▁odds ▁ratio s ▁cardiovascular ▁events
D-409	-1.2575631141662598	sst2/low-dose BB sst2/high-dose odds ratios cardiovascular events
P-409	-0.5470 -2.0552 -3.3538 -1.4741 -0.0179 -0.6612 -0.2369 -1.5001 -2.7912 -2.1691 -1.6818 -1.9918 -0.0339 -0.4191 -0.1191 -4.0261 -1.5989 -0.1161 -0.0977 -2.4891 -0.1698 -0.1164
S-1994	The centrifugal flow pump is designed for enhanced hemocompatibility by incorporating a magnetically levitated rotor with wide blood-flow paths and an artificial pulse.<unk>
T-1994	centrifugal_flow_pump hemocompatibility blood-flow pulse
H-1994	-0.5527154207229614	▁centri fu gal _ ▁flow _ pump ▁hem o com pati bility ▁magnet ically ▁le vita ted ▁ro tor ▁blood - flow _ path s ▁artificial _ ▁puls e
D-1994	-0.5527154207229614	centrifugal_ flow_pump hemocompatibility magnetically levitated rotor blood-flow_paths artificial_ pulse
P-1994	-0.0918 -0.0593 -0.0383 -0.3226 -2.0852 -1.4229 -0.7072 -1.5013 -0.0582 -0.0578 -0.0446 -0.1934 -0.0275 -0.1465 -0.5929 -0.0117 -1.1346 -0.0214 -0.0165 -1.6930 -0.1234 -0.0828 -1.8377 -1.0050 -0.0489 -0.1171 -1.7639 -1.6295 -0.1006 -0.1395 -0.0590
S-1264	CONCLUSIONS: This meta-analysis indicated that biomedical treatment plus CHM is more effective than biomedical treatment alone in treating patients with DCM and heart failure.<unk>
T-1264	meta-analysis biomedical biomedical patients dcm heart_failure
H-1264	-1.0865793228149414	▁bio medic al ▁treatment ▁CH m ▁bio medic al ▁treatment ▁d CM ▁heart _ ▁failure
D-1264	-1.0865793228149414	biomedical treatment CHm biomedical treatment dCM heart_ failure
P-1264	-0.0454 -0.1317 -0.0090 -3.7887 -3.7832 -0.1768 -0.3487 -0.0362 -0.0093 -3.7133 -1.2723 -0.0774 -1.0004 -1.5348 -2.0689 -0.3627 -0.1133
S-436	CONCLUSIONS: A multiparametric echocardiographic score is helpful in selecting patients likely to undergo reverse remodeling after CRT and predicts clinical outcomes.<unk>
T-436	echocardiographic patients reverse_remodeling crt clinical outcomes
H-436	-0.39548593759536743	▁multi para metric ▁e cho car dio graphic ▁score ▁rever se ▁remodel ing ▁c RT
D-436	-0.39548593759536743	multiparametric echocardiographic score reverse remodeling cRT
P-436	-0.9844 -0.0464 -0.1185 -0.1466 -0.3127 -0.0667 -0.5868 -1.1477 -0.3343 -0.4497 -0.0072 -0.2993 -0.0341 -0.9437 -0.1360 -1.0377 -0.0714
S-57	As the authors suggest, patient categorization in the emergency department is perhaps the single most important component that is not focused on in modern acute heart failure (AHF) clinical studies.<unk>
T-57	patient emergency_department acute_heart_failure ahf clinical
H-57	-1.1685353517532349	▁patient _ ▁categori z ation ▁emergency _ ▁department ▁a cute _ heart _ ▁failure ▁a HF
D-57	-1.1685353517532349	patient_ categorization emergency_ department acute_heart_ failure aHF
P-57	-3.2782 -1.5268 -1.9482 -0.0998 -0.0189 -1.7362 -2.0468 -0.9624 -0.1604 -0.2251 -0.0564 -2.9720 -0.5017 -2.9490 -1.1711 -0.0736 -1.2083 -0.0988
S-1056	MATERIALS AND METHODS: Yorkshire swine were implanted with pacemakers and were ventricularly paced at 200 beats/min to induce heart failure.<unk>
T-1056	yorkshire implanted pacemakers ventricularly beats heart_failure
H-1056	-0.7267451882362366	▁York shire ▁s win e ▁implant ed ▁pace makers ▁vent ri cular ly ▁pace d
D-1056	-0.7267451882362366	Yorkshire swine implanted pacemakers ventricularly paced
P-1056	-2.8371 -0.0067 -0.2569 -0.2059 -0.0811 -0.2746 -0.7037 -0.7075 -0.0946 -0.0118 -0.0408 -0.0167 -0.0757 -1.3482 -0.1850 -5.3234 -0.1848
S-516	OBJECTIVES: The study aimed to determine whether isolated heart rate (HR) reduction with ivabradine reduces afterload of patients with systolic heart failure.<unk>
T-516	heart_rate ivabradine afterload patients systolic_heart_failure
H-516	-1.363692283630371	▁heart _ re duction ▁i va bra dine ▁patients ▁sy sto lic _ heart _ ▁failure
D-516	-1.363692283630371	heart_reduction ivabradine patients systolic_heart_ failure
P-516	-3.4892 -1.3764 -3.1674 -0.0058 -0.1847 -0.0180 -0.4741 -0.0072 -5.6449 -1.6909 -0.1910 -4.4130 -0.3627 -1.5823 -0.5746 -1.0585 -0.2187 -0.0871
S-1786	Reduced mitochondrial complex V activity was evident at 3 weeks post-AAC, concomitant with a reduction in the ratio of phosphocreatine to ATP.<unk>
T-1786	mitochondrial_complex_v_activity phosphocreatine atp
H-1786	-0.9087741374969482	▁mito cho ndri al _ ▁complex _ V ▁activity ▁a ac ▁ phos pho creati ne ▁ATP
D-1786	-0.9087741374969482	mitochondrial_ complex_V activity aac phosphocreatine ATP
P-1786	-0.9000 -1.6506 -0.1501 -0.0384 -0.9366 -1.1426 -0.7427 -1.7521 -2.0663 -1.2138 -0.5636 -1.0245 -0.0339 -1.7386 -1.5777 -1.1500 -0.2273 -0.2103 -0.1476
S-1243	Perturbations in skeletal muscle sarcomere structure in patients with heart failure and type 2 diabetes: restorative effects of (-)-epicatechin-rich cocoa.<unk>
T-1243	skeletal_muscle sarcomere patients heart_failure type_2_diabetes
H-1243	-0.5911431312561035	▁skelet al ▁muscle _ ▁sar com er ▁structure ▁heart _ ▁failure ▁diabetes ▁e pica tech in - rich ▁coco a
D-1243	-0.5911431312561035	skeletal muscle_ sarcomer structure heart_ failure diabetes epicatechin-rich cocoa
P-1243	-0.2964 -0.1679 -1.7169 -0.4001 -0.5518 -0.1374 -2.5143 -2.3927 -1.3484 -0.9035 -1.0867 -0.1534 -0.3188 -0.0032 -0.0319 -0.1922 -0.3359 -0.0001 -0.1047 -0.0329 -0.2476 -0.0685
S-696	BACKGROUND: ST2 is involved in cardioprotective signaling in the myocardium and has been identified as a potentially promising biomarker in heart failure (HF).<unk>
T-696	st2 cardioprotective_signaling myocardium biomarker heart_failure hf
H-696	-0.677080512046814	▁ST 2 ▁cardio protec tive _ ▁signal ing ▁my o car dium ▁bio mark er _ ▁in _ heart _ ▁failure HF
D-696	-0.677080512046814	ST2 cardioprotective_ signaling myocardium biomarker_ in_heart_ failureHF
P-696	-3.7303 -0.2691 -0.1072 -0.0166 -0.0120 -0.7152 -0.9952 -0.3596 -0.9649 -0.0227 -0.0030 -0.0315 -0.0155 -0.0021 -0.0763 -1.6835 -0.2311 -0.9372 -1.1027 -0.5317 -2.1122 -2.1370 -0.1349 -0.0587
S-1550	Treatment of MI animals with metoprolol partially reversed the elevated levels of plasma norepinephrine and dopamine without affecting the elevated levels of epinephrine.<unk>
T-1550	mi metoprolol elevated plasma_norepinephrine dopamine elevated epinephrine
H-1550	-0.6520951390266418	▁MI ▁met o pro lol ▁plasma ▁no re pine ph rine ▁dop amine ▁e pine ph rine
D-1550	-0.6520951390266418	MI metoprolol plasma norepinephrine dopamine epinephrine
P-1550	-1.7692 -3.5539 -0.0708 -0.0269 -0.1672 -0.1037 -0.5600 -0.1089 -0.8312 -2.9739 -0.3539 -0.0116 -0.0280 -0.0775 -0.0296 -1.2660 -0.1593 -0.1880 -0.1102
S-1602	The current ongoing Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial may provide more concrete data regarding the role of stenting in RAS.<unk>
T-1602	cardiovascular_outcomes_in_renal_atherosclerotic_lesions coral stenting ras
H-1602	-0.5041118264198303	▁Card io vas cular ▁out com es ▁Ren al _ ▁Ath eros cle ro tic _ ▁Les ions ▁CO RAL ▁sten ting ▁ RAS
D-1602	-0.5041118264198303	Cardiovascular outcomes Renal_ Atherosclerotic_ Lesions CORAL stenting RAS
P-1602	-0.1615 -0.4988 -0.0553 -0.1075 -3.6028 -0.0143 -0.1047 -0.1747 -0.0344 -0.4264 -0.0715 -0.0771 -0.0796 -0.8468 -1.0562 -0.5929 -0.4913 -0.0255 -2.4720 -0.0160 -0.7806 -1.0870 -0.1729 -0.0022 -0.0802 -0.0746
S-60	BACKGROUND: Many current predictors of mortality in heart failure (HF) were evaluated before the use of implantable cardioverter defibrillators (ICDs).<unk>
T-60	mortality heart_failure hf implantable_cardioverter_defibrillators icds
H-60	-0.7321200966835022	▁implant able _ ▁cardio ver ter _ de _ fi br illa teurs IC d s
D-60	-0.7321200966835022	implantable_ cardioverter_de_fibrillateursICds
P-60	-1.7365 -0.0845 -0.4678 -3.6982 -0.0957 -0.0454 -0.1633 -0.0281 -1.7713 -0.9864 -0.3495 -0.0089 -1.9288 -0.8994 -0.4452 -0.0352 -0.3515 -0.0826
S-686	We therefore evaluated associations of Mediterranean and Dietary Approaches to Stop Hypertension (DASH) diet scores with mortality among postmenopausal women with HF.<unk>
T-686	dietary_approaches_to_stop_hypertension dash mortality postmenopausal hf
H-686	-0.5438775420188904	▁Mediterrane an ▁Diet ary _ App ro ach es ▁Stop _ ▁Hyper tension DAS h ▁mortal ity ▁post meno paus al ▁women ▁ HF
D-686	-0.5438775420188904	Mediterranean Dietary_Approaches Stop_ HypertensionDASh mortality postmenopausal women HF
P-686	-0.0889 -0.0108 -1.7175 -0.4018 -1.4262 -1.1289 -0.0499 -0.6240 -0.0125 -1.0293 -0.1375 -1.5248 -0.0009 -0.2863 -0.7607 -0.2265 -0.2112 -0.4509 -0.0793 -0.0073 -0.0188 -2.4232 -1.2076 -0.0048 -0.1238 -0.1873
S-1025	Several POC systems for measuring NP levels are now available: these produce test results within 15 minutes and appear sufficiently sensitive and robust to be used routinely in diagnostic evaluations.<unk>
T-1025	poc diagnostic
H-1025	-1.5598771572113037	▁ NP
D-1025	-1.5598771572113037	NP
P-1025	-3.4337 -0.1584 -2.5194 -0.1281
S-1977	DESIGN, SETTING, AND PARTICIPANTS: Randomized, attention-controlled, 2 × 2 factorial trial conducted from February 2009 through November 2014 in an urban academic medical center.<unk>
T-1977	randomized medical
H-1977	-2.013812780380249	
D-1977	-2.013812780380249	
P-1977	-4.0048 -0.0229
S-151	DATA SOURCES: Fourteen electronic databases (including MEDLINE, EMBASE and PsycINFO) were searched to January 2012, and supplemented by hand-searching relevant articles.<unk>
T-151	medline embase psycinfo
H-151	-0.5813268423080444	▁électronique ▁database s ▁MED LINE ▁ EMBA se ▁Psy c INFO
D-151	-0.5813268423080444	électronique databases MEDLINE EMBAse PsycINFO
P-151	-2.0209 -2.0655 -0.1027 -0.7582 -0.5981 -0.2656 -0.0045 -1.1623 -0.0759 -0.0192 -0.0087 -0.4312 -0.0445
S-1725	We used patient-level regression to compare 30-day risk-adjusted mortality, readmissions, and costs across volume groups, controlling for patient, physician, and hospital characteristics.<unk>
T-1725	mortality readmissions costs patient physician hospital
H-1725	-0.6917375326156616	▁patient - level _ re gression ▁risk - ad just ed _ ▁mortal ity ▁read missions ▁costs ▁patient ▁physician ▁hospital
D-1725	-0.6917375326156616	patient-level_regression risk-adjusted_ mortality readmissions costs patient physician hospital
P-1725	-1.4134 -0.0252 -0.0533 -1.9311 -0.8132 -0.0010 -3.2821 -0.0303 -0.0069 -0.0026 -0.0648 -0.5825 -0.4820 -0.1430 -0.8245 -0.0362 -0.8297 -1.7823 -2.2239 -0.0899 -0.5205 -0.0799
S-890	CONCLUSIONS: In patients with LBBB, there was a continuous relationship between broader QRS and greater benefit from implantable cardioverter defibrillator-CRT.<unk>
T-890	patients lbbb qrs implantable
H-890	-0.466433584690094	LB BB ▁implant able ▁implant able _ ▁cardio ver ter _ de _ fi br illa tor - C RT
D-890	-0.466433584690094	LBBB implantable implantable_ cardioverter_de_fibrillator-CRT
P-890	-1.9213 -0.5389 -0.1774 -0.0186 -0.9882 -0.0235 -1.0442 -0.8554 -0.0737 -0.0222 -0.1055 -0.0211 -1.0359 -0.7026 -0.4743 -0.0075 -0.0746 -0.4879 -1.3265 -0.0578 -0.2518 -0.0527
S-453	At the end of a 10-week treatment period, echocardiography revealed reduced cardiac diameters and improved cardiac function in B-treated compared with vehicle-treated rats.<unk>
T-453	echocardiography cardiac cardiac_function
H-453	-0.8183313012123108	▁e cho card i ography ▁cardiac _ ▁diameter s ▁b - tre ated
D-453	-0.8183313012123108	echocardiography cardiac_ diameters b-treated
P-453	-0.1008 -0.2651 -0.1764 -0.8594 -0.5261 -0.4205 -3.1822 -1.8149 -0.0291 -0.8054 -0.2344 -0.0222 -0.8232 -2.9321 -0.0834
S-618	RESULTS: Overall significant improvements were not found in quality of life or functional capacity; some participants demonstrated significant improvements with others showing minor improvement or no improvement in one or both domains.<unk>
T-618	quality_of_life functional_capacity
H-618	-1.7209969758987427	▁quality _ of _ ▁life ▁functional _ capaci tation
D-618	-1.7209969758987427	quality_of_ life functional_capacitation
P-618	-2.6529 -0.3739 -2.2380 -0.2111 -3.2238 -1.6790 -2.7458 -1.2649 -4.1291 -0.3402 -0.0725
S-1950	We aimed to assess the safety and potential efficacy of therapeutic left-to-right interatrial shunting in patients with heart failure with reduced ejection fraction.<unk>
T-1950	therapeutic interatrial_shunting patients heart_failure_with_reduced_ejection_fraction
H-1950	-0.7159688472747803	▁ therapeut ic ▁left - to - right ▁inter at rial _ ▁sh unting ▁heart _ ▁failure ▁e je ction _ fraction
D-1950	-0.7159688472747803	therapeutic left-to-right interatrial_ shunting heart_ failure ejection_fraction
P-1950	-1.9919 -0.0742 -0.3381 -1.1098 -0.0573 -0.6718 -0.1479 -0.0936 -0.1064 -0.3186 -0.2609 -1.8294 -1.3470 -0.2598 -1.5234 -0.8569 -3.2199 -0.6912 -0.4368 -0.0354 -1.5847 -0.0105 -0.1108 -0.1069
S-336	Four years later he developed heart failure, severe hypertension, mild mitral regurgitation, and significant mitral stenosis, which were reversed by aggressive medical treatment for heart failure.<unk>
T-336	heart_failure hypertension mitral_regurgitation mitral_stenosis medical_treatment heart_failure
H-336	-0.5155351758003235	▁heart _ ▁failure ▁hyper tension ▁mit ral _ ▁re gur gi tation ▁mit ral ▁sten osis
D-336	-0.5155351758003235	heart_ failure hypertension mitral_ regurgitation mitral stenosis
P-336	-0.3952 -0.6853 -2.2271 -1.0107 -0.0013 -0.1478 -0.0073 -0.5472 -1.1206 -0.0142 -0.0345 -0.0038 -0.1971 -0.0071 -0.2918 -0.0154 -2.5010 -0.0723
S-636	The use of antagonists and inhibitors of the renin-angiotensin-aldosterone and sympathetic nervous systems has significantly improved clinical outcomes in CHF.<unk>
T-636	antagonists renin-angiotensin-aldosterone sympathetic_nervous_systems clinical outcomes chf
H-636	-0.8138419389724731	▁anta gon ists ▁re nin - angi oten sin - al do ster one ▁sympa the tic _ ▁ner vous ▁systems ▁CHF
D-636	-0.8138419389724731	antagonists renin-angiotensin-aldosterone sympathetic_ nervous systems CHF
P-636	-2.4102 -0.1350 -0.5790 -0.5292 -0.5536 -0.0238 -0.0215 -0.0180 -1.8851 -0.6946 -0.1076 -0.8834 -0.0328 -1.3798 -0.0442 -0.3505 -1.6705 -0.2605 -2.4579 -2.1074 -3.1426 -0.1607 -0.0396 -0.0444
S-831	CONCLUSIONS: Exercise-induced PASP increase is of high clinical and prognostic relevance in pulmonary hypertension patients and may indicate right ventricular contractile reserve.<unk>
T-831	exercise-induced_pasp clinical prognostic pulmonary_hypertension patients right_ventricular_contractile_reserve
H-831	-0.6485925316810608	▁implant ation ▁pulmonar y ▁hyper tension ▁vent ri cular _ contract ile _ ▁reserve
D-831	-0.6485925316810608	implantation pulmonary hypertension ventricular_contractile_ reserve
P-831	-3.1665 -1.6406 -1.1133 -0.1408 -0.7736 -0.0010 -0.1027 -0.1141 -0.3139 -0.8237 -0.5578 -0.3656 -0.7215 -0.3139 -0.1572 -0.0712
S-1650	All patients will be followed up until the end of the trial for the composite primary outcome of cardiovascular death, stroke, worsening of heart failure, and myocardial infarction.<unk>
T-1650	patients followed_up composite_primary_outcome cardiovascular_death stroke heart_failure myocardial_infarction
H-1650	-0.9108353853225708	▁cardiovascular _ ▁death ▁heart _ ▁failure ▁my o card ial _ ▁in far ction
D-1650	-0.9108353853225708	cardiovascular_ death heart_ failure myocardial_ infarction
P-1650	-1.9342 -2.6271 -1.1277 -3.0011 -0.3247 -1.9985 -0.7057 -0.1483 -0.1359 -0.1731 -1.3949 -0.3436 -0.2891 -0.0475 -0.2329 -0.0890
S-1861	SETTING AND PARTICIPANTS: Patients with an implantable cardioverter-defibrillator, from the Heart Function Clinic at University Health Network (Toronto, Canada).<unk>
T-1861	patients implantable_cardioverter-defibrillator heart_function_clinic university_health_network toronto canada
H-1861	-0.6329939365386963	▁implant able ▁implant able ▁cardio ver ter - de fi br illa tor ▁Heart _ ▁Fun ction ▁Clinic ▁University _ ▁Health ▁Network Tor onto
D-1861	-0.6329939365386963	implantable implantable cardioverter-defibrillator Heart_ Function Clinic University_ Health NetworkToronto
P-1861	-0.0004 -0.0129 -1.1006 -0.0192 -1.4894 -0.1147 -0.0472 -0.3820 -0.0084 -2.9159 -0.8164 -0.0101 -0.0285 -0.4609 -0.1775 -0.1996 -0.0010 -1.2827 -1.9691 -0.1949 -0.9597 -1.4454 -0.7772 -0.0015 -1.9778 -0.0650
S-1086	PERK activation destabilized SCN5A and, surprisingly, Kv4.3 channel mRNAs but not transient receptor potential cation channel M7 (TRPM7) channel mRNA.<unk>
T-1086	perk scn5a kv4.3 mrnas transient_receptor_potential_cation_channel_m7 trpm7 mrna
H-1086	-1.1884475946426392	▁PER K _ activa tion ▁destabiliz ed ▁S CN 5 a ▁kv 4.3 ▁m RNA s ▁trans ient ▁receptor _ potentsiaal ▁ cation ▁channel ▁m 7 TR PM 7) ▁m RNA
D-1086	-1.1884475946426392	PERK_activation destabilized SCN5a kv4.3 mRNAs transient receptor_potentsiaal cation channel m7TRPM7) mRNA
P-1086	-2.2894 -0.4596 -4.8556 -0.3819 -0.0097 -4.1090 -0.3574 -0.3234 -0.0168 -1.1403 -0.2555 -0.3884 -0.8925 -0.8840 -0.1019 -0.7003 -0.0022 -0.0791 -0.4352 -2.5378 -2.9720 -2.0818 -0.0432 -0.9119 -0.3341 -4.0618 -3.0114 -0.2730 -3.9360 -0.6639 -0.0342 -0.5188 -0.1570
S-845	BACKGROUND: Cardiac-resynchronization therapy (CRT) reduces morbidity and mortality in chronic systolic heart failure with a wide QRS complex.<unk>
T-845	cardiac-resynchronization_therapy crt morbidity mortality chronic_systolic_heart_failure wide_qrs_complex
H-845	-0.914772093296051	▁Card iac - re syn chron ization _ therapy ▁c RT ▁morbi d ity _ de _ ▁mortal ity ▁chronic _ syn chron _ heart _ ▁failure ▁QR S
D-845	-0.914772093296051	Cardiac-resynchronization_therapy cRT morbidity_de_ mortality chronic_synchron_heart_ failure QRS
P-845	-0.4274 -0.0633 -0.2060 -0.1296 -0.0338 -0.0004 -0.9409 -1.2711 -1.2980 -0.6683 -0.1145 -2.8559 -0.0321 -0.1839 -2.7779 -1.4904 -0.1906 -0.1615 -0.0737 -0.3146 -1.2114 -1.7458 -0.4651 -3.0859 -2.5895 -0.9124 -3.3618 -0.0036 -1.4722 -0.2146 -0.0618
S-423	In patients with systolic HF, CXL-1020 reduced both left and right heart filling pressures and systemic vascular resistance, while increasing cardiac and stroke volume index.<unk>
T-423	patients systolic_hf cxl-1020 right_heart_filling_pressures systemic_vascular_resistance cardiac stroke_volume_index
H-423	-1.1987969875335693	▁sy sto lic ▁ HF ▁ HF ▁left _ ▁right ▁heart _ ▁fill ing _ tension s ▁system ic _ ▁vas cular _ ▁resist ance ▁cardiac ▁stroke
D-423	-1.1987969875335693	systolic HF HF left_ right heart_ filling_tensions systemic_ vascular_ resistance cardiac stroke
P-423	-2.5456 -0.1346 -1.0099 -0.7838 -0.0114 -4.0383 -0.2108 -4.0590 -2.3044 -3.1983 -1.5645 -2.4048 -0.1644 -0.0823 -1.6273 -0.7346 -0.1374 -1.8669 -0.4089 -0.3832 -0.4398 -0.1107 -1.5503 -1.7100 -0.0044 -0.0651 -2.4050 -0.6925 -0.1167
S-1799	LA is under the awful paradox of having the HF risk factors and HF epidemiology of developed countries with the added factors of SH, C'D, and rheumatic fever.<unk>
T-1799	hf hf epidemiology rheumatic_fever
H-1799	-0.7334317564964294	▁ HF ▁ HF ▁ HF ▁epidemi ologie ▁SH ▁c d ▁rhe u matic ▁fe ver
D-1799	-0.7334317564964294	HF HF HF epidemiologie SH cd rheumatic fever
P-1799	-0.2868 -0.0646 -1.0987 -0.1012 -2.0917 -0.1546 -3.0347 -1.8179 -0.5132 -1.5855 -0.7539 -0.0540 -0.0511 -1.0367 -0.0409 -0.0111 -0.3498 -0.1557
S-1976	OBJECTIVE: To determine whether caloric restriction (diet) or aerobic exercise training (exercise) improves exercise capacity and QOL in obese older patients with HFPEF.<unk>
T-1976	exercise training exercise exercise_capacity qol obese patients hfpef
H-1976	-0.6643787026405334	▁calor ic ▁restriction _ diet ▁aero bic ▁exercise _ training _ exe rci se ▁Q OL ▁h f f
D-1976	-0.6643787026405334	caloric restriction_diet aerobic exercise_training_exercise QOL hff
P-1976	-0.2262 -0.3915 -0.1195 -3.4660 -0.4030 -0.5400 -0.0221 -1.2547 -0.5366 -1.0124 -1.2976 -0.1250 -0.0093 -0.0677 -1.0026 -0.0707 -1.6838 -0.7079 -0.3321 -0.6054 -0.0780
S-1813	In these studies, we evaluated mice with cardiac myocyte-specific Mena overexpression (TTA/TgTetMena) comparable to that observed in cardiac pathology.<unk>
T-1813	cardiac myocyte-specific_mena_overexpression cardiac pathology
H-1813	-0.66933274269104	▁cardiac _ My o cy te _ specific ▁Men a _ over expression ▁t g t et Men a ▁cardiac _ path ology
D-1813	-0.66933274269104	cardiac_Myocyte_specific Mena_overexpression tgtetMena cardiac_pathology
P-1813	-0.6937 -0.5248 -1.9547 -0.1868 -0.0341 -0.0609 -2.0201 -0.6877 -0.1605 -0.1006 -2.4391 -1.6274 -0.1015 -1.3508 -0.1210 -0.3631 -1.1975 -0.5019 -0.0339 -0.0141 -0.7644 -0.3549 -1.2345 -0.1421 -0.0633
S-722	Some data suggest that outpatient assessments of patients with heart failure within 7 days of hospital discharge may prevent readmissions, although little is known about patient needs at 7-day follow-up visits.<unk>
T-722	outpatient patients heart_failure hospital discharge readmissions patient follow-up
H-722	-1.496812343597412	▁in patient s ▁heart _ ▁failure ▁hospital _ dis charge
D-722	-1.496812343597412	inpatients heart_ failure hospital_discharge
P-722	-3.6726 -0.0411 -2.5665 -3.7241 -1.0288 -2.7302 -0.4767 -0.8689 -0.1120 -0.0102 -2.6283 -0.1025
S-839	It was hypothesized that baseline Hgb would be correlated with baseline KCCQ scales and that Hgb would moderate the beneficial effect of exercise training on HRQoL.<unk>
T-839	baseline hgb correlated baseline kccq hgb exercise training hrqol
H-839	-1.0581324100494385	▁base line ▁h gb ▁k cc q ▁h gb ▁h gb
D-839	-1.0581324100494385	baseline hgb kccq hgb hgb
P-839	-2.3448 -0.3541 -1.1896 -0.0391 -0.8170 -0.0709 -0.5805 -1.5259 -0.1158 -1.9899 -0.2067 -4.4043 -0.1170
S-1172	BACKGROUND: Because symptoms of HFpEF are typically exertional, optimization of diastolic filling time by controlling heart rate may delay the onset of symptoms.<unk>
T-1172	symptoms hfpef diastolic_filling_time heart_rate symptoms
H-1172	-1.090662956237793	▁ HF p EF ▁dia sto lic _ ▁fill ing ▁temps ▁heart _ ▁rate
D-1172	-1.090662956237793	HFpEF diastolic_ filling temps heart_ rate
P-1172	-0.5817 -0.2513 -0.3282 -1.3469 -2.2441 -0.6845 -2.2129 -2.2905 -0.6837 -0.0287 -1.8552 -2.2163 -1.7864 -0.7049 -0.1483 -0.0868
S-1472	Understanding of chronic heart failure (HF) has progressed from the concept of a purely hemodynamic disorder to that of a syndrome that results from dysfunction in interconnected molecular pathways.<unk>
T-1472	chronic_heart_failure hf hemodynamic syndrome dysfunction molecular_pathways
H-1472	-0.722028374671936	▁chronic _ heart _ ▁failure ▁ HF ▁hem o dynamic ▁disorder ▁syndrome ▁dys function ▁inter connect ed _ ▁molecular ▁path ways
D-1472	-0.722028374671936	chronic_heart_ failure HF hemodynamic disorder syndrome dysfunction interconnected_ molecular pathways
P-1472	-1.3954 -0.5046 -2.0952 -0.4286 -2.6304 -2.1748 -0.0334 -1.1690 -0.0633 -0.0267 -1.5171 -0.6781 -0.1671 -0.6477 -0.5735 -0.0079 -0.1691 -0.8287 -0.1388 -1.0653 -0.0714 -0.1290 -0.0916
S-1458	In this guideline, the International Right Heart Foundation Working Group moves a step forward to develop a common language to describe the development and defects that exemplify the common syndrome of right heart failure.<unk>
T-1458	international_right_heart_foundation_working_group step syndrome right_heart_failure
H-1458	-1.5141469240188599	▁Right _ ▁Heart _ ▁Foundation
D-1458	-1.5141469240188599	Right_ Heart_ Foundation
P-1458	-3.7509 -1.6995 -0.4886 -0.8707 -0.2686 -3.4153 -0.1055
S-667	CONCLUSIONS: Variation in the use of guideline-recommended medications for patients with heart failure and reduced ejection fraction exists in the outpatient setting.<unk>
T-667	medications patients heart_failure_and_reduced_ejection_fraction outpatient
H-667	-0.7656497955322266	▁guide line - re com mend ed ▁medication s ▁patients ▁heart _ ▁failure ▁e je ction _ fraction
D-667	-0.7656497955322266	guideline-recommended medications patients heart_ failure ejection_fraction
P-667	-3.3191 -0.0237 -0.6677 -0.0254 -0.0237 -0.0121 -0.1396 -0.1785 -0.0721 -1.2791 -1.3178 -0.9988 -1.4651 -2.0893 -1.1059 -0.0325 -1.3470 -0.0108 -1.0458 -0.1593
S-1081	In this work, we tested whether truncated Na+ channels activate the unfolded protein response (UPR), contributing to SCN5A electric remodeling in HF.<unk>
T-1081	activate unfolded_protein_response upr scn5a remodeling hf
H-1081	-0.4146289825439453	▁tru nca ted ▁na + ▁channel s ▁un fold ed ▁protein ▁response ▁u PR ▁S CN 5 a ▁electric ▁remodel ing ▁ HF
D-1081	-0.4146289825439453	truncated na+ channels unfolded protein response uPR SCN5a electric remodeling HF
P-1081	-0.6126 -0.0074 -1.0732 -0.4454 -2.2445 -0.1884 -0.0593 -0.0879 -0.0005 -0.0542 -0.6206 -1.2699 -0.0444 -0.0516 -1.8039 -0.0492 -0.4199 -0.5403 -0.1059 -0.2019 -0.0168 -0.2065 -0.0189 -0.1384 -0.1041
S-1780	METHODS AND RESULTS: Mice were subjected to cardiac hypertrophy secondary to pressure-overload as a result of an abdominal aortic constriction (AAC).<unk>
T-1780	cardiac_hypertrophy pressure-overload abdominal_aortic_constriction aac
H-1780	-0.6417787671089172	▁cardiac ▁hyper trop hy ▁pressure - over load ▁abdominal ▁a or tic _ con stri ction ▁a ac
D-1780	-0.6417787671089172	cardiac hypertrophy pressure-overload abdominal aortic_constriction aac
P-1780	-0.4852 -1.3274 -0.0097 -0.0401 -1.7865 -0.1982 -0.0750 -0.0880 -0.0539 -0.6739 -1.1640 -2.6462 -1.3248 -0.0976 -0.0872 -0.0357 -1.4763 -1.0552 -0.1163 -0.0944
S-1355	Additional progress is needed, including better tools for risk stratification and clarity regarding the need for antiplatelet agents in combination with anticoagulants for those with other vascular diseases.<unk>
T-1355	risk_stratification antiplatelet_agents combination anticoagulants vascular_diseases
H-1355	-0.9225144386291504	▁anti plate let ▁agents ▁antico a gul ants ▁vas cular ▁disease s
D-1355	-0.9225144386291504	antiplatelet agents anticoagulants vascular diseases
P-1355	-3.0633 -1.9884 -1.5600 -0.2110 -0.3189 -0.4119 -0.2402 -0.0289 -1.1340 -0.0842 -3.6189 -0.0174 -0.1687 -0.0694
S-477	In conclusion, allopurinol improves LV contractile function and efficiency possibly by diminishing the known XO-mediated ROS effects on myofilament Ca(2+) sensitivity.<unk>
T-477	allopurinol lv_contractile_function xo-mediated_ros myofilament sensitivity
H-477	-0.6679604649543762	▁allo puri nol ▁LV ▁contract ile _ f ré que nce ▁ XO - media ted ▁ ROS ▁my o fila ment
D-477	-0.6679604649543762	allopurinol LV contractile_fréquence XO-mediated ROS myofilament
P-477	-1.0827 -0.0278 -0.0913 -1.1717 -0.0886 -0.2761 -0.8480 -3.3780 -0.3684 -0.1511 -0.0424 -0.3123 -2.0256 -0.0233 -0.0767 -0.6257 -0.1283 -0.1210 -3.3784 -0.0234 -0.0285 -0.0923 -1.5359 -0.1333
S-1562	Similarly, crude and adjusted ankle-brachial index, pulse-wave velocity, and coronary artery calcium scores did not differ between the two groups.<unk>
T-1562	ankle-brachial_index pulse-wave coronary_artery_calcium_scores
H-1562	-0.4339717626571655	▁an kle - bra chi al ▁index ▁puls e - wa ve _ ▁veloci ty ▁corona ry ▁arter y ▁calci um ▁score s
D-1562	-0.4339717626571655	ankle-brachial index pulse-wave_ velocity coronary artery calcium scores
P-1562	-0.6159 -0.0574 -0.0863 -0.5404 -0.1645 -0.0825 -0.0845 -0.2003 -0.0760 -0.0993 -0.1339 -0.0257 -0.8194 -3.4161 -0.4900 -0.0066 -0.4058 -1.5890 -0.4105 -0.4481 -0.0251 -0.5265 -0.2984 -0.1953 -0.0518
S-1156	These changes in myofiber dynamics delay the onset of myofiber shortening, thus giving rise to prolonged EMD in dyssynchronous HF.<unk>
T-1156	myofiber_dynamics myofiber_shortening emd dyssynchronous_hf
H-1156	-0.6263753175735474	▁my o fi ber ▁dynamic s ▁my o fi ber _ short en ing ▁EM d ▁dys syn chron ous ▁ HF
D-1156	-0.6263753175735474	myofiber dynamics myofiber_shortening EMd dyssynchronous HF
P-1156	-1.4498 -0.1789 -0.5539 -0.1239 -1.6857 -0.0165 -1.5134 -0.0357 -0.5127 -0.1229 -1.8113 -1.1102 -0.0486 -0.1254 -1.1135 -0.3035 -0.0491 -0.0005 -0.0001 -3.1922 -0.7416 -0.0072 -0.1810 -0.1552
S-225	We hypothesized that Fontan failure is hemodynamically distinct from traditional heart failure and characterized by low systemic vascular resistance (SVR) index and preserved cardiac index.<unk>
T-225	fontan_failure hemodynamically heart_failure systemic_vascular_resistance svr cardiac_index
H-225	-1.141485571861267	▁Font an _ ▁failure ▁hem o dynamic ally ▁heart _ ▁failure ▁system ic _ ▁vas cular _ ▁resist ance ▁s VR ▁cardiac ▁index
D-225	-1.141485571861267	Fontan_ failure hemodynamically heart_ failure systemic_ vascular_ resistance sVR cardiac index
P-225	-0.2004 -0.5643 -1.3797 -4.1208 -3.2999 -0.0186 -0.0047 -0.3182 -2.3962 -0.9430 -0.4273 -4.3136 -0.9622 -0.2123 -1.4218 -0.3219 -1.1735 -2.0523 -0.0105 -1.7153 -0.0961 -1.9594 -0.3948 -0.1369 -0.0935
S-16	During follow up body weight was unaltered in all groups even though FM increased by 1.35 kg (p<0.05) and FFM decreased by 0.5 kg (p<0.05) in CC patients.<unk>
T-16	follow_up ffm patients
H-16	-1.3722138404846191	▁figure f f f f
D-16	-1.3722138404846191	figureffff
P-16	-2.3296 -2.0405 -0.1166 -0.1865 -0.6370 -4.2118 -0.0834
S-1776	Men should be counseled on physical activity with the goal of achieving at least a moderate level of CRF, thereby presumably decreasing their risk of HF mortality.<unk>
T-1776	physical activity crf hf mortality
H-1776	-1.0921821594238281	▁physical ▁activity ▁c RF ▁ HF
D-1776	-1.0921821594238281	physical activity cRF HF
P-1776	-3.3843 -1.8363 -0.2396 -0.2391 -1.4486 -0.1932 -1.3080 -0.0881
S-1610	Data processing and differential analysis were carried out with packages of R. Cluster analysis was also performed for all the samples to globally observe the difference among the three groups of samples.<unk>
T-1610	differential_analysis cluster_analysis
H-1610	-1.88336980342865	
D-1610	-1.88336980342865	
P-1610	-3.7205 -0.0462
S-1715	MEASUREMENTS: Thirty-day rehospitalization derived from Medicare hospital claims using the implementation of Medicare's post-acute care transfer policy as a quasi-experiment.<unk>
T-1715	rehospitalization medicare hospital medicare policy
H-1715	-0.8407948017120361	▁re hospital ization ▁Medica re ▁hospital _ ▁claims ▁Medica re ▁post - a cute _ care _ transfer _ policy
D-1715	-0.8407948017120361	rehospitalization Medicare hospital_ claims Medicare post-acute_care_transfer_policy
P-1715	-3.2325 -0.0319 -0.3570 -0.0103 -0.0007 -1.1265 -0.9717 -0.2126 -0.0330 -0.0018 -2.7674 -0.0101 -0.0222 -0.0133 -0.1140 -5.1976 -0.3550 -1.2885 -1.3330 -0.5798 -0.6027 -0.2360
S-710	METHODS AND RESULTS: Between January 2000 and December 2009, adult patients undergoing isolated heart transplant were prospectively classified as ECCT based on prespecified criteria.<unk>
T-710	patients heart_transplant prospectively ecct
H-710	-2.054208993911743	
D-710	-2.054208993911743	
P-710	-4.0473 -0.0611
S-663	A median rate ratio was calculated for each therapy, which describes the likelihood that the treatment of a patient with given comorbidities would differ at 2 randomly selected practices.<unk>
T-663	rate_ratio therapy patient comorbidities
H-663	-1.7148245573043823	▁ therapy ▁como rbi di ties
D-663	-1.7148245573043823	therapy comorbidities
P-663	-2.8076 -1.1639 -5.9318 -0.0269 -1.2343 -2.3326 -0.1506 -0.0709
S-1242	CONCLUSION: In the study population, the therapeutic strategy used to manage AF in patients with severe heart failure appears to have little influence on the overall financial burden, which remains substantial.<unk>
T-1242	therapeutic patients severe_heart_failure financial
H-1242	-1.4658249616622925	▁ therapeut ic ▁af ▁in ▁patients _ con tre _ heart _ ▁failure ▁financière
D-1242	-1.4658249616622925	therapeutic af in patients_contre_heart_ failure financière
P-1242	-1.3236 -0.0407 -0.3802 -3.5483 -4.2973 -2.3306 -0.5719 -2.1581 -0.6787 -0.4774 -1.9725 -0.8211 -1.6243 -1.7930 -1.3772 -0.0585
S-1823	While our country has physicians experienced in the management of patients with advanced heart failure, these professionals are not distributed evenly across the country, and equitable access to therapeutic options is not provided.<unk>
T-1823	physicians patients heart_failure equitable therapeutic
H-1823	-1.6045700311660767	▁physician s ▁management ▁patients ▁advanced _ heart _ ▁failure ▁ therapeut ic
D-1823	-1.6045700311660767	physicians management patients advanced_heart_ failure therapeutic
P-1823	-2.2209 -0.0177 -3.8838 -1.4981 -3.5103 -0.6206 -1.8704 -1.0904 -2.4734 -2.4407 -0.0871 -0.8388 -1.8004 -0.1115
S-1543	The risk of heart failure increased significantly with increasing refill compliance for etidronate (P for trend < 0.01), whereas it decreased for alendronate (P for trend < 0.01).<unk>
T-1543	heart_failure compliance etidronate alendronate
H-1543	-0.991523027420044	▁risk _ de _ heart _ pu issa nce ▁et id rona te ▁ale ndr onate
D-1543	-0.991523027420044	risk_de_heart_puissance etidronate alendronate
P-1543	-1.8779 -0.9718 -1.3669 -0.1303 -0.9071 -1.1482 -4.5885 -0.0290 -0.0105 -3.8915 -0.8429 -0.1036 -0.0315 -1.2417 -0.0393 -0.3473 -0.2406 -0.0786
S-1762	Nonidentification of AT remained associated to prognosis also when compared with metabolic exercise and cardiac and kidney index score (P<0.01; HR=1.459; CI=1.09-1.10).<unk>
T-1762	prognosis metabolic_exercise cardiac kidney
H-1762	-1.1878339052200317	▁metabol ic _ ▁exercise ▁cardiac ▁ki dne y ▁index ▁score
D-1762	-1.1878339052200317	metabolic_ exercise cardiac kidney index score
P-1762	-2.8348 -0.0676 -2.3170 -0.6642 -0.0210 -6.6407 -0.0383 -0.0524 -0.0269 -1.2575 -0.2290 -0.1047
S-249	OBJECTIVE: This study was performed to evaluate the impact of ET on HDL-mediated protective effects and the respective molecular pathways in patients with chronic heart failure (CHF).<unk>
T-249	molecular_pathways patients chronic_heart_failure chf
H-249	-1.247307538986206	▁ET ▁HD L - media ted _ protec ive ▁effects ▁molecular ▁path ways ▁chronic _ heart _ ▁failure CH f
D-249	-1.247307538986206	ET HDL-mediated_protecive effects molecular pathways chronic_heart_ failureCHf
P-249	-2.6580 -3.9572 -0.7390 -0.3122 -0.0455 -0.8648 -0.4751 -0.4883 -1.0961 -2.6547 -0.5905 -0.9474 -0.1291 -3.7191 -0.5732 -2.2340 -0.8569 -3.3957 -1.0384 -0.4927 -0.1082 -0.0647
S-451	Importantly, β-adrenergic receptor blocker therapy has been also shown to improve myocardial perfusion by enhancing neoangiogenesis in the failing heart.<unk>
T-451	β-adrenergic_receptor_blocker_therapy myocardial_perfusion neoangiogenesis heart
H-451	-0.3161071240901947	▁β - ad r energi c ▁receptor _ block er ▁ therapy ▁my o card ial _ per fusion ▁neo angi ogen es is ▁fail ing ▁heart
D-451	-0.3161071240901947	β-adrenergic receptor_blocker therapy myocardial_perfusion neoangiogenesis failing heart
P-451	-0.0284 -0.0989 -0.0154 -0.0695 -0.2602 -0.0733 -1.2769 -0.7861 -0.7621 -0.0435 -0.9036 -0.0157 -1.4228 -0.0915 -0.1533 -0.1062 -0.3176 -0.2805 -0.0174 -0.0134 -0.1708 -0.4577 -0.0520 -0.4494 -0.1388 -0.1561 -0.7320 -0.1522 -0.1219
S-1996	METHODS: The primary endpoint was 6-month survival compared with INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support)-derived performance goal.<unk>
T-1996	primary_endpoint intermacs interagency_registry_for_mechanically_assisted_circulatory_support
H-1996	-0.6926702857017517	▁inter age ncy _ ▁Registr y _ ▁for _ ▁Mechanic ally _ assist ed _ ▁Circula tory _ ▁Support
D-1996	-0.6926702857017517	interagency_ Registry_ for_ Mechanically_assisted_ Circulatory_ Support
P-1996	-0.8091 -1.9542 -0.0059 -0.4495 -3.0832 -0.0712 -0.5276 -1.6468 -0.8616 -0.0391 -0.9632 -0.2723 -1.0093 -0.1358 -0.0978 -0.3109 -0.4403 -1.1658 -0.3029 -0.2926 -0.1069
S-1260	Meta-analysis was performed on the overall effects on effective rate, left ventricular ejection fraction, left ventricular diastolic end diameter, and other outcome measures.<unk>
T-1260	meta-analysis left_ventricular_ejection_fraction left_ventricular_diastolic_end_diameter outcome
H-1260	-0.7293869256973267	▁vent ri cular _ é je ction _ fraction ▁vent ri cular _ ▁dia sto lic _ ▁end
D-1260	-0.7293869256973267	ventricular_éjection_fraction ventricular_ diastolic_ end
P-1260	-0.2762 -0.1720 -0.3691 -1.0687 -1.5506 -1.5253 -0.0414 -0.6698 -0.0058 -0.9577 -0.1395 -0.1460 -0.2867 -2.2441 -0.1804 -1.3673 -1.1228 -0.2934 -2.0637 -0.1072
S-1887	Half of these patients have normal, or near normal, left ventricular ejection fraction and are classified as heart failure with preserved ejection fraction (HFpEF).<unk>
T-1887	patients left_ventricular_ejection_fraction heart_failure_with_preserved_ejection_fraction hfpef
H-1887	-0.9539312720298767	▁vent ri cular _ ▁e je ction _ fraction ▁heart _ ▁failure ▁ fraction HF p EF
D-1887	-0.9539312720298767	ventricular_ ejection_fraction heart_ failure fractionHFpEF
P-1887	-0.5435 -0.1832 -0.2017 -1.6321 -2.4076 -0.5828 -0.1038 -0.7437 -0.0154 -0.9863 -0.4684 -3.2285 -4.2094 -0.4741 -1.8066 -0.0210 -0.2421 -0.1359 -0.1387
S-1523	Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction.<unk>
T-1523	prevalence clinical outcomes concentric_left_ventricular_hypertrophy heart_failure_with_preserved_ejection_fraction
H-1523	-1.2423824071884155	▁vent ri cular _ ▁hyper trop hy ▁heart _ ▁failure
D-1523	-1.2423824071884155	ventricular_ hypertrophy heart_ failure
P-1523	-5.3278 -0.4267 -0.3076 -1.1472 -1.3258 -0.0160 -0.0409 -1.2109 -0.5766 -3.0801 -1.3597 -0.0894
S-1085	Induction of SCN5A variants with AngII or hypoxia or the expression of exogenous variants induced the UPR with concomitant downregulation of Na+ current.<unk>
T-1085	scn5a angii hypoxia expression upr downregulation
H-1085	-1.102877140045166	▁s CN 5 a ▁ang II ▁hypo xia ▁u PR
D-1085	-1.102877140045166	sCN5a angII hypoxia uPR
P-1085	-1.9236 -0.5145 -3.1063 -0.4665 -1.2233 -1.2880 -0.0303 -0.0506 -0.0332 -0.3049 -4.0421 -0.2514
S-1708	CONCLUSIONS: AAs with HF exhibited less hyperkalemia and more hypokalemia with spironolactone compared with non-AAs and seemed to derive less clinical benefit.<unk>
T-1708	aas hf hyperkalemia hypokalemia spironolactone clinical
H-1708	-0.547300398349762	▁ HF ▁hyper kal emia ▁hypo kal emia ▁spi rono lac tone
D-1708	-0.547300398349762	HF hyperkalemia hypokalemia spironolactone
P-1708	-2.1386 -0.1120 -0.3257 -0.2781 -0.1347 -0.4308 -1.2841 -0.4169 -0.2060 -0.0117 -0.0818 -0.0953 -2.0737 -0.0728
S-1888	Newer imaging techniques have confirmed that systolic function in HFpEF patients is not completely normal, with reduced long axis function and extensive but subtle changes on exercise.<unk>
T-1888	systolic_function hfpef patients long_axis_function exercise
H-1888	-1.1481009721755981	▁implant g ▁techniques ▁ HF p EF ▁long _ a xis _ fon cti onnement
D-1888	-1.1481009721755981	implantg techniques HFpEF long_axis_fonctionnement
P-1888	-1.8655 -2.1274 -0.6913 -1.9602 -0.2878 -0.2618 -1.2881 -2.9631 -0.6398 -0.8270 -0.0749 -1.4639 -2.8700 -0.4032 -0.4226 -1.2255 -0.1457
S-1407	Importantly, both of these receptors can be regulated by the actions of G-protein-coupled receptor kinase-2, which triggers desensitization and downregulation processes.<unk>
T-1407	receptors g-protein-coupled_receptor kinase-2 downregulation
H-1407	-0.7791721224784851	▁g - prote in - co up led ▁receptor _ ▁kina se
D-1407	-0.7791721224784851	g-protein-coupled receptor_ kinase
P-1407	-2.3211 -0.3013 -0.2887 -0.4763 -0.3052 -0.0133 -0.0092 -0.9494 -0.2055 -1.4217 -1.5473 -0.0251 -2.9069 -0.1375
S-1522	These findings support the development of a next generation NT-proBNP assay targeting nonterminal epitopes as well as avoiding the central glycosylated region of this molecule.<unk>
T-1522	nt-probnp nonterminal_epitopes central_glycosylated_region
H-1522	-0.9239824414253235	▁NT - pro B NP
D-1522	-0.9239824414253235	NT-proBNP
P-1522	-0.3696 -0.0830 -0.0283 -0.8015 -0.1163 -4.9611 -0.1081
S-82	Compared with placebo, there was no effect of low-dose dopamine or nesiritide on secondary end points reflective of decongestion, renal function, or clinical outcomes.<unk>
T-82	placebo dopamine nesiritide secondary_end_points renal_function clinical outcomes
H-82	-0.8114857077598572	▁dop amine ▁nesi riti de ▁de con gestion ▁renal
D-82	-0.8114857077598572	dopamine nesiritide decongestion renal
P-82	-5.1258 -0.2992 -0.1672 -0.0428 -0.0539 -0.7537 -0.0014 -0.0064 -0.0027 -2.4283 -0.0450
S-1571	Multivariate logistic regression analysis established that a high BNP was strongly and independently associated with the highest quartile of E/e', highlighting these patients' diastolic dysfunction.<unk>
T-1571	multivariate_logistic_regression_analysis bnp patients diastolic_dysfunction
H-1571	-1.2646433115005493	▁b NP
D-1571	-1.2646433115005493	bNP
P-1571	-0.2162 -0.9594 -3.8086 -0.0744
S-240	In HART, 208 patients had HFpEF and 692 had HF with reduced ejection fraction (HFrEF) and were followed for a median of 1,080 days.<unk>
T-240	hart patients hfpef hf_with_reduced_ejection_fraction hfref
H-240	-1.1967042684555054	▁h ART ▁h ART ▁ HF ▁h f ▁h f ▁ HF ▁h r f ▁h r f
D-240	-1.1967042684555054	hART hART HF hf hf HF hrf hrf
P-240	-0.2381 -0.1206 -0.7376 -0.4200 -1.4147 -0.0416 -2.3399 -1.3392 -2.4696 -0.9222 -2.7972 -0.1380 -2.3825 -2.3718 -1.5133 -0.9971 -1.0223 -1.4674 -1.0438 -0.1571
S-1312	Concurrent HF was associated with a multivariate-adjusted odds ratio of 2.2 for 28-day mortality and a hazard ratio of 2.2 for 1-year mortality in 28-day survivors.<unk>
T-1312	hf multivariate-adjusted_odds_ratio mortality hazard_ratio mortality
H-1312	-1.6730132102966309	▁ HF ▁ HF ▁fréquence ▁28- day ▁mortal ity ▁hazard
D-1312	-1.6730132102966309	HF HF fréquence 28-day mortality hazard
P-1312	-1.7998 -0.3428 -3.8263 -0.3806 -4.9438 -3.7070 -0.2084 -0.9620 -0.1982 -0.2758 -3.1821 -0.2495
S-741	Extracellular matrix of left ventricular biopsies (n=9), quantified by TissueFAXS technology correlated with T1 time (R=0.98; P<0.01).<unk>
T-741	extracellular_matrix left_ventricular biopsies tissuefaxs correlated t1_time
H-741	-0.6611139178276062	▁extra cel lular _ ▁matri x ▁left ▁vent ri cular _ ▁bio psi es ▁t issue FAX s ▁technologie
D-741	-0.6611139178276062	extracellular_ matrix left ventricular_ biopsies tissueFAXs technologie
P-741	-1.2520 -0.1274 -0.0218 -2.0469 -1.6821 -0.0136 -0.8793 -0.9526 -0.1916 -0.2496 -1.1299 -0.3001 -0.4828 -0.0848 -1.2813 -0.0106 -0.0659 -1.3896 -0.7633 -0.8219 -0.1363
S-773	As left ventricular assist devices (LVADs) have become more widely used for treating patients with advanced heart failure, the incidence of pump dysfunction requiring pump replacement has increased.<unk>
T-773	left_ventricular_assist_devices lvads patients heart_failure incidence pump_dysfunction pump
H-773	-1.0388139486312866	▁vent ri cular _ assist ▁devices ▁l VAD s ▁patients ▁advanced ▁heart _ ▁failure ▁pump
D-773	-1.0388139486312866	ventricular_assist devices lVADs patients advanced heart_ failure pump
P-773	-0.2956 -0.1004 -0.0635 -0.8345 -0.0868 -1.6995 -1.1946 -0.0207 -0.3697 -3.6933 -2.8380 -1.5085 -0.4982 -2.3616 -0.2059 -1.8211 -0.0680
S-98	The mechanisms underlying these defects involve perturbed bone morphogenetic protein 4 expression, decreased rRNA transcription, and a shift to more heterochromatic chromatin.<unk>
T-98	bone_morphogenetic_protein_4 expression rrna_transcription shift heterochromatic_chromatin
H-98	-0.6942070722579956	▁bone _ ▁mor pho gene tic ▁protein ▁r RNA ▁tran scription ▁hetero ch ro matic ▁chr omat in
D-98	-0.6942070722579956	bone_ morphogenetic protein rRNA transcription heterochromatic chromatin
P-98	-0.8999 -0.2707 -1.7355 -1.9442 -0.9584 -3.0274 -0.8920 -0.2516 -0.0089 -0.7490 -0.0233 -1.4714 -0.0748 -0.0298 -0.2930 -0.1949 -0.0198 -0.7438 -0.2362 -0.0592
S-939	These results suggest that elevated resistin is a biomarker of anthracycline-induced cardiotoxicity and may contribute in the development of heart failure via its direct effects on macrophages.<unk>
T-939	elevated resistin biomarker anthracycline-induced_cardiotoxicity heart_failure macrophages
H-939	-0.5995365381240845	▁bio mark er ▁an thra cycli ne _ indu ced _ ▁cardio toxic ity ▁heart _ ▁failure ▁macro pha ges
D-939	-0.5995365381240845	biomarker anthracycline_induced_ cardiotoxicity heart_ failure macrophages
P-939	-2.5141 -0.0066 -0.0282 -0.4302 -0.0170 -1.6495 -0.4860 -1.1173 -0.0005 -0.8147 -0.7746 -0.0619 -0.2489 -0.1759 -0.1480 -0.9653 -3.1913 -0.3498 -0.0158 -0.0631 -0.0834 -0.0476
S-873	The top pathways were in the categories of actin cytoskeleton, mitochondrial function, intermediate metabolism, glycolysis/gluconeogenesis, and citrate cycle.<unk>
T-873	actin_cytoskeleton mitochondrial_function metabolism glycolysis gluconeogenesis citrate_cycle
H-873	-0.4078899621963501	▁act in _ ▁cy tos kelet on ▁mito cho ndri al ▁metabolism ▁gly col ysis _ glu cone ogen es is ▁cit rate
D-873	-0.4078899621963501	actin_ cytoskeleton mitochondrial metabolism glycolysis_gluconeogenesis citrate
P-873	-0.1319 -0.4272 -0.3792 -1.3406 -0.5657 -0.0286 -0.1228 -0.0208 -0.6593 -0.1034 -0.0804 -2.1575 -0.0277 -0.5815 -0.0778 -1.1163 -0.3814 -0.0915 -0.4162 -0.0491 -0.1733 -0.0035 -0.0194 -1.1884 -0.0539
S-421	In conscious dogs with tachypacing-induced HF, CXL-1020 increased contractility assessed by end-systolic elastance and provided venoarterial dilation.<unk>
T-421	tachypacing-induced_hf cxl-1020 contractility end-systolic_elastance venoarterial_dilation
H-421	-0.5476548075675964	▁ conscious ▁dog s ▁ta chy pac ing - indu ced ▁ HF ▁contract ility ▁end - sy sto lic ▁elastan ce ▁ve no arte rial ▁di lation
D-421	-0.5476548075675964	conscious dogs tachypacing-induced HF contractility end-systolic elastance venoarterial dilation
P-421	-1.4197 -1.1490 -0.2627 -0.0912 -4.7719 -0.1339 -0.0039 -0.2487 -0.2215 -0.0007 -0.4828 -0.1507 -0.0066 -0.7704 -0.1083 -0.8739 -0.0091 -0.8798 -0.3808 -2.3856 -0.0435 -0.3910 -0.0468 -0.1020 -0.0613 -0.1407 -0.8903 -0.0087 -0.2534 -0.1407
S-704	In multivariable models, ST2 remained independently associated with outcomes after adjustment for clinical variables and amino-terminal pro-B-type natriuretic peptide.<unk>
T-704	multivariable_models st2 outcomes clinical amino-terminal_pro-b-type_natriuretic_peptide
H-704	-0.7455906867980957	▁ST 2 ▁amino - termin al _ pro - B - type ▁na tri ure tic ▁pe pti de
D-704	-0.7455906867980957	ST2 amino-terminal_pro-B-type natriuretic peptide
P-704	-2.7561 -1.0557 -1.2521 -0.0336 -0.0057 -0.0065 -1.9659 -0.2135 -0.0374 -0.3118 -0.1148 -0.0597 -0.5420 -0.0041 -0.2271 -5.3874 -1.1271 -0.1281 -0.1833 -0.1715 -0.0740
S-1304	In this review, the principal mechanisms, diagnostic approaches, and clinical trials are reviewed, along with a discussion of novel treatment strategies that are currently under investigation or hold promise for the future.<unk>
T-1304	principal diagnostic clinical
H-1304	-1.540836215019226	▁diagnostic s ▁clinic al
D-1304	-1.540836215019226	diagnostics clinical
P-1304	-2.1741 -2.4649 -0.9458 -0.0347 -3.5855 -0.0400
S-1538	RESULTS: The mean follow-up times were 2.8, 5.5 and 4.9 years for alendronate-, etidronate- and raloxifene-treated patients, respectively.<unk>
T-1538	follow-up patients
H-1538	-0.9835331439971924	▁al ndr onate ▁et id rona te ▁ra lo xi fen e
D-1538	-0.9835331439971924	alndronate etidronate raloxifene
P-1538	-5.2807 -2.0542 -0.5500 -2.3245 -0.3001 -0.0205 -0.0105 -0.3677 -0.0285 -0.0855 -0.9993 -0.1326 -1.5624 -0.0531
S-891	However, our data do not support the use of implantable cardioverter defibrillator-CRT in patients with non-LBBB, especially when the QRS duration is <160 ms.<unk>
T-891	implantable patients qrs_duration
H-891	-0.7167525291442871	▁implant able ▁implant able _ ▁cardio ver ter _ de _ fi br illa tor - C RT ▁ LB BB ▁QR S
D-891	-0.7167525291442871	implantable implantable_ cardioverter_de_fibrillator-CRT LBBB QRS
P-891	-0.0007 -0.0160 -1.8652 -0.0281 -0.6964 -1.0077 -0.1537 -0.0477 -0.1628 -0.0298 -1.6512 -1.8362 -0.9475 -0.0111 -0.1266 -0.7618 -2.0575 -0.1409 -2.8033 -0.3116 -0.5635 -0.0848 -1.3187 -1.2426 -0.0534
S-790	The KCCQ domains demonstrated high internal consistency among patients with HFpEF (Cronbach's α=0.96 for overall summary and ≥0.69 in all subdomains).<unk>
T-790	kccq patients hfpef
H-790	-1.077854037284851	▁k cc q ▁figure ▁ HF p EF
D-790	-1.077854037284851	kccq figure HFpEF
P-790	-0.8774 -0.1253 -0.7705 -5.2421 -0.7169 -0.3294 -0.1499 -1.1191 -1.3700 -0.0779
S-138	Using each metric, we calculated the absolute change and correlation between performance; the percent of hospitals remaining in extreme deciles and level of agreement; and differences in longitudinal performance.<unk>
T-138	change correlation hospitals longitudinal
H-138	-2.0636279582977295	
D-138	-2.0636279582977295	
P-138	-3.9870 -0.1403
S-1833	RESULTS: 78 553 saxagliptin users and 298 124 sitagliptin users contributed an average of 7 to 9 months of follow-up data to 1 or more pairwise comparisons.<unk>
T-1833	saxagliptin sitagliptin follow-up
H-1833	-1.1946886777877808	▁sax ag lip tin ▁si tag lip tin
D-1833	-1.1946886777877808	saxagliptin sitagliptin
P-1833	-0.0500 -0.4734 -2.1855 -3.1609 -0.8721 -0.0013 -0.7766 -2.2709 -2.0894 -0.0666
S-31	Methods: This guideline is based on published literature in the English language on anemia and iron deficiency from 1947 to July 2012 that was identified using MEDLINE and the Cochrane Library.<unk>
T-31	anemia medline cochrane_library
H-31	-0.6340359449386597	▁literature ▁an emia ▁ir on _ de fici en cy ▁MED LINE ▁co ch rane ▁Library
D-31	-0.6340359449386597	literature anemia iron_deficiency MEDLINE cochrane Library
P-31	-5.2436 -0.4003 -0.0441 -1.0253 -0.0538 -0.3861 -0.0274 -0.2219 -0.2768 -0.3518 -0.6872 -0.5984 -0.3511 -0.0596 -0.0086 -1.4510 -0.1386 -0.0873
S-473	Sprague-Dawley rats were randomized to either sham or ACF ± allopurinol (100 mg·kg(-1)·day(-1), n ≥7 rats/group).<unk>
T-473	sprague-dawley randomized acf allopurinol
H-473	-0.35981976985931396	▁Spr a gue - Da w ley ▁sham ▁a CF ▁allo puri nol
D-473	-0.35981976985931396	Sprague-Dawley sham aCF allopurinol
P-473	-0.1823 -0.2082 -0.0370 -0.1121 -0.6948 -0.0776 -0.2900 -0.3898 -1.7685 -0.1665 -0.2718 -0.0221 -0.2457 -0.8193 -0.1118
S-408	Compared with low sST2/high-dose BB, those with high sST2 treated with low-dose BB had an odds ratio of 6.77 (P<0.001) for a cardiovascular event.<unk>
T-408	sst2 sst2 odds_ratio cardiovascular_event
H-408	-1.7080862522125244	▁s st _ de _ high - dos e ▁BB
D-408	-1.7080862522125244	sst_de_high-dose BB
P-408	-0.3599 -2.7234 -4.7562 -3.3094 -0.9632 -3.1130 -0.0721 -0.9289 -0.2521 -1.6205 -2.2847 -0.1136
S-1064	These T1 changes appear to be associated with increases in the percentage of myocardial collagen that in this study were not detected by traditional myocardial delayed enhancement imaging.<unk>
T-1064	t1 myocardial_collagen myocardial
H-1064	-0.787701427936554	▁my o card ial _ ▁collage n
D-1064	-0.787701427936554	myocardial_ collagen
P-1064	-2.2365 -0.2060 -0.1858 -0.0928 -0.5956 -0.6719 -0.1378 -2.9197 -0.0431
S-1259	DESIGN: Studies on biomedical treatment plus CHM versus biomedical treatment alone in treating patients with DCM and heart failure were retrieved from PubMed and other major databases (1980-2011).<unk>
T-1259	biomedical biomedical patients dcm heart_failure pubmed
H-1259	-0.883613646030426	▁bio medic al ▁treatment ▁CH m ▁bio medic al ▁treatment ▁d CM ▁heart _ ▁failure ▁Pub Med
D-1259	-0.883613646030426	biomedical treatment CHm biomedical treatment dCM heart_ failure PubMed
P-1259	-0.1377 -0.0282 -0.0021 -3.8626 -3.2038 -0.1931 -0.2063 -0.0179 -0.0038 -2.5623 -0.8588 -0.0720 -1.4593 -1.1724 -1.9369 -0.5147 -0.0238 -0.4732 -0.0597
S-587	At the second evaluation, higher serum levels of creatinine and BNP, higher furosemide dose and oxygen flow, and dobutamine or norepinephrine requirement were associated with poor outcome.<unk>
T-587	creatinine bnp furosemide dobutamine norepinephrine outcome
H-587	-0.5362395644187927	▁creati nine ▁b NP ▁fur os em ide ▁dose ▁oxygen ▁flow ▁dobu tamine ▁no re pine ph rine
D-587	-0.5362395644187927	creatinine bNP furosemide dose oxygen flow dobutamine norepinephrine
P-587	-1.6503 -0.2919 -0.2479 -0.5116 -0.0376 -0.1710 -0.0371 -0.0179 -3.4669 -0.3972 -1.3820 -0.0725 -0.0215 -0.0395 -0.0161 -0.0660 -1.0184 -0.0516 -1.1852 -0.0426
S-319	BACKGROUND: Biventricular pacing (BiVP) improves cardiac output (CO) in selected cardiac surgery patients, but response remains variable, necessitating a better understanding of the mechanism.<unk>
T-319	biventricular_pacing bivp cardiac_output cardiac surgery patients
H-319	-1.0326611995697021	▁bi ven tri cular _ pa cing ▁bi VP ▁cardiac _ co ▁cardiac ▁surgery
D-319	-1.0326611995697021	biventricular_pacing biVP cardiac_co cardiac surgery
P-319	-0.5883 -0.2394 -0.1855 -1.3251 -1.0354 -0.1697 -1.6524 -1.2851 -0.5938 -0.0867 -2.6739 -4.1978 -0.9923 -0.8765 -0.5524 -0.0682
S-111	Contemporary heart failure (HF) therapies have not resulted in improved outcomes among patients with HF and preserved left ventricular ejection fraction (LVEF).<unk>
T-111	heart_failure hf therapies outcomes patients hf preserved_left_ventricular_ejection_fraction lvef
H-111	-0.7101678848266602	▁con tempor ary _ heart _ ▁failure ▁ HF ▁ therapie s ▁ HF ▁pres er ved ▁left ▁vent ri cular _ ▁e je ction _ fraction LV EF
D-111	-0.7101678848266602	contemporary_heart_ failure HF therapies HF preserved left ventricular_ ejection_fractionLVEF
P-111	-1.1883 -0.0003 -0.0852 -0.9534 -1.9355 -0.5638 -2.3767 -1.0803 -0.4940 -1.3241 -0.1862 -0.0188 -1.2240 -0.7868 -2.9865 -0.0269 -0.4175 -0.0959 -0.3470 -0.3320 -0.5124 -1.0842 -1.2705 -0.8713 -0.1930 -1.1973 -0.1233 -0.0888 -0.0071 -0.1171 -0.1267
S-389	METHODS AND RESULTS: Patients with systolic HF were identified in The Danish Heart Failure database and new-onset ESRD from the Danish Registry on Dialysis.<unk>
T-389	patients systolic_hf the_danish_heart_failure_database esrd danish_registry_on_dialysis
H-389	-0.6469482779502869	▁sy sto lic ▁ HF ▁Danish ▁Heart _ ▁Fail ure ▁ES RD ▁Danish ▁Registr y _ ▁on _ Dia lys is
D-389	-0.6469482779502869	systolic HF Danish Heart_ Failure ESRD Danish Registry_ on_Dialysis
P-389	-3.9924 -0.1258 -1.6186 -0.5713 -0.0082 -0.3852 -1.4041 -0.3848 -0.0635 -0.0382 -2.0968 -0.0444 -0.3503 -0.5072 -0.1012 -0.2194 -0.9468 -0.2131 -1.0087 -0.2300 -0.0939 -0.3820 -0.0938
S-674	Chemotherapy, trastuzumab use, comorbidities, and CHF were identified using International Classification of Diseases, version 9, and Healthcare Common Procedure Coding System codes.<unk>
T-674	chemotherapy trastuzumab comorbidities chf international_classification_of_diseases healthcare_common_procedure_coding_system_codes
H-674	-0.752449631690979	▁Che mo therapy ▁tras tuz um ab ▁CHF ▁Health care _ ▁Common _ ▁Procedur e ▁code s
D-674	-0.752449631690979	Chemotherapy trastuzumab CHF Healthcare_ Common_ Procedure codes
P-674	-1.4581 -0.0875 -0.0306 -0.1270 -0.0009 -0.0162 -0.0763 -2.7897 -3.4584 -0.0883 -2.4196 -0.9704 -0.5381 -0.9326 -0.0931 -0.8973 -0.0273 -0.2086 -0.0766
S-1283	The interval from transplantation to consultation was shorter for the MT group (50 vs 82 days; P = 0.015), whereas the interval from consultation to operation was longer (5 vs 1 day; P = 0.03).<unk>
T-1283	transplantation consultation consultation operation
H-1283	-1.650131344795227	▁implant ation
D-1283	-1.650131344795227	implantation
P-1283	-3.1636 -0.0158 -3.3222 -0.0990
S-853	There were 45 deaths in the CRT group and 26 in the control group (11.1% vs. 6.4%; hazard ratio, 1.81; 95% CI, 1.11 to 2.93; P=0.02).<unk>
T-853	deaths crt hazard_ratio
H-853	-1.0844007730484009	▁c RT ▁figure ▁hazard ▁ratio
D-853	-1.0844007730484009	cRT figure hazard ratio
P-853	-0.3614 -0.4977 -4.7790 -0.4864 -0.8387 -0.5540 -0.0737
S-11	We tested the hypothesis that neurohormones and adipokines are associated with body composition in CC and that a progressive loss of fat free mass (FFM) and fat mass (FM) takes place.<unk>
T-11	neurohormones adipokines fat_free_mass ffm fat_mass
H-11	-1.0766856670379639	▁neuro hormon es ▁adi pok ines ▁body _ con stitu tion ▁CC ▁fat _ ▁free ▁mass f m ▁fat FM
D-11	-1.0766856670379639	neurohormones adipokines body_constitution CC fat_ free massfm fatFM
P-11	-0.0761 -0.0219 -0.0743 -0.5535 -0.0540 -0.1880 -2.0909 -2.2373 -2.2321 -1.2976 -0.5361 -0.7074 -4.0410 -2.0435 -0.8704 -0.7001 -1.6410 -0.0637 -0.9872 -2.9902 -0.2105 -0.0701
S-1678	However, our results do not rule out the possibility that decreased expression, mistargeting or altered regulation of Rad Q66P may reduce the RGK protein's efficacy in vivo.<unk>
T-1678	rule expression regulation rad q66p rgk_protein in_vivo
H-1678	-0.8090991377830505	▁expression ▁mis tar ge ting ▁rad ▁Q 66 p ▁R GK _ ▁protein ▁ef fica cy ▁in ▁vivo
D-1678	-0.8090991377830505	expression mistargeting rad Q66p RGK_ protein efficacy in vivo
P-1678	-0.8980 -0.6695 -0.0161 -0.0342 -2.4557 -1.3757 -2.0396 -0.4049 -0.4819 -1.4677 -0.0402 -1.7656 -1.0723 -0.8478 -0.0017 -0.6735 -1.1371 -0.4953 -0.2300 -0.0752
S-1411	CONCLUSIONS: We demonstrate that restoration of cardiac plasma membrane levels of S1PR1 produces beneficial effects that counterbalance the deleterious β1AR overstimulation in heart failure.<unk>
T-1411	cardiac_plasma_membrane s1pr1 β1ar heart_failure
H-1411	-1.0940589904785156	▁resto ration ▁cardiac _ ▁plasma ▁membran e ▁S 1 PR 1 ▁delete rious ▁β 1 AR ▁over stimul ation ▁heart _ ▁failure
D-1411	-1.0940589904785156	restoration cardiac_ plasma membrane S1PR1 deleterious β1AR overstimulation heart_ failure
P-1411	-4.4384 -0.0062 -0.5615 -1.7411 -1.7543 -0.2691 -0.1110 -3.1721 -0.1022 -0.2397 -2.0172 -4.2284 -0.0371 -0.2010 -0.2423 -0.6106 -2.4557 -0.1062 -0.0165 -0.3438 -1.0259 -2.3646 -0.1425 -0.0701
S-1518	Consistent with this result, AlphaLISA immunoassays demonstrated that antibodies targeting the extreme N or C termini measured a low apparent concentration of circulating NT-proBNP.<unk>
T-1518	alphalisa immunoassays antibodies c_termini nt-probnp
H-1518	-0.7197463512420654	▁Alpha LIS a ▁immun o assa ys ▁anti bo dies ▁c ▁termini ▁circula ting ▁NT - pro B NP
D-1518	-0.7197463512420654	AlphaLISa immunoassays antibodies c termini circulating NT-proBNP
P-1518	-0.0678 -0.0964 -1.8947 -0.0500 -0.1841 -0.2219 -1.6016 -0.0597 -0.0082 -1.7321 -5.7136 -0.1691 -0.1951 -2.0297 -0.1219 -0.0527 -0.0073 -0.7171 -0.0266 -0.0843 -0.0810
S-2002	Support with the fully magnetically levitated LVAS significantly reduced mortality risk by 66% compared with the Seattle Heart Failure Model-predicted survival of 78% (p = 0.0093).<unk>
T-2002	fully_magnetically_levitated_lvas mortality seattle heart_failure
H-2002	-0.886522114276886	▁fully ▁magnet ically _ ▁le vita ted ▁l VAS ▁mortal ity _ risk ▁Seattle _ ▁Heart _ ▁Fail ure
D-2002	-0.886522114276886	fully magnetically_ levitated lVAS mortality_risk Seattle_ Heart_ Failure
P-2002	-4.5806 -0.9202 -0.1946 -1.1422 -0.5139 -0.0116 -0.6931 -2.2483 -0.0524 -1.4451 -0.1067 -2.6121 -0.4707 -0.0024 -1.4306 -0.4853 -0.3613 -0.1174 -0.0574 -1.0818 -0.0893
S-89	Myocyte hypertrophy antecedent to heart failure involves changes in global gene expression, although the preceding mechanisms to coordinate DNA accessibility on a genomic scale are unknown.<unk>
T-89	myocyte_hypertrophy heart_failure global_gene_expression dna genomic
H-89	-0.9623854160308838	▁My o cy te _ ▁hyper trop hy _ ▁antecede nt _ to _ ▁heart _ ▁failure ▁gene ▁expression
D-89	-0.9623854160308838	Myocyte_ hypertrophy_ antecedent_to_ heart_ failure gene expression
P-89	-0.4116 -0.0326 -0.1057 -0.1838 -1.1904 -0.4412 -0.0093 -0.0594 -3.4224 -0.0626 -0.0378 -0.3067 -3.4602 -0.5967 -0.6971 -0.5222 -2.4629 -2.7871 -0.9769 -2.2844 -0.1589
S-944	METHODS: Catheter ablation for AF was performed in a consecutive 74 patients with compensated HFPEF (left ventricular [LV] ejection fraction >50%).<unk>
T-944	catheter_ablation patients compensated_hfpef left_ventricular ejection_fraction
H-944	-0.7478957176208496	▁cat heter ▁ab lation _ for _ ▁AF ▁compensa ted ▁h f f f ▁vent ri cular LV ▁e je ction _ fraction
D-944	-0.7478957176208496	catheter ablation_for_ AF compensated hfff ventricularLV ejection_fraction
P-944	-2.2571 -0.0134 -0.5689 -0.0062 -1.8258 -1.5860 -1.3978 -0.3601 -1.1213 -0.2920 -0.7546 -0.6414 -0.2887 -1.2125 -2.3064 -0.2707 -0.0986 -0.5743 -0.5562 -0.1924 -0.0099 -1.8911 -0.0026 -0.3918 -0.0777
S-1952	Patients (aged ≥18 years) with New York Heart Association (NYHA) class III chronic heart failure with reduced ejection fraction were enrolled under the Canadian special access programme.<unk>
T-1952	patients new_york_heart_association nyha chronic_heart_failure reduced_ejection_fraction
H-1952	-1.2506577968597412	▁New ▁York _ ▁Heart _ ▁Association NY HA ▁class _ ▁III ▁chronic _ heart _ ▁failure ▁e je ction _ fraction ▁Canadian
D-1952	-1.2506577968597412	New York_ Heart_ AssociationNYHA class_ III chronic_heart_ failure ejection_fraction Canadian
P-1952	-1.9900 -0.7250 -1.5464 -1.5486 -1.4306 -1.0191 -1.9894 -0.1089 -1.1673 -0.2573 -1.5010 -2.3250 -0.2504 -2.1676 -0.5611 -4.1741 -2.6295 -0.4724 -0.0449 -0.7312 -0.0386 -1.2793 -1.9334 -0.1249
S-972	The Swedish National Inpatient Registry was used to obtain the primary end point, which was rehospitalization for stroke, myocardial infarction, or heart failure ≤90 days after CABG.<unk>
T-972	inpatient primary_end_point rehospitalization stroke myocardial_infarction heart_failure cabg
H-972	-0.5914509892463684	▁Swedish _ national _ in patient _ ▁Registr y ▁re hospital ization ▁stroke ▁my o card ial ▁in far ction ▁heart _ ▁failure ▁CA BG
D-972	-0.5914509892463684	Swedish_national_inpatient_ Registry rehospitalization stroke myocardial infarction heart_ failure CABG
P-972	-0.0687 -1.7796 -0.4944 -0.7732 -1.2820 -0.2560 -1.2860 -1.1879 -0.0477 -0.6126 -0.0061 -0.4359 -1.4338 -0.8434 -0.1659 -0.0483 -0.0627 -0.4394 -0.9901 -0.0382 -0.1358 -1.0344 -1.2599 -1.1013 -0.0298 -0.0870 -0.0689
S-1826	Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study.<unk>
T-1826	hospitalized heart_failure saxagliptin sitagliptin antihyperglycemic_drugs retrospective_cohort_study
H-1826	-0.5379659533500671	▁Hospital ized _ ▁Heart _ ▁Fail ure ▁Sax ag lip tin ▁si tag lip tin ▁anti hy per gly ce mic ▁Drug s
D-1826	-0.5379659533500671	Hospitalized_ Heart_ Failure Saxagliptin sitagliptin antihyperglycemic Drugs
P-1826	-2.5356 -0.5202 -0.4302 -0.2018 -0.8462 -0.0295 -0.0234 -0.0523 -0.0891 -0.6437 -1.6857 -0.5909 -0.0001 -0.0588 -0.9747 -0.2095 -0.0389 -0.0385 -2.1810 -0.2936 -1.0330 -0.6764 -0.0481 -0.1896 -0.0583
S-431	Cox proportional hazards models were used to identify the association of the score with death, transplantation or LV assist device implantation, and heart failure hospitalization during 57±22 months of follow-up.<unk>
T-431	cox_proportional_hazards_models death transplantation lv_assist_device_implantation heart_failure hospitalization follow-up
H-431	-1.1728960275650024	▁co x ▁proportion al _ ▁hazard s ▁score ▁implant ation ▁LV _ assist _ ▁device _ ▁implant ation ▁heart
D-431	-1.1728960275650024	cox proportional_ hazards score implantation LV_assist_ device_ implantation heart
P-431	-2.6396 -0.0025 -1.8122 -0.0260 -1.6329 -0.2124 -0.0950 -3.7993 -2.7803 -0.0104 -0.4913 -1.0142 -0.2089 -2.4222 -1.7470 -1.4198 -0.0122 -0.0259 -0.1118 -4.0445 -0.1227
S-964	Nicorandil also preserved phosphocreatine and adenine nucleotides contents by restoring mitochondrial oxidative phosphorylation capacity and creatine kinase activity.<unk>
T-964	nicorandil phosphocreatine adenine_nucleotides mitochondrial_oxidative_phosphorylation_capacity creatine kinase activity
H-964	-0.4542190432548523	▁Nico rand il ▁ phos pho creati ne ▁a den ine ▁nucleo ti des ▁mito cho ndri al ▁oxid ative ▁ phos phor y lation ▁creati ne ▁kina se
D-964	-0.4542190432548523	Nicorandil phosphocreatine adenine nucleotides mitochondrial oxidative phosphorylation creatine kinase
P-964	-0.0767 -0.1756 -0.5133 -0.0346 -0.0055 -0.2447 -0.3588 -0.7390 -0.2161 -0.0024 -0.1589 -0.2471 -0.0090 -0.0190 -0.8020 -0.7532 -0.0917 -0.1998 -1.2665 -0.1868 -0.3790 -0.0247 -0.3296 -2.1558 -0.0073 -2.8917 -0.1813 -1.2026 -0.0162 -0.7004 -0.0914
S-801	The intraclass correlation coefficient (ICC), kappa coefficient, standard error of measurement, and absolute and relative minimal detectable change (MDC) values were calculated.<unk>
T-801	intraclass_correlation_coefficient icc kappa_coefficient standard_error_of_measurement minimal_detectable_change mdc
H-801	-0.5877820253372192	▁intra class ▁corre lation _ co e ffi cient IC c ▁ka ppa ▁co e ffi cient ▁m DC
D-801	-0.5877820253372192	intraclass correlation_coefficientICc kappa coefficient mDC
P-801	-2.5816 -0.2145 -1.7568 -0.0597 -0.5018 -0.5333 -0.8334 -0.0330 -0.0495 -0.6913 -1.1890 -0.1933 -0.0273 -0.1309 -0.0425 -0.0064 -0.0256 -1.1207 -1.8272 -0.4229 -0.1025
S-1629	Race, exercise training, and outcomes in chronic heart failure: findings from Heart Failure - a Controlled Trial Investigating Outcomes in Exercise TraiNing (HF-ACTION).<unk>
T-1629	exercise training outcomes chronic_heart_failure heart_failure_-_a_controlled_trial_investigating_outcomes_in_exercise_training hf-action
H-1629	-1.3767297267913818	▁Race _ training ▁chronic _ heart _ ▁failure ▁Heart _ ▁Fail ure
D-1629	-1.3767297267913818	Race_training chronic_heart_ failure Heart_ Failure
P-1629	-1.1248 -3.4685 -1.1061 -2.5219 -1.3742 -1.3252 -0.5926 -1.3193 -1.6681 -0.3622 -0.2596 -0.0541 -3.9670 -0.1306
S-990	The ability of cardiomyocytes to detect mechanical and humoral stimuli is critical for adaptation of the myocardium in response to new conditions and for sustaining the increased workload during stress.<unk>
T-990	cardiomyocytes myocardium conditions
H-990	-0.5022301077842712	▁cardio my o cy tes ▁mechanic al ▁humor al ▁stimul i ▁my o car dium ▁conditions
D-990	-0.5022301077842712	cardiomyocytes mechanical humoral stimuli myocardium conditions
P-990	-0.0698 -0.2046 -0.2937 -0.1172 -0.1660 -3.0187 -0.0039 -0.9819 -0.0371 -0.0741 -0.0932 -0.4751 -0.0289 -0.0035 -0.2826 -0.9514 -2.1396 -0.0989
S-301	The mean duration of biventricular support was 17 ± 11.9 days (range, 6 to 56 days) with 91.8% (n = 31) of RVADs successfully explanted.<unk>
T-301	biventricular_support rvads explanted
H-301	-1.092300534248352	▁bi ven tri cular _ support
D-301	-1.092300534248352	biventricular_support
P-301	-0.7591 -0.3156 -0.0410 -0.9629 -2.1832 -1.2290 -3.1238 -0.1239
S-411	CONCLUSIONS: Although BB therapy exerted dose-related benefits across all study participants, sST2 measurement identifies patients with chronic heart failure who may particularly benefit from higher BB doses.<unk>
T-411	therapy sst2 patients chronic_heart_failure
H-411	-1.651620864868164	▁BB ▁ therapy
D-411	-1.651620864868164	BB therapy
P-411	-0.5821 -2.3554 -0.2750 -4.8918 -0.1538
S-1337	Therefore, the objective of this study was to determine the effect of CHF on the number and phenotype of cardiac explant c-Kit+ progenitors and elucidate mechanisms of their regulation.<unk>
T-1337	chf phenotype cardiac explant progenitors regulation
H-1337	-0.69342041015625	▁CHF ▁cardiac ▁ex plant ▁c - K it _ pro geni tors
D-1337	-0.69342041015625	CHF cardiac explant c-Kit_progenitors
P-1337	-0.4985 -1.9124 -1.7615 -0.0252 -0.0472 -0.0961 -0.2464 -0.0092 -1.1559 -0.4920 -0.0208 -1.8250 -1.5710 -0.0468
S-396	CONCLUSIONS: ESRD is rare in outpatients with systolic HF and is mainly observed in patients with an eGFR <30 mL/min per 1.73 m(2).<unk>
T-396	esrd outpatients systolic_hf patients egfr
H-396	-0.9703980088233948	▁ES RD ▁in patient s ▁sy sto lic ▁ HF ▁e G FR
D-396	-0.9703980088233948	ESRD inpatients systolic HF eGFR
P-396	-0.8279 -0.0389 -4.1743 -0.4900 -0.0256 -0.9253 -0.2216 -3.5361 -1.3712 -0.0123 -0.0303 -1.0152 -0.9936 -0.7416 -0.1518
S-1579	INTERVENTION: An intensive transitions of care program was implemented to ensure adequate self-management training of patients and appropriate out-patient follow-up and monitoring of the patient by the health care system.<unk>
T-1579	transitions training patients out-patient follow-up patient health_care
H-1579	-0.9042572379112244	▁transition s _ de _ ca pit aux ▁self - management ▁techniques ▁out - patient _ ▁follow - up
D-1579	-0.9042572379112244	transitions_de_capitaux self-management techniques out-patient_ follow-up
P-1579	-0.0195 -0.0508 -0.2405 -0.9968 -0.0467 -3.5804 -1.7424 -1.1729 -1.2145 -0.0103 -0.0021 -4.6841 -0.4133 -0.0316 -0.0081 -1.6716 -0.3774 -0.1250 -0.0044 -2.4305 -0.1664
S-425	CONCLUSIONS: These data show the functional efficacy of a novel pure HNO donor to enhance myocardial function and present first-in-man evidence for its potential usefulness in HF.<unk>
T-425	hno_donor myocardial_function evidence hf
H-425	-1.1696672439575195	▁functional _ ▁ef fica cy ▁h no ▁h no _ ▁donor ▁my o card ial _ fon ction nel ▁ HF
D-425	-1.1696672439575195	functional_ efficacy hno hno_ donor myocardial_fonctionnel HF
P-425	-4.6678 -1.7402 -0.1572 -0.0026 -0.5349 -0.4659 -0.3879 -3.6210 -0.2695 -3.2621 -0.3980 -4.8423 -0.1126 -0.1220 -0.0531 -0.5973 -3.3381 -0.5591 -0.6545 -0.8158 -0.1448 -0.1060 -0.0498
S-172	In the TUNEL assay there was no significant difference between numbers of apoptotic cells in any of the groups, although a few TUNEL-positive cells were detected in the paced groups.<unk>
T-172	tunel apoptotic_cells tunel-positive_cells
H-172	-1.0461902618408203	▁TU nel _ as say ▁apo pto tic ▁cell s
D-172	-1.0461902618408203	TUnel_assay apoptotic cells
P-172	-0.9372 -0.8507 -2.3302 -1.8538 -0.0766 -2.2396 -0.0781 -1.1854 -0.4019 -0.0314 -2.4864 -0.0829
S-501	The TAPSE vs. PASP relationship as a possible index of the length-force relationship may be a step forward for a more efficient RV function evaluation and is not affected by the quality of LV dysfunction.<unk>
T-501	tapse pasp step rv_function lv_dysfunction
H-501	-1.5786470174789429	▁gain _ force ▁ RV _ ▁dys function
D-501	-1.5786470174789429	gain_force RV_ dysfunction
P-501	-5.6795 -2.0620 -0.8206 -0.3238 -0.1190 -2.3458 -3.5659 -0.5658 -0.2364 -0.0678
S-1013	As the biological phenotype is not routinely assessed clinically, the deficit index, which can be ascertained from medical records, is a feasible alternative to ascertain frailty.<unk>
T-1013	biological_phenotype clinically deficit_index medical frailty
H-1013	-0.7828385233879089	▁bi ological _ ▁ph eno type ▁deficit _ ▁index ▁medical _ ▁records
D-1013	-0.7828385233879089	biological_ phenotype deficit_ index medical_ records
P-1013	-0.0347 -0.2002 -1.6187 -0.9070 -0.0697 -0.0094 -2.2729 -0.9335 -1.1287 -0.1560 -1.6139 -0.7167 -1.2498 -0.0487
S-1380	Conversely, the tachycardia in response to intravenous atropine (indicative of cardiac vagal tone) was not improved in CHF-DNx vs. CHF-INV animals.<unk>
T-1380	tachycardia intravenous atropine cardiac vagal_tone
H-1380	-0.4607885181903839	▁ta chy car dia ▁intra ven ous ▁a tropi ne ▁cardiac _ va gal ▁tone ▁CHF - DN x ▁CHF - IN V
D-1380	-0.4607885181903839	tachycardia intravenous atropine cardiac_vagal tone CHF-DNx CHF-INV
P-1380	-1.8179 -0.4695 -0.0204 -0.7084 -0.2250 -0.0210 -3.3388 -0.3289 -0.0369 -0.7218 -0.0074 -0.6457 -0.8416 -0.0338 -0.7769 -0.0173 -0.0165 -0.1640 -0.0169 -0.0471 -0.0084 -0.2151 -0.5529 -0.4353 -0.0522
S-1583	CONCLUSIONS: An intensive transitions of care program decreases the 30-day readmission rate for patients with congestive heart failure in a non-urbanized Midwestern state like South Dakota.<unk>
T-1583	transitions readmission patients congestive_heart_failure south_dakota
H-1583	-1.515133023262024	▁transition s _ de _ ca pit aux ▁con ges tive _ ▁heart _ ▁failure
D-1583	-1.515133023262024	transitions_de_capitaux congestive_ heart_ failure
P-1583	-0.5956 -0.0256 -0.6672 -1.4031 -0.0881 -3.8549 -2.3577 -1.2494 -4.4122 -1.5890 -0.0836 -0.2803 -2.5507 -0.9803 -1.9007 -3.4853 -0.2335
S-162	CONCLUSIONS: STS HH and TM with medical support provided during office hours showed beneficial trends, particularly in reducing all-cause mortality for recently discharged patients with heart failure.<unk>
T-162	sts hh medical all-cause_mortality discharged patients heart_failure
H-162	-1.8362979888916016	▁ HH ▁medical _ support ▁office _ ▁hours ▁mortal ity
D-162	-1.8362979888916016	HH medical_support office_ hours mortality
P-162	-3.2600 -0.2852 -4.3473 -2.4833 -1.3967 -0.6196 -0.6505 -0.8271 -4.7914 -0.1526 -3.1310 -0.0908
S-452	METHODS AND RESULTS: Eight weeks from surgically induced myocardial infarction, heart failure rats were randomized to receive bisoprolol (B) or vehicle.<unk>
T-452	surgically myocardial_infarction heart_failure randomized bisoprolol
H-452	-0.45964887738227844	▁sur g ically ▁induc ed ▁my o card ial ▁in far ction ▁heart _ ▁failure ▁bis o pro lol ▁vehicle
D-452	-0.45964887738227844	surgically induced myocardial infarction heart_ failure bisoprolol vehicle
P-452	-0.4876 -0.0822 -0.1764 -1.7876 -0.2522 -0.5004 -0.1211 -0.1412 -0.1404 -0.3676 -1.0228 -0.0453 -0.0887 -1.3689 -0.2967 -1.5803 -0.0500 -0.0255 -0.0636 -1.2896 -0.1615 -0.0627
S-1444	SDQT remained elevated in the HFVT(+) group relative to the HNorm group despite acute β-adrenoceptor blockade with esmolol (P = 0.02).<unk>
T-1444	sdqt elevated acute β-adrenoceptor_blockade esmolol
H-1444	-0.7877270579338074	▁SD QT ▁ HF VT ▁h Nor m ▁β - ad re no cept or ▁block ade ▁es mol ol
D-1444	-0.7877270579338074	SDQT HFVT hNorm β-adrenoceptor blockade esmolol
P-1444	-0.1336 -0.9379 -2.0546 -0.0220 -3.5210 -0.2484 -0.8965 -0.0015 -2.1192 -0.0134 -0.0094 -0.0283 -0.1087 -1.3121 -0.6865 -1.4386 -2.6543 -0.7424 -0.0342 -0.0336 -0.2610 -0.0728
S-137	STUDY DESIGN: We calculated 30-day readmission rates using three metrics, for three disease groups: heart failure (HF), acute myocardial infarction (AMI), and pneumonia.<unk>
T-137	readmission disease heart_failure hf acute_myocardial_infarction ami pneumonia
H-137	-1.4019356966018677	▁implant ation _ de _ ré mission _ ▁rates ▁heart _ ▁failure ▁ HF ▁a cute _ ▁my o card ial ▁in far ction ▁pneu monia
D-137	-1.4019356966018677	implantation_de_rémission_ rates heart_ failure HF acute_ myocardial infarction pneumonia
P-137	-5.8481 -1.2443 -3.6641 -2.9433 -0.9006 -4.4066 -0.6681 -2.2100 -2.4384 -2.6501 -0.3448 -1.3494 -2.2311 -0.0227 -0.0659 -0.0041 -0.0649 -4.9489 -0.3647 -0.1761 -0.1461 -0.6764 -0.8611 -0.0958 -0.3774 -0.1448 -0.3286 -0.0775
S-894	BACKGROUND: Peritoneal dialysis (PD) for long-term management of diuretic resistant volume overload in heart failure (HF) may provide potential benefit with few adverse consequences.<unk>
T-894	peritoneal_dialysis pd diuretic volume_overload heart_failure hf
H-894	-0.7020032405853271	▁Peri tone al _ di al ysis PD ▁di ure tic _ ▁resist ant _ ▁volume _ ▁over load ▁heart _ ▁failure
D-894	-0.7020032405853271	Peritoneal_dialysisPD diuretic_ resistant_ volume_ overload heart_ failure
P-894	-0.1391 -0.0922 -0.0634 -0.5570 -1.3169 -0.0791 -0.0800 -0.5446 -0.3324 -0.0395 -2.7046 -0.2811 -2.8349 -0.0421 -0.7362 -0.9288 -0.1263 -0.9037 -0.1313 -0.6912 -0.6559 -2.7704 -0.7303 -0.0670
S-415	Here, we report on effects of a novel, stable, pure HNO donor (CXL-1020) in isolated myoctyes and intact hearts in experimental models and in patients with heart failure (HF).<unk>
T-415	report stable hno_donor cxl-1020 myoctyes hearts patients heart_failure hf
H-415	-1.3298105001449585	▁h no _ ▁donor ▁c XL _ -10 20) ▁intact ▁heart s ▁ HF
D-415	-1.3298105001449585	hno_ donor cXL_-1020) intact hearts HF
P-415	-0.5771 -0.4051 -3.8221 -0.8280 -1.7603 -0.1764 -3.1185 -2.9459 -0.5834 -1.6439 -0.5343 -0.0707 -3.6563 -0.6225 -0.4492 -0.0831
S-1567	Peripheral artery disease (PAD) and heart failure (HF) share many risk factors; however, the prevalence and characteristics of HF in patients with PAD have not been fully examined.<unk>
T-1567	peripheral_artery_disease pad heart_failure hf prevalence hf patients pad
H-1567	-0.8630169034004211	▁Peri pher al ▁arter y ▁disease PAD ▁heart _ ▁failure ▁ HF
D-1567	-0.8630169034004211	Peripheral artery diseasePAD heart_ failure HF
P-1567	-0.7507 -0.0136 -0.0791 -1.2738 -0.4923 -2.2825 -0.2232 -1.4071 -0.8228 -1.4841 -0.8821 -0.0120 -2.2307 -0.1283
S-1974	IMPORTANCE: More than 80% of patients with heart failure with preserved ejection fraction (HFPEF), the most common form of heart failure among older persons, are overweight or obese.<unk>
T-1974	patients heart_failure_with_preserved_ejection_fraction hfpef heart_failure obese
H-1974	-1.3344638347625732	▁heart _ pu issa nce ▁h f f f ▁heart _ pu issa nce
D-1974	-1.3344638347625732	heart_puissance hfff heart_puissance
P-1974	-2.4011 -0.7967 -5.2470 -0.3944 -0.0089 -1.1571 -0.4157 -0.2100 -0.6390 -3.9302 -0.8126 -3.4004 -0.2036 -0.0036 -1.6609 -0.0702
S-387	BACKGROUND: Renal dysfunction is an important prognostic factor in heart failure (HF), but whether this dysfunction progresses to end-stage renal disease (ESRD) is unknown.<unk>
T-387	renal_dysfunction prognostic heart_failure hf dysfunction end-stage_renal_disease esrd
H-387	-0.8963013291358948	▁Ren al _ ▁dys function ▁heart _ ▁failure ▁ HF ▁dys function ▁end - s tage ▁renal ▁disease es RD
D-387	-0.8963013291358948	Renal_ dysfunction heart_ failure HF dysfunction end-stage renal diseaseesRD
P-387	-1.7852 -0.1433 -1.1222 -0.9547 -0.4246 -1.5376 -0.4064 -1.4982 -2.4785 -0.0318 -2.7878 -0.3802 -0.1147 -0.0351 -0.1009 -0.0007 -0.4661 -2.8674 -2.1898 -0.1070 -0.2007 -0.0859
S-963	Nicorandil was effective in alleviating the decrement of heart rate and aortic blood flow and the state of mitochondrial oxidative stress induced by doxorubicin cardiotoxicity.<unk>
T-963	nicorandil heart_rate aortic blood_flow mitochondrial oxidative_stress doxorubicin cardiotoxicity
H-963	-0.46751123666763306	▁Nico rand il ▁heart ▁rate ▁a or tic ▁blood ▁flow ▁mito cho ndri al ▁oxid ative ▁stress ▁do xor ubi cin ▁cardio toxic ity
D-963	-0.46751123666763306	Nicorandil heart rate aortic blood flow mitochondrial oxidative stress doxorubicin cardiotoxicity
P-963	-0.0423 -0.0962 -0.1217 -2.4140 -2.8298 -0.0245 -0.0098 -0.3703 -0.5572 -1.1369 -0.0024 -0.5787 -0.0959 -0.0466 -1.3174 -0.1341 -1.6105 -0.0086 -0.0057 -0.0175 -0.0403 -0.1923 -0.1440 -0.1595 -0.1320 -0.0668
S-1492	OBJECTIVES: The peripheral muscle pump is key in promoting cardiac filling during exercise, especially in subjects who lack a subpulmonary ventricle (the Fontan circulation).<unk>
T-1492	peripheral_muscle_pump cardiac_filling exercise subpulmonary_ventricle fontan_circulation
H-1492	-0.597673773765564	▁per i pher al ▁muscle _ pump ▁cardiac _ ▁fill ing ▁sub pul mon ary ▁vent ric le ▁Font an _ ▁circulation
D-1492	-0.597673773765564	peripheral muscle_pump cardiac_ filling subpulmonary ventricle Fontan_ circulation
P-1492	-0.1394 -0.2989 -0.0330 -0.0341 -1.3782 -1.2745 -0.6027 -0.5846 -1.9250 -0.0917 -0.0365 -0.5458 -0.0373 -1.6990 -0.6024 -0.2991 -2.6218 -0.1434 -0.0440 -0.4214 -0.8244 -0.4088 -0.2124 -0.0859
S-430	Regression analysis was performed to create an echocardiographic score for prediction of LV reverse remodeling (defined as ≥15% reduction in the LV end-systolic volume).<unk>
T-430	regression_analysis echocardiographic lv_reverse_remodeling lv_end-systolic_volume
H-430	-0.4975244402885437	▁e cho car dio graphic ▁score ▁LV ▁rever se _ ▁remodel ing ▁LV ▁end - sy sto lic ▁volume
D-430	-0.4975244402885437	echocardiographic score LV reverse_ remodeling LV end-systolic volume
P-430	-0.0621 -0.2649 -0.0395 -0.4670 -0.6784 -0.1730 -0.0605 -0.5009 -0.0063 -1.2430 -0.0383 -0.1537 -0.3794 -1.4097 -0.0424 -1.2954 -0.9258 -1.4180 -1.0079 -0.1861 -0.0957
S-660	METHODS AND RESULTS: Cardiology practices participating in the National Cardiovascular Disease Registry Practice Innovation and Clinical Excellence registry from July 2008 to December 2010 were evaluated.<unk>
T-660	cardiology national_cardiovascular_disease_registry_practice_innovation_and_clinical_excellence_registry
H-660	-1.0797148942947388	▁Card io vas cular _ ▁Disease ▁Registr y _ ▁Practic e _ ▁Innovation ▁Clinic al _ ▁Excellence
D-660	-1.0797148942947388	Cardiovascular_ Disease Registry_ Practice_ Innovation Clinical_ Excellence
P-660	-0.5074 -4.5786 -2.1252 -0.7077 -1.1114 -1.3903 -1.8459 -0.0489 -1.5367 -3.0138 -0.0307 -0.7031 -0.2604 -0.8863 -0.0044 -0.4039 -0.8066 -0.4877 -0.0657
S-440	We identified all adults with newly diagnosed heart failure, left ventricular ejection fraction of <40%, and no previous spironolactone use from 2006 to 2008 in Kaiser Permanente Northern California.<unk>
T-440	diagnosed heart_failure left_ventricular_ejection_fraction spironolactone kaiser_permanente northern_california
H-440	-0.9120798110961914	▁vent ri cular _ é je ction ▁spi rono lac tone ▁Kaiser ▁Permanent e ▁Northern ▁California
D-440	-0.9120798110961914	ventricular_éjection spironolactone Kaiser Permanente Northern California
P-440	-5.8755 -0.4272 -0.3026 -1.5326 -1.3149 -1.1523 -0.0558 -0.5000 -0.0091 -0.0933 -0.0754 -1.7163 -0.6846 -0.1094 -2.1439 -0.0541 -0.2985 -0.0718
S-1894	Physical examination should include the patient's BMI and weight, heart rate and rhythm, lying and standing blood pressure and auscultation to rule out valvular disease and pulmonary congestion.<unk>
T-1894	physical_examination patient bmi heart_rate rhythm blood_pressure auscultation rule valvular_disease pulmonary_congestion
H-1894	-0.7843676209449768	▁b mi ▁heart ▁rate ▁ rhythm ▁ly ing ▁standing ▁blood _ tension ▁val vu lar _ ▁disease ▁pulmonar y _ con gestion
D-1894	-0.7843676209449768	bmi heart rate rhythm lying standing blood_tension valvular_ disease pulmonary_congestion
P-1894	-0.1361 -0.8207 -3.6169 -1.2438 -0.7900 -0.0247 -0.0250 -0.0655 -1.0628 -0.3290 -1.4142 -0.7303 -0.4409 -0.9687 -0.4923 -1.0159 -3.7256 -0.0070 -0.0857 -1.2190 -0.1236 -0.0037 -0.3429 -0.1405
S-735	Our aims were to estimate myocardial extracellular matrix using cardiac magnetic resonance T1 mapping and to assess the relationship between pathobiology/pathophysiology and prognosis.<unk>
T-735	myocardial_extracellular_matrix cardiac_magnetic_resonance t1_mapping pathobiology pathophysiology prognosis
H-735	-0.529958963394165	▁my o card ial _ ▁extra cel lular ▁matri x ▁cardiac _ ▁magnetic _ ▁res on ance _ ▁T 1 ▁path obi ology _ pat ho phy si ology ▁prognos is
D-735	-0.529958963394165	myocardial_ extracellular matrix cardiac_ magnetic_ resonance_ T1 pathobiology_pathophysiology prognosis
P-735	-0.3955 -0.2075 -0.0465 -0.0246 -0.1601 -0.6207 -0.6159 -0.0333 -0.9545 -0.0381 -0.0014 -1.1175 -0.3632 -1.2153 -1.5885 -0.0395 -0.0139 -2.0620 -0.7342 -0.0639 -3.8621 -0.1196 -1.1718 -1.1624 -0.0645 -0.0613 -0.0059 -0.1022 -0.3571 -0.1440 -0.0144 -0.0594 -0.0676
S-1948	Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction: a safety and proof-of-principle cohort study.<unk>
T-1948	interatrial_shunting patients heart_failure_with_reduced_ejection_fraction proof-of-principle_cohort_study
H-1948	-1.0738967657089233	▁left - to - right ▁inter at rial _ ▁sh unting ▁patients ▁heart _ ▁failure ▁e je ction _ fraction
D-1948	-1.0738967657089233	left-to-right interatrial_ shunting patients heart_ failure ejection_fraction
P-1948	-6.2167 -0.0497 -1.8777 -0.0978 -0.0641 -0.0314 -0.1444 -0.1509 -2.9833 -2.5092 -0.1259 -1.4208 -1.6396 -0.4717 -2.4981 -0.6046 -0.4337 -0.0718 -0.9682 -0.0077 -1.1302 -0.1284
S-1738	These trial results provide the background for aldosterone antagonist therapy in chronic advanced heart failure patients as well as post-myocardial infarction heart failure patients with reduced ejection.<unk>
T-1738	aldosterone_antagonist therapy chronic_advanced_heart_failure patients post-myocardial_infarction heart_failure patients
H-1738	-0.9062874913215637	▁al do ster one _ ▁anta gon ist ▁ therapy ▁heart _ ▁failure ▁post - my o card ial ▁in far ction _ ▁heart _ ▁failure
D-1738	-0.9062874913215637	aldosterone_ antagonist therapy heart_ failure post-myocardial infarction_ heart_ failure
P-1738	-0.2937 -0.1428 -0.0341 -2.1099 -1.1300 -0.2552 -0.1641 -2.1024 -1.3739 -0.0195 -5.0887 -0.8995 -1.4217 -1.1332 -0.0080 -0.9409 -0.2158 -0.2188 -0.1974 -0.7253 -2.2169 -0.0245 -0.9010 -1.5853 -0.5214 -0.5895 -0.8895 -0.1731
S-968	Relation between preoperative renal dysfunction and cardiovascular events (stroke, myocardial infarction, or heart failure or death) within three months of isolated coronary artery bypass grafting.<unk>
T-968	preoperative renal_dysfunction cardiovascular_events stroke myocardial_infarction heart_failure death isolated_coronary_artery_bypass_grafting
H-968	-0.49877139925956726	▁pre operativ e ▁renal ▁dys function ▁cardiovascular ▁events stro ke ▁my o card ial ▁in far ction ▁heart ▁failure
D-968	-0.49877139925956726	preoperative renal dysfunction cardiovascular eventsstroke myocardial infarction heart failure
P-968	-0.8505 -0.0247 -0.0687 -0.0499 -0.2194 -0.2319 -0.1045 -0.5130 -3.5102 -0.0796 -0.4076 -0.0813 -0.0244 -0.0248 -0.1365 -0.2389 -0.0204 -0.0330 -0.9873 -2.7556 -0.1121
S-554	Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity).<unk>
T-554	clinical outcomes heart_failure charm candesartan_in_heart_failure_assessment_of_reduction_in_mortality_and_morbidity
H-554	-0.7311432957649231	▁clinic al ▁heart _ fail ure ▁CHA RM ▁programme ▁can des ar tan _ ▁in _ ▁Heart _ ▁Fail ure ▁Mor t ality ▁Morbi d ity
D-554	-0.7311432957649231	clinical heart_failure CHARM programme candesartan_ in_ Heart_ Failure Mortality Morbidity
P-554	-3.2567 -0.0338 -5.0334 -0.8409 -2.4830 -0.2978 -1.0824 -0.2054 -1.2321 -0.8141 -0.0076 -0.3522 -0.0050 -1.1018 -0.3391 -0.8839 -0.3394 -0.2870 -0.1415 -0.0328 -0.7680 -0.0069 -0.0332 -0.3034 -0.0226 -0.3159 -0.1858 -0.0663
S-947	RESULTS: During a 34 ± 16-month follow-up period, single- and multiple-procedure drug-free success rates were 27% (n = 20) and 45% (n = 33), respectively.<unk>
T-947	follow-up
H-947	-1.5723892450332642	
D-947	-1.5723892450332642	
P-947	-3.0919 -0.0528
S-1027	Furthermore, the use of protocol-driven POC testing of NP within the time frame of a patient consultation in the ED may facilitate and accelerate the throughput and disposition of at-risk patients.<unk>
T-1027	poc frame patient consultation patients
H-1027	-0.7121247053146362	▁protocol - driv en ▁PO C ▁ NP ▁patient ▁consultation ▁ED ▁through put
D-1027	-0.7121247053146362	protocol-driven POC NP patient consultation ED throughput
P-1027	-0.5354 -0.1081 -0.0015 -0.0552 -0.7576 -1.0216 -1.2367 -0.0433 -2.8809 -0.0851 -0.7625 -0.1367 -0.0043 -2.8861 -0.1669
S-1730	The relationship between physician volume and mortality was strongest for internists (9.2% versus 10.6%; P<0.001) and weakest for cardiologists (6.4% versus 6.7%; P=0.485).<unk>
T-1730	physician mortality internists cardiologists
H-1730	-0.7437692284584045	▁physician _ ▁volume _ de _ ▁mortal ity ▁intern ists ▁cardio logist s
D-1730	-0.7437692284584045	physician_ volume_de_ mortality internists cardiologists
P-1730	-0.1971 -0.6983 -1.4640 -1.1143 -1.2792 -0.0644 -0.7083 -0.4182 -0.2803 -3.7594 -0.1170 -0.0763 -0.2801 -0.6149 -0.0845
S-1322	Similar improvements in shuttle walk test (18% vs 19%), body mass (-1.3 kg vs -1.0 kg), and hand grip strength (2.1 kg vs 2.5 kg) from baseline were observed in both groups.<unk>
T-1322	shuttle_walk_test hand baseline
H-1322	-1.0200903415679932	▁shu ttle _ walk _ test ▁body _ ▁mass ▁hand _ grip _ ▁strength
D-1322	-1.0200903415679932	shuttle_walk_test body_ mass hand_grip_ strength
P-1322	-0.8200 -0.0068 -0.2961 -1.4320 -1.5956 -1.7436 -1.5761 -1.4722 -1.0933 -1.3127 -0.1398 -2.5274 -0.6335 -0.4265 -1.1193 -0.1263
S-457	After 10 weeks, histological analysis revealed reduced capillary and coronary perfusion in B-treated plus Ad-Flk rats compared with B-treated plus Ad-C rats.<unk>
T-457	histological capillary coronary_perfusion
H-457	-0.8333095908164978	▁cap illa ry _ de _ ▁corona ry _ per fusion ▁b - tre ated ▁ad - f lk ▁rat s
D-457	-0.8333095908164978	capillary_de_ coronary_perfusion b-treated ad-flk rats
P-457	-2.0773 -0.0037 -0.4227 -2.1181 -3.1411 -0.2104 -2.6352 -0.8875 -0.6946 -0.2363 -0.0227 -0.7955 -0.1181 -0.0025 -1.8521 -0.7163 -0.0279 -0.2270 -0.0755 -0.2442 -0.0310 -2.5127 -0.1140
S-1901	Recent evidence suggests that exercise prevents cell senescence, and active individuals are at lower risk of developing certain malignancies including cancer of the prostate and the colon, osteoporosis, depression and dementia.<unk>
T-1901	evidence exercise cell_senescence active osteoporosis
H-1901	-0.7404559850692749	▁cell ▁se nesc ence ▁active ▁malign a ncies ▁cancer ▁prostat e ▁colon ▁osteo por osis ▁depression
D-1901	-0.7404559850692749	cell senescence active malignancies cancer prostate colon osteoporosis depression
P-1901	-4.0140 -1.7000 -0.0920 -0.0048 -1.9188 -1.2026 -0.6787 -0.2286 -0.2179 -0.6791 -0.0226 -0.6155 -0.1455 -0.1135 -0.0081 -0.4693 -1.1764 -0.0408
S-374	In addition to the leaflet configurations, the serial evaluation strongly suggested that the MS in this patient was subvalvular and therefore dynamic, as opposed to annular MS with a fixed ring size.<unk>
T-374	leaflet patient subvalvular annular_ms
H-374	-1.1000133752822876	▁le a flet ▁serial ▁evaluation ▁MS ▁sub val vu lar ▁ann ular ▁MS
D-374	-1.1000133752822876	leaflet serial evaluation MS subvalvular annular MS
P-374	-1.7959 -0.0348 -0.0007 -3.5883 -2.0359 -0.5704 -1.1132 -1.0786 -0.3393 -0.1836 -2.1489 -0.0076 -0.4634 -3.0208 -0.1188
S-1630	BACKGROUND: The strength of race as an independent predictor of long-term outcomes in a contemporary chronic heart failure (HF) population and its association with exercise training response have not been well established.<unk>
T-1630	outcomes chronic_heart_failure hf exercise training
H-1630	-1.333309292793274	▁strength _ de _ race ▁long - term _ ▁outcome s ▁con tempor ary _ ▁chronic _ heart _ ▁failure ▁ HF ▁exercise
D-1630	-1.333309292793274	strength_de_race long-term_ outcomes contemporary_ chronic_heart_ failure HF exercise
P-1630	-4.6022 -1.5211 -1.3641 -0.1184 -1.2798 -3.5965 -0.0626 -0.1917 -2.3370 -2.5615 -0.0278 -1.9340 -0.0285 -0.2237 -1.0318 -1.1189 -0.1753 -2.3064 -0.5694 -2.3686 -1.9945 -0.0053 -1.7161 -2.1072 -0.0902
S-227	Fifty-four predominantly asymptomatic pediatric Fontan (PF) patients who underwent catheterization during the same period were randomly selected to perform a control:case cohort analysis.<unk>
T-227	asymptomatic pediatric_fontan patients catheterization
H-227	-0.9081131219863892	▁pediatr ic ▁Font an ▁ PF
D-227	-0.9081131219863892	pediatric Fontan PF
P-227	-1.0558 -0.6027 -0.1620 -0.5946 -2.3737 -0.0391 -2.3383 -0.0987
S-1152	We used MRI-based models of dyssynchronous nonfailing and HF canine electromechanics and constructed additional models in which varying combinations of the four remodeling aspects were represented.<unk>
T-1152	dyssynchronous_nonfailing hf combinations remodeling
H-1152	-0.30878549814224243	▁m RI - based ▁models ▁dys syn chron ous _ non fail ing ▁ HF ▁can ine _ électro me chan iques ▁remodel ing
D-1152	-0.30878549814224243	mRI-based models dyssynchronous_nonfailing HF canine_électromechaniques remodeling
P-1152	-0.3019 -0.2474 -0.8106 -0.1077 -1.7773 -0.1092 -0.0006 -0.0002 -0.9848 -0.1203 -0.1849 -0.0091 -0.0313 -0.0858 -0.0116 -0.1663 -0.1181 -0.6023 -0.2361 -0.0117 -0.2454 -0.4978 -0.2215 -0.0378 -1.0044 -0.1044
S-835	Anemia in HF remains poorly understood, with significant gaps in its impact on health-related quality of life (HRQoL), with most studies in HF being retrospective or from registries.<unk>
T-835	anemia hf health-related_quality_of_life hrqol hf
H-835	-0.7543331980705261	▁an emia ▁ HF ▁health - related _ quality _ of _ ▁life HR Qo L ▁ HF
D-835	-0.7543331980705261	anemia HF health-related_quality_of_ lifeHRQoL HF
P-835	-0.4349 -0.0044 -1.2151 -0.0478 -1.6683 -0.0925 -0.1247 -1.4623 -2.5793 -0.4577 -1.8186 -0.1891 -2.0535 -0.9866 -0.0239 -0.1387 -0.4690 -0.0325 -1.1923 -0.0953
S-1990	CONCLUSIONS AND RELEVANCE: Among obese older patients with clinically stable HFPEF, caloric restriction or aerobic exercise training increased peak VO2, and the effects may be additive.<unk>
T-1990	obese patients clinically stable hfpef exercise training peak_vo2
H-1990	-1.030999779701233	▁obes e ▁h f f f ▁calor ic ▁restriction ▁aero bic _ ▁exercise
D-1990	-1.030999779701233	obese hfff caloric restriction aerobic_ exercise
P-1990	-3.6632 -0.0312 -1.3359 -0.3683 -0.2090 -0.2073 -1.2899 -0.5986 -0.3976 -0.2358 -0.0495 -2.3467 -1.6585 -2.9639 -0.1094
S-1336	For instance, the majority of potential candidates for cell therapy suffer from chronic heart failure (CHF), and it is unclear how this disease affects the explant-derived progenitor cells.<unk>
T-1336	cell_therapy chronic_heart_failure chf disease progenitor_cells
H-1336	-0.8799495697021484	▁implant - der i ved _ pro gen itor _ cell s
D-1336	-0.8799495697021484	implant-derived_progenitor_cells
P-1336	-4.6159 -0.6459 -0.3641 -0.1023 -0.8617 -0.7202 -0.1863 -0.2423 -0.1280 -2.9977 -0.7258 -0.2828 -0.3597 -0.0867
S-1807	In The Lancet, Anoop Shah and colleagues provide a new systematic review of the effects of air pollution on heart failure, a common disorder associated with high morbidity and mortality, especially in elderly people.<unk>
T-1807	the_lancet anoop_shah air heart_failure morbidity mortality
H-1807	-0.557449996471405	▁Lance t ▁air ▁pollution ▁heart _ ▁failure ▁morbi d ity ▁mortal ity
D-1807	-0.557449996471405	Lancet air pollution heart_ failure morbidity mortality
P-1807	-0.0133 -0.0204 -0.0525 -0.7278 -0.7792 -0.5896 -1.5566 -1.8786 -0.0663 -0.1490 -1.0288 -0.1402 -0.6708 -0.1313
S-1586	The majority of studies have shown that patients with reduced or abnormal HR variability have an increased risk of mortality within a few years after an AMI or after a diagnosis of CHF/LV dysfunction.<unk>
T-1586	patients hr_variability mortality ami diagnosis chf lv_dysfunction
H-1586	-1.5108516216278076	▁HR _ ▁variabil ity ▁mortal ity ▁ AMI ▁CHF / LV
D-1586	-1.5108516216278076	HR_ variability mortality AMI CHF/LV
P-1586	-2.6095 -2.7414 -1.5467 -0.2307 -3.1540 -0.1641 -0.2456 -0.0361 -1.4718 -4.0203 -0.9877 -2.3299 -0.1032
S-284	Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk--the atherosclerosis risk in communities study.<unk>
T-284	troponin_t n-terminal_pro-b-type_natriuretic_peptide biomarker heart_failure atherosclerosis_risk_in_communities
H-284	-0.8953372240066528	▁Tro ponin _ t ▁n - termin al _ pro - B - type ▁na tri ure tic _ pe pti de ▁bio mark er ▁heart _ ▁failure _ risk ▁at hero sc ler osis
D-284	-0.8953372240066528	Troponin_t n-terminal_pro-B-type natriuretic_peptide biomarker heart_ failure_risk atherosclerosis
P-284	-0.1682 -0.0008 -3.0458 -1.8187 -3.9201 -0.0161 -0.0058 -0.0043 -1.8102 -0.6111 -0.0211 -0.3382 -0.1228 -0.1840 -0.4896 -0.0044 -0.1286 -4.4386 -1.4610 -0.4479 -0.2228 -0.2045 -0.5748 -0.0017 -0.0503 -2.1615 -0.3847 -1.8939 -2.2946 -1.0496 -0.1601 -0.2623 -1.7623 -1.4711 -0.0809 -1.4312 -0.0839
S-1660	Interestingly, because patients with ventricular assist devices are housed on units accustomed to managing the device, cardiac nurses are often asked about the management of gastrointestinal bleeding.<unk>
T-1660	patients ventricular_assist_devices cardiac nurses gastrointestinal_bleeding
H-1660	-0.41179847717285156	▁vent ri cular _ assist ▁devices ▁cardiac ▁nurse s ▁management ▁gastro inte stin al _ ▁ble ed ing
D-1660	-0.41179847717285156	ventricular_assist devices cardiac nurses management gastrointestinal_ bleeding
P-1660	-0.0086 -0.1284 -0.1302 -0.7728 -0.1041 -1.7296 -0.7919 -0.7608 -0.0539 -0.2380 -1.2544 -0.0154 -0.3309 -0.1155 -0.5872 -0.4414 -0.3633 -0.1758 -0.1671 -0.0669
S-708	BACKGROUND: Extended criteria cardiac transplant (ECCT) programs expand the transplant pool by matching donors and recipients typically excluded from the transplant process because of age or comorbidity.<unk>
T-708	extended_criteria_cardiac_transplant ecct transplant donors transplant comorbidity
H-708	-1.4564610719680786	▁cardiac ▁transplant ▁e CT ▁transplant ▁pool
D-708	-1.4564610719680786	cardiac transplant eCT transplant pool
P-708	-0.7118 -1.6320 -1.7163 -1.7294 -1.0263 -2.1187 -2.6618 -0.0553
S-782	METHODS AND RESULTS: Using a prospective HF registry, we dichotomized patients into HF with reduced EF (EF≤ 40) and HFpEF (EF≥50).<unk>
T-782	prospective hf patients hf_with_reduced_ef ef hfpef ef
H-782	-0.922240674495697	▁prospect ive ▁ HF ▁ HF ▁ HF ▁ef f ▁ HF p EF
D-782	-0.922240674495697	prospective HF HF HF eff HFpEF
P-782	-2.0312 -0.0027 -0.0800 -0.0377 -1.9326 -0.2266 -2.7151 -0.2847 -3.0409 -0.7904 -0.9407 -0.0425 -1.2211 -0.4422 -0.8452 -0.1224
S-1633	We examined characteristics and outcomes (mortality/hospitalization, mortality, and cardiovascular mortality/HF hospitalization) by race using adjusted Cox models and explored an interaction with exercise training.<unk>
T-1633	outcomes mortality hospitalization mortality cardiovascular_mortality hf hospitalization cox_models exercise training
H-1633	-1.044008493423462	▁mortal ity ▁cardiovascular _ ▁mortal ity HF
D-1633	-1.044008493423462	mortality cardiovascular_ mortalityHF
P-1633	-2.3577 -0.1336 -1.1998 -1.7031 -0.2111 -0.1077 -1.1818 -2.4002 -0.1011
S-30	Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the treatment of anemia and iron deficiency in adult patients with heart disease.<unk>
T-30	american_college_of_physicians acp evidence clinical anemia patients heart_disease
H-30	-0.7655854821205139	▁American ▁College _ of _ ▁Physic ians ▁a CP ▁an emia ▁ir on _ de fici en cy
D-30	-0.7655854821205139	American College_of_ Physicians aCP anemia iron_deficiency
P-30	-1.5060 -0.4132 -0.0737 -1.0633 -0.1292 -1.0617 -0.0406 -0.3546 -0.0200 -4.9365 -0.1559 -0.1802 -0.0472 -0.3905 -0.0398 -0.1784 -0.2153 -0.1871 -4.2331 -0.0854
S-1877	BAT significantly reduced N-terminal pro-brain natriuretic peptide (p = 0.02) and was associated with a trend toward fewer days hospitalized for HF (p = 0.08).<unk>
T-1877	bat n-terminal_pro-brain_natriuretic_peptide hospitalized hf
H-1877	-0.7152117490768433	▁BAT ▁N - termin al _ pro - bra in _ ▁na tri ure tic _ pe pti de ▁ HF
D-1877	-0.7152117490768433	BAT N-terminal_pro-brain_ natriuretic_peptide HF
P-1877	-0.4920 -4.6511 -0.0220 -0.0495 -0.0083 -0.2733 -1.1485 -0.1223 -0.8845 -0.2518 -0.3107 -0.3908 -0.0065 -0.2049 -3.1085 -2.1127 -0.2693 -0.2409 -0.1046 -1.3587 -0.2235 -0.1248 -0.0905
S-1549	MI-induced decreases in septum (systolic) thickness as well as increase in LV posterior wall thickness and LV internal diameter were partially or fully reversible by metoprolol.<unk>
T-1549	septum systolic lv_posterior_wall lv_internal_diameter metoprolol
H-1549	-1.0050251483917236	▁sept um _ sy sto lic _ ▁thi ck ness ▁LV ▁posterior _ ▁wall _ ▁thi ck ness ▁LV ▁internal _ ▁diameter ▁met o pro lol
D-1549	-1.0050251483917236	septum_systolic_ thickness LV posterior_ wall_ thickness LV internal_ diameter metoprolol
P-1549	-2.4453 -0.0778 -2.0387 -1.6709 -1.1835 -1.6379 -2.8465 -1.9979 -0.2175 -1.3661 -0.1247 -2.5305 -0.9857 -2.6615 -0.3333 -1.5438 -0.0375 -0.5118 -0.1684 -0.9002 -1.1467 -1.1273 -0.1489 -0.0442 -0.0112 -0.0661 -0.1253 -0.1915
S-1139	The tachycardic response caused by methylatropine was considered to be the vagal tone, whereas the bradycardic response caused by propranolol was considered to be the sympathetic tone.<unk>
T-1139	tachycardic methylatropine vagal_tone bradycardic propranolol sympathetic_tone
H-1139	-0.8269649147987366	▁ta chy car dic _ ▁response ▁met hy la tropi ne ▁va gal ▁tone ▁bra dy car dic _ ▁response ▁propra no lol ▁sympa the tic ▁tone
D-1139	-0.8269649147987366	tachycardic_ response methylatropine vagal tone bradycardic_ response propranolol sympathetic tone
P-1139	-2.7547 -0.9941 -0.1230 -0.2177 -4.1930 -1.7344 -1.4976 -0.0279 -0.2303 -0.0495 -0.9563 -0.0183 -0.0069 -2.3725 -0.2555 -0.4219 -0.0616 -0.1742 -2.2259 -1.4316 -0.3395 -0.0097 -0.0758 -0.0818 -0.3875 -2.4254 -0.7731 -0.0913 -0.0509
S-442	We used Cox regression with time-varying covariates to evaluate the independent association between spironolactone use and death, hospitalization, severe hyperkalemia, and acute kidney injury.<unk>
T-442	cox_regression covariates spironolactone death hospitalization hyperkalemia acute_kidney_injury
H-442	-1.2656134366989136	▁co x ▁re gression ▁spi rono lac tone
D-442	-1.2656134366989136	cox regression spironolactone
P-442	-3.4854 -0.0278 -0.8797 -0.0106 -2.0346 -0.0542 -0.7645 -0.4285 -4.7951 -0.1757
S-1095	We will then focus on two distinct populations of patients who are at risk for acute RV failure: those with chronic pulmonary arterial hypertension (PAH) and those with acute pulmonary embolism.<unk>
T-1095	patients acute_rv_failure chronic_pulmonary_arterial_hypertension pah acute pulmonary_embolism
H-1095	-0.7225689888000488	▁a cute ▁ RV _ ▁failure ▁chronic ▁pulmonar y _ ▁arterial _ ▁hyper tension PA h ▁a cute ▁pulmonar y _ ▁e mbol ism
D-1095	-0.7225689888000488	acute RV_ failure chronic pulmonary_ arterial_ hypertensionPAh acute pulmonary_ embolism
P-1095	-2.0299 -0.0389 -1.0072 -0.1361 -2.0990 -0.9808 -2.0297 -0.0999 -0.0410 -0.6587 -0.4712 -0.5773 -1.4261 -0.0004 -0.6598 -0.8456 -0.6608 -0.0121 -0.8318 -0.0585 -0.2556 -2.0515 -0.0014 -1.4497 -0.2898 -0.0740
S-962	Moreover, mitochondrial oxidative phosphorylation capacity, creatine kinase activity and oxidative stress markers were measured together with the examination of DNA fragmentation and ultrastructural changes.<unk>
T-962	mitochondrial_oxidative_phosphorylation_capacity creatine kinase activity oxidative_stress dna_fragmentation
H-962	-0.8082823157310486	▁mito cho ndri al _ oxid ative _ phos phor y lation _ pu issa nce ▁creati ne ▁kina se ▁activity ▁oxid ative _ stress ▁marker s ▁DNA
D-962	-0.8082823157310486	mitochondrial_oxidative_phosphorylation_puissance creatine kinase activity oxidative_stress markers DNA
P-962	-0.0040 -0.5978 -0.0504 -0.0504 -0.7997 -1.7031 -2.0877 -0.6747 -0.4899 -0.4061 -1.7278 -0.0038 -2.6276 -2.7099 -0.0322 -0.0173 -0.0132 -0.2240 -0.4341 -0.0226 -2.5316 -0.0047 -0.0904 -0.8409 -1.8973 -1.4905 -0.0383 -0.1995 -2.4136 -0.0655
S-751	BACKGROUND: Current guidelines recommend cardiac resynchronization therapy (CRT) in mild heart failure (HF) patients with QRS prolongation and ejection fraction (EF) ≤30%.<unk>
T-751	cardiac_resynchronization_therapy crt mild_heart_failure hf patients qrs_prolongation ejection_fraction ef
H-751	-0.7497382164001465	▁cardiac _ re syn chron ization ▁ therapy ▁c RT ▁mild ▁heart _ ▁failure ▁ HF ▁QR s ▁e je ction _ fraction EF
D-751	-0.7497382164001465	cardiac_resynchronization therapy cRT mild heart_ failure HF QRs ejection_fractionEF
P-751	-0.5068 -1.7040 -0.9856 -0.0083 -0.0003 -0.6943 -2.3068 -0.0381 -0.5874 -0.0771 -1.4317 -1.1081 -0.5508 -2.1094 -2.1863 -0.0009 -0.0537 -1.3073 -0.6765 -0.6199 -0.0295 -1.4228 -0.0082 -0.7541 -0.2221 -0.1033
S-509	Fractional flow reserve measurements and positron emission tomography imaging showed severe ischemia after bottleneck stenting covering over 50% of the left ventricle in the proximal LAD model.<unk>
T-509	fractional_flow_reserve positron_emission_tomography ischemia bottleneck_stenting left_ventricle lad
H-509	-0.6919203996658325	▁Fra ction al _ ▁flow _ ▁reserve ▁posi tron ▁e mission _ tom ography _ ▁imagin g ▁ ische mia ▁bottle ne ck ▁sten ting ▁left ▁vent ric le ▁proxima l ▁ LAD
D-509	-0.6919203996658325	Fractional_ flow_ reserve positron emission_tomography_ imaging ischemia bottleneck stenting left ventricle proximal LAD
P-509	-0.6751 -0.0002 -0.2272 -0.4599 -2.9604 -0.6358 -0.5107 -1.5582 -0.0181 -0.7573 -0.0490 -0.6467 -0.3043 -0.4418 -2.4468 -0.0846 -0.0292 -1.6214 -0.1294 -0.1946 -0.0405 -0.0234 -0.5060 -1.9311 -1.8439 -0.0650 -0.2345 -3.7228 -0.3196 -1.0128 -0.0054 -0.4039 -0.0029 -0.2763 -0.0784
S-2007	Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure.<unk>
T-2007	tools_for_economic_analysis_of_patient_management_interventions_in_heart_failure_cost-effectiveness_model disease heart_failure
H-2007	-1.080527901649475	▁économique _ analys is ▁Patient _ Management _ ▁Interven tions ▁Heart _ ▁Fail ure ▁Cost - E ff ective ness
D-2007	-1.080527901649475	économique_analysis Patient_Management_ Interventions Heart_ Failure Cost-Effectiveness
P-2007	-0.9222 -4.0964 -1.1375 -0.0116 -3.0594 -1.0908 -1.8872 -0.5948 -1.4732 -0.0086 -0.3565 -0.2018 -0.2376 -0.0436 -1.4633 -0.0473 -0.9993 -1.6947 -0.0090 -0.8886 -3.4039 -0.1444
S-1462	Neprilysin inhibitors augment the natriuretic peptide system by preventing the breakdown of atrial natriuretic peptide and B-type natriuretic peptide.<unk>
T-1462	neprilysin_inhibitors natriuretic_peptide atrial_natriuretic_peptide b-type_natriuretic_peptide
H-1462	-0.8739243149757385	▁Ne pri ly sin _ ▁inhibi tors ▁na tri ure tic _ pe pti de ▁break down ▁at rial _ ▁na tri ure tic _ pe pti de ▁b - type ▁na tri ure tic _ pe pti de
D-1462	-0.8739243149757385	Neprilysin_ inhibitors natriuretic_peptide breakdown atrial_ natriuretic_peptide b-type natriuretic_peptide
P-1462	-2.3748 -0.0340 -3.1294 -0.4451 -2.5552 -0.1064 -1.1387 -0.0507 -0.0126 -0.4414 -3.8493 -0.8775 -0.2570 -0.4406 -0.5254 -3.1543 -0.0501 -0.2310 -0.0384 -1.1627 -0.8847 -0.0055 -0.3135 -3.1290 -0.9831 -0.2637 -0.0565 -0.1723 -0.6944 -0.1029 -0.2150 -1.1886 -0.0092 -0.2007 -4.9133 -0.8797 -0.2885 -0.0804 -0.1824 -0.2666 -0.1263
S-1326	Functional electrical stimulation of peripheral muscles improves endothelial function and clinical and emotional status in heart failure patients with preserved left ventricular ejection fraction.<unk>
T-1326	functional_electrical_stimulation peripheral_muscles endothelial_function clinical heart_failure patients preserved_left_ventricular_ejection_fraction
H-1326	-0.6726776957511902	▁electric al ▁stimul ation ▁per i pher al ▁muscle s ▁en dot heli al ▁function ▁heart _ ▁failure ▁vent ri cular ▁e je ction ▁ fraction
D-1326	-0.6726776957511902	electrical stimulation peripheral muscles endothelial function heart_ failure ventricular ejection fraction
P-1326	-1.3536 -0.0386 -0.5831 -0.0064 -0.4100 -0.4033 -0.0778 -0.1330 -0.3170 -0.0159 -0.1277 -0.5536 -0.0099 -0.0089 -6.0823 -0.5047 -1.6472 -1.5337 -0.7974 -0.1105 -0.1323 -0.7247 -0.2874 -0.0936 -2.6267 -0.0004 -0.1568 -0.0985
S-1441	There was a trend toward a higher baseline SDQT-to-SDRR ratio in the HFVT(+) group compared with the HFVT(-) and HNorm groups (P = 0.09).<unk>
T-1441	baseline
H-1441	-0.6274285316467285	▁SD QT - to - SD RR ▁ HF VT ▁h Nor m
D-1441	-0.6274285316467285	SDQT-to-SDRR HFVT hNorm
P-1441	-0.4529 -0.9489 -0.6840 -0.8715 -0.0144 -0.0175 -0.1812 -1.3550 -0.2020 -2.1914 -0.1716 -1.5165 -0.0028 -0.7287 -0.0730
S-1148	Among the most important are altered ventricular structure (both geometry and fiber/sheet orientation), abnormal Ca(2+) handling, slowed conduction, and reduced wall stiffness.<unk>
T-1148	ventricular wall_stiffness
H-1148	-0.9194778800010681	▁vent ri cular ▁structure ▁fiber she et ▁ orientation ▁handling ▁slow ed ▁con duction ▁wall ▁sti ff ness
D-1148	-0.9194778800010681	ventricular structure fibersheet orientation handling slowed conduction wall stiffness
P-1148	-0.0072 -0.2041 -0.1676 -1.3181 -1.3821 -3.0659 -0.0118 -0.8135 -0.0008 -1.8665 -2.2760 -1.0689 -0.4046 -0.0157 -1.0065 -2.1926 -0.2704 -1.9839 -0.2419 -0.0916
S-1677	Thus, we conclude that if Rad Q66P contributes to cardiomyopathy, it does so via a mechanism that is not related to its ability to inhibit L-type channel-dependent processes per se.<unk>
T-1677	rad q66p cardiomyopathy
H-1677	-0.9978225827217102	▁rad ▁Q 66 p ▁cardio my o pathy
D-1677	-0.9978225827217102	rad Q66p cardiomyopathy
P-1677	-0.7119 -3.0730 -0.1968 -0.4833 -0.0507 -1.7880 -0.3867 -0.0378 -3.1312 -0.1187
S-937	Intriguingly, serum resistin levels in women undergoing anthracycline-containing chemotherapy increased significantly at 3 months and remained elevated at 6 months in those with subsequent cardiotoxicity.<unk>
T-937	resistin chemotherapy elevated cardiotoxicity
H-937	-0.7207310199737549	▁se rum _ ▁resist in ▁women ▁an thra cycli ne - conta ining _ che mo therapy ▁cardio toxic ity
D-937	-0.7207310199737549	serum_ resistin women anthracycline-containing_chemotherapy cardiotoxicity
P-937	-0.7375 -0.0723 -1.1109 -0.5866 -0.3405 -3.8401 -0.0286 -0.0131 -3.0670 -1.0566 -0.6693 -0.1192 -0.3482 -0.3806 -2.1261 -0.0954 -0.1008 -0.1403 -0.3601 -0.4529 -0.1377 -0.0722
S-405	Patients with low sST2 titrated to high-dose BB had the lowest cardiovascular event rate at 0.53 events (P=0.001), and lowest cumulative hazard (P=0.003).<unk>
T-405	patients sst2 titrated cardiovascular_event
H-405	-2.0646679401397705	▁s st ▁figure ▁cardiovascular _ event _ ▁rate
D-405	-2.0646679401397705	sst figure cardiovascular_event_ rate
P-405	-0.9923 -2.0704 -5.0253 -1.7741 -2.9825 -2.2193 -1.6982 -2.5902 -1.2148 -0.0795
S-533	Postoperative survival of patients with preoperative hypoalbuminemia (<3.5 g/dl, n = 125) and those with normal albumin concentration (≥3.5 g/dl, n = 147) was compared.<unk>
T-533	postoperative patients preoperative hypoalbuminemia albumin
H-533	-1.0465288162231445	▁pre operativ e ▁hypo album in emia
D-533	-1.0465288162231445	preoperative hypoalbuminemia
P-533	-2.0998 -0.0368 -0.1331 -2.2915 -0.6154 -1.0843 -0.8432 -2.2384 -0.0764
S-174	Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.<unk>
T-174	uptitration renin-angiotensin_system_blocker beta-blocker therapy patients hospitalized heart_failure preserved_left_ventricular_ejection_fractions
H-174	-0.7305673956871033	▁re nin - angi oten sin _ system _ ▁block er ▁beta - block er ▁ therapy ▁heart _ ▁failure ▁vent ri cular ▁e je ction
D-174	-0.7305673956871033	renin-angiotensin_system_ blocker beta-blocker therapy heart_ failure ventricular ejection
P-174	-0.0422 -0.5756 -0.0360 -0.2483 -0.1216 -1.1729 -2.1792 -0.3233 -1.2186 -1.1564 -0.1198 -0.8087 -0.0187 -0.0430 -0.0388 -1.3211 -0.0135 -0.2403 -1.6924 -3.4012 -1.9046 -0.1377 -0.2324 -1.1981 -0.3696 -0.0766 -1.6001 -0.1650
S-1180	(Use of Exercise and Medical Therapies to Improve Cardiac Function Among Patients With Exertional Shortness of Breath Due to Lung Congestion; ACTRN12610001087044).<unk>
T-1180	use_of_exercise_and_medical_therapies_to_improve_cardiac_function_among_patients_with_exertional_shortness_of_breath_due_to_lung_congestion
H-1180	-0.8268629312515259	▁Medical ▁Therapie s ▁Card iac _ ▁Fun ction ▁Breath ▁Lung _ con gestion
D-1180	-0.8268629312515259	Medical Therapies Cardiac_ Function Breath Lung_congestion
P-1180	-3.7345 -0.9935 -0.0481 -0.4097 -0.0751 -0.6250 -0.1687 -0.0016 -4.2695 -0.3414 -1.0553 -0.0779 -0.0045 -0.5519 -0.0462
S-206	The authors evaluated how often the nurse assessment of cognitive impairment at hospitalization was documented by the physician at the time of discharge in a cohort of elderly patients hospitalized for heart failure.<unk>
T-206	nurse hospitalization physician discharge patients hospitalized heart_failure
H-206	-0.8748737573623657	▁nurse ▁cognitive ▁im pair ment ▁hospital ization ▁physician ▁dis charge ▁el der ly ▁patients ▁heart _ ▁failure
D-206	-0.8748737573623657	nurse cognitive impairment hospitalization physician discharge elderly patients heart_ failure
P-206	-0.3024 -1.2643 -0.4573 -0.0908 -0.0779 -1.8385 -0.9706 -0.1439 -1.9905 -0.0019 -0.3365 -0.0917 -0.4539 -1.4697 -2.5592 -1.3985 -2.8616 -0.1956 -0.1178
S-1822	Still, patients with advanced heart failure should be managed by a "heart team," as indicated by guidelines; communication and collaboration among cardiologists, cardiovascular surgeons, and other medical staff responsible for patient care is necessary.<unk>
T-1822	patients heart_failure heart cardiologists cardiovascular surgeons medical patient
H-1822	-1.0821906328201294	▁patients _ with _ ▁advanced _ heart _ ▁failure heart _ team ▁cardio logist s ▁cardiovascular ▁surge ons ▁medical
D-1822	-1.0821906328201294	patients_with_ advanced_heart_ failureheart_team cardiologists cardiovascular surgeons medical
P-1822	-1.6653 -1.5518 -4.7307 -0.5484 -0.7660 -0.3238 -0.7256 -0.3380 -3.5889 -1.2418 -1.0487 -1.0267 -0.4435 -0.0601 -0.1119 -0.1883 -1.4848 -0.0384 -0.6961 -2.0746 -0.0724
S-1632	METHODS: We performed an analysis of HF-ACTION, which randomized 2331 patients with HF having an ejection fraction ≤35% to usual care with or without exercise training.<unk>
T-1632	hf-action randomized patients hf ejection_fraction exercise training
H-1632	-1.2250139713287354	▁ HF - ac tion ▁ HF ▁ HF ▁e je ction _ fraction
D-1632	-1.2250139713287354	HF-action HF HF ejection_fraction
P-1632	-0.3425 -0.2785 -0.7086 -1.7889 -0.7028 -0.8923 -0.4218 -2.8634 -0.5772 -3.5902 -1.9894 -0.0277 -1.9041 -0.0100 -3.3638 -0.1390
S-1542	When the two most commonly used bisphosphonates, alendronate and etidronate, were analysed separately, significant trends in the risk of heart failure were observed across refill compliance strata.<unk>
T-1542	bisphosphonates alendronate etidronate heart_failure compliance
H-1542	-0.571029543876648	▁bis phos phon ates ▁ale ndr onate ▁et id rona te ▁risk _ de _ heart _ ▁failure ▁re fill
D-1542	-0.571029543876648	bisphosphonates alendronate etidronate risk_de_heart_ failure refill
P-1542	-0.5652 -0.0161 -0.1548 -0.2840 -0.8802 -0.0163 -0.1019 -0.0227 -0.2274 -0.0100 -0.0028 -1.2983 -0.9469 -1.3640 -0.1883 -1.3084 -1.3351 -2.1526 -0.0563 -0.0113 -1.5538 -0.0663
S-1097	Individuals with acute RV failure in the setting of pulmonary embolism represent a group with particularly high mortality, and the specific diagnostic and management strategies that are important for improved survival will be discussed.<unk>
T-1097	acute_rv_failure pulmonary_embolism mortality diagnostic
H-1097	-0.666871964931488	▁a cute ▁ RV _ ▁failure ▁pulmonar y _ ▁e mbol ism ▁mortal ity
D-1097	-0.666871964931488	acute RV_ failure pulmonary_ embolism mortality
P-1097	-1.3641 -0.0207 -0.6081 -0.1028 -2.3989 -1.5343 -0.0405 -0.0297 -0.4643 -1.1607 -0.0031 -1.5674 -0.8577 -0.1653 -0.2747 -0.0777
S-500	This study shows that the TAPSE vs. PASP relationship is shifted downward in nonsurvivors with a similar distribution in HFrEF and HFpEF, and their ratio improves prognostic resolution.<unk>
T-500	tapse pasp downward hfref hfpef prognostic resolution
H-500	-0.8643012046813965	▁T AP se ▁PAS p ▁non sur viv ors ▁h Fr EF ▁h f p EF
D-500	-0.8643012046813965	TAPse PASp nonsurvivors hFrEF hfpEF
P-500	-2.4338 -0.1647 -1.1553 -1.1114 -0.5309 -3.5177 -0.0003 -0.0238 -0.3642 -0.1669 -0.6954 -0.7340 -1.1234 -1.1359 -0.1047 -0.8380 -1.3622 -0.0947
S-1258	OBJECTIVES: To evaluate the effectiveness and safety of Chinese herbal medicine (CHM) as an adjunctive treatment for patients with dilated cardiomyopathy (DCM) and heart failure.<unk>
T-1258	medicine patients dilated_cardiomyopathy dcm heart_failure
H-1258	-0.7057516574859619	▁Chinese _ ▁herbal ▁medicine CH m ▁ad ju nc tive ▁treatment ▁dil ated _ ▁cardio my o pathy DC m ▁heart _ ▁failure
D-1258	-0.7057516574859619	Chinese_ herbal medicineCHm adjunctive treatment dilated_ cardiomyopathyDCm heart_ failure
P-1258	-1.5502 -1.6773 -0.5176 -0.3572 -2.9142 -0.2166 -0.9175 -0.0005 -0.0174 -0.0029 -2.4223 -0.7514 -0.2275 -0.2334 -0.1264 -2.1342 -0.6630 -0.0141 -0.2820 -0.3736 -0.1180 -1.0767 -0.8474 -0.1264 -0.0761
S-1376	Baroreflex sensitivity and time domain heart rate variability (HRV) were both decreased in the CHF-INV group compared with sham-INV and were restored to sham levels by renal DNx.<unk>
T-1376	baroreflex_sensitivity heart_rate_variability hrv renal_dnx
H-1376	-0.7477657794952393	▁Baro re flex _ sensitiv ity ▁time _ ▁domain ▁heart _ ▁rate _ vari able ▁h v ▁CHF - in v ▁sham - in v ▁renal ▁DN x
D-1376	-0.7477657794952393	Baroreflex_sensitivity time_ domain heart_ rate_variable hv CHF-inv sham-inv renal DNx
P-1376	-0.1350 -0.0146 -0.1657 -2.0111 -0.1827 -0.0493 -2.8910 -1.0326 -0.1834 -0.8482 -0.5806 -1.4997 -1.0126 -0.5622 -1.4449 -1.1139 -1.1222 -0.0453 -0.0778 -1.1692 -1.0159 -0.0323 -0.1884 -0.9007 -0.8496 -2.3775 -0.4507 -0.0334 -0.2948 -0.1477
S-347	This time, he had severe hypertension of 191/104 mm Hg, diabetes mellitus, and grade 2 to 3/6 systolic as well as diastolic murmurs were audible at the apex.<unk>
T-347	hypertension diabetes_mellitus grade systolic diastolic_murmurs apex
H-347	-0.45689237117767334	▁hyper tension ▁h g ▁diabetes ▁mell itus ▁sy sto lic ▁mur mur s
D-347	-0.45689237117767334	hypertension hg diabetes mellitus systolic murmurs
P-347	-0.2062 -0.0004 -1.4160 -0.0114 -0.0714 -0.2422 -0.0647 -0.4763 -0.0478 -1.5963 -2.2435 -0.0684 -0.0966 -0.2522 -0.0601
S-956	In the present study, the cardioprotective effect of nicorandil was investigated on hemodynamic alterations and mitochondrial dysfunction induced by cumulative administration of doxorubicin in rats.<unk>
T-956	cardioprotective nicorandil hemodynamic mitochondrial_dysfunction administration doxorubicin
H-956	-0.35140860080718994	▁cardio protec tive _ effet ▁nic oran dil ▁hem o dynamic _ ▁altera tions ▁mito cho ndri al ▁dys function ▁do xor ubi cin ▁rat s
D-956	-0.35140860080718994	cardioprotective_effet nicorandil hemodynamic_ alterations mitochondrial dysfunction doxorubicin rats
P-956	-0.0408 -0.0352 -0.0074 -1.8131 -1.8529 -1.0248 -0.1190 -0.2618 -0.5792 -0.0291 -0.0116 -1.4494 -0.4368 -0.0108 -0.0030 -0.5352 -0.0313 -0.0400 -0.4445 -0.0554 -0.5090 -0.0491 -0.0191 -0.0487 -0.2140 -0.0231 -0.1440 -0.0511
S-1147	In addition to the left bundle branch block type of electrical activation, there are further remodeling aspects associated with dyssynchronous heart failure (HF) that affect the electromechanical behavior of the heart.<unk>
T-1147	left_bundle_branch_block remodeling dyssynchronous_heart_failure hf heart
H-1147	-0.7704656720161438	▁electric al _ activa tion ▁dys syn chron ous _ ▁heart _ ▁failure ▁ HF ▁electro me chan ical _ ▁behavior
D-1147	-0.7704656720161438	electrical_activation dyssynchronous_ heart_ failure HF electromechanical_ behavior
P-1147	-2.1744 -0.0280 -0.9818 -0.4242 -0.0145 -0.0507 -0.0011 -0.0002 -1.3439 -0.8826 -1.4175 -0.6116 -1.8693 -2.1393 -0.0159 -0.0193 -0.0092 -0.0761 -0.2096 -1.1853 -1.3953 -2.7526 -0.1184
S-643	Furthermore, in vivo inhibition of miR-25 by a specific antagomir evoked spontaneous cardiac dysfunction and sensitized the murine myocardium to heart failure in a Hand2-dependent manner.<unk>
T-643	in_vivo mir-25 antagomir cardiac_dysfunction murine myocardium heart_failure
H-643	-0.8083001375198364	▁in ▁vivo ▁inhibi tion ▁mi R -25 ▁spontane ous ▁cardiac _ ▁dys function ▁mur ine _ my o car dium ▁heart _ ▁failure ▁Hand 2- dependent
D-643	-0.8083001375198364	in vivo inhibition miR-25 spontaneous cardiac_ dysfunction murine_myocardium heart_ failure Hand2-dependent
P-643	-1.3464 -0.2075 -0.2484 -0.0140 -0.4708 -0.8201 -0.3021 -3.9215 -0.4623 -0.2681 -2.2474 -0.0757 -0.1986 -0.0124 -0.4973 -0.4608 -2.6565 -0.0722 -0.0120 -0.3580 -1.2141 -0.8840 -3.5101 -0.1457 -1.1760 -0.0890 -0.7572 -0.2044
S-270	CONCLUSION: Elevated NT-proBNP levels at the time of admission are a strong and independent predictor of all-cause mortality in patients with acute HF 4 years after admission.<unk>
T-270	elevated nt-probnp admission all-cause_mortality patients acute_hf admission
H-270	-0.8467304110527039	▁NT - pro B NP
D-270	-0.8467304110527039	NT-proBNP
P-270	-0.0657 -0.0321 -0.0081 -1.0821 -0.0585 -4.5530 -0.1275
S-1041	Both epigenetic 'writer' proteins (histone acetyltransferases) and epigenetic 'erasers' (histone deacetylases) have been implicated in cardiac development and disease.<unk>
T-1041	epigenetic proteins histone_acetyltransferases epigenetic histone_deacetylases cardiac disease
H-1041	-0.6853607296943665	▁epi gene tic _ writer ▁protein s hi stone ▁a ce tyl transfer as es ▁epi gene tic _ eras ers hi stone _ de ace ty las es ▁cardiac
D-1041	-0.6853607296943665	epigenetic_writer proteinshistone acetyltransferases epigenetic_erasershistone_deacetylases cardiac
P-1041	-1.1968 -0.0422 -0.7001 -2.0766 -0.2376 -3.0347 -0.0078 -0.0350 -0.0760 -0.6238 -0.0661 -0.3723 -0.0695 -0.3341 -0.0201 -0.3388 -0.0256 -1.1477 -1.6812 -0.6923 -0.0182 -0.0732 -0.6363 -0.4152 -0.0995 -2.4037 -2.5539 -0.2447 -0.0035 -0.0131 -2.5767 -0.1150
S-1449	Haematopoietic cell transplantation (HCT) survivors are at increased risk for developing congestive heart failure (CHF), primarily due to pre-HCT exposure to anthracyclines.<unk>
T-1449	haematopoietic_cell_transplantation hct congestive_heart_failure chf anthracyclines
H-1449	-0.7441025376319885	▁ha e mato po ie tique _ cell ▁transplant ation ▁h CT ▁con ges tive _ ▁heart _ ▁failure CH f ▁pre - H CT ▁an thra cycli nes
D-1449	-0.7441025376319885	haematopoietique_cell transplantation hCT congestive_ heart_ failureCHf pre-HCT anthracyclines
P-1449	-1.5528 -0.0976 -0.0790 -1.4867 -0.1939 -1.0354 -1.9694 -1.7598 -0.6403 -0.0115 -0.1281 -0.8311 -2.3181 -1.3229 -0.0704 -0.3416 -1.6125 -0.7905 -1.3433 -2.0288 -0.3057 -0.6818 -0.0036 -0.2973 -0.3512 -0.4666 -0.0071 -0.8859 -0.2025 -0.1851 -0.0673
S-1111	Carvedilol, a nonselective β-blocker, may be more effective than the selective β-blocker metoprolol in reducing the risk of thromboembolic events in heart failure.<unk>
T-1111	carvedilol nonselective_β-blocker selective_β-blocker metoprolol thromboembolic_events heart_failure
H-1111	-0.9278720021247864	▁car vedi lol ▁β - block er ▁β - block er ▁met o pro lol ▁ thro mbo e mbol ic
D-1111	-0.9278720021247864	carvedilol β-blocker β-blocker metoprolol thromboembolic
P-1111	-0.8286 -0.0178 -0.0745 -1.1380 -0.0315 -0.2714 -0.2122 -4.2166 -0.0244 -0.4589 -0.3525 -2.5163 -0.1363 -0.0348 -0.1476 -0.4179 -0.4011 -0.2738 -1.8349 -0.0393 -2.6161 -5.0509 -0.2455
S-1700	CONCLUSIONS: Composite measures of quality for HF, AMI, and PNA performed better than existing measures at explaining variation in future mortality and predicting future high and low performers.<unk>
T-1700	hf ami pna mortality
H-1700	-1.0980554819107056	▁ HF ▁ AMI ▁p na ▁mortal ity
D-1700	-1.0980554819107056	HF AMI pna mortality
P-1700	-2.2461 -1.2668 -1.0479 -0.5259 -1.1266 -0.6444 -3.3796 -0.1374 -0.5195 -0.0863
S-716	After adjustment for baseline characteristics, standard criteria cardiac transplant survival was higher than ECCT at 1 (89% versus 86%; P=0.18) and 5 (77% versus 66%; P=0.035) years.<unk>
T-716	baseline cardiac_transplant ecct
H-716	-2.1720807552337646	
D-716	-2.1720807552337646	
P-716	-4.2926 -0.0516
S-685	BACKGROUND: Current dietary recommendations for patients with heart failure (HF) are largely based on data from non-HF populations; evidence on associations of dietary patterns with outcomes in HF is limited.<unk>
T-685	patients heart_failure hf evidence outcomes hf
H-685	-1.7712520360946655	▁dieta ry _ ▁recommendations ▁patients ▁heart _ ▁failure ▁ HF
D-685	-1.7712520360946655	dietary_ recommendations patients heart_ failure HF
P-685	-4.9292 -0.2597 -2.5651 -2.5764 -1.5180 -3.7476 -0.3965 -2.4902 -1.5659 -0.0081 -1.1234 -0.0748
S-1590	Because of remodeling of the arrhythmia substrate after AMI, early measurement of HR variability to identify those at high risk should likely be repeated later in order to assess the risk of fatal arrhythmia events.<unk>
T-1590	remodeling arrhythmia ami hr_variability arrhythmia
H-1590	-1.0777698755264282	▁implant ing ▁ar rhythm ia _ ▁substrat e ▁ AMI ▁HR _ ▁variabil ity
D-1590	-1.0777698755264282	implanting arrhythmia_ substrate AMI HR_ variability
P-1590	-1.5107 -1.2891 -3.5819 -0.2236 -0.8920 -1.6899 -0.1890 -0.2364 -0.4785 -0.0289 -0.2203 -3.8994 -0.8295 -0.1745 -1.8445 -0.1561
S-919	METHODS AND RESULTS: Thirteen patients with treated hypertension and compensated HFPEF consumed the DASH/SRD (target sodium, 50 mmol/2100 kcal) for 21 days.<unk>
T-919	patients hypertension compensated_hfpef dash sodium
H-919	-0.8813874125480652	▁hyper tension ▁compensa ted ▁H FP EF ▁DAS h _ s RD ▁so dium
D-919	-0.8813874125480652	hypertension compensated HFPEF DASh_sRD sodium
P-919	-1.3268 -0.0097 -0.7975 -0.6384 -0.7226 -0.1611 -1.1286 -0.0375 -0.3540 -2.3331 -1.1149 -0.2307 -2.1898 -0.1286 -2.8781 -0.0510
S-1154	The simulation results revealed that deranged Ca(2+) handling is the primary culprit in extending EMD in dyssynchronous HF, with the other aspects of remodeling contributing insignificantly.<unk>
T-1154	emd dyssynchronous_hf remodeling insignificantly
H-1154	-0.6934917569160461	▁em d ▁dys syn chron ous ▁ HF ▁remodel ing
D-1154	-0.6934917569160461	emd dyssynchronous HF remodeling
P-1154	-4.9411 -0.3061 -0.2043 -0.0015 -0.0002 -1.8154 -0.7182 -0.0059 -0.0589 -0.0306 -0.1514 -0.0884
S-1997	Patients were adults with ejection fraction ≤ 25%, cardiac index ≤ 2.2 l/min/m(2) without inotropes or were inotrope-dependent on optimal medical management, or listed for transplant.<unk>
T-1997	patients ejection_fraction cardiac_index inotropes medical transplant
H-1997	-0.3910027742385864	▁e je ction _ fraction ▁cardiac ▁index ▁in o trop es ▁in ot rope
D-1997	-0.3910027742385864	ejection_fraction cardiac index inotropes inotrope
P-1997	-0.4183 -0.2554 -0.0281 -1.0295 -0.0016 -0.0365 -0.2893 -0.0037 -0.3042 -0.0117 -0.2330 -0.0076 -0.3480 -0.0327 -3.1483 -0.1081
S-933	Moreover, doxorubicin-induced cardiotoxicity was greater in the Hum-Retn mice than in littermate controls not expressing human resistin (Retn(-/-)).<unk>
T-933	doxorubicin-induced_cardiotoxicity resistin retn
H-933	-0.3989909589290619	▁do xor ubi cin - indu ced ▁cardio toxic ity ▁Hum - re t n ▁litt er mate ▁resist in
D-933	-0.3989909589290619	doxorubicin-induced cardiotoxicity Hum-retn littermate resistin
P-933	-0.0016 -0.0113 -0.0453 -0.0937 -0.2578 -0.0010 -1.6213 -0.7504 -0.4249 -0.3860 -0.0400 -0.0244 -1.0233 -0.2246 -0.0477 -0.5275 -0.0090 -0.2483 -1.9527 -0.1434 -0.9001 -0.0436
S-1302	While early research focused on the importance of diastolic dysfunction in the pathophysiology of HFpEF, recent studies have revealed that multiple non-diastolic abnormalities in cardiovascular function also contribute.<unk>
T-1302	diastolic_dysfunction pathophysiology hfpef cardiovascular_function
H-1302	-0.8530534505844116	▁dia sto lic _ ▁dys function ▁pat ho phy si ology ▁ HF p EF
D-1302	-0.8530534505844116	diastolic_ dysfunction pathophysiology HFpEF
P-1302	-0.3162 -0.5005 -5.3844 -0.7374 -0.3723 -0.3019 -0.7512 -0.0389 -0.0221 -0.4967 -1.2516 -0.3498 -0.0336 -0.0339 -0.1786 -3.6536 -0.0794
S-1432	8-fluo-cAMP binding by wild type and phosphomimic Ser77 and Ser83 mutant RIα proteins demonstrated reduced Kd for the double mutant as compared to WT RIα.<unk>
T-1432	8-fluo-camp phosphomimic ser77 ser83 riα proteins riα
H-1432	-0.8236385583877563	flu o - c AMP ▁ binding ▁ phos pho mi mic ▁Ser 83 ▁mu tant ▁RI α ▁double _ mu tant ▁ WT _ ri α
D-1432	-0.8236385583877563	fluo-cAMP binding phosphomimic Ser83 mutant RIα double_mutant WT_riα
P-1432	-3.8427 -0.0633 -0.1214 -0.0962 -0.0138 -0.1031 -0.0675 -0.4995 -0.4379 -0.1793 -0.0645 -0.7055 -0.1757 -4.5849 -0.8386 -0.0647 -2.2441 -0.6674 -0.8770 -1.6011 -0.4877 -0.0353 -1.1169 -0.4261 -2.5427 -0.2109 -1.2544 -0.4008 -0.1626
S-246	RATIONALE: High-density lipoprotein (HDL) exerts endothelial-protective effects via stimulation of endothelial cell (EC) nitric oxide (NO) production.<unk>
T-246	high-density_lipoprotein hdl endothelial_cell nitric_oxide
H-246	-0.6743924021720886	▁High - dens ity ▁lipo prote in HD L ▁en dot heli al - protec tive ▁effects ▁en dot heli al ▁cell ▁ni tric ▁oxid e
D-246	-0.6743924021720886	High-density lipoproteinHDL endothelial-protective effects endothelial cell nitric oxide
P-246	-4.1852 -0.1507 -0.0107 -0.0767 -0.2260 -0.7526 -0.6810 -0.4872 -1.0901 -0.1157 -0.5075 -0.0542 -0.0224 -0.3197 -0.0064 -0.0170 -4.2003 -0.1576 -1.2019 -0.0949 -0.0189 -1.6775 -1.6145 -0.0436 -0.0234 -0.0762 -0.9722 -0.0988
S-910	Dialysis patients demonstrated the following 3-year event rates: HF hospitalization, 31%; all-cause hospitalization, 100%; mortality, 73%; and HF hospitalization or death, 82%.<unk>
T-910	dialysis patients hf hospitalization all-cause_hospitalization mortality hf hospitalization death
H-910	-1.0297863483428955	▁Dia lys is ▁ HF ▁hospital ization
D-910	-1.0297863483428955	Dialysis HF hospitalization
P-910	-1.2208 -0.0615 -0.0290 -2.3466 -0.0275 -1.3018 -1.2189 -2.9783 -0.0837
S-1398	The purpose of this study was to determine whether a significant difference in outcome ratings exists from admission to discharge for hospitalized older adults with heart failure (HF) using Nursing Outcomes Classification (NOC).<unk>
T-1398	outcome admission discharge hospitalized heart_failure hf nursing_outcomes_classification noc
H-1398	-1.005864143371582	▁ad mission _ dis charge ▁hospital ized _ ▁older ▁adults ▁heart _ ▁failure ▁Nur sing _ out com es _ ▁Classifica tion
D-1398	-1.005864143371582	admission_discharge hospitalized_ older adults heart_ failure Nursing_outcomes_ Classification
P-1398	-1.6282 -0.0036 -0.3505 -1.8547 -0.0008 -0.7170 -0.4190 -1.1534 -0.8551 -0.9906 -1.8697 -0.5832 -2.9316 -3.0111 -0.1641 -1.2098 -1.4220 -0.0663 -0.0370 -2.6283 -0.1520 -0.0091 -1.9896 -0.0941
S-1840	CONCLUSION: In this large cohort study, a higher risk for hHF was not observed in users of saxagliptin or sitagliptin compared with other selected antihyperglycemic agents.<unk>
T-1840	cohort_study saxagliptin sitagliptin antihyperglycemic_agents
H-1840	-0.5676454901695251	▁h f ▁sax ag lip tin ▁si tag lip tin ▁anti hy per gly ce mic ▁agents
D-1840	-0.5676454901695251	hf saxagliptin sitagliptin antihyperglycemic agents
P-1840	-0.0091 -1.4311 -0.9142 -0.1395 -0.5818 -1.6914 -0.1253 -0.0002 -0.1112 -0.9838 -0.0213 -0.0333 -0.0640 -2.3903 -0.2335 -1.6445 -0.1693 -0.2060 -0.0353
S-535	Multivariate analysis revealed that preoperative albumin was independently associated with mortality after LVAD implantation (hazard ratio 0.521, 95% confidence interval 0.290 to 0.934; p = 0.029.)<unk>
T-535	multivariate_analysis preoperative albumin mortality lvad implantation hazard_ratio confidence_interval
H-535	-0.40697431564331055	▁pre operativ e ▁album in ▁mortal ity ▁l VAD ▁implant ation
D-535	-0.40697431564331055	preoperative albumin mortality lVAD implantation
P-535	-1.0196 -0.1503 -0.1473 -0.4575 -0.3562 -0.1168 -0.2044 -1.9554 -0.0329 -0.1134 -0.0375 -0.5794 -0.1201
S-854	CONCLUSIONS: In patients with systolic heart failure and a QRS duration of less than 130 msec, CRT does not reduce the rate of death or hospitalization for heart failure and may increase mortality.<unk>
T-854	patients systolic_heart_failure qrs_duration crt death hospitalization heart_failure mortality
H-854	-1.3988144397735596	▁sy sto lic _ ▁heart _ ▁failure ▁QR s ▁c RT ▁hospital ization _ for _ heart _ ▁failure ▁mortal ity
D-854	-1.3988144397735596	systolic_ heart_ failure QRs cRT hospitalization_for_heart_ failure mortality
P-854	-3.4988 -0.3948 -3.6542 -0.7779 -2.0089 -0.8758 -2.2285 -0.0270 -1.5833 -0.9297 -0.6523 -4.3832 -1.3571 -0.6420 -3.4971 -0.2876 -1.0637 -0.3750 -2.8246 -0.6511 -0.2151 -0.1568 -0.0884
S-1608	This study aims to discover differentially expressed genes (DEGs) between non-ischemic or ischemic heart failure samples and healthy control, which may be used for diagnosis and treatment of heart failure.<unk>
T-1608	differentially_expressed_genes degs ischemic_heart_failure healthy diagnosis heart_failure
H-1608	-1.495666742324829	▁d de g s ▁non - ische mic ▁ ische mic ▁heart _ ▁failure ▁healthy
D-1608	-1.495666742324829	ddegs non-ischemic ischemic heart_ failure healthy
P-1608	-4.5504 -2.2533 -1.6023 -0.3299 -4.8974 -0.0132 -0.6682 -0.0739 -2.6458 -0.4427 -0.1053 -2.0310 -1.4567 -1.1751 -0.1144 -2.9324 -0.1344
S-2003	Key adverse events included reoperation for bleeding (14%), driveline infection (10%), gastrointestinal bleeding (8%), and debilitating stroke (modified Rankin Score > 3) (8%).<unk>
T-2003	adverse_events reoperation bleeding driveline infection gastrointestinal_bleeding stroke rankin_score
H-2003	-0.424541711807251	▁ble ed ing ▁drive line _ ▁infection ▁gastro inte stin al ▁ble ed ing ▁de bilitat ing ▁stroke
D-2003	-0.424541711807251	bleeding driveline_ infection gastrointestinal bleeding debilitating stroke
P-2003	-4.5123 -0.3764 -0.3692 -0.0431 -0.1592 -0.9123 -0.5765 -0.0047 -0.0062 -0.2189 -0.1140 -0.1919 -0.1667 -0.1845 -0.2358 -0.0028 -0.0475 -0.1576 -0.1632 -0.0482
S-605	These groups were compared in Cox regression models stratified by propensity score decile and adjusted for oral glucocorticoid dosage, prior HF hospitalisations, and the use of loop diuretics.<unk>
T-605	cox_regression_models propensity_score oral glucocorticoid hf hospitalisations loop_diuretics
H-605	-0.6898099184036255	▁co x ▁re gression ▁models ▁pro pens ity ▁score _ de cile ▁oral ▁gluco cor tico id ▁ HF ▁loop _ di ure tics
D-605	-0.6898099184036255	cox regression models propensity score_decile oral glucocorticoid HF loop_diuretics
P-605	-0.1568 -0.0023 -0.5911 -0.0085 -4.0563 -0.0418 -0.0073 -0.1296 -0.7374 -0.7130 -0.0744 -0.0864 -0.0527 -0.0523 -0.0380 -1.4249 -0.4237 -2.9210 -0.0083 -2.1013 -0.5822 -1.4980 -0.5218 -1.3001 -0.3274 -0.0786
S-653	Insulin resistance is a hallmark of type 2 diabetes, and insulin receptor substrates 1 and 2 (IRS1 and IRS2) are the major insulin-signaling components regulating cellular metabolism and survival.<unk>
T-653	insulin_resistance type_2_diabetes insulin_receptor_substrates_1 irs1 irs2 cellular_metabolism
H-653	-0.6824050545692444	▁in s ulin _ ▁resist ance ▁diabetes ▁insulin ▁receptor ▁substrat es ▁i RS ▁insulin - signal ing
D-653	-0.6824050545692444	insulin_ resistance diabetes insulin receptor substrates iRS insulin-signaling
P-653	-0.3709 -1.0002 -0.0122 -0.4310 -0.8617 -0.0029 -0.5016 -0.0076 -1.3835 -1.7290 -0.1128 -1.4811 -1.5516 -0.8527 -0.0729 -0.0262 -0.1969 -2.2570 -0.1139
S-1149	In dyssynchronous HF, the electromechanical delay (EMD), the time interval between local myocyte depolarization and myofiber shortening onset, is prolonged.<unk>
T-1149	dyssynchronous_hf electromechanical_delay emd myocyte_depolarization myofiber_shortening
H-1149	-0.48736682534217834	▁dys syn chron ous ▁ HF ▁electro me chan ical _ de lay ▁em d ▁my o cy te _ de po lar ization ▁my o fi ber
D-1149	-0.48736682534217834	dyssynchronous HF electromechanical_delay emd myocyte_depolarization myofiber
P-1149	-0.2503 -0.0006 -0.0000 -1.8337 -0.2375 -0.0024 -0.0025 -0.0126 -0.4704 -0.4527 -0.4420 -0.0712 -0.4832 -2.0985 -0.0855 -2.1162 -0.0615 -0.8935 -0.1738 -0.9488 -0.0521 -1.1490 -0.0514 -0.2598 -0.3743 -0.0185 -0.5368 -0.0561 -1.3552 -0.1309
S-1936	OBJECTIVE: Beta blockers reduce all-cause mortality and readmissions in heart failure with reduced ejection fraction (HFrEF), which may be explained by their effect on heart rate (HR).<unk>
T-1936	beta_blockers all-cause_mortality readmissions heart_failure_with_reduced_ejection_fraction hfref heart_rate
H-1936	-1.1148022413253784	▁Beta _ block ers ▁mortal ity ▁read missions ▁heart _ ▁failure ▁e je ction _ fraction ▁h r EF ▁heart _ ▁rate HR
D-1936	-1.1148022413253784	Beta_blockers mortality readmissions heart_ failure ejection_fraction hrEF heart_ rateHR
P-1936	-2.0796 -2.2190 -1.8086 -0.0381 -4.5688 -0.1149 -0.3387 -0.0223 -0.3565 -0.3882 -2.3446 -2.5109 -0.7695 -0.0319 -1.1484 -0.0223 -1.1691 -0.0831 -0.7942 -0.4242 -1.0084 -3.5162 -1.7344 -0.2995 -0.0786
S-1327	BACKGROUND: Functional electrical stimulation (FES) improves exercise capacity, quality of life, emotional stress, and endothelial function in chronic heart failure with impaired systolic function.<unk>
T-1327	functional_electrical_stimulation fes exercise_capacity quality_of_life endothelial_function chronic_heart_failure systolic_function
H-1327	-1.0544557571411133	▁Fun ction al _ ▁electric al _ ▁stimul ation ▁f es ▁exercise _ ▁capacity ▁emotional ▁stress ▁en dot heli al _ ▁function ▁chronic ▁heart _ ▁failure
D-1327	-1.0544557571411133	Functional_ electrical_ stimulation fes exercise_ capacity emotional stress endothelial_ function chronic heart_ failure
P-1327	-1.2418 -0.0002 -0.1063 -0.2722 -2.0409 -0.0181 -1.9100 -0.9116 -0.0101 -2.5053 -0.2403 -4.1229 -1.7616 -2.7309 -0.1769 -0.6239 -0.0433 -0.3270 -0.0220 -0.0035 -1.6920 -1.4372 -1.8226 -0.7553 -0.7161 -1.3137 -2.6688 -0.0502
S-595	Here, we present a case report of a patient with right atrial myxoma and massive embolism to the pulmonary arteries treated surgically with right atrial mass removal and pulmonary embolectomy.<unk>
T-595	report patient right_atrial_myxoma massive_embolism pulmonary_arteries surgically right_atrial pulmonary_embolectomy
H-595	-0.7583067417144775	▁right ▁at rial _ My xo ma ▁pulmonar y ▁arteri es ▁right _ ▁at rial _ ▁mass _ ▁remo val ▁pulmonar y ▁e mbol ecto my
D-595	-0.7583067417144775	right atrial_Myxoma pulmonary arteries right_ atrial_ mass_ removal pulmonary embolectomy
P-595	-4.2691 -0.8589 -0.0593 -0.6821 -2.4192 -0.0653 -0.0588 -0.3938 -0.0360 -1.1009 -0.0232 -3.6772 -1.0468 -0.8075 -0.1552 -0.6299 -1.1697 -0.2378 -0.0544 -0.3390 -0.0002 -0.0238 -1.3521 -0.0014 -0.1605 -1.3108 -0.2500 -0.0496
S-896	METHODS: A consecutive case series of 10 transplant ineligible patients receiving PD solely for HF volume management between 2007 and 2011 was evaluated with clinical data reviewed pre- and post-PD initiation.<unk>
T-896	transplant patients pd hf clinical
H-896	-0.8276821374893188	▁transplant ▁in elig ible ▁patients ▁ HF ▁volume _ management
D-896	-0.8276821374893188	transplant ineligible patients HF volume_management
P-896	-0.9281 -0.4586 -0.0003 -0.0739 -0.5103 -0.8066 -0.2387 -2.2037 -1.5276 -0.7407 -2.3966 -0.0471
S-1478	We discuss the need for strict statistical standards in biomarker studies, provide an overview of biomarker-guided clinical trial design, and discuss the therapeutic potential of a multimarker-based strategy.<unk>
T-1478	biomarker clinical therapeutic
H-1478	-0.7034245729446411	▁statistic al ▁standard s ▁bio mark er - guide d _ ▁clinic al _ ▁trial ▁ therapeut ic
D-1478	-0.7034245729446411	statistical standards biomarker-guided_ clinical_ trial therapeutic
P-1478	-1.1033 -0.0501 -2.8190 -0.0134 -0.0115 -0.0051 -0.0333 -0.5581 -0.0094 -0.0485 -1.0734 -0.3066 -0.0228 -0.8742 -1.3331 -1.7494 -0.0126 -0.2999 -3.6565 -0.0883
S-231	By imaging, the SAF cohort demonstrated a greater incidence of abnormal liver texture changes (96% vs 75%, p = 0.04) and nodularity (77% vs 42%, p = 0.02).<unk>
T-231	saf incidence liver nodularity
H-231	-1.3200677633285522	▁ SAF ▁ab normal ▁ liver _ ▁texture s
D-231	-1.3200677633285522	SAF abnormal liver_ textures
P-231	-1.3934 -0.1419 -3.5159 -0.1479 -0.4069 -1.0958 -1.5426 -2.2563 -2.4444 -1.3869 -0.1888
S-1004	Frailty according to the biological phenotype was defined as 3 or more of: weak grip strength, physical exhaustion, slowness, low activity and unintentional weight loss >10 lb in 1 year.<unk>
T-1004	frailty biological_phenotype physical activity
H-1004	-0.8343929052352905	▁Fra il ty ▁bi ological _ ▁ph eno type ▁we ak ▁grip _ ▁strength ▁physical _ ▁exhaust ion ▁slow ness ▁activité
D-1004	-0.8343929052352905	Frailty biological_ phenotype weak grip_ strength physical_ exhaustion slowness activité
P-1004	-1.1401 -0.2631 -2.1300 -1.0177 -0.3248 -1.4194 -0.7104 -0.2023 -0.0128 -1.1487 -0.0073 -0.2147 -0.7618 -1.3455 -0.8352 -1.1440 -0.4822 -0.0252 -0.7671 -2.0452 -1.8303 -1.2839 -0.0792
S-109	In conclusion, our data suggest that treatment with CRT-D does not reduce the risk of IE in patients with IC and that the benefit of CRT-D is attenuated after the development of IEs in this population.<unk>
T-109	crt-d patients ic crt-d ies
H-109	-0.9355687499046326	▁c RT - d ▁IE ▁IC ▁c RT - d
D-109	-0.9355687499046326	cRT-d IE IC cRT-d
P-109	-1.3315 -0.1621 -0.0948 -0.9138 -2.5117 -0.9329 -1.0396 -0.2059 -0.1218 -0.8648 -2.9461 -0.1019
S-467	Conclusions—Low-volume EDs were more likely to discharge patients with heart failure home, but low-volume ED cases exhibited worse outcomes (driven largely by readmissions or repeat ED visits).<unk>
T-467	eds discharge patients heart_failure outcomes driven readmissions
H-467	-1.7537294626235962	▁ volu me ▁ED s ▁heart _ ▁failure _ home
D-467	-1.7537294626235962	volume EDs heart_ failure_home
P-467	-5.2357 -3.4594 -0.0231 -1.4562 -1.6824 -1.7126 -0.5787 -1.6238 -1.4122 -0.9741 -2.7929 -0.0937
S-879	Impact of QRS morphology and duration on outcomes after cardiac resynchronization therapy: Results from the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT).<unk>
T-879	qrs_morphology outcomes cardiac_resynchronization_therapy resynchronization-defibrillation_for_ambulatory_heart_failure_trial raft
H-879	-0.4208258390426636	▁QR s ▁ morph ologie ▁cardiac ▁re syn chron ization _ ▁ therapy ▁Re syn chron ization - Def i bril lation ▁Amb ulator y _ ▁Heart _ ▁Fail ure _ tri al RAF t
D-879	-0.4208258390426636	QRs morphologie cardiac resynchronization_ therapy Resynchronization-Defibrillation Ambulatory_ Heart_ Failure_trialRAFt
P-879	-0.0271 -0.5367 -0.6349 -0.0160 -1.1639 -0.5580 -0.3421 -0.0017 -0.0002 -0.4537 -0.7392 -3.1782 -0.0167 -1.3184 -0.0017 -0.0008 -0.4465 -0.7224 -0.5035 -0.9304 -0.1336 -0.0018 -0.1092 -0.0075 -0.0507 -0.5472 -0.0835 -0.4081 -0.1095 -0.0867 -0.5248 -0.7736 -0.0287 -0.0885 -0.8132 -0.1239 -0.0880
S-1295	Based on the acute right heart failure with therapy refractory cardiogenic shock we decided within our heart team for an extra corporeal membrane oxygenation (ECMO) applied during CPR in the ICU.<unk>
T-1295	acute_right_heart_failure therapy refractory_cardiogenic_shock heart extra_corporeal_membrane_oxygenation ecmo cpr icu
H-1295	-0.7033335566520691	▁a cute _ ▁right ▁heart _ ▁failure ▁ therapy _ ▁re frac tory _ ▁cardio ge nic ▁shock ▁heart _ team ▁extra ▁corpore al _ ▁membran e _ ▁oxygen ation ▁c PR ▁ ICU
D-1295	-0.7033335566520691	acute_ right heart_ failure therapy_ refractory_ cardiogenic shock heart_team extra corporeal_ membrane_ oxygenation cPR ICU
P-1295	-0.2624 -0.0051 -0.4823 -2.3680 -1.5936 -0.4273 -1.1757 -0.5196 -0.0054 -0.3710 -1.0230 -0.0210 -1.5547 -0.1065 -0.5478 -0.1933 -1.4776 -0.7314 -2.1415 -1.9612 -1.3502 -1.1549 -0.1112 -0.0791 -1.2451 -0.2156 -0.1628 -0.3474 -1.0062 -0.0194 -1.1104 -0.0836 -1.2475 -0.0016 -0.1133 -0.1035
S-201	The guidelines are intended to assist practitioners in office-based or emergency room practice, who encounter children with undiagnosed heart disease and symptoms of possible HF, rather than those who have already received surgical palliation.<unk>
T-201	emergency_room undiagnosed heart_disease symptoms hf surgical_palliation
H-201	-0.86458420753479	▁office - based ▁emergency ▁room _ prac ti tioner s ▁children ▁un diagnos ed ▁heart ▁disease ▁ HF ▁sur g ical ▁palli ation
D-201	-0.86458420753479	office-based emergency room_practitioners children undiagnosed heart disease HF surgical palliation
P-201	-2.0083 -0.0457 -0.0719 -3.3993 -0.4463 -1.2466 -4.2524 -0.0754 -0.0090 -0.9086 -2.7983 -1.6071 -0.0165 -0.0492 -0.3906 -2.0922 -0.5929 -0.0273 -0.5641 -0.0698 -0.1947 -0.3864 -0.0329 -0.2138 -0.1152
S-168	Gene expression of Bax remained unchanged during the pacing period; Bcl-2 mRNA expression transiently decreased in moderate heart failure and their ratio (Bcl-2/Bax) was not significantly altered.<unk>
T-168	gene_expression bax pacing bcl-2 mrna expression heart_failure bcl-2 bax
H-168	-0.8885529041290283	▁Bax ▁b cl -2 ▁m RNA ▁heart _ ▁failure ▁b cl - 2/ Ba x
D-168	-0.8885529041290283	Bax bcl-2 mRNA heart_ failure bcl-2/Bax
P-168	-1.9390 -0.5796 -0.0935 -1.8377 -0.0105 -0.0225 -3.8970 -1.5237 -2.0963 -0.1607 -0.0540 -0.1253 -0.0302 -2.3277 -0.0044 -0.3043 -0.0989
S-745	This study aimed to verify the impact of heart magnetic resonance imaging on chelation choices and patient compliance in a single-institution cohort as well as its predictive value for heart failure and arrhythmias.<unk>
T-745	heart_magnetic_resonance_imaging chelation patient compliance heart_failure arrhythmias
H-745	-0.7933722734451294	▁heart _ ▁magnetic _ ▁res on ance _ ▁imagin g ▁che lation _ ▁choice s ▁patient _ con du ite
D-745	-0.7933722734451294	heart_ magnetic_ resonance_ imaging chelation_ choices patient_conduite
P-745	-0.7447 -0.7427 -0.5930 -1.4635 -1.5092 -0.0895 -0.0610 -0.4852 -0.5995 -0.0349 -0.0399 -0.0049 -0.7775 -1.9001 -0.0139 -0.8097 -0.5305 -1.9618 -1.4616 -0.6296 -2.9204 -0.0814
S-413	BACKGROUND: The nitroxyl (HNO) donor, Angeli's salt, exerts positive inotropic, lusitropic, and vasodilator effects in vivo that are cAMP independent.<unk>
T-413	nitroxyl hno inotropic lusitropic vasodilator in_vivo camp
H-413	-0.3173754811286926	▁ni tro x yl ▁h no ▁Angeli s ▁salt ▁in o tropi c ▁ lusi tropi c ▁vaso dila tor ▁c AMP
D-413	-0.3173754811286926	nitroxyl hno Angelis salt inotropic lusitropic vasodilator cAMP
P-413	-0.0633 -0.0436 -0.0258 -0.1800 -0.3154 -0.4221 -0.5031 -1.7267 -0.0048 -0.3597 -0.3796 -0.0117 -0.1116 -0.2091 -0.0106 -0.1218 -0.1046 -0.0195 -0.0347 -0.0658 -2.3160 -0.0122 -0.4674 -0.1080
S-897	RESULTS: The mean ejection fraction (EF) pre-PD was 24.5 ± 6.0% with the majority of patients having NYHA class IIIB symptoms and moderate-severe right ventricular dysfunction.<unk>
T-897	ejection_fraction ef patients nyha_class_iiib symptoms right_ventricular_dysfunction
H-897	-1.0617263317108154	▁e je ction _ fraction _ f ▁pre - PD ▁NY HA ▁class _ ▁III b ▁vent ri cular _ ▁dys function
D-897	-1.0617263317108154	ejection_fraction_f pre-PD NYHA class_ IIIb ventricular_ dysfunction
P-897	-0.8218 -0.8245 -0.0157 -1.1637 -0.0070 -4.0287 -2.6793 -0.9906 -0.0059 -0.1200 -2.2039 -0.2146 -3.1259 -0.4110 -1.1423 -1.0451 -3.7654 -0.1223 -0.4450 -0.7806 -0.6866 -0.4971 -0.2780 -0.1064
S-124	CPCs were measured as early-outgrowth colony-forming units (EO-CFUs) and circulating CD34+, VEGFR2+ and/or CD133+ cells.<unk>
T-124	cpcs early-outgrowth_colony-forming_units eo-cfus cells
H-124	-0.738821268081665	▁c PC s ▁early - out g row th ▁colon y - form ing ▁unit s EO - c FU s ▁circula ting ▁CD 34 ▁v EG FR 2 ▁CD 133
D-124	-0.738821268081665	cPCs early-outgrowth colony-forming unitsEO-cFUs circulating CD34 vEGFR2 CD133
P-124	-0.5052 -0.3090 -0.6628 -2.6446 -0.0428 -0.6846 -0.5903 -0.0417 -0.0351 -1.3614 -0.0457 -0.1554 -0.0210 -0.1643 -3.1506 -0.1183 -1.6585 -0.0338 -0.5684 -0.4721 -0.1955 -0.1282 -1.9401 -0.0988 -1.5873 -0.8831 -0.0856 -0.7369 -2.7003 -0.2904 -0.0912 -2.2227 -0.1554
S-309	We reviewed the evidence on clinical effects and cost-effectiveness of 2 types of continuous-flow LVADs (HeartMate II [HM II] and HeartWare), for BTT and DT patients.<unk>
T-309	evidence clinical continuous-flow_lvads heartmate_ii hm_ii heartware btt dt patients
H-309	-1.0712965726852417	▁clinic al _ effect ive ness ▁continuo us - flow _ la VAD s ▁he art Mate _ ▁II ▁Heart War e ▁b TT ▁ DT
D-309	-1.0712965726852417	clinical_effectiveness continuous-flow_laVADs heartMate_ II HeartWare bTT DT
P-309	-4.1034 -0.0281 -2.9726 -0.9030 -0.0311 -2.9812 -0.9325 -0.0716 -0.1527 -0.0468 -1.2938 -3.6999 -0.4763 -0.9817 -2.6860 -0.0935 -0.2702 -3.5064 -0.2543 -1.3358 -0.6656 -0.0139 -0.3462 -0.9132 -0.9907 -0.0249 -0.1681 -0.0528
S-1643	BACKGROUND: Even on optimal therapy including anticoagulation and rate control, major cardiovascular complications (stroke, cardiovascular death, and acute heart failure) are common in patients with atrial fibrillation (AF).<unk>
T-1643	therapy anticoagulation rate_control cardiovascular complications stroke cardiovascular_death acute_heart_failure patients atrial_fibrillation
H-1643	-0.8105236291885376	▁antico ag ulation ▁rate _ control ▁cardiovascular ▁complica tions stro ke ▁cardiovascular ▁death ▁a cute _ ▁heart _ ▁failure ▁at rial _ ▁fi bril lation AF
D-1643	-0.8105236291885376	anticoagulation rate_control cardiovascular complicationsstroke cardiovascular death acute_ heart_ failure atrial_ fibrillationAF
P-1643	-4.3832 -0.6606 -0.0131 -2.1217 -0.8461 -0.0443 -0.8663 -0.5915 -0.0405 -4.5388 -0.0409 -0.2684 -1.3688 -0.0464 -0.0031 -0.1636 -1.4128 -0.7579 -0.9981 -0.3711 -0.1196 -0.2929 -2.1180 -0.0095 -0.0261 -0.3961 -0.1509 -0.0444
S-753	METHODS AND RESULTS: The results of patients with baseline EF >30% (n=177) and those with EF ≤30% (n=431), as determined by a blinded core laboratory, were compared.<unk>
T-753	patients baseline ef ef core
H-753	-1.506809949874878	▁base line ▁EF
D-753	-1.506809949874878	baseline EF
P-753	-4.2518 -0.1697 -0.1667 -2.8881 -0.0577
S-197	CONCLUSIONS: In a large registry, we found that despite sex/EF differences in BNP values, there was no significant difference in the ability of BNP to predict inhospital mortality among these subgroups.<unk>
T-197	ef bnp bnp inhospital mortality
H-197	-1.4335452318191528	▁b p ▁in hospital ▁mortal ity
D-197	-1.4335452318191528	bp inhospital mortality
P-197	-1.4066 -1.6826 -3.5980 -0.6048 -3.8914 -0.0887 -0.1312 -0.0649
S-693	CONCLUSIONS: Higher DASH diet scores were associated with modestly lower mortality in women with HF, and there was a nonsignificant trend toward an inverse association with Mediterranean diet scores.<unk>
T-693	dash mortality hf nonsignificant
H-693	-0.9265567064285278	▁DAS h ▁mortal ity ▁ HF
D-693	-0.9265567064285278	DASh mortality HF
P-693	-0.1499 -0.6381 -3.5219 -0.1374 -0.6999 -0.0182 -2.1632 -0.0839
S-1499	Skeletal muscle mass assessed by relative appendicular lean mass index was significantly reduced compared with age-matched and sex-matched reference values (Z-score -1.46±0.22, p<0.0001).<unk>
T-1499	skeletal_muscle lean_mass z-score
H-1499	-1.6714799404144287	▁s kelet al _ s kelet al _ tension ▁figure
D-1499	-1.6714799404144287	skeletal_skeletal_tension figure
P-1499	-2.8770 -0.0051 -0.1209 -1.1746 -5.9680 -0.1227 -0.1539 -0.5205 -4.1797 -3.6070 -1.1742 -0.1542
S-706	CONCLUSIONS: ST2 was modestly associated with functional capacity and was significantly associated with outcomes in a well-treated cohort of ambulatory patients with HF although it did not significantly affect reclassification of risk.<unk>
T-706	st2 functional_capacity outcomes ambulatory patients hf
H-706	-1.0960617065429688	▁ST 2 ▁functional _ ▁capacity ▁well - tre ated ▁ambula tory ▁patients ▁ HF
D-706	-1.0960617065429688	ST2 functional_ capacity well-treated ambulatory patients HF
P-706	-4.3296 -0.7301 -0.6469 -2.7747 -2.0956 -2.2182 -0.0148 -0.0061 -0.4475 -1.0765 -0.6500 -1.2506 -0.5252 -0.0053 -0.6250 -0.1408
S-561	Quality of life was worse, but all-cause mortality was lowest in the youngest age group (3-year mortality rates across the respective age categories: 12%, 13%, 13%, 19%, and 31%, respectively).<unk>
T-561	quality_of_life all-cause_mortality mortality
H-561	-1.2629549503326416	▁Quality _ of _ ▁life ▁all - ca use ▁mortal ity
D-561	-1.2629549503326416	Quality_of_ life all-cause mortality
P-561	-0.9765 -0.3515 -1.5698 -0.1811 -2.2522 -5.2371 -0.0233 -0.0048 -0.0193 -2.4533 -0.2311 -2.9817 -0.1370
S-1046	Gene expression profiling of cultured cardiomyocytes in the presence or absence of JQ1 showed that the drug abrogated the induction of a substantial subset of phenylephrine-induced genes.<unk>
T-1046	gene_expression cardiomyocytes jq1 drug genes
H-1046	-0.9025010466575623	▁implant ing ▁culture d _ ▁cardio my o cy tes ▁j q 1 ▁drug ▁ phen yle ph rine - indu ced ▁gene s
D-1046	-0.9025010466575623	implanting cultured_ cardiomyocytes jq1 drug phenylephrine-induced genes
P-1046	-4.2852 -1.1270 -0.8010 -0.2968 -0.5387 -1.5710 -2.0345 -0.9985 -0.3658 -0.2010 -1.0608 -0.5388 -1.1911 -0.2026 -0.5306 -0.1601 -1.4581 -2.1412 -0.2055 -0.6772 -0.0002 -2.4475 -0.3299 -0.0143 -0.2065 -0.0811
S-1801	A CLCNKA polymorphism (rs10927887; p.Arg83Gly) previously linked to heart failure is associated with the estimated glomerular filtration rate in the RENASTUR cohort.<unk>
T-1801	clcnka polymorphism rs10927887 p.arg83gly heart_failure estimated_glomerular_filtration_rate renastur
H-1801	-0.7582151889801025	▁CL CN KA ▁poly morph ism ▁heart _ ▁failure ▁glo mer ular _ ▁filtr ation _ ▁rate ▁RE NAS TUR
D-1801	-0.7582151889801025	CLCNKA polymorphism heart_ failure glomerular_ filtration_ rate RENASTUR
P-1801	-0.0883 -2.3109 -0.8713 -0.0779 -0.0136 -0.4779 -1.7592 -1.5776 -3.3796 -0.0591 -0.0262 -0.0795 -1.6733 -0.2782 -0.0235 -1.8473 -0.6972 -0.3455 -0.0053 -0.5101 -0.4536 -0.1256
S-285	BACKGROUND: Among the various cardiovascular diseases, heart failure (HF) is projected to have the largest increases in incidence over the coming decades; therefore, improving HF prediction is of significant value.<unk>
T-285	cardiovascular_diseases heart_failure hf incidence hf
H-285	-0.8518223762512207	▁cardiovascular ▁disease s ▁heart _ ▁failure ▁ HF
D-285	-0.8518223762512207	cardiovascular diseases heart_ failure HF
P-285	-0.1299 -3.6992 -0.0293 -0.4093 -0.4768 -2.0701 -1.0590 -0.0132 -0.5748 -0.0566
S-455	Importantly, 2 weeks after B treatment was started, increased cardiac VEGF expression and Akt and endothelial NO synthase activation were observed by comparing B-treated with drug-untreated failing hearts.<unk>
T-455	cardiac_vegf_expression endothelial_no_synthase_activation hearts
H-455	-0.583785355091095	▁cardiac _ ve GF ▁expression ▁Akt ▁en dot heli al _ no ▁synth ase _ activa tion ▁drug - un tre ated ▁fail ing ▁heart s
D-455	-0.583785355091095	cardiac_veGF expression Akt endothelial_no synthase_activation drug-untreated failing hearts
P-455	-0.5104 -1.8090 -1.2174 -0.2496 -1.1037 -0.0228 -0.0222 -0.5612 -0.0072 -0.0065 -0.7024 -1.3813 -0.5080 -1.9222 -0.5735 -0.4140 -0.0104 -1.0713 -0.1114 -0.0504 -0.0006 -1.2772 -0.5498 -0.1327 -1.7639 -0.0810 -0.2158 -0.0701
S-1924	Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients: Insights From Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION).<unk>
T-1924	psychosocial exercise outcomes heart_failure patients heart_failure outcomes exercise training hf-action
H-1924	-0.9824661612510681	▁Psycho social ▁Factor s ▁Heart _ ▁Fail ure ▁Heart _ ▁Fail ure ▁ HF - AC TION
D-1924	-0.9824661612510681	Psychosocial Factors Heart_ Failure Heart_ Failure HF-ACTION
P-1924	-1.0901 -0.0012 -1.6573 -0.0379 -3.1576 -0.9114 -0.2842 -0.0901 -3.3192 -0.3707 -0.1962 -0.1545 -2.9852 -1.9055 -0.1976 -0.8163 -1.0919 -0.2917 -0.1084
S-402	METHODS AND RESULTS: A total of 151 subjects with heart failure attributable to left ventricular systolic dysfunction were examined in this post hoc analysis; >96% were taking BB at enrollment.<unk>
T-402	heart_failure left_ventricular_systolic_dysfunction post_hoc_analysis
H-402	-1.2411497831344604	▁heart _ ▁failure ▁left ▁vent ri cular _ syn sto lic _ ▁dys function ▁BB
D-402	-1.2411497831344604	heart_ failure left ventricular_synstolic_ dysfunction BB
P-402	-1.7436 -1.4958 -2.9500 -0.6468 -1.0950 -0.4131 -0.3515 -0.2814 -1.2961 -2.1152 -4.8709 -0.5287 -0.2236 -0.7412 -2.0377 -0.2473 -0.0617
S-1186	A derivation cohort was formed of consecutive patients who had undergone coronary angiography with a primary diagnosis of systolic HF of unclear etiology (ejection fraction <50%).<unk>
T-1186	patients coronary_angiography diagnosis systolic_hf etiology ejection_fraction
H-1186	-0.7046225666999817	▁deriva tion _ co hor t ▁corona ry _ ▁ang i ography ▁sy sto lic ▁ HF ▁un clear ▁et i ology
D-1186	-0.7046225666999817	derivation_cohort coronary_ angiography systolic HF unclear etiology
P-1186	-1.7365 -0.0073 -1.8935 -0.9423 -0.0404 -0.0515 -1.3514 -0.8305 -0.6632 -1.6934 -0.9955 -0.2229 -0.7234 -0.1200 -1.8424 -0.8446 -0.0062 -0.7374 -0.0017 -0.2187 -0.4236 -1.0011 -0.4703 -0.0936
S-1784	Marked cardiac insulin-resistance by 2 weeks post-AAC was evidenced by a significant decrease in insulin-stimulated rates of glycolysis and glucose oxidation, and plasma membrane translocation of glucose transporter 4.<unk>
T-1784	cardiac insulin-resistance glycolysis glucose_oxidation plasma_membrane_translocation glucose
H-1784	-0.292677104473114	▁cardiac _ ▁insulin - re si stance ▁a ac ▁insulin - stimul ated ▁rates ▁gly col ysis ▁gluco se ▁oxid ation ▁plasma ▁membran e ▁trans location ▁gluco se ▁transporter
D-1784	-0.292677104473114	cardiac_ insulin-resistance aac insulin-stimulated rates glycolysis glucose oxidation plasma membrane translocation glucose transporter
P-1784	-0.1067 -1.2151 -0.3740 -0.0521 -0.0492 -0.0472 -0.0000 -0.7960 -1.0201 -0.2819 -0.0501 -0.0169 -0.4527 -0.0979 -0.0572 -0.2547 -0.0616 -0.1111 -0.0575 -0.6083 -0.0064 -0.0223 -0.2673 -0.0551 -0.6791 -0.1635 -0.7101 -0.0212 -1.2221 -0.1493 -0.0661
S-1083	Cells were exposed to angiotensin II (AngII) and hypoxia, known activators of abnormal SCN5A mRNA splicing, or were induced to overexpress SCN5A variants.<unk>
T-1083	cells angiotensin_ii angii hypoxia scn5a mrna_splicing scn5a
H-1083	-0.6450002789497375	▁ang io ten sin ▁II ▁ang II ▁hypo xia ▁activa teurs ▁s CN 5 a ▁m RNA ▁s plic ing
D-1083	-0.6450002789497375	angiotensin II angII hypoxia activateurs sCN5a mRNA splicing
P-1083	-0.0163 -1.2869 -0.1678 -0.5260 -1.0183 -0.4445 -0.5504 -0.0557 -0.0123 -1.7879 -1.3033 -2.3064 -0.5970 -0.9801 -0.4219 -0.0025 -0.0144 -0.4756 -0.2645 -0.0518 -1.7917 -0.1147
S-824	On the basis of the assumption that exercise-induced PASP is a measure of right ventricular contractile reserve, patients were classified into 2 groups according to an exercise-induced PASP increase above or below the median.<unk>
T-824	exercise-induced_pasp right_ventricular_contractile_reserve patients exercise-induced_pasp
H-824	-0.7015862464904785	▁vent ri cular _ contract ile _ ▁reserve
D-824	-0.7015862464904785	ventricular_contractile_ reserve
P-824	-1.8591 -0.2029 -0.5334 -0.4026 -0.6454 -0.6233 -0.2603 -0.4319 -1.9792 -0.0777
S-922	Effective arterial elastance (Ea) end-systolic elastance (Ees) and ventricular-arterial coupling (defined as the ratio Ees:Ea) were determined using previously published techniques.<unk>
T-922	arterial_elastance ea end-systolic_elastance ees ventricular-arterial_coupling ees ea
H-922	-0.5617181062698364	▁arterial _ ▁elastan ce ▁end - sy sto lic ▁elastan ce ▁vent ri cular - arte rial ▁coup ling ▁ratio ▁e es
D-922	-0.5617181062698364	arterial_ elastance end-systolic elastance ventricular-arterial coupling ratio ees
P-922	-0.5239 -1.6547 -2.3686 -0.1980 -0.3427 -0.0344 -0.7687 -0.0671 -1.9779 -0.6606 -0.1925 -0.0882 -0.0264 -0.0805 -0.3459 -0.0846 -0.0728 -0.2977 -1.2022 -0.3504 -1.0606 -0.0263 -0.9157 -0.1408
S-920	We measured baseline and post-DASH/SRD brachial and central blood pressure (via radial arterial tonometry) and cardiovascular function with echocardiographic measures (all previously invasively validated).<unk>
T-920	baseline central_blood_pressure radial_arterial_tonometry cardiovascular_function echocardiographic invasively
H-920	-0.9835027456283569	DAS h _ s RD ▁bra chi al _ central _ ▁blood _ tension ▁radi al _ ▁arterial _ ▁ton ometr y ▁cardiovascular ▁e cho car dio graphic
D-920	-0.9835027456283569	DASh_sRD brachial_central_ blood_tension radial_ arterial_ tonometry cardiovascular echocardiographic
P-920	-0.9400 -0.6871 -3.3364 -1.1674 -0.1035 -4.3235 -0.0281 -0.0140 -2.1172 -1.5457 -0.3061 -0.8312 -1.0144 -1.5175 -0.0104 -0.0128 -0.8468 -1.2088 -0.2583 -2.9189 -0.1561 -0.0955 -0.1738 -3.7973 -0.0354 -0.0256 -0.3397 -0.7403 -0.8720 -0.0813
S-1609	MATERIALS AND METHODS: Gene expression profile GSE9128 was downloaded from Gene Expression Omnibus, including 3 normal samples, 4 non-ischemic heart failure samples and 4 ischemic samples.<unk>
T-1609	gene_expression_profile gse9128 gene_expression_omnibus non-ischemic_heart_failure ischemic
H-1609	-1.1155116558074951	▁Gene _ expression _ profil ▁g se 91 28 ▁Gene _ ▁Express ion _ ▁Omni bus ▁ ische mic ▁heart _ ▁failure
D-1609	-1.1155116558074951	Gene_expression_profil gse9128 Gene_ Expression_ Omnibus ischemic heart_ failure
P-1609	-0.5399 -2.3420 -0.7776 -1.4352 -4.0768 -3.1165 -0.1558 -2.3281 -0.3157 -0.2898 -0.8988 -0.4016 -0.0148 -0.2408 -0.0060 -0.0043 -4.4318 -1.3949 -0.2187 -1.3834 -0.5326 -1.0435 -0.7325 -0.0913
S-1653	Early rhythm control therapy will consist of usual care plus rhythm control therapy by antiarrhythmic drugs, catheter ablation, and a patient-operated electrocardiographic device to monitor the ongoing rhythm.<unk>
T-1653	rhythm_control_therapy rhythm_control_therapy antiarrhythmic_drugs catheter_ablation electrocardiographic rhythm
H-1653	-0.326494961977005	▁ rhythm _ control ▁ therapy ▁anti ar rhythm ic ▁drugs ▁cat heter ▁ab lation ▁electro car dio graphic ▁device ▁ rhythm
D-1653	-0.326494961977005	rhythm_control therapy antiarrhythmic drugs catheter ablation electrocardiographic device rhythm
P-1653	-0.2265 -0.1884 -1.2947 -0.0292 -0.6819 -0.0300 -0.1422 -0.7501 -0.1545 -0.4545 -0.1356 -0.1062 -0.0007 -0.6543 -0.0021 -0.0084 -0.0083 -0.1145 -0.4619 -0.7314 -0.7566 -0.2859 -0.4470 -0.1715
S-1240	However, these differences were offset by higher expenditures due to hospitalizations for noncardiovascular diagnoses, implantable cardiac arrhythmia devices, and noncardiovascular drugs in the rate-control group.<unk>
T-1240	expenditures hospitalizations noncardiovascular diagnoses implantable_cardiac_arrhythmia_devices noncardiovascular drugs rate-control
H-1240	-0.7651359438896179	▁hospital isation s ▁implant able ▁cardiac _ ar rhythm ia ▁devices ▁non car dio vas cular ▁drugs
D-1240	-0.7651359438896179	hospitalisations implantable cardiac_arrhythmia devices noncardiovascular drugs
P-1240	-3.8871 -0.5814 -0.1235 -0.1266 -0.0606 -0.0716 -1.4144 -1.1651 -0.0610 -0.3339 -1.1216 -0.9322 -0.0079 -0.2141 -0.2774 -1.1721 -1.5926 -1.3335 -0.0611
S-1488	Although there is good evidence for the treatment of HF with reduced ejection fraction (HFrEF), the treatment for HF with preserved ejection fraction (HFpEF) is not well defined.<unk>
T-1488	evidence hf_with_reduced_ejection_fraction hfref hf_with_preserved_ejection_fraction hfpef
H-1488	-1.4850338697433472	▁ HF ▁ HF ▁ HF ▁ HF _ de _ ré que nce _ fraction ▁h r EF
D-1488	-1.4850338697433472	HF HF HF HF_de_réquence_fraction hrEF
P-1488	-0.6695 -0.0448 -3.0890 -0.1063 -3.7496 -0.2716 -4.0715 -0.6250 -4.4326 -2.6833 -0.5335 -3.3267 -0.8618 -0.5274 -0.2681 -0.2963 -1.4933 -0.2807 -0.5589 -3.2110 -0.0850
S-1298	CONCLUSION: Extracorporeal life support is feasible und effective for bridging therapy in patients with acute ischemic right heart failure with refractory cardiogenic shock and successful reperfusion therapy.<unk>
T-1298	extracorporeal_life_support therapy patients acute_ischemic_right_heart_failure refractory_cardiogenic_shock reperfusion therapy
H-1298	-0.790608286857605	▁extra corp o real _ ▁life _ support ▁ brid ging ▁ therapy ▁a cute ▁ ische mic _ ▁right ▁heart _ ▁failure ▁re frac tory _ ▁cardio ge nic _ ▁shock ▁reper fusion ▁ therapy
D-1298	-0.790608286857605	extracorporeal_ life_support bridging therapy acute ischemic_ right heart_ failure refractory_ cardiogenic_ shock reperfusion therapy
P-1298	-2.1807 -0.0071 -0.1460 -0.0099 -1.2156 -0.7199 -1.1855 -0.9562 -0.4519 -0.1239 -0.1536 -1.5794 -0.0230 -1.1981 -0.0210 -2.7986 -1.0642 -0.2550 -0.5785 -3.5580 -2.5008 -0.6754 -0.4395 -0.0122 -0.0131 -1.7701 -0.6552 -0.3048 -0.3373 -2.9223 -0.9025 -0.2325 -0.0316 -0.0045 -0.7040 -0.0098 -0.1787 -0.1228
S-1332	CONCLUSION: As in heart failure and reduced left ventricular ejection fraction, FES also improves exercise capacity, quality of life, emotional status, and endothelial function in HFpEF.<unk>
T-1332	heart_failure reduced_left_ventricular_ejection_fraction fes exercise_capacity quality_of_life endothelial_function hfpef
H-1332	-0.8489843606948853	▁heart _ ▁failure ▁left ▁vent ri cular _ ▁e je ction _ fraction ▁F es ▁exercise _ capaci tion ▁emotional ▁status ▁en dot heli al _ ▁function ▁ HF p EF
D-1332	-0.8489843606948853	heart_ failure left ventricular_ ejection_fraction Fes exercise_capacition emotional status endothelial_ function HFpEF
P-1332	-0.1094 -1.0748 -1.4804 -0.7469 -0.4298 -0.2069 -0.8913 -0.7151 -1.4059 -0.8008 -0.1031 -1.0060 -0.0182 -1.7892 -0.2134 -1.1026 -0.9101 -1.5623 -4.0120 -2.4143 -0.9772 -0.3759 -0.9700 -0.0596 -0.0090 -0.9830 -2.1778 -0.8755 -0.0878 -0.0427 -0.3334 -0.0638 -0.0685
S-220	Intubation rates declined from 3.6% in 1996 to 1.7% in 2008, a 53% (95% CI: 31%-68%, P < .001, R(2) = 0.83, P < .001) relative decrease.<unk>
T-220	intubation
H-220	-0.4832340478897095	▁in tub ation
D-220	-0.4832340478897095	intubation
P-220	-0.0580 -0.0096 -0.0242 -2.2539 -0.0704
S-1814	We found that the hearts of TTA/TgTetMena mice were functionally and morphologically comparable to wild-type littermates, except for mildly increased heart mass in the transgenic mice.<unk>
T-1814	hearts heart_mass transgenic
H-1814	-0.9593546986579895	▁heart s ▁ TTA ▁t g t et Men a ▁mi ce ▁wild - type _ ▁litt er mates ▁heart _ ▁mass ▁trans ge nic ▁mi ce
D-1814	-0.9593546986579895	hearts TTA tgtetMena mice wild-type_ littermates heart_ mass transgenic mice
P-1814	-0.9005 -0.1831 -2.7531 -0.1239 -3.1587 -1.0438 -0.3854 -0.6868 -0.2852 -0.1891 -3.4774 -0.2019 -0.9200 -0.0220 -0.0353 -2.2043 -0.1685 -0.0159 -0.7651 -1.2731 -1.7017 -2.0178 -0.0073 -0.1402 -3.4315 -1.3799 -0.1221 -0.1601 -0.0679
S-1541	By comparison, raloxifene, which is used for the same indication but has a different mechanism of action, was not associated with an increased risk of heart failure: adjusted HR 1.07 (95% CI 0.76-1.50).<unk>
T-1541	raloxifene heart_failure
H-1541	-0.8944234251976013	▁ra lo xi fen e
D-1541	-0.8944234251976013	raloxifene
P-1541	-0.5660 -0.0505 -0.0888 -1.0750 -0.2824 -4.1003 -0.0980
S-1938	METHODS AND RESULTS: Fifty consecutive patients with recent onset HFrEF (<30 days) performed a standardized exercise protocol with respiratory gas analysis at baseline as well as after 6 and 12 months.<unk>
T-1938	patients hfref exercise respiratory_gas_analysis baseline
H-1938	-1.1726477146148682	▁h Fr f ▁respirator y _ gas
D-1938	-1.1726477146148682	hFrf respiratory_gas
P-1938	-0.8811 -2.7306 -1.1628 -3.0943 -0.0409 -0.8354 -0.7739 -0.9760 -0.0588
S-1126	RESULTS: Among 295 patients not receiving guideline-recommended drugs for heart failure, chart review identified biomedical reasons for nonprescribing in 42%-58% of patients and contextual reasons in 11%-17%.<unk>
T-1126	patients drugs heart_failure biomedical nonprescribing patients
H-1126	-0.481123685836792	▁guide line - re com mend ed ▁drugs ▁heart _ ▁failure ▁bio medic al ▁reasons
D-1126	-0.481123685836792	guideline-recommended drugs heart_ failure biomedical reasons
P-1126	-2.0562 -0.0148 -0.4026 -0.0127 -0.0127 -0.0026 -0.1729 -0.0562 -2.1583 -0.7241 -1.2321 -0.0282 -0.0096 -0.0056 -0.2252 -0.9849 -0.0803
S-1641	CONCLUSIONS: Black race in patients with chronic HF was associated with increased prevalence of modifiable risk factors, lower exercise performance, and increased HF hospitalization, but not increased mortality or a differential response to exercise training.<unk>
T-1641	patients chronic_hf prevalence exercise hf hospitalization mortality exercise training
H-1641	-1.450515627861023	▁black ▁race ▁ HF
D-1641	-1.450515627861023	black race HF
P-1641	-0.5568 -0.6682 -1.7682 -0.2118 -5.3676 -0.1305
S-1169	Wasting of fat but not of lean mass was predictive of adverse outcome, suggesting that fat loss is either a surrogate of enhanced catabolism or adipose tissue is cardioprotective in the context of HF.<unk>
T-1169	lean_mass adverse_outcome adipose_tissue cardioprotective hf
H-1169	-0.7301904559135437	▁Was ting _ de _ ▁fat ▁lean _ ▁mass ▁fat _ ▁loss ▁enhance d ▁cata bol ism ▁adi pose _ ▁tissu e ▁cardio protec tive ▁ HF
D-1169	-0.7301904559135437	Wasting_de_ fat lean_ mass fat_ loss enhanced catabolism adipose_ tissue cardioprotective HF
P-1169	-4.9046 -0.1062 -1.2035 -1.4166 -0.1562 -0.4757 -0.2654 -2.0239 -0.2937 -1.3738 -2.5268 -1.6429 -1.2879 -0.1460 -0.6548 -0.0476 -0.3701 -0.0066 -0.0202 -0.2152 -0.6280 -0.4154 -0.0137 -0.0073 -0.0085 -0.8133 -0.0082 -0.0736 -0.0700
S-546	Of these LVADs, 225 were CF devices (203 HeartMate II devices, Thoratec Corp, Pleasanton, Calif; and 22 HVAD devices, HeartWare Intl, Inc, Framingham, Mass).<unk>
T-546	lvads heartmate_ii thoratec_corp pleasanton calif hvad heartware framingham
H-546	-1.3455735445022583	▁l VAD s ▁implant s ▁h VAD ▁h VAD ▁in t l ▁Fram ing ham ▁Mass
D-546	-1.3455735445022583	lVADs implants hVAD hVAD intl Framingham Mass
P-546	-2.5951 -0.0340 -0.4324 -5.9236 -0.3174 -2.8439 -1.4011 -2.1032 -1.8183 -4.2845 -0.0118 -0.0046 -0.2414 -0.0236 -0.0084 -1.5508 -0.5477 -0.0785
S-97	However, hearts of fish lacking Nucleolin displayed severe developmental impairment, abnormal chamber patterning and functional deficits, ostensibly due to defects in cardiac looping and myocyte differentiation.<unk>
T-97	hearts nucleolin chamber_patterning cardiac_looping myocyte_differentiation
H-97	-0.8285750150680542	▁heart s _ de _ ▁fish _ ▁la cking ▁Nu cle olin ▁cha mber _ ▁pattern ing _ des _ fon cti onnement s ▁defect s ▁cardiac _ ▁loop ing ▁my o cy te
D-97	-0.8285750150680542	hearts_de_ fish_ lacking Nucleolin chamber_ patterning_des_fonctionnements defects cardiac_ looping myocyte
P-97	-0.1558 -0.0256 -0.9607 -2.8355 -0.1457 -1.5336 -1.1681 -0.8234 -0.0640 -1.1823 -0.0055 -0.2343 -3.7151 -0.0234 -0.5832 -0.6181 -0.9366 -2.6704 -3.9715 -0.2239 -0.9144 -0.5245 -0.0814 -0.1180 -2.5122 -0.0256 -0.0386 -0.7834 -1.0726 -0.1583 -0.8666 -0.0555 -0.0944 -0.0572 -0.5962 -0.0533
S-1520	CONCLUSIONS: In plasma collected from HF patients, immunoreactive NT-proBNP was present as multiple N- and C-terminally truncated fragments of the full length NT-proBNP molecule.<unk>
T-1520	plasma collected hf patients immunoreactive nt-probnp c-terminally nt-probnp
H-1520	-0.8331999778747559	▁ HF ▁immun ore active ▁NT - pro B NP
D-1520	-0.8331999778747559	HF immunoreactive NT-proBNP
P-1520	-1.9073 -0.0391 -0.3224 -2.7319 -0.0470 -0.0517 -0.0609 -0.0368 -1.0570 -0.0823 -3.5654 -0.0965
S-19	CONCLUSIONS: FM was associated with plasma NPs and total adiponectin at baseline; whereas changes in FM and FFM did not correlate to changes in NPs or adiponectin during follow up.<unk>
T-19	plasma_nps adiponectin baseline ffm correlate nps adiponectin follow_up
H-19	-0.7830258011817932	▁FM ▁plasma ▁ NP s ▁adi pon ect in ▁F FM ▁ NP s ▁adi pon ect in
D-19	-0.7830258011817932	FM plasma NPs adiponectin FFM NPs adiponectin
P-19	-0.9926 -1.1596 -0.1807 -0.0087 -0.0240 -1.3242 -0.0832 -0.0446 -2.0626 -4.1148 -0.8997 -1.2453 -0.1484 -0.0260 -0.7076 -0.1112 -0.0458 -1.7457 -0.6334 -0.1023
S-935	Macrophages, but not cardiomyocytes, from Hum-Retn mice treated with doxorubicin in vitro showed dramatic induction of hRetn (human resistin) mRNA and protein expression.<unk>
T-935	macrophages cardiomyocytes doxorubicin in_vitro resistin mrna protein_expression
H-935	-0.5196253657341003	▁cardio my o cy tes ▁Hum - re t n ▁do xor ubi cin ▁h re t n ▁h re t n ▁m RNA ▁protein ▁expression
D-935	-0.5196253657341003	cardiomyocytes Hum-retn doxorubicin hretn hretn mRNA protein expression
P-935	-1.3269 -0.7128 -0.2747 -0.0479 -0.0305 -0.1040 -0.0617 -0.5382 -0.4809 -0.0657 -2.7464 -0.3285 -0.0890 -0.0354 -0.0108 -1.2477 -0.0536 -0.0315 -1.7851 -1.7874 -0.8044 -0.0915 -0.4803 -0.0035 -0.8887 -0.2479 -0.2182 -0.0563
S-1438	The beat-to-beat QT interval was measured on 3-min records of surface ECGs at baseline and during interventions (atrial pacing and esmolol, isoprenaline, and atropine infusion).<unk>
T-1438	qt_interval ecgs baseline atrial_pacing esmolol isoprenaline atropine infusion
H-1438	-0.4172341525554657	▁beat - to - beat ▁ QT ▁figure ▁surface ▁E CG s ▁at rial ▁pa cing ▁es mol ol ▁iso pren a line ▁a tropi ne ▁in fusion
D-1438	-0.4172341525554657	beat-to-beat QT figure surface ECGs atrial pacing esmolol isoprenaline atropine infusion
P-1438	-0.5244 -0.0359 -0.2081 -0.0263 -0.0327 -0.1903 -0.0332 -4.7565 -0.2146 -0.6695 -0.0442 -0.3167 -1.8213 -0.1647 -0.8251 -0.8877 -0.1858 -0.0642 -0.0889 -0.0429 -0.0077 -0.2211 -0.0293 -0.0477 -0.0382 -0.3697 -0.0420 -0.0227 -0.4973 -0.1081
S-1378	To assess whether this was due to a withdrawal of sympathetic tone or an increase in parasympathetic tone, the heart rate response was measured after an intravenous bolus of metoprolol or atropine.<unk>
T-1378	sympathetic_tone parasympathetic_tone heart_rate intravenous_bolus metoprolol atropine
H-1378	-0.8282700777053833	▁withdraw al _ de _ ▁sympa the tic ▁tone ▁para sy mpa the tic _ ▁tone ▁heart _ ▁rate ▁met o pro lol ▁a tropi ne
D-1378	-0.8282700777053833	withdrawal_de_ sympathetic tone parasympathetic_ tone heart_ rate metoprolol atropine
P-1378	-1.6168 -0.0732 -1.0206 -2.8663 -0.1463 -1.6923 -0.5649 -1.8275 -0.4544 -0.1021 -0.1245 -0.1517 -1.3856 -1.8194 -1.1114 -0.1196 -0.0570 -1.3661 -0.7521 -5.1106 -0.2000 -0.0814 -0.1232 -0.0888 -0.0217 -0.0950 -0.1505 -0.0686
S-1533	In conclusion, the presence of EH denotes a distinct subset of HFpEF that is pathophysiologically similar to HF with reduced EF (HFrEF) and may benefit from HFrEF therapy.<unk>
T-1533	hfpef pathophysiologically hf_with_reduced_ef hfref hfref therapy
H-1533	-0.9502168893814087	▁EH ▁ HF p EF ▁h f f ▁h f f ▁h f f ▁h f f
D-1533	-0.9502168893814087	EH HFpEF hff hff hff hff
P-1533	-0.0015 -0.7777 -0.1589 -1.3332 -0.4859 -1.9871 -0.4821 -1.2702 -1.2252 -0.4686 -0.8689 -1.8362 -0.4845 -0.8365 -2.6366 -0.4404 -0.9912 -1.6682 -0.1012
S-4	The results show a significant decline in adverse event rates for acute myocardial infarction and congestive heart failure, translating to an estimated 81,000 in-hospital adverse events averted in 2010–2011.<unk>
T-4	adverse_event acute_myocardial_infarction congestive_heart_failure adverse_events
H-4	-0.8836119174957275	▁advers e ▁event _ ▁rates ▁a cute _ My o card ial _ ▁in far ction ▁con ges tive ▁heart _ ▁failure
D-4	-0.8836119174957275	adverse event_ rates acute_Myocardial_ infarction congestive heart_ failure
P-4	-2.0778 -0.0211 -1.0347 -2.2627 -3.0309 -0.0367 -0.0090 -0.2587 -4.1016 -0.4567 -0.1824 -0.0627 -1.1986 -0.1814 -1.3381 -0.0511 -0.1277 -0.1372 -0.0250 -2.0466 -0.7680 -0.3607 -1.3500 -0.0874
S-803	However, statistical improvement occurred in the total sample from the first to the second trial with large limits of agreement (mean difference, -.97s; 95% confidence interval, 3.00 to -4.94s; P<.01).<unk>
T-803	confidence_interval
H-803	-1.046770453453064	
D-803	-1.046770453453064	
P-803	-2.0490 -0.0445
S-721	OBJECTIVES: The study objectives were to quantify the change in 7-day follow-up visits and 30-day readmissions as part of a hospital quality improvement initiative and to characterize events at 7-day follow-up visits.<unk>
T-721	change follow-up readmissions hospital follow-up
H-721	-1.5377140045166016	▁hospital _ quality _ ▁improvement
D-721	-1.5377140045166016	hospital_quality_ improvement
P-721	-3.1364 -0.4437 -3.4975 -0.5150 -1.4581 -1.6126 -0.1007
S-1049	Detailed transcriptional analysis of cardiac tissue from mice that were either TAC- or sham-operated and treated with either JQ1 or vehicle revealed that BET inhibition suppresses a pathological cardiac gene expression programme.<unk>
T-1049	cardiac jq1 bet pathological cardiac gene_expression
H-1049	-1.0692952871322632	▁cardiac _ ▁tissu e ▁ TAC - ▁sham - opera ted ▁j q 1 ▁ BET _ ▁inhibi tion _ ▁sup press es ▁path ological _ ▁cardiac _ ▁gene ▁expression
D-1049	-1.0692952871322632	cardiac_ tissue TAC- sham-operated jq1 BET_ inhibition_ suppresses pathological_ cardiac_ gene expression
P-1049	-0.9981 -2.7942 -1.4818 -0.2416 -0.9038 -0.0288 -3.2189 -3.1637 -0.0218 -0.0010 -0.6034 -0.7674 -0.7141 -0.3822 -0.6319 -0.4751 -3.5473 -1.6257 -0.0351 -3.5518 -0.6885 -0.0516 -0.3627 -0.3474 -0.2296 -0.3123 -0.5830 -1.3543 -2.8771 -0.1388 -1.9423 -0.1423
S-1377	Power spectral analysis indicated an increase in low-frequency/high-frequency (LF/HF) ratio in the CHF-INV compared with the sham-INV, which was normalized to sham levels by DNx.<unk>
T-1377	power_spectral_analysis hf dnx
H-1377	-1.3549355268478394	▁Power _ ▁spec tral _ analyse ▁low - fre que ncy _ high - fre que ncy ▁h f ▁CHF - in v ▁sham - in v ▁sham - in v
D-1377	-1.3549355268478394	Power_ spectral_analyse low-frequency_high-frequency hf CHF-inv sham-inv sham-inv
P-1377	-0.9914 -2.7865 -3.0323 -0.0016 -4.7800 -1.8423 -3.2557 -0.0310 -0.0652 -0.0267 -0.0235 -1.3414 -1.8059 -0.1122 -0.0271 -0.0209 -0.0571 -4.0069 -0.0683 -1.6918 -0.0628 -0.8197 -1.1702 -0.0048 -0.3426 -0.9776 -1.2452 -0.4758 -4.0643 -3.4590 -2.6622 -3.1900 -0.2710
S-1511	BACKGROUND: The use of nonstandardized N-terminal pro-B-type natriuretic peptide (NT-proBNP) assays can contribute to the misdiagnosis of heart failure (HF).<unk>
T-1511	n-terminal_pro-b-type_natriuretic_peptide nt-probnp misdiagnosis heart_failure hf
H-1511	-0.9366652369499207	▁N - termin al ▁pro - B - type _ ▁na tri ure tic _ pe pti de NT - pro B NP ▁mis diagnos is _ de _ heart _ ▁failure HF
D-1511	-0.9366652369499207	N-terminal pro-B-type_ natriuretic_peptideNT-proBNP misdiagnosis_de_heart_ failureHF
P-1511	-5.0643 -0.0782 -0.0314 -0.0170 -1.5449 -0.0378 -0.2486 -0.2404 -0.0609 -1.1596 -0.6752 -0.0183 -0.3398 -5.2489 -1.3474 -0.4011 -0.2314 -0.2174 -1.1586 -0.0111 -0.0153 -0.5062 -0.0357 -0.0758 -0.0747 -0.0334 -2.4828 -1.8437 -0.9670 -1.5146 -0.7661 -4.2549 -1.8479 -0.1591 -0.0737
S-698	METHODS AND RESULTS: HF-ACTION randomized 2331 patients with left ventricular ejection fraction <0.35 and New York Heart Association class II to IV HF to either exercise training or usual care.<unk>
T-698	hf-action randomized patients left_ventricular_ejection_fraction new_york_heart_association_class_ii hf exercise training
H-698	-0.9130206108093262	▁ HF - ac tion ▁vent ri cular _ ▁e je ction ▁ fraction ▁New ▁York ▁Heart _ ▁Association ▁IV ▁ HF
D-698	-0.9130206108093262	HF-action ventricular_ ejection fraction New York Heart_ Association IV HF
P-698	-1.1495 -0.2000 -0.8874 -1.9720 -0.6425 -2.3649 -0.2530 -0.2999 -1.3554 -0.8671 -1.1776 -0.1390 -2.4507 -0.0022 -0.8409 -0.4637 -1.0362 -1.9712 -1.6128 -0.8498 -0.0855 -0.0163 -1.1568 -0.1180
S-762	The relative importance for myocardial DD of collagen deposition and titin modification was investigated in obese, diabetic ZSF1 rats after heart failure with preserved ejection fraction development at 20 weeks.<unk>
T-762	myocardial_dd collagen_deposition titin obese diabetic zsf1 heart_failure_with_preserved_ejection_fraction
H-762	-0.6771605014801025	▁my o card ial ▁ DD ▁collage n _ de position ▁titi n ▁modification ▁diabet ic ▁Z SF 1 ▁rat s ▁heart _ ▁failure
D-762	-0.6771605014801025	myocardial DD collagen_deposition titin modification diabetic ZSF1 rats heart_ failure
P-762	-1.4483 -0.0502 -0.0459 -0.0072 -1.9671 -0.0019 -0.2051 -0.1169 -1.4278 -0.0421 -0.1007 -0.4541 -0.0347 -2.2805 -0.2245 -0.2535 -0.8044 -0.0250 -0.3968 -0.4792 -0.1072 -0.8261 -0.7586 -4.2368 -1.2149 -0.0968
S-743	CONCLUSIONS: In the present preliminary study, cardiac magnetic resonance postcontrast T1 time is associated with prognosis in HFPEF, suggesting postcontrast T1 as possible biomarker for HFPEF.<unk>
T-743	cardiac_magnetic_resonance_postcontrast_t1_time prognosis hfpef postcontrast_t1 biomarker hfpef
H-743	-0.48712867498397827	▁cardiac _ ▁magnetic _ ▁res on ance ▁h FP EF ▁bio mark er ▁h FP EF
D-743	-0.48712867498397827	cardiac_ magnetic_ resonance hFPEF biomarker hFPEF
P-743	-0.0742 -0.8633 -0.4893 -1.6210 -0.6560 -0.0560 -0.0162 -0.2319 -1.1846 -1.6199 -0.1594 -0.0076 -0.0321 -0.4154 -0.5641 -0.5919 -0.1283 -0.0570
S-524	Although contractility remained unchanged, ventricular-arterial coupling was markedly improved (p = 0.002), resulting in a higher SV (p < 0.0001) in the ivabradine-treated patients.<unk>
T-524	contractility ventricular-arterial_coupling patients
H-524	-0.5750434398651123	▁vent ri cular - arte rial ▁coup ling ▁i va bra dine - tre ated
D-524	-0.5750434398651123	ventricular-arterial coupling ivabradine-treated
P-524	-0.5595 -0.1411 -0.1592 -0.2134 -0.0928 -0.1108 -0.2023 -2.9874 -1.3232 -0.0217 -0.3838 -0.0167 -0.3665 -0.0561 -2.3482 -0.6622 -0.1309
S-642	Conversely, conditional gene-targeted Hand2 mice demonstrated a marked resistance to pressure-overload-induced hypertrophy, fibrosis, ventricular dysfunction and induction of a fetal gene program.<unk>
T-642	hand2 hypertrophy fibrosis ventricular_dysfunction gene
H-642	-0.4813271462917328	▁condition al ▁gene - tar get ed ▁Hand ▁pressure - over load - indu ced ▁hyper trop hy ▁fibro sis ▁vent ri cular _ ▁dys function ▁fet al ▁gene
D-642	-0.4813271462917328	conditional gene-targeted Hand pressure-overload-induced hypertrophy fibrosis ventricular_ dysfunction fetal gene
P-642	-0.0230 -0.1299 -1.5355 -0.1166 -0.0832 -0.0872 -0.2368 -0.1863 -3.8315 -0.1231 -0.0892 -0.1196 -1.4517 -0.0042 -1.0468 -0.2458 -0.0062 -0.0912 -0.0492 -0.2381 -0.0006 -0.0657 -0.1333 -1.1405 -0.3870 -0.0459 -0.0290 -0.0215 -1.4020 -1.8822 -0.1183
S-264	To our best knowledge, our study is the first research done to identify a predictive cutoff value for admission NT-proBNP to the prescriptive 4-year survival of patients admitted to ED with acute HF diagnosis.<unk>
T-264	admission nt-probnp patients acute_hf diagnosis
H-264	-1.072998285293579	▁figure ▁ad mission ▁NT - pro B NP ▁pre script ive ▁4- year _ ▁survival ▁ED ▁a cute ▁ HF
D-264	-1.072998285293579	figure admission NT-proBNP prescriptive 4-year_ survival ED acute HF
P-264	-4.9082 -4.3744 -0.0100 -0.0443 -0.0236 -0.0166 -0.8041 -0.0512 -1.4910 -0.0107 -0.0061 -3.3223 -0.1597 -1.6590 -1.2762 -1.0007 -1.2986 -0.0048 -1.6166 -0.1776 -1.2077 -0.1425
S-1193	In conclusion, a simple clinical prediction rule can accurately identify patients with CAD and eliminate the need for angiography in a substantial proportion of patients with systolic HF, with potentially significant cost savings and risk avoidance.<unk>
T-1193	clinical rule patients cad angiography patients systolic_hf cost
H-1193	-0.9864963293075562	▁clinic al _ ▁predict ion _ ▁rule ▁CAD ▁ang i ography ▁sy sto lic ▁ HF ▁cost
D-1193	-0.9864963293075562	clinical_ prediction_ rule CAD angiography systolic HF cost
P-1193	-2.5656 -0.0218 -1.6414 -1.4797 -0.0062 -1.6956 -0.2820 -0.9270 -0.7165 -0.4138 -0.1875 -1.1315 -0.2312 -2.3879 -1.5650 -0.0084 -1.3734 -2.0340 -0.0749
S-1053	This study implicates epigenetic readers in cardiac biology and suggests that the manipulation of cardiac gene control via the targeting of chromatin-dependent signal transduction could potentially abrogate pathological gene expression and HF progression.<unk>
T-1053	epigenetic cardiac cardiac gene signal_transduction pathological gene_expression hf
H-1053	-0.6486815810203552	▁epi gene tic ▁readers ▁cardiac _ bi ology ▁cardiac _ control ▁chr omat in - dependent ▁signal _ trans duction ▁a bro gate ▁path ological _ ▁gene ▁expression ▁ HF
D-1053	-0.6486815810203552	epigenetic readers cardiac_biology cardiac_control chromatin-dependent signal_transduction abrogate pathological_ gene expression HF
P-1053	-0.9502 -0.0226 -0.6736 -0.1332 -0.1650 -1.5884 -0.3553 -0.6026 -0.9964 -0.9476 -3.9008 -0.5174 -0.0179 -0.7721 -0.1509 -0.0174 -0.8882 -0.9897 -0.2348 -0.0634 -0.4027 -0.0005 -0.0036 -0.9758 -0.2369 -1.3631 -0.8658 -1.4869 -0.3481 -0.0012 -0.9539 -0.1316
S-277	Systolic blood pressure was significantly elevated and left ventricular (LV) hypertrophy was found in AT, AN, AS, and ANS mice, and there were no significant differences in those parameters between the four groups.<unk>
T-277	systolic_blood_pressure elevated left_ventricular hypertrophy
H-277	-0.7959731817245483	▁Sy sto lic _ ▁blood _ tension ▁left ▁vent ri cular LV ▁hyper trop hy ▁AN ▁ ANS
D-277	-0.7959731817245483	Systolic_ blood_tension left ventricularLV hypertrophy AN ANS
P-277	-0.2890 -0.1309 -1.9005 -0.9436 -0.5552 -1.4849 -0.7784 -0.5973 -1.3440 -0.3303 -0.6267 -1.6813 -1.6283 -0.0092 -0.0229 -1.4208 -1.2579 -0.0999 -0.7048 -0.1136
S-1747	During follow-up, 271 patients (45%) reached a combined end point including death (heart failure related, n=142; sudden death, n=71; and noncardiac, n=22) or cardiac transplant (n=36).<unk>
T-1747	follow-up patients combined_end_point death heart_failure death cardiac_transplant
H-1747	-1.1607458591461182	▁heart _ ▁failure ▁sud den ▁death ▁non card iac ▁cardiac ▁transplant
D-1747	-1.1607458591461182	heart_ failure sudden death noncardiac cardiac transplant
P-1747	-5.1489 -0.8275 -2.5516 -2.5904 -0.0175 -1.4139 -0.5408 -0.0131 -0.0684 -0.0308 -1.4736 -0.3340 -0.0792
S-1601	Catheter-based percutaneous revascularization with angioplasty and stenting showed modest clinical benefit for patients in small retrospective studies, but data from randomized clinical trials failed to confirm these beneficial results.<unk>
T-1601	percutaneous revascularization angioplasty stenting clinical patients randomized clinical
H-1601	-0.8115372657775879	▁cat heter - based ▁per cuta ne ous _ re vas cular ization ▁ang io plast y ▁sten ting
D-1601	-0.8115372657775879	catheter-based percutaneous_revascularization angioplasty stenting
P-1601	-2.5033 -0.0042 -0.2327 -0.4356 -1.4356 -0.0157 -0.0767 -3.0207 -1.0259 -0.7801 -0.0899 -0.3580 -0.3089 -0.0366 -2.4946 -0.0649 -0.1602 -0.0450 -2.4549 -1.4415 -0.0573
S-1176	Work load-corrected chronotropic response (the difference in heart rate at the same exercise time at the baseline and follow-up tests) showed a slower increase in heart rate during exercise than in the placebo-treated group.<unk>
T-1176	chronotropic_response heart_rate exercise baseline follow-up tests heart_rate exercise
H-1176	-1.2093275785446167	▁load - corre cted ▁chr ono tropi c ▁figure ▁heart ▁rate
D-1176	-1.2093275785446167	load-corrected chronotropic figure heart rate
P-1176	-3.6479 -0.1826 -0.0410 -0.6788 -0.3840 -0.1146 -0.2117 -0.2236 -3.1231 -0.9719 -3.8443 -2.1859 -0.1118
S-1943	Peak oxygen consumption (VO2max) was significantly higher when resting HR was <70 versus ≥70 bpm (17.5±5.5 versus 14.4±3.3 mL/min/kg, respectively; P value=0.038).<unk>
T-1943	peak_oxygen_consumption vo2max resting_hr bpm p_value
H-1943	-2.0913567543029785	▁oxygen _ pu issa nce
D-1943	-2.0913567543029785	oxygen_puissance
P-1943	-3.0458 -2.7124 -3.6072 -0.3639 -0.0307 -4.7212 -0.1584
S-1624	Cox-proportional hazard models and negative binomial regression models were used to assess the relationship between the intervention and survival and utilization, controlling for demographic and health characteristics that were statistically different between groups after matching.<unk>
T-1624	cox-proportional_hazard_models negative_binomial_regression_models health
H-1624	-0.49615609645843506	▁co x - propor tional ▁hazard ▁models ▁negative ▁bi nom ial ▁re gression ▁models ▁intervention ▁survival _ ▁utiliza tion ▁demo graphic ▁health
D-1624	-0.49615609645843506	cox-proportional hazard models negative binomial regression models intervention survival_ utilization demographic health
P-1624	-0.3549 -0.0010 -0.0973 -0.0318 -0.0601 -1.2468 -3.2992 -0.1956 -0.1745 -0.0471 -0.0006 -0.3638 -0.0029 -0.6880 -0.2888 -1.0463 -2.4702 -0.4263 -0.0041 -0.0692 -0.0761 -0.5396 -0.3548 -0.0687
S-1251	In a pilot study, five patients with HF and T2D consumed ERC for 3 months; treadmill testing [VO2max (maximum oxygen consumption)] and SkM biopsies were performed.<unk>
T-1251	patients hf t2d erc vo2max maximum_oxygen_consumption skm biopsies
H-1251	-0.5536319017410278	▁ HF ▁ HF ▁t 2 d ▁ ERC ▁tre ad m ill _ ▁testing VO 2 max ▁oxygen _ ▁consum p tion ▁Sk m ▁bio psi es
D-1251	-0.5536319017410278	HF HF t2d ERC treadmill_ testingVO2max oxygen_ consumption Skm biopsies
P-1251	-0.4810 -0.0402 -0.9449 -0.3799 -3.6571 -0.0307 -0.2487 -0.1975 -0.0139 -0.1554 -0.0033 -0.0124 -0.1791 -3.1137 -1.8043 -1.8210 -0.0106 -0.0062 -0.3681 -1.9052 -0.4848 -0.0166 -0.0237 -0.1415 -0.1897 -0.0063 -0.0953 -0.0198 -0.1891 -0.0689
S-1961	One (10%) patient was admitted to hospital with gastrointestinal bleeding at month 1; one (10%) patient died after incessant ventricular tachycardia storm, which led to terminal heart failure 2 months post-procedure.<unk>
T-1961	patient hospital gastrointestinal_bleeding patient ventricular_tachycardia terminal_heart_failure
H-1961	-0.8425520062446594	▁hospital ▁gastro inte stin al _ ▁ble ed ing ▁vent ri cular _ ta chy car dia ▁storm ▁terminal
D-1961	-0.8425520062446594	hospital gastrointestinal_ bleeding ventricular_tachycardia storm terminal
P-1961	-1.1717 -0.5390 -0.0035 -0.8816 -0.0905 -2.2567 -0.1189 -0.1422 -0.0781 -0.2560 -0.1038 -0.1402 -1.1027 -3.0082 -0.0935 -0.0114 -1.8014 -0.2268 -1.6499 -3.9329 -0.0847
S-1214	Chronic β-AR stimulation via catecholamine infusions in rats enhanced PDE2 expression ~2-fold and cAMP hydrolytic activity ~4-fold, which correlated with blunted cardiac β-AR responsiveness.<unk>
T-1214	chronic β-ar catecholamine infusions pde2 expression camp activity correlated cardiac β-ar_responsiveness
H-1214	-0.4870174527168274	▁β - AR ▁stimul ation ▁cate chol amine ▁in fusion s ▁p de 2 ▁c AMP ▁hydro ly tic ▁activity ▁blu n ted _ ▁cardiac ▁β - AR ▁responsive ness
D-1214	-0.4870174527168274	β-AR stimulation catecholamine infusions pde2 cAMP hydrolytic activity blunted_ cardiac β-AR responsiveness
P-1214	-3.1044 -0.0519 -0.1645 -1.3988 -0.0118 -0.2593 -0.0139 -0.0260 -0.0141 -0.0098 -0.0600 -0.8182 -0.4740 -0.0636 -0.5245 -0.0087 -0.6169 -0.3872 -1.7280 -0.4056 -0.0116 -0.0500 -2.4429 -1.2999 -0.0706 -0.1333 -0.0043 -0.0073 -0.1380 -0.8739 -0.2975 -0.1140
S-758	CONCLUSIONS: Among subjects with mild HF, QRS prolongation, and LVEF >30%, CRT produced reverse remodeling and similar clinical benefit compared with subjects with more severe LV systolic dysfunction.<unk>
T-758	mild_hf qrs_prolongation lvef crt reverse_remodeling clinical systolic_dysfunction
H-758	-0.5341945886611938	▁ HF ▁QR s ▁prolong ation ▁LV EF ▁c RT ▁rever se ▁remodel ing
D-758	-0.5341945886611938	HF QRs prolongation LVEF cRT reverse remodeling
P-758	-0.2935 -0.0376 -0.0122 -1.1014 -1.2282 -0.0117 -0.1214 -0.0909 -0.3873 -0.1444 -0.0581 -0.0016 -0.5248 -0.0310 -4.4436 -0.0594
S-1096	In chronic PAH, we will examine clinical circumstances common to hospitalized patients that may provoke acute RV decompensation, as well as pharmacologic therapies that are unique to RV failure management in PAH.<unk>
T-1096	chronic_pah clinical hospitalized patients acute rv_decompensation pharmacologic therapies rv_failure pah
H-1096	-0.6349818110466003	▁chronic ▁P AH ▁hospital ized ▁ RV _ de com pensa tion ▁ pharma c ologic ▁ therapie s ▁ RV _ ▁failure _ management ▁P AH
D-1096	-0.6349818110466003	chronic PAH hospitalized RV_decompensation pharmacologic therapies RV_ failure_management PAH
P-1096	-0.6319 -2.1662 -0.0044 -2.6770 -0.3645 -1.0935 -0.5087 -1.7470 -0.0791 -0.4151 -0.0083 -0.0124 -0.0709 -0.1585 -0.0099 -0.1099 -0.4817 -0.0777 -0.0331 -0.3706 -0.0653 -0.8502 -1.3636 -1.5618 -0.5063 -2.5386 -0.0018 -0.3077 -0.1987
S-268	During the 4-year follow-up period, 76 patients died; survivors were significantly younger than non-survivors (64.26 ± 11.42 years vs 72.83 ± 11.07 years, P = .002).<unk>
T-268	follow-up patients
H-268	-1.4474762678146362	
D-268	-1.4474762678146362	
P-268	-2.8181 -0.0769
S-1129	The most common contextual reasons were comanagement with other clinicians (32%-35% of patients), patient preferences and nonadherence (15%-24%), and clinician belief that the medication is not indicated in the patient (12%-20%).<unk>
T-1129	clinicians patients patient clinician medication patient
H-1129	-0.9104427099227905	▁co management ▁clinic ians ▁patient _ adh er ence ▁medication
D-1129	-0.9104427099227905	comanagement clinicians patient_adherence medication
P-1129	-0.4204 -0.0213 -2.4027 -0.2569 -1.7702 -0.9285 -3.4386 -0.0383 -0.0116 -1.1899 -0.3552 -0.0918
S-628	Compared to non-frail participants, moderate (HR 1.36, 95% CI 1.08-1.71) and severe frailty (HR 1.88, 95% CI 1.02-3.47) by Gill index was associated with a higher risk for HF.<unk>
T-628	frailty gill_index hf
H-628	-1.6760226488113403	▁non - fra il ▁figure ▁Gill ▁ HF
D-628	-1.6760226488113403	non-frail figure Gill HF
P-628	-5.0230 -0.0124 -0.0060 -0.2293 -4.4163 -3.8051 -2.6785 -0.1982 -0.2470 -0.1445
S-625	METHODS: We assessed the association between frailty, using the Health ABC Short Physical Performance Battery (HABC Battery) and the Gill index, and incident HF in 2825 participants aged 70 to 79 years.<unk>
T-625	frailty health_abc_short_physical_performance_battery habc_battery gill_index hf
H-625	-0.7225471138954163	▁fra il ty ▁Health ▁ABC _ short _ phy al _ ▁Performance _ ▁Bat tery ▁h ABC _ bat tery ▁Gill ▁index ▁ HF
D-625	-0.7225471138954163	frailty Health ABC_short_phyal_ Performance_ Battery hABC_battery Gill index HF
P-625	-5.1228 -0.3337 -2.6045 -0.5661 -0.7215 -0.7465 -0.5307 -0.0179 -0.8037 -0.6042 -0.1918 -0.2365 -1.3185 -0.2659 -0.0025 -0.1270 -0.1357 -1.4647 -1.4776 -0.0050 -0.0577 -0.8788 -0.3618 -0.0107 -0.1508 -0.0494
S-295	Patients requiring temporary RV support after LVAD insertion are a heterogeneous group of patients consisting of those in cardiogenic shock after myocardial infarction, to those with chronic decompensated heart failure.<unk>
T-295	patients rv_support lvad patients cardiogenic_shock myocardial_infarction chronic_decompensated_heart_failure
H-295	-1.1292954683303833	▁ RV ▁ RV ▁l VAD _ insertion ▁cardio ge nic _ ▁shock ▁my o card ial ▁in far ction ▁chronic _ de com pensa ted _ heart _ ▁failure
D-295	-1.1292954683303833	RV RV lVAD_insertion cardiogenic_ shock myocardial infarction chronic_decompensated_heart_ failure
P-295	-0.9385 -0.1357 -3.4945 -0.5128 -6.0671 -0.0369 -3.4533 -0.0140 -0.1232 -0.1164 -2.2465 -0.9757 -0.2494 -2.5354 -0.1511 -0.1884 -0.1200 -0.5703 -2.1935 -0.0206 -1.2524 -0.7651 -0.2369 -0.5527 -0.0064 -2.4440 -0.8553 -1.5386 -1.5199 -2.2806 -0.3059 -0.2364
S-1357	PURPOSE OF REVIEW: Chronic heart failure (CHF) is increasingly recognized as a multisystem disease with important comorbidities such as anemia, insulin resistance, autonomic dysbalance, or cardiac cachexia.<unk>
T-1357	chronic_heart_failure chf multisystem_disease comorbidities anemia insulin_resistance autonomic_dysbalance cardiac_cachexia
H-1357	-0.6743927001953125	▁Chro nic _ heart _ ▁failure ▁ch f ▁multi system _ dis que nce ▁an emia ▁insulin _ ▁resist ance ▁autonomi c _ ▁dys balance ▁cardiac _ ▁cache xia
D-1357	-0.6743927001953125	Chronic_heart_ failure chf multisystem_disquence anemia insulin_ resistance autonomic_ dysbalance cardiac_ cachexia
P-1357	-0.9577 -0.5339 -0.2480 -1.9935 -0.2732 -2.0442 -2.7991 -0.0716 -0.0887 -0.0445 -0.9335 -2.1596 -2.8471 -0.4900 -0.2602 -0.0121 -0.0163 -1.1791 -0.5540 -0.0033 -0.0499 -0.1409 -0.7080 -0.3565 -0.0495 -0.0012 -1.1302 -0.6788 -0.0490 -0.1792 -0.0535
S-470	Xanthine oxidase (XO) is increased in human and rat left ventricular (LV) myocytes with volume overload (VO) of mitral regurgitation and aortocaval fistula (ACF).<unk>
T-470	xanthine_oxidase xo left_ventricular myocytes volume_overload vo mitral_regurgitation aortocaval_fistula acf
H-470	-0.8133732080459595	▁Xan thi ne ▁oxid ase ▁ XO ▁rat ▁left ▁vent ri cular LV ▁my o cy tes ▁volume _ ▁over load ▁mit ral _ ▁re gur gi tation ▁a orto ca val _ ▁fi stu la
D-470	-0.8133732080459595	Xanthine oxidase XO rat left ventricularLV myocytes volume_ overload mitral_ regurgitation aortocaval_ fistula
P-470	-0.0016 -0.0073 -0.1912 -0.1884 -0.1936 -2.9706 -0.0034 -1.7312 -1.3247 -0.5220 -0.1563 -0.2912 -0.8942 -5.8459 -0.0177 -0.0388 -0.0747 -2.4357 -0.7701 -0.6125 -0.0164 -4.8630 -0.0178 -1.2077 -0.7296 -0.0018 -0.0233 -0.0014 -0.0608 -0.1605 -0.0026 -1.1246 -0.4701 -2.8518 -0.0093 -0.0366 -0.9849 -0.0750
S-767	Only the obese ZSF1 groups had developed heart failure with preserved ejection fraction, which was evident from increased lung weight, preserved left ventricular ejection fraction, and left ventricular DD.<unk>
T-767	obese zsf1 heart_failure_with_preserved_ejection_fraction lung preserved_left_ventricular_ejection_fraction left_ventricular_dd
H-767	-0.9368563294410706	▁obes e ▁Z SF 1 ▁heart _ ▁failure ▁lung _ ▁weight ▁vent ri cular ▁e je ction _ fraction ▁left ▁vent ri cular ▁ DD
D-767	-0.9368563294410706	obese ZSF1 heart_ failure lung_ weight ventricular ejection_fraction left ventricular DD
P-767	-1.7203 -0.0372 -0.5998 -0.0671 -1.9984 -3.6654 -0.8111 -2.7029 -2.2758 -1.3254 -0.9512 -2.0199 -0.1578 -0.3835 -1.1439 -0.4170 -0.2347 -0.8521 -0.0171 -0.2829 -0.9319 -0.2566 -0.3007 -1.5553 -0.2007 -0.2688 -0.1175
S-1727	Patients cared for by the high-volume physicians had lower mortality than those by the low-volume physicians (8.9% versus 9.7%; P<0.001); this relationship was strongest in low-volume hospitals.<unk>
T-1727	patients physicians mortality physicians hospitals
H-1727	-1.0693368911743164	▁high - volu me ▁physician s ▁low - volu me
D-1727	-1.0693368911743164	high-volume physicians low-volume
P-1727	-4.4420 -0.0322 -0.0207 -0.0090 -0.9366 -0.0617 -2.9168 -0.0175 -0.0266 -0.0034 -4.1883 -0.1772
S-1307	METHODS AND RESULTS: Western Australian linked administrative health data were used to identify 20 812 consecutive patients, aged 40 to 84 years, without prior HF hospitalized with an index (first) AMI between 1996 and 2007.<unk>
T-1307	western administrative health patients hf hospitalized ami
H-1307	-1.1219208240509033	▁Western _ euro pé en _ link ed _ administra tive _ ▁health ▁figure ▁ HF ▁ AMI
D-1307	-1.1219208240509033	Western_européen_linked_administrative_ health figure HF AMI
P-1307	-1.3607 -1.8549 -3.1344 -0.2591 -0.2871 -1.4159 -0.6963 -0.0881 -0.5675 -1.0349 -0.1026 -0.1964 -2.2912 -4.1193 -0.8175 -2.0022 -1.7138 -0.2350 -0.1370 -0.1246
S-1825	The aims of the present consensus report are to strengthen the connection between certified, experienced centers and those that care for patients irrespective of disease phase and healthcare staff, as well as to raise awareness and provide information regarding conditions in Turkey.<unk>
T-1825	report connection patients disease healthcare conditions turkey
H-1825	-2.065544366836548	▁conditions
D-1825	-2.065544366836548	conditions
P-1825	-4.3894 -1.6868 -0.1204
S-1403	Validating and incorporating nursing-sensitive outcome measures in future prospective experimental research can contribute to the advancement of science regarding effective treatment of older adults hospitalized with HF, while highlighting the contribution of nursing care to outcomes.<unk>
T-1403	outcome prospective hospitalized hf nursing outcomes
H-1403	-1.0181822776794434	▁nur sing - sensitiv e ▁outcome s
D-1403	-1.0181822776794434	nursing-sensitive outcomes
P-1403	-2.2675 -0.0605 -0.1255 -0.0045 -0.0857 -3.1857 -0.6804 -2.6786 -0.0752
S-1310	Between the periods 1996-1998 and 2005-2007, the prevalence of HF after AMI declined from 28.1% to 16.5%, with an adjusted odds ratio of 0.50 (95% CI, 0.44 to 0.55).<unk>
T-1310	prevalence hf ami adjusted_odds_ratio
H-1310	-1.3483829498291016	▁ HF ▁ AMI
D-1310	-1.3483829498291016	HF AMI
P-1310	-1.0057 -0.7923 -1.2384 -3.2266 -1.7591 -0.0683
S-1482	miRNAs are small noncoding RNAs that regulate expression of target genes by sequence-specific binding to the 3' untranslated region of messenger RNA, which results in degradation or translational repression.<unk>
T-1482	mirnas rnas expression genes messenger_rna repression
H-1482	-0.9678961038589478	▁mi RNA s ▁ RNA s ▁ RNA s ▁ binding ▁messenger ▁ RNA
D-1482	-0.9678961038589478	miRNAs RNAs RNAs binding messenger RNA
P-1482	-2.1194 -0.0051 -0.0728 -1.6441 -0.0363 -0.1590 -2.5763 -0.2084 -0.3935 -3.0787 -1.9539 -0.8644 -0.4203 -0.0102 -1.8350 -0.1088
S-1055	OBJECTIVE: The purpose of this article is to evaluate a free-breathing pulse sequence to quantify myocardial T1 changes in a swine model of tachycardia-induced heart failure.<unk>
T-1055	pulse myocardial_t1 heart_failure
H-1055	-0.6750348806381226	▁free - bre a thing ▁puls e _ ▁se que nce ▁my o card ial _ ▁T 1 ▁s win e _ model ▁ta chy car dia - indu ced ▁heart _ ▁failure
D-1055	-0.6750348806381226	free-breathing pulse_ sequence myocardial_ T1 swine_model tachycardia-induced heart_ failure
P-1055	-0.8290 -0.0447 -0.1492 -0.0992 -0.1174 -0.3658 -0.0756 -2.1087 -1.5217 -0.0234 -0.0006 -0.2065 -0.0362 -0.0295 -0.0054 -2.0838 -0.8082 -0.0364 -0.8377 -0.1027 -0.0544 -3.2459 -1.2367 -2.7964 -0.0798 -0.0248 -2.2048 -0.6374 -0.0008 -1.5438 -0.6085 -0.6920 -0.8553 -0.0865 -0.0774
S-1173	METHODS: Sixty-one patients with HFpEF were randomly assigned to ivabradine 5 mg twice daily (n = 30) or placebo (n = 31) for 7 days in this double-blind trial.<unk>
T-1173	patients hfpef ivabradine placebo double-blind
H-1173	-0.6697669625282288	▁ HF p EF ▁i va bra dine
D-1173	-0.6697669625282288	HFpEF ivabradine
P-1173	-0.6882 -0.2337 -0.4280 -1.0090 -0.0288 -0.0148 -0.5703 -0.0040 -3.6592 -0.0617
S-229	The adults were more symptomatic than the PF cohort (New York Heart Association classes I and II or III and IV: 48% or 52% [SAF] vs 94% or 6% [PF], respectively, p <0.01).<unk>
T-229	symptomatic new_york_heart_association_classes saf
H-229	-1.4338786602020264	▁ PF _ co hor t ▁New ▁York _ ▁Heart _ ▁Association
D-229	-1.4338786602020264	PF_cohort New York_ Heart_ Association
P-229	-1.3014 -0.8221 -5.4210 -2.5188 -0.1339 -0.0706 -2.2343 -0.5476 -0.8549 -0.9263 -0.7375 -1.5195 -2.8953 -0.0909
S-463	Methods and Results—Retrospective cohort of all adults presenting to 93 EDs between 1999 and 2009 with a most responsible diagnosis of heart failure (n=44 925 ED visits; mean age, 76.4 years).<unk>
T-463	retrospective_cohort eds diagnosis heart_failure
H-463	-1.5591413974761963	▁ed s ▁ diagnos is _ de _ heart _ ▁failure
D-463	-1.5591413974761963	eds diagnosis_de_heart_ failure
P-463	-3.9319 -1.2310 -4.4881 -1.6583 -0.0370 -1.1023 -1.0476 -0.2470 -1.6225 -0.7091 -3.5676 -0.4755 -0.1508
S-1335	BACKGROUND: Cardiac c-Kit+ cells isolated from cardiac explant-derived cells modestly improve cardiac functions after myocardial infarction; however, their full potential has not yet been realized.<unk>
T-1335	cardiac cells cardiac cells cardiac_functions myocardial_infarction
H-1335	-0.5292673707008362	▁Card iac ▁c - K it ▁cardiac ▁ex plant - der i ved ▁cell s
D-1335	-0.5292673707008362	Cardiac c-Kit cardiac explant-derived cells
P-1335	-0.4854 -0.0119 -0.5705 -0.0564 -0.2210 -0.0170 -0.4749 -1.7042 -0.0172 -0.1179 -0.1679 -0.1036 -0.1104 -0.5200 -0.0242 -4.3247 -0.0703
S-2022	It is crucial for nurses to understand the pathophysiology of HF and the importance that nursing actions have on enhancing medical management to alleviate symptoms and to deter the advancement of the pathophysiologic state.<unk>
T-2022	nurses pathophysiology hf nursing medical symptoms pathophysiologic
H-2022	-0.6311102509498596	▁pat ho phy si ology ▁ HF ▁medical ▁management
D-2022	-0.6311102509498596	pathophysiology HF medical management
P-2022	-1.6705 -0.1019 -0.0255 -0.1677 -0.7029 -0.5295 -0.0200 -1.6144 -0.6922 -1.3732 -0.0444
S-1043	The group utilized the recently developed first-in-class inhibitor JQ1, which displaces BETs from chromatin, resulting in the suppression of downstream signalling to RNA polymerase II (Pol II).<unk>
T-1043	jq1 bets chromatin downstream_signalling rna polymerase_ii pol_ii
H-1043	-0.8880491852760315	▁inhibi tor ▁ BET s ▁chr omat in ▁ RNA _ poly mera se _ ▁II pol ▁II
D-1043	-0.8880491852760315	inhibitor BETs chromatin RNA_polymerase_ IIpol II
P-1043	-2.8836 -0.0189 -1.6632 -0.7500 -1.5401 -0.1078 -0.0330 -0.7507 -3.0332 -0.8281 -1.4975 -0.2968 -0.1991 -0.0486 -1.4462 -0.3699 -1.1891 -0.8400 -0.1967 -0.0684
S-1022	However, levels of NPs are likely to be used also to guide treatment and to assess risk of adverse outcomes in other patients at risk of developing heart failure, including those with pulmonary embolism or diabetes, or receiving chemotherapy.<unk>
T-1022	nps adverse_outcomes patients heart_failure pulmonary_embolism diabetes chemotherapy
H-1022	-1.2703765630722046	▁ NP s ▁pulmonar y _ ▁e mbol ism ▁diabetes
D-1022	-1.2703765630722046	NPs pulmonary_ embolism diabetes
P-1022	-1.7434 -0.0089 -0.1156 -5.1117 -0.0480 -1.4614 -1.2722 -0.0016 -1.7784 -0.1956 -3.3888 -0.1190
S-1691	OBJECTIVE: To combine structure, process, and outcome measures into an empirically derived composite quality measure for heart failure (HF), acute myocardial infarction (AMI), and pneumonia (PNA).<unk>
T-1691	outcome heart_failure hf acute_myocardial_infarction ami pneumonia pna
H-1691	-0.7922561168670654	▁em pir ically _ ▁deri ved ▁com posit e ▁quality _ de _ heart _ ▁failure ▁ HF ▁a cute _ mé o card ial ▁in far ction ▁pneu monia ▁p na
D-1691	-0.7922561168670654	empirically_ derived composite quality_de_heart_ failure HF acute_méocardial infarction pneumonia pna
P-1691	-2.0757 -0.0096 -0.1753 -1.4681 -2.3716 -0.1047 -1.9291 -0.0053 -0.0330 -1.3931 -1.0551 -2.2217 -0.2350 -1.3039 -0.3140 -0.9063 -2.0156 -0.0393 -0.0516 -0.0040 -0.0615 -4.2494 -0.6129 -0.0908 -0.0624 -0.6896 -0.6475 -0.0239 -0.6601 -0.2957 -0.7291 -0.7972 -0.2042 -0.1001
S-1360	This intestinal dysfunction and disturbed intestinal barrier may lead to both the chronic inflammatory state and catabolic/anabolic imbalance as seen in cardiac cachexia, as a terminal stage of CHF, which carries a particularly poor prognosis.<unk>
T-1360	intestinal_dysfunction intestinal lead chronic inflammatory catabolic anabolic cardiac_cachexia terminal chf prognosis
H-1360	-0.7272177934646606	▁intestinal _ dis function ▁disturb ed ▁intestinal _ ▁barrier ▁chronic _ ▁infla mma tory _ ▁state ▁cata bo lic _ ana bo lic ▁im balance ▁cardiac ▁cache xia ▁CHF
D-1360	-0.7272177934646606	intestinal_disfunction disturbed intestinal_ barrier chronic_ inflammatory_ state catabolic_anabolic imbalance cardiac cachexia CHF
P-1360	-0.2908 -1.5605 -0.5911 -1.8934 -3.8274 -0.0444 -0.8176 -0.6996 -0.3232 -0.5149 -0.2829 -0.5208 -0.4108 -0.4053 -1.3559 -1.3986 -0.0402 -0.0010 -1.7275 -0.2893 -0.8453 -0.0119 -0.9312 -1.1013 -0.0042 -0.0018 -1.4344 -0.0034 -0.8712 -0.2375 -0.1061
S-780	BACKGROUND: Despite the growing epidemic of heart failure with preserved ejection fraction (HFpEF), no valid measure of patients' health status (symptoms, function, and quality of life) exists.<unk>
T-780	epidemic heart_failure_with_preserved_ejection_fraction hfpef patients health symptoms quality_of_life
H-780	-0.9761883616447449	▁epidemi c ▁heart _ ▁failure ▁pres er ved ▁e je ction _ fraction HF p EF
D-780	-0.9761883616447449	epidemic heart_ failure preserved ejection_fractionHFpEF
P-780	-3.1059 -0.0655 -0.9701 -0.5327 -2.0378 -2.2930 -0.0228 -0.5459 -1.2760 -1.0019 -0.0892 -0.5404 -0.0368 -1.1716 -0.0166 -0.4865 -3.3207 -0.0580
S-1209	BACKGROUND: Diminished cyclic adenosine monophosphate (cAMP) and augmented cyclic guanosine monophosphate (cGMP) signaling is characteristic for failing hearts.<unk>
T-1209	cyclic_adenosine_monophosphate camp cyclic_guanosine_monophosphate cgmp hearts
H-1209	-0.6421030163764954	▁ cycli c ▁ad enos ine _ ▁mono phos pha te ▁c AMP ▁aug mente d ▁ cycli c ▁gua no sine _ ▁mono phos pha te ▁c g mp
D-1209	-0.6421030163764954	cyclic adenosine_ monophosphate cAMP augmented cyclic guanosine_ monophosphate cgmp
P-1209	-0.6238 -0.1524 -0.0914 -1.0587 -0.5325 -0.9893 -0.4036 -1.2683 -0.0055 -0.3693 -0.0382 -0.1290 -0.0102 -3.7198 -0.1520 -0.0034 -0.0431 -0.0260 -0.0742 -3.6151 -0.0175 -1.1208 -0.2874 -0.3924 -0.0039 -0.1625 -0.0438 -0.2267 -1.2067 -1.5531 -2.0423 -0.1844
S-1618	OBJECTIVES: To evaluate mortality and healthcare utilization effects of an intervention that combined care management and telehealth, targeting individuals with congestive heart failure, chronic obstructive pulmonary disease, or diabetes mellitus.<unk>
T-1618	mortality healthcare telehealth congestive_heart_failure chronic_obstructive_pulmonary_disease diabetes_mellitus
H-1618	-0.679549515247345	▁mortal ity ▁health care _ ▁utiliza tion ▁techniques ▁care ▁management ▁tele health ▁con ges tive _ heart _ ▁failure ▁chronic _ ▁ob struct ive _ ▁pulmonar y ▁diabetes ▁mell itus
D-1618	-0.679549515247345	mortality healthcare_ utilization techniques care management telehealth congestive_heart_ failure chronic_ obstructive_ pulmonary diabetes mellitus
P-1618	-0.1300 -0.1444 -0.5428 -0.0212 -1.8368 -0.1543 -0.0043 -4.2520 -3.5637 -0.5064 -1.6676 -0.1646 -0.1068 -0.0343 -0.0328 -0.4952 -1.8085 -0.5856 -0.1775 -0.0616 -0.6328 -1.3749 -0.0427 -0.0212 -0.4495 -0.1813 -0.1530 -2.3506 -0.0575 -0.0034 -0.1333 -0.0550
S-942	OBJECTIVES: This study sought to investigate the efficacy and safety of catheter ablation for atrial fibrillation (AF) in patients with heart failure with preserved ejection fraction (HFPEF).<unk>
T-942	catheter_ablation atrial_fibrillation patients heart_failure_with_preserved_ejection_fraction hfpef
H-942	-0.7578948736190796	▁ef fica cy ▁cat heter ▁ab lation ▁at rial _ ▁fi bril lation AF ▁heart _ ▁failure ▁h f f f
D-942	-0.7578948736190796	efficacy catheter ablation atrial_ fibrillationAF heart_ failure hfff
P-942	-1.5316 -0.0189 -1.0417 -0.6408 -0.0226 -0.4994 -0.0068 -1.4356 -0.1388 -0.3848 -2.1413 -0.0493 -0.0022 -2.9292 -0.5921 -0.6248 -3.3354 -0.4916 -0.4066 -0.2132 -0.4088 -0.4368 -0.0791
S-998	The described report deals with the case of a patient with diagnosis of ischemic-hypertensive cardiomyiopathy based on the history of angina and inducible myocardial ischemia with normal coronary arteries.<unk>
T-998	report patient diagnosis ischemic-hypertensive_cardiomyiopathy angina myocardial_ischemia coronary_arteries
H-998	-0.6475910544395447	▁ ische mic - hy per tensi ve ▁cardio mio pathy ▁ang ina ▁induc ible ▁my o card ial ▁ ische mia ▁corona ry ▁arteri es
D-998	-0.6475910544395447	ischemic-hypertensive cardiomiopathy angina inducible myocardial ischemia coronary arteries
P-998	-0.7639 -2.0559 -0.5054 -0.2332 -0.0100 -0.0102 -0.4332 -0.3224 -0.9876 -3.8757 -0.5511 -0.1224 -0.3870 -0.6227 -0.1453 -2.7377 -0.0620 -0.0981 -0.0650 -1.6921 -0.4311 -0.1744 -0.1290 -0.3582 -1.1445 -0.0249 -0.1481 -0.0416
S-604	Subjects with RA receiving methotrexate were eligible to enter the study cohort if they added or switched to a TNF antagonist or another non-biological disease modifying antirheumatic drug (nbDMARD).<unk>
T-604	ra methotrexate tnf_antagonist non-biological_disease_modifying_antirheumatic_drug nbdmard
H-604	-0.7277377843856812	▁RA ▁met ho tre xa te ▁T NF _ ▁anta gon ist ▁non - bi ological ▁disease _ mod ifying ▁anti r heu matic ▁drug n b DM ARD
D-604	-0.7277377843856812	RA methotrexate TNF_ antagonist non-biological disease_modifying antirheumatic drugnbDMARD
P-604	-1.1381 -1.6973 -0.1365 -0.0056 -0.0327 -0.0190 -1.1966 -0.0562 -2.6841 -0.0664 -0.0320 -0.9219 -2.6072 -0.0053 -0.0242 -0.2763 -0.6253 -2.2309 -0.4552 -0.0214 -0.5696 -1.7556 -2.2913 -0.6039 -0.3142 -2.0749 -0.0079 -0.3289 -0.0290 -0.1872 -0.1649
S-104	We used multivariate Cox proportional hazards regression modeling to identify risk factors for the development of IE (comprising hospitalization for acute coronary syndromes and/or coronary interventions during the trial) among study patients.<unk>
T-104	multivariate_cox_proportional_hazards_regression_modeling hospitalization acute_coronary_syndromes coronary_interventions patients
H-104	-0.8267996311187744	▁co x ▁proportion al ▁hazard s _ re gression _ modell ing ▁i e ▁a cute _ ▁corona ry ▁syndrome s ▁corona ry ▁intervention s
D-104	-0.8267996311187744	cox proportional hazards_regression_modelling ie acute_ coronary syndromes coronary interventions
P-104	-0.6785 -0.0028 -0.4356 -0.0413 -0.7605 -0.1242 -1.0521 -0.8859 -0.0029 -4.0138 -2.5169 -0.0908 -2.7635 -2.4087 -1.2100 -0.0044 -0.2824 -1.2218 -0.3672 -1.7074 -0.1328 -0.0668 -0.1900 -0.8641 -0.0568 -0.2734 -0.1689
S-1405	BACKGROUND: The sphingosine-1-phosphate receptor 1 (S1PR1) and β1-adrenergic receptor (β1AR) are G-protein-coupled receptors expressed in the heart.<unk>
T-1405	sphingosine-1-phosphate_receptor_1 s1pr1 β1-adrenergic_receptor β1ar g-protein-coupled_receptors heart
H-1405	-0.5271101593971252	▁sp hing os ine -1 - phos pha te ▁receptor ▁s 1 PR ▁β 1- ad r energi c ▁receptor β 1 AR ▁g - prote in - co up led
D-1405	-0.5271101593971252	sphingosine-1-phosphate receptor s1PR β1-adrenergic receptorβ1AR g-protein-coupled
P-1405	-0.0009 -0.2600 -1.4557 -0.8279 -3.6999 -0.4554 -0.0040 -0.0872 -0.0351 -0.2252 -2.3711 -0.0416 -0.0918 -0.7974 -0.1909 -0.0506 -0.1558 -0.9964 -0.2009 -0.1658 -0.6213 -0.0742 -0.2240 -0.5952 -0.0486 -0.0177 -0.3441 -0.4172 -0.0041 -0.0024 -0.1286 -2.7292 -0.0742
S-484	E/e'septal correlated more strongly with PCWP (r = 0.53) compared with E/e'lateral (r = 0.41) and E/e'mean (r = 0.50; all p values <0.001).<unk>
T-484	septal correlated pcwp p_values
H-484	-0.9911620020866394	sept al ▁PC WP
D-484	-0.9911620020866394	septal PCWP
P-484	-0.6683 -0.4578 -0.5905 -0.5753 -3.4053 -0.2498
S-864	The risk of inappropriate therapy caused by atrial fibrillation was also reduced in patients receiving carvedilol compared with metoprolol (HR: 0.50 [95% CI: 0.32 to 0.81]; p = 0.004).<unk>
T-864	therapy atrial_fibrillation patients carvedilol metoprolol
H-864	-0.37246328592300415	▁in appropria te ▁ therapy ▁at rial _ ▁fi bril lation ▁car vedi lol ▁met o pro lol
D-864	-0.37246328592300415	inappropriate therapy atrial_ fibrillation carvedilol metoprolol
P-864	-1.2146 -0.0434 -0.0807 -0.3752 -0.0230 -0.9550 -0.1119 -0.8774 -2.5347 -0.0727 -0.0293 -0.0956 -0.0695 -0.0734 -0.1087 -0.1393 -0.0163 -0.1325 -0.4127 -0.0834
S-820	CONCLUSIONS: GLS was a major parameter and stronger than LVEF and Sa in predicting adverse CV events and could offer an additional prognostic benefit over conventional clinical and echocardiographic systolic parameters in AF.<unk>
T-820	gls lvef prognostic clinical echocardiographic systolic
H-820	-1.3242744207382202	▁g LS ▁LV EF ▁sa ▁in ▁predict ing ▁advers e ▁CV
D-820	-1.3242744207382202	gLS LVEF sa in predicting adverse CV
P-820	-2.2827 -0.6589 -0.1357 -0.1245 -1.1094 -4.4250 -2.0775 -0.3036 -0.7312 -0.0612 -0.1529 -5.0482 -0.1050
S-1379	Bradycardia induced by intravenous metoprolol (indicative of cardiac sympathetic tone) was exacerbated in CHF-INV rabbits compared with sham-INV but was normalized in CHF-DNx.<unk>
T-1379	bradycardia intravenous metoprolol cardiac sympathetic_tone
H-1379	-0.6639299392700195	▁Brad y car dia ▁implant ed ▁met o pro lol ▁cardiac _ ▁sympa the tic ▁tone ▁CHF - IN V ▁sham - IN v ▁CHF - DN x
D-1379	-0.6639299392700195	Bradycardia implanted metoprolol cardiac_ sympathetic tone CHF-INV sham-INv CHF-DNx
P-1379	-0.0116 -0.0427 -0.0596 -2.4714 -3.7129 -0.3668 -3.6329 -0.0586 -0.0229 -0.1059 -0.0061 -0.6387 -1.1437 -0.1890 -2.2703 -0.2302 -0.0283 -0.0162 -0.8521 -0.9414 -0.5715 -0.0434 -0.6958 -0.9559 -0.1707 -0.0276 -0.0755 -0.0181 -0.4116 -0.1468
S-1849	Outcomes will include proportion of eligible patients who were: prescribed a CPG-recommended pharmacological treatment; referred for device consideration; provided self-care education at discharge; and provided left ventricular function assessment.<unk>
T-1849	outcomes patients prescribed pharmacological discharge left_ventricular_function
H-1849	-0.6287577748298645	▁c PG - re com mend ed ▁ pharma c ological ▁treatment ▁device
D-1849	-0.6287577748298645	cPG-recommended pharmacological treatment device
P-1849	-0.3191 -0.8698 -1.2705 -0.0227 -0.0152 -0.0049 -0.0557 -0.1104 -0.0092 -0.0251 -0.2976 -1.7438 -0.4687 -4.1062 -0.1125
S-569	The purpose of this study was to compare, through a single-centre, parallel-group, randomized controlled trial, the effects of Nordic walking and standard cardiac rehabilitation care on functional capacity and other outcomes in patients with moderate to severe heart failure.<unk>
T-569	randomized walking cardiac_rehabilitation functional_capacity outcomes patients severe_heart_failure
H-569	-1.6284596920013428	▁Nordic _ ▁walking ▁standard _ ▁cardiac ▁rehabilita tion _ de _ ca pit aux _ de _ fon cti onnement
D-569	-1.6284596920013428	Nordic_ walking standard_ cardiac rehabilitation_de_capitaux_de_fonctionnement
P-569	-3.5692 -0.9782 -3.9194 -2.1607 -0.0770 -0.4756 -1.0862 -0.0145 -1.0570 -2.6486 -0.2246 -4.2293 -0.2006 -2.0002 -0.6403 -2.9280 -0.0651 -4.5523 -1.1865 -0.1454 -3.5886 -0.0788
S-1674	Specifically, we have tested whether Rad Q66P limits, or even eliminates, the inhibitory actions of Rad on CaV1.2 and CaV1.3, the two L-type channel isoforms known to be expressed in the heart.<unk>
T-1674	rad q66p rad cav1.2 cav1.3 l-type_channel isoforms heart
H-1674	-1.2942522764205933	▁Rad ▁Q 66 p ▁inhibi tory ▁actions ▁Rad ▁ca V 1.2 ▁l - type _ ▁channel _ iso form s ▁heart
D-1674	-1.2942522764205933	Rad Q66p inhibitory actions Rad caV1.2 l-type_ channel_isoforms heart
P-1674	-1.4741 -2.4602 -0.3328 -0.3391 -1.5031 -0.9544 -0.4542 -1.2936 -1.9383 -1.1818 -5.0353 -4.1447 -0.1300 -0.0246 -1.0804 -4.8604 -0.4187 -1.3306 -0.1385 -0.0947 -0.3125 -0.1273 -0.1387
S-512	EF declined from 64 to 41% in the LCX model and to 44% in the LAD model 4 wk after stenting with 12 and 21% infarcted left ventricle in the LCX and LAD models, respectively.<unk>
T-512	ef lcx lad stenting infarcted left_ventricle lcx lad
H-512	-0.9571164846420288	▁EF ▁ LC x ▁ LAD ▁ LAD ▁figure ▁in far cted ▁left ▁vent ric le ▁ LC x ▁ LAD
D-512	-0.9571164846420288	EF LCx LAD LAD figure infarcted left ventricle LCx LAD
P-512	-1.3868 -0.7816 -0.0541 -0.3761 -1.1414 -0.1291 -2.9306 -0.3384 -3.7953 -0.5841 -0.4612 -1.2590 -0.6900 -0.7371 -3.2337 -0.1854 -0.6413 -0.2654 -0.5992 -1.2052 -0.1299 -0.9535 -0.1353
S-644	Our results reveal that signalling cascades integrate with microRNAs to induce the expression of the bHLH transcription factor Hand2 in the postnatal mammalian myocardium with impact on embryonic gene programs in heart failure.<unk>
T-644	micrornas expression bhlh transcription_factor hand2 myocardium gene heart_failure
H-644	-0.7251738905906677	▁signal ling ▁casca des ▁micro RNA s ▁b HL h ▁tran scription _ factor ▁Hand 2 ▁post na tal _ ▁mamma lian _ ▁my o car dium ▁em bry o nic _ ▁gene ▁programs ▁heart _ ▁failure
D-644	-0.7251738905906677	signalling cascades microRNAs bHLh transcription_factor Hand2 postnatal_ mammalian_ myocardium embryonic_ gene programs heart_ failure
P-644	-0.9390 -1.4866 -0.1282 -0.0072 -0.1975 -0.0011 -0.0223 -0.0065 -0.1025 -0.3769 -0.3219 -0.0543 -2.0263 -2.4858 -0.1378 -0.6046 -0.0219 -0.0911 -0.0276 -1.1753 -0.2406 -0.2835 -0.7115 -3.1145 -0.0922 -0.0040 -0.3601 -0.0581 -0.0026 -0.0633 -2.4226 -0.6121 -2.5427 -2.8445 -0.3655 -1.2089 -2.8259 -0.2218 -0.0930
S-1254	ERC induced recovery/enhancement of DAPC protein levels, sarcomeric microstructure and, in a co-ordinated fashion, alterations in markers of SkM growth/differentiation consistent with myofibre regeneration.<unk>
T-1254	erc dapc_protein sarcomeric_microstructure skm myofibre_regeneration
H-1254	-0.9164415597915649	ERC ▁ ERC ▁DAP c ▁protein _ ▁levels ▁sar come ric ▁micro structure ▁Sk m ▁growth ▁my o fi bre ▁regenera tion
D-1254	-0.9164415597915649	ERC ERC DAPc protein_ levels sarcomeric microstructure Skm growth myofibre regeneration
P-1254	-0.4759 -2.1316 -0.0012 -2.7511 -1.0880 -0.9748 -4.4699 -2.2658 -0.0172 -0.5072 -1.2399 -0.4424 -0.0310 -0.3762 -0.3005 -2.0083 -1.5255 -0.0250 -0.1422 -0.0650 -0.7986 -0.0181 -0.2693 -0.0700
S-360	Possible reasons for the modest reduction in MVA could be annular size reduction by the surgical ring implantation and mild restriction of leaflet motion by the leaflet resection and edge-to-edge anastomosis.<unk>
T-360	mva surgical implantation leaflet leaflet edge-to-edge_anastomosis
H-360	-0.3500831723213196	▁m va ▁sur g ical _ ▁ring ▁implant ation ▁le a flet _ ▁motion ▁le a flet _ ▁res ection ▁edge - to - ed ge ▁an asto mos is
D-360	-0.3500831723213196	mva surgical_ ring implantation leaflet_ motion leaflet_ resection edge-to-edge anastomosis
P-360	-0.2964 -0.2400 -0.8568 -0.0331 -0.1508 -1.4871 -1.1190 -0.0068 -0.0129 -0.0473 -0.0447 -0.0046 -1.0377 -1.1331 -0.9179 -0.0397 -0.0389 -0.7027 -1.2163 -0.0062 -0.3825 -0.1654 -0.4715 -0.1534 -0.1872 -0.0143 -0.1911 -0.0013 -0.0203 -0.0373 -0.1163 -0.0702
S-239	HART enrolled 902 patients in the New York Heart Association (NYHA) class II or III who had been recently hospitalized for HF to study the impact of self-management counseling on the primary outcome of death or HF hospitalization.<unk>
T-239	hart patients new_york_heart_association nyha hospitalized hf primary_outcome death hf hospitalization
H-239	-1.06244957447052	▁h ART ▁New ▁York _ ▁Heart _ ▁Association ▁NY HA ▁ HF ▁ HF
D-239	-1.06244957447052	hART New York_ Heart_ Association NYHA HF HF
P-239	-0.3751 -0.0991 -5.4492 -0.2959 -1.1661 -1.0739 -1.0154 -0.9510 -1.5648 -0.0432 -0.7839 -0.5744 -1.7692 -0.1710 -1.5475 -0.1197
S-1038	show that the BET family bromodomain proteins (BETs), a family of acetyl-lysine reader proteins, are central to HF pathogenesis and that they are promising targets for the prevention of HF.<unk>
T-1038	bet bromodomain_proteins bets acetyl-lysine_reader_proteins hf pathogenesis hf
H-1038	-0.7427412867546082	▁ BET _ bro modo main ▁protein s BET ▁a ce tyl - ly sine _ ▁reader _ ▁protein s ▁ HF
D-1038	-0.7427412867546082	BET_bromodomain proteinsBET acetyl-lysine_ reader_ proteins HF
P-1038	-0.4156 -0.0051 -4.2707 -0.4639 -0.0026 -0.2326 -1.0311 -0.0595 -0.7915 -2.7021 -0.0512 -0.1019 -0.1235 -1.4457 -0.7647 -1.0957 -0.2836 -1.3060 -1.7295 -0.0372 -0.0842 -0.0152 -0.7022 -0.1104
S-1783	In vivo assessment of cardiac function (via echocardiography) demonstrated diastolic dysfunction by 2 weeks (20% increase in E/E'), and systolic dysfunction by 3 weeks (16% decrease in % ejection fraction).<unk>
T-1783	in_vivo cardiac_function echocardiography diastolic_dysfunction systolic_dysfunction ejection_fraction
H-1783	-0.9252688884735107	▁cardiac _ fon cti onnement ▁e cho card i ography ▁dia sto lic _ ▁dys function ▁E / E ▁dys function ▁e je ction _ fraction
D-1783	-0.9252688884735107	cardiac_fonctionnement echocardiography diastolic_ dysfunction E/E dysfunction ejection_fraction
P-1783	-0.3319 -2.0206 -1.8342 -0.8424 -1.1592 -0.0806 -0.2169 -0.1194 -0.3624 -0.6810 -0.0362 -0.1356 -3.1314 -0.9329 -0.0717 -0.2295 -0.7379 -4.8908 -1.1358 -3.4115 -1.5286 -0.3513 -0.7633 -0.0166 -0.6255 -0.0017 -0.1834 -0.0755
S-1733	Aldosterone antagonism in heart failure Aldosterone, a neurohormone known to affect electrolytes, has recently been implicated as playing a major role in the progression of heart failure, particularly in patients with systolic dysfunction.<unk>
T-1733	aldosterone_antagonism heart_failure aldosterone neurohormone electrolytes heart_failure patients systolic_dysfunction
H-1733	-0.8017271161079407	▁al do ster one _ ▁anta gon ism _ ▁in _ ▁heart _ ▁failure ▁al do ster one ▁neuro hormon e ▁electro ly tes
D-1733	-0.8017271161079407	aldosterone_ antagonism_ in_ heart_ failure aldosterone neurohormone electrolytes
P-1733	-1.1203 -0.4021 -0.1629 -1.5877 -2.6712 -0.8226 -0.0679 -1.0100 -1.2606 -0.5055 -0.9957 -1.0541 -0.6139 -1.9936 -2.1491 -0.0523 -0.0311 -0.7852 -0.4253 -0.0532 -0.1111 -0.0258 -0.3090 -0.0147 -2.5024 -0.1177
S-1531	EH was also associated with increased LV compliance compared with CH (LV end-diastolic volume at an idealized LV end-diastolic pressure of 20 mm Hg β coefficient = 14.2; 95% CI 9.4 to 19.1 ml).<unk>
T-1531	lv_compliance lv_end-diastolic_volume lv_end-diastolic_pressure β_coefficient
H-1531	-1.481408953666687	▁EH ▁LV _ de _ ca pit aux _ pu issa nce ▁LV _ de _ ca pit aux _ pu issa nce ▁h g ▁co e ffi cient ▁ml
D-1531	-1.481408953666687	EH LV_de_capitaux_puissance LV_de_capitaux_puissance hg coefficient ml
P-1531	-0.5734 -2.1409 -3.7607 -3.4788 -2.5313 -4.1756 -0.4571 -1.8658 -3.1630 -3.7633 -0.0696 -0.0231 -2.2920 -2.5056 -1.6422 -1.2934 -3.2801 -0.1106 -1.1341 -2.8175 -1.4924 -0.0188 -0.0218 -1.8603 -0.1018 -1.6510 -0.0659 -0.0024 -0.0104 -0.1468 -0.7445 -0.2112
S-202	The guidelines have been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, and are accompanied by practical Recommendations for their application in the clinical setting, supplemented by online material.<unk>
T-202	grade clinical
H-202	-0.7805407643318176	▁Grad ing _ de _ re com mend ations ▁Evalua tion GRAD e
D-202	-0.7805407643318176	Grading_de_recommendations EvaluationGRADe
P-202	-1.6585 -0.8535 -2.4301 -0.4091 -0.2370 -0.3115 -0.0025 -0.0021 -0.0084 -3.8959 -0.0421 -0.2760 -0.2418 -1.2615 -0.0782
S-563	Three-year HF hospitalization rates were 24%, 15%, 15%, 22%, and 28% in ages 20 to 39, 40 to 49, 50 to 59, 60 to 69, and ≥70 years, respectively (p < 0.0001).<unk>
T-563	hf hospitalization
H-563	-1.1105543375015259	▁ HF
D-563	-1.1105543375015259	HF
P-563	-1.4545 -0.3891 -2.4414 -0.1572
S-1460	These definitions will form the foundation for describing a uniform nomenclature for right heart circulatory failure with a view to foster collaborative research initiatives and conjoint education in an effort to provide insight into mechanisms of disease unique to the right heart.<unk>
T-1460	right_heart_circulatory_failure disease right_heart
H-1460	-1.8150396347045898	▁implant ation _ de _ f ré que nce ▁right ▁heart _ ▁circula tory _ ▁failure
D-1460	-1.8150396347045898	implantation_de_fréquence right heart_ circulatory_ failure
P-1460	-6.7001 -0.9027 -2.9853 -3.2533 -0.6106 -4.9229 -0.0433 -0.0883 -0.0166 -3.3530 -3.8810 -0.1925 -1.3224 -1.0474 -0.4138 -2.1884 -0.6008 -0.1485
S-1671	Ca(2+) influx via L-type voltage-gated Ca(2+) channels supports the plateau phase of ventricular action potentials and is the trigger for excitation-contraction (EC) coupling in the myocardium.<unk>
T-1671	ventricular_action_potentials excitation-contraction myocardium
H-1671	-1.2621043920516968	▁influ x ▁l - type _ volta ge - ga ted ▁ca ▁figure ▁vent ri cular ▁action ▁é ▁coup ling
D-1671	-1.2621043920516968	influx l-type_voltage-gated ca figure ventricular action é coupling
P-1671	-4.1952 -0.0081 -2.7782 -0.1617 -0.0070 -1.6874 -1.1518 -0.0847 -0.2350 -0.0174 -0.1282 -1.0283 -4.6458 -1.0361 -0.2330 -0.5414 -0.0817 -3.9815 -1.5905 -1.4426 -2.4490 -0.2816
S-1967	Dual inhibition of AT1 receptors and neprilysin blocks renin-angiotensin-aldosteron (RAS) axis and concurrently supports natural vasodilatory and diuretic effect of natriuretic peptides.<unk>
T-1967	at1_receptors neprilysin renin-angiotensin-aldosteron ras vasodilatory diuretic natriuretic_peptides
H-1967	-0.6568357348442078	▁AT 1 ▁receptor s ▁nepri ly sin ▁block s ▁re nin - angi oten sin - al do ster on ▁ RAS ▁vaso dila tory ▁di ure tic ▁pe pti des
D-1967	-0.6568357348442078	AT1 receptors neprilysin blocks renin-angiotensin-aldosteron RAS vasodilatory diuretic peptides
P-1967	-3.0076 -0.2767 -0.7376 -0.2239 -0.5755 -0.0731 -0.7989 -0.1671 -0.0865 -0.3339 -0.2063 -0.0239 -0.0312 -0.0168 -2.2690 -0.4294 -0.0584 -1.3589 -0.0564 -0.2508 -0.8161 -0.0014 -2.7935 -0.0678 -0.8419 -0.7223 -0.0566 -2.3947 -2.1202 -0.1995 -0.0742 -0.4695 -0.1360
S-1171	OBJECTIVES: The aim of this study was to test the effects of treatment with ivabradine on exercise capacity and left ventricular filling in patients with heart failure with preserved ejection fraction (HFpEF).<unk>
T-1171	ivabradine exercise_capacity left_ventricular_filling patients heart_failure_with_preserved_ejection_fraction hfpef
H-1171	-0.8185958862304688	▁i va bra dine ▁vent ri cular _ ▁fill ing ▁heart _ ▁failure ▁h p EF
D-1171	-0.8185958862304688	ivabradine ventricular_ filling heart_ failure hpEF
P-1171	-0.0892 -0.0283 -0.6300 -0.0058 -2.7485 -0.0931 -0.0835 -2.1925 -0.2753 -0.0181 -1.2827 -0.4602 -4.0957 -1.7824 -0.0104 -0.7566 -0.1033 -0.0791
S-42	Study Selection: English-language trials of blood transfusions, iron, or erythropoiesis-stimulating agents in adults with anemia and congestive heart failure or coronary heart disease and observational studies of transfusion.<unk>
T-42	blood_transfusions erythropoiesis-stimulating_agents anemia congestive_heart_failure coronary_heart_disease transfusion
H-42	-0.6237369775772095	▁English - language ▁trans fusion s ▁ir on ▁er y thro po ies is - stimul ating ▁agents ▁an emia ▁con ges tive ▁heart _ ▁failure ▁corona ry _ heart _ de ▁trans fusion
D-42	-0.6237369775772095	English-language transfusions iron erythropoiesis-stimulating agents anemia congestive heart_ failure coronary_heart_de transfusion
P-42	-3.0244 -0.1961 -0.0131 -2.4339 -0.0249 -0.0685 -0.0255 -0.0081 -0.6188 -0.1240 -0.6222 -1.3830 -0.9286 -0.0365 -0.7218 -0.0240 -0.8529 -0.0320 -0.4386 -0.0070 -0.0571 -0.0567 -0.0264 -0.7099 -0.8751 -0.4443 -0.0069 -0.1825 -0.6023 -1.4540 -1.5165 -3.3724 -1.1838 -0.0056 -0.3025 -0.0745
S-1570	Univariate analysis showed that high BNP was associated with age, estimated glomerular filtration rate, hypertension, and transmitral E-wave/early diastolic mitral annular velocity (E/e') ratio.<unk>
T-1570	univariate_analysis bnp estimated_glomerular_filtration_rate hypertension transmitral e-wave diastolic_mitral_annular_velocity
H-1570	-0.6273327469825745	▁b NP ▁glo mer ular ▁filtr ation _ ▁rate ▁hyper tension ▁transmit ral ▁E - wa ve ▁dia sto lic _ ▁mit ral _ ▁ann ular _ ▁veloci ty
D-1570	-0.6273327469825745	bNP glomerular filtration_ rate hypertension transmitral E-wave diastolic_ mitral_ annular_ velocity
P-1570	-0.2941 -1.3588 -0.2672 -0.0081 -0.0190 -0.4064 -0.0128 -1.7968 -0.7715 -0.0129 -0.0001 -0.0851 -0.0122 -1.1549 -0.0109 -0.0402 -0.0153 -1.2036 -0.4402 -1.3693 -0.6014 -2.7163 -0.0192 -0.3261 -1.9351 -0.0003 -0.5011 -3.1783 -0.2889 -0.5120 -0.0892
S-1425	Nonetheless, β-blockade does not halt disease progression, suggesting that cAMP-dependent protein kinase (PKA) signaling downstream of β-adrenergic receptor activation may persist through unique post-translational states.<unk>
T-1425	β-blockade halt disease protein_kinase pka β-adrenergic_receptor
H-1425	-0.5692219138145447	▁β - block ade ▁c AMP - dependent ▁protein ▁kina se ▁p KA ▁β - ad r energi c ▁receptor _ activa tion
D-1425	-0.5692219138145447	β-blockade cAMP-dependent protein kinase pKA β-adrenergic receptor_activation
P-1425	-0.8290 -0.0809 -0.5504 -1.5446 -0.7594 -0.0404 -0.1495 -0.0506 -1.4394 -1.1328 -0.0539 -0.7402 -0.3594 -0.4949 -0.0167 -0.0391 -0.1733 -0.7868 -0.2495 -1.1326 -1.5840 -0.9531 -0.0500 -0.8622 -0.1578
S-47	Moderate- to high-strength evidence from 17 trials of erythropoiesis-stimulating agent therapy found they offered no consistent benefits, but their use may be associated with harms, such as venous thromboembolism.<unk>
T-47	evidence erythropoiesis-stimulating_agent therapy venous_thromboembolism
H-47	-1.1727330684661865	▁er y thro po ies is - stimul ation ▁agent _ therapy
D-47	-1.1727330684661865	erythropoiesis-stimulation agent_therapy
P-47	-4.9864 -0.0710 -1.6036 -2.4927 -1.5658 -0.1357 -0.5536 -0.0501 -1.1287 -0.6561 -1.1676 -0.2539 -1.7007 -0.0523
S-1456	A combined (clinical and genetic) CHF predictive model performed better [area under the curve (AUC), 0·79] than the genetic (AUC = 0·67) or the clinical (AUC = 0·69) models alone.<unk>
T-1456	clinical genetic chf area_under_the_curve auc genetic auc clinical auc
H-1456	-1.592637538909912	clin ical ▁genetic ▁CHF
D-1456	-1.592637538909912	clinical genetic CHF
P-1456	-2.3967 -0.0733 -2.5697 -0.5871 -3.8833 -0.0456
S-1638	After multivariable adjustment, black race was associated with increased mortality/hospitalization (hazard ratio [HR] 1.16, 95% CI 1.01-1.33) and cardiovascular mortality/HF hospitalization (HR 1.46, 95% CI 1.20-1.77).<unk>
T-1638	multivariable_adjustment mortality hospitalization hazard_ratio cardiovascular_mortality hf hospitalization
H-1638	-0.7916166186332703	▁black ▁race ▁mortal ity _ hospital ization haz ard ▁ratio ▁cardiovascular _ ▁mortal ity HF
D-1638	-0.7916166186332703	black race mortality_hospitalizationhazard ratio cardiovascular_ mortalityHF
P-1638	-0.1333 -2.1457 -2.1481 -0.2615 -2.4171 -0.1305 -1.0538 -0.1642 -0.0043 -0.9270 -0.6627 -1.6481 -0.1537 -0.1902 -0.7788 -0.5127 -0.1259
S-504	In this study we developed a novel percutaneous one- and two-vessel model for chronic myocardial ischemia using a stent coated with a polytetrafluoroethylene tube formed in a bottleneck shape.<unk>
T-504	percutaneous chronic_myocardial_ischemia stent polytetrafluoroethylene
H-504	-0.8288976550102234	▁per cuta ne ous _ des _ ves sel ▁model ▁chronic _ My o card ial _ ▁ ische mia ▁sten t ▁poly te tra flu oro e thy lene ▁tube ▁bottle ne ck
D-504	-0.8288976550102234	percutaneous_des_vessel model chronic_Myocardial_ ischemia stent polytetrafluoroethylene tube bottleneck
P-504	-1.7365 -0.0084 -0.0150 -1.3416 -2.9964 -4.7554 -1.0119 -0.1342 -0.0040 -3.0179 -0.9705 -0.1303 -3.4083 -0.2713 -0.2991 -0.0843 -0.1706 -4.2422 -1.2938 -0.4275 -0.0181 -0.0139 -0.0139 -0.0411 -0.1598 -0.1150 -0.2298 -1.2244 -0.1340 -0.2418 -0.3026 -0.0928 -0.0069 -0.4392 -0.4138 -0.0739
S-1031	The Centers for Medicare and Medicaid Services (CMS) has operationalized hospital quality of care outcomes through publicly reported 30-day risk-standardized mortality and readmission rates and associated penalties for higher-than-expected rates.<unk>
T-1031	centers_for_medicare_and_medicaid_services cms hospital outcomes reported mortality readmission penalties
H-1031	-1.1110048294067383	▁Center s _ for _ ▁Medica re _ ▁and _ ▁Medica id ▁Services ▁c MS ▁hospital _ quality _ de _ ca pit aux _ de _ ca pit aux ▁mortal ity ▁read mission ▁penal ties
D-1031	-1.1110048294067383	Centers_for_ Medicare_ and_ Medicaid Services cMS hospital_quality_de_capitaux_de_capitaux mortality readmission penalties
P-1031	-0.2309 -0.0387 -0.1828 -3.6915 -0.4315 -0.0593 -0.0015 -1.5035 -1.9416 -1.9678 -0.1133 -0.6196 -1.1013 -0.1596 -0.4453 -4.0079 -0.7509 -2.2897 -0.1744 -1.4074 -0.0700 -2.6183 -2.0538 -0.9405 -1.2203 -0.6576 -0.1056 -2.9615 -1.1822 -0.3122 -4.8716 -0.1125 -0.7163 -0.0215 -2.6071 -0.3370 -0.1850 -0.1270
S-601	BACKGROUND: While heart failure (HF) is associated with elevations in tumor necrosis factor (TNF)α, several trials of TNF antagonists showed no benefit and possibly worsening of disease in those with known severe HF.<unk>
T-601	heart_failure hf tumor_necrosis_factor tnf tnf_antagonists disease severe_hf
H-601	-0.8283700942993164	▁heart _ ▁failure ▁tumor _ ▁nec rosi s ▁factor TN f ▁t NF ▁anta gon ists ▁ HF
D-601	-0.8283700942993164	heart_ failure tumor_ necrosis factorTNf tNF antagonists HF
P-601	-0.1918 -0.6008 -2.8941 -1.0071 -0.5101 -1.5702 -0.0687 -0.0551 -1.3506 -0.9751 -0.6848 -1.3742 -0.0279 -1.8440 -0.0616 -0.2265 -2.4801 -0.3677 -0.2337 -0.0433
S-1040	These activate a signal transduction cascade that converges on a defined set of transcription factors, and pathological changes in cardiomyocytes occur through an interplay between these transcription factors and epigenetic changes in chromatin structure.<unk>
T-1040	activate signal_transduction transcription_factors pathological cardiomyocytes transcription_factors epigenetic chromatin_structure
H-1040	-0.7297757863998413	▁signal ▁trans duction ▁casca de ▁tran scription ▁factors ▁cardio my o cy tes ▁tran scription ▁factors ▁epi gene tic ▁changes ▁chr omat in ▁structure
D-1040	-0.7297757863998413	signal transduction cascade transcription factors cardiomyocytes transcription factors epigenetic changes chromatin structure
P-1040	-0.1101 -0.4012 -0.3219 -1.0833 -0.0038 -1.2601 -0.1234 -2.5857 -0.4674 -1.1925 -0.7293 -0.2614 -0.1582 -0.7080 -0.2263 -2.4602 -0.8627 -0.0808 -1.4447 -1.1123 -0.2582 -0.0146 -1.3086 -1.4643 -0.1971 -0.1380
S-1416	We used Cox proportional hazard models with time-dependent covariates to analyze the effect of follow-up with a familiar physician within the first month after discharge on the primary outcome of death or urgent all-cause readmission over 6 months.<unk>
T-1416	cox_proportional_hazard_models covariates follow-up physician discharge primary_outcome death all-cause_readmission
H-1416	-0.9540852904319763	▁co x ▁proportion al ▁hazard _ modellen ▁temps - dependent ▁co varia tes ▁follow - up ▁physician
D-1416	-0.9540852904319763	cox proportional hazard_modellen temps-dependent covariates follow-up physician
P-1416	-2.6680 -0.0065 -0.6624 -0.0192 -0.1772 -2.1276 -2.1825 -1.0078 -0.2058 -0.0902 -1.4626 -0.8471 -0.0488 -0.8912 -0.0127 -0.0067 -1.2936 -4.2842 -0.1333
S-1760	At multivariable logistic analysis, failure in detecting AT resulted significantly in reduced peak oxygen uptake and higher metabolic exercise and cardiac and kidney index score value, a powerful prognostic composite HF index (P<0.001).<unk>
T-1760	multivariable_logistic_analysis peak_oxygen_uptake metabolic_exercise cardiac kidney prognostic hf_index
H-1760	-1.7271580696105957	▁multi vari able ▁logistic ▁analysis
D-1760	-1.7271580696105957	multivariable logistic analysis
P-1760	-5.3100 -0.0001 -0.0061 -0.3537 -1.3234 -4.9636 -0.1332
S-334	The mechanism is a combination of annular size reduction by surgery and diastolic mitral valve tethering, restricting the anterior leaflet opening due to posteriorly displaced papillary muscles with left ventricular dilatation.<unk>
T-334	combination surgery diastolic_mitral_valve_tethering anterior_leaflet papillary_muscles left_ventricular_dilatation
H-334	-0.6324109435081482	▁ann ular _ ▁size _ re duction ▁surgery ▁dia sto lic _ ▁mit ral _ ▁val ve _ ▁te ther ing ▁anterior ▁le a flet ▁opening ▁papil lar y _ ▁muscle s ▁left ▁vent ri cular _ ▁di la tation
D-334	-0.6324109435081482	annular_ size_reduction surgery diastolic_ mitral_ valve_ tethering anterior leaflet opening papillary_ muscles left ventricular_ dilatation
P-334	-0.2279 -0.0002 -2.4019 -1.4658 -1.5036 -1.1815 -0.0009 -0.3701 -0.0065 -0.0519 -1.7181 -0.8949 -2.0363 -0.0055 -0.9654 -1.4959 -0.1253 -0.9705 -0.7997 -0.0023 -0.0171 -0.2121 -0.2984 -0.0828 -0.0010 -1.2434 -2.0119 -0.5467 -0.3637 -1.7155 -0.2201 -0.0695 -0.4330 -0.1031 -0.0906 -0.0597 -0.5975 -1.9434 -0.0563 -0.0031 -0.1852 -0.0833
S-926	CONCLUSIONS: In patients with hypertensive HFPEF, the sodium-restricted DASH diet was associated with favorable changes in ventricular diastolic function, arterial elastance, and ventricular-arterial coupling.<unk>
T-926	patients hypertensive_hfpef dash ventricular_diastolic_function arterial_elastance ventricular-arterial_coupling
H-926	-0.5128116011619568	▁hyper tensi ve ▁H FP EF ▁so dium - re strict ed ▁DAS H ▁vent ri cular _ ▁dia sto lic _ fon cti onnement ▁arterial _ ▁elastan ce ▁vent ri cular - arte rial ▁coup ling
D-926	-0.5128116011619568	hypertensive HFPEF sodium-restricted DASH ventricular_ diastolic_fonctionnement arterial_ elastance ventricular-arterial coupling
P-926	-0.6742 -0.8563 -0.2544 -0.5867 -0.5786 -0.9665 -0.2555 -0.0139 -0.0094 -0.0016 -0.0091 -0.0630 -0.0135 -0.7954 -0.3372 -0.0367 -0.0636 -0.3560 -1.3699 -0.2223 -1.8540 -2.3348 -2.7333 -0.5029 -0.3489 -0.0286 -1.3682 -0.1829 -0.2810 -0.0025 -0.0326 -0.0454 -0.5916 -0.1276 -0.0811 -0.0336 -1.7313 -0.1854 -0.0703
S-1450	We examined the association between the development of CHF after HCT and polymorphisms in 16 candidate genes involved in anthracycline metabolism, iron homeostasis, anti-oxidant defence, and myocardial remodelling.<unk>
T-1450	chf hct polymorphisms genes anthracycline metabolism iron_homeostasis anti-oxidant_defence myocardial_remodelling
H-1450	-0.31452634930610657	▁CHF ▁h CT ▁poly morph ism s ▁an thra cycli ne ▁metabolism ▁ir on ▁home osta sis ▁anti - oxid ant _ de _ fen ce ▁my o card ial ▁remodel ling
D-1450	-0.31452634930610657	CHF hCT polymorphisms anthracycline metabolism iron homeostasis anti-oxidant_de_fence myocardial remodelling
P-1450	-0.2721 -0.6945 -1.6517 -2.8989 -0.0036 -0.2045 -0.0210 -0.0293 -0.0017 -0.4627 -0.2294 -0.1596 -0.0090 -0.0039 -0.8349 -0.0609 -0.0575 -0.0033 -0.0682 -0.0010 -0.1778 -0.3864 -0.0700 -1.3184 -0.1462 -0.1129 -0.1747 -0.0263 -0.1460 -0.0185 -0.0855 -0.1151 -0.2028 -0.0454
S-1187	Using multivariate logistic regression analysis, we derived a prediction rule for severe CAD (≥50% diameter stenosis in the left main, 3-vessel CAD, and 2-vessel CAD involving the proximal left anterior descending artery).<unk>
T-1187	multivariate_logistic_regression_analysis rule cad stenosis 3-vessel_cad 2-vessel_cad left_anterior_descending_artery
H-1187	-1.9646354913711548	▁implant ation _ de _ lut te _ de _ con du ite _ de _ con du ite _ de _ lut te _ de _ con du ite _ de _ ca pit aux ▁diameter _ ▁sten osis
D-1187	-1.9646354913711548	implantation_de_lutte_de_conduite_de_conduite_de_lutte_de_conduite_de_capitaux diameter_ stenosis
P-1187	-7.3680 -1.4783 -3.2026 -3.8280 -0.3832 -4.9967 -0.2996 -0.7821 -2.6271 -0.6878 -3.8626 -2.1114 -0.4170 -1.6174 -2.6189 -0.2763 -4.4370 -1.0984 -0.1813 -2.1477 -2.6514 -0.2822 -4.5148 -0.0803 -1.3493 -1.8300 -0.5129 -3.5329 -1.0667 -0.1542 -2.3429 -2.2564 -0.3355 -2.8650 -0.6735 -2.4053 -2.6416 -1.1738 -0.1529 -0.0432 -7.1365 -0.0921
S-1305	Trends from 1996 to 2007 in incidence and mortality outcomes of heart failure after acute myocardial infarction: a population-based study of 20,812 patients with first acute myocardial infarction in Western Australia.<unk>
T-1305	incidence mortality outcomes heart_failure acute_myocardial_infarction patients acute_myocardial_infarction western_australia
H-1305	-1.1108722686767578	▁heart _ ▁failure ▁a cute _ My o card ial _ ▁in far ction
D-1305	-1.1108722686767578	heart_ failure acute_Myocardial_ infarction
P-1305	-2.9217 -0.6673 -2.2598 -0.6402 -0.0058 -0.0751 -4.6200 -0.7443 -0.4401 -0.1533 -1.4155 -0.2212 -1.2130 -0.0841 -2.1738 -0.1388
S-1735	The first was the Randomized Aldactone Evaluation Study, which was done in symptomatic chronic advanced heart failure patients and showed that an aldosterone antagonist, spironolactone, reduced mortality significantly compared with placebo.<unk>
T-1735	randomized_aldactone_evaluation_study symptomatic_chronic_advanced_heart_failure patients aldosterone_antagonist spironolactone mortality placebo
H-1735	-0.9437282085418701	▁al da cto ne _ ▁Evalua tion _ ▁Study ▁symptom a tic ▁chronic _ ▁advanced _ heart _ ▁failure ▁al do ster one _ ▁anta gon ist ▁spi rono lac tone ▁mortal ity
D-1735	-0.9437282085418701	aldactone_ Evaluation_ Study symptomatic chronic_ advanced_heart_ failure aldosterone_ antagonist spironolactone mortality
P-1735	-0.7456 -1.2316 -0.4211 -0.0851 -2.8120 -0.4855 -0.0146 -3.2017 -1.4439 -3.9794 -0.0399 -0.7840 -1.4859 -0.4843 -1.6014 -0.4808 -1.8309 -0.6856 -1.4038 -2.7053 -0.2174 -0.0796 -2.0073 -0.6661 -0.0393 -0.0413 -2.1798 -0.0145 -0.0089 -0.0792 -0.1236 -0.5036 -0.4701 -0.6012 -0.0765
S-559	They were less likely to adhere to medication (nonadherence in youngest vs. oldest: 24% vs. 7%, p = 0.001), salt intake, and other dietary measures (21% vs. 9%, p = 0.002).<unk>
T-559	medication
H-559	-1.1611384153366089	▁medication
D-559	-1.1611384153366089	medication
P-559	-1.2591 -2.0558 -0.1685
S-1278	Given the different pathophysiological origin, a multivariate assessment with the inclusion of all the aforementioned parameters should be encouraged, not only for diagnostic and prognostic purposes but also for evaluating the effect of interventions.<unk>
T-1278	pathophysiological diagnostic prognostic
H-1278	-0.7448546290397644	▁pat ho phy si ological
D-1278	-0.7448546290397644	pathophysiological
P-1278	-0.5011 -0.3388 -0.0429 -0.2723 -0.2861 -3.7224 -0.0504
S-534	Survival after LVAD surgery was better in patients with normal albumin levels compared with those with hypoalbuminemia before surgery (3 and 12 months: 93.2% vs 82.4% and 88.4% vs 75.2%, respectively, p <0.001).<unk>
T-534	lvad surgery patients albumin hypoalbuminemia surgery
H-534	-1.5509220361709595	▁l VAD
D-534	-1.5509220361709595	lVAD
P-534	-2.0852 -0.0745 -3.9216 -0.1224
S-310	We systematically searched the scientific literature (January 2008-June 2012) and identified 14 clinical studies (approximately 2900 HM II and approximately 200 HeartWare patients), and 3 economic evaluations (HM II) using simulation models.<unk>
T-310	clinical hm_ii heartware patients economic hm_ii
H-310	-1.3878324031829834	▁scientific ▁literature ▁ HM _ ▁II ▁Heart War e
D-310	-1.3878324031829834	scientific literature HM_ II HeartWare
P-310	-0.5469 -3.0327 -1.7771 -0.0229 -2.4905 -1.2275 -1.4308 -0.3908 -0.0482 -4.1806 -0.1182
S-717	In a multivariate model that included listing criteria, creatinine (hazard ratio, 1.05 per 0.1 mg/dL; 95% confidence interval, 1.02-1.09; P=0.001) was a significant predictor of post-transplant mortality.<unk>
T-717	multivariate_model creatinine hazard_ratio confidence_interval mortality
H-717	-0.9642857909202576	▁creati nine haz ard ▁ratio ▁d L
D-717	-0.9642857909202576	creatininehazard ratio dL
P-717	-0.6155 -0.7421 -0.3753 -0.0051 -2.7271 -1.4698 -0.3174 -2.3270 -0.0994
S-313	Although complications after implantation are frequent, LVAD therapy is often highly effective across transplantation eligibility status and device, with 1-year survival reaching 86% for BTT and 78% for DT (compared with 25% for medical therapy).<unk>
T-313	complications implantation lvad_therapy transplantation btt dt medical_therapy
H-313	-0.6718207001686096	▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation
D-313	-0.6718207001686096	implantation implantation implantation implantation implantation
P-313	-0.2091 -0.0271 -0.7014 -0.0119 -0.9905 -0.0099 -1.1149 -0.0092 -1.1686 -0.0098 -3.7374 -0.0720
S-580	METHODS: Clinical, biologic, and radial artery tonometry variables were prospectively obtained at admission and at day 3 to 5 in 53 consecutive patients with PH admitted to our ICU for clinical deterioration.<unk>
T-580	clinical artery_tonometry prospectively admission patients icu clinical
H-580	-0.8069003820419312	▁radi al _ ▁arter y _ ▁ton ometr y
D-580	-0.8069003820419312	radial_ artery_ tonometry
P-580	-1.1154 -0.0259 -1.2492 -0.9798 -0.2449 -0.2122 -1.1662 -0.0591 -0.0985 -3.6478 -0.0769
S-1591	Future randomized trials using HR variability/turbulence as one of the pre-defined inclusion criteria will show whether routine measurement of HR variability/turbulence will become a routine clinical tool for risk stratification of cardiac patients.<unk>
T-1591	randomized hr_variability hr_variability clinical risk_stratification cardiac patients
H-1591	-0.8413822650909424	▁HR ▁variabil ity _ tur bul ence
D-1591	-0.8413822650909424	HR variability_turbulence
P-1591	-1.9105 -1.8198 -0.3751 -0.4403 -0.4251 -0.0021 -0.0751 -2.2370 -0.2875
S-72	IMPORTANCE: Small studies suggest that low-dose dopamine or low-dose nesiritide may enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction; however, neither strategy has been rigorously tested.<unk>
T-72	dopamine nesiritide renal_function patients acute_heart_failure renal_dysfunction
H-72	-1.274277925491333	▁low - dos e ▁dop amine ▁nesi riti de ▁renal ▁dys function
D-72	-1.274277925491333	low-dose dopamine nesiritide renal dysfunction
P-72	-4.4471 -0.0331 -0.6113 -0.2453 -1.1599 -0.1014 -3.9755 -0.1170 -0.0602 -0.2249 -5.3521 -1.0493 -0.4088 -0.0540
S-977	The risk of death was significantly increased in patients with estimated glomerular filtration rate of 15 to 45 ml/min/1.73 m(2) (odds ratio 1.76, 95% confidence interval 1.38 to 2.25) even after adjustment for all confounders.<unk>
T-977	death patients estimated_glomerular_filtration_rate odds_ratio confidence_interval
H-977	-0.8699607253074646	▁risk _ de _ ▁death ▁glo mer ular _ ▁filtr ation
D-977	-0.8699607253074646	risk_de_ death glomerular_ filtration
P-977	-1.3631 -1.2295 -0.7859 -0.1608 -1.0884 -0.6387 -0.0620 -0.0985 -1.3911 -0.6687 -0.1156 -3.4521 -0.2551
S-672	Breast cancer patients at least 66 years old with full Medicare coverage, diagnosed with stage I-III breast cancer between 2005 and 2009, and treated with chemotherapy were identified in the SEER-Medicare and in the Texas Cancer Registry–Medicare databases.<unk>
T-672	breast_cancer patients medicare diagnosed breast_cancer chemotherapy seer-medicare texas medicare
H-672	-0.7712343335151672	▁Medica re ▁breast ▁cancer ▁breast ▁cancer ▁che mo therapy ▁s EER - Medic are ▁Texas _ cancer ▁Registr y _ Medic are
D-672	-0.7712343335151672	Medicare breast cancer breast cancer chemotherapy sEER-Medicare Texas_cancer Registry_Medicare
P-672	-0.6660 -0.0023 -1.4530 -0.7549 -3.3354 -0.9498 -0.5734 -0.0120 -0.0190 -1.2322 -0.0057 -0.0401 -0.0131 -0.4704 -0.0796 -2.0969 -1.9109 -3.1413 -0.0128 -0.3266 -0.0886 -0.5739 -0.6415 -0.1101
S-995	ERK1/2 signalling requires a signalosome complex where a scaffold protein drives the assembly of these three kinases into a linear pathway to facilitate their sequential phosphorylation, ultimately targeting specific effector molecules.<unk>
T-995	signalosome_complex scaffold_protein drives kinases phosphorylation effector_molecules
H-995	-0.8368512988090515	▁signal o some _ ▁complex ▁sc af fold _ ▁protein ▁kina ses ▁sequenti al ▁ phos phor y lation
D-995	-0.8368512988090515	signalosome_ complex scaffold_ protein kinases sequential phosphorylation
P-995	-1.4557 -3.7507 -1.2490 -1.9133 -0.6269 -0.0134 -0.1924 -0.0899 -1.1374 -0.4992 -0.2849 -0.0934 -0.1303 -0.0371 -1.0031 -0.2621 -0.4143 -3.3212 -0.0213 -0.9510 -0.1273
S-2006	CONCLUSIONS: The results show that the fully magnetically levitated centrifugal-flow chronic LVAS is safe, with high 30-day and 6-month survival rates, a favorable adverse event profile, and improved quality of life and functional status.<unk>
T-2006	fully_magnetically_levitated_centrifugal-flow_chronic_lvas adverse_event quality_of_life functional_status
H-2006	-0.7021812200546265	▁magnet ically ▁le vita ted ▁centri fu gal - flow _ chron ▁L VAS
D-2006	-0.7021812200546265	magnetically levitated centrifugal-flow_chron LVAS
P-2006	-1.4802 -0.1872 -0.7856 -0.0165 -0.8500 -1.0980 -0.1652 -0.1402 -0.2260 -0.1884 -0.9550 -1.1094 -2.7385 -0.0332 -1.1963 -0.0651
S-1215	In diseased cardiomyocytes, higher PDE2 activity could be further enhanced by stimulation of cGMP synthesis via nitric oxide donors, whereas specific PDE2 inhibition partially restored β-AR responsiveness.<unk>
T-1215	diseased cardiomyocytes pde2 activity cgmp_synthesis nitric_oxide donors pde2_inhibition β-ar_responsiveness
H-1215	-0.6323438882827759	▁cardio my o cy tes ▁p de 2 ▁activity ▁c G MP ▁ni tric ▁oxid e _ ▁donor s ▁p de 2 ▁inhibi tion ▁β - AR ▁responsive ness
D-1215	-0.6323438882827759	cardiomyocytes pde2 activity cGMP nitric oxide_ donors pde2 inhibition β-AR responsiveness
P-1215	-1.2542 -1.7120 -0.9401 -0.1386 -0.1418 -0.7237 -0.2026 -0.0846 -1.6069 -0.0057 -1.4650 -0.6783 -1.0466 -0.0954 -0.2104 -0.0828 -3.0138 -0.5223 -0.0888 -0.6161 -0.2058 -0.1846 -2.1906 -0.0649 -0.0354 -0.0065 -0.0253 -0.9028 -1.0755 -0.2187 -0.0629
S-186	Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: findings from the Get With The Guideline-Heart Failure Registry.<unk>
T-186	ejection_fraction b-type_natriuretic_peptide patients hospitalized heart_failure inhospital outcomes get_with_the_guideline-heart_failure_registry
H-186	-0.9457228779792786	▁e je ction _ fraction ▁b - type ▁na tri ure tic _ pe pti de ▁patients _ hospital ized ▁heart _ ▁Fail ure
D-186	-0.9457228779792786	ejection_fraction b-type natriuretic_peptide patients_hospitalized heart_ Failure
P-186	-1.0051 -0.5537 -0.0071 -1.1128 -0.0010 -0.6424 -0.1127 -0.0864 -0.2783 -0.0136 -0.1243 -3.0634 -1.9071 -0.3661 -0.0653 -0.1300 -2.4545 -2.8480 -0.2437 -1.4435 -1.3160 -0.6685 -4.0635 -0.0739 -1.7852 -0.2223
S-1404	beta1-adrenergic receptor and sphingosine-1-phosphate receptor 1 (S1PR1) reciprocal downregulation influences cardiac hypertrophic response and progression to heart failure: protective role of S1PR1 cardiac gene therapy.<unk>
T-1404	beta1-adrenergic_receptor sphingosine-1-phosphate_receptor_1 s1pr1 downregulation cardiac hypertrophic heart_failure s1pr1 cardiac gene therapy
H-1404	-0.8765987157821655	▁ad r energi c ▁receptor ▁sp hing os ine _ phos pha te ▁receptor ▁S 1 PR ▁cardiac _ ▁hyper trop hic ▁response ▁heart _ ▁failure
D-1404	-0.8765987157821655	adrenergic receptor sphingosine_phosphate receptor S1PR cardiac_ hypertrophic response heart_ failure
P-1404	-3.1535 -0.0345 -0.0479 -0.0790 -0.5207 -0.0107 -0.0647 -0.7040 -0.4344 -1.4690 -0.3564 -0.0801 -0.0511 -0.8337 -2.2382 -0.0343 -0.2497 -2.7938 -1.1928 -1.4591 -0.0026 -0.2934 -2.3447 -0.9547 -0.7248 -3.3947 -0.9265 -0.0957
S-251	ECs were incubated with HDL, and phosphorylation of eNOS-Ser(1177), eNOS-Thr(495), PKC-βII-Ser(660), and p70S6K-Ser(411) was evaluated.<unk>
T-251	ecs hdl phosphorylation
H-251	-0.4746532738208771	▁EC s ▁HD L ▁ phos phor y lation ▁e NOS - Ser ▁e NOS - Th r ▁PK c - β II - Ser
D-251	-0.4746532738208771	ECs HDL phosphorylation eNOS-Ser eNOS-Thr PKc-βII-Ser
P-251	-0.2777 -1.5342 -1.1724 -1.3218 -0.0308 -0.0023 -0.0335 -1.1879 -0.0145 -0.0359 -0.0259 -0.1626 -1.1805 -0.0338 -0.0183 -0.1558 -0.3760 -0.0028 -0.0485 -0.3985 -0.3542 -0.2819 -1.5088 -0.1197 -0.1224 -2.2588 -0.1559
S-155	RESULTS: Twenty-one RCTs that enrolled 6317 patients were identified (11 studies evaluated STS (10 of which were HH, while 1 was HM), 9 studies assessed TM, and 1 study assessed both STS and TM).<unk>
T-155	rcts patients sts hh sts
H-155	-1.4491040706634521	▁r CT s ▁s ts ▁h ▁h m ▁s ts ▁TM
D-155	-1.4491040706634521	rCTs sts h hm sts TM
P-155	-4.8018 -0.7712 -0.3131 -1.4832 -0.4323 -0.3709 -1.2055 -2.6638 -2.3980 -1.0140 -2.7178 -0.6202 -0.0465
S-417	In adult mouse ventricular myocytes, it dose dependently increased sarcomere shortening by 75% to 210% (50-500 μmol/L), with a ≈30% rise in the peak Ca(2+) transient only at higher doses.<unk>
T-417	ventricular_myocytes sarcomere shortening
H-417	-0.7355168461799622	▁mouse ▁vent ri cular _ My o cy tes ▁sar com ere
D-417	-0.7355168461799622	mouse ventricular_Myocytes sarcomere
P-417	-0.4008 -0.1348 -0.0861 -0.2920 -0.8713 -2.1320 -0.1449 -0.1265 -0.1823 -0.3887 -0.0985 -0.8651 -4.4999 -0.0743
S-1415	METHODS: We used data from linked administrative databases for all adults aged 20 years or more in the province of Alberta who were discharged alive from hospital between January 1999 and June 2009 with a first-time diagnosis of heart failure.<unk>
T-1415	administrative alberta discharged hospital diagnosis heart_failure
H-1415	-0.8131687641143799	▁administrative ▁database s ▁province _ de _ ▁Albert a ▁dis charge d _ ▁ali ve ▁hospital
D-1415	-0.8131687641143799	administrative databases province_de_ Alberta discharged_ alive hospital
P-1415	-0.3622 -4.1607 -0.0768 -0.8009 -0.6460 -1.5645 -0.2415 -0.4423 -0.0848 -1.3881 -0.0025 -0.5155 -0.3279 -0.0194 -0.0977 -0.2341 -3.6100 -0.0622
S-829	Low PASP was associated with a significantly lower 6-minute walking distance, peak o2 per kilogram, and 1-, 3-, and 4-year survival rates (92%, 69%, and 48%, respectively, versus 96%, 92%, and 89%).<unk>
T-829	pasp 6-minute_walking_distance peak_o2
H-829	-1.8731685876846313	▁PAS p
D-829	-1.8731685876846313	PASp
P-829	-1.9364 -1.5998 -3.8636 -0.0928
S-757	After adjusting for important covariates, the CRT ON assignment remained independently associated with improved time to death or first HF hospitalization (hazard ratio, 0.54; P=0.035), whereas there was no significant interaction with LVEF.<unk>
T-757	covariates crt death hf hospitalization hazard_ratio lvef
H-757	-1.2183761596679688	▁c RT _ on _ ▁assign ment ▁temps _ ▁to _ ▁death ▁ HF haz ard ▁LV EF
D-757	-1.2183761596679688	cRT_on_ assignment temps_ to_ death HFhazard LVEF
P-757	-0.2990 -0.4189 -3.4207 -0.5057 -3.7018 -1.3286 -0.0091 -1.8585 -2.0003 -1.7718 -1.1755 -0.4058 -0.4906 -0.0929 -5.3952 -0.0147 -0.9526 -0.3581 -0.0948 -0.0728
S-1062	The animals with heart failure also had a difference histologically in the percentage of myocardial collagen compared with tissue from healthy control animals (control, 5.4% ± 1.0%; heart failure, 9.4% ± 1.6%; p < 0.001).<unk>
T-1062	heart_failure histologically myocardial_collagen healthy heart_failure
H-1062	-1.1016497611999512	▁heart _ ▁failure ▁my o card ial _ ▁collage n ▁tissu e
D-1062	-1.1016497611999512	heart_ failure myocardial_ collagen tissue
P-1062	-3.7940 -1.0732 -2.7537 -1.8737 -0.2032 -0.1055 -0.0350 -0.9956 -0.1648 -0.0831 -0.4247 -0.1231 -3.6985 -0.0948
S-656	L-DKO mice had decreased cardiac IRS1 and IRS2 proteins and exhibited features of heart failure, with impaired cardiac energy metabolism gene expression and activation of p38α mitogen-activated protein kinase (p38).<unk>
T-656	l-dko cardiac irs1 irs2 proteins heart_failure cardiac_energy_metabolism_gene_expression p38α mitogen-activated_protein_kinase p38
H-656	-0.9560096859931946	▁l - d KO ▁cardiac ▁I RS 1 ▁i RS 2 ▁protein s ▁heart _ ▁failure ▁im pair ed ▁cardiac _ ener gy _ ▁metabolism ▁p 38 α ▁mit ogen - activa tion ▁protein ▁kina se
D-656	-0.9560096859931946	l-dKO cardiac IRS1 iRS2 proteins heart_ failure impaired cardiac_energy_ metabolism p38α mitogen-activation protein kinase
P-656	-4.4466 -0.4651 -0.5253 -0.8323 -1.1465 -1.1054 -0.0641 -2.0368 -1.3840 -0.2720 -0.1981 -3.5222 -0.0571 -0.1471 -0.9020 -1.5052 -1.8177 -0.0017 -0.0457 -0.1495 -0.8595 -1.0517 -1.7185 -1.4271 -0.1228 -2.0820 -0.7955 -2.3566 -0.8600 -0.1541 -0.2110 -0.0509 -2.6624 -0.7310 -0.3298 -0.0085 -0.1805 -0.1021
S-967	In conclusion, nicorandil was effective against the development of doxorubicin-induced heart failure in rats as indicated by improvement of hemodynamic perturbations, mitochondrial dysfunction and ultrastructural changes without affecting its antitumor activity.<unk>
T-967	nicorandil heart_failure hemodynamic mitochondrial_dysfunction antitumor activity
H-967	-0.3814551830291748	▁nic oran dil ▁do xor ubi cin - indu ced ▁heart _ ▁failure ▁rat s ▁hem o dynamic ▁perturba tions ▁mito cho ndri al ▁dys function ▁ultra struct ural ▁anti tum or
D-967	-0.3814551830291748	nicorandil doxorubicin-induced heart_ failure rats hemodynamic perturbations mitochondrial dysfunction ultrastructural antitumor
P-967	-2.3057 -0.0067 -0.1047 -0.0135 -0.0121 -0.0362 -0.0686 -0.2833 -0.0005 -1.1361 -1.1371 -0.8653 -1.5582 -2.1614 -0.0180 -0.0274 -0.0108 -0.0165 -0.4203 -0.0062 -0.0040 -0.4499 -0.0208 -0.0477 -0.3971 -0.0618 -0.0633 -0.0080 -0.0207 -0.1761 -0.0967 -0.0317 -1.3465 -0.0567
S-1646	RATIONALE: Rhythm control therapy applied early after the first diagnosis of AF could preserve atrial structure and function and maintain sinus rhythm more effectively than the current practice of delayed rhythm control (when symptoms persist after otherwise effective rate control).<unk>
T-1646	rhythm_control_therapy diagnosis atrial sinus_rhythm rhythm_control symptoms rate_control
H-1646	-0.7934216260910034	▁ Rhythm _ control ▁ therapy ▁af ▁at rial ▁structure ▁sinus ▁ rhythm ▁de lay ed ▁ rhythm _ control
D-1646	-0.7934216260910034	Rhythm_control therapy af atrial structure sinus rhythm delayed rhythm_control
P-1646	-0.6621 -0.8294 -0.7509 -0.0729 -0.9656 -0.0707 -1.6637 -3.6713 -0.0583 -0.4849 -2.3594 -0.1739 -0.1054 -2.1806 -0.0260 -0.2504 -0.2115 -0.3906 -1.7704 -0.0549 -0.5925 -0.1099
S-1540	The relative risk (RR) of heart failure was significantly increased in users of bisphophonates: crude RR 1.71 [95% confidence interval (CI) 1.63-1.79]; adjusted hazard ratio (HR) 1.41 (95% CI 1.34-1.48).<unk>
T-1540	relative_risk rr heart_failure bisphophonates rr confidence_interval hazard_ratio
H-1540	-1.5421615839004517	▁ RR _ de _ heart _ pu issa nce ▁bis pho phon ates ▁cru de ▁ RR
D-1540	-1.5421615839004517	RR_de_heart_puissance bisphophonates crude RR
P-1540	-2.9831 -0.2159 -4.2290 -0.8897 -0.4528 -1.8654 -0.9887 -4.6196 -0.0343 -0.0057 -3.3301 -0.6133 -0.8118 -2.4898 -1.4022 -0.0052 -0.6761 -0.0154 -5.0522 -0.1629
S-1841	Effectiveness of implementation strategies in improving physician adherence to guideline recommendations in heart failure: a systematic review protocol Introduction The uptake of Clinical Practice Guideline (CPG) recommendations that improve outcomes in heart failure (HF) remains suboptimal.<unk>
T-1841	physician heart_failure clinical_practice_guideline cpg outcomes heart_failure hf
H-1841	-1.0743428468704224	▁physician ▁ad her ence ▁guide line _ ▁recommendations ▁heart _ ▁failure ▁Clinic al _ ▁Practic e CP g
D-1841	-1.0743428468704224	physician adherence guideline_ recommendations heart_ failure Clinical_ PracticeCPg
P-1841	-0.8610 -0.5676 -0.0142 -0.0015 -0.1145 -0.0176 -1.6112 -2.3693 -1.5513 -0.5487 -2.0221 -3.1248 -0.0210 -0.2302 -0.7796 -0.0617 -3.0228 -0.5527 -3.8669 -0.1481
S-83	CONCLUSION AND RELEVANCE: In participants with acute heart failure and renal dysfunction, neither low-dose dopamine nor low-dose nesiritide enhanced decongestion or improved renal function when added to diuretic therapy.<unk>
T-83	acute_heart_failure renal_dysfunction dopamine nesiritide renal_function diuretic therapy
H-83	-0.7155702114105225	▁a cute _ heart _ ▁failure ▁renal ▁dys function ▁low - dos e ▁dop amine ▁nesi riti de ▁renal ▁fonction ▁di ure tic ▁ therapy
D-83	-0.7155702114105225	acute_heart_ failure renal dysfunction low-dose dopamine nesiritide renal fonction diuretic therapy
P-83	-0.6459 -0.0107 -1.1635 -1.6901 -0.6090 -0.8279 -0.1605 -0.5154 -0.2116 -1.0677 -0.0137 -0.1435 -0.0831 -0.5396 -0.0888 -1.7271 -0.1317 -0.0571 -0.8076 -4.9707 -0.1093 -0.1673 -2.7773 -0.4898 -0.0332 -0.2074 -0.0708
S-1161	METHODS: Subjects with advanced HF (n = 408) underwent prospective assessment of body composition (skinfold thickness, dual-energy X-ray absorptiometry), comprehensive echocardiography, and blood testing.<unk>
T-1161	hf prospective dual-energy_x-ray_absorptiometry echocardiography blood
H-1161	-0.7126017808914185	▁ HF ▁implant ation _ de _ ▁body _ ▁composition s kin fold _ ▁thi ck ness ▁dual - ener gy ▁X - ray _ ▁ab sor pti ometr y ▁e cho card i ography ▁blood
D-1161	-0.7126017808914185	HF implantation_de_ body_ compositionskinfold_ thickness dual-energy X-ray_ absorptiometry echocardiography blood
P-1161	-0.9665 -0.1022 -5.9337 -1.6602 -3.6802 -1.6015 -0.3434 -1.7611 -0.6934 -0.9887 -0.8385 -1.7644 -0.6710 -0.3222 -0.9935 -0.1385 -0.3300 -0.1145 -0.0188 -0.0013 -0.0014 -0.8464 -0.0188 -0.1128 -0.8065 -0.4232 -0.0172 -0.0551 -0.0760 -0.0555 -0.0959 -0.0613 -0.1766 -0.4121 -0.1976 -0.0805 -0.6187 -0.0996
S-1621	PARTICIPANTS: High-cost Medicare fee-for-service beneficiaries (N = 1,767) enrolled in two Centers for Medicare and Medicaid Services demonstration participating clinics and a propensity-score matched control group.<unk>
T-1621	medicare centers_for_medicare_and_medicaid_services clinics propensity-score
H-1621	-0.6634825468063354	▁Medica re ▁fee - for - service _ ▁beneficiar ies ▁Center s _ de _ ▁Medica re ▁Medica re ▁Medica id ▁Services ▁pro pens ity - s core
D-1621	-0.6634825468063354	Medicare fee-for-service_ beneficiaries Centers_de_ Medicare Medicare Medicaid Services propensity-score
P-1621	-1.9274 -0.0064 -1.6240 -0.0730 -0.0134 -0.0320 -0.0086 -2.1966 -1.0538 -0.2757 -0.2098 -0.1121 -0.2952 -3.1336 -0.1301 -0.3047 -0.0022 -1.2836 -0.0604 -1.8218 -1.7050 -1.6150 -0.4336 -0.0026 -0.1451 -0.3331 -0.0812 -0.4030 -0.5265 -0.0950
S-1032	The objective of the measure is to motivate hospitals to improve the quality of care they provide patients hospitalized for heart failure (HF) and other conditions such as acute myocardial infarction, pneumonia, with expected future expansion to other conditions.<unk>
T-1032	hospitals patients hospitalized heart_failure hf conditions acute_myocardial_infarction pneumonia conditions
H-1032	-0.9441236257553101	▁hospital s ▁conditions ▁a cute _ mé o card ial ▁in far ction ▁pneu monia ▁conditions
D-1032	-0.9441236257553101	hospitals conditions acute_méocardial infarction pneumonia conditions
P-1032	-3.3832 -0.2591 -3.2807 -3.3081 -0.0117 -0.1685 -3.9191 -0.2372 -0.0707 -0.0469 -0.4369 -0.4658 -0.0293 -0.0015 -0.0447 -1.0215 -0.1774 -0.1319
S-1744	Patients were subdivided in 4 enrollment periods on the basis of heart failure treatment eras: (1) 1977-1984 (n=66); (2) 1985-1990 (n=102); (3) 1991-2000 (n=197); (4) 2001-2011 (n=238).<unk>
T-1744	patients heart_failure
H-1744	-1.263612985610962	▁en roll ment _ period s ▁heart _ ▁failure
D-1744	-1.263612985610962	enrollment_periods heart_ failure
P-1744	-3.1737 -0.0489 -0.0429 -2.2697 -2.1721 -0.2559 -0.3504 -0.7470 -2.7936 -1.9221 -0.1234
S-788	KCCQ summary scores were strongly associated with New York Heart Association class in both patients with HFpEF (r=-0.62; P<0.001) and HF with reduced EF (r=-0.55; P=0.27 for interaction).<unk>
T-788	kccq new_york_heart_association_class patients hfpef hf_with_reduced_ef
H-788	-1.2018630504608154	▁k cc q ▁k cc cc q ▁New ▁York _ ▁Heart _ ▁Association ▁ HF p EF ▁ HF ▁ef
D-788	-1.2018630504608154	kccq kccccq New York_ Heart_ Association HFpEF HF ef
P-788	-0.7706 -0.2832 -1.3066 -2.8790 -0.1464 -2.5432 -2.3951 -4.6390 -0.5336 -0.9109 -1.3952 -0.8588 -2.0515 -1.1115 -0.1465 -0.1620 -0.1913 -0.2197 -0.1581 -3.0103 -0.6206 -0.1079
S-36	Recommendation 1: ACP recommends using a restrictive red blood cell transfusion strategy (trigger hemoglobin threshold of 7 to 8 g/dL compared with higher hemoglobin levels) in hospitalized patients with coronary heart disease.<unk>
T-36	acp red_blood_cell_transfusion hemoglobin hemoglobin hospitalized patients coronary_heart_disease
H-36	-1.396955966949463	▁a CP ▁restrict ive ▁red _ ▁blood _ cell _ trans fusion ▁stratégie
D-36	-1.396955966949463	aCP restrictive red_ blood_cell_transfusion stratégie
P-36	-1.3055 -0.1848 -0.0622 -0.0022 -0.1435 -2.2936 -1.6426 -1.5473 -1.3073 -1.1262 -0.7303 -0.0476 -4.4847 -5.9162 -0.1602
S-1962	INTERPRETATION: This first-in-man experience with an implanted left-to-right interatrial shunt demonstrates initial safety and early beneficial clinical and haemodynamic outcomes in patients with heart failure with reduced ejection fraction.<unk>
T-1962	implanted interatrial_shunt clinical haemodynamic outcomes patients heart_failure_with_reduced_ejection_fraction
H-1962	-0.6569915413856506	▁implant ed ▁left - to - right ▁inter at rial _ ▁shu nt ▁ha emo dynamic
D-1962	-0.6569915413856506	implanted left-to-right interatrial_ shunt haemodynamic
P-1962	-0.0039 -0.2096 -0.9171 -0.0369 -0.4178 -0.1345 -0.0572 -0.0374 -0.3373 -0.3372 -1.6695 -0.9044 -0.0994 -0.7204 -0.9872 -0.0721 -4.8043 -0.0797
S-1973	Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.<unk>
T-1973	exercise training peak_oxygen_consumption quality_of_life obese patients heart_failure_with_preserved_ejection_fraction randomized clinical
H-1973	-0.48959723114967346	▁Cal o ric _ re stri ction ▁Aero bic _ ▁Exerci se ▁Peak ▁O xy gen ▁Consum p tion ▁Quality _ of _ ▁Life ▁Old er ▁Patient s ▁Heart _ ▁Fail ure ▁Pres er ved ▁E je ction _ fra ction
D-1973	-0.48959723114967346	Caloric_restriction Aerobic_ Exercise Peak Oxygen Consumption Quality_of_ Life Older Patients Heart_ Failure Preserved Ejection_fraction
P-1973	-0.2736 -0.0326 -0.7904 -1.3374 -0.1688 -0.0153 -0.0017 -0.1987 -0.0518 -1.3698 -0.3995 -0.0730 -0.8773 -1.6982 -0.0074 -0.0676 -0.7160 -0.0346 -0.0142 -0.0729 -0.5703 -1.0339 -0.3869 -0.5208 -2.9976 -0.0215 -0.2307 -0.3489 -0.0919 -0.6835 -0.2507 -0.0462 -0.9637 -0.0345 -0.3119 -1.1123 -0.3941 -0.0080 -1.0241 -1.2435 -0.0099 -0.5139 -0.0530
S-308	Left ventricular assist devices (LVADs) are used in chronic end-stage heart failure as "bridge to transplantation" (BTT) and, more recently, for transplant-ineligible patients as "destination therapy" (DT).<unk>
T-308	left_ventricular_assist_devices lvads chronic_end-stage_heart_failure bridge_to_transplantation btt patients destination_therapy dt
H-308	-0.778251588344574	▁vent ri cular _ assist ▁devices ▁l VAD s ▁chronic ▁end - s tage _ heart _ ▁failure ▁b t ▁transplant ation
D-308	-0.778251588344574	ventricular_assist devices lVADs chronic end-stage_heart_ failure bt transplantation
P-308	-0.9781 -0.2160 -0.1682 -0.9355 -0.0698 -1.2247 -1.1855 -0.0341 -0.2491 -1.4695 -0.6978 -0.0621 -0.2833 -0.0018 -0.2051 -2.0808 -0.7415 -2.1258 -0.9547 -0.7286 -0.4713 -0.4530 -3.2423 -0.0994
S-742	T1 time also correlated with right ventricular-pulmonary arterial coupling (pulmonary vascular resistance: R=-0.36; P<0.01; right ventricular ejection fraction: R=0.28; P=0.01).<unk>
T-742	t1_time correlated right_ventricular-pulmonary_arterial_coupling pulmonary_vascular_resistance right_ventricular_ejection_fraction
H-742	-0.9683756232261658	▁vent ri cular _ pul man ary _ pul man ary _ ▁arterial _ ▁coup ling pul mon ary _ ▁vas cular _ ▁resist ance ▁right ▁vent ri cular _ ▁e je ction
D-742	-0.9683756232261658	ventricular_pulmanary_pulmanary_ arterial_ couplingpulmonary_ vascular_ resistance right ventricular_ ejection
P-742	-0.1641 -0.1494 -0.1959 -1.0588 -0.4932 -2.7243 -1.1933 -0.4853 -2.6157 -2.2049 -0.9796 -0.4129 -3.2264 -1.1885 -0.7267 -3.0896 -0.6168 -0.3539 -0.2435 -0.1760 -0.8934 -0.0509 -1.1690 -1.9486 -0.0106 -1.3992 -0.1507 -0.1033 -0.3345 -0.5175 -3.2786 -0.2515 -0.0627 -1.3183 -0.1056
S-855	Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy).<unk>
T-855	carvedilol metoprolol implantable_cardioverter-defibrillator therapy madit-crt multicenter_automatic_defibrillator_implantation_with_cardiac_resynchronization_therapy
H-855	-0.8842405080795288	▁car vedi lol ▁met o pro lol ▁implant able ▁implant able _ ▁cardio ver ter - de _ de _ fi br illa tor _ therapy ▁MAD it - c RT ▁implant ation ▁implant able _ de _ f ré syn chron ization _ ▁Therapy
D-855	-0.8842405080795288	carvedilol metoprolol implantable implantable_ cardioverter-de_de_fibrillator_therapy MADit-cRT implantation implantable_de_frésynchronization_ Therapy
P-855	-0.1441 -0.0076 -0.0302 -1.0374 -0.0311 -0.0043 -0.0558 -0.0002 -0.0104 -0.2369 -0.0127 -1.9964 -0.7642 -0.1161 -0.0305 -0.6021 -0.0170 -1.9437 -1.9500 -1.9761 -2.3504 -1.3139 -0.0074 -0.1700 -1.2634 -0.3449 -0.0098 -0.9922 -0.0585 -0.6621 -0.2870 -2.3150 -0.1772 -3.7904 -0.5571 -0.5013 -3.0100 -1.2793 -1.7123 -0.7934 -4.8598 -0.0021 -1.1461 -1.4125 -0.8134 -0.6930 -0.0701
S-610	Oral glucocorticoids were associated with a dose-related gradient of HF risk: compared with no use, 1≤5 mg HR 1.30 (95% CI 0.91 to 1.85), ≥5 mg HR 1.54 (95% CI 1.09 to 2.19).<unk>
T-610	oral glucocorticoids hf
H-610	-1.1926909685134888	▁gluco cor tico ids ▁ HF
D-610	-1.1926909685134888	glucocorticoids HF
P-610	-2.4306 -0.0387 -2.0823 -0.4260 -0.8153 -0.0340 -3.6355 -0.0791
S-523	After 8 months of treatment, HR was significantly reduced in the ivabradine group (p < 0.0001) and was accompanied by marked reduction in Ea (p < 0.0001) and improved TAC (p = 0.004) compared with placebo.<unk>
T-523	ivabradine ea tac placebo
H-523	-1.0702710151672363	▁i va bra dine _ group ▁Ea ▁ TAC
D-523	-1.0702710151672363	ivabradine_group Ea TAC
P-523	-1.8433 -0.0418 -0.6280 -0.0028 -4.8802 -0.5544 -2.8515 -0.6694 -0.0086 -0.1852 -0.1079
S-385	CONCLUSIONS: The HFPSI uses readily available data to predict the 6-month risk of death and/or all-cause medical hospitalization in HF clinic outpatients and could potentially help allocate specialized HF resources within health systems.<unk>
T-385	hfpsi death medical hospitalization hf clinic outpatients hf health
H-385	-0.9157299399375916	▁ HF PSI ▁risk _ de _ ▁death ▁medical ▁hospital ization ▁ HF ▁clinic _ ▁out patient s ▁ HF ▁resources
D-385	-0.9157299399375916	HFPSI risk_de_ death medical hospitalization HF clinic_ outpatients HF resources
P-385	-0.2590 -0.2075 -0.7676 -4.4539 -2.1405 -0.6810 -0.2783 -0.6667 -0.3084 -1.0867 -0.3923 -0.1055 -0.0109 -2.7971 -0.4542 -1.0964 -0.0078 -0.0399 -0.8680 -0.1817 -1.9811 -2.1306 -0.1468
S-1265	However, further studies with long-term follow-up, systemic adverse events evaluation, and other ethnic groups are still required to verify the efficacy and safety of CHM as an adjunctive treatment in all patients with DCM and heart failure.<unk>
T-1265	follow-up systemic adverse_events patients dcm heart_failure
H-1265	-1.015316128730774	▁CH m ▁ad ju nc tive ▁d CM ▁heart _ ▁failure
D-1265	-1.015316128730774	CHm adjunctive dCM heart_ failure
P-1265	-5.1049 -0.2990 -0.5838 -0.0018 -0.0200 -0.0046 -3.4719 -0.1046 -1.1164 -1.1308 -1.2208 -0.0951 -0.0456
S-862	Treatment with carvedilol was associated with a significantly decreased risk of inappropriate therapy compared with metoprolol (hazard ratio [HR]: 0.64 [95% confidence interval (CI): 0.48 to 0.85]; p = 0.002).<unk>
T-862	carvedilol therapy metoprolol hazard_ratio confidence_interval
H-862	-0.40963834524154663	▁car vedi lol ▁in appropria te ▁ therapy ▁met o pro lol haz ard
D-862	-0.40963834524154663	carvedilol inappropriate therapy metoprololhazard
P-862	-1.2102 -0.0616 -0.1449 -0.7805 -0.0816 -0.0821 -1.0646 -0.0238 -0.1821 -0.1606 -0.0342 -0.0953 -0.1311 -0.0039 -2.3978 -0.1000
S-1325	CONCLUSIONS: This study shows for the first time that testosterone supplementation during a program of exercise rehabilitation is feasible and can positively impact on a range of key health outcomes in elderly male patients with CHF who have a low testosterone status.<unk>
T-1325	testosterone_supplementation exercise_rehabilitation health outcomes patients chf testosterone
H-1325	-1.416719675064087	▁testosteron e
D-1325	-1.416719675064087	testosterone
P-1325	-0.7403 -0.0131 -4.8623 -0.0512
S-1987	The change in peak VO2 was positively correlated with the change in percent lean body mass (r = 0.32; P = .003) and the change in thigh muscle:intermuscular fat ratio (r = 0.27; P = .02).<unk>
T-1987	change peak_vo2 correlated change lean_body_mass change thigh muscle
H-1987	-1.4583675861358643	▁pe ak ▁VO 2 ▁change ▁lean _ ▁body _ ▁mass ▁change _ ▁in ▁th igh ▁muscle inter mus cular _ ▁fat ▁ratio
D-1987	-1.4583675861358643	peak VO2 change lean_ body_ mass change_ in thigh muscleintermuscular_ fat ratio
P-1987	-5.2866 -0.1231 -0.4160 -0.0369 -1.8425 -4.0330 -1.1622 -1.3617 -1.0211 -1.4784 -0.5499 -3.4871 -2.5777 -4.0210 -0.1466 -3.0297 -1.1973 -0.2410 -0.1429 -1.1170 -0.5794 -0.8547 -0.1453 -0.1494
S-189	METHODS: We included hospitals in Get With The Guidelines-Heart Failure that admitted 99,930 HF patients with reduced (EF <40%), borderline (EF 40%-49%), or preserved (EF ≥50%) EF.<unk>
T-189	hospitals get_with_the_guidelines-heart_failure hf patients ef ef ef ef
H-189	-0.9170448184013367	▁guide lines - He art _ ▁Fail ure ▁ HF
D-189	-0.9170448184013367	guidelines-Heart_ Failure HF
P-189	-2.2449 -0.6133 -0.8888 -0.8811 -0.0659 -0.5714 -0.2897 -0.0446 -0.9002 -0.0507 -4.3641 -0.0898
S-830	In the multivariate Cox model analysis adjusted for age and sex, PASP increase during exercise and peak o2 per kilogram remained independent prognostic markers (hazard ratio, 2.56 for peak o2 per kilogram and 2.84 for PASP increase).<unk>
T-830	multivariate_cox_model pasp exercise peak_o2 prognostic hazard_ratio peak_o2 pasp
H-830	-2.2650325298309326	▁multi varia te ▁co x _ model ▁figure ▁PAS p
D-830	-2.2650325298309326	multivariate cox_model figure PASp
P-830	-6.5363 -0.4045 -0.1116 -0.5303 -0.0034 -3.5007 -1.9058 -4.6635 -4.0595 -1.0613 -4.2327 -0.1707
S-1787	CONCLUSIONS: The development of cardiac insulin-resistance and decreased mitochondrial oxidative metabolism are early metabolic changes in the development of cardiac hypertrophy, which create an energy deficit that may contribute to the progression from hypertrophy to heart failure.<unk>
T-1787	cardiac insulin-resistance mitochondrial_oxidative_metabolism metabolic cardiac_hypertrophy hypertrophy heart_failure
H-1787	-0.6177570223808289	▁cardiac ▁insulin - re si stance ▁mito cho ndri al ▁oxid ative ▁metabolism ▁cardiac ▁hyper trop hy ▁energy _ ▁deficit ▁hyper trop hy ▁heart
D-1787	-0.6177570223808289	cardiac insulin-resistance mitochondrial oxidative metabolism cardiac hypertrophy energy_ deficit hypertrophy heart
P-1787	-0.0426 -0.9799 -0.0344 -0.0230 -1.5583 -0.0000 -0.2377 -0.3799 -0.0682 -0.0403 -0.7592 -0.0894 -0.1008 -0.8845 -0.6540 -0.0022 -0.0234 -2.6361 -2.6042 -0.2455 -0.3766 -0.0123 -0.0443 -0.9151 -3.2806 -0.0691
S-1672	Rad, a member of the RGK (Rem, Rem2, Rad, Gem/Kir) family of monomeric G proteins, regulates ventricular action potential duration and EC coupling gain through its ability to inhibit cardiac L-type channel activity.<unk>
T-1672	rad rgk rem rem2 rad monomeric_g_proteins ventricular_action_potential gain cardiac l-type_channel activity
H-1672	-0.9627113938331604	▁rad ▁rad ▁rem ▁rem 2 ▁rad ▁Gem _ Kir ▁family _ ▁mono me ric _ g ▁protein s ▁vent ri cular ▁action ▁EC ▁coup ling ▁cardiac _ type _ ▁channel _ ▁activity
D-1672	-0.9627113938331604	rad rad rem rem2 rad Gem_Kir family_ monomeric_g proteins ventricular action EC coupling cardiac_type_ channel_ activity
P-1672	-0.8841 -1.6316 -0.5969 -0.6601 -0.3948 -0.2016 -2.0166 -3.6810 -0.0337 -3.5577 -1.2109 -2.1835 -0.0089 -0.4908 -2.2285 -1.2966 -1.7768 -0.0214 -0.0225 -0.0544 -0.3097 -0.1053 -0.1714 -0.0887 -0.3737 -1.2753 -0.8876 -1.2184 -0.7660 -1.6664 -0.5812 -1.8914 -0.2290 -0.2157
S-338	The mechanism is a combination of annular size reduction by surgery and diastolic mitral valve tethering, restricting the anterior leaflet opening due to posteriorly displaced papillary muscles with left ventricular (LV) dilatation.<unk>
T-338	combination surgery diastolic_mitral_valve_tethering anterior_leaflet papillary_muscles left_ventricular dilatation
H-338	-0.68174809217453	▁ann ular _ ▁size _ re duction ▁surgery ▁dia sto lic _ ▁mit ral _ ▁val ve _ ▁te ther ing ▁anterior ▁le a flet ▁opening ▁papil lar y _ ▁muscle s ▁left ▁vent ri cular LV
D-338	-0.68174809217453	annular_ size_reduction surgery diastolic_ mitral_ valve_ tethering anterior leaflet opening papillary_ muscles left ventricularLV
P-338	-0.2718 -0.0002 -2.5889 -1.4297 -1.7635 -1.2093 -0.0007 -0.3544 -0.0068 -0.0464 -1.6603 -0.8898 -2.0636 -0.0055 -0.8113 -1.7627 -0.0999 -0.9363 -0.8841 -0.0024 -0.0166 -0.1174 -0.2948 -0.0774 -0.0009 -1.5276 -1.8271 -0.4480 -0.2257 -1.6441 -0.2140 -0.0888 -0.2358 -0.6633 -0.1289 -0.0419 -0.8543 -1.2633 -0.1307
S-734	BACKGROUND: The underlying pathophysiology of heart failure with preserved ejection fraction (HFPEF) is incompletely understood, but myocardial extracellular matrix accumulation is thought to play a major role.<unk>
T-734	pathophysiology heart_failure_with_preserved_ejection_fraction hfpef myocardial_extracellular_matrix
H-734	-0.5155478119850159	▁pat ho phy si ology ▁heart _ ▁failure ▁pres er ved ▁e je ction _ fraction ▁h FP f ▁my o card ial _ ▁extra cel lular ▁matri x ▁accumula tion
D-734	-0.5155478119850159	pathophysiology heart_ failure preserved ejection_fraction hFPf myocardial_ extracellular matrix accumulation
P-734	-1.7325 -0.1491 -0.0155 -0.4025 -0.5918 -0.5446 -0.4631 -1.1502 -0.8781 -0.0181 -0.3065 -1.2398 -0.5671 -0.0334 -0.4122 -0.0190 -0.2083 -2.7198 -0.7914 -1.0474 -0.0433 -0.0804 -0.0343 -0.2870 -0.5474 -0.7664 -0.0489 -0.9870 -0.0658 -0.4619 -0.0327 -0.2975 -0.0702
S-1346	A protocol was originally designed to study breathing control during and following cardiac arrest in humans, taking advantage of the period of pulseless ventricular fibrillation (PVF) produced while testing a newly implanted cardioverter-defibrillator device.<unk>
T-1346	breathing cardiac_arrest advantage pulseless_ventricular_fibrillation pvf implanted cardioverter-defibrillator_device
H-1346	-0.4958094358444214	▁breath ing _ control ▁cardiac ▁arrest ▁puls e less ▁vent ri cular _ ▁fi bril lation PV f ▁implant ed ▁cardio ver ter - de _ fi br illa tor
D-1346	-0.4958094358444214	breathing_control cardiac arrest pulseless ventricular_ fibrillationPVf implanted cardioverter-de_fibrillator
P-1346	-1.1014 -0.0789 -0.7445 -0.0119 -0.1823 -0.2525 -0.5038 -0.0502 -0.5069 -0.5499 -0.1410 -0.1509 -0.2537 -3.8059 -0.0550 -0.0129 -0.4358 -0.2658 -0.0049 -0.2677 -0.1841 -0.0500 -0.0219 -0.5488 -0.0085 -1.4195 -1.5503 -0.3114 -0.0062 -0.1192 -2.1843 -0.0859
S-14	RESULTS: N-terminal proBNP (NT-proBNP), midregional proANP (MR-proANP), and total adiponectin were elevated in CHF (p<0.001) and correlated inversely to BMI and FM.<unk>
T-14	n-terminal_probnp nt-probnp midregional_proanp mr-proanp adiponectin elevated chf correlated bmi
H-14	-0.7387871742248535	▁n - termin al ▁pro B NP ▁t - pro B NP ▁mid region al ▁pro AN p MR - pro AN p ▁adi pon ect in ▁CHF ▁b MI ▁FM
D-14	-0.7387871742248535	n-terminal proBNP t-proBNP midregional proANpMR-proANp adiponectin CHF bMI FM
P-14	-4.1602 -0.0976 -0.0514 -0.0039 -0.4151 -0.3821 -0.0477 -4.8086 -0.0084 -0.0657 -1.0059 -0.0803 -1.5117 -0.0325 -0.0689 -0.2420 -3.0753 -0.8799 -0.2671 -0.0252 -0.0022 -2.2765 -0.6764 -0.3654 -0.0138 -0.0060 -0.1941 -1.8172 -0.2016 -0.9630 -0.4358 -0.1379 -0.0606
S-1136	We investigated the long-term (4 wk) effects of the acetylcholinesterase inhibitor pyridostigmine on sympathovagal balance, cardiac remodeling, and cardiac function in the onset of HF following myocardial infarction.<unk>
T-1136	acetylcholinesterase_inhibitor pyridostigmine sympathovagal_balance cardiac_remodeling cardiac_function hf myocardial_infarction
H-1136	-0.5938740372657776	▁a ce tyl cho line ster ase ▁inhibi tor _ ▁py rido stig mine ▁sympa t hova gal ▁balance ▁cardiac _ ▁remodel ing ▁ HF ▁my o card ial ▁in far ction
D-1136	-0.5938740372657776	acetylcholinesterase inhibitor_ pyridostigmine sympathovagal balance cardiac_ remodeling HF myocardial infarction
P-1136	-0.1196 -0.1126 -0.3391 -1.7053 -0.5878 -1.4796 -1.6088 -0.8230 -0.0197 -0.3908 -1.5414 -0.0147 -0.0003 -0.1743 -0.0668 -0.0605 -0.5142 -0.0402 -1.1274 -0.0014 -2.5925 -0.0949 -0.0342 -0.4662 -0.0200 -3.2795 -0.6818 -0.4174 -0.3235 -0.6078 -0.6342 -0.1057 -0.1499 -0.0566
S-1112	The aim of this study was, first, to assess whether there is a differential response in cardiac sympathetic activity by (123)I-meta-iodobenzylguanidine ((123)I-MIBG) imaging when either β-blocker is used.<unk>
T-1112	cardiac_sympathetic_activity β-blocker
H-1112	-0.6073312759399414	▁cardiac _ ▁sympa the tic ▁activity ▁i - meta - i odob enz yl guan i dine ▁i - MI BG ▁β - block er
D-1112	-0.6073312759399414	cardiac_ sympathetic activity i-meta-iodobenzylguanidine i-MIBG β-blocker
P-1112	-2.0148 -0.9833 -3.1683 -0.4323 -1.5552 -1.0103 -0.6926 -1.2994 -0.2932 -0.0262 -0.5477 -0.0175 -0.0772 -2.0517 -0.0512 -0.3419 -0.0011 -0.3424 -0.3395 -0.4961 -0.0997 -0.1912 -0.0080 -0.0432 -0.0388 -0.1729 -0.1021
S-971	From the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies registry, we included all 36,284 patients who underwent primary isolated CABG from 2000 to 2008 in Sweden.<unk>
T-971	evidence-based heart_disease therapies patients cabg sweden
H-971	-1.0039875507354736	▁Swedish ▁Swedish ▁web - system ▁e viden ce - based _ care ▁Heart _ ▁disease ▁Reco mmende d ▁Therapie s
D-971	-1.0039875507354736	Swedish Swedish web-system evidence-based_care Heart_ disease Recommended Therapies
P-971	-0.1476 -1.9346 -2.9188 -0.0281 -0.0327 -2.3265 -0.2643 -0.0263 -0.0774 -0.0093 -0.9979 -2.2871 -0.7656 -1.4189 -3.2285 -0.2745 -0.0015 -0.0477 -0.8566 -0.0095 -4.2847 -0.1494
S-756	In the LVEF <30% subgroup, significant improvements in clinical composite response (P=0.02), reverse remodeling parameters, and time to death or first HF hospitalization (hazard ratio, 0.58; P=0.047) were observed.<unk>
T-756	lvef clinical reverse_remodeling death hf hospitalization hazard_ratio
H-756	-0.7129345536231995	▁LV EF ▁clinic al _ com posit e _ ▁response ▁rever se ▁remodel ing ▁temps ▁ HF
D-756	-0.7129345536231995	LVEF clinical_composite_ response reverse remodeling temps HF
P-756	-0.0478 -0.1790 -2.9139 -0.0153 -0.9192 -0.6963 -0.0022 -0.0311 -2.0971 -0.9226 -0.0457 -0.0011 -0.1412 -0.0548 -2.3457 -1.2082 -0.2318 -1.6172 -0.0754
S-1569	In all, 36 (30%) patients had brain natriuretic peptide (BNP) levels ≥ 100 pg/mL (high BNP group), and 84 (70%) patients had BNP levels < 100 pg/mL (low BNP group).<unk>
T-1569	patients brain_natriuretic_peptide bnp bnp patients bnp bnp
H-1569	-0.9035108685493469	▁brain _ ▁na tri ure tic _ pe pti de ▁b NP ▁b NP
D-1569	-0.9035108685493469	brain_ natriuretic_peptide bNP bNP
P-1569	-0.3910 -0.9791 -0.2380 -0.0116 -0.1211 -6.0067 -0.8304 -0.4180 -0.4554 -0.7068 -0.1970 -0.1877 -0.5431 -0.4012 -2.9024 -0.0666
S-1210	Among the PDE superfamily, PDE2 has the unique property of being able to be stimulated by cGMP, thus leading to a remarkable increase in cAMP hydrolysis mediating a negative cross talk between cGMP and cAMP signaling.<unk>
T-1210	pde pde2 cgmp leading camp_hydrolysis cross_talk cgmp camp_signaling
H-1210	-0.6896523237228394	▁p de _ ▁super family ▁p de 2 ▁c g mp ▁c AMP _ hydro lys is ▁negative ▁cross ▁talk ▁c g mp ▁c AMP ▁signal ing
D-1210	-0.6896523237228394	pde_ superfamily pde2 cgmp cAMP_hydrolysis negative cross talk cgmp cAMP signaling
P-1210	-0.4815 -0.0533 -1.9006 -0.6423 -0.0318 -1.3899 -0.0668 -0.6727 -0.0210 -2.1107 -0.8583 -0.1948 -2.0746 -1.0631 -0.4135 -0.1133 -0.0311 -0.6355 -1.6035 -1.2823 -0.0051 -1.3580 -1.1476 -0.0544 -0.4980 -0.9596 -0.1468 -0.1068 -0.0832
S-493	We hypothesized that the relationship between TAPSE (longitudinal RV fiber shortening) and PASP (force generated by the RV) provides an index of in vivo RV length-force relationship, with their ratio better disclosing prognosis.<unk>
T-493	tapse longitudinal_rv_fiber_shortening pasp rv in_vivo rv prognosis
H-493	-1.1107299327850342	▁T AP se long itud in al ▁ RV _ ▁fiber _ short en ing ▁PAS p ▁ RV ▁in ▁vivo ▁ RV _ ▁length - force
D-493	-1.1107299327850342	TAPselongitudinal RV_ fiber_shortening PASp RV in vivo RV_ length-force
P-493	-5.2978 -0.1480 -0.9876 -0.4773 -0.5963 -0.5879 -0.8106 -0.2432 -0.1345 -2.1505 -2.2366 -0.8547 -1.1653 -0.1071 -0.3090 -0.9555 -0.8249 -1.0511 -1.2462 -3.5703 -0.3017 -0.1881 -0.1630 -2.9016 -3.1593 -0.2297 -0.1279 -1.1758 -0.2096
S-870	BACKGROUND: We investigated the protective effects of mitochondrial-targeted antioxidant and protective peptides, Szeto-Schiller (SS) 31 and SS20, on cardiac function, proteomic remodeling, and signaling pathways.<unk>
T-870	peptides szeto-schiller ss ss20 cardiac_function proteomic_remodeling signaling_pathways
H-870	-0.7576967477798462	▁mito cho ndri al - tar get ed ▁antioxidant ▁protection ive _ pe pti des ▁Sze to - Sch iller ▁SS 20 ▁cardiac ▁implant ▁prote om ic ▁remodel ing ▁path ways
D-870	-0.7576967477798462	mitochondrial-targeted antioxidant protectionive_peptides Szeto-Schiller SS20 cardiac implant proteomic remodeling pathways
P-870	-2.0311 -0.5723 -0.1914 -0.0316 -0.1943 -0.0501 -0.0904 -0.0128 -0.0895 -3.3278 -0.2398 -2.8744 -0.3551 -0.0978 -0.0410 -0.0696 -0.0121 -0.0016 -0.0620 -0.0030 -1.0121 -3.9825 -0.0516 -3.7586 -1.8828 -0.0127 -1.0707 -0.1710 -0.0210 -2.4106 -0.1221 -0.1218 -0.0389
S-2017	CONCLUSION: The Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model provides researchers and providers with a tool for conducting long-term cost-effectiveness analyses of disease management programs in heart failure.<unk>
T-2017	tools_for_economic_analysis_of_patient_management_interventions_in_heart_failure_cost-effectiveness_model disease heart_failure
H-2017	-0.9365062117576599	▁économique _ ▁Analys is ▁Patient _ ▁Management _ ▁Interven tions ▁Heart _ ▁Fail ure ▁Cost - E ff ective ness
D-2017	-0.9365062117576599	économique_ Analysis Patient_ Management_ Interventions Heart_ Failure Cost-Effectiveness
P-2017	-0.7791 -4.2587 -1.5266 -0.0160 -1.8602 -1.0839 -1.1926 -0.9268 -1.4073 -0.0081 -0.2805 -0.2343 -0.1927 -0.0454 -0.5981 -0.0564 -0.6720 -1.4005 -0.0070 -0.7075 -3.2197 -0.1298
2021-01-17 13:50:53 | INFO | fairseq.logging.progress_bar | :    101 / 145 wps=152
S-900	There was a significant decrease in re-hospitalization from an average of 3.2 ± 2.5 to 0.1 ± 0.3 admissions per patient (p = 0.007) and reduced average length of stay from 37 ± 36.7 to 0.78 ± 2.3 days (p = 0.019).<unk>
T-900	re-hospitalization admissions patient
H-900	-0.4590589702129364	▁re - hospital ization ▁ad missions
D-900	-0.4590589702129364	re-hospitalization admissions
P-900	-0.1419 -0.1828 -0.0361 -0.8842 -0.1727 -0.0226 -2.1650 -0.0672
S-79	MAIN OUTCOMES AND MEASURES: Coprimary end points included 72-hour cumulative urine volume (decongestion end point) and the change in serum cystatin C from enrollment to 72 hours (renal function end point).<unk>
T-79	outcomes coprimary_end_points end_point change serum_cystatin_c renal_function end_point
H-79	-0.9892809391021729	▁co prima ry _ ▁end ▁points ▁cum ul ative _ ▁urin e ▁volume ▁de con gestion _ ▁end ▁point ▁se rum ▁cyst atin ▁c ▁en roll ment
D-79	-0.9892809391021729	coprimary_ end points cumulative_ urine volume decongestion_ end point serum cystatin c enrollment
P-79	-0.3390 -0.0003 -0.1117 -1.9571 -0.7908 -0.5057 -1.6162 -0.0299 -0.0393 -0.6764 -1.5226 -0.1825 -1.6938 -4.0159 -0.0061 -0.0131 -2.5392 -0.5064 -0.1146 -0.3666 -0.1581 -0.5305 -1.2151 -1.3271 -4.0419 -0.0200 -0.0424 -4.2291 -0.0976
S-1291	HISTORY AND CLINICAL FINDINGS: We present a 41-year-old man with cardiac arrest in need of cardiopulmonary resuscitation (CPR) with the diagnosis of a posterior wall infarction, who was hospitalized in our cardiac centre.<unk>
T-1291	clinical cardiac_arrest cardiopulmonary_resuscitation cpr diagnosis posterior_wall_infarction hospitalized cardiac
H-1291	-0.7861911654472351	▁cardiac _ ▁arrest ▁cardio pul mon ary _ ▁res uscita tion ▁c PR ▁posterior _ ▁wall _ ▁in far ction ▁cardiac ▁centre
D-1291	-0.7861911654472351	cardiac_ arrest cardiopulmonary_ resuscitation cPR posterior_ wall_ infarction cardiac centre
P-1291	-2.4371 -2.1064 -0.2532 -0.0746 -0.0323 -3.4322 -0.4870 -0.2269 -1.1228 -0.0019 -0.0451 -0.4924 -0.1012 -0.0793 -1.0158 -1.8550 -0.5797 -0.2776 -0.6424 -0.0244 -0.0315 -3.3537 -0.1376 -0.0588
S-1831	PATIENTS: Patients aged 18 years or older with type 2 diabetes who initiated therapy with saxagliptin, sitagliptin, pioglitazone, second-generation sulfonylureas, or long-acting insulin products from 2006 to 2013.<unk>
T-1831	patients patients type_2_diabetes therapy saxagliptin sitagliptin pioglitazone second-generation_sulfonylureas insulin
H-1831	-0.37752363085746765	▁diabetes ▁sax ag lip tin ▁si tag lip tin ▁pi og lita zone ▁sul fon yl ure as ▁long - ac ting ▁insulin
D-1831	-0.37752363085746765	diabetes saxagliptin sitagliptin pioglitazone sulfonylureas long-acting insulin
P-1831	-2.3032 -0.6779 -0.0615 -0.5654 -1.0062 -0.2076 -0.0001 -0.1789 -1.0094 -0.0039 -0.0646 -0.0418 -0.0225 -0.9961 -0.0021 -0.4363 -0.0362 -0.0465 -0.7510 -0.0072 -0.0122 -0.2220 -0.0857 -0.6512 -0.0484
S-1702	BACKGROUND: The incidence of hyperkalemia caused by mineralocorticoid receptor antagonists may vary by race, but whether race influences efficacy of mineralocorticoid receptor antagonists in heart failure (HF) is unknown.<unk>
T-1702	incidence hyperkalemia mineralocorticoid_receptor_antagonists mineralocorticoid_receptor_antagonists heart_failure hf
H-1702	-0.8248311281204224	▁hyper kal emia ▁mineral o cor tico id ▁receptor _ ▁anta gon ists _ ▁in _ heart _ ▁failure
D-1702	-0.8248311281204224	hyperkalemia mineralocorticoid receptor_ antagonists_ in_heart_ failure
P-1702	-0.2134 -0.3111 -0.2160 -0.7386 -0.0721 -0.0542 -1.7380 -0.7272 -0.9006 -0.9256 -0.4665 -0.0547 -0.8512 -2.7091 -1.2544 -1.7909 -0.9199 -0.4321 -1.9672 -0.9095 -0.0692
S-37	(Grade: weak recommendation; low-quality evidence) Recommendation 2: ACP recommends against the use of erythropoiesis-stimulating agents in patients with mild to moderate anemia and congestive heart failure or coronary heart disease.<unk>
T-37	grade evidence acp erythropoiesis-stimulating_agents patients anemia congestive_heart_failure coronary_heart_disease
H-37	-1.560448408126831	▁a CP ▁er y thro po ies is - stimul ation ▁agents
D-37	-1.560448408126831	aCP erythropoiesis-stimulation agents
P-37	-2.7370 -0.7028 -4.9347 -0.1027 -2.3352 -2.2643 -2.1139 -0.1734 -0.9535 -0.1411 -1.1451 -0.3903 -3.7666 -0.0857
S-175	In ambulatory patients with heart failure (HF) and reduced ejection fraction (rEF), renin-angiotensin system (RAS) and β-blockers at guideline-recommended target dose reduce all-cause mortality and readmissions.<unk>
T-175	ambulatory patients heart_failure hf reduced_ejection_fraction renin-angiotensin_system ras β-blockers all-cause_mortality readmissions
H-175	-0.8010107278823853	▁ambula tory ▁patients ▁heart _ ▁failure ▁e je ction _ fraction r EF ▁re nin - angi oten sin _ system ▁ RAS ▁β - block ers
D-175	-0.8010107278823853	ambulatory patients heart_ failure ejection_fractionrEF renin-angiotensin_system RAS β-blockers
P-175	-1.8537 -0.0947 -1.4377 -0.8650 -0.6002 -1.4816 -3.2497 -0.6448 -0.0280 -0.9556 -0.0053 -0.4654 -0.0450 -0.0059 -1.4454 -0.0358 -0.1400 -0.1151 -1.8609 -3.3267 -0.3183 -1.9004 -0.0043 -0.0480 -0.0026 -0.0224 -0.0290 -2.0771 -0.1707
S-1082	METHODS AND RESULTS: UPR and SCN5A were analyzed in human ventricular systolic HF tissue samples and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).<unk>
T-1082	upr scn5a ventricular_systolic_hf human_induced_pluripotent_stem_cell-derived_cardiomyocytes hipsc-cms
H-1082	-0.5597831010818481	▁u PR ▁vent ri cular _ syn sto lic ▁ HF ▁implant ed ▁pluri potent ▁stem _ cell - der i ved ▁cardio my o cy tes hi PS c - CM s
D-1082	-0.5597831010818481	uPR ventricular_synstolic HF implanted pluripotent stem_cell-derived cardiomyocyteshiPSc-CMs
P-1082	-0.1336 -0.0431 -0.7245 -0.0865 -0.0988 -1.1335 -1.0513 -3.0383 -1.4384 -0.6515 -0.0333 -2.5015 -0.2470 -0.3906 -0.0022 -0.2481 -1.1290 -0.5220 -0.7994 -0.0420 -0.1211 -0.1638 -0.7281 -1.8253 -0.8408 -0.0807 -0.0881 -0.7366 -0.1741 -0.2717 -0.0454 -0.0127 -0.0147 -0.1136 -0.0610
S-802	RESULTS: Good agreement was observed, in general, for both the total sample and subgroups (COPD, CHF, CRF), with ICC values ranging from .85 to .98, and kappa coefficients from .49 to 1.00.<unk>
T-802	copd chf crf icc kappa_coefficients
H-802	-0.3390718996524811	▁co PD ▁CHF ▁c RF ▁ICC ▁ka ppa ▁co ef fici ents
D-802	-0.3390718996524811	coPD CHF cRF ICC kappa coefficients
P-802	-1.7390 -0.4100 -0.1526 -0.6933 -0.1064 -0.0666 -0.6925 -0.0368 -0.3157 -0.0282 -0.0170 -0.0473 -0.3862 -0.0554
S-1865	CONCLUSION: The patient preferences identified in this study support the need to include information on implantable cardioverter-defibrillator deactivation at implant, with change in clinical status and within broader discussions about end-of-life treatment preferences.<unk>
T-1865	patient implantable_cardioverter-defibrillator implant change clinical
H-1865	-0.7191781997680664	▁implant able ▁implant able ▁implant able ▁cardio ver ter - de fi br illa tor _ de _ activa tion ▁implant
D-1865	-0.7191781997680664	implantable implantable implantable cardioverter-defibrillator_de_activation implant
P-1865	-0.0033 -0.0244 -0.7091 -0.0377 -1.5505 -0.0677 -1.7441 -0.0689 -0.0229 -0.5500 -0.0076 -4.5245 -0.9581 -0.0088 -0.1049 -1.0704 -0.0230 -1.5127 -0.4581 -0.0361 -0.0019 -2.9934 -0.0632
S-1913	METHODS: Patients (n = 5) with stable heart failure and a left ventricular ejection fraction of less than 45% completed a four-week aerobic training period with three trainings per week and an integrated dynamic resistance training of the lower limbs.<unk>
T-1913	patients stable_heart_failure left_ventricular_ejection_fraction training training
H-1913	-1.3680450916290283	▁heart _ ▁failure ▁left ▁vent ri cular _ ▁e je ction ▁ fraction
D-1913	-1.3680450916290283	heart_ failure left ventricular_ ejection fraction
P-1913	-2.9423 -1.4673 -1.4961 -0.0665 -0.8469 -0.3137 -0.6621 -1.2939 -1.1967 -0.6926 -0.0727 -4.1226 -0.0054 -5.2358 -0.1061
S-987	The remaining patients, which will be focused on below, have heart failure that is principally related to poor myocardial function and largely comprise those children with dilated poorly contracting ventricles, which can be related to specific aetiologies in some cases.<unk>
T-987	patients heart_failure myocardial_function dilated contracting ventricles aetiologies
H-987	-1.1202983856201172	▁heart _ ▁failure ▁my o card ial _ function ▁children ▁dil ated ▁vent ric les
D-987	-1.1202983856201172	heart_ failure myocardial_function children dilated ventricles
P-987	-0.7339 -0.7664 -1.9059 -4.4360 -0.0984 -0.1617 -0.0919 -0.7654 -2.3452 -1.6768 -0.4699 -0.1538 -2.6265 -2.3604 -0.0482 -0.3075 -0.0972
S-1847	We will classify interventions according to their level of application (ie, provider, organisation, systems level) and common underlying characteristics (eg, education, decision-support, financial incentives) using the Cochrane Effective Practice and Organisation of Care Taxonomy.<unk>
T-1847	financial cochrane_effective_practice_and_organisation_of_care_taxonomy
H-1847	-0.4473320245742798	▁co ch rane _ ▁Effective _ ▁Practic e ▁organisation _ of _ ▁Care _ ▁Tax ono my
D-1847	-0.4473320245742798	cochrane_ Effective_ Practice organisation_of_ Care_ Taxonomy
P-1847	-0.9686 -0.1000 -0.0174 -1.2284 -0.6669 -1.1369 -0.0677 -0.0104 -1.1085 -0.1826 -0.7547 -0.2592 -0.3768 -0.6824 -0.5438 -0.0182 -0.1435 -0.1787 -0.0545
S-1675	We have found that mouse Rad Q65P (the murine equivalent of human Rad Q66P) inhibits L-type currents conducted by CaV1.2 or CaV1.3 channels as potently as wild-type Rad (>95% inhibition of both channels).<unk>
T-1675	rad q65p murine rad q66p l-type_currents cav1.2 cav1.3 wild-type_rad
H-1675	-1.7534137964248657	▁mouse ▁rad _ q 65 p ▁mur ine ▁human ▁Rad ▁Q 66 p ▁l - type _ ▁current s ▁ca v 1.2 ▁ca v 1.3 ▁rad
D-1675	-1.7534137964248657	mouse rad_q65p murine human Rad Q66p l-type_ currents cav1.2 cav1.3 rad
P-1675	-0.4029 -2.8870 -4.2074 -2.0147 -0.3983 -0.4183 -0.2415 -0.3820 -5.3547 -0.9294 -1.5726 -0.1918 -0.2935 -5.3152 -0.1111 -0.0150 -1.2895 -2.0240 -0.2645 -1.2026 -1.8648 -3.8411 -4.1042 -1.0598 -2.3454 -4.2656 -1.9979 -0.1009
S-1866	Using this process to help patients determine and communicate their implantable cardioverter-defibrillator deactivation preferences may reduce the number of patients experiencing distressing implantable cardioverter-defibrillator shocks at end of life.<unk>
T-1866	patients implantable_cardioverter-defibrillator patients implantable_cardioverter-defibrillator
H-1866	-0.9743960499763489	▁implant able ▁implant able ▁cardio ver ter - de _ de _ activa tion ▁implant able ▁implant able _ ▁cardio ver ter - de _ de _ activa tion ▁implant able _ ▁cardio ver ter - de _ de fi br illa tor _ ▁shock s
D-1866	-0.9743960499763489	implantable implantable cardioverter-de_de_activation implantable implantable_ cardioverter-de_de_activation implantable_ cardioverter-de_defibrillator_ shocks
P-1866	-0.0005 -0.0238 -0.6765 -0.0404 -2.8307 -0.1140 -0.0330 -0.5542 -0.0100 -2.1448 -1.3618 -1.8924 -1.9040 -0.0992 -0.8873 -0.0948 -2.1308 -0.1181 -0.5675 -3.5004 -0.1887 -0.0391 -0.3877 -0.0124 -1.1902 -0.4796 -1.4165 -4.8602 -0.1204 -1.2001 -0.1557 -0.3662 -4.6659 -0.2901 -0.0623 -0.3836 -0.0125 -1.1654 -0.2449 -5.2728 -0.9156 -0.0136 -0.1741 -0.8117 -2.6932 -0.1623 -0.3955 -0.1065
S-274	Although the mouse heart failure (HF) model of hypertensive heart disease (HHD) is useful to investigate the pathophysiology and new therapeutic targets for HHD, the model using simple experimental procedures and stable phenotypes has not been established.<unk>
T-274	heart_failure hf hypertensive_heart_disease hhd pathophysiology therapeutic hhd stable phenotypes
H-274	-0.6567486524581909	▁mouse _ heart _ ▁failure ▁ HF ▁hyper tensi ve _ heart _ ▁disease ▁h HD ▁pat ho phy si ology ▁h HD ▁ therapeut ic _ ▁target s ▁h HD
D-274	-0.6567486524581909	mouse_heart_ failure HF hypertensive_heart_ disease hHD pathophysiology hHD therapeutic_ targets hHD
P-274	-0.0294 -0.6495 -1.5014 -0.3517 -0.8229 -2.0094 -0.0056 -0.3803 -0.3891 -0.2679 -0.2373 -2.5035 -0.6781 -2.7379 -0.2580 -0.6173 -1.6089 -0.0191 -0.0123 -0.1849 -0.4462 -0.4673 -0.5777 -0.5863 -0.0123 -0.1474 -2.1127 -0.3651 -0.0769 -0.3770 -0.8768 -0.2894 -0.0731
S-1108	Further adjustment for patient and MI characteristics yielded hazard ratios of 0.86 (95% CI: 0.66, 1.11) and 0.63 (95% CI: 0.45, 0.88) for early- and late-onset HF, respectively.<unk>
T-1108	patient mi hazard_ratios hf
H-1108	-2.047870397567749	▁MI ▁h f
D-1108	-2.047870397567749	MI hf
P-1108	-3.0808 -4.4315 -2.0589 -0.5147 -0.1534
S-1693	RESEARCH DESIGN: Using national Medicare data, we created a cohort of older patients treated at an acute care hospital for HF (n=1,203,595), AMI (n=625,595), or PNA (n=1,234,299).<unk>
T-1693	medicare patients acute hospital hf ami pna
H-1693	-0.9146128296852112	▁national ▁Medica re ▁patients ▁a cute _ hospital ▁ HF ▁ AMI ▁p na
D-1693	-0.9146128296852112	national Medicare patients acute_hospital HF AMI pna
P-1693	-2.9308 -0.2024 -0.0036 -3.8900 -0.6382 -0.1753 -0.2627 -2.8705 -0.4951 -0.6707 -0.5762 -0.0672 -0.6336 -0.8663 -0.2675 -0.0839
S-289	Adding cTnT and NT-proBNP to the ARIC HF model significantly improved all statistical parameters (AUCs increased by 0.040 and 0.057; the continuous NRIs were 50.7% and 54.7% in women and men, respectively).<unk>
T-289	ctnt nt-probnp aric hf aucs nris
H-289	-0.6334303021430969	▁c t n t ▁NT - pro B NP ▁a RIC ▁ HF ▁figure ▁au c s ▁continuo us ▁NR Is
D-289	-0.6334303021430969	ctnt NT-proBNP aRIC HF figure aucs continuous NRIs
P-289	-0.1416 -0.1457 -0.7923 -0.2954 -0.3677 -0.0129 -0.0038 -1.0730 -0.0258 -0.2455 -1.0710 -1.3657 -0.4238 -2.2318 -2.4857 -0.3866 -0.9504 -0.0495 -0.0052 -0.2596 -1.2426 -0.9308 -0.0625
S-404	Cardiovascular events were examined as a function of baseline sST2 status (low ≤35 versus high >35 ng/mL) and final achieved BB dose (high ≥50 versus low <50 mg daily equivalent dose of metoprolol succinate).<unk>
T-404	cardiovascular_events baseline sst2 metoprolol_succinate
H-404	-1.9904230833053589	▁Card io vas cular ▁events ▁s ST 2 ▁status
D-404	-1.9904230833053589	Cardiovascular events sST2 status
P-404	-1.1800 -3.6606 -2.3485 -0.5263 -4.0163 -0.4639 -1.1757 -0.4432 -3.4015 -4.6360 -0.0425
S-255	Incubation of EC with HDL(NYHA-IIIb) triggered a lower stimulation of phosphorylation at eNOS-Ser(1177) and a higher phosphorylation at eNOS-Thr(495) when compared with HDL(healthy).<unk>
T-255	hdl nyha-iiib phosphorylation phosphorylation hdl healthy
H-255	-0.7401348948478699	▁in cuba tion ▁EC ▁HD L ▁NY HA - III b ▁ phos phor y lation ▁e NOS - Ser ▁ phos phor y lation ▁e NOS - Th r ▁HD L
D-255	-0.7401348948478699	incubation EC HDL NYHA-IIIb phosphorylation eNOS-Ser phosphorylation eNOS-Thr HDL
P-255	-0.8026 -0.0006 -0.0053 -2.0630 -4.7315 -1.0800 -2.5074 -0.2194 -0.6788 -0.0606 -0.0259 -0.6827 -0.5920 -0.7739 -2.2404 -0.0196 -0.1674 -0.0107 -0.1743 -0.0770 -0.2730 -0.1065 -0.2932 -1.4864 -0.0277 -0.9059 -0.0328 -0.6480 -0.9979 -0.0141 -1.1482 -0.9806 -1.1579 -0.1793
S-117	In conclusion, patients hospitalized for HF who have preserved LVEF experience similar long-term mortality as patients with mild or moderate reductions in LVEF, whereas severely reduced LVEF remains an independent predictor of long-term mortality in this population.<unk>
T-117	patients hospitalized hf preserved_lvef mortality patients lvef lvef mortality
H-117	-0.6935024857521057	▁ HF ▁long - term _ ▁mortal ity ▁LV EF
D-117	-0.6935024857521057	HF long-term_ mortality LVEF
P-117	-1.5356 -0.0535 -2.1099 -0.0751 -0.5004 -0.4139 -0.9408 -0.1148 -1.1405 -0.0950 -1.2641 -0.0785
S-1551	Although sarcoplasmic reticular (SR) Ca(2+)-uptake, as well as protein content for SR Ca(2+)-pump and phospholamban, were reduced in the infarcted hearts; these changes were partially reversible with metoprolol.<unk>
T-1551	sarcoplasmic_reticular protein phospholamban infarcted hearts metoprolol
H-1551	-0.6670769453048706	▁sar co plas mic _ ▁reti cular SR ▁ca (2 +) - up take ▁protein s ▁SR ▁ca (2 +) - pump ▁ phos pho lam ban ▁in far cted ▁heart s ▁met o pro lol
D-1551	-0.6670769453048706	sarcoplasmic_ reticularSR ca(2+)-uptake proteins SR ca(2+)-pump phospholamban infarcted hearts metoprolol
P-1551	-0.0147 -0.0387 -0.1714 -2.9336 -0.3114 -0.2052 -0.2599 -1.0366 -2.7839 -0.6738 -0.0084 -0.0923 -0.0517 -0.1215 -2.1445 -3.7738 -1.5000 -2.2376 -0.3489 -0.0048 -0.0275 -0.0046 -0.1036 -0.0120 -0.3063 -0.7682 -0.0938 -0.0056 -0.2601 -2.3413 -1.9897 -0.1034 -0.3785 -0.0359 -0.0096 -0.0526 -0.0818 -0.0618
S-809	OBJECTIVE: Although global left ventricular longitudinal systolic strain (GLS) is a sensitive measure of left ventricular mechanics, its relationship with adverse cardiovascular (CV) events in atrial fibrillation (AF) has not been evaluated.<unk>
T-809	global_left_ventricular_longitudinal_systolic_strain gls left_ventricular cardiovascular atrial_fibrillation
H-809	-0.6255914568901062	▁global ▁left _ vent ri cular _ ▁longitud in al _ ▁sy sto lic ▁strain ▁g LS ▁left _ vent ri cular _ ▁mechanic s ▁advers e ▁cardiovascular CV ▁at rial _ ▁fi bril lation AF
D-809	-0.6255914568901062	global left_ventricular_ longitudinal_ systolic strain gLS left_ventricular_ mechanics adverse cardiovascularCV atrial_ fibrillationAF
P-809	-0.7570 -0.3882 -0.7815 -1.5179 -0.4860 -0.3216 -0.2277 -1.0027 -0.1335 -0.0973 -0.2468 -4.2190 -0.1680 -1.1964 -0.4423 -1.2254 -0.1827 -1.2131 -0.9645 -0.3926 -0.1438 -0.1897 -0.1036 -1.1273 -0.0098 -1.9016 -0.0123 -0.2316 -1.0808 -0.6648 -0.0324 -0.2172 -1.4048 -0.0058 -0.0038 -0.5136 -0.0890 -0.0760
S-1109	Declines in early-onset and late-onset HF were observed for HF with reduced EF (<50%) but not for HF with preserved EF, indicating a change in the case mix of HF after MI that requires new prevention strategies.<unk>
T-1109	hf hf_with_reduced_ef hf_with_preserved_ef change hf mi
H-1109	-0.9395533204078674	▁early - ons et ▁ HF ▁ HF ▁EF ▁ HF ▁ HF ▁ HF ▁ HF ▁MI ▁pre vention
D-1109	-0.9395533204078674	early-onset HF HF EF HF HF HF HF MI prevention
P-1109	-5.0311 -0.0954 -0.1187 -0.1023 -0.0877 -0.0484 -0.8890 -0.0394 -1.9226 -0.2572 -0.0553 -1.1227 -0.0975 -1.9968 -0.2382 -2.4921 -0.5604 -3.0927 -0.9833 -0.0154 -1.3397 -0.0843
S-1118	In addition, treatment with carvedilol resulted in a lower von Willebrand factor than did metoprolol (149% ± 13% vs. 157% ± 13%, respectively, P = 0.01), irrespective of β2-adrenergic receptor haplotype.<unk>
T-1118	carvedilol von_willebrand_factor metoprolol β2-adrenergic_receptor_haplotype
H-1118	-0.6379746794700623	▁car vedi lol ▁Will e brand ▁met o pro lol ▁β 2- ad r energi c ▁receptor _ ha plo type
D-1118	-0.6379746794700623	carvedilol Willebrand metoprolol β2-adrenergic receptor_haplotype
P-1118	-2.7979 -0.2737 -0.4153 -0.4389 -0.0600 -0.0271 -5.3284 -0.0692 -0.0241 -0.1650 -0.5359 -0.8271 -0.0463 -0.1169 -0.8236 -0.1335 -0.2426 -1.5770 -0.4720 -0.0207 -0.1505 -0.0895 -0.0381
S-1317	BACKGROUND: This study assessed the feasibility of a 12-week program of exercise, with and without intramuscular testosterone supplementation, in male patients with chronic heart failure (CHF) and low testosterone status and collected preliminary data for key health outcomes.<unk>
T-1317	exercise intramuscular_testosterone_supplementation patients chronic_heart_failure chf testosterone collected health outcomes
H-1317	-1.6987751722335815	▁fe asi bility ▁implant _ de _ ▁exercise ▁intra mus cular ▁testosteron e _ ▁supplement ation
D-1317	-1.6987751722335815	feasibility implant_de_ exercise intramuscular testosterone_ supplementation
P-1317	-4.8256 -0.2674 -0.2173 -3.6182 -5.0626 -0.7761 -0.3113 -3.4452 -2.8497 -0.0602 -0.0333 -0.3887 -0.0123 -3.0288 -0.3439 -0.0077 -5.2590 -0.0705
S-187	BACKGROUND: In heart failure (HF), there are known differences in plasma B-type natriuretic peptide (BNP) levels between reduced and preserved ejection fraction (EF), but few HF studies have explored sex differences.<unk>
T-187	heart_failure hf plasma_b-type_natriuretic_peptide bnp preserved_ejection_fraction ef hf
H-187	-0.9349409341812134	▁heart _ ▁failure ▁ HF ▁plasma ▁b - type _ ▁na tri ure tic _ pe pti de ▁b NP ▁e je ction _ fraction ▁ HF ▁sex
D-187	-0.9349409341812134	heart_ failure HF plasma b-type_ natriuretic_peptide bNP ejection_fraction HF sex
P-187	-0.2158 -0.5979 -2.6057 -3.2042 -0.0151 -0.6669 -0.8654 -0.5354 -0.0540 -1.0800 -0.7513 -0.0114 -0.3656 -5.8726 -1.3292 -0.3463 -0.2755 -0.4722 -0.2504 -0.4416 -1.7841 -1.7559 -0.0693 -0.7403 -0.0913 -1.0078 -1.0546 -0.7091 -0.7837 -0.0958
S-818	In direct comparison, GLS outperformed left ventricular ejection fraction (LVEF) and systolic mitral annulus velocity (Sa) in predicting adverse CV events both in univariate and multivariate models (p ≤ 0.043).<unk>
T-818	gls left_ventricular_ejection_fraction lvef systolic_mitral_annulus_velocity multivariate_models
H-818	-0.9343402981758118	▁g LS ▁left ▁vent ri cular _ ▁e je ction _ fraction LV EF ▁sy sto lic _ ▁mit ral _ ▁ann ulus _ ▁veloci ty ▁CV
D-818	-0.9343402981758118	gLS left ventricular_ ejection_fractionLVEF systolic_ mitral_ annulus_ velocity CV
P-818	-1.6194 -0.9270 -1.2000 -0.9883 -0.3116 -0.8132 -1.3303 -2.0291 -1.0130 -0.2349 -1.0365 -0.0402 -0.5148 -0.0462 -0.0657 -0.1178 -1.5592 -0.4605 -3.1058 -0.0221 -0.3819 -0.6045 -0.3995 -0.3798 -2.3402 -0.2278 -3.7782 -1.3703 -0.1782
S-153	RM interventions included home telemonitoring (TM) (including implanted monitoring devices) with medical support provided during office hours or 24/7 and structured telephone support (STS) programmes delivered via human-to-human contact (HH) or human-to-machine interface (HM).<unk>
T-153	rm telemonitoring implanted medical structured_telephone_support sts human-to-human_contact hh human-to-machine_interface
H-153	-1.0507538318634033	▁implant ed _ monitor ing ▁implant ed _ ▁implant ed _ ▁monitoring ▁devices ▁office ▁hours ▁structure d _ ▁telephone ▁support ▁st s ▁human - to - human ▁contact ▁h ▁machine ▁interface HM
D-153	-1.0507538318634033	implanted_monitoring implanted_ implanted_ monitoring devices office hours structured_ telephone support sts human-to-human contact h machine interfaceHM
P-153	-1.0288 -0.1869 -2.1097 -0.9765 -0.1982 -1.6878 -0.1976 -1.0895 -2.8436 -0.1861 -0.9421 -2.4654 -1.6484 -3.1243 -1.0592 -0.1912 -0.0673 -0.7176 -0.4617 -1.8747 -5.1621 -0.1828 -2.1748 -0.0226 -0.0553 -0.0330 -0.0210 -0.0047 -0.1546 -2.2916 -0.5362 -1.6811 -0.2994 -0.0499
S-794	OBJECTIVE: To investigate the within-day test-retest reliability of the Timed Up & Go (TUG) test in patients with advanced chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF), and chronic renal failure (CRF).<unk>
T-794	tug patients chronic_obstructive_pulmonary_disease copd chronic_heart_failure chf chronic_renal_failure crf
H-794	-1.339156150817871	▁temps _ de _ up _ go ▁tu g ▁chronic _ ▁ob struct ive _ ▁pulmonar y ▁disease ▁co PD ▁chronic _ ▁heart _ ▁failure ▁CH f ▁chronic _ ▁renal _ ▁failure CR f
D-794	-1.339156150817871	temps_de_up_go tug chronic_ obstructive_ pulmonary disease coPD chronic_ heart_ failure CHf chronic_ renal_ failureCRf
P-794	-1.3799 -2.0637 -4.0687 -0.2294 -0.8111 -1.6682 -1.3595 -0.6969 -1.3321 -6.0742 -0.2604 -1.7256 -0.0764 -0.0469 -0.3567 -0.4352 -0.0801 -2.9757 -3.0582 -0.3868 -1.7352 -0.1565 -3.4086 -0.4690 -0.6842 -2.6923 -0.2551 -1.0246 -0.2446 -0.6734 -2.6423 -1.9374 -2.3566 -0.6256 -0.1066 -0.1118
S-859	Using time-dependent Cox regression analysis, we compared patients treated with different types of beta-blockers or no beta-blockers on the primary endpoint of inappropriate therapy, delivered as antitachycardia pacing (ATP) or shock therapy.<unk>
T-859	cox_regression_analysis patients beta-blockers beta-blockers primary_endpoint therapy antitachycardia_pacing atp shock_therapy
H-859	-0.5765557289123535	▁temps - dependent ▁co x ▁re gression ▁figure ▁beta - block ers ▁beta - block ers ▁in appropria te ▁ therapy ▁anti ta chy car dia _ pa cing ▁a TP ▁shock ▁ therapy
D-859	-0.5765557289123535	temps-dependent cox regression figure beta-blockers beta-blockers inappropriate therapy antitachycardia_pacing aTP shock therapy
P-859	-1.2208 -0.7740 -0.2685 -0.5433 -0.0067 -1.6809 -0.0355 -4.5732 -1.2517 -0.0347 -0.1475 -0.0232 -1.0600 -0.0301 -0.2374 -0.0310 -0.1485 -0.0579 -0.0409 -0.2149 -0.0158 -0.0134 -0.6298 -0.3425 -0.0458 -2.7251 -1.5058 -0.5592 -0.6262 -1.1541 -0.1304 -0.0645 -0.3618 -0.0181 -0.0986 -0.0844
S-1680	Two of the most ethically complex situations in pediatrics are those involving families whose religious beliefs preclude the provision of life-sustaining treatment and those involving young adults who have reached the age of legal majority and who face decisions about life-sustaining treatment.<unk>
T-1680	ethically legal decisions
H-1680	-0.9555571675300598	▁et h ically _ ▁complex ▁situations ▁pediatr ics ▁families ▁religious _ ▁belief s ▁life - s usta ining
D-1680	-0.9555571675300598	ethically_ complex situations pediatrics families religious_ beliefs life-sustaining
P-1680	-1.2687 -0.0803 -0.4626 -2.5337 -1.2069 -0.2958 -0.1374 -1.0486 -1.7616 -0.3932 -1.1356 -0.5043 -0.0240 -3.1588 -0.0175 -0.5031 -0.1065 -0.3639 -4.0282 -0.0803
S-1122	BACKGROUND: Little is known about how often contextual factors such as patient preferences and competing priorities impact prescribing of guideline-recommended medications, or about the extent to which these factors are documented in medical records and available to performance measurement systems.<unk>
T-1122	patient prescribing medications medical
H-1122	-0.5712707042694092	▁patient ▁preference s ▁priorit ies ▁guide line - re com mend ed ▁medication s
D-1122	-0.5712707042694092	patient preferences priorities guideline-recommended medications
P-1122	-4.0124 -1.1799 -0.0166 -0.6579 -0.3267 -0.7492 -0.0482 -0.1827 -0.0083 -0.0219 -0.0107 -0.0838 -0.3244 -0.0308 -1.4273 -0.0595
S-1241	The total cost per patient was not significantly different between rhythm-control ($72,764 [95% CI, $61,575-$85,145]) and rate-control ($78,767 [95% CI, $67,101-$92,139]) strategies.<unk>
T-1241	cost patient rhythm-control rate-control
H-1241	-0.9499502182006836	▁coût ▁ rhythm - control
D-1241	-0.9499502182006836	coût rhythm-control
P-1241	-1.4643 -0.5319 -1.5108 -0.2311 -0.0140 -2.7027 -0.1949
S-393	Median age was 70 years (Q, 61-77), 28% were women, median left ventricular ejection fraction was 30% (Q, 24-40), and median eGFR was 68 (Q, 51-85) mL/min per 1.73 m(2).<unk>
T-393	left_ventricular_ejection_fraction egfr
H-393	-1.5283904075622559	▁figure ▁vent ri cular ▁e je ction ▁ fraction ▁figure ▁media n ▁e G FR ▁m l
D-393	-1.5283904075622559	figure ventricular ejection fraction figure median eGFR ml
P-393	-3.5937 -4.0633 -0.1066 -0.5345 -1.2095 -2.8492 -0.3290 -2.7328 -0.0033 -3.0254 -1.8329 -0.0842 -0.5717 -2.7670 -1.0787 -0.6840 -2.1386 -1.2735 -0.1616
S-127	A decrease in CD34+VEGFR2+ cells was independently associated with increased functional capacity; a 10-cell decrease in CD34+VEGFR2+ cells was associated with an increase of 0.2 mL/kg/min in peak VO2 (P < 0.05).<unk>
T-127	cells functional_capacity cells peak_vo2
H-127	-2.094449043273926	▁CD 34 _ ve g FR 2 _ cell s ▁functional _ capaci tation ▁CD 34 _ ve g FR 2 _ cell s
D-127	-2.094449043273926	CD34_vegFR2_cells functional_capacitation CD34_vegFR2_cells
P-127	-0.6594 -0.9728 -3.8165 -1.2485 -1.8144 -2.5314 -1.1514 -4.2274 -1.2276 -0.3397 -3.5432 -3.0155 -2.1748 -2.1475 -2.6582 -0.7142 -3.2487 -4.0161 -1.7068 -3.7939 -0.6433 -3.2773 -1.7596 -0.1693 -3.4327 -0.1656
S-1773	When grouped into categories of fit and unfit (upper 80% and lower 20% of CRF distribution, respectively), hazard ratios were significantly lower in fit compared with unfit men in normal and overweight body mass index strata (P<0.002) but not in obese men.<unk>
T-1773	crf hazard_ratios body_mass_index obese
H-1773	-1.267520785331726	▁fit ▁un fit ▁c RF ▁hazard ▁ratio s
D-1773	-1.267520785331726	fit unfit cRF hazard ratios
P-1773	-1.0540 -3.8894 -0.0962 -0.2127 -0.0816 -1.3000 -1.4476 -0.1024 -4.4265 -0.0648
S-2	This study used the Medicare Patient Safety Monitoring System (MPSMS) database to assess national trends in adverse event rates between 2005 through 2011 for patients hospitalized with acute myocardial infarction, congestive heart failure, pneumonia, or conditions requiring surgery.<unk>
T-2	medicare_patient_safety_monitoring_system mpsms adverse_event patients hospitalized acute_myocardial_infarction congestive_heart_failure pneumonia conditions surgery
H-2	-0.7239066362380981	▁Medica re _ ▁Patient _ ▁Safety _ monitor ing _ system ▁mp SMS ▁advers e ▁event _ ▁rates ▁a cute _ My o card ial ▁in far ction ▁con ges tive _ ▁heart _ ▁failure ▁pneu monia ▁conditions ▁surgery
D-2	-0.7239066362380981	Medicare_ Patient_ Safety_monitoring_system mpSMS adverse event_ rates acute_Myocardial infarction congestive_ heart_ failure pneumonia conditions surgery
P-2	-0.0212 -0.0005 -1.4772 -0.2594 -0.2843 -0.0639 -1.0291 -0.9970 -0.0527 -1.4939 -0.5384 -1.8785 -0.0886 -2.6836 -0.0271 -0.8200 -2.2130 -1.9521 -1.8008 -0.0094 -0.1192 -3.9994 -0.5100 -0.1373 -0.0530 -0.6194 -1.3083 -0.0185 -0.0803 -0.0361 -0.0202 -0.9804 -1.2400 -0.6744 -0.4129 -0.0003 -0.0471 -1.2401 -0.3238 -0.0817 -0.0871
S-382	The HFPSI model included blood urea nitrogen, B-type natriuretic peptide, New York Heart Association class, diabetes status, history of atrial fibrillation/flutter, and all-cause hospitalization within the prior 1 and 2 to 6 months.<unk>
T-382	hfpsi blood_urea_nitrogen b-type_natriuretic_peptide new_york_heart_association_class diabetes atrial_fibrillation all-cause_hospitalization
H-382	-0.7776800990104675	▁ HF PSI ▁blood ▁u rea _ ▁nit rogen ▁b - type ▁na tri ure tic _ pe pti de ▁New ▁York ▁Heart _ ▁Association ▁diabetes ▁at rial _ ▁fi bril lation _ flu tter
D-382	-0.7776800990104675	HFPSI blood urea_ nitrogen b-type natriuretic_peptide New York Heart_ Association diabetes atrial_ fibrillation_flutter
P-382	-1.0314 -0.3885 -2.9537 -2.8032 -0.1931 -2.4577 -1.4480 -0.1273 -0.0617 -0.6723 -0.0340 -0.0253 -0.2646 -0.0050 -0.0635 -3.8004 -1.3276 -0.4499 -0.1252 -0.1958 -0.5791 -0.1372 -0.2903 -1.4083 -1.3347 -0.3878 -1.7815 -0.0417 -0.2510 -1.1211 -0.0371 -0.0176 -1.6682 -0.0295 -0.0132 -1.1719 -0.0756
S-852	The primary outcome occurred in 116 of 404 patients in the CRT group, as compared with 102 of 405 in the control group (28.7% vs. 25.2%; hazard ratio, 1.20; 95% confidence interval [CI], 0.92 to 1.57; P=0.15).<unk>
T-852	primary_outcome patients crt hazard_ratio confidence_interval
H-852	-1.161757469177246	▁c RT
D-852	-1.161757469177246	cRT
P-852	-0.7630 -0.3408 -3.4644 -0.0788
S-1311	The crude 28-day case-fatality rate for patients with concurrent HF declined marginally from 20.5% to 15.9% (P < 0.05) compared with those without concurrent HF, in whom the case-fatality rate declined from 11.0% to 4.8% (P < 0.001).<unk>
T-1311	case-fatality_rate patients hf hf case-fatality_rate
H-1311	-1.1354498863220215	▁cru de ▁28- day ▁figure - fat ality ▁ HF
D-1311	-1.1354498863220215	crude 28-day figure-fatality HF
P-1311	-2.5803 -0.0171 -3.0128 -0.1077 -2.8484 -0.3422 -0.0833 -0.0273 -2.0659 -0.2260 -2.2350 -0.0793
S-659	BACKGROUND: The objective of this study is to examine practice-level variation in rates of guideline-recommended treatment for outpatients with heart failure and reduced ejection fraction, and to examine the association between treatment variation and practice site, independent of patient factors.<unk>
T-659	outpatients heart_failure_and_reduced_ejection_fraction patient
H-659	-0.9787881374359131	▁pratiques _ level _ re com mend ed ▁treatment ▁out patient s ▁heart _ ▁failure ▁reduce d ▁e je ction _ fraction
D-659	-0.9787881374359131	pratiques_level_recommended treatment outpatients heart_ failure reduced ejection_fraction
P-659	-5.1980 -2.3956 -1.4073 -3.7782 -1.6840 -0.0543 -0.1358 -0.1999 -0.6471 -1.1583 -0.0079 -0.0132 -0.8084 -0.4961 -0.5102 -1.1180 -0.0124 -0.9621 -0.6495 -0.0162 -0.7994 -0.0101 -1.3510 -0.0779
S-1453	This cohort formed the sampling frame for selecting controls (without CHF) matched on: age, race/ethnicity, cumulative anthracycline exposure, stem cell source (allogeneic, autologous), and length of follow-up.<unk>
T-1453	frame chf anthracycline stem_cell allogeneic autologous follow-up
H-1453	-0.8083717823028564	▁sa mp ling ▁CHF ▁race _ eth nici ty ▁cum ul ative ▁an thra cycli ne ▁exposure ▁stem _ cell ▁auto logo us
D-1453	-0.8083717823028564	sampling CHF race_ethnicity cumulative anthracycline exposure stem_cell autologous
P-1453	-4.8357 -0.1060 -0.6478 -1.6585 -2.3799 -1.2682 -0.1494 -0.0527 -0.5134 -0.4482 -0.0144 -0.0079 -0.0178 -0.0253 -1.2309 -0.6682 -1.3988 -0.0096 -1.7327 -1.5336 -1.1777 -0.0022 -0.0900 -0.1925 -0.0478
S-765	Resting tension (Fpassive)-sarcomere length relations were obtained in small muscle strips before and after KCl-KI treatment, which unanchors titin and allows contributions of titin and extracellular matrix to Fpassive to be discerned.<unk>
T-765	resting_tension fpassive muscle kcl-ki titin titin extracellular_matrix fpassive
H-765	-0.8430573344230652	▁tension _ f pass ive _ sar com ere ▁length ▁muscle _ ▁strip s ▁k c l - KI ▁treatment ▁titi n ▁extra cel lular ▁matri x ▁F pass ive
D-765	-0.8430573344230652	tension_fpassive_sarcomere length muscle_ strips kcl-KI treatment titin extracellular matrix Fpassive
P-765	-0.5517 -3.2976 -0.5633 -0.1347 -0.0065 -2.5950 -2.1164 -0.0138 -0.6190 -2.4763 -1.5621 -3.3780 -0.3477 -0.0087 -0.6450 -0.1899 -0.0797 -0.1536 -0.0591 -4.3333 -1.4026 -0.0400 -0.4056 -0.2901 -0.0341 -0.7601 -0.0075 -0.5247 -0.0020 -0.0028 -0.3236 -0.0536
S-1922	The combined aerobic and resistance training intervention with augmented feedback resulted in benefits in exercise capacity, muscle strength and quality of life, as well as an improvement of cardiac (NT-ProBNP) and inflammatory (IL6, hsCRP) biomarkers.<unk>
T-1922	training exercise_capacity muscle quality_of_life cardiac nt-probnp inflammatory il6 hscrp biomarkers
H-1922	-1.2789925336837769	▁aero bic _ de _ ▁resist ance _ training ▁conditions ▁exercise _ pu issa nce ▁muscle _ streng th ▁quality _ of _ ▁life ▁cardiac _ pro B NP ▁infla mma tory ▁h s CR p
D-1922	-1.2789925336837769	aerobic_de_ resistance_training conditions exercise_puissance muscle_strength quality_of_ life cardiac_proBNP inflammatory hsCRp
P-1922	-0.3348 -0.0872 -2.0889 -2.7804 -0.1650 -1.3244 -0.0135 -2.2324 -0.8199 -5.8721 -1.6028 -0.5129 -3.1566 -0.0358 -0.0163 -0.3245 -0.7697 -4.6543 -1.6495 -2.8575 -0.5664 -0.7887 -0.2872 -1.5475 -0.5086 -5.3747 -1.7312 -0.9177 -0.0706 -0.8513 -0.4144 -1.5075 -0.7548 -0.0142 -0.3396 -0.2824 -1.2689 -0.0774
S-135	OBJECTIVE: To quantify the differential impact on hospital performance of three readmission metrics: all-cause readmission (ACR), 3M Potential Preventable Readmission (PPR), and Centers for Medicare and Medicaid 30-day readmission (CMS).<unk>
T-135	hospital readmission all-cause_readmission acr potential_preventable_readmission ppr medicare medicaid readmission cms
H-135	-0.8882364630699158	▁hospital ▁read mission ▁a CR ▁Potential _ ▁Prev en table _ ▁Read mission ▁p PR ▁Center s _ de _ ▁Medica re ▁Medica id ▁c MS
D-135	-0.8882364630699158	hospital readmission aCR Potential_ Preventable_ Readmission pPR Centers_de_ Medicare Medicaid cMS
P-135	-3.0803 -4.0262 -0.0816 -1.4122 -0.9994 -1.5783 -0.3745 -0.0977 -0.0068 -0.0353 -0.5244 -0.2094 -0.0143 -0.8286 -0.1448 -0.5341 -0.0513 -0.2924 -3.4398 -0.1857 -0.0645 -0.0032 -1.8992 -0.8399 -2.5258 -1.3325 -0.2065 -0.0819
S-1547	In order to examine the reversibility of heart failure due to myocardial infarction (MI) by β-adrenoceptor blockade, 12 weeks infarcted rats were treated with or without metoprolol (50 mg/kg/day) for 8 weeks.<unk>
T-1547	heart_failure myocardial_infarction mi β-adrenoceptor_blockade infarcted metoprolol
H-1547	-0.6542514562606812	▁rever si bility ▁heart _ ▁failure ▁my o card ial ▁in far ction ▁m ▁β - ad re no cept or ▁block ade ▁in far cted ▁rat s ▁met o pro lol
D-1547	-0.6542514562606812	reversibility heart_ failure myocardial infarction m β-adrenoceptor blockade infarcted rats metoprolol
P-1547	-1.3697 -0.0833 -0.1450 -2.5025 -1.1462 -1.6090 -0.6279 -0.3002 -0.2583 -0.1338 -0.8862 -1.7403 -0.0433 -1.2108 -2.0470 -0.0083 -0.0154 -0.0322 -0.1457 -1.8138 -0.5620 -1.1207 -1.0255 -0.1387 -0.6254 -1.2844 -0.4064 -0.0917 -0.2965 -0.0832 -0.0170 -0.0767 -0.3159 -0.0816
S-1882	The exercise duration was increased from 8 min to 23 min after rehabilitation (P < 0.001); distance 6 minutes walking was increased from 394 m to 470 m (P < 0.05); score of Minnesota quality of life was decreased from 25 to 3 in exercise group (P < 0.01).<unk>
T-1882	exercise rehabilitation walking minnesota_quality_of_life exercise
H-1882	-2.338759183883667	
D-1882	-2.338759183883667	
P-1882	-4.5635 -0.1140
S-218	Congestive heart failure visits declined from 1.6% of all ED visits in 1996 to 1.2% in 2008, a 26% relative decrease (95% CI: 21%-30%, P < .001, correlation coefficient R(2) = 0.94, P < .001).<unk>
T-218	congestive_heart_failure correlation_coefficient
H-218	-1.3545844554901123	▁con ges tive _ ▁heart _ ▁failure
D-218	-1.3545844554901123	congestive_ heart_ failure
P-218	-0.8670 -0.0185 -0.0238 -0.5276 -2.9641 -0.6675 -3.1227 -3.8913 -0.1086
S-637	Excessive secretion of arginine vasopressin (AVP) has the potential for deleterious effects on various physiologic processes in CHF Inhibition of AVP through vasopressin receptor antagonist therapy is a potentially beneficial new therapeutic approach to CHF.<unk>
T-637	arginine_vasopressin avp physiologic chf avp vasopressin_receptor_antagonist therapy therapeutic chf
H-637	-0.5931861996650696	▁secret ion ▁argi nine _ ▁vaso press in ▁a VP ▁physio logi que _ process es ▁CHF ▁in hib i tion ▁a VP ▁vaso press in _ ▁receptor _ ▁anta gon ist ▁ therapy ▁CHF
D-637	-0.5931861996650696	secretion arginine_ vasopressin aVP physiologique_processes CHF inhibition aVP vasopressin_ receptor_ antagonist therapy CHF
P-637	-3.9865 -0.0627 -0.3993 -0.1342 -1.0657 -0.3323 -0.1060 -0.4956 -0.5643 -0.0435 -2.6473 -0.5684 -0.8231 -1.3194 -1.5063 -0.0220 -0.0439 -0.6569 -0.0161 -0.1054 -0.0095 -1.0937 -0.0325 -0.3607 -0.0370 -0.4242 -0.9603 -0.3094 -0.9164 -0.2802 -0.0164 -0.9457 -0.9902 -0.0647 -0.2024 -0.2560 -0.1498
S-1205	(1) With therapies ranging from medication and physical therapy to implantable defibrillators and circulatory support, and possibly transplantation, accurate risk stratification of patient with heart failure and delivery of therapies appropriate to the level of their disease severity is becoming increasingly important.<unk>
T-1205	therapies medication physical_therapy implantable_defibrillators circulatory_support transplantation risk_stratification patient heart_failure therapies disease
H-1205	-0.841793954372406	▁implant able _ de fi br illa tors ▁circula tory _ ▁support ▁transplant ation ▁heart _ ▁failure ▁ therapie s ▁disease
D-1205	-0.841793954372406	implantable_defibrillators circulatory_ support transplantation heart_ failure therapies disease
P-1205	-0.1654 -0.0251 -1.6195 -0.0559 -2.4673 -1.1537 -0.0139 -1.6910 -0.7475 -0.1398 -1.2117 -0.7275 -0.3415 -0.0045 -2.9608 -0.9876 -1.4790 -1.0528 -0.0254 -0.0187 -1.1116 -1.2842 -0.0766
S-961	Rats were then sacrificed and hearts were rapidly excised for estimation of caspase-3 activity, phosphocreatine and adenine nucleotides contents in addition to cytochrome c, Bcl2, Bax and caspase 3 expression.<unk>
T-961	hearts caspase-3 activity phosphocreatine adenine_nucleotides cytochrome_c bcl2 bax caspase_3 expression
H-961	-0.5339889526367188	▁rat s ▁cas pas e -3 ▁activity ▁ phos pho creati ne ▁a den ine ▁nucleo ti des ▁cy to ch rom e ▁b cl 2 ▁Bax ▁cas pas e
D-961	-0.5339889526367188	rats caspase-3 activity phosphocreatine adenine nucleotides cytochrome bcl2 Bax caspase
P-961	-0.6462 -0.1541 -2.0059 -0.9774 -0.3671 -2.5232 -1.0389 -0.1325 -0.0037 -0.5029 -0.5569 -0.8465 -0.0874 -0.0076 -0.1377 -1.4292 -0.0047 -0.0265 -1.0702 -0.0840 -0.0921 -0.0136 -0.0973 -1.0155 -0.0188 -0.4160 -0.0328 -0.0017 -0.4574 -0.3136 -1.8778 -0.1480
S-166	After 7 weeks rapid right ventricular pacing, gene expressions of Bax, Bcl-2 and Caspase-3 were measured by RTQ-PCR from interventricular septum biopsies that were taken weekly in 21 beagle dogs during the development of heart failure.<unk>
T-166	right_ventricular_pacing gene_expressions bax bcl-2 caspase-3 rtq-pcr interventricular_septum biopsies heart_failure
H-166	-0.6472578048706055	▁rapid _ ▁right ▁vent ri cular _ pa cing ▁Bax ▁b cl -2 ▁Cas pas e -3 ▁RT q - PC r ▁interven tri cular _ ▁sept um ▁bio psi es ▁beag le ▁dog s ▁heart _ ▁failure
D-166	-0.6472578048706055	rapid_ right ventricular_pacing Bax bcl-2 Caspase-3 RTq-PCr interventricular_ septum biopsies beagle dogs heart_ failure
P-166	-2.4307 -0.4957 -2.9075 -1.3261 -0.0803 -0.1762 -0.5376 -0.2343 -0.5235 -0.5113 -0.1215 -0.0179 -2.2359 -0.2587 -0.3426 -0.0291 -1.7935 -1.0753 -0.6729 -0.1785 -0.0936 -0.6133 -0.0254 -0.0034 -0.1119 -0.6368 -0.9803 -0.0250 -0.7261 -0.0232 -0.0201 -0.0022 -0.0222 -1.6089 -0.0387 -0.5555 -1.2521 -3.0035 -0.1399 -0.0590
S-661	Practice rates of treatment with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and β-blockers and an optimal combined treatment measure were determined for patients with heart failure and reduced ejection fraction and no documented contraindications.<unk>
T-661	angiotensin-converting_enzyme_inhibitors angiotensin_receptor_blockers β-blockers patients heart_failure_and_reduced_ejection_fraction
H-661	-0.9370556473731995	▁ang io ten sin _ con ver ting ▁enzym e _ ▁inhibi tor _ angi oten sin _ ▁receptor _ block ers ▁β - block ers ▁heart _ ▁failure ▁e je ction _ fraction
D-661	-0.9370556473731995	angiotensin_converting enzyme_ inhibitor_angiotensin_ receptor_blockers β-blockers heart_ failure ejection_fraction
P-661	-2.4726 -1.0266 -0.3651 -1.3770 -2.1306 -0.0008 -0.0305 -1.9542 -0.4802 -0.0767 -1.8639 -0.3233 -2.2917 -2.2233 -0.4755 -0.0349 -0.7543 -0.5659 -1.4517 -2.1205 -1.1030 -0.0189 -0.0537 -0.0103 -0.0584 -0.0288 -2.5018 -0.7867 -4.4920 -0.7953 -0.1318 -0.0084 -1.4679 -0.0051 -0.1711 -0.0813
S-918	We hypothesized that the sodium-restricted dietary approaches to stop hypertension diet (DASH/SRD) would improve left ventricular diastolic function, arterial elastance, and ventricular-arterial coupling in hypertensive HFPEF.<unk>
T-918	dietary_approaches_to_stop_hypertension dash left_ventricular_diastolic_function arterial_elastance ventricular-arterial_coupling hypertensive_hfpef
H-918	-0.7073301672935486	▁so dium - re strict ed ▁hyper tension _ die t DAS h ▁vent ri cular _ ▁dia sto lic _ ▁function ▁arterial _ ▁elastan ce ▁vent ri cular - arte rial ▁coup ling ▁hyper tensi ve ▁h FP EF
D-918	-0.7073301672935486	sodium-restricted hypertension_dietDASh ventricular_ diastolic_ function arterial_ elastance ventricular-arterial coupling hypertensive hFPEF
P-918	-1.0092 -0.0222 -0.0426 -0.0038 -0.0149 -0.0470 -4.3631 -0.0008 -3.6912 -0.7593 -0.0896 -0.2067 -0.3319 -3.4554 -0.0497 -0.0719 -0.2738 -1.5747 -0.1140 -1.3764 -2.4674 -2.9772 -0.0429 -0.7481 -0.3178 -0.2357 -0.0032 -0.0418 -0.0425 -0.7340 -0.0855 -0.0488 -0.0328 -1.2285 -0.1745 -0.8532 -0.1940 -0.9010 -0.4056 -0.5509 -0.0521 -0.0725
S-1017	Despite neutral results in many acute HF trials, recent studies including RELAX-AHF, ASTRONAUT, and PRONTO have highlighted the role of appropriate timing of patient enrollment, targeting the "right" patients, and selecting appropriate end points and sites.<unk>
T-1017	acute_hf relax-ahf astronaut pronto patient patients end_points
H-1017	-0.8861678838729858	▁a cute ▁ HF ▁ HF ▁ AST RON AUT ▁PR ONTO ▁patient ▁en roll ment
D-1017	-0.8861678838729858	acute HF HF ASTRONAUT PRONTO patient enrollment
P-1017	-0.2968 -0.0232 -1.2715 -0.0372 -3.4362 -1.4428 -2.8704 -0.6695 -0.2621 -0.0232 -0.2116 -0.0038 -2.6575 -1.7765 -0.0062 -0.0378 -0.8440 -0.0808
S-1119	CONCLUSION: Compared with metoprolol, carvedilol resulted in greater reduction of sympathetic activity after 6 wk of treatment and lower von Willebrand factor concentrations in both Arg16/Gln27 and Gly16/Glu27 individuals.<unk>
T-1119	metoprolol carvedilol sympathetic_activity von_willebrand_factor
H-1119	-0.684723973274231	▁met o pro lol ▁car vedi lol ▁sympa the tic ▁activity
D-1119	-0.684723973274231	metoprolol carvedilol sympathetic activity
P-1119	-0.5313 -0.0994 -0.0276 -0.0709 -0.0583 -0.2098 -0.1783 -0.2166 -0.2969 -1.6388 -1.5297 -3.9909 -0.0529
S-1832	MEASUREMENTS: Hospitalized HF, identified by International Classification of Diseases, Ninth Revision, Clinical Modification codes 402.x1, 404.x1, 404.x3, and 428.xx recorded as the principal discharge diagnosis.<unk>
T-1832	hospitalized hf international_classification_of_diseases clinical principal discharge diagnosis
H-1832	-0.7161744236946106	▁Hospital ized ▁ HF ▁Disease s ▁Clinic al _ ▁Modifica tion ▁code s
D-1832	-0.7161744236946106	Hospitalized HF Diseases Clinical_ Modification codes
P-1832	-0.8951 -0.3490 -0.6223 -0.0125 -4.8709 -0.0310 -0.6756 -0.0034 -1.2468 -0.0611 -0.0225 -0.2995 -0.0282 -1.5640 -0.0609
S-1676	In addition, Rad Q65P attenuates the gating movement of both channels as effectively as wild-type Rad, indicating that the Q65P substitution does not differentially impair any of the three described modes of L-type channel inhibition by RGK proteins.<unk>
T-1676	rad q65p movement wild-type_rad q65p l-type_channel rgk_proteins
H-1676	-1.2288612127304077	▁Rad ▁Q 65 p ▁ga ting _ ▁movement ▁wild - type ▁Rad ▁Q 65 p ▁substitut ion ▁l - type _ ▁channel _ ▁inhibi tion ▁R GK
D-1676	-1.2288612127304077	Rad Q65p gating_ movement wild-type Rad Q65p substitution l-type_ channel_ inhibition RGK
P-1676	-2.2122 -2.0907 -0.8213 -0.5921 -3.7025 -0.8113 -0.9523 -0.6492 -3.8527 -0.0071 -0.0072 -0.8690 -0.6286 -0.1784 -0.5410 -5.3278 -0.0148 -3.3458 -0.1561 -0.0212 -0.9206 -3.2123 -0.5949 -0.0924 -0.0267 -1.3155 -0.0085 -2.5425 -0.1421
S-876	SS20 had only modest effects on heart failure and this tracked with only partial attenuation of global proteomics changes; furthermore, actin cytoskeleton pathways were significantly protected in SS20, whereas mitochondrial and metabolic pathways essentially were not.<unk>
T-876	ss20 heart_failure proteomics actin_cytoskeleton ss20 mitochondrial metabolic_pathways
H-876	-1.1412417888641357	▁heart _ pu issa nce ▁prote o mics ▁changes ▁act in _ cy tos kelet on _ path ways ▁mito cho ndri al ▁metabol ic ▁path ways
D-876	-1.1412417888641357	heart_puissance proteomics changes actin_cytoskeleton_pathways mitochondrial metabolic pathways
P-876	-2.5720 -1.4806 -5.3405 -0.0235 -0.0125 -3.8042 -0.9873 -0.0095 -4.5890 -0.1273 -0.1496 -0.3259 -1.9283 -0.9787 -0.0396 -0.1208 -1.9179 -0.4351 -0.1440 -4.3581 -0.4127 -0.0203 -0.0159 -1.1366 -0.1936 -1.3428 -0.0928 -0.4336 -0.1033
S-324	Echocardiograms were taken of the left ventricular base, midpapillary, and apex during baseline, IVC occlusion, and each BiVP setting for STE analysis of twist, apical and basal rotations, CS, RS, and synchrony.<unk>
T-324	echocardiograms left_ventricular_base midpapillary apex baseline ivc_occlusion bivp ste rs
H-324	-0.5457049012184143	▁e cho card i ogram s ▁left ▁vent ri cular ▁base ▁mid pap illa ry ▁IV c ▁oc clusi on ▁bi VP ▁ STE ▁twist ▁bas al ▁rota tions ▁RS ▁synchron y
D-324	-0.5457049012184143	echocardiograms left ventricular base midpapillary IVc occlusion biVP STE twist basal rotations RS synchrony
P-324	-0.8373 -0.1184 -0.0347 -0.3333 -0.0105 -0.1179 -0.4180 -0.0379 -0.1428 -0.0724 -0.3541 -1.7805 -0.1238 -0.0116 -0.1559 -2.6371 -0.4183 -1.5711 -0.0198 -0.0597 -0.6896 -0.0667 -2.1113 -0.3749 -2.7258 -0.7809 -0.0045 -0.4143 -0.0062 -1.5869 -0.1154 -0.0475 -0.2718 -0.1030
S-1145	It was demonstrated that the long-term administration of pyridostigmine started right after coronary artery ligation augmented cardiac vagal and reduced sympathetic tone, attenuating cardiac remodeling and left ventricular dysfunction during the progression of HF in rats.<unk>
T-1145	administration pyridostigmine coronary_artery_ligation cardiac sympathetic_tone cardiac_remodeling left_ventricular_dysfunction hf
H-1145	-0.47791242599487305	▁py rido stig mine ▁corona ry ▁arter y _ ▁liga tion ▁cardiac ▁va gal ▁sympa the tic ▁tone ▁cardiac ▁remodel ing ▁vent ri cular ▁dys function ▁ HF
D-1145	-0.47791242599487305	pyridostigmine coronary artery_ ligation cardiac vagal sympathetic tone cardiac remodeling ventricular dysfunction HF
P-1145	-4.9932 -0.0434 -0.0005 -0.1212 -0.1174 -0.1315 -0.9214 -0.3898 -1.0625 -0.1829 -0.4009 -0.0153 -1.7581 -0.0045 -0.2388 -0.1040 -0.9208 -0.1763 -0.0183 -0.0765 -0.0645 -1.3734 -0.0663 -0.0903 -0.2566 -0.2122 -0.2532 -0.0221 -0.2791 -0.0421
S-1229	(A Comparison Of Outcomes In Patients In New York Heart Association [NYHA] Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines [EMPHASIS-HF Study]; NCT00232180).<unk>
T-1229	outcomes patients new_york_heart_association nyha heart_failure eplerenone placebo heart_failure medicines emphasis-hf
H-1229	-1.3333072662353516	▁implant s ▁New ▁York _ ▁Heart _ association ▁NY HA ▁class _ ▁II ▁Heart _ ▁Fail ure ▁e pler en one ▁place bo ▁standard _ ▁Heart _ ▁Fail ure _ ▁Medicine s
D-1229	-1.3333072662353516	implants New York_ Heart_association NYHA class_ II Heart_ Failure eplerenone placebo standard_ Heart_ Failure_ Medicines
P-1229	-5.4714 -1.3180 -4.5326 -0.4765 -2.2513 -2.2631 -1.3826 -2.1327 -4.9702 -0.1712 -1.7813 -0.3826 -0.4902 -0.3412 -0.3718 -0.2568 -0.0498 -0.5893 -0.0741 -0.1264 -2.8488 -3.5292 -0.0030 -1.8774 -0.3205 -0.7845 -0.3221 -0.3570 -0.2607 -1.6573 -1.3194 -0.0122 -2.4710 -0.1363
S-1418	RESULTS: In the first month after discharge, 5336 (21.9%) of the 24 373 identified patients had no follow-up visits, 16 855 (69.2%) saw a familiar physician, and 2182 (9.0%) saw unfamiliar physician(s) exclusively.<unk>
T-1418	discharge patients follow-up physician physician
H-1418	-0.9825084209442139	▁dis charge
D-1418	-0.9825084209442139	discharge
P-1418	-2.2155 -0.0182 -1.6652 -0.0311
S-1665	As a consequence of the worldwide increase in life expectancy, and due to improvements in the treatment of heart failure in recent years, the proportion of patients that reach an advanced phase of the disease, so-called end stage, refractory or terminal heart failure, is steadily growing.<unk>
T-1665	life_expectancy heart_failure patients disease terminal_heart_failure
H-1665	-1.4820116758346558	▁life _ ▁expect an cy ▁heart _ pu issa nce
D-1665	-1.4820116758346558	life_ expectancy heart_puissance
P-1665	-5.0471 -1.5108 -0.5919 -0.2679 -0.1342 -2.9833 -0.6579 -5.0417 -0.0678 -0.0203 -1.3668 -0.0944
S-723	METHODS: We performed a single-center, retrospective chart review of all heart failure discharges at the University of Connecticut Health Center (398 patients) the year before (2008) and the year after (2011) a quality improvement initiative that included mandatory 7-day follow-up visits.<unk>
T-723	heart_failure discharges university_of_connecticut_health_center patients follow-up
H-723	-1.2285380363464355	▁heart _ ▁failure _ dis charge s ▁University _ of _ connect i cut _ ▁Health ▁Center
D-723	-1.2285380363464355	heart_ failure_discharges University_of_connecticut_ Health Center
P-723	-4.2822 -0.5174 -3.5482 -2.9034 -0.1690 -0.0057 -0.0259 -1.0703 -0.5532 -1.7644 -0.5347 -1.3322 -0.3170 -0.0506 -0.6916 -1.8590 -1.2624 -2.3504 -0.1045
S-1959	Pulmonary capillary wedge pressure was reduced from a mean of 23 mm Hg (SD 5) at baseline to 17 mm Hg (8) at 3 months (p=0·035), with no changes in right atrial pressure, pulmonary arterial pressure, or pulmonary resistance.<unk>
T-1959	pulmonary_capillary_wedge_pressure baseline right_atrial_pressure pulmonary_arterial_pressure pulmonary_resistance
H-1959	-0.8684384226799011	▁Pul mon ary _ ca illa ry _ we dge _ tension ▁h g ▁h g ▁figure ▁right _ ▁at rial _ tension ▁pulmonar y _ tension ▁pulmonar y _ tension ▁pulmonar y ▁resist ance
D-1959	-0.8684384226799011	Pulmonary_caillary_wedge_tension hg hg figure right_ atrial_tension pulmonary_tension pulmonary_tension pulmonary resistance
P-1959	-0.4649 -3.2068 -0.5721 -0.8700 -4.1982 -0.2918 -0.0524 -0.2777 -2.4976 -0.0410 -0.9855 -1.1074 -0.3388 -0.0472 -0.8662 -0.0289 -4.8912 -0.7884 -0.9363 -0.5784 -0.1058 -0.9665 -0.6508 -0.0032 -0.0199 -0.4533 -0.8368 -0.0007 -0.0562 -0.3873 -2.5918 -0.0831 -0.0699 -2.6354 -0.0181 -0.1558 -0.0570
S-1015	The last decade of acute heart failure (HF) research is characterized by disappointments in large phase 2 and 3 pharmacologic studies of therapeutics including calcium-sensitizing agents and antagonists of endothelin, vasopressin, and adenosine.<unk>
T-1015	acute_heart_failure hf pharmacologic therapeutics calcium-sensitizing_agents antagonists endothelin vasopressin adenosine
H-1015	-0.4620612561702728	▁a cute _ heart _ ▁failure HF ▁ pharma c ologic ▁studies ▁calci um - sensi t izing ▁agents ▁en do the lin ▁vaso press in ▁ad enos ine
D-1015	-0.4620612561702728	acute_heart_ failureHF pharmacologic studies calcium-sensitizing agents endothelin vasopressin adenosine
P-1015	-0.4702 -0.0428 -0.2284 -1.6943 -0.5642 -3.2245 -2.0522 -0.5531 -0.1011 -0.0320 -0.1388 -1.3511 -0.2792 -0.0471 -0.0550 -0.0020 -1.1522 -0.0858 -0.0171 -0.1344 -0.0674 -0.4350 -1.1312 -0.0221 -0.0128 -0.1003 -0.0064 -0.0100 -0.0220 -0.1902 -0.1012
S-542	OBJECTIVES: New-onset aortic insufficiency (AI) can be encountered after instituting mechanical circulatory support and seems more common and severe with continuous flow (CF) left ventricular assist devices (LVADs) compared with pulsatile devices.<unk>
T-542	aortic_insufficiency mechanical_circulatory_support continuous_flow left_ventricular_assist_devices lvads pulsatile_devices
H-542	-0.6460241675376892	▁a or tic _ insu ffi cie ncy ▁mechanic al _ ▁circula tory _ ▁support ▁continuo us _ ▁flow ▁left ▁vent ri cular _ assist ▁devices ▁pulsa tile ▁devices
D-542	-0.6460241675376892	aortic_insufficiency mechanical_ circulatory_ support continuous_ flow left ventricular_assist devices pulsatile devices
P-542	-0.4842 -0.1227 -1.7151 -0.5527 -0.7582 -0.2066 -1.7799 -0.0218 -3.1287 -0.0103 -0.1468 -0.8335 -0.6656 -0.7326 -0.5305 -0.2189 -0.3754 -0.7134 -0.6780 -1.6912 -0.3586 -0.1048 -0.1063 -0.3516 -0.1250 -0.4979 -0.7196 -0.0233 -2.1539 -0.1251 -0.0945
S-1047	In vivo experiments of HF induced in mice via phenylephrine or haemodynamic stress (using the surgical method of transverse aortic constriction (TAC)) showed that JQ1 protected against several pathological changes, including cardiac hypertrophy.<unk>
T-1047	in_vivo hf phenylephrine haemodynamic surgical transverse_aortic_constriction tac jq1 pathological cardiac_hypertrophy
H-1047	-0.6398641467094421	▁ HF ▁ HF ▁ HF ▁ phen yle ph rine ▁ha emo dynamic ▁stress ▁sur g ical ▁trans verse _ a or tic _ con stri ction TAC ▁j q 1 ▁cardiac ▁hyper trop hy
D-1047	-0.6398641467094421	HF HF HF phenylephrine haemodynamic stress surgical transverse_aortic_constrictionTAC jq1 cardiac hypertrophy
P-1047	-0.6800 -0.0234 -0.8752 -0.3719 -0.7302 -1.9571 -0.6134 -1.9519 -0.2454 -0.4855 -0.0490 -0.3936 -0.2388 -0.0833 -1.0558 -0.2796 -0.0770 -0.1007 -0.8027 -0.0250 -0.6611 -0.8822 -0.1709 -1.8076 -0.8655 -0.2613 -0.0441 -0.0137 -1.4642 -1.8369 -0.3967 -3.1786 -0.5516 -0.8887 -0.0012 -0.0280 -0.1730 -0.0506
S-1490	This review aims to look first at the evidence for these drugs, and second at the newer drugs that act on the RAAS, namely, direct renin inhibitors, neutral endopeptidase inhibitors, vasopeptidase inhibitors, and angiotensin receptor blockers.<unk>
T-1490	evidence drugs drugs raas renin_inhibitors endopeptidase_inhibitors vasopeptidase_inhibitors angiotensin_receptor_blockers
H-1490	-0.6639529466629028	▁RA as ▁direct _ re nin ▁inhibi tors ▁neutral ▁en dop ep tida se _ ▁inhibi tors ▁vaso pe pti das e ▁inhibi tors ▁ang io ten sin ▁receptor _ block ers
D-1490	-0.6639529466629028	RAas direct_renin inhibitors neutral endopeptidase_ inhibitors vasopeptidase inhibitors angiotensin receptor_blockers
P-1490	-5.1491 -0.7239 -0.0164 -1.3476 -0.3728 -0.9366 -0.7950 -0.2797 -1.1888 -0.1707 -0.0144 -0.6985 -0.1503 -0.0564 -1.8261 -0.0846 -0.7094 -0.0193 -0.1296 -0.3628 -1.4180 -0.1461 -0.5010 -0.7088 -0.0149 -0.2091 -0.1058 -0.5099 -0.4695 -2.3256 -0.9697 -0.0052 -0.1124 -0.0465
S-1216	Accordingly, PDE2 overexpression in healthy cardiomyocytes reduced the rise in cAMP levels and L-type Ca2(+) current amplitude, and abolished the inotropic effect following acute β-AR stimulation, without affecting basal contractility.<unk>
T-1216	pde2 healthy cardiomyocytes camp inotropic_effect acute β-ar contractility
H-1216	-0.8381602764129639	▁p de 2 _ over expression ▁healthy ▁cardio my o cy tes ▁c AMP ▁c AMP ▁ca 2 ▁in o tropi c ▁effect ▁a cute ▁β - AR _ stimul ation ▁bas al _ contract ility
D-1216	-0.8381602764129639	pde2_overexpression healthy cardiomyocytes cAMP cAMP ca2 inotropic effect acute β-AR_stimulation basal_contractility
P-1216	-0.7977 -0.0897 -0.2563 -4.1402 -1.5964 -0.0201 -0.8750 -0.4676 -0.8801 -0.7955 -0.3550 -0.2066 -0.0020 -0.0123 -2.4756 -0.6396 -3.6879 -0.1015 -0.6835 -0.7642 -0.0925 -0.1821 -3.6220 -1.3532 -0.0042 -0.4358 -0.0050 -0.0761 -4.3976 -1.0686 -0.0383 -0.0021 -0.0413 -0.3308 -0.4820 -0.5662 -0.1834 -0.1223
S-505	The bottleneck stent was implanted in the proximal left anterior descending (LAD) or proximal circumflex artery (LCX), or in both proximal LCX and mid LAD 1 wk later (2-vessel model), and pigs were followed for 4-5 wk.<unk>
T-505	bottleneck_stent implanted lad circumflex_artery lcx lcx lad
H-505	-0.8090963363647461	▁bottle ne ck _ ▁sten t ▁implant ed ▁proxima l _ ▁left _ ▁anterior ▁descend ing ▁ LAD ▁proxima l _ ▁circum flex ▁arter y ▁ LC x ▁ LAD
D-505	-0.8090963363647461	bottleneck_ stent implanted proximal_ left_ anterior descending LAD proximal_ circumflex artery LCx LAD
P-505	-0.0834 -0.0082 -0.2230 -3.5976 -0.7711 -0.0185 -1.2514 -0.7236 -1.6973 -0.0183 -0.9971 -2.0621 -0.1843 -1.5700 -0.5590 -0.0381 -0.7296 -0.0030 -0.1814 -0.0343 -0.3542 -2.2589 -0.0642 -0.1285 -0.1975 -2.0016 -0.0500 -0.3870 -2.6753 -1.1351 -1.7100 -0.1778
S-1306	BACKGROUND: Advances in treatment for acute myocardial infarction (AMI) are likely to have had a beneficial impact on the incidence of and deaths attributable to heart failure (HF) complicating AMI, although limited data are available to support this contention.<unk>
T-1306	acute_myocardial_infarction ami incidence deaths heart_failure hf ami
H-1306	-0.941388726234436	▁a cute _ My o card ial _ ▁in far ction ▁ AMI ▁incide nce ▁heart _ ▁failure ▁ HF ▁complicat ing ▁ AMI
D-1306	-0.941388726234436	acute_Myocardial_ infarction AMI incidence heart_ failure HF complicating AMI
P-1306	-0.9222 -0.0667 -0.2701 -4.7208 -0.3978 -0.2241 -0.1598 -0.5490 -0.4515 -1.5289 -0.0305 -2.0145 -0.2174 -2.0987 -0.0017 -1.3164 -0.6911 -3.2667 -1.0948 -1.1519 -2.3720 -0.2852 -0.4768 -0.0078 -0.1041 -0.0557
S-1117	RESULTS: (123)I-MIBG cardiac washout was lower during carvedilol than metoprolol treatment (12.9% ± 3.9% vs. 22.1% ± 2.8%, respectively, P = 0.003), irrespective of β2-adrenergic receptor haplotype.<unk>
T-1117	cardiac_washout carvedilol metoprolol β2-adrenergic_receptor_haplotype
H-1117	-1.0101369619369507	▁i - MI BG ▁cardiac _ ▁was hout ▁car vedi lol ▁met o pro lol ▁treatment ▁β 2- ad r energi c ▁receptor
D-1117	-1.0101369619369507	i-MIBG cardiac_ washout carvedilol metoprolol treatment β2-adrenergic receptor
P-1117	-0.4121 -3.2582 -1.9594 -1.0698 -0.8868 -2.5046 -4.8004 -0.0033 -0.1941 -0.0483 -0.0504 -0.1907 -0.0675 -0.0158 -0.1349 -5.1114 -0.1203 -0.8848 -0.0532 -0.0879 -0.9007 -0.1023 -0.4168 -1.9240 -0.0557
S-1502	Muscle aerobic capacity, measured by the rate constant (k) of postexercise phosphocreatine resynthesis, was significantly impaired in Fontan adults versus controls (1.48±0.13 vs 2.40±0.33 min(-1), p=0.02).<unk>
T-1502	muscle_aerobic_capacity postexercise_phosphocreatine_resynthesis fontan
H-1502	-0.7121910452842712	▁Mus cle _ ▁aero bic _ ▁capacity ▁poste xer ci se ▁ phos pho creati ne _ re syn the sis ▁Font an
D-1502	-0.7121910452842712	Muscle_ aerobic_ capacity postexercise phosphocreatine_resynthesis Fontan
P-1502	-0.1120 -0.0325 -0.0581 -0.5160 -0.1356 -2.2240 -2.0170 -0.0447 -0.0369 -0.0389 -0.5573 -1.6654 -0.0703 -1.0596 -1.7298 -2.2882 -0.3221 -1.0892 -0.0101 -1.2003 -0.6693 -0.0846 -0.1972 -1.5876 -0.0580
S-904	Cardiac resynchronization therapy (CRT) is often deferred in dialysis-dependent patients with heart failure (HF) because of a perceived lack of benefit and potentially higher risks, although the outcomes associated with CRT in dialysis have not been reported.<unk>
T-904	cardiac_resynchronization_therapy crt patients heart_failure hf outcomes crt dialysis reported
H-904	-0.6219621896743774	▁Card iac _ re syn chron ization _ therapy ▁c RT ▁di al ysis - dependent ▁patients ▁heart _ ▁failure ▁ HF
D-904	-0.6219621896743774	Cardiac_resynchronization_therapy cRT dialysis-dependent patients heart_ failure HF
P-904	-0.1687 -0.0334 -0.2442 -0.5057 -0.0238 -0.0002 -0.7928 -0.8071 -0.5163 -0.8671 -0.0600 -0.7602 -0.1127 -0.0494 -0.3609 -0.1267 -1.0845 -1.0799 -0.5635 -2.6039 -2.4220 -0.0048 -1.6680 -0.0713
S-1221	Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).<unk>
T-1221	eplerenone patients hyperkalemia renal_function emphasis-hf eplerenone patients hospitalization heart_failure
H-1221	-0.9748584628105164	▁ef fica cy ▁e pler en one ▁hyper kal emia ▁renal ▁fonction ▁EM PHA SIS - HF ▁e pler en _ in _ ▁Mil d ▁Patient s ▁Hospital ization ▁Sur v I val ▁Heart _ ▁Fail ure
D-1221	-0.9748584628105164	efficacy eplerenone hyperkalemia renal fonction EMPHASIS-HF epleren_in_ Mild Patients Hospitalization SurvIval Heart_ Failure
P-1221	-3.5999 -0.0054 -0.4993 -0.0779 -0.8781 -0.6760 -5.6561 -0.4756 -0.6147 -0.1296 -0.2207 -4.3672 -0.0969 -0.0075 -0.0661 -0.0391 -0.0028 -0.8095 -0.9426 -0.4383 -5.7661 -3.5120 -1.1422 -0.6881 -0.0053 -0.2668 -0.1281 -0.4318 -1.1384 -2.0847 -0.1191 -0.3773 -0.0960 -0.5981 -1.5240 -0.2102 -0.0375 -0.1730 -0.1174
S-655	H-DKO mice had reduced ventricular mass; developed cardiac apoptosis, fibrosis, and failure; and showed diminished Akt→forkhead box class O-1 signaling that was accompanied by impaired cardiac metabolic gene expression and reduced ATP content.<unk>
T-655	h-dko ventricular_mass cardiac_apoptosis fibrosis cardiac_metabolic_gene_expression atp
H-655	-0.8338735103607178	▁h - d KO ▁vent ri cular ▁mass ▁cardiac _ ▁apo pto sis ▁fibro sis
D-655	-0.8338735103607178	h-dKO ventricular mass cardiac_ apoptosis fibrosis
P-655	-1.1184 -2.0408 -0.3210 -0.7850 -0.0983 -0.1184 -0.1364 -0.9418 -0.0149 -1.6674 -0.5144 -0.0628 -1.1534 -0.0503 -0.0629 -4.9241 -0.1655
S-863	The reduction in risk was consistent for inappropriate ATP (HR: 0.66 [95% CI: 0.48 to 0.90]; p = 0.009) and inappropriate shock therapy (HR: 0.54 [95% CI: 0.36 to 0.80]; p = 0.002).<unk>
T-863	atp shock_therapy
H-863	-0.501557469367981	▁in appropria te ▁ATP ▁in appropria te ▁shock ▁ therapy
D-863	-0.501557469367981	inappropriate ATP inappropriate shock therapy
P-863	-0.9337 -0.1595 -0.0461 -0.3658 -0.9241 -0.4431 -0.0622 -1.7174 -0.8909 -0.0394 -0.3413 -0.0951
S-1766	BACKGROUND: We evaluated the individual and joint associations among cardiorespiratory fitness (CRF), body mass index, and heart failure (HF) mortality, as well as the additive effect of an increasing number of cardiovascular risk factors on HF mortality in fit versus unfit men.<unk>
T-1766	joint cardiorespiratory_fitness crf body_mass_index heart_failure hf mortality cardiovascular hf mortality
H-1766	-0.941071093082428	▁cardio re spira tory _ ▁fitness ▁cr f ▁body _ ▁mass ▁index ▁heart _ ▁failure ▁ HF ▁mortal ity ▁cardiovascular _ risk
D-1766	-0.941071093082428	cardiorespiratory_ fitness crf body_ mass index heart_ failure HF mortality cardiovascular_risk
P-1766	-1.0008 -0.0201 -0.2199 -0.4129 -1.2598 -0.1676 -1.5194 -0.0140 -0.2613 -1.6553 -0.7725 -0.0122 -0.1306 -0.3552 -1.4320 -1.0166 -0.1313 -3.7101 -0.2319 -0.7993 -2.4924 -0.3403 -4.5731 -0.0572
S-1827	BACKGROUND: Recent postmarketing trials produced conflicting results about the risk for hospitalized heart failure (hHF) associated with dipeptidyl peptidase-4 (DPP-4) inhibitors, creating uncertainty about the safety of these antihyperglycemic agents.<unk>
T-1827	hospitalized heart_failure dipeptidyl_peptidase-4 dpp-4 antihyperglycemic_agents
H-1827	-1.1179206371307373	▁hospital ized ▁h HF ▁di pe pti dy l _ ▁pep tida se -4 ▁d PP -4 ▁anti hy per gly ce mic ▁agents
D-1827	-1.1179206371307373	hospitalized hHF dipeptidyl_ peptidase-4 dPP-4 antihyperglycemic agents
P-1827	-4.6056 -0.6871 -3.8147 -0.2584 -0.0449 -0.0206 -0.0422 -5.7497 -1.7855 -1.5620 -0.2016 -0.0964 -0.0992 -1.1876 -0.4312 -0.6552 -3.0196 -0.1038 -0.0737 -0.0175 -2.0063 -0.1748 -1.9689 -0.2081 -0.1861 -0.0654
S-380	METHODS AND RESULTS: Using a quality improvement database and multivariable Cox modeling, we derived the Heart Failure Patient Severity Index (HFPSI) in the University of Michigan HF clinic (UM cohort, n = 1,536; 314 reached primary outcome).<unk>
T-380	cox_modeling heart_failure_patient_severity_index hfpsi university_of_michigan hf clinic primary_outcome
H-380	-0.7321788668632507	▁quality _ ▁improvement ▁database ▁multi vari able ▁Co x ▁model ing ▁Heart _ ▁Fail ure _ ▁Patient _ ▁Sever ity _ ▁Index ▁h PSI ▁University _ ▁Michigan ▁ HF
D-380	-0.7321788668632507	quality_ improvement database multivariable Cox modeling Heart_ Failure_ Patient_ Severity_ Index hPSI University_ Michigan HF
P-380	-1.0664 -1.4325 -0.6655 -1.7132 -0.8967 -0.0004 -0.0056 -1.2173 -0.0037 -2.9841 -0.1107 -0.5267 -0.2498 -0.2304 -0.0767 -1.2480 -0.2726 -0.2398 -0.1943 -0.1373 -1.6556 -0.8421 -1.2664 -0.5728 -0.9390 -0.5074 -0.7157 -0.3068 -0.1237 -2.4021 -0.0942
S-1585	Heart rate (HR) variability has been extensively studied in cardiac patients, especially in patients surviving an acute myocardial infarction (AMI) and also in patients with congestive heart failure (CHF) or left ventricular (LV) dysfunction.<unk>
T-1585	heart_rate cardiac patients patients acute_myocardial_infarction ami patients congestive_heart_failure chf left_ventricular dysfunction
H-1585	-0.7898094058036804	▁cardiac ▁patients ▁a cute _ mé o card ial ▁in far ction ▁ AMI ▁con ges tive ▁heart _ ▁failure CH f ▁left ▁vent ri cular LV
D-1585	-0.7898094058036804	cardiac patients acute_méocardial infarction AMI congestive heart_ failureCHf left ventricularLV
P-1585	-4.1659 -1.5670 -0.1042 -0.0031 -0.2347 -3.1439 -0.3624 -0.1023 -0.1742 -0.6963 -1.0478 -0.0462 -3.7835 -0.0173 -0.6341 -0.0537 -0.0410 -1.0037 -0.6902 -0.3387 -2.4802 -0.1670 -0.0463 -0.7681 -0.1485 -0.0823 -0.2209 -0.6411 -0.1401
S-657	Using neonatal rat ventricular cardiomyocytes, we further found that chronic insulin exposure reduced IRS1 and IRS2 proteins and prevented insulin action through activation of p38, revealing a fundamental mechanism of cardiac dysfunction during insulin resistance and type 2 diabetes.<unk>
T-657	ventricular_cardiomyocytes chronic insulin irs1 irs2 proteins insulin p38 cardiac_dysfunction insulin_resistance type_2_diabetes
H-657	-0.6617947220802307	▁ne ona tal ▁rat ▁vent ri cular ▁cardio my o cy tes ▁chronic ▁insulin ▁exposure ▁I RS 1 ▁i RS 2 ▁protein s ▁insulin ▁action
D-657	-0.6617947220802307	neonatal rat ventricular cardiomyocytes chronic insulin exposure IRS1 iRS2 proteins insulin action
P-657	-1.3381 -0.0098 -0.0105 -0.1734 -0.0525 -0.0913 -0.2674 -0.5351 -0.7041 -0.2586 -0.0766 -0.1036 -0.4008 -0.4321 -1.5180 -0.8109 -0.0128 -1.6735 -1.6429 -0.2223 -0.1655 -2.3206 -0.0328 -0.7164 -0.8659 -3.2748 -0.1579
S-323	Echocardiograms of the left ventricular midpapillary level were taken at varying atrioventricular delay (AVD) and interventricular delay (VVD) for STE analysis of regional circumferential strain (CS) and radial strain (RS).<unk>
T-323	echocardiograms left_ventricular midpapillary atrioventricular_delay avd interventricular_delay vvd ste circumferential_strain radial_strain rs
H-323	-0.6438125967979431	▁e cho card i ogram s ▁left ▁vent ri cular _ ▁mid pap illa ry ▁at rio ven tri cular _ de lay ▁av d ▁interven tri cular _ de lay ▁v d ▁ STE ▁circum fér ential ▁strain ▁radi al ▁strain RS
D-323	-0.6438125967979431	echocardiograms left ventricular_ midpapillary atrioventricular_delay avd interventricular_delay vd STE circumférential strain radial strainRS
P-323	-2.7086 -0.1228 -0.0264 -0.3802 -0.0377 -0.1638 -0.3390 -0.0402 -0.1901 -0.2228 -0.7347 -1.9903 -0.3054 -0.0160 -0.2022 -4.0192 -0.1908 -0.0754 -0.1149 -0.2426 -0.2839 -0.1152 -0.3342 -0.7435 -0.1257 -0.0670 -0.0459 -0.1121 -0.2447 -0.0541 -0.6629 -1.2731 -0.0325 -2.2212 -0.3594 -5.1561 -0.8330 -0.2775 -0.0659 -0.6966 -0.0437 -1.9975 -0.9353 -0.1004 -0.0670
S-1870	METHODS: Patients with New York Heart Association (NYHA) functional class III HF and ejection fractions < 35% on chronic stable guideline-directed medical therapy (GDMT) were enrolled at 45 centers in the United States, Canada, and Europe.<unk>
T-1870	patients new_york_heart_association nyha functional_class hf ejection_fractions chronic stable guideline-directed_medical_therapy gdmt united_states canada europe
H-1870	-0.8802430629730225	▁New ▁York _ ▁Heart _ ▁Association _ NY HA ▁ HF ▁e je ction ▁ fraction s ▁chronic _ direct ed _ ▁medical ▁ therapy GD MT
D-1870	-0.8802430629730225	New York_ Heart_ Association_NYHA HF ejection fractions chronic_directed_ medical therapyGDMT
P-1870	-2.5882 -0.7609 -1.8090 -1.8013 -1.3536 -1.1058 -3.5393 -1.4383 -0.0614 -1.6255 -0.3475 -0.2900 -0.3504 -0.0137 -1.5228 -0.0002 -0.0360 -0.3360 -0.6613 -1.6021 -0.1962 -0.3304 -0.8309 -0.5792 -0.0271 -1.8313 -0.0990 -0.3343 -0.0552
S-889	In patients with non-LBBB and QRS ≥160 ms, the hazard ratio for the primary outcome was 0.52 (0.29-0.96; P=0.033); in patients with QRS <160 ms, the hazard ratio was 1.38 (0.88-2.14; P=0.155).<unk>
T-889	patients qrs hazard_ratio primary_outcome patients qrs hazard_ratio
H-889	-1.2586654424667358	▁ LB BB ▁QR s
D-889	-1.2586654424667358	LBBB QRs
P-889	-3.4673 -0.1570 -0.3172 -0.9995 -1.5214 -2.1725 -0.1759
S-1428	Examination of PKA subunits demonstrated no change in type II regulatory (RIIα) or catalytic (Cα) subunit expression, although site specific RIIα (Ser96) and Cα (Thr197) phosphorylation were increased in HF.<unk>
T-1428	pka change riiα cα expression riiα ser96 cα thr197 phosphorylation hf
H-1428	-0.9913687705993652	▁p ka ▁regulator y ▁r II α ▁cata ly tic ▁c α ▁ phos phor y lation ▁ HF
D-1428	-0.9913687705993652	pka regulatory rIIα catalytic cα phosphorylation HF
P-1428	-0.7108 -1.1020 -4.8099 -0.1550 -3.8439 -1.7506 -1.6241 -0.8908 -0.2699 -0.5380 -0.3615 -0.6466 -0.8212 -0.4169 -0.4263 -0.9710 -0.0144 -1.2238 -0.0113 -0.1143 -0.1165
S-1155	Mechanistically, we found that abnormal Ca(2+) handling in dyssynchronous HF slows myofiber shortening velocity at the early-activated septum and depresses both myofiber shortening and stretch rate at the late-activated lateral wall.<unk>
T-1155	dyssynchronous_hf myofiber_shortening septum myofiber_shortening stretch wall
H-1155	-1.1518573760986328	▁ab normal ▁ca (2 +) ▁handling ▁dys syn chron ous ▁ HF ▁my o fi ber _ ▁short en ing _ pu issa nce ▁sept um ▁de press es ▁my o fi ber _ ▁short en ing _ pu issa nce
D-1155	-1.1518573760986328	abnormal ca(2+) handling dyssynchronous HF myofiber_ shortening_puissance septum depresses myofiber_ shortening_puissance
P-1155	-5.3416 -0.0151 -1.1616 -1.9105 -0.0537 -0.2572 -0.0716 -0.0006 -0.0002 -2.8542 -0.6480 -0.0411 -5.9083 -0.0565 -0.6622 -0.1307 -3.4162 -0.7866 -0.0766 -0.6493 -1.4546 -5.0642 -0.0907 -0.0109 -1.8238 -0.0819 -2.6864 -0.0768 -0.4094 -0.7067 -0.0178 -0.3477 -0.0825 -1.9422 -0.9569 -0.0529 -0.5951 -1.7773 -3.6830 -0.0588 -0.0062 -3.4323 -0.1302
S-1342	CHF-derived c-Kit+ cells exhibited upregulated transforming growth factor-β (TGF-β) signaling, increased level of epithelial to mesenchymal transition markers, and diminished expression of pluripotency markers compared with shams.<unk>
T-1342	cells transforming_growth_factor-β tgf-β epithelial mesenchymal transition expression pluripotency_markers
H-1342	-0.6708401441574097	▁CHF ▁c - K it _ cell s ▁transform ing ▁growth _ factor - β ▁t GF - β ▁epi the li al ▁mes en chy mal ▁transition ▁pluri pote ncy ▁sham s
D-1342	-0.6708401441574097	CHF c-Kit_cells transforming growth_factor-β tGF-β epithelial mesenchymal transition pluripotency shams
P-1342	-0.6537 -3.2432 -0.2283 -0.8357 -0.0159 -3.7286 -1.2181 -0.1568 -0.1431 -0.0999 -3.3849 -2.1759 -1.1834 -0.4351 -0.0093 -0.6450 -0.1341 -0.3543 -0.0143 -0.1879 -0.0557 -0.0538 -0.0363 -0.0186 -0.1652 -0.1056 -0.1070 -0.2341 -2.3471 -0.0848 -0.0148 -1.1564 -0.0185 -0.1554 -0.0787
S-871	METHODS AND RESULTS: We applied an improved label-free shotgun proteomics approach to evaluate the global proteomics changes in transverse aortic constriction (TAC)-induced heart failure and the associated signaling pathway changes using ingenuity pathway analysis.<unk>
T-871	proteomics proteomics transverse_aortic_constriction tac heart_failure signaling_pathway ingenuity_pathway_analysis
H-871	-0.9251700043678284	▁label - free ▁shot gun _ prote o mics ▁global _ prote o mics ▁trans verse _ ▁a or tic _ con stri ction ▁ TAC ▁heart
D-871	-0.9251700043678284	label-free shotgun_proteomics global_proteomics transverse_ aortic_constriction TAC heart
P-871	-0.1455 -0.0633 -0.2143 -0.0475 -0.0615 -1.3075 -2.4003 -0.9049 -0.0022 -3.3132 -1.5033 -2.2547 -0.6638 -0.0020 -0.1954 -0.0219 -0.8840 -1.1438 -0.1610 -1.8543 -0.4180 -0.2395 -0.7980 -0.0344 -0.9778 -0.0623 -1.3533 -5.7342 -0.0681
S-178	In consecutive patients (209 HFrEF with left ventricular ejection fraction <40% and 108 HFpEF with left ventricular ejection fraction ≥40%), RAS- and β-blocker dose changes were followed during 6 months after an index HF hospitalization.<unk>
T-178	patients hfref left_ventricular_ejection_fraction hfpef left_ventricular_ejection_fraction β-blocker hf hospitalization
H-178	-0.7170899510383606	▁h f f ▁vent ri cular _ ▁e je ction ▁ fraction ▁h f p EF ▁left ▁vent ri cular _ ▁e je ction ▁ fraction ▁ RAS - ▁β - block er ▁index ▁ HF
D-178	-0.7170899510383606	hff ventricular_ ejection fraction hfpEF left ventricular_ ejection fraction RAS- β-blocker index HF
P-178	-0.1070 -0.5881 -0.8214 -2.2512 -0.2948 -0.9428 -1.3806 -1.6108 -1.4569 -0.3702 -1.2130 -0.0068 -1.3847 -0.3298 -0.6742 -0.6475 -0.2090 -1.0958 -0.5341 -1.2288 -0.6894 -1.3530 -1.2989 -0.4211 -1.0560 -0.0132 -0.1553 -0.0890 -1.1110 -1.0599 -0.0196 -0.0456 -0.0481 -1.3300 -0.6888 -0.0167 -0.5148 -0.1917
S-257	In addition, an elevated activation of p70S6K, PKC-βII by HDL(NYHA-IIIb), and a higher amount of malondialdehyde bound to HDL(NYHA-IIIb) compared with HDL(healthy) was measured.<unk>
T-257	elevated p70s6k pkc-βii hdl nyha-iiib malondialdehyde bound hdl nyha-iiib hdl healthy
H-257	-0.9124805927276611	▁activa tion ▁PK c - β II ▁HD L ▁NY HA - III b ▁malo ndi alde hy de
D-257	-0.9124805927276611	activation PKc-βII HDL NYHA-IIIb malondialdehyde
P-257	-3.4726 -0.0285 -0.3945 -0.3988 -0.1504 -0.1389 -0.9676 -2.2211 -1.1226 -4.1968 -0.2866 -0.5093 -0.2977 -0.1047 -0.0161 -0.0094 -0.1756 -0.1941 -0.0239 -4.3529 -0.1000
S-1410	This cross talk between these 2 distinct G-protein-coupled receptors appears to have physiological significance, because they interact and show reciprocal regulation in mouse hearts undergoing chronic β-adrenergic receptor stimulation and in a rat model of postischemic heart failure.<unk>
T-1410	cross_talk g-protein-coupled_receptors physiological significance regulation hearts chronic β-adrenergic_receptor postischemic_heart_failure
H-1410	-0.821068525314331	▁g - prote in - co up led ▁receptor s
D-1410	-0.821068525314331	g-protein-coupled receptors
P-1410	-1.1653 -0.2594 -0.5805 -0.6481 -0.2135 -0.0094 -0.0065 -0.3269 -0.6765 -0.1750 -5.6446 -0.1470
S-1989	Body weight decreased by 7% (7 kg [SD, 1]) in the diet group, 3% (4 kg [SD, 1]) in the exercise group, 10% (11 kg [SD, 1] in the exercise + diet group, and 1% (1 kg [SD, 1]) in the control group.<unk>
T-1989	exercise exercise
H-1989	-1.9721322059631348	▁figure
D-1989	-1.9721322059631348	figure
P-1989	-3.2761 -2.5239 -0.1164
S-1920	NT-ProBNP (+233 to –733 ng/ml) and the inflammatory biomarkers (hsCRP and IL6) decreased in four of five patients (IL 6: +0.5 to –2 mg/l, hsCRP: +0.2 to –6.5 mg/l).<unk>
T-1920	nt-probnp inflammatory biomarkers hscrp il6 patients hscrp
H-1920	-0.5418615341186523	▁NT - pro B NP ▁infla mma tory _ ▁bio mark ers ▁h s CR p ▁IL
D-1920	-0.5418615341186523	NT-proBNP inflammatory_ biomarkers hsCRp IL
P-1920	-0.0463 -0.0878 -0.6823 -0.3590 -0.0226 -1.4755 -0.3283 -0.5973 -1.2126 -0.3095 -0.0024 -0.0266 -0.0139 -0.0148 -0.3853 -0.4196 -0.5480 -3.6084 -0.1552
S-1010	After adjustment for age, sex and ejection fraction, patients categorized as frail by the biological phenotype had a 2-fold increased risk of death compared to those with no frailty, whereas a 0.1 unit increase in the deficit index was associated with a 44% increased risk of death.<unk>
T-1010	ejection_fraction patients frail biological_phenotype death frailty deficit_index death
H-1010	-0.7794229388237	▁e je ction _ fraction ▁fra il ▁bi ological _ ▁ph eno type ▁risk _ de _ ▁death
D-1010	-0.7794229388237	ejection_fraction frail biological_ phenotype risk_de_ death
P-1010	-4.1782 -0.4498 -0.0107 -1.3789 -0.0017 -1.1903 -0.1387 -0.0909 -0.3627 -1.0653 -1.0571 -0.0243 -0.0138 -2.4767 -0.8765 -0.9722 -0.1687 -0.5288 -0.5056 -0.0974
S-1945	Patients in whom resting HR decreased at follow-up compared to baseline had a 2.0±3.2 mL/min/kg increase in VO2max compared to a 1.2±7.7 mL/min/kg increase in patients who did not demonstrate a lower resting HR (P value=0.033).<unk>
T-1945	patients resting_hr follow-up baseline vo2max patients resting_hr p_value
H-1945	-1.775699496269226	▁rest ing _ HR
D-1945	-1.775699496269226	resting_HR
P-1945	-3.6070 -0.3088 -2.2285 -0.3932 -3.8025 -0.3142
S-1344	CONCLUSIONS: Taken together, our findings suggest that TGF-β inhibition positively modulates c-Kit+ cell phenotype and function in vitro, and this strategy may be considered in optimizing cardiac progenitor function and cell expansion protocols for clinical application.<unk>
T-1344	tgf-β cell phenotype in_vitro cardiac_progenitor_function cell clinical
H-1344	-0.710716187953949	▁T GF - β ▁inhibi tion ▁c - K it _ cell _ ▁ph eno type ▁cardiac _ pro gen itor _ ▁function ▁cell _ ▁exp an sion
D-1344	-0.710716187953949	TGF-β inhibition c-Kit_cell_ phenotype cardiac_progenitor_ function cell_ expansion
P-1344	-1.4588 -0.2149 -0.2814 -0.0576 -1.5541 -0.0693 -0.0246 -0.1046 -0.7634 -0.0141 -0.9752 -0.6831 -1.8461 -2.1897 -0.0204 -0.0067 -3.2045 -1.0839 -0.5796 -0.3663 -0.1548 -1.1405 -1.9626 -0.5722 -0.6707 -0.2704 -0.1944 -0.1527 -0.6547 -0.0503
S-1044	Investigating the role of BETs in an in vitro model of neurohormonally induced heart disease, the authors showed that nanomolar doses of JQ1 significantly blocked phenylephrine-mediated hypertrophy of cardiomyocytes and pathological gene induction.<unk>
T-1044	bets in_vitro neurohormonally heart_disease nanomolar jq1 phenylephrine-mediated_hypertrophy cardiomyocytes pathological gene_induction
H-1044	-0.482261061668396	▁ BET s ▁neuro hormon ally _ ▁induc ed _ heart ▁disease ▁j q 1 ▁ phen yle ph rine - media ted ▁hyper trop hy ▁cardio my o cy tes ▁path ological ▁gene ▁in duction
D-1044	-0.482261061668396	BETs neurohormonally_ induced_heart disease jq1 phenylephrine-mediated hypertrophy cardiomyocytes pathological gene induction
P-1044	-0.6283 -0.0083 -0.6166 -0.5429 -0.0708 -1.1595 -0.7624 -0.2400 -0.0765 -0.9944 -1.3866 -2.7327 -0.8416 -1.2909 -1.6512 -0.5176 -0.2085 -0.4137 -0.7975 -0.1026 -0.8618 -0.0472 -0.3759 -0.1291 -0.0018 -0.0241 -0.0571 -0.4250 -0.7176 -0.0836 -0.0540 -0.0420 -0.1051 -0.0692 -0.0363 -0.0029 -0.1729 -0.0781
S-1524	Although concentric remodeling (CR) and concentric hypertrophy (CH) are common forms of left ventricular (LV) remodeling in heart failure with preserved ejection fraction (HFpEF), eccentric hypertrophy (EH) can also occur in these patients.<unk>
T-1524	concentric_remodeling concentric_hypertrophy left_ventricular remodeling heart_failure_with_preserved_ejection_fraction hfpef eccentric_hypertrophy patients
H-1524	-0.8444392681121826	▁concentr ic _ ▁remodel ing CR ▁concentr ic _ ▁hyper trop hy CH ▁left ▁vent ri cular LV ▁heart _ ▁failure ▁h p EF ▁ecce n tric ▁hyper trop hy EH
D-1524	-0.8444392681121826	concentric_ remodelingCR concentric_ hypertrophyCH left ventricularLV heart_ failure hpEF eccentric hypertrophyEH
P-1524	-0.3929 -0.0519 -2.4629 -0.1631 -0.0440 -4.7507 -2.9724 -0.0272 -0.3658 -0.8798 -0.0077 -0.0170 -3.1366 -0.5157 -0.9119 -0.1150 -0.1129 -0.2137 -4.3272 -1.0009 -1.4627 -1.7999 -0.0226 -0.8061 -0.6996 -0.0110 -0.0346 -0.1063 -0.0006 -0.0097 -0.0736 -0.2504 -0.1201
S-1878	CONCLUSIONS: BAT is safe and improves functional status, quality of life, exercise capacity, N-terminal pro-brain natriuretic peptide, and possibly the burden of heart failure hospitalizations in patients with GDMT-treated NYHA functional class III HF.<unk>
T-1878	bat functional_status quality_of_life exercise_capacity n-terminal_pro-brain_natriuretic_peptide heart_failure hospitalizations patients nyha_functional_class_iii hf
H-1878	-1.0509343147277832	▁BAT ▁implant al _ pro - bra in _ ▁na tri ure tic _ pe pti de ▁burde n _ de _ heart _ ▁failure ▁GD MT - tre ated ▁NY HA
D-1878	-1.0509343147277832	BAT implantal_pro-brain_ natriuretic_peptide burden_de_heart_ failure GDMT-treated NYHA
P-1878	-1.4218 -5.1599 -3.0501 -1.6788 -0.4043 -0.1201 -0.2333 -0.0969 -0.7082 -0.2942 -0.0053 -0.0853 -2.4489 -1.9274 -0.3641 -0.0816 -0.0511 -1.0749 -0.0161 -2.6720 -0.7432 -0.7363 -0.8280 -1.9225 -1.9472 -0.5496 -0.4239 -1.4518 -0.0017 -1.7249 -0.5691 -0.0486 -2.8049 -0.0859
S-1986	There was no statistically significant change in MLHF total score with exercise and with diet (main effect: exercise, -1 unit [95% CI, -8 to 5], P = .70; diet, -6 units [95% CI, -12 to 1], P = .08).<unk>
T-1986	change exercise exercise
H-1986	-0.982003390789032	▁ ML HF ▁ ML HF
D-1986	-0.982003390789032	MLHF MLHF
P-1986	-0.4287 -0.0569 -0.4015 -2.5326 -0.2955 -0.3204 -3.6947 -0.1258
S-1374	Four treatment groups were used: nonpace, non-DNx [Sham-Innervated (Sham-INV)], nonpace DNx (sham-DNx), pace non-DNx (CHF-INV) or pace DNx (CHF-DNx).<unk>
T-1374	dnx dnx
H-1374	-1.3290061950683594	▁non pa ce _ non - DN x ▁s ham - I nner vat ed ▁in v ▁non pa ce ▁DN x ▁pace _ non - DN x ▁ch f - in v ▁pace _ ▁DN x ▁ch f - DN x
D-1374	-1.3290061950683594	nonpace_non-DNx sham-Innervated inv nonpace DNx pace_non-DNx chf-inv pace_ DNx chf-DNx
P-1374	-6.7810 -0.3473 -0.0799 -5.7373 -0.5887 -0.0527 -1.7708 -0.1571 -5.1888 -0.2199 -0.0261 -0.7132 -0.0005 -0.0321 -0.1351 -4.8695 -1.5653 -4.0091 -0.0541 -0.0783 -3.0841 -0.0297 -4.2739 -2.2130 -0.2669 -0.0077 -1.7455 -0.1034 -3.2374 -0.1745 -0.1834 -0.6804 -0.5369 -1.3398 -1.8423 -1.0362 -0.0478 -3.1162 -0.0845 -0.0499 -1.4911 -0.0189 -0.4389 -0.0672
S-1929	Exercise time at 3 and 12 months correlated with PSSS (r= 0.09 and r= 0.13, respectively) and BTES (r=-0.11 and r=-0.12, respectively), with higher exercise time associated with higher PSSS and lower BTES (All P<0.005).<unk>
T-1929	exercise correlated psss btes exercise psss btes
H-1929	-1.046617031097412	▁PS SS ▁b tes ▁b tes
D-1929	-1.046617031097412	PSSS btes btes
P-1929	-4.3451 -1.0176 -0.1741 -0.1238 -2.1490 -0.1362 -0.3818 -0.0454
S-836	The purpose of this study was to explore the relation of hemoglobin (Hgb) with HRQoL and training-induced changes in HRQoL in a cohort of patients in Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION).<unk>
T-836	hemoglobin hgb hrqol hrqol patients heart_failure outcomes exercise training hf-action
H-836	-0.509915828704834	▁hem o glob in ▁h gb ▁HR Qo L ▁training - indu ced ▁changes ▁HR Qo L ▁patients ▁Heart _ ▁Fail ure ▁ HF - AC TION
D-836	-0.509915828704834	hemoglobin hgb HRQoL training-induced changes HRQoL patients Heart_ Failure HF-ACTION
P-836	-1.2594 -0.0633 -0.0169 -0.3972 -0.1328 -0.0085 -0.3528 -0.0429 -0.3282 -2.6694 -0.2877 -0.0003 -0.1481 -0.4557 -1.1166 -0.1086 -0.1731 -0.6738 -0.8498 -0.5020 -0.1685 -0.0270 -2.6763 -0.9745 -0.0675 -0.4948 -0.5754 -0.1487 -0.0679
S-1166	Risk of event was greater in subjects with RV dysfunction (hazard ratio: 3.09 [95% confidence interval (CI): 2.18 to 4.45]) and cachexia (hazard ratio: 2.90 [95% CI: 2.00 to 4.12]) in univariate and multivariate analyses.<unk>
T-1166	rv_dysfunction hazard_ratio confidence_interval cachexia hazard_ratio multivariate_analyses
H-1166	-1.5085242986679077	▁Risk ▁ RV _ ▁dys function haz ard _ de _ fon cti onnement ▁c ▁cache xia
D-1166	-1.5085242986679077	Risk RV_ dysfunctionhazard_de_fonctionnement c cachexia
P-1166	-1.5673 -0.7147 -0.0606 -1.4053 -0.9069 -0.9912 -3.6850 -0.0106 -3.9819 -4.1267 -0.4765 -1.9699 -0.1702 -0.1262 -4.2926 -0.9037 -1.0044 -2.1406 -0.1274
S-1234	METHODS: In a substudy of the Atrial Fibrillation and Congestive Heart Failure trial, health care expenditures of patients from Québec randomized to rhythm and rate-control treatment strategies were compared from a single-payer perspective using a cost-minimization approach.<unk>
T-1234	atrial_fibrillation congestive_heart_failure health_care expenditures patients québec randomized rhythm rate-control
H-1234	-0.9203119874000549	▁at rial _ f bril lation _ con ges tive _ ▁Heart _ ▁Fail ure ▁ex pendi tures ▁patients ▁ rhythm ▁rate - control
D-1234	-0.9203119874000549	atrial_fbrillation_congestive_ Heart_ Failure expenditures patients rhythm rate-control
P-1234	-0.8101 -0.0243 -0.6825 -1.0802 -1.1879 -0.0038 -2.6561 -0.4792 -0.5413 -0.0347 -0.4109 -0.1424 -0.4395 -0.0671 -0.0449 -6.1378 -0.0020 -0.0692 -2.1956 -0.7238 -0.4856 -1.2109 -0.2633 -0.0117 -4.1177 -0.1057
S-640	Here we report that increased calcineurin/Nfat signalling and decreased miR-25 expression integrate to re-express the basic helix-loop-helix (bHLH) transcription factor dHAND (also known as Hand2) in the diseased human and mouse myocardium.<unk>
T-640	report calcineurin nfat mir-25 expression basic_helix-loop-helix bhlh transcription_factor dhand hand2 diseased myocardium
H-640	-0.788253664970398	▁calci ne uri n _ n fat ▁figure ▁mi R -25 ▁expression ▁heli x - loop - heli x ▁b HL h ▁tran scription _ ▁factor ▁Hand ▁disease d ▁human ▁mouse _ mé o car dium
D-640	-0.788253664970398	calcineurin_nfat figure miR-25 expression helix-loop-helix bHLh transcription_ factor Hand diseased human mouse_méocardium
P-640	-0.0051 -0.4635 -0.0252 -0.0683 -3.5962 -0.6771 -0.0891 -4.2974 -0.7151 -0.3216 -0.1188 -0.1540 -1.9131 -0.0269 -0.0522 -0.0272 -0.1645 -0.0198 -0.0274 -0.4399 -0.1689 -0.2083 -1.2435 -0.0043 -2.4004 -1.3839 -1.2874 -3.8203 -0.0721 -0.6514 -0.0938 -0.5438 -3.6888 -0.0864 -0.0036 -0.6535 -0.3351 -0.1055
S-1668	Every attempt should be made to identify and correct reversible causes for a worsening of heart failure, such as poor patient compliance, myocardial ischaemia, tachy- or bradyarrhythmias, valvular regurgitation, pulmonary embolism, infection, or renal dysfunction.<unk>
T-1668	heart_failure patient compliance myocardial_ischaemia bradyarrhythmias valvular_regurgitation pulmonary_embolism infection renal_dysfunction
H-1668	-0.5675763487815857	▁heart _ ▁failure ▁my o card ial _ is cha emia ▁ta chy - ▁bra dy ar rhythm ias ▁val vu lar _ ▁re gur gi tation ▁pulmonar y ▁e mbol ism ▁renal ▁dys function
D-1668	-0.5675763487815857	heart_ failure myocardial_ischaemia tachy- bradyarrhythmias valvular_ regurgitation pulmonary embolism renal dysfunction
P-1668	-4.4844 -1.4506 -1.7495 -0.9602 -0.0264 -0.1120 -0.0350 -0.5948 -3.3661 -0.0043 -0.0385 -0.7989 -0.0182 -0.0313 -2.8213 -0.6101 -0.1856 -0.0756 -0.1777 -0.0174 -0.1970 -0.1337 -0.4083 -1.1432 -0.0043 -0.0132 -0.0035 -0.0005 -0.0102 -0.6458 -0.0001 -0.3556 -0.0122 -0.1737 -0.0762 -0.2040 -0.0610
S-629	HABC Battery score was linearly associated with HF risk after adjusting for the Health ABC HF Model (HR 1.24, 95% CI 1.13-1.36 per SD decrease in score) and remained significant when controlled for death as a competing risk (HR 1.30; 95% CI 1.00-1.55).<unk>
T-629	habc_battery hf health_abc_hf_model death
H-629	-1.6584076881408691	▁h ABC ▁ HF ▁ HF ▁ HF ▁ HF ▁h z ▁SD
D-629	-1.6584076881408691	hABC HF HF HF HF hz SD
P-629	-0.3176 -1.1368 -1.9561 -0.1312 -2.6002 -0.1576 -3.2057 -0.2047 -3.6730 -0.3241 -3.1792 -2.5412 -1.6421 -3.6136 -0.1930
S-269	The optimal NT-proBNP cutoff point for predicting 4-year survival at the time of admission was 2300 pg/mL, which had 85.9% sensitivity and 39.1% specificity (95% confidence interval, area under the curve: 0.639, P = .044).<unk>
T-269	nt-probnp admission sensitivity specificity confidence_interval area_under_the_curve
H-269	-0.8586815595626831	▁NT - pro B NP ▁figure
D-269	-0.8586815595626831	NT-proBNP figure
P-269	-0.1666 -0.0645 -0.1371 -1.1845 -0.1760 -3.2222 -1.8113 -0.1072
S-1588	The prognostic power of various measures, except of those reflecting rapid R-R interval oscillations, has been almost identical, albeit some non-linear HR variability measures, such as short-term fractal scaling exponent have provided somewhat better prognostic information than the others.<unk>
T-1588	prognostic r-r_interval hr_variability short-term_fractal_scaling_exponent prognostic
H-1588	-0.990512490272522	▁prognos tic _ power ▁r - r ▁interval _ ▁os cilla tions ▁HR _ ▁variabil ity ▁short - term _ fra c tal _ ▁scal ing
D-1588	-0.990512490272522	prognostic_power r-r interval_ oscillations HR_ variability short-term_fractal_ scaling
P-1588	-2.5999 -0.6337 -1.5166 -0.3199 -1.3533 -0.2648 -1.2531 -0.9475 -1.1498 -0.8053 -0.0011 -0.0421 -3.3862 -3.0452 -1.1968 -0.2759 -3.8569 -0.0399 -0.4599 -0.2250 -1.0145 -0.1855 -0.7043 -0.5124 -0.2098 -0.0809 -1.5333 -0.1207
S-1437	This study was performed in 29 subjects: 10 heart failure (HF) patients with spontaneous ventricular tachycardia [HFVT(+)], 10 HF patients without spontaneous VT [HFVT(-)], and 9 subjects with structurally normal hearts (HNorm).<unk>
T-1437	heart_failure hf patients spontaneous_ventricular_tachycardia hf patients spontaneous_vt hearts
H-1437	-1.0044879913330078	▁heart _ ▁failure ▁ HF ▁vent ri cular _ ta chy car dia ▁ HF ▁ HF ▁ VT ▁h nor m
D-1437	-1.0044879913330078	heart_ failure HF ventricular_tachycardia HF HF VT hnorm
P-1437	-0.2501 -0.9375 -2.1489 -2.0020 -0.0327 -0.4183 -0.1597 -0.2207 -0.5150 -3.0464 -0.1698 -0.0156 -1.0721 -1.7867 -0.0540 -2.3546 -0.4833 -2.9352 -1.4987 -1.9387 -1.4033 -0.0050 -0.5855 -0.0737
S-819	Besides, the addition of GLS to a Cox model containing chronic heart failure, hypertension, age ≥ 75 years, diabetes, prior stroke score, estimated glomerular filtration rate, LVEF and Sa provided an additional benefit in the prediction of adverse CV events (p=0.022).<unk>
T-819	gls cox_model chronic_heart_failure hypertension diabetes stroke estimated_glomerular_filtration_rate lvef
H-819	-0.9260785579681396	▁g LS ▁co x ▁model ▁chronic _ ▁heart _ ▁failure ▁hyper tension ▁diabetes ▁glo mer ular _ ▁filtr ation _ ▁rate ▁LV EF ▁advers e ▁CV
D-819	-0.9260785579681396	gLS cox model chronic_ heart_ failure hypertension diabetes glomerular_ filtration_ rate LVEF adverse CV
P-819	-1.9941 -0.8560 -0.5970 -0.0037 -2.6354 -1.0348 -1.1347 -2.0307 -0.4932 -2.0469 -0.0824 -0.0008 -0.0817 -3.1230 -0.0239 -0.0845 -1.1017 -0.4476 -0.0214 -2.1354 -0.6227 -0.1317 -0.0519 -3.0279 -0.0293 -1.0080 -1.0401 -0.0899
S-921	Diastolic function was quantified via the parametrized diastolic filling formalism that yields relaxation/viscoelastic (c) and passive/stiffness (k) constants through the analysis of Doppler mitral inflow velocity (E-wave) contours.<unk>
T-921	diastolic_function diastolic_filling_formalism relaxation doppler_mitral_inflow_velocity e-wave
H-921	-0.501414954662323	▁dia sto lic ▁fill ing _ ▁formal ism ▁relax ation vis co ela stic ▁passiv e _ sti ff ness ▁do pp ler _ ▁mit ral ▁in flow _ ▁veloci ty ▁e - wa ve
D-921	-0.501414954662323	diastolic filling_ formalism relaxationviscoelastic passive_stiffness doppler_ mitral inflow_ velocity e-wave
P-921	-0.1795 -0.0327 -0.9219 -2.9700 -0.0606 -3.0637 -1.5108 -0.2717 -0.3013 -0.0030 -0.4184 -0.0032 -0.0384 -0.0073 -0.0051 -0.0281 -1.4491 -0.3348 -0.2162 -0.1325 -0.4748 -0.0125 -0.7525 -0.6568 -2.0756 -0.0131 -0.1940 -0.3311 -0.4075 -0.4448 -0.2042 -0.6920 -0.0161 -0.0394 -0.0169 -0.1734 -0.0993
S-1387	The patient population was divided into three groups: the VAD group included patients receiving ventricular assist device support; the ECMO group included patients receiving extracorporeal membrane oxygenation membrane support for more than 14 days; and the ECMO+VAD group included patients receiving ECMO followed by VAD support.<unk>
T-1387	patient vad patients ventricular_assist_device ecmo patients extracorporeal_membrane_oxygenation ecmo vad patients ecmo vad
H-1387	-0.7897771596908569	▁ VAD ▁vent ri cular _ assist _ ▁device _ ▁support ▁EC mo ▁extra corp o real _ ▁membran e _ ▁oxygen ation _ ▁membran e ▁ VAD
D-1387	-0.7897771596908569	VAD ventricular_assist_ device_ support ECmo extracorporeal_ membrane_ oxygenation_ membrane VAD
P-1387	-1.6703 -0.0626 -0.0262 -0.0612 -0.1227 -0.4440 -0.1415 -1.8353 -1.3611 -1.0382 -1.1340 -0.2519 -0.9489 -3.7971 -0.0790 -0.2651 -0.9215 -0.6046 -1.0922 -0.1810 -0.2342 -0.9569 -0.0694 -0.3140 -0.2170 -0.0639 -2.7023 -0.3776 -2.3517 -0.3677
S-244	In conclusion, indicators of functional status (6-MWT and NYHA class) were common to both patients with HFpEF and those with HFrEF, whereas gender and adherence to prescribed therapy were unique to patients having HFpEF in predicting death or HF hospitalization.<unk>
T-244	functional_status 6-mwt nyha_class patients hfpef hfref prescribed therapy patients hfpef death hf hospitalization
H-244	-0.944101095199585	▁m t ▁NY HA ▁ HF p EF ▁h Fr EF ▁ HF p EF ▁ HF p EF
D-244	-0.944101095199585	mt NYHA HFpEF hFrEF HFpEF HFpEF
P-244	-0.8872 -0.0363 -1.3116 -0.7722 -1.2117 -0.3510 -0.1325 -0.2122 -0.1706 -0.9695 -0.9856 -1.8862 -0.7082 -0.4970 -0.7237 -1.5735 -0.2862 -3.0800 -1.6454 -2.2824 -0.1030
S-2016	Simulations to evaluate the cost-effectiveness of heart failure disease management programs across 3 scenarios demonstrate how the model can be used to design a program in which short-term improvements in functioning and use of evidence-based treatments are sufficient to demonstrate good long-term value to the health care system.<unk>
T-2016	heart_failure disease evidence-based health_care
H-2016	-1.4214056730270386	▁coût - effect ive ness ▁heart _ ▁failure _ de _ con du ite
D-2016	-1.4214056730270386	coût-effectiveness heart_ failure_de_conduite
P-2016	-1.4809 -0.1992 -0.2108 -0.0380 -3.2140 -0.5583 -0.3763 -1.9202 -0.4365 -3.4150 -0.1723 -4.0059 -2.1482 -0.0852 -4.3539 -0.1279
S-930	To further our understanding of the role of human resistin in heart failure, we studied a humanized mouse model lacking murine resistin but transgenic for the human Retn gene (Hum-Retn mice), which exhibits basal and inflammation-stimulated resistin levels similar to humans.<unk>
T-930	resistin heart_failure murine resistin transgenic retn gene resistin
H-930	-0.9824563264846802	▁human ized ▁mouse _ la cking ▁mur ine _ ▁resist in ▁human ▁Ret n ▁gene ▁h um - re t n _ mi ce ▁ inflammation - stimul ated ▁resist in
D-930	-0.9824563264846802	humanized mouse_lacking murine_ resistin human Retn gene hum-retn_mice inflammation-stimulated resistin
P-930	-2.2670 -3.6600 -0.9636 -3.8322 -4.5758 -0.0427 -0.4324 -0.3909 -0.5575 -0.4736 -0.3505 -2.5050 -0.9379 -0.0038 -1.7157 -0.1870 -0.1708 -0.0190 -0.5592 -0.0313 -0.0036 -2.4948 -0.8625 -0.0969 -0.4950 -0.0154 -0.1152 -0.0075 -1.7741 -1.7242 -0.1336 -0.8882 -0.1342
S-1745	Rates of patients receiving angiotensin-converting enzyme inhibitors/angiotensin receptors blockers, β-blockers, and devices at final evaluation increased from 56%, 12%, 8% (period 1) to 97%, 86%, 17% (period 4), respectively (P<0.05).<unk>
T-1745	patients angiotensin-converting_enzyme_inhibitors angiotensin_receptors_blockers β-blockers
H-1745	-0.8180728554725647	▁ang io ten sin _ con ver ting _ ▁enzym e _ ▁inhibi tor _ angi oten sin _ ▁receptor s _ block ers ▁β - block ers
D-1745	-0.8180728554725647	angiotensin_converting_ enzyme_ inhibitor_angiotensin_ receptors_blockers β-blockers
P-1745	-0.4178 -1.0034 -0.6358 -1.7544 -2.4517 -0.0009 -0.0393 -2.4111 -1.2991 -1.1781 -0.0875 -1.1637 -0.4574 -2.3482 -1.5788 -0.1802 -0.0353 -1.0867 -0.9235 -0.8995 -0.5388 -1.2446 -1.3375 -0.0374 -0.0954 -0.0054 -0.0332 -0.0287 -1.1880 -0.0809
S-1815	Interestingly, TTA/TgTetMena mice were particularly susceptible to cardiac injury, as these animals experienced pronounced decreases in ejection fraction and fractional shortening as well as heart dilatation and hypertrophy after transverse aortic constriction (TAC).<unk>
T-1815	cardiac_injury ejection_fraction fractional_shortening heart_dilatation hypertrophy transverse_aortic_constriction tac
H-1815	-0.8547078371047974	▁t t ▁men a _ mi ce ▁cardiac ▁injury ▁e je ction _ fraction ▁ fraction ▁heart _ di la tation ▁hyper trop hy ▁trans verse _ a or tic _ con stri ction TAC
D-1815	-0.8547078371047974	tt mena_mice cardiac injury ejection_fraction fraction heart_dilatation hypertrophy transverse_aortic_constrictionTAC
P-1815	-4.3036 -0.7048 -4.0515 -0.9925 -3.1114 -0.7456 -0.2072 -0.0304 -0.8993 -0.4656 -0.1593 -0.0231 -0.7521 -0.0031 -1.3173 -0.0005 -3.5953 -0.4376 -2.2024 -0.3870 -0.0070 -0.2694 -0.0053 -0.0268 -0.0021 -0.0454 -0.5258 -0.8018 -0.5839 -2.3672 -0.9038 -0.2318 -0.1927 -0.0828 -0.9665 -0.1246 -0.0973
S-1505	In a sample of 659 heart failure patients from Italy, we performed confirmatory factor analysis (CFA) to test the original construct of the SCHFI v.6.2 scales (Self-Care Maintenance, Self-Care Management, and Self-Care Confidence), with limited success.<unk>
T-1505	heart_failure patients italy confirmatory_factor_analysis cfa schfi_v.6.2 self-care_maintenance self-care_management self-care_confidence
H-1505	-0.7440021634101868	▁heart _ ▁failure ▁implant ation ▁c fa ▁ SCH f ▁Self - Car e _ ▁Main ten ance ▁Self - Car e ▁Management ▁Self - Car e _ ▁Confi den ce
D-1505	-0.7440021634101868	heart_ failure implantation cfa SCHf Self-Care_ Maintenance Self-Care Management Self-Care_ Confidence
P-1505	-2.0512 -0.6199 -3.1913 -3.8134 -0.3051 -1.0635 -0.8530 -1.1728 -0.2077 -1.5932 -3.4660 -0.0725 -0.6330 -0.0466 -0.3971 -0.2962 -0.0333 -0.0112 -0.3398 -0.0210 -0.3120 -0.0338 -1.1774 -0.2268 -0.0174 -0.4860 -0.0450 -0.3949 -1.3403 -0.0047 -0.0210 -0.1941 -0.1107
S-882	METHODS AND RESULTS: The Resynchronization-Defibrillation for Ambulatory Heart Failure Trial showed that implantable cardioverter defibrillator-CRT was associated with a significant reduction in the primary end point of all-cause mortality or heart failure hospitalization.<unk>
T-882	resynchronization-defibrillation_for_ambulatory_heart_failure_trial implantable primary_end_point all-cause_mortality heart_failure hospitalization
H-882	-0.5448468923568726	▁re syn chron ization - Def i bril lation ▁Amb ulator y ▁Heart ▁Fail ure ▁Tri al ▁implant able ▁cardio ver ter _ de _ fi br illa tor - C RT
D-882	-0.5448468923568726	resynchronization-Defibrillation Ambulatory Heart Failure Trial implantable cardioverter_de_fibrillator-CRT
P-882	-1.7108 -0.0004 -0.0001 -0.2709 -0.2549 -0.7136 -0.9785 -0.2053 -0.0018 -0.3781 -0.0074 -0.0378 -1.0652 -0.6324 -0.0627 -2.4823 -0.0252 -0.0002 -0.0136 -0.6962 -0.1058 -0.0153 -0.2890 -0.0357 -2.1509 -0.7151 -0.2525 -0.0046 -0.0849 -0.5492 -1.6285 -0.1844 -2.9115 -0.0601
S-102	There are limited data regarding risk factors for the development of ischemic events (IEs) among patients with ischemic cardiomyopathy (IC) who receive cardiac resynchronization therapy with a defibrillator (CRT-D) and their effect on the efficacy of the device.<unk>
T-102	ischemic_events ies patients ischemic_cardiomyopathy ic cardiac_resynchronization_therapy defibrillator crt-d
H-102	-0.7994148135185242	▁ ische mic ▁events ▁i s ▁ ische mic _ ▁cardio my o pathy IC ▁cardiac _ ▁re syn chron ization ▁ therapy ▁de fi br illa tor ▁c RT - d ▁ef fica cy
D-102	-0.7994148135185242	ischemic events is ischemic_ cardiomyopathyIC cardiac_ resynchronization therapy defibrillator cRT-d efficacy
P-102	-1.7818 -0.8574 -0.2477 -3.5739 -1.6643 -2.6223 -1.2753 -0.4340 -0.1067 -0.7792 -0.4076 -2.5967 -0.8831 -0.0213 -1.4377 -0.0166 -1.0805 -1.3055 -0.0016 -0.0003 -0.4042 -1.3649 -0.0113 -1.0282 -0.5756 -0.2247 -0.0090 -0.0417 -0.8938 -0.2422 -0.1045 -1.0604 -0.8955 -0.0013 -0.3607 -1.1835 -0.0836
S-69	Age, renal dysfunction, chronic obstructive pulmonary disease, diabetes, peripheral vascular disease, decreased left ventricular ejection fraction, and ICD shocks during follow-up were strong predictors of mortality; ischemic cardiomyopathy and male sex were not.<unk>
T-69	renal_dysfunction chronic_obstructive_pulmonary_disease diabetes peripheral_vascular_disease left_ventricular_ejection_fraction icd_shocks follow-up mortality ischemic_cardiomyopathy
H-69	-0.4296841025352478	▁renal ▁dys function ▁chronic _ ▁ob struct ive ▁pulmonar y ▁disease ▁diabetes ▁per i pher al _ ▁vas cular ▁disease ▁left ▁vent ri cular ▁e je ction _ fraction ▁I CD ▁shock s ▁ ische mic _ ▁cardio my o pathy ▁male ▁sex
D-69	-0.4296841025352478	renal dysfunction chronic_ obstructive pulmonary disease diabetes peripheral_ vascular disease left ventricular ejection_fraction ICD shocks ischemic_ cardiomyopathy male sex
P-69	-0.0817 -0.3441 -0.1394 -0.1045 -0.9482 -0.9383 -0.0191 -0.0455 -0.1369 -0.0685 -0.8227 -0.0896 -0.1727 -0.1359 -0.0392 -0.0900 -0.4864 -0.5591 -0.0351 -1.8561 -0.1128 -0.2030 -0.0992 -0.1840 -1.7826 -0.2966 -0.0417 -1.2354 -0.0262 -0.8015 -0.0296 -1.6293 -0.1587 -1.5580 -0.1855 -0.1015 -0.6006 -0.3238 -0.6411 -0.1958 -0.0489 -0.4259 -1.2321 -0.2204 -0.0886
S-1318	METHODS: Male patients with CHF (n = 41, age 67.2 years, range 51-84 years) with mean ± SD testosterone levels of 10.7 ± 2.6 nmol/L (309 ± 76 ng/dL) were randomly allocated to exercise with testosterone or placebo groups.<unk>
T-1318	patients chf testosterone exercise testosterone placebo
H-1318	-1.071449875831604	▁CHF ▁CHF ▁SD ▁testosteron e
D-1318	-1.071449875831604	CHF CHF SD testosterone
P-1318	-0.3902 -2.4440 -1.4401 -0.1590 -0.0103 -2.9965 -0.0602
S-996	Interestingly, a number of different Raf-MEK1/2-ERK1/2 scaffold proteins have been identified, and their role in determining the adaptive or maladaptive cardiac remodelling is a promising field of investigation for the development of therapeutic strategies capable of selectively potentiating the adaptive response.<unk>
T-996	scaffold_proteins cardiac_remodelling field therapeutic
H-996	-1.0758076906204224	▁Raf - MEK - er k _ ▁sc af fold _ ▁protein s ▁adapt ive ▁mal adapt ive ▁cardiac ▁remodel ling ▁ therapeut ic
D-996	-1.0758076906204224	Raf-MEK-erk_ scaffold_ proteins adaptive maladaptive cardiac remodelling therapeutic
P-996	-0.2850 -0.1100 -0.0125 -4.5146 -3.6193 -0.2136 -3.7648 -4.6028 -0.2987 -0.0634 -1.8157 -0.5648 -0.0184 -0.7368 -0.0033 -2.8873 -0.0269 -0.0051 -0.2827 -0.2429 -0.2012 -0.9497 -0.0237 -0.6526 -2.0425 -0.0326
S-341	In addition, because functional MS is dynamic and proportional to LV dilatation, treatment for heart failure (HF), acting to reduce the LV size, can potentially improve such functional MS. A 52-year-old man had HF with severe MR due to prolapse of a degenerative mitral valve in 2008.<unk>
T-341	functional_ms lv_dilatation heart_failure hf functional_ms hf prolapse degenerative_mitral_valve
H-341	-1.081465244293213	▁functional ▁MS ▁LV _ di la tation ▁heart _ ▁failure ▁ HF ▁LV ▁functional ▁MS ▁ HF ▁MR ▁de genera tive _ ▁mit ral ▁val ve
D-341	-1.081465244293213	functional MS LV_dilatation heart_ failure HF LV functional MS HF MR degenerative_ mitral valve
P-341	-1.7082 -0.2793 -1.4932 -2.2861 -1.0482 -0.0264 -0.0012 -4.6120 -0.3222 -1.0550 -2.2825 -0.0526 -0.1207 -5.8702 -0.6035 -1.0619 -0.1731 -2.6025 -0.1640 -0.1925 -0.0174 -0.2846 -2.7342 -0.0094 -0.5817 -0.0246 -0.6049 -0.0690
S-1130	CONCLUSIONS: Contextual reasons for not prescribing angiotensin converting enzyme inhibitor / angiotensin-receptor blockers and β-blockers are present in two thirds of patients with heart failure who did not receive these medications, yet are poorly documented in medical records.<unk>
T-1130	prescribing angiotensin_converting_enzyme_inhibitor angiotensin-receptor_blockers β-blockers patients heart_failure medications medical
H-1130	-0.7817830443382263	▁ang io ten sin ▁convert ing _ ▁enzym e _ ▁inhibi tor ▁ang io ten sin - recept or _ block ers ▁β - block ers ▁heart _ ▁failure
D-1130	-0.7817830443382263	angiotensin converting_ enzyme_ inhibitor angiotensin-receptor_blockers β-blockers heart_ failure
P-1130	-1.4776 -2.0382 -0.5440 -0.5727 -0.0435 -0.3474 -0.9965 -2.1814 -0.0573 -0.7936 -0.3247 -0.0523 -0.0970 -0.8086 -0.3525 -0.6177 -1.5260 -0.0529 -0.2823 -1.1266 -1.9831 -0.0688 -0.3410 -0.0227 -0.0520 -0.1155 -1.7626 -1.9759 -2.5420 -0.9827 -0.0962
S-783	The associations between New York Heart Association class, a commonly used criterion standard, and KCCQ Overall Summary and Total Symptom domains were evaluated using Spearman correlations and 2-way ANOVA with differences between patients with HF with reduced EF and HFpEF tested with interaction terms.<unk>
T-783	new_york_heart_association_class kccq symptom spearman_correlations 2-way_anova patients hf_with_reduced_ef hfpef
H-783	-1.3413106203079224	▁associations ▁New ▁York _ ▁Heart _ association ▁k cc q ▁k cc q ▁symptom _ ▁domain s ▁Spe ar man ▁corre lation s ▁ HF
D-783	-1.3413106203079224	associations New York_ Heart_association kccq kccq symptom_ domains Spearman correlations HF
P-783	-3.3574 -1.0837 -0.1709 -1.5143 -0.7809 -1.0943 -1.6703 -1.2646 -0.1066 -0.6907 -3.0558 -0.0691 -0.9515 -2.2691 -3.0212 -3.9997 -0.0125 -2.6451 -0.0213 -0.0017 -0.1848 -0.0003 -0.0169 -1.1197 -2.3785 -4.6457 -0.0886
S-951	LV systolic indices (LV ejection fraction, LV strain/strain rate at systole) and diastolic indices (E/E', ratio of LV strain rate at diastole with early transmitral flow) were improved only in patients maintaining sinus rhythm at follow-up.<unk>
T-951	systolic lv_ejection_fraction lv_strain strain systole diastolic lv_strain_rate diastole transmitral_flow patients sinus_rhythm follow-up
H-951	-1.1714060306549072	▁LV ▁e je ction _ fraction ▁LV ▁strain _ de _ stra in _ ▁rate _ ▁at _ syn stol e ▁dia sto lic ▁indice s ▁LV ▁strain _ ▁rate ▁dia stol e _ con ▁early _ ▁transmit ral _ ▁flow ▁sinus ▁ rhythm
D-951	-1.1714060306549072	LV ejection_fraction LV strain_de_strain_ rate_ at_synstole diastolic indices LV strain_ rate diastole_con early_ transmitral_ flow sinus rhythm
P-951	-0.3430 -1.0541 -0.6765 -0.0384 -0.7889 -0.0108 -0.0547 -1.3643 -0.6195 -4.0824 -0.2132 -0.2761 -0.1116 -0.4138 -0.9040 -2.0809 -1.1640 -0.6768 -3.4446 -1.6874 -0.0655 -2.4171 -2.8055 -0.8113 -0.3479 -0.0089 -0.8882 -2.2218 -0.4102 -2.4285 -4.0046 -0.0221 -0.3608 -2.0403 -4.5740 -2.7255 -0.2248 -3.8418 -0.0608 -0.8343 -1.1580 -0.8291 -0.1926 -0.0619 -0.3566 -0.1880
S-276	Eight-week-old C57BL/6 male mice were treated with ANG II infusion (AT), ANG II infusion and uninephrectomy (AN), ANG II infusion and salt loading (AS), or ANG II infusion, uninephrectomy, and salt loading (ANS).<unk>
T-276	ang_ii_infusion ang_ii_infusion uninephrectomy ang_ii_infusion salt_loading ang_ii_infusion uninephrectomy salt_loading
H-276	-1.2048945426940918	▁c 57 b ▁figure ▁ANG _ ▁II ▁in fusion ▁in fusion ▁un ine ph r ecto my ▁ANG _ ▁II ▁in fusion ▁salt _ ▁load ing ▁in fusion ▁un ine ph r ecto my ▁salt _ ▁load ing
D-276	-1.2048945426940918	c57b figure ANG_ II infusion infusion uninephrectomy ANG_ II infusion salt_ loading infusion uninephrectomy salt_ loading
P-276	-1.7940 -2.2595 -1.2978 -3.9402 -2.6158 -1.8087 -1.8046 -0.0160 -0.0699 -3.4487 -1.1553 -0.3292 -0.1190 -2.1260 -0.1299 -0.0931 -0.8679 -2.0445 -1.3067 -2.5359 -0.0329 -0.2120 -0.4329 -1.3550 -0.1546 -0.0091 -4.6323 -2.4423 -1.8181 -0.1351 -2.0754 -0.1315 -0.3728 -1.2773 -0.1661 -1.5443 -0.3776 -0.0104 -1.1644 -0.0888
S-480	The ratio of early transmitral blood flow velocity over tissue Doppler early diastolic mitral annulus velocity (E/e') was found unreliable for estimating pulmonary capillary wedge pressure (PCWP) in patients with decompensated systolic heart failure (HF).<unk>
T-480	transmitral_blood_flow_velocity tissue_doppler diastolic_mitral_annulus_velocity pulmonary_capillary_wedge_pressure pcwp patients decompensated_systolic_heart_failure hf
H-480	-1.1490216255187988	▁early _ trans ral _ ▁blood _ ▁flow _ f ré que nce _ ▁over _ ▁tissu e ▁do pp ler _ ▁early _ ▁dia sto lic _ ▁mit ral _ ▁ann ulus _ ▁veloci ty ▁pulmonar y _ ▁cap illa ry _ we dge _ tension PC WP ▁de com pensa ted _ ▁sy sto lic _ heart _ ▁failure HF
D-480	-1.1490216255187988	early_transral_ blood_ flow_fréquence_ over_ tissue doppler_ early_ diastolic_ mitral_ annulus_ velocity pulmonary_ capillary_wedge_tensionPCWP decompensated_ systolic_heart_ failureHF
P-480	-4.8191 -1.0802 -3.1248 -0.1805 -0.8950 -1.2673 -0.5462 -0.4927 -0.8325 -3.7670 -0.3573 -0.2789 -0.0907 -1.9137 -2.7106 -0.5264 -0.8773 -0.2734 -0.8080 -0.0029 -0.1757 -2.1885 -0.9139 -0.1851 -2.2796 -1.9463 -2.7654 -0.4544 -4.1572 -0.0142 -0.6565 -0.1890 -0.3306 -1.0038 -1.3116 -0.1380 -0.0314 -0.0111 -0.5420 -2.3764 -0.0056 -0.2991 -0.0704 -1.8914 -0.0470 -0.5648 -1.3573 -1.2845 -0.4326 -4.2011 -0.0059 -0.0053 -1.0932 -0.5605 -3.3923 -0.9623 -3.8457 -0.1362 -2.2839 -0.5232 -3.2440 -0.6089 -0.1405 -0.0663
S-1984	By main effects analysis, peak VO2 was increased significantly by both interventions: exercise, 1.2 mL/kg body mass/min (95% CI, 0.7 to 1.7), P < .001; diet, 1.3 mL/kg body mass/min (95% CI, 0.8 to 1.8), P < .001.<unk>
T-1984	peak_vo2 exercise
H-1984	-1.4814565181732178	▁pe ak ▁VO 2
D-1984	-1.4814565181732178	peak VO2
P-1984	-3.0122 -0.0734 -1.3458 -0.0788 -4.1711 -0.2073
S-1698	In 2009, if an AMI patient had chosen a hospital in the worst versus best quintile of performance using 2005-2008 composite (vs. Hospital Compare) rankings, he or she would have had 1.61 (vs. 1.39) times the odds of dying in 30 days (P-value for difference <0.001).<unk>
T-1698	ami patient hospital hospital_compare p-value
H-1698	-1.0775060653686523	▁ AMI ▁hospital
D-1698	-1.0775060653686523	AMI hospital
P-1698	-0.2073 -0.0291 -1.2135 -3.7971 -0.1406
S-789	One-year event-free rates by KCCQ category among patients with HFpEF were 0 to 25=13.8%, 26 to 50=59.1%, 51 to 75=73.8%, and 76 to 100=77.8% (log rank P<0.001), with no significant interaction by EF (P=0.37).<unk>
T-789	kccq patients hfpef log_rank ef
H-789	-1.1783448457717896	▁k cc q ▁figure ▁ HF p EF
D-789	-1.1783448457717896	kccq figure HFpEF
P-789	-1.2592 -0.0649 -1.6988 -4.6705 -0.8372 -0.2057 -0.0444 -0.9206 -1.9873 -0.0948
S-292	A simple sex-specific model that includes age, race, cTnT, and NT-proBNP (which can be incorporated in a laboratory report) provides a good model, whereas adding cTnT and NT-proBNP to clinical characteristics results in an excellent HF prediction model.<unk>
T-292	ctnt nt-probnp report ctnt nt-probnp clinical hf
H-292	-0.7863003611564636	▁c t n t ▁NT - pro b NP ▁ HF
D-292	-0.7863003611564636	ctnt NT-probNP HF
P-292	-2.7036 -0.1710 -0.5437 -0.5994 -0.8405 -0.0476 -0.0119 -1.0881 -0.1608 -1.1965 -1.1371 -1.4800 -0.2417
S-1517	RESULTS: Mass spectrometry identified the presence of several N- and C-terminally processed forms of circulating NT-proBNP, with physiological proteolysis between Pro2-Leu3, Leu3-Gly4, Pro6-Gly7, and Pro75-Arg76.<unk>
T-1517	mass_spectrometry c-terminally nt-probnp physiological proteolysis
H-1517	-0.7384932637214661	▁c - termin ally ▁circula ting ▁NT - pro B NP ▁physio logic al _ ▁prote ol ysis ▁le u 3- G ly
D-1517	-0.7384932637214661	c-terminally circulating NT-proBNP physiological_ proteolysis leu3-Gly
P-1517	-4.7176 -0.2467 -0.0448 -0.5028 -1.5285 -1.4885 -0.0336 -0.0238 -0.0260 -0.6061 -0.0582 -0.0158 -0.9711 -0.0171 -1.0536 -0.8842 -0.2237 -0.0758 -1.1525 -0.0072 -0.9695 -1.3984 -0.0504 -2.3106 -0.0561
S-1329	METHODS: Thirty HFpEF patients, 18 female and 12 male, aged 69 ± 8 years, in New York Heart Association class II or III and with mean ejection fraction 63% ± 6%, were randomly (1:1) assigned to a 6-week FES program or placebo.<unk>
T-1329	hfpef patients new_york_heart_association_class_ii ejection_fraction fes placebo
H-1329	-1.1547801494598389	▁ HF p EF ▁patients ▁New ▁York ▁Heart _ ▁Association ▁figure ▁e je ction _ fraction
D-1329	-1.1547801494598389	HFpEF patients New York Heart_ Association figure ejection_fraction
P-1329	-0.1527 -0.1303 -0.2463 -0.3446 -3.1053 -3.2399 -0.2687 -0.6242 -1.1869 -1.3528 -2.6780 -2.5727 -0.9544 -0.0442 -1.5861 -0.0059 -2.2214 -0.0717
S-1548	The depressed left ventricular (LV) systolic pressure, positive and negative rates of changes in pressure development, ejection fraction, fractional shortening and cardiac output, as well as increased LV end-diastolic pressure in 20 weeks MI animals were partially reversed by metoprolol.<unk>
T-1548	left_ventricular systolic_pressure ejection_fraction fractional_shortening cardiac_output lv_end-diastolic_pressure mi metoprolol
H-1548	-1.2049626111984253	▁de press ed ▁left _ vent ri cular LV _ de press ed _ de press ed _ ▁left _ vent ri cular _ LV _ ▁sy sto lic _ tension ▁pressure ▁e je ction _ fraction ▁ fraction _ ▁short en ing ▁cardiac _ pu issa nce ▁LV ▁end - dia sto lic _ tension ▁met o pro lol
D-1548	-1.2049626111984253	depressed left_ventricularLV_depressed_depressed_ left_ventricular_LV_ systolic_tension pressure ejection_fraction fraction_ shortening cardiac_puissance LV end-diastolic_tension metoprolol
P-1548	-0.3486 -0.0083 -0.2415 -0.6092 -1.3756 -0.7564 -0.8465 -0.1590 -1.9268 -3.5485 -2.8577 -1.5796 -0.5475 -0.6844 -4.5016 -0.7712 -0.4229 -0.4408 -2.3600 -0.1322 -0.4498 -0.8983 -0.3434 -2.1305 -1.6524 -2.8062 -4.0999 -0.1939 -3.0045 -1.1928 -0.9114 -2.7780 -1.9552 -0.2250 -0.0051 -1.4551 -0.0025 -1.3628 -0.0003 -1.3544 -0.6473 -0.0409 -0.6636 -0.3125 -2.8224 -3.2513 -0.0247 -0.0127 -0.9086 -2.8261 -0.1128 -1.6378 -1.2703 -2.4449 -0.7892 -0.9581 -4.5059 -0.1572 -0.0337 -0.0520 -0.1239 -0.1720
S-1867	Comment on "Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction" OBJECTIVES: The objective of this clinical trial was to assess the safety and efficacy of carotid baroreflex activation therapy (BAT) in advanced heart failure (HF).<unk>
T-1867	baroreflex_activation_therapy_for_the_treatment_of_heart_failure_with_a_reduced_ejection_fraction clinical carotid baroreflex_activation_therapy bat heart_failure hf
H-1867	-0.8332204818725586	bar ore flex _ ▁Activ ation ▁Therapy ▁Heart _ ▁Fail ure ▁Red u ced _ ▁E je ction _ ▁Fra ction
D-1867	-0.8332204818725586	baroreflex_ Activation Therapy Heart_ Failure Reduced_ Ejection_ Fraction
P-1867	-2.8203 -1.6077 -1.6318 -0.5166 -1.3312 -0.0102 -0.9760 -0.4265 -0.3151 -0.1401 -0.0370 -1.2847 -0.0185 -1.4686 -0.8132 -1.5271 -0.2941 -0.0244 -0.2112 -0.8860 -0.0019 -2.7573 -0.0645
S-1748	A more recent enrollment period represented the most powerful independent predictor of favorable outcome {period 2 versus 1 (hazard ratio [HR], 0.64; P=0.04), period 3 versus 1 (HR, 0.35; P<0.001), period 4 versus 1 (HR, 0.14; P<001)}.<unk>
T-1748	outcome hazard_ratio
H-1748	-1.443885326385498	▁en roll ment
D-1748	-1.443885326385498	enrollment
P-1748	-2.6892 -0.0124 -0.0595 -4.3349 -0.1235
S-1793	LA is a heterogeneous region with HF risk factors of developed and nondeveloped countries, including lower risk of raised blood glucose levels, obesity, tobacco, and aging, whereas systemic hypertension (SH), rheumatic fever, and Chagas' disease (C'D) are higher in LA.<unk>
T-1793	hf blood_glucose obesity systemic_hypertension rheumatic_fever disease
H-1793	-0.9544033408164978	▁ HF ▁ HF ▁ HF ▁ HF ▁ HF ▁ HF ▁ HF ▁raised _ ▁blood ▁gluco se ▁levels ▁obes ity ▁to ba cco ▁ aging ▁system ic ▁hyper tension SH ▁rhe u matic ▁fe ver ▁Cha gas _ ▁disease
D-1793	-0.9544033408164978	HF HF HF HF HF HF HF raised_ blood glucose levels obesity tobacco aging systemic hypertensionSH rheumatic fever Chagas_ disease
P-1793	-0.6520 -0.0081 -2.2430 -0.0208 -2.7771 -0.0448 -3.0950 -0.0857 -3.2958 -0.1593 -3.4812 -0.2828 -3.6548 -0.4860 -3.6093 -1.8213 -0.3278 -0.6733 -0.0353 -1.5113 -0.5818 -0.1971 -0.1206 -0.0196 -0.0429 -0.1213 -0.0039 -3.0730 -0.4505 -0.2849 -0.0002 -0.9167 -0.0333 -0.0145 -0.3442 -0.0381 -0.0144 -0.7332 -0.0547 -1.3471 -2.0697 -2.1067 -0.2061
S-1107	The age- and sex-adjusted risk declined from 1990-1996 to 2004-2010, with hazard ratios of 0.67 (95% confidence interval (CI): 0.54, 0.85) for early-onset HF and 0.63 (95% CI: 0.45, 0.86) for late-onset HF.<unk>
T-1107	hazard_ratios confidence_interval hf hf
H-1107	-1.3705313205718994	▁age - ad just ed ▁risk ▁ HF
D-1107	-1.3705313205718994	age-adjusted risk HF
P-1107	-0.4123 -0.2393 -5.2771 -0.0013 -0.0833 -2.0774 -3.6898 -1.2491 -0.5676 -0.1082
S-1772	Adjusted hazard ratios across high, moderate, and low CRF categories were 1.0, 1.63, and 3.97, respectively, whereas those of normal, overweight, and obese body mass index categories were 1.0, 1.56, and 3.71, respectively (P for trend <0.0001 for each).<unk>
T-1772	hazard_ratios crf obese body_mass_index
H-1772	-1.9508540630340576	▁c f ▁figure
D-1772	-1.9508540630340576	cf figure
P-1772	-1.9651 -1.5547 -3.1416 -3.0103 -0.0826
S-395	Baseline eGFR group II (P<0.001), eGFR group III (P<0.001), eGFR group IV (P<0.001), uncontrolled hypertension (P=0.049), need of diuretics, and age <60 years (P=0.016) were associated with time to ESRD.<unk>
T-395	baseline egfr egfr egfr hypertension diuretics esrd
H-395	-1.070797085762024	▁e G FR ▁e G FR ▁figure ▁un control led ▁hyper tension ▁di ure tics ▁temps
D-395	-1.070797085762024	eGFR eGFR figure uncontrolled hypertension diuretics temps
P-395	-0.1012 -1.0518 -0.8869 -2.4137 -1.1770 -0.8838 -3.6721 -2.2315 -0.0052 -0.5391 -0.1522 -0.0006 -0.3718 -0.1674 -1.3041 -1.9045 -2.2933 -0.1182
S-1208	OBJECTIVES: This study investigated whether myocardial phosphodiesterase-2 (PDE2) is altered in heart failure (HF) and determined PDE2-mediated effects on beta-adrenergic receptor (β-AR) signaling in healthy and diseased cardiomyocytes.<unk>
T-1208	myocardial phosphodiesterase-2 pde2 heart_failure hf beta-adrenergic_receptor β-ar healthy diseased cardiomyocytes
H-1208	-0.670045018196106	▁my o card ial _ phos pho dies tera se -2 ▁p de 2 ▁heart _ ▁failure ▁ HF ▁p de 2- media ted ▁beta - ad r energi c ▁receptor β - AR ▁cardio my o cy tes
D-1208	-0.670045018196106	myocardial_phosphodiesterase-2 pde2 heart_ failure HF pde2-mediated beta-adrenergic receptorβ-AR cardiomyocytes
P-1208	-0.9365 -0.1012 -0.0359 -0.1540 -1.1809 -0.3379 -3.3970 -3.5480 -0.0620 -0.3918 -2.4513 -0.6589 -0.1603 -1.8116 -0.7721 -0.8883 -0.7526 -1.7012 -0.0026 -0.6081 -0.1606 -0.3435 -0.6328 -0.5578 -1.2617 -0.0229 -0.0154 -0.1048 -1.0028 -0.2100 -0.1244 -0.4995 -0.0056 -0.0603 -0.9540 -0.8551 -0.2652 -0.1349 -0.0960 -0.1387 -0.0735
S-866	CONCLUSIONS: In heart failure patients undergoing either cardiac resynchronization therapy with a defibrillator or with an implantable cardioverter-defibrillator device, carvedilol was associated with a 36% lower rate of inappropriate ATP and shock therapy compared with metoprolol.<unk>
T-866	heart_failure patients cardiac_resynchronization_therapy defibrillator implantable_cardioverter-defibrillator carvedilol atp shock_therapy metoprolol
H-866	-0.7523847222328186	▁heart _ ▁failure ▁cardiac _ ▁re syn chron ization ▁ therapy ▁implant able ▁cardio ver ter - de fi br illa tor ▁device ▁car vedi lol ▁in appropria te ▁ATP ▁ therapy ▁met o pro lol
D-866	-0.7523847222328186	heart_ failure cardiac_ resynchronization therapy implantable cardioverter-defibrillator device carvedilol inappropriate ATP therapy metoprolol
P-866	-0.9290 -0.8227 -1.8176 -0.1506 -1.0640 -0.8314 -0.0052 -0.0004 -0.5372 -1.8654 -0.0161 -0.6032 -0.0085 -1.4574 -0.1683 -0.0394 -0.4899 -0.0062 -5.3355 -2.4804 -0.0476 -0.2169 -3.7940 -0.0628 -0.0154 -0.0254 -1.4837 -0.0121 -0.0322 -0.0216 -3.7484 -0.0159 -0.1919 -0.0655 -0.0045 -0.0264 -0.1537 -0.0440
S-1245	We have demonstrated recently that (-)-ERC (epicatechin-rich cocoa) improves SkM mitochondrial structure [Taub, Ramirez-Sanchez, Ciaraldi, Perkins, Murphy, Naviaux, Hogan, Ceballos, Maisel, Henry et al.<unk>
T-1245	epicatechin-rich_cocoa skm mitochondrial_structure taub ramirez-sanchez ciaraldi perkins murphy naviaux hogan ceballos maisel henry
H-1245	-0.31916770339012146	▁e pica tech in - rich ▁coco a ▁Sk m ▁mito cho ndri al ▁structure ▁Ram i rez - S anche z ▁ci ar aldi ▁Per kin s ▁Murphy ▁na vi aux ▁Hoga n ▁ce ball os ▁Mais el ▁Henry
D-1245	-0.31916770339012146	epicatechin-rich cocoa Skm mitochondrial structure Ramirez-Sanchez ciaraldi Perkins Murphy naviaux Hogan ceballos Maisel Henry
P-1245	-0.9062 -0.0046 -0.0531 -0.3598 -0.1800 -0.0015 -0.0430 -0.0123 -0.5760 -0.2832 -1.2317 -0.8649 -0.1609 -0.0114 -0.6537 -2.8805 -0.0248 -0.0772 -0.0152 -1.0553 -0.0027 -0.0002 -0.3017 -0.0115 -0.0010 -1.1269 -0.0270 -0.0031 -0.0387 -0.6057 -0.0008 -0.0027 -0.4609 -0.0023 -0.0649 -0.0133 -0.1585 -0.8209 -0.0002 -0.1856 -0.1052 -0.0761
S-1420	Taking into account all follow-up visits over the 6-month period, we found that the risk of death or urgent readmission was lower among patients who had all of their visits with a familiar physician than among those followed by unfamiliar physicians (adjusted HR 0.91, 95% CI 0.85-0.98).<unk>
T-1420	follow-up death readmission patients physician physicians
H-1420	-1.3285740613937378	▁risk _ de _ ▁death ▁urgent _ ▁read mission
D-1420	-1.3285740613937378	risk_de_ death urgent_ readmission
P-1420	-5.1004 -1.4388 -0.5747 -0.1678 -1.9291 -1.3255 -0.2502 -1.5546 -0.0333 -2.1716 -0.0683
S-1816	By "turning off" Mena overexpression in TTA/TgTetMena mice either immediately prior to or immediately after TAC surgery, we discovered that normalizing Mena levels eliminated cardiac hypertrophy in TTA/TgTetMena animals but did not preclude post-TAC cardiac functional deterioration.<unk>
T-1816	mena_overexpression tac surgery mena cardiac_hypertrophy cardiac
H-1816	-1.5601040124893188	▁Men a _ over expression ▁ TTA ▁t g t et _ Men a _ mi ce ▁ TAC
D-1816	-1.5601040124893188	Mena_overexpression TTA tgtet_Mena_mice TAC
P-1816	-1.2130 -0.2733 -3.5747 -2.0250 -0.0424 -0.8496 -0.1094 -5.8071 -0.7604 -0.3470 -1.4656 -4.7086 -1.8118 -0.1329 -3.1659 -0.8655 -0.1605 -0.4788 -0.0485 -4.7032 -0.2191
S-901	SUMMARY: Objective criteriabased institution of PD for the treatment of diuretic refractory severe-end-stage HF was well tolerated and demonstrated favorable outcomes; these included improved clinical status, reduced hospitalizations and length of stay, with very few and easily treatable PDrelated complications.<unk>
T-901	pd diuretic hf outcomes clinical hospitalizations pdrelated complications
H-901	-0.892382025718689	▁PD ▁di ure tic _ re frac tory _ ▁severe - end - s tage ▁ HF
D-901	-0.892382025718689	PD diuretic_refractory_ severe-end-stage HF
P-901	-5.0074 -0.3026 -0.0270 -2.7449 -0.1125 -0.4430 -0.0469 -1.0880 -0.4120 -2.9641 -0.3283 -0.9634 -0.0401 -0.0912 -0.0005 -0.3508 -0.0032 -1.9742 -0.0551
S-1785	Overall ATP production rates were decreased at 2 and 3 weeks post-AAC (by 37% and 47%, respectively) because of a reduction in mitochondrial oxidation of glucose, lactate, and fatty acids that was not accompanied by an increase in myocardial glycolysis rates.<unk>
T-1785	atp mitochondrial_oxidation glucose lactate fatty_acids myocardial glycolysis
H-1785	-0.38485220074653625	▁ATP ▁a ac ▁mito cho ndri al ▁oxid ation ▁gluco se ▁lac tate ▁fa tty ▁acid s ▁my o card ial _ ▁gly col ysis
D-1785	-0.38485220074653625	ATP aac mitochondrial oxidation glucose lactate fatty acids myocardial_ glycolysis
P-1785	-0.2453 -4.4583 -1.2990 -0.0968 -0.3362 -0.0462 -0.0139 -0.0997 -0.0075 -0.0945 -0.0316 -0.0118 -0.0174 -0.0103 -0.2703 -0.1442 -0.0275 -0.6518 -0.0444 -0.1681 -0.1969 -0.7465 -0.4342 -0.3135 -0.0318 -0.4958 -0.0976
S-456	To test whether the proangiogenic effects of B act via activation of VEGF pathway, rats were intravenously injected with adenoviral vector encoding a decoy VEGF receptor (Ad-Flk) or a control adenovirus (Ad-C), at the start of the treatment with B.<unk>
T-456	proangiogenic vegf_pathway intravenously injected adenoviral vegf_receptor adenovirus
H-456	-0.6545248031616211	▁pro angi ogen ic ▁effects ▁b ▁activa tion ▁VE GF _ path way ▁a den ovi ral _ ve ctor ▁de co y ▁VE GF _ ▁receptor ▁ad - f lk ▁ade no virus ▁ad - c
D-456	-0.6545248031616211	proangiogenic effects b activation VEGF_pathway adenoviral_vector decoy VEGF_ receptor ad-flk adenovirus ad-c
P-456	-0.2138 -0.0655 -0.0478 -0.6724 -1.1218 -0.9050 -4.1790 -0.0135 -1.3543 -0.0624 -1.9734 -1.1903 -0.1858 -0.2041 -0.0098 -0.8551 -0.0249 -1.2342 -1.4059 -0.6427 -0.0400 -0.0035 -0.2145 -1.2293 -0.1679 -2.2786 -0.0658 -1.1814 -0.0763 -0.1162 -0.0442 -1.8664 -0.0345 -0.0029 -0.3372 -0.0116 -0.3372 -1.0938 -0.0631
S-1226	RESULTS: In all high-risk subgroups, patients treated with eplerenone had an increased risk of potassium >5.5 mmol/l but not of potassium >6.0 mmol/l, and of hospitalization for hyperkalemia or discontinuation of study medication due to adverse events.<unk>
T-1226	patients eplerenone potassium potassium hospitalization hyperkalemia medication adverse_events
H-1226	-0.7149901390075684	▁e pler en one ▁po tas s ium ▁po tas s ium ▁hyper kal emia ▁medication
D-1226	-0.7149901390075684	eplerenone potassium potassium hyperkalemia medication
P-1226	-1.4703 -0.2564 -0.4533 -5.9231 -0.0326 -0.2297 -0.1584 -0.0741 -0.1342 -0.2971 -0.0565 -0.2605 -0.5819 -0.0889 -0.0423 -2.2186 -0.5296 -0.0624
S-514	The implantation of a novel bottleneck stent in the proximal LAD or LCX is a novel porcine model of reversible myocardial ischemia (open stent) and ischemic heart failure (occluded stent) and is feasible for the development of new therapeutic approaches.<unk>
T-514	implantation bottleneck_stent lad lcx myocardial_ischemia stent ischemic_heart_failure stent therapeutic
H-514	-0.8200704455375671	▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁proxima l ▁ LAD ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁proxima l ▁ LAD ▁ LC x ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁proxima l ▁ LAD ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁implant ation ▁
D-514	-0.8200704455375671	implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation proximal LAD implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation proximal LAD LCx implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation proximal LAD implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation implantation
P-514	-0.0031 -0.0088 -0.2986 -0.0036 -0.3651 -0.0037 -0.3851 -0.0041 -0.4248 -0.0044 -0.4835 -0.0048 -0.5692 -0.0056 -0.6602 -0.0060 -0.7891 -0.0069 -0.9680 -0.0075 -1.9783 -0.0085 -0.3009 -0.0019 -2.4269 -0.0195 -0.8268 -0.0087 -0.6700 -0.0082 -0.6664 -0.0088 -0.6878 -0.0091 -0.7418 -0.0093 -0.8129 -0.0098 -0.8394 -0.0104 -0.9216 -0.0111 -1.0406 -0.0120 -1.0995 -0.0128 -1.1863 -0.0138 -1.2882 -0.0146 -1.4170 -0.0156 -1.7492 -0.0128 -0.4967 -0.0088 -2.2735 -0.0828 -0.6400 -1.0748 -0.0848 -0.8120 -0.0519 -0.8359 -0.0445 -0.9108 -0.0414 -0.9824 -0.0385 -1.0515 -0.0373 -1.1055 -0.0362 -1.1528 -0.0365 -1.1794 -0.0355 -1.2584 -0.0356 -1.3333 -0.0362 -1.3606 -0.0379 -1.4023 -0.0403 -1.3587 -0.0417 -1.4683 -0.0445 -1.5238 -0.0458 -1.5313 -0.0494 -1.6127 -0.0528 -1.6788 -0.0545 -1.6892 -0.0597 -4.1648 -0.0164 -1.0542 -0.0384 -2.0633 -0.1454 -1.3590 -0.0989 -1.3266 -0.1020 -1.3672 -0.1040 -1.3829 -0.1074 -1.4147 -0.1135 -1.4523 -0.1175 -1.4986 -0.1176 -1.5164 -0.1225 -1.5563 -0.1236 -1.6301 -0.1253 -1.6039 -0.1318 -1.6533 -0.1370 -1.6575 -0.1368 -1.7484 -0.1382 -1.7520 -0.1379 -1.7358 -0.1432 -1.7001 -0.1424 -1.7656 -0.1494 -1.8469 -0.1507 -1.8612 -0.1531 -1.8574 -0.1586 -1.8966 -0.1580 -1.8469 -0.1598 -1.9470 -0.1615 -1.9243 -0.1563 -1.9462 -0.1614 -1.9513 -0.1659 -2.0145 -0.1641 -2.0108 -0.1642 -2.0334 -0.1651 -2.0034 -0.1663 -2.0012 -0.1677 -2.0427 -0.1651 -2.0758 -0.1626 -2.0560 -0.1653 -2.0509 -0.1609 -2.0709 -0.1621 -2.1317 -0.1584 -2.0738 -0.1608 -2.1342 -0.1548 -2.1384 -0.1554 -2.0697 -0.1578 -2.0764 -0.1600 -2.1259 -0.1519 -2.1461 -0.1541 -2.1109 -0.1529 -2.1311 -0.1501 -3.1239 -7.0856
S-1347	A patient aged in his 60s with New York Heart Association class III heart failure (HF) (left ventricular ejection fraction of 25%) who was originally part of this study displayed permanent periodic breathing (PB) and was then excluded from the final data analysis; his response is presented in this report.<unk>
T-1347	patient new_york_heart_association_class_iii heart_failure hf left_ventricular_ejection_fraction periodic_breathing pb report
H-1347	-1.2758312225341797	▁a ged ▁New ▁York ▁Heart _ ▁Association _ ▁class _ ▁III ▁heart _ ▁failure ▁ HF ▁le ft ▁vent ri cular _ ▁e je ction ▁p p
D-1347	-1.2758312225341797	aged New York Heart_ Association_ class_ III heart_ failure HF left ventricular_ ejection pp
P-1347	-5.4186 -0.0161 -4.6708 -0.2288 -0.6980 -1.1105 -1.7181 -1.4606 -0.7034 -0.5699 -0.6399 -1.7328 -0.4664 -5.9190 -1.4140 -0.0299 -1.7096 -0.1602 -0.3511 -0.1938 -0.2836 -0.5157 -1.3620 -0.2832 -0.0131 -1.6108 -3.2122 -0.4092 -0.0975
S-1705	Potassium increased with spironolactone in non-AAs (4.29±0.5-4.55±0.49 mmol/L) but not in AAs (4.32±0.54-4.31±0.49 mmol/L; race by treatment interaction, P=0.03) during the first month and remained higher throughout the trial.<unk>
T-1705	potassium spironolactone aas
H-1705	-0.6028373837471008	▁po tas s ium ▁spi rono lac tone ▁AA s ▁race _ ▁by _ ré que nce
D-1705	-0.6028373837471008	potassium spironolactone AAs race_ by_réquence
P-1705	-0.6109 -0.1744 -0.0755 -0.0794 -0.3471 -0.0301 -0.2328 -0.1476 -0.4131 -0.2422 -0.5010 -0.5017 -2.5022 -0.8967 -1.5461 -0.9424 -0.0888 -2.0344 -0.0875
S-1880	METHODS: We performed symptom limited maximal CPET in 10 patients with CHF, randomly divided into two groups: 5 patients as control without exercise and 5 exercise patients used Δ50%W intensity to exercise 30 min/d, 5 d/w, x12 w. Before and after 12 w rehabilitation, we evaluated functions.<unk>
T-1880	symptom cpet patients chf patients exercise exercise patients exercise rehabilitation
H-1880	-1.4121277332305908	▁c PET ▁CHF
D-1880	-1.4121277332305908	cPET CHF
P-1880	-0.7345 -0.2090 -0.7582 -5.2966 -0.0624
S-357	Repeated echocardiography 4 months later demonstrated a reduction in LV end-diastolic volume of 66 mL/m2, disappearance of MR, improvement of the mitral valve opening to an MVA of 1.7 cm2, and a mean pressure gradient of 4.6 mm Hg (Fig 1C).<unk>
T-357	echocardiography lv_end-diastolic_volume mitral_valve_opening mva
H-357	-0.9043172597885132	▁e cho card i ography ▁LV ▁end - dia sto lic ▁volume ▁MR ▁mit ral ▁val ve ▁m VA ▁pressure
D-357	-0.9043172597885132	echocardiography LV end-diastolic volume MR mitral valve mVA pressure
P-357	-0.0985 -0.4185 -0.1964 -0.6098 -0.3530 -1.1381 -2.5387 -0.0338 -1.6560 -0.7284 -1.5495 -1.0816 -3.6015 -0.2561 -0.0130 -0.3473 -0.0892 -0.3817 -0.9844 -1.6390 -2.0974 -0.0832
S-552	CONCLUSIONS: Surgical treatment of post-LVAD AI with aortic valve oversewing or leaflet repair or by bioprosthetic aortic valve replacement is effective at restoring functional capacity for CF LVAD patients who develop symptomatic, severe AI and can be performed safely with good results.<unk>
T-552	surgical post-lvad_ai aortic_valve leaflet bioprosthetic_aortic_valve_replacement functional_capacity lvad patients symptomatic
H-552	-0.7760550379753113	▁post - L VAD ▁AI ▁a or tic ▁val ve _ ▁over se wing ▁le a flet ▁repair ▁bio pro sthetic ▁a or tic _ ▁val ve _ ▁replace ment
D-552	-0.7760550379753113	post-LVAD AI aortic valve_ oversewing leaflet repair bioprosthetic aortic_ valve_ replacement
P-552	-4.7891 -0.0217 -1.3680 -0.0177 -3.6397 -0.2131 -0.0630 -1.2942 -0.8728 -0.0671 -2.3224 -0.7454 -0.0127 -0.0758 -0.0038 -0.0128 -0.0006 -0.1416 -0.0028 -0.0011 -0.0008 -0.1245 -0.1448 -1.0216 -0.8008 -0.7360 -0.0348 -1.0454 -0.1402 -0.0086 -5.0397 -0.0712
S-1123	METHODS: Mixed-methods study of 295 veterans aged 50 years and older in 4 VA health care systems who had systolic heart failure and were not prescribed a β-blocker and/or an angiotensin converting enzyme inhibitor or angiotensin-receptor blocker.<unk>
T-1123	mixed-methods_study health_care systolic_heart_failure prescribed β-blocker angiotensin_converting_enzyme_inhibitor angiotensin-receptor_blocker
H-1123	-0.8331688046455383	▁veteran s ▁VA ▁health _ care s ▁sy sto lic _ ▁heart _ ▁failure ▁β - block er ▁ang io ten sin ▁convert ing ▁enzym e _ ▁inhibi tor ▁ang io ten sin - recept or _ block er
D-1123	-0.8331688046455383	veterans VA health_cares systolic_ heart_ failure β-blocker angiotensin converting enzyme_ inhibitor angiotensin-receptor_blocker
P-1123	-3.7766 -0.0671 -1.0176 -1.7803 -3.1793 -0.9988 -2.0255 -1.6124 -0.0903 -3.3183 -0.3252 -1.6103 -0.8050 -2.0873 -0.2182 -0.0230 -0.0555 -0.1750 -0.0420 -0.6600 -1.0730 -0.7465 -0.5510 -0.2970 -0.9417 -0.0719 -1.6880 -0.0600 -0.0117 -0.0357 -0.7757 -0.4700 -0.6232 -0.7716 -0.0467 -0.2119 -0.4815 -0.9950 -0.0302 -0.3339 -0.0758
S-822	BACKGROUND: This study sought to analyze a new approach to assess exercise-induced pulmonary artery systolic pressure (PASP) increase by means of stress Doppler echocardiography as a possible measure of right ventricular contractile reserve in patients with severe pulmonary hypertension and right heart failure.<unk>
T-822	exercise-induced_pulmonary_artery_systolic_pressure pasp stress_doppler_echocardiography right_ventricular_contractile_reserve patients pulmonary_hypertension right_heart_failure
H-822	-0.6821445226669312	▁exercise - indu ced ▁pulmonar y _ ▁arter y _ ▁sy sto lic _ tension PAS p ▁stress ▁do pp ler ▁e cho card i ography ▁right ▁vent ri cular _ contract ile _ ▁reserve ▁pulmonar y _ ▁hyper tension ▁right _ heart _ ▁failure
D-822	-0.6821445226669312	exercise-induced pulmonary_ artery_ systolic_tensionPASp stress doppler echocardiography right ventricular_contractile_ reserve pulmonary_ hypertension right_heart_ failure
P-822	-2.6724 -0.4482 -0.0037 -0.6699 -0.0446 -0.1330 -1.1931 -1.6076 -0.1385 -0.4832 -3.4773 -0.2313 -2.6692 -1.1984 -0.6667 -2.2246 -0.5933 -0.2472 -0.8678 -0.0147 -0.2483 -0.3153 -0.2868 -0.2225 -0.1996 -0.2533 -0.1239 -0.1227 -0.2149 -0.2335 -0.1926 -0.8952 -0.2641 -0.3480 -0.1130 -0.2639 -0.0313 -1.3280 -0.5806 -0.0004 -0.8913 -0.7786 -1.9466 -1.4215 -0.9936 -0.1430 -0.0635
S-1844	Methods and analysis We will conduct a literature search in the databases of MEDLINE, EMBASE, HEALTHSTAR, CINAHL, Cochrane Library, Campbell Collaboration, Joanna Briggs Institute Evidence Based Practice, Centre for Reviews and Dissemination and Evidence Based Practice Centres.<unk>
T-1844	medline embase healthstar cinahl cochrane_library campbell_collaboration joanna_briggs_institute_evidence_based_practice centre_for_reviews_and_dissemination evidence_based_practice_centres
H-1844	-0.537766695022583	▁MED LINE ▁ EMBA se ▁HE al th STAR ▁c INA HL ▁co ch rane ▁Library ▁Campbell ▁Joan na ▁Brig gs ▁Institute ▁E viden ce _ ▁Base d ▁Practic e
D-1844	-0.537766695022583	MEDLINE EMBAse HEalthSTAR cINAHL cochrane Library Campbell Joanna Briggs Institute Evidence_ Based Practice
P-1844	-2.8661 -0.8080 -0.6358 -0.0041 -0.9942 -1.2388 -1.3518 -0.6251 -0.1075 -0.4084 -0.3668 -0.3281 -0.3350 -0.0169 -0.0011 -0.4322 -0.0798 -1.7326 -0.0047 -0.0062 -0.0291 -0.4241 -2.1056 -0.0137 -0.0036 -0.4252 -0.4631 -0.0065 -0.7568 -0.0389 -0.4656 -0.1330
S-647	The base of treatment of heart failure is the blockade of the neuro-hormonal system, which includes the use of angiotensin converting enzyme inhibitors (angiotensin receptor blockers in case of angiotensin converting enzyme inhibitors intolerance), beta receptor blockers and mineralocorticoid receptor antagonists.<unk>
T-647	heart_failure neuro-hormonal_system angiotensin_converting_enzyme_inhibitors angiotensin_receptor_blockers angiotensin_converting_enzyme_inhibitors beta_receptor_blockers mineralocorticoid_receptor_antagonists
H-647	-1.0435212850570679	▁heart _ ▁failure ▁neuro - hormon al _ system ▁ang io ten sin ▁convert ing ▁enzym e _ ▁inhibi tors ▁ang io ten sin _ ▁convert ing _ ▁enzym e _ ▁inhibi teurs _ ▁in tolerance ▁mineral o cor tico id ▁receptor
D-647	-1.0435212850570679	heart_ failure neuro-hormonal_system angiotensin converting enzyme_ inhibitors angiotensin_ converting_ enzyme_ inhibiteurs_ intolerance mineralocorticoid receptor
P-647	-2.7785 -0.9904 -3.2288 -0.7103 -0.0962 -0.0144 -0.0539 -3.5197 -0.5142 -0.0802 -0.3491 -0.5868 -1.5245 -0.1979 -0.4983 -0.9706 -0.1215 -1.2789 -0.3159 -1.8805 -1.9381 -3.4208 -0.9632 -0.9305 -2.1861 -0.2713 -0.4770 -0.6886 -3.6860 -0.1431 -0.5122 -1.0662 -2.6402 -1.1083 -0.5573 -0.0198 -0.2263 -0.0417 -0.0801 -3.0578 -0.6072 -0.1042 -1.4172 -0.0613
S-330	CONCLUSIONS: In an open chest model, twist, RS, RS synchrony, and CS analyzed by STE may be noninvasive surrogates for changes in CO. During RVPO, changes in RS synchrony and CS with varying regional strain contributions may be the primary mechanism in which BiVP improves CO.<unk>
T-330	chest rs rs_synchrony ste noninvasive rvpo rs_synchrony strain bivp
H-330	-1.16459321975708	▁open ▁che st ▁model ▁twist ▁RS ▁RS ▁synchron y ▁CS ▁ STE ▁co
D-330	-1.16459321975708	open chest model twist RS RS synchrony CS STE co
P-330	-0.2789 -0.4622 -0.0070 -2.2120 -0.0054 -0.0619 -1.4099 -0.0256 -0.1738 -0.5250 -2.3461 -2.0651 -4.5124 -3.1520 -0.2317
S-498	Given the TAPSE, PASP, and TAPSE-to-PASP ratio (TAPSE/PASP) collinearity, separate Cox regression and Kaplan-Meier analyses were performed: one with TAPSE and PASP as individual measures, and the other combining them in ratio form.<unk>
T-498	tapse pasp tapse pasp cox_regression kaplan-meier_analyses tapse pasp
H-498	-0.9571391344070435	▁T AP se - to - PAS p ▁ratio TA PS e _ pass p ▁co x _ ▁re gression ▁Ka plan - me ier
D-498	-0.9571391344070435	TAPse-to-PASp ratioTAPSe_passp cox_ regression Kaplan-meier
P-498	-1.9748 -0.2636 -1.0558 -1.7249 -0.6792 -0.0227 -0.2599 -0.6153 -0.5487 -4.6739 -0.7437 -0.5651 -1.8641 -4.6062 -0.6723 -0.9749 -0.0120 -1.2138 -0.3957 -0.0083 -0.3813 -0.1161 -0.0518 -0.6344 -0.0470 -1.6392 -0.0979
S-1978	Of 577 initially screened participants, 100 older obese participants (mean [SD]: age, 67 years [5]; body mass index, 39.3 [5.6]) with chronic, stable HFPEF were enrolled (366 excluded by inclusion and exclusion criteria, 31 for other reasons, and 80 declined participation).<unk>
T-1978	obese body_mass_index chronic stable hfpef
H-1978	-1.8685762882232666	▁older ▁obes e ▁h f f f
D-1978	-1.8685762882232666	older obese hfff
P-1978	-3.8457 -1.0746 -0.0450 -5.6170 -0.7013 -0.4656 -1.8998 -3.0611 -0.1071
S-1080	BACKGROUND: Human heart failure (HF) increases alternative mRNA splicing of the type V, voltage-gated cardiac Na+ channel α-subunit (SCN5A), generating variants encoding truncated, nonfunctional channels that are trapped in the endoplasmic reticulum.<unk>
T-1080	heart_failure hf mrna_splicing cardiac scn5a endoplasmic_reticulum
H-1080	-1.1244686841964722	▁Human ▁heart _ ▁failure ▁m RNA ▁m RNA ▁volta ge - ga ted _ ▁cardiac _ na + ▁channel _ sub un it ▁s CN 5 a ▁tru nca ted _ non function al ▁channel s ▁en do plas mic ▁reti culum
D-1080	-1.1244686841964722	Human heart_ failure mRNA mRNA voltage-gated_ cardiac_na+ channel_subunit sCN5a truncated_nonfunctional channels endoplasmic reticulum
P-1080	-3.7167 -0.8242 -0.7565 -1.6910 -0.1692 -0.0070 -1.4668 -0.0330 -3.5960 -0.0057 -0.2923 -0.2050 -0.6449 -1.0998 -0.8351 -1.9122 -1.0544 -1.4330 -0.3330 -3.3384 -1.6561 -0.0355 -0.0107 -1.2801 -1.9526 -4.3885 -0.2994 -0.7717 -0.0713 -0.4308 -3.6316 -2.9314 -0.3517 -0.0449 -3.0085 -0.1158 -0.4502 -0.6846 -0.0943 -3.1721 -0.3383 -0.0011 -0.2482 -0.0930
S-988	Particular topics of debate in paediatric heart failure concern: the diagnosis and management of myocarditis versus dilated cardiomyopathy the most appropriate investigations for new onset heart failure cellular responses to heart failure the increasing population of anthracycline treated survivors of childhood malignant disease treatment strategies.<unk>
T-988	heart_failure diagnosis myocarditis dilated_cardiomyopathy heart_failure heart_failure anthracycline disease
H-988	-0.7711041569709778	▁pa e dia tric ▁heart _ ▁failure ▁my o card itis ▁dil ated ▁cardio my o pathy ▁heart _ ▁failure ▁an thra cycli ne ▁child hood ▁malign ant ▁disease
D-988	-0.7711041569709778	paediatric heart_ failure myocarditis dilated cardiomyopathy heart_ failure anthracycline childhood malignant disease
P-988	-0.8700 -0.0085 -4.3879 -0.9703 -0.9108 -1.3558 -0.6396 -2.5507 -0.0890 -0.1693 -0.2153 -0.2300 -0.1665 -0.7668 -0.6592 -0.1837 -0.0186 -1.3381 -0.8036 -0.7457 -0.4745 -0.0065 -0.8229 -0.1362 -1.9462 -1.0193 -0.1441 -0.1206 -1.4423 -0.6429 -0.0694
S-2010	METHODS: We developed the Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model, a Web-based simulation tool designed to integrate data on demographic, clinical, and laboratory characteristics; use of evidence-based medications; and costs to generate predicted outcomes.<unk>
T-2010	tools_for_economic_analysis_of_patient_management_interventions_in_heart_failure_cost-effectiveness_model clinical evidence-based medications costs outcomes
H-2010	-0.9803900718688965	▁économique _ ▁Analys is ▁Patient _ ▁Management _ ▁Interven tions ▁Heart _ ▁Fail ure ▁Cost - E ff ective ness _ ▁Model
D-2010	-0.9803900718688965	économique_ Analysis Patient_ Management_ Interventions Heart_ Failure Cost-Effectiveness_ Model
P-2010	-0.9908 -4.1449 -1.6556 -0.0209 -1.0316 -1.4020 -1.0339 -1.2881 -0.9936 -0.0068 -0.1287 -0.3531 -0.1160 -0.0392 -0.6587 -0.0562 -0.7694 -1.9843 -0.0205 -0.5307 -2.2439 -1.3989 -2.6109 -0.0510
S-1020	The measurement of natriuretic peptides (NPs), B-type NP or N-terminal pro-B-type NP, can be an important tool in the diagnosis of acute heart failure in patients presenting to an Emergency Department (ED) with acute dyspnea, according to international guidelines.<unk>
T-1020	natriuretic_peptides nps b-type_np n-terminal_pro-b-type_np diagnosis acute_heart_failure patients emergency_department acute_dyspnea
H-1020	-0.7818477153778076	▁na tri ure tic _ pe pti des NP s ▁b - type ▁ NP ▁n - termin al _ pro - B - type ▁ NP ▁a cute _ heart _ ▁failure ▁Emer gen cy _ de _ ED ▁a cute _ ▁dys pne a
D-1020	-0.7818477153778076	natriuretic_peptidesNPs b-type NP n-terminal_pro-B-type NP acute_heart_ failure Emergency_de_ED acute_ dyspnea
P-1020	-0.0040 -0.0050 -0.0839 -4.4636 -2.5274 -0.4150 -0.1731 -0.1844 -3.1127 -0.4729 -1.6630 -0.1026 -0.2656 -1.5828 -0.0240 -3.9537 -0.0327 -0.0011 -0.0026 -2.6242 -0.3327 -0.0270 -0.2139 -0.0554 -0.0287 -0.5135 -0.0105 -1.5478 -0.0565 -0.1914 -3.1754 -0.6154 -0.6824 -0.3810 -0.0197 -0.0728 -0.9328 -1.9601 -0.5928 -2.0055 -0.3001 -0.0117 -0.0817 -1.1589 -0.0274 -0.2365 -0.4208 -0.1820
S-1275	Besides the widely accepted peak oxygen consumption (peak VO2) and VEN/VCO2 slope, other exercise variables - exercise oscillatory ventilation (EOV) and partial pressure of end-tidal CO2, (PETCO2) - should gain attention in the interpretation of cardiopulmonary exercise testing.<unk>
T-1275	peak_oxygen_consumption peak_vo2 exercise exercise_oscillatory_ventilation eov partial_pressure_of_end-tidal_co2 petco2 gain cardiopulmonary_exercise_testing
H-1275	-0.6296059489250183	▁pe ak ▁VO 2 ▁v co 2 ▁s lope ▁exercise ▁os cilla tory ▁ventilation ▁e OV ▁pressure ▁end - ti dal _ co 2 PET co 2 ▁cardio pul mon ary
D-1275	-0.6296059489250183	peak VO2 vco2 slope exercise oscillatory ventilation eOV pressure end-tidal_co2PETco2 cardiopulmonary
P-1275	-0.3511 -0.0045 -1.6656 -0.2985 -1.9101 -0.9306 -0.0460 -0.8548 -0.0974 -0.8446 -0.5415 -0.0004 -0.3025 -0.2579 -0.3829 -0.0419 -0.3634 -2.6566 -0.0452 -0.0033 -0.1038 -2.2608 -0.4935 -0.1372 -0.6190 -0.6779 -0.8894 -0.0865 -0.0111 -0.8310 -0.7042 -2.2517 -0.1121
S-1536	DESIGN: In this nationwide retrospective cohort study from Denmark, all users of bisphosphonates and raloxifene between 1996 and 2006 (n = 102 342) were included in the 'exposed' group and three age- and gender-matched subjects (n = 307.026) from the general population comprised the control group.<unk>
T-1536	retrospective_cohort_study denmark bisphosphonates raloxifene
H-1536	-1.3964587450027466	▁Denmark ▁bis phos phon ates ▁ra lo xi fen e
D-1536	-1.3964587450027466	Denmark bisphosphonates raloxifene
P-1536	-6.4216 -3.3344 -0.0302 -0.3449 -0.7491 -1.6353 -0.1090 -0.1199 -1.0127 -0.2946 -2.6432 -0.0625
S-429	METHODS AND RESULTS: Global longitudinal strain of left ventricle was added to standard echocardiographic measurements in 334 consecutive patients (224 men; mean, 65±12 years) who underwent baseline echocardiography before CRT and underwent follow-up echocardiograms at 1 year.<unk>
T-429	longitudinal strain left_ventricle echocardiographic patients baseline echocardiography crt follow-up echocardiograms
H-429	-0.7634930610656738	▁longitud in al ▁strain _ de _ ▁left _ vent ric le ▁e cho car dio graphic ▁measure ments ▁patients ▁base line ▁e cho card i ography ▁c RT ▁e cho card i ogram s
D-429	-0.7634930610656738	longitudinal strain_de_ left_ventricle echocardiographic measurements patients baseline echocardiography cRT echocardiograms
P-429	-3.5107 -0.0754 -0.1016 -1.4275 -1.4181 -2.2609 -0.1457 -0.7302 -0.5105 -0.2349 -4.0401 -0.3289 -0.0781 -0.0953 -0.0529 -0.6421 -0.6076 -2.6199 -0.0334 -3.5583 -0.9255 -0.0107 -0.4011 -0.2669 -0.1714 -1.0074 -0.2253 -0.4535 -0.1946 -0.6160 -0.0835 -0.1126 -0.7404 -0.0239 -0.3006 -0.1836 -0.0603
S-365	At this time, he had severe hypertension, moderate LV dilatation, LV dysfunction, mild MR, and significant MS. As the mitral valve demonstrated restricted closure and opening without any clear organic lesion, being consistent with systolic and diastolic tethering, a functional etiology of MR and MS was considered.<unk>
T-365	hypertension lv_dilatation lv_dysfunction mitral_valve organic lesion systolic diastolic_tethering etiology
H-365	-0.6584357023239136	▁hyper tension ▁LV _ di la tation ▁LV ▁dys function ▁MR ▁MS
D-365	-0.6584357023239136	hypertension LV_dilatation LV dysfunction MR MS
P-365	-0.6960 -0.0005 -0.0180 -1.6037 -1.2836 -0.0452 -0.0044 -0.2378 -0.5440 -0.2757 -0.7004 -2.1705 -1.5577 -0.0808
S-250	METHODS AND RESULTS: HDL was isolated from 16 healthy controls (HDL(healthy)) and 16 patients with CHF-NYHA-III (HDL(NYHA-IIIb)) before and after ET, as well as from 8 patients with CHF-NYHA-II (HDL(NYHA-II)).<unk>
T-250	hdl healthy hdl healthy patients chf-nyha-iii hdl nyha-iiib patients chf-nyha-ii hdl nyha-ii
H-250	-1.2631932497024536	▁HD L _ health y ▁CHF - NY HA - III HD L ▁NY HA - II ▁CHF - NY HA - II
D-250	-1.2631932497024536	HDL_healthy CHF-NYHA-IIIHDL NYHA-II CHF-NYHA-II
P-250	-1.6649 -1.3229 -5.9092 -0.2088 -0.0110 -2.7859 -0.1023 -0.5592 -0.1333 -0.1797 -0.0807 -1.7022 -0.9889 -6.1437 -0.1217 -0.1631 -2.1899 -3.1714 -0.1514 -0.9486 -0.1914 -0.1122 -0.6830 -1.9928 -0.0616
S-1267	This study aimed at evaluating the changes in platelet-activating factor (PAF) and its metabolic enzymes over a 6-week follow-up period in patients with newly diagnosed heart failure ([HF] n = 12) compared with age-, sex-, and BMI-matched apparently healthy volunteers (n = 10).<unk>
T-1267	platelet-activating_factor paf metabolic enzymes follow-up patients diagnosed heart_failure hf healthy
H-1267	-1.1274993419647217	▁plate let - activa ting ▁factor PA f ▁metabol ic ▁enzym es
D-1267	-1.1274993419647217	platelet-activating factorPAf metabolic enzymes
P-1267	-0.9096 -0.9457 -0.3207 -0.0443 -3.9017 -1.5877 -1.9616 -0.3095 -0.0293 -0.1196 -0.9356 -0.0189 -4.6439 -0.0567
S-1281	We reviewed our institutional experience between 2008 and 2012 with acute care surgery (ACS) consultations and procedures within 1 year of OHT in recipients bridged to transplantation with medical therapy (MT, n = 169), including intravenous inotropes, and ventricular assist devices (VADs, n = 74).<unk>
T-1281	acute_care_surgery acs consultations oht transplantation medical_therapy intravenous inotropes ventricular_assist_devices vads
H-1281	-0.6228698492050171	▁a cute _ care _ ▁surgery ▁oc s ▁o HT ▁transplant ation ▁medical ▁ therapy ▁intra ven ous ▁in o trop es ▁vent ri cular _ assist ▁devices VAD s
D-1281	-0.6228698492050171	acute_care_ surgery ocs oHT transplantation medical therapy intravenous inotropes ventricular_assist devicesVADs
P-1281	-0.0167 -0.0258 -0.7130 -3.9339 -1.4535 -0.9135 -3.3792 -1.0551 -0.3688 -0.3122 -1.2414 -0.0132 -0.5534 -0.4406 -0.0084 -0.1918 -0.0106 -1.9482 -0.0193 -0.2183 -0.0074 -0.0614 -0.0015 -0.0226 -0.0451 -0.9237 -0.1642 -0.3298 -0.5309 -0.6262 -0.3174 -0.0851
S-1489	The renin-angiotensin-aldosterone system (RAAS) has been shown to be an effective target in the treatment of HFrEF using angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone blockade, although the evidence in HFpEF is less clear.<unk>
T-1489	renin-angiotensin-aldosterone_system raas hfref angiotensin-converting_enzyme_inhibitors angiotensin_receptor_blockers aldosterone_blockade evidence hfpef
H-1489	-0.6707773208618164	▁re nin - angi oten sin - al do ster one _ system ra as ▁h f f ▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁ang io ten sin _ con ver ting _ ▁enzym e _ ▁inhibi tors ▁al do ster one _ block ade ▁ HF p EF
D-1489	-0.6707773208618164	renin-angiotensin-aldosterone_systemraas hff angiotensin-converting enzyme inhibitors angiotensin_converting_ enzyme_ inhibitors aldosterone_blockade HFpEF
P-1489	-0.0547 -0.2554 -0.0439 -0.1043 -0.0075 -2.0646 -0.3291 -0.0681 -1.4539 -0.0633 -1.5457 -2.9774 -0.5971 -1.0820 -0.8810 -0.9586 -1.6171 -0.4980 -0.2990 -0.8987 -0.2979 -0.7267 -0.9636 -0.0015 -0.0350 -1.3742 -0.2793 -0.0487 -0.8617 -0.9980 -0.0550 -0.8145 -0.2748 -0.4086 -0.9155 -0.6528 -0.1016 -1.7295 -0.4414 -1.9144 -0.0864 -0.6887 -0.2432 -1.9946 -0.4917 -0.2815 -0.0366 -0.7656 -1.0331 -0.6170 -2.3186 -0.4060 -0.0263 -0.0147 -0.4097 -0.0695 -0.0568
S-1178	CONCLUSIONS: In patients with HFpEF, short-term treatment with ivabradine increased exercise capacity, with a contribution from improved left ventricular filling pressure response to exercise as reflected by the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity.<unk>
T-1178	patients hfpef ivabradine exercise_capacity left_ventricular_filling_pressure exercise peak_early_diastolic_mitral_flow_velocity peak_early_diastolic_mitral_annular_velocity
H-1178	-1.3949283361434937	▁ HF p f ▁i va bra dine ▁vent ri cular _ ▁fill ing _ pu issa nce ▁vent ri cular _ pu issa nce _ respons ive ▁exercise
D-1178	-1.3949283361434937	HFpf ivabradine ventricular_ filling_puissance ventricular_puissance_responsive exercise
P-1178	-0.8801 -0.1771 -1.5146 -0.8825 -0.3852 -0.0386 -0.9754 -0.0051 -2.4602 -0.2563 -0.2435 -3.3375 -1.7448 -0.0568 -0.4184 -3.6370 -0.0625 -0.0298 -4.9597 -0.5898 -0.3381 -1.5763 -4.5134 -0.0253 -0.0105 -4.0101 -1.2882 -0.8487 -3.9090 -3.9711 -0.0971
S-583	At admission, the LVET was shorter in patients with unfavorable outcome (median, 228 milliseconds [25th-75th percentiles, 212-278 milliseconds] vs 257 milliseconds [237-277 milliseconds], P = .032), whereas other tonometric indices were similar.<unk>
T-583	admission lvet patients outcome tonometric
H-583	-1.41721773147583	▁ad mission ▁l VET ▁un favor able ▁outcome
D-583	-1.41721773147583	admission lVET unfavorable outcome
P-583	-3.5068 -0.0200 -1.5055 -2.4550 -3.3018 -0.0036 -0.0255 -1.3305 -1.8576 -0.1658
S-182	After correction for age, heart rate, blood pressure, renal function, and spironolactone use, this association remained significant for RAS blockers (HR 0.54, 95% CI 0.31 to 0.93, p = 0.027) but not for β-blockers (HR 0.65, 95% CI 0.39 to 1.09, p = 0.101).<unk>
T-182	heart_rate blood_pressure renal_function spironolactone ras_blockers β-blockers
H-182	-1.2508798837661743	▁heart ▁rate _ ▁blood _ tension ▁renal e ▁spi rono lac tone ▁ RAS _ block ers
D-182	-1.2508798837661743	heart rate_ blood_tension renale spironolactone RAS_blockers
P-182	-3.4889 -1.8383 -3.8803 -1.8222 -1.0818 -0.8407 -0.3206 -3.2994 -0.5148 -0.0094 -0.1048 -0.0636 -1.5909 -0.0979 -2.7136 -0.3506 -0.0511 -1.6061 -0.0915
S-1553	The results suggest that partial improvement of cardiac performance by β-adrenoceptor blockade at advanced stages of heart failure may be due to partial reversal of changes in SR Ca(2+)-pump function whereas partial to complete reverse cardiac remodeling may be due to partial reduction in the elevated levels of plasma catecholamines.<unk>
T-1553	cardiac β-adrenoceptor_blockade heart_failure reverse cardiac_remodeling elevated plasma_catecholamines
H-1553	-0.7148626446723938	▁cardiac _ ▁performance ▁β - ad re no cept or _ block ade ▁heart _ ▁failure ▁SR _ ca (2 +) - pump ▁rever se ▁cardiac ▁remodel ing ▁plasma ▁cate chol amine s
D-1553	-0.7148626446723938	cardiac_ performance β-adrenoceptor_blockade heart_ failure SR_ca(2+)-pump reverse cardiac remodeling plasma catecholamines
P-1553	-2.2520 -2.6818 -1.0330 -0.1724 -0.0246 -0.0174 -0.0258 -0.2063 -1.0458 -0.3596 -1.2079 -0.8442 -1.1191 -0.7035 -0.4947 -1.9921 -0.4322 -2.7643 -0.0875 -1.6547 -0.0176 -0.0959 -0.0269 -3.0029 -0.0042 -1.1646 -0.3245 -0.0846 -0.1508 -0.5803 -0.0018 -0.0859 -0.0458 -0.2261 -0.0892
S-874	Concomitant treatment with SS31 ameliorated the congestive heart failure phenotypes and mitochondrial damage induced by TAC, in parallel with global attenuation of mitochondrial proteome changes, with an average of 84% protection of mitochondrial and 69% of nonmitochondrial protein changes.<unk>
T-874	ss31 congestive_heart_failure phenotypes mitochondrial tac mitochondrial_proteome mitochondrial nonmitochondrial_protein
H-874	-0.926391065120697	▁con ges tive _ ▁heart _ ▁failure ▁mito cho ndri al _ ▁damage ▁ TAC ▁mito cho ndri al _ ▁prote ome
D-874	-0.926391065120697	congestive_ heart_ failure mitochondrial_ damage TAC mitochondrial_ proteome
P-874	-1.9922 -0.2400 -0.0385 -0.6992 -2.0767 -0.6161 -1.8949 -0.6594 -0.9658 -0.2332 -0.0239 -1.8750 -1.7155 -0.7535 -0.0040 -0.6993 -0.5644 -0.1426 -0.0272 -0.9762 -2.0728 -0.7659 -3.1375 -0.0598
S-837	Using data from HF-ACTION, a randomized controlled trial of exercise training in patients with HF and low left ventricular ejection fractions, HRQoL was measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ) at baseline, 3 and 12 months, and annually up to 4 years.<unk>
T-837	hf-action randomized exercise training patients hf left_ventricular_ejection_fractions hrqol kansas_city_cardiomyopathy_questionnaire kccq baseline
H-837	-0.8303939700126648	▁ HF - AC tion ▁ HF ▁ HF ▁vent ri cular _ ▁e je ction _ fraction s ▁HR Qo L ▁Kansas ▁City ▁Card i om yo pathy ▁k cc q
D-837	-0.8303939700126648	HF-ACtion HF HF ventricular_ ejection_fractions HRQoL Kansas City Cardiomyopathy kccq
P-837	-0.4003 -0.0505 -0.2059 -1.0402 -0.5303 -1.4319 -0.3232 -2.2426 -0.2781 -3.3377 -0.1105 -0.3166 -1.4095 -1.5685 -1.0439 -0.0547 -2.6859 -0.0052 -0.0271 -0.4873 -0.0697 -0.8622 -0.0044 -1.9930 -0.6279 -0.2171 -0.0288 -3.5257 -0.4123 -1.8853 -0.3696 -0.4902 -0.1226 -0.0747
S-1196	Currently, tolvaptan is indicated for the treatment of severe hyponatremia in most countries, including the United States, but in Japan the indication is broader; it can be used in congestive heart failure patients in addition to standard or optimal diuretic therapy, regardless of their serum sodium levels or systolic function.<unk>
T-1196	tolvaptan hyponatremia united_states japan congestive_heart_failure patients diuretic therapy serum_sodium systolic_function
H-1196	-1.006731390953064	▁to lv ap tan ▁hypo na trem ia ▁Japan ▁con ges tive _ ▁heart _ ▁failure ▁di ure tic _ therapy ▁se rum _ so dium _ ▁levels ▁sy sto lic _ ▁function
D-1196	-1.006731390953064	tolvaptan hyponatremia Japan congestive_ heart_ failure diuretic_therapy serum_sodium_ levels systolic_ function
P-1196	-1.4201 -2.9496 -0.1038 -0.0326 -4.3941 -0.1394 -0.2924 -1.4275 -2.0503 -0.7099 -0.2902 -0.0481 -0.6400 -1.3909 -0.8271 -0.3259 -2.0614 -0.3263 -2.8881 -1.9437 -0.3822 -0.4794 -0.0627 -0.3354 -0.2131 -0.0051 -2.1979 -2.0287 -0.1270 -0.0713 -1.2994 -1.5408 -1.9199 -0.2367 -0.0747
S-1552	Depressed myofibrillar Ca(2+)-stimulated ATPase activity, as well as mRNA levels for SR Ca(2+)-pump, phospholamban and α-myosin heavy chain, were unaffected whereas increased mRNA level for β-myosin heavy chain was partially reversed by metoprolol.<unk>
T-1552	myofibrillar atpase activity mrna phospholamban α-myosin_heavy_chain mrna β-myosin_heavy_chain metoprolol
H-1552	-0.9719644784927368	▁de press ed ▁my o fi bril lar ▁ca (2 +) - stimul ated ▁ATP ase ▁activity ▁m RNA ▁m RNA ▁m RNA ▁ phos pho lam ban ▁α - my os in _ ▁heavy ▁chain ▁m RNA ▁m RNA
D-1552	-0.9719644784927368	depressed myofibrillar ca(2+)-stimulated ATPase activity mRNA mRNA mRNA phospholamban α-myosin_ heavy chain mRNA mRNA
P-1552	-4.5696 -0.0893 -0.6729 -1.4235 -0.1081 -1.0328 -0.1011 -0.3453 -2.1818 -1.8868 -0.0305 -0.2314 -0.0966 -0.6387 -0.2884 -2.7096 -2.5463 -0.1184 -0.0077 -2.3489 -0.0290 -4.3772 -0.1161 -3.4524 -0.1767 -0.4265 -0.5211 -0.0165 -0.2488 -0.0123 -0.2795 -0.2108 -0.8529 -0.5256 -0.2776 -0.3950 -0.3166 -0.0573 -1.9031 -0.2129 -4.8972 -0.0897
S-420	In anesthetized dogs with coronary microembolization-induced HF, CXL-1020 reduced left ventricular end-diastolic pressure and myocardial oxygen consumption while increasing ejection fraction from 27% to 40% and maximal ventricular power index by 42% (both P<0.05).<unk>
T-420	anesthetized coronary_microembolization-induced_hf cxl-1020 left_ventricular_end-diastolic_pressure myocardial_oxygen_consumption ejection_fraction maximal_ventricular_power_index
H-420	-0.6574219465255737	▁in est het ized ▁dog s ▁corona ry _ micro e mbol ization - indu ced ▁ HF ▁vent ri cular _ ▁end - dia sto lic _ tension ▁my o card ial _ ▁oxygen ▁e je ction ▁vent ri cular _ power
D-420	-0.6574219465255737	inesthetized dogs coronary_microembolization-induced HF ventricular_ end-diastolic_tension myocardial_ oxygen ejection ventricular_power
P-420	-1.4214 -0.0220 -2.5337 -0.6478 -0.2336 -0.1010 -0.0539 -0.1642 -0.6395 -1.5703 -0.2219 -0.0003 -0.4144 -0.9386 -0.0002 -0.2034 -0.0565 -0.0050 -2.8561 -0.1107 -0.1348 -1.3964 -1.8956 -0.1294 -1.9879 -0.4922 -1.7523 -1.4078 -1.9272 -0.2765 -0.0645 -0.0975 -0.0521 -0.2658 -0.9256 -0.7649 -0.1006 -0.0038 -1.0972 -0.0365 -0.2478 -0.1802 -1.1072 -0.9347 -0.1111
S-1061	RESULTS: In the study cohort, differences were found between the baseline and heart failure T1-mapping values before the administration of contrast agent (960 ± 96 and 726 ± 94 ms, respectively; p = 0.02) and after contrast agent administration (546 ± 180 and 300 ± 171 ms, respectively; p = 0.005).<unk>
T-1061	baseline heart_failure t1-mapping administration administration
H-1061	-1.2787691354751587	▁base line ▁heart _ pu issa nce ▁figure ▁administration _ de _ ▁contrast ▁agent ▁ms
D-1061	-1.2787691354751587	baseline heart_puissance figure administration_de_ contrast agent ms
P-1061	-2.1490 -1.4018 -0.8204 -1.1828 -5.0429 -0.1863 -0.0338 -2.8928 -0.8739 -1.5396 -1.6824 -0.5271 -1.0345 -0.6098 -0.7122 -0.9894 -0.0606
S-805	For the total sample, a standard error of measurement value of approximately 1.6 seconds, an absolute value of MDC at the 95% confidence level (MDC95%) of approximately 4.5 seconds, and a relative value of MDC at the 95% confidence level (MDC95%%) of approximately 35% were found between the first 2 trials, with similar values found for the subgroups.<unk>
T-805	standard_error_of_measurement mdc mdc
H-805	-1.3476759195327759	▁m DC ▁m DC ▁m d d ▁figure
D-805	-1.3476759195327759	mDC mDC mdd figure
P-805	-0.4017 -1.1460 -1.0764 -1.4107 -1.8216 -0.5615 -2.2844 -3.2903 -1.3368 -0.1473
S-1794	Main etiologies of HF in LA are idiopathic dilated cardiomyopathy (from 1.3% to 37%), C'D (from 1.3% to 21%), ischemic (from 68% to 17%), SH (from 14% to 76%), valvular (from 3% to 22%), and alcohol related (from 1.1% to 8%).<unk>
T-1794	etiologies hf idiopathic_dilated_cardiomyopathy ischemic valvular
H-1794	-0.4869077205657959	▁ HF ▁ idio pathi c ▁dil ated _ ▁cardio my o pathy ▁c ' d ▁ ische mic ▁SH ▁val vu lar ▁alcohol
D-1794	-0.4869077205657959	HF idiopathic dilated_ cardiomyopathy c'd ischemic SH valvular alcohol
P-1794	-0.5044 -0.4404 -1.0241 -2.4103 -0.0142 -0.0979 -0.3455 -0.4344 -0.5125 -0.4599 -2.0979 -0.6866 -0.0100 -0.1709 -1.4252 -0.1347 -0.1814 -0.2440 -0.0386 -0.3402 -0.0215 -0.0250 -0.1278 -0.0611 -0.7763 -0.0749
S-697	We evaluated ST2 levels and their association with functional capacity and long-term clinical outcomes in a cohort of ambulatory patients with HF enrolled in the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study-a multicenter, randomized study of exercise training in HF.<unk>
T-697	st2 functional_capacity clinical outcomes ambulatory patients hf heart_failure outcomes exercise training hf-action randomized exercise training hf
H-697	-0.911726713180542	▁ST 2 ▁functional ▁capacity ▁ambula tory ▁patients ▁ HF ▁Heart _ ▁Fail ure ▁figure ▁Exerci se _ ▁Training ▁ HF - AC TION ▁ HF
D-697	-0.911726713180542	ST2 functional capacity ambulatory patients HF Heart_ Failure figure Exercise_ Training HF-ACTION HF
P-697	-0.6814 -0.8629 -2.5401 -4.0341 -1.0301 -0.3288 -0.3869 -0.3665 -0.0081 -0.4835 -0.3042 -0.1805 -0.0176 -2.4123 -1.9813 -0.0254 -0.2344 -0.1950 -0.8974 -0.0252 -1.4804 -0.9365 -0.8073 -2.1560 -1.3511 -0.8062 -0.0834
S-856	OBJECTIVES: The goal of this study was to evaluate the effects of carvedilol and metoprolol on the endpoint of inappropriate implantable cardioverter-defibrillator therapy in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy) study.<unk>
T-856	carvedilol metoprolol endpoint implantable_cardioverter-defibrillator therapy madit-crt multicenter_automatic_defibrillator_implantation_with_cardiac_resynchronization_therapy
H-856	-0.588435173034668	▁implant able _ car vedi lol ▁implant able _ ▁cardio ver ter - de _ fi br illa tor ▁ therapy ▁MAD it - c RT ▁multi center _ automat ic _ de ib rilla tor ▁implant ation ▁Card iac _ re syn chron ization ▁Therapy
D-856	-0.588435173034668	implantable_carvedilol implantable_ cardioverter-de_fibrillator therapy MADit-cRT multicenter_automatic_deibrillator implantation Cardiac_resynchronization Therapy
P-856	-0.2439 -0.0142 -1.5481 -1.1330 -0.0554 -0.1008 -1.7962 -0.0314 -0.2971 -1.3939 -0.1459 -0.0443 -0.7288 -0.0143 -1.7984 -3.2309 -0.8368 -0.0088 -0.1634 -1.5676 -0.0217 -0.0157 -1.5798 -0.0928 -0.6692 -0.3177 -2.2409 -0.0311 -0.2084 -0.4819 -0.1323 -0.0983 -0.8666 -1.7522 -0.5067 -0.0571 -0.2084 -0.0226 -0.6689 -0.1039 -0.1821 -0.8111 -0.0044 -0.0001 -0.5329 -1.2523 -0.1846 -0.0481
S-666	The adjusted median rate ratio was 1.11 (95% confidence interval, 1.08-1.18) for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy, 1.08 (95% confidence interval, 1.05-1.15) for β-blockers therapy, and 1.17 (1.13-1.26) for optimal combined treatment.<unk>
T-666	rate_ratio confidence_interval angiotensin-converting_enzyme_inhibitors angiotensin_receptor_blockers therapy confidence_interval β-blockers therapy
H-666	-0.8598524332046509	▁ang io ten sin - con ver ting ▁enzym e _ ▁inhibi tors angi oten sin _ ▁receptor _ block ers ▁β - block ers ▁ therapy
D-666	-0.8598524332046509	angiotensin-converting enzyme_ inhibitorsangiotensin_ receptor_blockers β-blockers therapy
P-666	-2.8031 -1.5362 -0.2911 -1.1061 -1.2505 -0.0020 -0.0578 -1.5386 -0.4172 -0.0658 -2.1860 -0.1060 -1.3552 -2.3106 -0.0142 -0.3478 -1.1762 -0.3915 -1.6572 -0.6586 -0.0178 -2.3978 -0.0090 -0.0816 -0.0125 -2.7848 -0.0337 -0.2284 -0.0985
S-1704	AA participants were significantly younger, less likely to have an ischemic HF pathogenesis, more likely to be NYHA functional class IV, and more likely to have a higher estimated glomerular filtration rate and heart rate, less hypertension, diabetes mellitus, or history of myocardial infarction compared with non-AA participants.<unk>
T-1704	aa ischemic_hf pathogenesis nyha_functional_class_iv estimated_glomerular_filtration_rate heart_rate hypertension diabetes_mellitus myocardial_infarction
H-1704	-0.6895846128463745	▁ ische mic ▁ HF _ path ogen es is ▁NY HA _ ▁functional _ ▁class _ ▁IV ▁glo mer ular ▁filtr ation _ ▁rate ▁heart ▁hyper tension ▁diabetes ▁mell itus ▁my o card ial ▁in far ction
D-1704	-0.6895846128463745	ischemic HF_pathogenesis NYHA_ functional_ class_ IV glomerular filtration_ rate heart hypertension diabetes mellitus myocardial infarction
P-1704	-1.0266 -0.4065 -0.0891 -0.3342 -0.0954 -4.7303 -2.4469 -0.2619 -0.0226 -0.1880 -0.0087 -0.0376 -2.4198 -0.3349 -2.6378 -0.2479 -1.0344 -0.4403 -0.0291 -0.0071 -0.0247 -0.7274 -0.0125 -1.3572 -0.8736 -0.8247 -1.7810 -0.0001 -0.0913 -1.8374 -0.0176 -1.0705 -0.3262 -0.1283 -0.0775 -0.7663 -0.1995 -0.0256 -0.5652 -0.0779
S-752	To assess the effect of CRT in less severe systolic dysfunction, outcomes in the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study were evaluated in which patients with left ventricular (LV) ejection fraction (LVEF) >30% were included.<unk>
T-752	crt systolic_dysfunction outcomes resynchronization_reverses_remodeling_in_systolic_left_ventricular_dysfunction reverse patients left_ventricular ejection_fraction lvef
H-752	-0.9847410917282104	▁c RT ▁re syn chron ization _ re VE rse s ▁re syn chron ization _ re ve rse s ▁Sy sto lic _ ▁left _ ▁v _ en tri cular _ ▁dys function
D-752	-0.9847410917282104	cRT resynchronization_reVErses resynchronization_reverses Systolic_ left_ v_entricular_ dysfunction
P-752	-0.4864 -0.2737 -4.7537 -0.0160 -0.0001 -0.4171 -1.0027 -0.7224 -1.6521 -0.0108 -0.0187 -1.2537 -3.5292 -0.0012 -1.3148 -0.6369 -0.2146 -2.8701 -0.0326 -0.0169 -0.5912 -0.0669 -2.1328 -1.0448 -0.3999 -0.7310 -1.1376 -2.3558 -1.2616 -0.1020 -0.5495 -0.8780 -0.2136 -0.3416 -4.2219 -0.1988
S-1408	Although classic signaling paradigms suggest that simultaneous activation of β1ARs and S1PR1s in a myocyte would simply result in opposing action on cAMP production, in this report we have uncovered a direct interaction between these 2 receptors, with regulatory involvement of G-protein-coupled receptor kinase-2.<unk>
T-1408	β1ars s1pr1s myocyte camp report receptors g-protein-coupled_receptor kinase-2
H-1408	-0.9035614728927612	▁action ▁β 1 AR s ▁s 1 PR 1 s ▁my o cy te ▁c AMP ▁receptor s ▁g - prote in - co up led _ ▁receptor _ ▁kina se
D-1408	-0.9035614728927612	action β1ARs s1PR1s myocyte cAMP receptors g-protein-coupled_ receptor_ kinase
P-1408	-4.4175 -1.9188 -0.3138 -0.2268 -0.3931 -3.8114 -0.2058 -0.1963 -0.9604 -0.1591 -1.5636 -0.0584 -0.1871 -0.0704 -0.1223 -0.0651 -4.4615 -0.5036 -3.2124 -0.0760 -0.4429 -0.3230 -0.2951 -0.0162 -0.0054 -0.6310 -1.3573 -0.2562 -1.3722 -0.6986 -0.0127 -1.3679 -0.1155
S-1270	At follow-up, PAF-CPT and PAF levels marginally increased (P = .1), lyso-PAF-AT (P < .001) remained downregulated, while PAF-AH (P = .004) and Lp-PLA2 (P < .001) remained elevated compared with the controls.<unk>
T-1270	follow-up paf-cpt paf lyso-paf-at downregulated paf-ah lp-pla2 elevated
H-1270	-0.7724276185035706	▁PA f - c PT ▁PA f ▁figure ▁lys o - PA f - AT ▁PA f - AH ▁l p - PLA 2
D-1270	-0.7724276185035706	PAf-cPT PAf figure lyso-PAf-AT PAf-AH lp-PLA2
P-1270	-0.5571 -0.2580 -0.8646 -0.4861 -1.0158 -1.8456 -0.2655 -5.1459 -0.0984 -0.0246 -0.0307 -0.4169 -0.1833 -0.8850 -0.2405 -3.5857 -0.2450 -1.0332 -0.9214 -0.7464 -0.0020 -0.0885 -0.0093 -0.5756 -0.4444 -0.1137
S-488	E/e'lateral showed good diagnostic performance only in patients with s'lateral of >4.5 cm/s (n = 77, 59%; AUC = 0.82; 95% CI 0.71 to 0.92; s'lateral of ≤4.5 cm/s: AUC = 0.54; 95% CI 0.38 to 0.70; p = 0.005).<unk>
T-488	diagnostic patients auc auc
H-488	-1.9283071756362915	▁angle ▁a UC
D-488	-1.9283071756362915	angle aUC
P-488	-4.4963 -3.3616 -0.2277 -1.2308 -0.3251
S-1239	Rate-control patients had fewer cardiac procedures (146 vs. 238, P < 0.001), driven by fewer cardioversions, and lower costs related to antiarrhythmic drugs (CAD $48 per patient [95% confidence interval {CI}, $21-$96] vs. $1319 per patient [95% CI, $1124-$1522]).<unk>
T-1239	rate-control patients cardiac driven cardioversions costs antiarrhythmic_drugs cad patient confidence_interval patient
H-1239	-0.9121811985969543	▁Rate - control ▁patients ▁cardio version s ▁coût ▁anti ar rhythm ic ▁drugs
D-1239	-0.9121811985969543	Rate-control patients cardioversions coût antiarrhythmic drugs
P-1239	-2.0905 -0.1161 -0.0024 -2.1207 -3.3763 -0.0171 -0.0503 -1.1478 -0.5298 -0.9074 -0.3229 -0.3294 -1.4398 -1.1572 -0.0748
S-443	Among 2,538 eligible patients with a median follow-up of 2.5 years, 521 patients (22%) initiated spironolactone, which was not associated with risk of hospitalization (adjusted hazard ratio 0.91, 95% confidence interval 0.77 to 1.08) or death (adjusted hazard ratio 0.93, confidence interval 0.60 to 1.44).<unk>
T-443	patients follow-up patients spironolactone hospitalization hazard_ratio confidence_interval death hazard_ratio confidence_interval
H-443	-1.5852898359298706	▁implant ation ▁spi rono lac tone
D-443	-1.5852898359298706	implantation spironolactone
P-443	-5.1646 -1.6338 -0.9860 -0.0449 -0.6571 -0.8176 -3.2770 -0.1013
S-906	We constructed a descriptive assessment of these patients (n = 15) and performed a case-control analysis matching for age, gender, bundle branch morphology, diabetes mellitus, cardiomyopathy origin, and β-blocker and angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use.<unk>
T-906	patients bundle_branch_morphology diabetes_mellitus cardiomyopathy β-blocker angiotensin-converting_enzyme_inhibitor angiotensin_ii_receptor_blocker
H-906	-0.5403777956962585	▁diabetes _ ▁mell itus ▁cardio my o pathy ▁β - block er ▁ang io ten sin - con ver ting ▁enzym e _ ▁inhibi tor ▁ang io ten sin _ ▁II ▁receptor _ block er
D-906	-0.5403777956962585	diabetes_ mellitus cardiomyopathy β-blocker angiotensin-converting enzyme_ inhibitor angiotensin_ II receptor_blocker
P-906	-3.5275 -1.2526 -1.0472 -0.0451 -0.0086 -0.5117 -0.3669 -0.0212 -2.4595 -0.0091 -0.0351 -0.0458 -0.0237 -0.1949 -0.3683 -0.4762 -0.6729 -0.0044 -0.0330 -1.1881 -0.2028 -0.0421 -1.3484 -0.0534 -0.0201 -0.0440 -0.2607 -0.1968 -0.2024 -0.7506 -1.0529 -0.3840 -1.2322 -1.1617 -0.0317 -0.6696 -0.0487
S-1737	Another study, the Eplerenone Post myocardial infarction Heart failure Efficacy and SUrvival Study (EPHESUS), done in post-myocardial infarction patients with heart failure, demonstrated a significant reduction in mortality and hospitalizations for patients randomized to the aldosterone antagonist eplerenone.<unk>
T-1737	eplerenone_post_myocardial_infarction_heart_failure_efficacy_and_survival_study ephesus post-myocardial_infarction patients heart_failure mortality hospitalizations patients randomized aldosterone_antagonist eplerenone
H-1737	-0.8849509954452515	▁e pler en _ Post _ my o card ial _ ▁in far ction _ ▁Heart _ ▁failure ▁SU rvi val ▁Study ▁e he SUS ▁post - my o card ial _ ▁in far ction ▁heart _ ▁failure ▁mortal ity ▁al do ster one ▁anta gon ist ▁e pler en
D-1737	-0.8849509954452515	epleren_Post_myocardial_ infarction_ Heart_ failure SUrvival Study eheSUS post-myocardial_ infarction heart_ failure mortality aldosterone antagonist epleren
P-1737	-0.4373 -0.0449 -0.5456 -5.2942 -1.4265 -0.3506 -2.5118 -0.3895 -0.4081 -0.2126 -0.5015 -0.3964 -2.4333 -0.0563 -1.4411 -0.4059 -0.4561 -1.0479 -2.4777 -0.0259 -0.1868 -1.5562 -0.6842 -5.5042 -0.4263 -0.7747 -0.0208 -1.4070 -0.2319 -0.9002 -0.1853 -0.5739 -0.2258 -2.3016 -0.0298 -1.3032 -0.7656 -0.3830 -0.3385 -0.2081 -0.3125 -0.1129 -0.0440 -0.9839 -0.6986 -0.0423 -0.7083 -0.1187 -0.1096 -0.1018 -3.7220 -0.1926
S-1879	Preliminary report of using cardiopulmonary exercise testing guide exercise rehabilitation in patients with chronic heart failure OBJECTIVE: The exercise rehabilitation in patient with chronic heart failure (CHF) is standard clinical practice, but it is rare using CardioPulmonary Exercise Testing (CPET) guide to prescribe exercise rehabilitation in China.<unk>
T-1879	report cardiopulmonary_exercise_testing exercise_rehabilitation patients chronic_heart_failure exercise_rehabilitation patient chronic_heart_failure chf clinical cardiopulmonary_exercise_testing cpet exercise_rehabilitation china
H-1879	-0.9934877753257751	▁cardio pul mon ary _ ▁exercise _ ▁rehabilita tion ▁patients _ chron _ ▁heart _ ▁failure CH f ▁Card io P ul mon ary _ ▁Exerci se _ ▁Test ing ▁c PET ▁exercise _ ▁rehabilita tion
D-1879	-0.9934877753257751	cardiopulmonary_ exercise_ rehabilitation patients_chron_ heart_ failureCHf CardioPulmonary_ Exercise_ Testing cPET exercise_ rehabilitation
P-1879	-0.0958 -0.0363 -2.8194 -0.5152 -2.2220 -1.9941 -0.6033 -2.6800 -0.0080 -1.1345 -0.8924 -2.9848 -1.7322 -1.3426 -0.6363 -1.6190 -3.6851 -0.2652 -0.9773 -0.1166 -1.0974 -0.2031 -3.3080 -0.1466 -0.5555 -0.1475 -0.0381 -0.7120 -0.5065 -0.0386 -0.7288 -0.1444 -1.0261 -0.2141 -0.5120 -0.0091 -1.8628 -0.1421
S-1749	Each period was associated with a 42% risk reduction versus the previous one (HR, 0.58; 95% confidence interval, 0.50-0.67; P<0.001), reflecting marked decreases in heart failure-related mortality and sudden death (period 4 versus 1: HR, 0.10; P<001 and HR, 0.13; P<0.0001, respectively).<unk>
T-1749	confidence_interval heart mortality death
H-1749	-1.1698888540267944	▁risk _ re duction ▁heart _ related _ ▁mortal ity ▁sud den ▁death
D-1749	-1.1698888540267944	risk_reduction heart_related_ mortality sudden death
P-1749	-2.6049 -2.1911 -0.7275 -0.0025 -2.2009 -0.3031 -4.5888 -0.2954 -1.1597 -0.1359 -0.5462 -0.0103 -2.3127 -0.3989 -0.0703
S-924	The DASH/SRD reduced clinic and 24-hour brachial systolic pressure (155 ± 35 to 138 ± 30 and 130 ± 16 to 123 ± 18 mm Hg; both P=0.02), and central end-systolic pressure trended lower (116 ± 18 to 111 ± 16 mm Hg; P=0.12).<unk>
T-924	dash clinic brachial_systolic_pressure central_end-systolic_pressure
H-924	-1.2246724367141724	▁DAS h _ s RD ▁24- ho ur ▁bra chi al _ syn sto lic ▁pressure ▁central _ en - sy sto lic _ tension ▁h g
D-924	-1.2246724367141724	DASh_sRD 24-hour brachial_synstolic pressure central_en-systolic_tension hg
P-924	-0.0280 -0.4142 -3.2322 -0.8115 -0.0673 -4.2406 -0.0247 -0.0379 -1.6745 -0.0601 -0.1790 -0.3260 -1.5002 -2.5041 -3.0116 -1.1851 -1.5318 -0.1750 -4.7873 -0.3924 -0.9709 -0.5815 -2.4005 -1.7323 -1.9444 -0.9884 -0.0323 -0.5832 -0.0985
S-113	All-cause mortality at 4 years after hospitalization for HF was assessed by LVEF (categorized as preserved [≥50%], mildly [40% to 49%], moderately [30% to 39%], and severely [<30%] reduced) among 1,620 patients enrolled in the Heart Failure Survey in ISrael.<unk>
T-113	all-cause_mortality hospitalization hf lvef patients heart_failure_survey israel
H-113	-0.9368511438369751	▁all - ca use _ ▁mortal ity ▁ HF ▁LV EF
D-113	-0.9368511438369751	all-cause_ mortality HF LVEF
P-113	-5.8726 -0.1207 -0.0153 -0.0163 -0.4633 -0.3381 -0.0909 -0.5036 -0.1194 -0.3841 -0.1309 -4.0525 -0.0713
S-558	RESULTS: The youngest patients with HF were more likely to be obese (youngest vs. oldest: body mass index ≥35 kg/m(2): 23% vs. 6%), of black ethnicity (18% vs. 2%), and have idiopathic-dilated cardiomyopathy (62% vs. 9%) (all p < 0.0001).<unk>
T-558	patients hf obese body_mass_index idiopathic-dilated_cardiomyopathy
H-558	-0.7853670120239258	▁ HF ▁obes e ▁body _ ▁index ▁black ▁et hni city ▁ idio pathi c - dila ted _ ▁cardio my o pathy
D-558	-0.7853670120239258	HF obese body_ index black ethnicity idiopathic-dilated_ cardiomyopathy
P-558	-1.1208 -0.1110 -4.3510 -0.0345 -1.6030 -0.9743 -0.6955 -2.5086 -1.6571 -0.0804 -1.0849 -0.1381 -0.0117 -0.0137 -0.3070 -0.3955 -0.0090 -1.1629 -0.7026 -0.1259 -1.8631 -0.3479 -0.0170 -0.2728 -0.0459
S-1743	METHODS AND RESULTS: From 1977 to 2011, 603 consecutive patients (age, 53±12 years; 73% men; left ventricular ejection fraction, 32±10%) fulfilling World Health Organization criteria for idiopathic dilated cardiomyopathy, including negative coronary angiography, were followed up for 8.8±6.3 years.<unk>
T-1743	patients left_ventricular_ejection_fraction world_health_organization idiopathic_dilated_cardiomyopathy coronary_angiography followed_up
H-1743	-0.6215372681617737	▁vent ri cular _ ▁e je ction _ fraction ▁World _ ▁Health ▁Organization ▁ idio pathi c _ ▁dil ated _ ▁cardio my o pathy ▁negative ▁corona ry ▁ang i ography
D-1743	-0.6215372681617737	ventricular_ ejection_fraction World_ Health Organization idiopathic_ dilated_ cardiomyopathy negative coronary angiography
P-1743	-2.5661 -0.1581 -0.2118 -1.3825 -2.1131 -0.3313 -0.0300 -1.3324 -0.0012 -0.3138 -1.0417 -1.1360 -1.8741 -0.4689 -0.0057 -0.0167 -0.1070 -0.2343 -0.9423 -0.2827 -0.4920 -0.0935 -1.5994 -0.3729 -0.0388 -0.0261 -0.6521 -0.3612 -1.3122 -0.4714 -0.2069 -0.2699 -0.0647
S-27	The European Society of Cardiology guidelines based definition of HFPEF requires a presence of signs and symptoms of heart failure, preserved LV ejection fraction of a non-dilated left ventricle, and evidence of diastolic dysfunction (impaired LV relaxation or increased LV diastolic stiffness) with elevated LV filling pressures.<unk>
T-27	european_society_of_cardiology hfpef symptoms heart_failure preserved_lv_ejection_fraction non-dilated_left_ventricle evidence diastolic_dysfunction lv_relaxation lv_diastolic_stiffness elevated lv_filling_pressures
H-27	-0.9884900450706482	▁European ▁Society _ of _ ▁Card i ology ▁h f f f ▁h f f f ▁heart _ ▁failure ▁LV ▁e je ction _ fraction ▁non - dila ted ▁left ▁vent ric le ▁dia sto lic _ ▁dys function ▁in impa i red ▁LV _ ▁relax ation ▁LV ▁dia sto _ ▁sti ff ness ▁LV ▁fill ing _ tension s
D-27	-0.9884900450706482	European Society_of_ Cardiology hfff hfff heart_ failure LV ejection_fraction non-dilated left ventricle diastolic_ dysfunction inimpaired LV_ relaxation LV diasto_ stiffness LV filling_tensions
P-27	-4.7311 -1.3550 -0.0857 -1.5358 -0.2828 -0.9676 -0.3985 -0.9209 -0.6376 -0.8847 -0.1487 -0.3426 -5.6384 -0.0809 -0.1574 -1.0709 -2.1858 -0.6767 -1.4633 -0.8130 -2.2616 -0.1483 -0.0056 -3.9981 -0.0669 -5.2211 -0.0062 -0.0066 -0.1255 -0.4106 -0.3848 -1.5337 -0.1229 -0.3215 -0.2979 -2.8718 -0.4155 -1.2004 -0.0389 -3.2865 -1.3084 -0.0569 -0.3219 -0.0070 -0.9776 -0.4163 -0.0081 -0.0423 -1.9627 -0.3107 -4.1379 -0.2925 -0.2511 -0.4874 -0.6281 -0.4663 -0.0239 -1.2847 -0.8755 -0.0351 -0.1979 -0.0924
S-1803	The following variables were significantly associated with an estimated glomerular filtration rate of (eGFR) <60 ml/min./1.73 m(2): age, type 2 diabetes, total cholesterol, LDL-cholesterol, and the CLCNKA GG genotype (p=0.03; OR=1.65, 95% CI=1.04-2.62).<unk>
T-1803	estimated_glomerular_filtration_rate egfr type_2_diabetes cholesterol ldl-cholesterol clcnka genotype
H-1803	-0.7013781070709229	▁glo mer ular ▁filtr ation _ ▁rate ▁e G FR ▁diabetes ▁cholesterol ▁CL CN KA ▁ GG ▁geno type
D-1803	-0.7013781070709229	glomerular filtration_ rate eGFR diabetes cholesterol CLCNKA GG genotype
P-1803	-0.5592 -0.0508 -0.0426 -1.7404 -0.0186 -2.4738 -1.1104 -0.0622 -1.4568 -0.3520 -1.2140 -1.2385 -0.8546 -0.5652 -0.3272 -0.9935 -0.1796 -1.3183 -0.0206 -0.0969 -0.0537
S-474	Echocardiography at 8 wk demonstrated a similar 37% increase in LV end-diastolic dimension (P < 0.001), a twofold increase in LV end-diastolic pressure/wall stress (P < 0.05), and a twofold increase in lung weight (P < 0.05) in treated and untreated ACF groups versus the sham group.<unk>
T-474	echocardiography lv_end-diastolic_dimension lv_end-diastolic_pressure wall_stress lung acf
H-474	-1.2550448179244995	▁e cho card i ography ▁LV ▁end - _ dia sto lic _ dimension ▁LV ▁end - _ dia sto lique _ tension _ wall _ ▁stress ▁lung _ weight ▁A CF
D-474	-1.2550448179244995	echocardiography LV end-_diastolic_dimension LV end-_diastolique_tension_wall_ stress lung_weight ACF
P-474	-0.2427 -0.2915 -0.2070 -0.6447 -0.2818 -1.6567 -1.2641 -0.0672 -4.1559 -0.6599 -1.4489 -4.0171 -1.8312 -0.0708 -0.7799 -1.3022 -0.0553 -3.2899 -1.0751 -1.3224 -4.7191 -0.7433 -1.2763 -1.2785 -1.5756 -0.4012 -1.6703 -0.0775 -1.6033 -1.3938 -2.1376 -0.0798 -0.9379 -0.1129
S-570	METHODS: Between 2008 and 2009, 54 patients (aged 62.4 ± 11.4 years) with heart failure (mean ejection fraction = 26.9% ± 5.0%) were randomly assigned to standard cardiac rehabilitation care (n = 27) or Nordic walking (n = 27); both groups performed 200 to 400 minutes of exercise per week for 12 weeks.<unk>
T-570	patients heart_failure ejection_fraction cardiac_rehabilitation walking exercise
H-570	-0.930230438709259	▁heart _ ▁failure ▁e je ction _ fraction ▁standard _ ▁cardiac _ ▁rehabilita tion _ care ▁Nordic _ ▁walking
D-570	-0.930230438709259	heart_ failure ejection_fraction standard_ cardiac_ rehabilitation_care Nordic_ walking
P-570	-2.3711 -0.7529 -2.9307 -2.4559 -0.4634 -0.0091 -1.3822 -0.0011 -1.2804 -0.7171 -0.0702 -1.6498 -0.3188 -0.0264 -0.5842 -2.3116 -0.0600 -0.9133 -0.8769 -0.3090 -0.0508
S-1836	The DRS-stratified hazard ratios were 0.74 (CI, 0.64 to 0.85) for sitagliptin versus pioglitazone, 0.86 (CI, 0.77 to 0.95) for sitagliptin versus sulfonylureas, and 0.71 (CI, 0.64 to 0.78) for sitagliptin versus insulin.<unk>
T-1836	hazard_ratios sitagliptin pioglitazone sitagliptin sulfonylureas sitagliptin insulin
H-1836	-0.551314651966095	▁d RS - stra t ified ▁hazard ▁ratio s ▁si tag lip tin ▁pi og lita zone ▁si tag lip tin ▁sul fon yl ure as ▁insulin
D-1836	-0.551314651966095	dRS-stratified hazard ratios sitagliptin pioglitazone sitagliptin sulfonylureas insulin
P-1836	-0.5800 -0.4106 -0.4230 -0.0178 -0.0126 -0.0522 -0.5564 -2.1770 -0.0290 -0.4823 -0.0016 -1.2107 -2.6929 -0.1013 -0.9455 -0.0902 -0.1464 -0.1915 -0.0024 -0.5172 -2.1967 -0.9185 -0.0042 -0.2122 -0.0482 -0.1116 -1.6068 -0.1736 -0.0758
S-1501	Overall, skeletal muscle mass T-score (derived from comparison with young normal reference mean) was -1.47±0.21; 4/16 Fontan subjects had sarcopenic range muscle wasting (T-score <-2.0) and 9/16 had less marked, but clinically significant wasting (T-score <-1.0 but ≥-2.0).<unk>
T-1501	skeletal_muscle t-score fontan sarcopenic_range_muscle_wasting t-score clinically t-score
H-1501	-0.9978643655776978	▁skelet al _ ▁muscle _ ▁mass ▁t - s core ▁figure
D-1501	-0.9978643655776978	skeletal_ muscle_ mass t-score figure
P-1501	-0.0564 -0.0462 -0.7466 -1.9245 -1.0234 -2.2185 -0.9779 -0.0561 -0.0467 -0.1089 -1.8692 -3.8526 -0.0453
S-181	Both RAS- and β-blocker uptitrations were associated with significant reductions in the composite end-point of all-cause mortality or HF readmissions in HFrEF (hazard ratio [HR] 0.36, 95% confidence interval [CI] 0.22 to 0.60 and HR 0.51, 95% CI 0.32 to 0.81, respectively).<unk>
T-181	β-blocker uptitrations composite_end-point all-cause_mortality hf readmissions hfref hazard_ratio confidence_interval
H-181	-0.8009558916091919	▁ RAS - ▁β - block er _ up ti tra tions ▁end - point _ de _ ▁all - ca use _ ▁mortal ity ▁h f f ▁h f ▁figure
D-181	-0.8009558916091919	RAS- β-blocker_uptitrations end-point_de_ all-cause_ mortality hff hf figure
P-181	-0.3082 -0.0090 -0.7924 -1.4330 -0.0095 -0.0748 -0.0336 -3.6686 -1.0310 -0.0284 -0.0333 -0.0178 -5.1073 -0.0330 -0.0277 -0.7234 -0.8912 -0.1359 -1.3442 -0.0143 -0.0007 -0.0119 -0.2847 -0.0480 -0.0841 -0.4985 -0.6365 -1.2849 -1.4847 -0.3833 -4.3506 -1.5045 -0.1424
S-1323	The exercise with testosterone group showed improvements from baseline in peak oxygen uptake (P < .01), Beck Depression Inventory (P < .05), leg strength (P < .05), and several Medical Outcomes Study Short-Form quality of life domains (P < .05), which were generally not apparent in the exercise with placebo group.<unk>
T-1323	exercise testosterone baseline peak_oxygen_uptake beck_depression_inventory leg medical_outcomes_study_short-form quality_of_life exercise placebo
H-1323	-0.8107483983039856	▁testosteron e ▁oxygen _ up take ▁Beck _ de pression ▁in ven tory ▁leg _ ▁strength ▁Medical
D-1323	-0.8107483983039856	testosterone oxygen_uptake Beck_depression inventory leg_ strength Medical
P-1323	-0.7269 -0.0082 -3.0680 -3.0931 -0.3540 -0.0368 -0.0090 -1.0313 -0.0455 -0.0315 -0.5342 -0.1775 -0.0191 -0.0079 -0.7114 -0.7521 -0.7585 -3.9736 -0.0656
S-1927	METHODS AND RESULTS: Of patients enrolled in Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION), 2279 (97.8%) completed surveys to assess social support and barriers to exercise, resulting in the perceived social support score (PSSS) and barriers to exercise score (BTES).<unk>
T-1927	patients heart_failure outcomes exercise training hf-action exercise perceived_social_support_score psss barriers_to_exercise_score btes
H-1927	-1.2249208688735962	▁implant ation ▁Heart _ ▁Fail ure ▁ HF - ac tion ▁social _ ▁support ▁barrier s _ ▁to _ ▁exercise
D-1927	-1.2249208688735962	implantation Heart_ Failure HF-action social_ support barriers_ to_ exercise
P-1927	-3.3718 -1.3447 -1.6039 -0.4379 -0.3137 -0.0209 -3.0385 -1.4236 -0.2638 -1.1146 -0.5176 -0.1119 -1.2517 -1.2998 -4.5614 -0.0048 -0.4980 -0.3001 -0.8317 -1.1584 -3.3994 -0.0801
S-703	In univariable analysis, ST2 was significantly associated with death or hospitalization (hazard ratio, 1.48; P<0.0001), cardiovascular death or HF hospitalization (hazard ratio, 2.14; P<0.0001), and all-cause mortality (hazard ratio, 2.33; P<0.0001; all hazard ratios for log2 ng/mL).<unk>
T-703	univariable_analysis st2 death hospitalization hazard_ratio cardiovascular_death hf hospitalization hazard_ratio all-cause_mortality hazard_ratio hazard_ratios
H-703	-1.2404570579528809	▁ST 2 ▁cardiovascular _ ▁death ▁ HF ▁hospital isation haz ard _ ▁ratio ▁all - ca use _ ▁mortal ity
D-703	-1.2404570579528809	ST2 cardiovascular_ death HF hospitalisationhazard_ ratio all-cause_ mortality
P-703	-2.2775 -2.2617 -2.6830 -2.7759 -0.6074 -0.6951 -0.0085 -2.7034 -2.0382 -2.0199 -0.0127 -1.8542 -0.3501 -4.2991 -0.0247 -0.0017 -0.0161 -0.2602 -0.0574 -0.3427 -1.8347 -0.1657
S-1495	DESIGN AND PATIENTS: Sixteen New York Heart Association Class I/II Fontan adults (30±2 years) underwent cardiopulmonary exercise testing and lean mass quantification with dual x-ray absorptiometry (DXA); eight had calf muscle (31)P magnetic resonance spectroscopy as did eight healthy age-matched and sex-matched controls.<unk>
T-1495	patients new_york_heart_association_class_i fontan cardiopulmonary_exercise_testing lean_mass_quantification dual_x-ray_absorptiometry dxa calf muscle magnetic_resonance_spectroscopy healthy
H-1495	-0.8398274779319763	▁New ▁York _ ▁Heart _ ▁Association ▁cardio pul mon ary _ ▁exercise ▁lean _ ▁mass _ ▁quant ification ▁dual ▁x - ray _ ▁ab sor pti ometr y ▁cal f _ ▁muscle ▁magnetic _ ▁res on ance _ ▁spec tros copy
D-1495	-0.8398274779319763	New York_ Heart_ Association cardiopulmonary_ exercise lean_ mass_ quantification dual x-ray_ absorptiometry calf_ muscle magnetic_ resonance_ spectroscopy
P-1495	-3.3610 -0.4769 -1.8327 -1.2818 -1.0333 -1.5919 -0.9455 -0.0985 -3.5882 -0.9086 -0.9886 -1.2394 -0.1389 -0.4290 -1.7464 -2.7603 -0.6756 -0.0083 -0.4565 -1.0150 -0.0655 -0.4377 -0.5032 -0.5214 -0.1020 -0.1721 -0.1496 -0.1275 -1.5157 -0.0025 -1.4630 -0.2328 -0.2182 -0.7058 -1.8470 -0.0985 -0.0367 -0.6445 -1.1011 -0.0465 -0.5151 -0.9625 -0.0671
S-73	OBJECTIVE: To test the 2 independent hypotheses that, compared with placebo, addition of low-dose dopamine (2 μg/kg/min) or low-dose nesiritide (0.005 μg/kg/min without bolus) to diuretic therapy will enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction.<unk>
T-73	placebo dopamine nesiritide bolus diuretic therapy renal_function patients acute_heart_failure renal_dysfunction
H-73	-0.9357631206512451	▁place bo ▁dop amine ▁low - dos e ▁nesi riti de ▁di ure tic ▁ therapy ▁renal
D-73	-0.9357631206512451	placebo dopamine low-dose nesiritide diuretic therapy renal
P-73	-3.5749 -0.0758 -0.7741 -0.0498 -3.3796 -0.0046 -0.1369 -0.0578 -1.3370 -0.0228 -0.0424 -0.4180 -0.2056 -2.5614 -0.8128 -0.0412 -0.2014 -4.0249 -0.0585
S-847	METHODS: We conducted a randomized trial involving 115 centers to evaluate the effect of CRT in patients with New York Heart Association class III or IV heart failure, a left ventricular ejection fraction of 35% or less, a QRS duration of less than 130 msec, and echocardiographic evidence of left ventricular dyssynchrony.<unk>
T-847	randomized crt patients new_york_heart_association_class_iii heart_failure left_ventricular_ejection_fraction qrs_duration echocardiographic evidence left_ventricular_dyssynchrony
H-847	-0.8929411172866821	▁c RT ▁vent ri cular _ ▁e je ction ▁QR s ▁e cho car dio graphic _ de _ ▁left _ vent ri cular _ syn chron y
D-847	-0.8929411172866821	cRT ventricular_ ejection QRs echocardiographic_de_ left_ventricular_synchrony
P-847	-1.6261 -0.8498 -5.2502 -0.1728 -0.2582 -1.7171 -2.2416 -0.9561 -0.0336 -0.0076 -0.7741 -0.3846 -0.1026 -0.0439 -0.2443 -0.6776 -1.4493 -3.5458 -0.1336 -1.2359 -0.3581 -0.5289 -1.5767 -0.6161 -0.0780 -0.6148 -0.0004 -0.8432 -0.3917 -0.0756
S-482	Therefore, 130 consecutive patients with a left ventricular (LV) ejection fraction of <35% and stable HF underwent right-sided cardiac catheterization and transthoracic echocardiography with measurement of transmitral flow velocities (E, A) and mitral annulus velocities during systole (s') and diastole (e').<unk>
T-482	patients left_ventricular ejection_fraction stable_hf right-sided_cardiac_catheterization transthoracic_echocardiography transmitral_flow mitral_annulus_velocities systole diastole
H-482	-0.9187110066413879	▁left ▁vent ri cular ▁vent ri cular ▁ HF ▁ HF ▁trans t hora cic ▁e cho card i ography ▁transmit ral _ ▁flow _ ▁veloci ties ▁mit ral ▁ann ulus ▁veloci ties ▁dia stol e
D-482	-0.9187110066413879	left ventricular ventricular HF HF transthoracic echocardiography transmitral_ flow_ velocities mitral annulus velocities diastole
P-482	-1.5153 -0.3360 -0.1990 -0.1581 -4.6324 -0.2900 -0.2839 -1.5488 -3.2634 -2.2559 -1.9116 -3.0665 -0.0844 -0.0660 -0.0826 -0.6714 -0.3765 -0.1586 -0.2323 -0.3166 -0.1454 -0.0567 -0.9225 -0.7152 -2.4875 -3.1581 -0.8278 -0.0994 -0.0065 -0.8919 -0.1209 -2.5754 -1.0337 -0.0425 -0.0002 -0.0717 -0.2533 -0.0529
S-1367	For patients with acute coronary syndromes, data have been derived from a great number of studies, whereas in patients with stable CAD, only a limited amount of recent data is available; although limited, these data show that elevations in BNP and NT-proBNP levels are associated with the extent of CAD, thus providing prognostic information for an unfavourable clinical outcome.<unk>
T-1367	patients acute_coronary_syndromes patients stable cad bnp nt-probnp cad prognostic clinical outcome
H-1367	-0.7861243486404419	▁a cute _ ▁corona ry ▁syndrome s
D-1367	-0.7861243486404419	acute_ coronary syndromes
P-1367	-0.3398 -0.0030 -0.4386 -0.9182 -0.2772 -0.9916 -0.0292 -3.9931 -0.0842
S-1269	At baseline, patients with HF had lower median activities of lyso-PAF-AT (P < .001) and PAF-CPT (P = .07) in parallel with PAF levels (P = .05) and higher activities of PAF-AH (P = .02) and Lp-PLA2 (P < .001) than controls.<unk>
T-1269	baseline patients hf lyso-paf-at paf-cpt paf paf-ah lp-pla2
H-1269	-0.6595621705055237	▁ HF ▁lys o - PA f - AT ▁PA f - c PT ▁PA f - AH ▁l p - PLA 2
D-1269	-0.6595621705055237	HF lyso-PAf-AT PAf-cPT PAf-AH lp-PLA2
P-1269	-0.7731 -0.0187 -3.2548 -0.0262 -0.0501 -0.4104 -0.2664 -0.5069 -0.1050 -0.1179 -0.3428 -0.2349 -0.6920 -1.0449 -0.2271 -0.2597 -1.8389 -3.3843 -1.6502 -0.0019 -0.1484 -0.0079 -0.3584 -0.6524 -0.1159
S-549	After medical therapy had failed, 4 patients underwent redo sternotomy for aortic valve procedures (1 bioprosthetic valve replacement, 1 Dacron patch closure, and 2 aortic valve repairs), and 2 patients underwent transcatheter aortic valve procedure, with 1 requiring revision by open surgery for aortic valve replacement.<unk>
T-549	medical_therapy patients redo_sternotomy aortic_valve bioprosthetic_valve_replacement dacron_patch_closure aortic_valve patients transcatheter_aortic_valve_procedure surgery aortic_valve
H-549	-0.5811219215393066	▁medical ▁ therapy ▁ster no to my ▁a or tic _ ▁val ve ▁bio pro sthetic ▁val ve _ ▁replace ment ▁da cro n ▁patch _ closure ▁a or tic _ ▁val ve _ ▁repair s ▁trans cat heter ▁a or tic _ ▁val ve _ ▁replace ment
D-549	-0.5811219215393066	medical therapy sternotomy aortic_ valve bioprosthetic valve_ replacement dacron patch_closure aortic_ valve_ repairs transcatheter aortic_ valve_ replacement
P-549	-0.9309 -1.2376 -0.0146 -0.9277 -0.0130 -0.1724 -0.6340 -0.0482 -0.0206 -1.8088 -1.3845 -0.6949 -0.0413 -0.6515 -0.0115 -0.0046 -2.5366 -0.0547 -1.8250 -0.9270 -0.0070 -0.6871 -0.0503 -0.0102 -0.3240 -0.8043 -0.2126 -0.0178 -0.0251 -0.8067 -0.9772 -0.3741 -0.0646 -1.5000 -0.2801 -0.6007 -0.0026 -0.0406 -0.0007 -0.3265 -0.0421 -0.9981 -1.2395 -0.1614 -0.0192 -2.0843 -2.8514 -0.0113 -0.5360 -0.0615
S-263	OBJECTIVE: The main objective of this study was to determine a predictive cutoff value for plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) that could successfully predict the long-term (4-year) survival of patients with acute heart failure (HF) at the time of admission to the emergency department (ED).<unk>
T-263	plasma_n-terminal_pro-b-type_natriuretic_peptide nt-probnp patients acute_heart_failure hf admission emergency_department
H-263	-0.8867404460906982	▁plasma _ n - termin al _ pro - B - type _ ▁na tri ure tic _ pe pti de NT - pro B NP ▁survival ▁patients ▁a cute _ ▁heart _ ▁failure
D-263	-0.8867404460906982	plasma_n-terminal_pro-B-type_ natriuretic_peptideNT-proBNP survival patients acute_ heart_ failure
P-263	-3.7038 -2.9487 -1.0067 -0.0271 -0.0154 -0.0071 -1.1315 -0.2606 -0.0216 -0.4307 -0.1698 -0.0360 -0.6688 -0.3704 -0.0161 -0.1907 -3.4783 -0.9895 -0.4281 -0.0944 -0.0786 -1.5713 -0.0368 -0.0253 -0.8057 -0.0962 -1.3375 -1.8213 -1.2557 -0.0463 -0.0718 -1.7584 -0.3026 -2.9329 -3.6921 -0.0948
S-286	We evaluated whether cardiac troponin T (cTnT) measured with a high-sensitivity assay and N-terminal pro-B-type natriuretic peptide (NT-proBNP), biomarkers strongly associated with incident HF, improve HF risk prediction in the Atherosclerosis Risk in Communities (ARIC) study.<unk>
T-286	cardiac_troponin_t ctnt n-terminal_pro-b-type_natriuretic_peptide nt-probnp biomarkers hf hf atherosclerosis_risk_in_communities aric
H-286	-0.8015294075012207	▁cardiac _ ▁trop onin ▁t ▁c t n t ▁bio mark ers ▁incident ▁ HF ▁ HF ▁Ath eros cle rosi s ▁Risk _ ▁in _ ▁Communi ties ARI c
D-286	-0.8015294075012207	cardiac_ troponin t ctnt biomarkers incident HF HF Atherosclerosis Risk_ in_ CommunitiesARIc
P-286	-0.0086 -3.1113 -0.2767 -0.0250 -0.7467 -1.1247 -0.1085 -0.0144 -1.0507 -4.5512 -0.0350 -0.0812 -0.0280 -0.3812 -0.0136 -2.0801 -0.3685 -2.5825 -0.0289 -0.3161 -0.8563 -0.0350 -0.3093 -1.4373 -0.6644 -0.6319 -2.1597 -0.3698 -1.2630 -0.7031 -0.2187 -0.0675
S-1167	Increased body mass index was associated with a lower event rate (HR per kg/m(2): 0.92 [95% CI: 0.88 to 0.96]), and this protection was mediated by a higher fat mass (0.91 [95% CI: 0.87 to 0.96]) but not a fat-free mass index (0.97 [95% CI: 0.92 to 1.03]).<unk>
T-1167	body_mass_index fat_mass fat-free_mass
H-1167	-2.127068281173706	▁figure
D-1167	-2.127068281173706	figure
P-1167	-2.0594 -4.1950 -0.1268
S-797	PARTICIPANTS: Subjects (N=235, 64% men; median age, 70y [interquartile range, 61-77y]; median body mass index, 25.6kg/m(2) [interquartile range, 22.8-29.4kg/m(2)]) with advanced COPD (n=95), CHF (n=68), or CRF (n=72).<unk>
T-797	interquartile_range body_mass_index interquartile_range copd chf crf
H-797	-2.197808027267456	▁figure
D-797	-2.197808027267456	figure
P-797	-2.5185 -3.9632 -0.1118
S-911	In the case-control analysis, controls demonstrated superior reverse remodeling (+9.2 ± 9.5% increase in ejection fraction), decreased mortality (73% vs 44%, p = 0.038), and all-cause hospitalizations (76% vs 100%, p = 0.047), with no difference in HF hospitalizations (p = 0.39), compared with dialysis patients.<unk>
T-911	reverse_remodeling ejection_fraction mortality all-cause_hospitalizations hf hospitalizations dialysis patients
H-911	-0.3719788193702698	▁rever se _ ▁remodel ing ▁e je ction _ fraction ▁mortal ity ▁ HF ▁di al ysis
D-911	-0.3719788193702698	reverse_ remodeling ejection_fraction mortality HF dialysis
P-911	-0.1530 -0.0084 -1.3069 -0.0498 -0.0666 -0.0105 -0.2077 -0.0186 -0.6841 -0.0013 -0.0872 -0.1696 -1.1292 -0.0826 -1.6212 -0.0344 -0.0511 -1.3255 -0.0599
S-1530	After adjustment for covariates, EH was associated with reduced LV contractility compared with CH: lower LVEF (β coefficient = -3.2; 95% confidence interval [CI] -5.4 to -1.1%) and ratio of systolic blood pressure to end-systolic volume (β coefficient = -1.0; 95% CI -1.5 to -0.5 mm Hg/ml).<unk>
T-1530	covariates lv_contractility lvef β_coefficient confidence_interval systolic_blood_pressure end-systolic_volume β_coefficient
H-1530	-1.4508358240127563	▁EH ▁LV f ▁figure ▁ratio _ de _ syn sto lic _ ▁blood _ tension ▁end - sy sto lic _ ▁volume ▁h g ▁ml
D-1530	-1.4508358240127563	EH LVf figure ratio_de_synstolic_ blood_tension end-systolic_ volume hg ml
P-1530	-0.6432 -2.9027 -2.5003 -5.1485 -4.4271 -1.2158 -1.3782 -0.1954 -2.9395 -1.5423 -2.4904 -0.1947 -0.9606 -0.5215 -1.9714 -0.6707 -0.0487 -0.9110 -1.8416 -1.7477 -1.2474 -0.4095 -0.6957 -0.0201 -1.9177 -0.5263 -0.1048
S-348	Echocardiography demonstrated moderately dilated LV with an end-diastolic volume index of 84 mL/m2, reduced LV ejection fraction of 0.40, mild MR, and limited mitral valve opening, resulting in a significant MS with an MVA of 1.2 cm2 and a mean pressure gradient of 8.4 mm Hg (Fig 1B).<unk>
T-348	echocardiography dilated_lv end-diastolic_volume_index lv_ejection_fraction mitral_valve_opening mva
H-348	-1.1178131103515625	▁e cho card i ography ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml ▁ml va ▁mean _ tension _ ▁gradi ent ▁h g
D-348	-1.1178131103515625	echocardiography ml ml ml ml ml ml ml ml ml ml ml ml ml ml ml ml ml ml ml ml ml ml ml ml ml ml ml ml ml ml ml ml ml ml ml ml ml ml ml ml ml mlva mean_tension_ gradient hg
P-348	-0.6982 -0.3876 -0.6992 -0.7569 -0.2098 -5.9728 -2.6654 -0.8782 -0.6491 -0.6400 -0.6094 -0.6635 -0.6982 -0.7343 -0.7746 -0.8066 -0.8498 -0.8761 -0.8947 -0.9207 -0.9594 -0.9877 -1.0177 -1.0396 -1.0618 -1.1049 -1.1062 -1.1035 -1.1696 -1.1933 -1.1692 -1.1910 -1.2212 -1.2234 -1.2173 -1.2425 -1.2475 -1.2605 -1.2564 -1.2528 -1.2462 -1.2801 -1.2648 -1.2690 -1.2676 -1.3069 -1.3086 -2.6499 -2.8225 -0.7817 -0.4696 -1.5193 -0.2155 -0.0295 -2.3728 -0.0589 -0.4822 -0.0770
S-74	DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, placebo-controlled clinical trial (Renal Optimization Strategies Evaluation [ROSE]) of 360 hospitalized patients with acute heart failure and renal dysfunction (estimated glomerular filtration rate of 15-60 mL/min/1.73 m2), randomized within 24 hours of admission.<unk>
T-74	double-blind clinical renal_optimization_strategies_evaluation rose hospitalized patients acute_heart_failure renal_dysfunction estimated_glomerular_filtration_rate randomized admission
H-74	-0.7089294195175171	▁double - blind ▁place bo - control led ▁clinic al ▁trial ▁re nal ▁Optim ization ▁stratégie s ROS e ▁hospital ized ▁patients ▁a cute _ ▁heart _ ▁failure ▁renal ▁dys function ▁glo mer ular ▁filtr ation
D-74	-0.7089294195175171	double-blind placebo-controlled clinical trial renal Optimization stratégiesROSe hospitalized patients acute_ heart_ failure renal dysfunction glomerular filtration
P-74	-3.2267 -0.0117 -0.0257 -2.1639 -0.0040 -0.0097 -0.0021 -0.9003 -0.2913 -0.0287 -2.6489 -2.1392 -0.0236 -0.8133 -0.1132 -2.6923 -0.0619 -1.4342 -0.1007 -1.7238 -0.6693 -1.1925 -0.1421 -0.0024 -0.6250 -1.4149 -0.6237 -0.5630 -0.1089 -0.7141 -0.2199 -0.0029 -0.0203 -0.0173 -0.1268 -0.0210 -1.9824 -0.0779
S-1051	Further molecular analysis revealed that BETs play a crucial role in chromatin-mediated signal transduction to Pol II, co-activating transcription factor networks that are known to be causal in HF pathogenesis, including nuclear factor of activated T cells (NFAT), nuclear factor-κB (NF-κB) and the transcription factor GATA4.<unk>
T-1051	bets signal_transduction pol_ii transcription_factor hf pathogenesis nuclear_factor_of_activated_t_cells nfat nuclear_factor-κb nf-κb transcription_factor gata4
H-1051	-0.959157407283783	▁ BET s ▁chr omat in - media ted ▁signal ▁trans duction ▁Pol ▁II ▁co - activa tion ▁tran scription _ ▁factor ▁ HF ▁nucléaire _ factor _ de _ activa tion _ ▁T ▁cell s ▁nucléaire _ f b NF - κ b ▁tran scription _ ▁factor
D-1051	-0.959157407283783	BETs chromatin-mediated signal transduction Pol II co-activation transcription_ factor HF nucléaire_factor_de_activation_ T cells nucléaire_fbNF-κb transcription_ factor
P-1051	-0.7643 -0.0345 -1.4261 -0.3418 -0.0153 -0.3343 -0.1147 -0.0141 -0.3534 -0.3085 -0.0897 -0.0357 -0.3483 -0.3332 -0.7717 -0.0061 -0.0103 -0.5788 -0.1062 -0.0532 -1.9599 -1.3205 -1.8885 -0.3964 -1.9434 -1.6866 -2.2707 -1.2921 -2.9737 -0.1867 -0.4332 -0.8624 -0.9674 -1.0345 -1.3075 -0.0336 -2.7492 -1.8915 -3.6718 -0.4879 -2.7025 -0.7167 -3.9172 -0.8485 -0.1989 -0.0555 -1.8897 -0.7219 -1.3129 -0.1961
S-33	Outcomes evaluated for this guideline included mortality; hospitalization; exercise tolerance; quality of life; and cardiovascular events (defined as myocardial infarction, congestive heart failure exacerbation, arrhythmia, or cardiac death) and harms, including hypertension, venous thromboembolic events, and ischemic cerebrovascular events.<unk>
T-33	outcomes mortality hospitalization exercise_tolerance quality_of_life cardiovascular_events myocardial_infarction congestive_heart_failure arrhythmia cardiac_death hypertension venous_thromboembolic_events ischemic_cerebrovascular_events
H-33	-0.8202833533287048	▁mortal ity ▁hospital ization ▁exercise ▁ tolerance ▁cardiovascular ▁events ▁my o card ial ▁in far ction ▁con ges tive ▁heart _ ▁failure ▁ar rhythm ia ▁cardiac ▁death ▁hyper tension ▁ve nous _ thro mbo e mbol ic ▁cerebro vas cular ▁events
D-33	-0.8202833533287048	mortality hospitalization exercise tolerance cardiovascular events myocardial infarction congestive heart_ failure arrhythmia cardiac death hypertension venous_thromboembolic cerebrovascular events
P-33	-2.6821 -0.2260 -1.3346 -0.5900 -0.6936 -0.3664 -0.0005 -1.7818 -2.0106 -0.3959 -0.0503 -0.0772 -0.0395 -0.4396 -1.1645 -0.0354 -0.0675 -0.1099 -0.0203 -0.3062 -1.5941 -0.4604 -1.5526 -0.1250 -0.8411 -0.0447 -1.9868 -0.2790 -0.0007 -1.0530 -0.9248 -1.2798 -0.1069 -1.2661 -3.1013 -0.0024 -1.6762 -4.2446 -0.1253 -0.7249 -1.1902 -0.2398 -0.0606
S-128	We found an interaction effect (P = 0.02) between EO-CFUs and diabetes: in patients without diabetes, a 10-EO-CFU increase was independently associated with increased peak VO2 of 0.28 mL/kg/min (P = 0.01), and in patients with diabetes, a decrease in EO-CFUs was associated with an increased peak VO2 (P < 0.05).<unk>
T-128	eo-cfus diabetes patients diabetes peak_vo2 patients diabetes eo-cfus peak_vo2
H-128	-1.3996020555496216	▁ EO - c FU s ▁diabetes ▁ EO - c FU ▁figure
D-128	-1.3996020555496216	EO-cFUs diabetes EO-cFU figure
P-128	-1.1014 -0.1555 -0.0728 -0.9331 -1.6608 -1.6504 -0.1950 -3.1937 -0.2821 -0.1389 -1.4378 -1.4174 -5.3014 -3.2084 -0.2454
S-562	Compared with the referent age group of 60 to 69 years, both all-cause and cardiovascular mortality were lower in the youngest group even after multivariable adjustment (hazard ratio: 0.60, 95% confidence interval: 0.36 to 1.00; p = 0.049, and hazard ratio: 0.71, 95% confidence interval: 0.42 to 1.18, p = 0.186, respectively).<unk>
T-562	cardiovascular_mortality multivariable_adjustment hazard_ratio confidence_interval hazard_ratio confidence_interval
H-562	-0.8159805536270142	▁all - ca use ▁cardiovascular ▁mortal ity
D-562	-0.8159805536270142	all-cause cardiovascular mortality
P-562	-3.3702 -0.0768 -0.0131 -0.0194 -0.3977 -1.0186 -0.2307 -2.1407 -0.0767
S-1212	METHODS: Immunoblotting, radioenzymatic- and fluorescence resonance energy transfer-based assays, video edge detection, epifluorescence microscopy, and L-type Ca2(+) current measurements were performed in myocardial tissues and/or isolated cardiomyocytes from human and/or experimental HF, respectively.<unk>
T-1212	immunoblotting video_edge_detection epifluorescence_microscopy myocardial_tissues cardiomyocytes hf
H-1212	-0.5084699988365173	▁immun o blo tting ▁radio en zy matic - ▁fluor esc ence _ ▁res on ance _ énergie _ ▁transfer - based ▁as say s ▁video ▁edge ▁det ection ▁epi flu o resc ence _ ▁micro s copy ▁l - type _ ca 2 ▁my o card ial _ ▁tissu es ▁cardio my o cy tes ▁ HF
D-1212	-0.5084699988365173	immunoblotting radioenzymatic- fluorescence_ resonance_énergie_ transfer-based assays video edge detection epifluorescence_ microscopy l-type_ca2 myocardial_ tissues cardiomyocytes HF
P-1212	-0.3572 -0.0271 -0.0189 -0.1323 -0.0636 -0.0452 -0.0030 -0.1300 -0.2782 -2.2307 -3.0599 -0.0124 -0.7629 -2.7352 -0.0507 -0.0276 -0.4247 -1.5084 -0.9682 -1.1874 -0.2731 -0.1923 -1.2037 -0.0015 -0.0224 -0.2683 -0.7010 -1.4047 -0.0055 -0.0265 -0.0032 -0.4332 -0.1791 -0.0075 -0.4811 -0.7302 -0.0372 -0.1205 -2.2833 -0.0545 -0.0061 -0.9344 -0.0107 -0.1534 -1.8100 -0.0459 -0.0326 -0.0495 -0.8110 -1.2597 -0.9852 -0.0184 -0.2138 -0.2200 -0.0746 -0.0255 -1.2752 -0.0209 -0.0787 -0.0301
S-1980	MAIN OUTCOMES AND MEASURES: Exercise capacity measured as peak oxygen consumption (VO2, mL/kg/min; co-primary outcome) and QOL measured by the Minnesota Living with Heart Failure (MLHF) Questionnaire (score range: 0-105, higher scores indicate worse heart failure-related QOL; co-primary outcome).<unk>
T-1980	outcomes exercise_capacity peak_oxygen_consumption vo2 co-primary_outcome qol minnesota heart_failure heart qol co-primary_outcome
H-1980	-0.9556680917739868	▁Exerci se _ pu issa nce ▁pe ak _ ▁oxygen _ ▁consum p tion vo 2 ▁m l _ kg / min ▁Q OL ▁Minnesota _ ▁Living _ ▁with _ ▁Heart _ ▁Fail ure ▁m HF
D-1980	-0.9556680917739868	Exercise_puissance peak_ oxygen_ consumptionvo2 ml_kg/min QOL Minnesota_ Living_ with_ Heart_ Failure mHF
P-1980	-3.1789 -0.1878 -0.5753 -2.1855 -0.1569 -0.0048 -1.9451 -0.0096 -1.2302 -0.5079 -2.0875 -0.3027 -0.0284 -0.0211 -1.7784 -0.0189 -0.2315 -1.0801 -3.4057 -0.9995 -2.7355 -0.2403 -1.5556 -0.4510 -0.4373 -0.9023 -0.8254 -0.1028 -2.2676 -0.1276 -0.1740 -0.2496 -0.3370 -0.2857 -1.3621 -1.0033 -3.1840 -0.1382
S-1649	DESIGN: The EAST (Early treatment of Atrial fibrillation for Stroke prevention Trial) will randomize approximately 3,000 patients with recent onset AF at risk for stroke (CHA2DS2VASc score ≥2) to either guideline-mandated usual care or to usual care plus early rhythm control therapy in a prospective, randomized, open, blinded outcome assessment trial.<unk>
T-1649	east early_treatment_of_atrial_fibrillation_for_stroke_prevention_trial randomize patients stroke rhythm_control_therapy prospective randomized outcome
H-1649	-0.7827644944190979	▁e AST ▁at rial _ ▁fi bril lation _ for _ ▁Stro ke _ ▁pre vention _ tri al
D-1649	-0.7827644944190979	eAST atrial_ fibrillation_for_ Stroke_ prevention_trial
P-1649	-1.0469 -0.1604 -1.8817 -0.1092 -0.3753 -1.9015 -0.0300 -0.0033 -1.2856 -1.3645 -0.4088 -0.0285 -0.1553 -0.3710 -0.7388 -0.0167 -2.2151 -0.4667 -0.0128 -3.7734 -0.0925
S-55	Both patients with low left ventricular ejection fraction and patients with HF with preserved left ventricular ejection fraction are admitted to the hospital frequently and serially and keep physicians busy, in the acute and outpatient settings, for their management, also prompting them to search for better ways to deal with this worldwide epidemic and its impact on medical resources and financial costs.<unk>
T-55	patients left_ventricular_ejection_fraction patients hf preserved_left_ventricular_ejection_fraction hospital physicians acute outpatient epidemic medical financial_costs
H-55	-1.0578776597976685	▁patients ▁ HF ▁vent ri cular _ ▁e je ction _ fraction ▁hospital ▁a cute _ ▁out patient _ setting s
D-55	-1.0578776597976685	patients HF ventricular_ ejection_fraction hospital acute_ outpatient_settings
P-55	-1.3653 -2.1939 -0.0575 -2.8255 -0.1152 -0.6235 -0.8177 -1.9683 -1.1558 -0.0986 -1.2046 -0.0129 -0.5068 -0.6072 -0.0025 -1.3615 -1.4845 -0.0097 -3.6341 -1.1341 -0.0247 -3.0036 -0.1240
S-878	The global attenuation of TAC-induced proteomic alterations by the mitochondrial-targeted peptide SS31 suggests that perturbed mitochondrial function may be an upstream signal to many of the pathway alterations in TAC and supports the potential clinical application of mitochondrial-targeted peptide drugs for the treatment heart failure.<unk>
T-878	proteomic mitochondrial-targeted_peptide ss31 mitochondrial_function tac clinical mitochondrial-targeted_peptide drugs heart_failure
H-878	-0.7694847583770752	▁ TAC - indu ced ▁prote om ic ▁altera tions ▁mito cho ndri al - tar get ed _ pe pti de _ ▁SS 31 ▁per tur bed ▁mito cho ndri al _ fon cti onnement ▁path way _ ▁altera tions ▁ TAC ▁mito cho ndri al - tar get ed _ pe pti de _ ▁drugs ▁heart _ ▁failure
D-878	-0.7694847583770752	TAC-induced proteomic alterations mitochondrial-targeted_peptide_ SS31 perturbed mitochondrial_fonctionnement pathway_ alterations TAC mitochondrial-targeted_peptide_ drugs heart_ failure
P-878	-0.2614 -0.0106 -0.6208 -0.0323 -1.3009 -0.3611 -0.0580 -0.2077 -3.1958 -0.0179 -0.4223 -0.9242 -0.6420 -0.0826 -0.4492 -0.1852 -0.1469 -0.0561 -1.0015 -0.6593 -0.1630 -0.1404 -3.2287 -2.3062 -0.5812 -0.4198 -0.0054 -0.0269 -1.1248 -0.9988 -0.2572 -0.0333 -0.4588 -3.8674 -0.5275 -0.3353 -4.6188 -0.1058 -0.8608 -1.5684 -0.0136 -0.2589 -0.0381 -3.2436 -0.7814 -1.4091 -0.0746 -0.3217 -0.3757 -0.1662 -0.0437 -0.3103 -0.6478 -0.1191 -0.1446 -0.9991 -1.2464 -1.7254 -0.7588 -2.5151 -0.1224 -0.1282
S-494	Two hundred ninety-three HF patients with reduced (HFrEF, n = 247) or with preserved left ventricular (LV) ejection fraction (HFpEF, n = 46) underwent echo-Doppler studies and N-terminal pro-brain-type natriuretic peptide assessment and were tracked for adverse events.<unk>
T-494	hf patients hfref left_ventricular ejection_fraction hfpef echo-doppler n-terminal_pro-brain-type_natriuretic_peptide adverse_events
H-494	-0.7902494072914124	▁ HF ▁h f ▁vent ri cular LV ▁e je ction ▁ fraction ▁h p f ▁e cho - D opp ler ▁studies ▁pro - bra in - type _ ▁na tri ure tic _ pe pti de
D-494	-0.7902494072914124	HF hf ventricularLV ejection fraction hpf echo-Doppler studies pro-brain-type_ natriuretic_peptide
P-494	-1.3055 -0.0088 -1.6991 -0.9091 -2.8329 -0.2433 -0.4142 -0.9142 -0.9618 -0.8176 -0.0189 -1.0009 -0.0009 -1.0309 -0.3956 -0.6231 -0.1260 -0.1344 -0.0137 -0.2215 -0.0002 -0.0911 -2.9268 -2.0270 -0.0175 -0.5274 -0.0628 -0.1956 -0.0099 -1.4034 -0.9032 -0.0027 -0.0824 -5.5520 -2.6076 -0.2149 -0.0810 -0.2104 -0.8985 -0.1232
S-464	Cases seen in low-volume EDs had less comorbidities and were less likely to be hospitalized (54.5%) than those seen in medium (61.8%; adjusted odds ratio [aOR] 1.16, [95% confidence interval {CI} 1.10–1.23]) or high-volume EDs (73.6%; aOR, 1.95 [95% CI, 1.83–2.07]).<unk>
T-464	eds comorbidities hospitalized adjusted_odds_ratio aor confidence_interval eds aor
H-464	-0.9893145561218262	▁low - volu me ▁ED s
D-464	-0.9893145561218262	low-volume EDs
P-464	-2.5504 -0.0314 -0.0213 -0.0057 -0.6570 -0.3863 -4.1620 -0.1005
S-631	Addition of HABC Battery scores to the Health ABC HF Risk Model improved discrimination (change in C-index, 0.014; 95% CI 0.018-0.010) and appropriately reclassified 13.4% (net-reclassification-improvement 0.073, 95% CI 0.021-0.125; P = .006) of participants (8.3% who developed HF and 5.1% who did not).<unk>
T-631	habc_battery health_abc_hf_risk_model change c-index net-reclassification-improvement hf
H-631	-1.388584852218628	▁h ABC ▁h bc ▁h z ▁h z ▁h f ▁h f ▁h f ▁h f ▁h f ▁h f ▁h f ▁discrimina tion ▁c - index ▁figure net - re class ification - improv ement
D-631	-1.388584852218628	hABC hbc hz hz hf hf hf hf hf hf hf discrimination c-index figurenet-reclassification-improvement
P-631	-0.2392 -0.5468 -1.8198 -1.9765 -1.6652 -2.4972 -1.9451 -1.6399 -1.8686 -1.8475 -1.7066 -1.3714 -1.9657 -1.2069 -2.2616 -1.1811 -2.5253 -1.1268 -2.7985 -1.1156 -2.9911 -1.1269 -4.2868 -0.0341 -0.2039 -0.0537 -0.0224 -3.3867 -3.2447 -0.0317 -0.0319 -0.0226 -0.0202 -0.0677 -0.0068 -0.0072 -3.8282 -0.0944
S-715	Compared with the patients who underwent standard criteria cardiac transplant, ECCT patients were older (median, 66.6 years versus 53.2 years; P<0.001), with higher frequency of diabetes mellitus (46.4% versus 24.6%; P<0.001) and chronic kidney disease (median estimated glomerular filtration rate, 55 versus 61.6 mL/min; P=0.001).<unk>
T-715	patients cardiac_transplant ecct patients diabetes_mellitus chronic_kidney_disease estimated_glomerular_filtration_rate
H-715	-0.6610806584358215	▁cardiac ▁transplant ▁EC CT ▁diabetes ▁mell itus ▁chronic _ ▁ki dne y _ ▁disease ▁glo mer ular ▁filtr ation
D-715	-0.6610806584358215	cardiac transplant ECCT diabetes mellitus chronic_ kidney_ disease glomerular filtration
P-715	-0.5046 -0.9435 -0.2211 -0.4168 -1.2758 -0.4513 -0.0482 -0.1106 -0.7988 -1.0289 -0.0566 -0.2285 -3.1803 -2.0314 -0.0042 -0.0092 -0.0128 -0.7036 -0.0403 -1.7220 -0.0941
S-1507	Construct validity of individual scales showed excellent fit indices: CFI = .92, RMSEA = .05 for the Self-Care Maintenance Scale; CFI = .95, RMSEA = .07 for the Self-Care Management Scale; CFI = .99, RMSEA = .02 for the Self-Care Confidence scale.<unk>
T-1507	cfi rmsea self-care_maintenance cfi rmsea self-care_management cfi rmsea self-care_confidence
H-1507	-0.9173951148986816	▁c f ▁m se a ▁Self - Car e _ ▁Main ten ance _ ▁Scal e ▁c f ▁m se a ▁Self - Car e _ management _ ▁Scal e ▁m se a ▁Self - Car e _ ▁Confi den ce ▁scale
D-1507	-0.9173951148986816	cf msea Self-Care_ Maintenance_ Scale cf msea Self-Care_management_ Scale msea Self-Care_ Confidence scale
P-1507	-3.3520 -1.8819 -3.6460 -0.2934 -0.8147 -1.1956 -0.0368 -0.9797 -0.1116 -0.4008 -0.8492 -0.0999 -0.0079 -2.4433 -0.0464 -0.0144 -0.9271 -1.7228 -3.1223 -0.1177 -0.5924 -0.8146 -0.0390 -1.0418 -0.0760 -0.2415 -1.2360 -1.3315 -0.0735 -0.0057 -3.2821 -0.3203 -0.7733 -1.8146 -0.0461 -2.3674 -0.1436 -0.1112 -2.4310 -0.0111 -0.0379 -1.1994 -0.1842 -0.1276
S-1876	Patients assigned to BAT, compared with control group patients, experienced improvements in the distance walked in 6 min (59.6 ± 14 m vs. 1.5 ± 13.2 m; p = 0.004), quality-of-life score (–17.4 ± 2.8 points vs. 2.1 ± 3.1 points; p < 0.001), and NYHA functional class ranking (p = 0.002 for change in distribution).<unk>
T-1876	patients bat patients quality-of-life nyha_functional_class change
H-1876	-1.421927809715271	▁BAT ▁distance _ ▁walked ▁figure ▁quality - of - life
D-1876	-1.421927809715271	BAT distance_ walked figure quality-of-life
P-1876	-0.5587 -3.5974 -1.2623 -0.1892 -4.9084 -1.3000 -0.1143 -0.0111 -0.1690 -0.1074 -4.7100 -0.1353
S-537	Subgroup analysis of patients with preoperative hypoalbuminemia and postoperative normalization of albumin levels (n = 81) showed improved survival compared with those who remained hypoalbuminemia (n = 44) or those who had decreasing albumin levels during LVAD support (n = 40; 3-month survival: 92.6% vs 63.6% and 65.0%; p <0.01).<unk>
T-537	patients preoperative hypoalbuminemia postoperative albumin hypoalbuminemia albumin lvad
H-537	-1.1355383396148682	▁pre operativ e ▁hypo album in emia ▁post operativ e _ ▁normal ization ▁album in ▁levels
D-537	-1.1355383396148682	preoperative hypoalbuminemia postoperative_ normalization albumin levels
P-537	-1.2562 -0.2661 -0.1096 -0.2710 -0.8661 -1.5487 -0.3209 -1.2398 -0.2569 -0.2250 -1.9087 -2.1206 -0.5801 -1.6864 -0.7139 -3.4665 -3.5261 -0.0770
S-1717	A 1-day decrease in length of stay was associated with an absolute increase in 30-day rehospitalization of 1.56 percentage points (95% confidence interval (CI) = 0.30-2.82) for acute myocardial infarction (AMI) with major complications and 0.81 percentage points (95% CI = 0.03-1.60) for kidney infection or urinary tract infection (UTI) without major complications.<unk>
T-1717	rehospitalization confidence_interval acute_myocardial_infarction ami complications kidney_infection urinary_tract_infection uti complications
H-1717	-1.3443610668182373	▁implant ation ▁a cute _ mé o card ial _ ▁in far ction ▁ AMI
D-1717	-1.3443610668182373	implantation acute_méocardial_ infarction AMI
P-1717	-5.8042 -1.2217 -0.5670 -0.2018 -0.1747 -3.7568 -1.2499 -0.2156 -0.0732 -0.8422 -0.3336 -1.3051 -0.0664 -2.7963 -0.0550 -4.0398 -0.1509
S-54	Management of patients with heart failure (HF), stemming from ischemic and nonischemic cardiomyopathies, continues to be problematic, despite the inroads made in the pharmacological armamentarium, by implantable cardioverter defibrillators, cardiac resynchronization therapy, and the eventual resort to cardiac transplantation, and left and/or right ventricular assist devices.<unk>
T-54	patients heart_failure hf ischemic nonischemic_cardiomyopathies pharmacological implantable_cardioverter_defibrillators cardiac_resynchronization_therapy cardiac_transplantation right_ventricular_assist_devices
H-54	-0.6786758303642273	▁heart _ ▁failure ▁ ische mic _ non ische mic ▁cardio my o pathi es ▁implant able ▁implant able ▁cardio ver ter _ de fi br illa tors ▁cardiac ▁re syn chron ization _ therapy ▁cardiac ▁transplant ation ▁vent ri cular ▁assist ▁devices
D-54	-0.6786758303642273	heart_ failure ischemic_nonischemic cardiomyopathies implantable implantable cardioverter_defibrillators cardiac resynchronization_therapy cardiac transplantation ventricular assist devices
P-54	-4.2454 -0.6902 -1.8154 -0.5568 -2.3887 -0.0882 -1.4477 -0.5247 -0.5409 -0.1764 -0.5936 -1.3160 -0.6496 -0.0321 -0.0289 -0.6516 -0.0423 -0.7606 -0.0553 -0.7261 -0.0965 -0.0248 -0.2116 -0.0519 -2.8678 -0.6717 -0.0102 -1.3375 -0.0103 -1.1190 -0.0006 -0.0001 -0.3023 -1.9347 -0.5635 -0.0344 -1.0075 -0.0072 -0.4800 -0.0230 -0.0194 -2.1375 -0.1521 -0.1073 -0.0385
S-230	SAF versus PF mean catheterization findings were central venous pressure 18 ± 6 versus 14 ± 3 mm Hg (p <0.01), SVR index 1,680 ± 368 versus 1,960 ± 550 dyn s/cm(5)/m(2) (p = 0.02), and cardiac index 2.7 ± 0.8 versus 2.8 ± 0.7 L/min/m(2) (p = 0.25).<unk>
T-230	saf catheterization central_venous_pressure svr cardiac_index
H-230	-2.2064924240112305	▁ SAF ▁ PF ▁ PF ▁figure ▁central _ ve nous _ tension ▁h g ▁h g ▁s VR ▁figure ▁cardiac ▁index
D-230	-2.2064924240112305	SAF PF PF figure central_venous_tension hg hg sVR figure cardiac index
P-230	-1.5428 -0.8252 -2.8294 -0.2620 -4.7465 -1.0991 -3.4790 -5.9031 -0.9622 -3.1939 -4.7740 -2.1487 -2.2302 -0.2217 -0.0495 -3.7358 -0.2940 -0.8616 -0.2085 -4.4060 -4.5095 -3.5310 -0.8721 -0.2700
S-193	Women compared with men had higher admission median BNP levels with the greatest difference among reduced EF and smallest difference among preserved EF (median BNP in women vs men: EF reduced 1,259 vs 1,113 pg/mL, borderline 821 vs 732 pg/mL, and preserved 559 vs 540 pg/mL; P < .001 all comparisons).<unk>
T-193	admission bnp reduced_ef preserved_ef bnp ef
H-193	-1.1229463815689087	▁ad mission _ media n ▁b NP ▁figure ▁EF
D-193	-1.1229463815689087	admission_median bNP figure EF
P-193	-1.2704 -0.0104 -1.7210 -0.4938 -0.0277 -0.4787 -1.0306 -3.1275 -1.3798 -2.6513 -0.1613
S-435	The score was associated with heart failure admission, heart transplantation/LV assist device, or death (hazard ratio, 0.97; 95% confidence interval, 0.95-0.98; P<0.001) and all-cause death (hazard ratio, 0.97; 95% confidence interval, 0.96-0.98; P<0.001), independent of age, sex, ischemic cause, and initial functional class.<unk>
T-435	heart_failure admission heart_transplantation lv_assist_device death hazard_ratio confidence_interval death hazard_ratio confidence_interval ischemic functional_class
H-435	-1.4960767030715942	▁heart _ pu issa nce _ ad mission ▁heart ▁implant ation LV _ assist ▁device ▁death
D-435	-1.4960767030715942	heart_puissance_admission heart implantationLV_assist device death
P-435	-0.9237 -1.2838 -5.0157 -0.1101 -0.0081 -3.0801 -0.4323 -0.0066 -3.5974 -3.5423 -0.0167 -1.1914 -0.4791 -0.1193 -2.7106 -2.1222 -2.2029 -0.0871
S-475	LV ejection fraction, velocity of circumferential shortening, maximal systolic elastance, and contractile efficiency were significantly depressed in ACF and significantly improved in ACF + allopurinol rats, all of which occurred in the absence of changes in the maximum O2 consumption rate measured in isolated cardiomyocytes using the extracellular flux analyzer.<unk>
T-475	lv_ejection_fraction shortening systolic_elastance contractile_efficiency acf acf allopurinol cardiomyocytes extracellular_flux_analyzer
H-475	-0.5879153609275818	▁e je ction _ fraction ▁vitesse _ de _ ▁circum fer ential _ ▁short en ing ▁sy sto lic ▁elastan ce ▁contract ile _ ▁efficiency ▁A CF ▁allo puri nol ▁rat s ▁o 2 ▁consum p tion _ ▁rate ▁cardio my o cy tes ▁extra cel lular ▁flux
D-475	-0.5879153609275818	ejection_fraction vitesse_de_ circumferential_ shortening systolic elastance contractile_ efficiency ACF allopurinol rats o2 consumption_ rate cardiomyocytes extracellular flux
P-475	-0.8229 -0.3227 -0.0043 -0.6547 -0.0025 -2.9114 -0.6395 -1.0165 -0.1775 -0.1646 -1.1588 -0.1764 -0.5730 -0.4819 -0.0285 -0.0933 -2.1585 -0.0661 -0.4212 -0.6517 -0.1139 -0.0059 -0.1377 -0.2090 -0.9261 -0.8768 -0.0977 -3.2508 -0.0768 -0.1163 -1.7037 -0.0452 -0.9713 -0.0552 -3.2737 -0.1028 -0.0679 -0.6053 -0.3931 -0.4773 -0.8859 -0.3635 -0.2054 -0.1167 -0.0057 -0.2333 -0.0136 -0.1645 -1.3073 -0.0672
S-1526	We prospectively studied 402 patients with HFpEF, divided into 4 groups based on LV structure: normal geometry (no LV hypertrophy [LVH] and relative wall thickness [RWT] ≤0.42); CR (no LVH and RWT >0.42); CH (LVH and RWT >0.42); and EH (LVH and RWT ≤0.42).<unk>
T-1526	prospectively patients hfpef lv_hypertrophy lvh relative_wall_thickness rwt lvh rwt lvh rwt lvh rwt
H-1526	-1.210195779800415	▁ HF p EF ▁LV _ ge ometr y ▁LV _ ▁hyper trop hy ▁LV h ▁wall _ ▁thi ck ness ▁CR ▁LV h ▁R WT
D-1526	-1.210195779800415	HFpEF LV_geometry LV_ hypertrophy LVh wall_ thickness CR LVh RWT
P-1526	-0.6033 -0.1390 -0.0990 -0.2341 -1.1384 -3.6971 -4.8733 -0.3597 -0.1835 -1.0314 -2.7446 -0.2845 -0.0094 -0.0208 -2.2663 -2.0418 -2.3713 -0.3295 -1.7507 -0.1945 -1.2443 -2.7256 -0.5373 -0.9004 -1.2492 -0.0279 -2.7299 -0.0985
S-1463	LCZ696, an angiotensin receptor neprilysin inhibitor composed of a neprilysin inhibitor prodrug and the angiotensin receptor antagonist valsartan, has proven effective in hypertension, has shown promise in a pilot trial of heart failure with preserved ejection fraction, and is being tested in a large outcomes trial of heart failure with reduced ejection fraction.<unk>
T-1463	lcz696 angiotensin_receptor_neprilysin_inhibitor neprilysin_inhibitor prodrug angiotensin_receptor_antagonist valsartan hypertension heart_failure_with_preserved_ejection_fraction outcomes heart_failure_with_reduced_ejection_fraction
H-1463	-0.8604170680046082	▁ang io ten sin _ ▁receptor _ ▁nepri ly sin _ ▁inhibi tor _ pro drug ▁ang io ten sin _ ▁receptor _ ▁anta gon ist _ ▁val sar tan ▁hyper tension
D-1463	-0.8604170680046082	angiotensin_ receptor_ neprilysin_ inhibitor_prodrug angiotensin_ receptor_ antagonist_ valsartan hypertension
P-1463	-0.1461 -2.0288 -1.1372 -1.9662 -2.3594 -0.3790 -0.5419 -1.8764 -0.3779 -1.6585 -0.7647 -1.8377 -0.0320 -0.8128 -0.3847 -0.1225 -0.0166 -0.5612 -0.6428 -1.4280 -1.4562 -0.1214 -0.4909 -1.2544 -0.0385 -1.9987 -0.5701 -0.1681 -0.1749 -0.0075 -0.0055 -0.0007 -3.7518 -0.1411
S-343	His blood pressure was 120/70 mm Hg, he underwent mitral valve plasty for degenerative MR, he had P3 prolapse with 2 chordal ruptures and he underwent triangular resection, edge-to-edge anastomosis, and ring annuloplasty with a Physio Ring 30 (Edwards Lifesciences, Irvine, CA) of just size.<unk>
T-343	blood_pressure mitral_valve_plasty degenerative_mr p3_prolapse chordal_ruptures triangular_resection edge-to-edge_anastomosis ring_annuloplasty physio_ring_30 edwards_lifesciences irvine
H-343	-0.3765203356742859	▁blood ▁pressure ▁mit ral ▁val ve ▁plast y ▁de genera tive ▁MR ▁p 3 ▁chor dal ▁rup tures ▁tri ang ular ▁res ection ▁edge - to - ed ge ▁an asto mos is ▁ring _ ▁ann ulo plast y ▁Ph y sio ▁Ring
D-343	-0.3765203356742859	blood pressure mitral valve plasty degenerative MR p3 chordal ruptures triangular resection edge-to-edge anastomosis ring_ annuloplasty Physio Ring
P-343	-0.2946 -3.2240 -0.2713 -0.0041 -0.1418 -0.0402 -0.0900 -0.2398 -0.0776 -0.1100 -0.0143 -0.0398 -1.7312 -0.0230 -0.2414 -0.1268 -0.0733 -0.0920 -1.1845 -0.0036 -0.0007 -2.6883 -0.0037 -0.2626 -0.0478 -0.2048 -0.1288 -0.1951 -0.0157 -0.2944 -0.0010 -0.0557 -0.0128 -0.0134 -0.2941 -0.9425 -0.5769 -0.0173 -0.0255 -0.8097 -0.0054 -0.0152 -0.2231 -2.0312 -0.0543
S-1320	Outcomes included an incremental shuttle walk test, peak oxygen uptake, muscular strength, echocardiographic measures, N-terminal pro-brain natriuretic peptide, inflammatory markers, depression (Beck Depression Inventory), and health-related quality of life (Minnesota Living with Heart Failure Questionnaire and Medical Outcomes Study Short-Form).<unk>
T-1320	outcomes incremental_shuttle_walk_test peak_oxygen_uptake muscular echocardiographic n-terminal_pro-brain_natriuretic_peptide inflammatory beck_depression_inventory health-related_quality_of_life minnesota_living_with_heart_failure_questionnaire medical_outcomes_study_short-form
H-1320	-0.738058865070343	▁shu ttle _ walk _ test ▁oxygen _ up take ▁muscular _ ▁strength ▁e cho car dio graphic ▁measure s ▁N - termin al ▁pro - bra in _ ▁na tri ure tic _ pe pti de ▁infla mma tory ▁marker s ▁depression ▁be ck _ de pression _ in ven tory ▁health - related _ quality _ of _ ▁life ▁min nes ota ▁Heart _ ▁Fail ure ▁Medical ▁Out com es
D-1320	-0.738058865070343	shuttle_walk_test oxygen_uptake muscular_ strength echocardiographic measures N-terminal pro-brain_ natriuretic_peptide inflammatory markers depression beck_depression_inventory health-related_quality_of_ life minnesota Heart_ Failure Medical Outcomes
P-1320	-0.1898 -0.0017 -0.4046 -0.9689 -1.3991 -3.2229 -2.5521 -0.8304 -0.5081 -0.0068 -0.0146 -0.8049 -1.9315 -0.0227 -0.0160 -0.0066 -0.1258 -0.5898 -1.4486 -0.0062 -3.2601 -0.0125 -0.0050 -0.0045 -0.2796 -0.0083 -0.1474 -0.0698 -1.1552 -0.5153 -0.0020 -0.0691 -3.2765 -1.2632 -0.3992 -0.1049 -0.0544 -0.8127 -0.3672 -0.4259 -0.8248 -0.0034 -1.4951 -2.3818 -0.2399 -0.3629 -0.0525 -0.1686 -1.5931 -0.7847 -0.8191 -0.1101 -1.6669 -0.0277 -0.1256 -1.7461 -2.2534 -1.1076 -0.4857 -0.2639 -1.7258 -1.0210 -0.0252 -0.2344 -3.9576 -0.2264 -0.2782 -0.1182 -0.5241 -2.3261 -0.0286 -0.0228 -0.2575 -0.0735
S-116	Interaction term analysis showed that the risk associated with severely reduced LVEF was evident only among patients ≤75 years (HR 1.49, p = 0.003), whereas among older patients, there was no difference in the risk of long-term mortality between those with preserved versus severely reduced LVEF (HR 1.02 [p = 0.86]; p value for age-by-LVEF interaction = 0.03).<unk>
T-116	interaction_term_analysis lvef patients patients mortality lvef p_value
H-116	-1.4926164150238037	▁inter action _ ter me ▁LV EF ▁long - term _ ▁mortal ity
D-116	-1.4926164150238037	interaction_terme LVEF long-term_ mortality
P-116	-3.8996 -0.0023 -0.6135 -0.5075 -0.2854 -6.6750 -0.1992 -5.4831 -0.0629 -0.6023 -0.8998 -0.3445 -0.3067 -2.3953 -0.1121
S-763	METHODS AND RESULTS: Four groups of rats (Wistar-Kyoto, n=11; lean ZSF1, n=11; obese ZSF1, n=11, and obese ZSF1 with high-fat diet, n=11) were followed up for 20 weeks with repeat metabolic, renal, and echocardiographic evaluations and hemodynamically assessed at euthanization.<unk>
T-763	wistar-kyoto zsf1 obese zsf1 obese zsf1 followed_up metabolic renal echocardiographic hemodynamically euthanization
H-763	-0.8174825310707092	▁gre star - K yo to ▁lean ▁Z SF ▁obes e ▁Z SF 1 ▁high - fat ▁die t ▁metabol ic ▁renal ▁e cho car dio graphic ▁evaluation s ▁eu than ization
D-763	-0.8174825310707092	grestar-Kyoto lean ZSF obese ZSF1 high-fat diet metabolic renal echocardiographic evaluations euthanization
P-763	-4.9564 -0.1489 -0.0272 -2.2909 -0.0915 -0.0123 -0.0050 -0.7499 -0.0858 -1.0712 -0.0161 -0.8991 -0.2140 -4.7921 -2.7610 -0.0060 -0.2126 -1.1733 -0.0576 -0.3674 -0.0248 -0.0497 -0.0267 -0.0119 -0.0084 -0.0986 -0.6206 -4.0723 -0.5490 -1.6448 -0.0038 -0.6316 -0.0775 -0.0363
S-384	Kaplan-Meier curves and log-rank testing demonstrated excellent risk stratification, particularly between a large, low-risk group (40% of patients, 6-month event rates in the UM/VA/VA-RT cohorts 8%/12%/12%) and a small, high-risk group (10% of patients, 6-month event rates in the UM/VA/VA-RT cohorts 57%/58%/79%).<unk>
T-384	kaplan-meier_curves log-rank_testing risk_stratification patients patients
H-384	-1.1243029832839966	▁Ka plan - Me ier ▁cur ves ▁log - rank
D-384	-1.1243029832839966	Kaplan-Meier curves log-rank
P-384	-1.2223 -0.0732 -0.0216 -1.1143 -0.0492 -4.6295 -0.2501 -0.6272 -0.0177 -0.0008 -5.2837 -0.2019
S-950	Multivariate Cox regression analyses revealed that AF type (other than long-standing persistent AF) and lack of hypertension were independently associated with maintenance of sinus rhythm (hazard ratio [HR]: 1.81, 95% confidence interval [CI]: 1.03 to 3.17, p = 0.04; HR: 0.49, 95% CI: 0.24 to 0.96, p = 0.04, respectively).<unk>
T-950	multivariate_cox_regression_analyses hypertension sinus_rhythm hazard_ratio confidence_interval
H-950	-1.0858745574951172	▁multi varia te ▁co x _ ▁re gression ▁AF _ type ▁long - standing _ ▁persist ent ▁AF ▁hyper tension ▁maintenance ▁sinus ▁ rhythm haz ard ▁ratio
D-950	-1.0858745574951172	multivariate cox_ regression AF_type long-standing_ persistent AF hypertension maintenance sinus rhythmhazard ratio
P-950	-5.3853 -0.3179 -0.0638 -0.3479 -0.0086 -2.6514 -1.3186 -0.0192 -2.3166 -4.9074 -2.2835 -1.7336 -0.0327 -0.0023 -0.1999 -0.5529 -0.0919 -1.5408 -0.2896 -0.0006 -0.7979 -2.0739 -1.0118 -0.1358 -0.2730 -0.0046 -0.5641 -2.4267 -0.1382
S-1228	CONCLUSIONS: In patients with chronic HF-REF, in NYHA functional class II, and meeting specific inclusion and exclusion criteria, including an eGFR >30 ml/min/1.73 m(2) and potassium <5.0 mmol/l, eplerenone was both efficacious and safe when carefully monitored, even in subgroups at high risk of developing hyperkalemia or WRF.<unk>
T-1228	patients chronic hf-ref nyha_functional_class_ii egfr potassium eplerenone hyperkalemia
H-1228	-0.8539800047874451	▁chronic ▁ HF - re f ▁NY HA _ ▁functional ▁class _ ▁II ▁e G FR ▁po tas s ium ▁e pler en one
D-1228	-0.8539800047874451	chronic HF-ref NYHA_ functional class_ II eGFR potassium eplerenone
P-1228	-2.4196 -0.2958 -0.1271 -0.1726 -0.4315 -0.3089 -0.0388 -0.0817 -2.6334 -0.8622 -0.7885 -0.8586 -0.7311 -0.9281 -3.6683 -1.1931 -0.1935 -0.3318 -0.0902 -0.0105 -0.0325 -0.1173 -0.1448 -2.7899 -2.8511 -0.1023
S-12	METHODS: Body composition with regard to FFM, FM, and body fat distribution was assessed by dual energy X-ray absorptiometry (DXA) in 19 non-diabetic patients with chronic heart failure (CHF) and CC and 38 controls (non-cachectic CHF and individuals with prior myocardial infarction-both n = 19) who were followed for 12 months.<unk>
T-12	ffm dual_energy_x-ray_absorptiometry dxa patients chronic_heart_failure chf non-cachectic_chf myocardial
H-12	-1.0085182189941406	f f f f f f ▁double _ ener gy _ ▁X - ray _ ▁ab sor pti ometr y ▁d XA ▁non - dia be tic ▁patients ▁chronic _ ▁heart _ ▁failure ▁CC ca che ctic ▁CHF ▁my o card ial ▁in far ction - bo th
D-12	-1.0085182189941406	ffffff double_energy_ X-ray_ absorptiometry dXA non-diabetic patients chronic_ heart_ failure CCcachectic CHF myocardial infarction-both
P-12	-2.4620 -0.0844 -0.1219 -0.3892 -1.1826 -2.2009 -5.3394 -1.7937 -2.6007 -1.7980 -3.3017 -1.9939 -0.0473 -0.1857 -1.0403 -0.5553 -0.0533 -0.0649 -0.2635 -0.1105 -0.4519 -0.1830 -5.0647 -0.0050 -0.1061 -0.0315 -1.7003 -1.0376 -2.5780 -0.6735 -1.7585 -1.1244 -0.6288 -1.4885 -4.7378 -0.0298 -0.1018 -0.0026 -1.1140 -0.0740 -0.0777 -0.0996 -0.3606 -0.2508 -0.0508 -0.6616 -0.0003 -0.0017 -0.3867 -0.0552
S-1707	After adjustment for differences in baseline characteristics and achieved study drug dose, spironolactone reduced the combined end point of death or hospitalization for HF in non-AAs (hazard ratio, 0.63; 95% confidence interval, 0.55-0.73) but not in AAs (hazard ratio, 1.07; 95% confidence interval, 0.67-1.71; P value for interaction=0.032).<unk>
T-1707	baseline drug spironolactone combined_end_point death hospitalization hf hazard_ratio confidence_interval aas hazard_ratio confidence_interval p_value
H-1707	-1.007119059562683	▁drug ▁dose ▁spi rono lac tone ▁end ▁point _ de _ ▁death ▁hospital ization ▁ HF ▁AA s
D-1707	-1.007119059562683	drug dose spironolactone end point_de_ death hospitalization HF AAs
P-1707	-2.7551 -4.0679 -1.6181 -0.0219 -0.3640 -0.6210 -0.5992 -0.0580 -0.9929 -1.6655 -0.2776 -0.8509 -1.4542 -0.8480 -1.2248 -0.0043 -1.1323 -0.2695 -1.2238 -0.0935
S-823	METHODS AND RESULTS: In this prospective study, patients with invasively diagnosed pulmonary arterial hypertension or inoperable chronic thromboembolic pulmonary hypertension and impaired right ventricular pump function despite a stable targeted pulmonary arterial hypertension medication underwent a broad panel of noninvasive assessments, including stress echocardiography and cardiopulmonary exercise testing.<unk>
T-823	prospective_study patients invasively diagnosed pulmonary_arterial_hypertension inoperable chronic_thromboembolic_pulmonary_hypertension right_ventricular pump stable pulmonary_arterial_hypertension medication noninvasive stress_echocardiography cardiopulmonary_exercise_testing
H-823	-0.6805378198623657	▁pulmonar y _ ▁arterial _ ▁hyper tension ▁in opera ble ▁chronic ▁ thro mbo e mbol ic ▁pulmonar y _ ▁hyper tension ▁im pair ed ▁right ▁vent ri cular _ pu issa nce ▁implant ed ▁pulmonar y _ ▁arterial _ ▁hyper tension ▁medication ▁stress ▁e cho card i ography ▁cardio pul mon ary _ ▁exercise
D-823	-0.6805378198623657	pulmonary_ arterial_ hypertension inoperable chronic thromboembolic pulmonary_ hypertension impaired right ventricular_puissance implanted pulmonary_ arterial_ hypertension medication stress echocardiography cardiopulmonary_ exercise
P-823	-1.4869 -0.0310 -1.7455 -0.9660 -0.7288 -1.4307 -0.0006 -1.7525 -0.0446 -0.0215 -0.1046 -0.4385 -0.0187 -0.4981 -0.2852 -0.0060 -0.9658 -0.3128 -0.0752 -0.4667 -1.6113 -0.0009 -0.9048 -0.0039 -0.1282 -1.5466 -0.4059 -0.1446 -0.0416 -0.6517 -2.3195 -0.2919 -0.0729 -4.0548 -1.6861 -0.0194 -0.0178 -0.9469 -0.3374 -0.7826 -1.0503 -0.0005 -3.9445 -0.0999 -0.1143 -0.0419 -0.1400 -0.2952 -0.1893 -0.0083 -0.0464 -1.4220 -1.0390 -1.1871 -1.4767 -0.3381 -0.0488
S-1930	For cardiovascular death or HF hospitalization, there was a significant interaction between the randomization group and BTES (P=0.035), which corresponded to a borderline association between increasing BTES and cardiovascular death or HF hospitalization in the exercise group (hazard ratio 1.25, 95% confidence interval 0.99, 1.59), but no association in the usual care group (hazard ratio 0.83, 95% confidence interval 0.66, 1.06).<unk>
T-1930	cardiovascular_death hf hospitalization randomization btes btes cardiovascular_death hf hospitalization exercise hazard_ratio confidence_interval hazard_ratio confidence_interval
H-1930	-1.3016295433044434	▁cardiovascular _ ▁death ▁b tes ▁b tes ▁cardiovascular _ ▁death ▁ HF
D-1930	-1.3016295433044434	cardiovascular_ death btes btes cardiovascular_ death HF
P-1930	-1.1821 -1.8678 -2.0603 -1.0460 -0.2147 -2.0801 -0.1966 -1.3512 -1.1663 -1.5369 -0.6953 -0.0110 -4.7406 -0.0740
S-466	Of patients hospitalized at the time of their index ED visit, low-volume ED cases exhibited a higher risk of 30-day death/all-cause readmission (24.3%) than those seen in medium (21.9%; aOR, 0.83 [95% CI, 0.76–0.91]) or high-volume EDs (18.1%; aOR, 0.77 [95% CI, 0.70–0.85]).<unk>
T-466	patients hospitalized death all-cause_readmission aor eds aor
H-466	-1.484208345413208	▁index _ de _ f ré que nce _ de _ f ré que nce _ de _ la _ f ré que nce _ de _ f ré que nce _ de _ pu issa nce _ de _ ca use _ ▁read mission
D-466	-1.484208345413208	index_de_fréquence_de_fréquence_de_la_fréquence_de_fréquence_de_puissance_de_cause_ readmission
P-466	-0.0754 -0.6257 -4.4584 -0.6160 -4.6828 -2.8966 -0.1223 -0.0091 -2.3879 -2.9752 -0.4279 -4.8636 -0.2745 -0.0815 -0.0038 -2.1462 -2.2426 -0.4350 -5.0556 -1.1269 -3.0112 -0.2004 -0.0394 -0.0044 -1.8619 -1.4141 -0.4067 -4.2926 -0.0590 -0.0452 -0.0044 -2.4688 -1.6536 -0.4981 -5.8210 -0.0342 -0.0032 -2.5273 -1.8373 -0.6562 -3.4244 -0.1156 -0.1484 -1.1526 -0.0483 -2.3739 -0.1482
S-1863	Patients identified three stages where they felt implantable cardioverter-defibrillator deactivation should be discussed: (1) prior to implantation, (2) with any significant deterioration but while they were of sound mind to engage in and communicate their preferences and (3) at end of life, where patients wished further review of their previously established preferences and decisions about implantable cardioverter-defibrillator deactivation.<unk>
T-1863	patients implantable_cardioverter-defibrillator implantation engage patients decisions implantable_cardioverter-defibrillator
H-1863	-0.8075068593025208	▁implant able ▁implant able _ ▁cardio ver ter - de _ de _ activa tion ▁implant ation ▁implant able _ ▁cardio ver ter - de _ de _ activa tion
D-1863	-0.8075068593025208	implantable implantable_ cardioverter-de_de_activation implantation implantable_ cardioverter-de_de_activation
P-1863	-0.0004 -0.0220 -1.4973 -0.1022 -0.7893 -2.3971 -0.0664 -0.0600 -0.5989 -0.0127 -1.6780 -2.0405 -1.8775 -1.0544 -0.0464 -0.1209 -0.4694 -0.4844 -0.3336 -0.3563 -3.1146 -0.1224 -0.0634 -0.4409 -0.0159 -1.1526 -0.8377 -1.4332 -2.8896 -0.0425 -1.6588 -0.0607
S-739	Cardiac magnetic resonance T1 time (hazard ratio, 0.99; 95% confidence interval, 0.98-0.99; P=0.046), left atrial area (hazard ratio, 1.08; 95% confidence interval, 1.03-1.13; P<0.01), and pulmonary vascular resistance (hazard ratio, 1.01; 95% confidence interval, 1.00-1.01; P=0.03) were significantly associated with cardiac events.<unk>
T-739	cardiac_magnetic_resonance t1_time hazard_ratio confidence_interval left_atrial_area hazard_ratio confidence_interval pulmonary_vascular_resistance hazard_ratio confidence_interval cardiac_events
H-739	-0.9394968152046204	▁Card iac _ ▁magnetic _ ▁res on ance ▁left _ ▁at rial _ ▁area ▁pulmonar y _ ▁vas cular _ ▁resist ance
D-739	-0.9394968152046204	Cardiac_ magnetic_ resonance left_ atrial_ area pulmonary_ vascular_ resistance
P-739	-0.5625 -0.0562 -0.4109 -0.8505 -1.6295 -2.7884 -0.2300 -0.1686 -2.8196 -1.2447 -0.4093 -0.0685 -3.5118 -1.5022 -0.2515 -0.0522 -0.2574 -0.5545 -0.1536 -1.3576 -1.8766 -0.0154 -1.6968 -0.0795
S-1755	METHODS AND RESULTS: We recruited and prospectively followed up, in 14 dedicated HF units, 3058 patients with systolic (left ventricular ejection fraction <40%) HF in stable clinical conditions, New York Heart Association class I to III, who underwent clinical, laboratory, echocardiographic, and cardiopulmonary exercise test investigations at study enrollment.<unk>
T-1755	prospectively followed_up hf patients systolic left_ventricular_ejection_fraction hf stable clinical conditions new_york_heart_association_class_i clinical echocardiographic cardiopulmonary_exercise_test
H-1755	-0.8857003450393677	▁ HF ▁vent ri cular _ é je ction ▁ fraction ▁ HF ▁New ▁York ▁Heart _ ▁Association ▁e cho car dio graphic ▁cardio pul mon ary _ ▁exercise
D-1755	-0.8857003450393677	HF ventricular_éjection fraction HF New York Heart_ Association echocardiographic cardiopulmonary_ exercise
P-1755	-0.8230 -0.7050 -4.7793 -0.1016 -0.2539 -1.4078 -1.3308 -2.1124 -0.1235 -1.1306 -0.0247 -0.6243 -0.1839 -3.0546 -0.3338 -0.1952 -1.0981 -1.4388 -1.0447 -0.0465 -0.0185 -0.2568 -0.2662 -0.3117 -0.0728 -1.9074 -0.5046 -1.6071 -1.0875 -0.5563 -0.0553
S-1666	Patients with end stage heart failure fall into stage D of the ABCD classification of the American College of Cardiology (ACC)/American Heart Association (AHA), and class III–IV of the New York Heart Association (NYHA) functional classification; they are characterised by advanced structural heart disease and pronounced symptoms of heart failure at rest or upon minimal physical exertion, despite maximal medical treatment according to current guidelines.<unk>
T-1666	patients end_stage_heart_failure abcd_classification american_college_of_cardiology acc american_heart_association aha new_york_heart_association nyha heart_disease symptoms heart_failure physical medical_treatment
H-1666	-1.4690182209014893	▁ab d ▁classifica tion ▁American ▁College _ of _ ▁Card i ology ▁a cc ▁association ▁ AHA ▁New ▁York _ ▁Heart _ association ▁NY HA ▁structura l _ ▁heart _ ▁disease
D-1666	-1.4690182209014893	abd classification American College_of_ Cardiology acc association AHA New York_ Heart_association NYHA structural_ heart_ disease
P-1666	-5.2869 -0.0803 -3.5662 -0.0131 -1.2906 -0.1080 -0.1532 -1.4341 -0.1813 -0.4136 -0.3275 -0.1879 -0.3507 -0.1701 -4.1556 -1.5185 -0.0368 -3.2199 -0.2732 -1.8823 -2.7099 -1.8000 -2.3223 -2.1369 -0.0435 -4.6211 -0.0310 -1.2838 -0.8714 -1.6496 -4.0855 -2.1455 -0.1269
S-345	The MVA was obtained by a continuity equation (LV end-diastolic volume - LV end-systolic volume = mitral filling flow volume = MVA × velocity time integral of mitral filling flow by continuous wave Doppler echocardiography), which can be utilized even in the presence of MR. His mitral valve plasty was successfully performed without major concerns.<unk>
T-345	mva continuity_equation lv_end-diastolic_volume lv_end-systolic_volume mitral_filling_flow mva mitral_filling_flow continuous_wave_doppler_echocardiography mitral_valve_plasty
H-345	-0.709500253200531	▁m va ▁continu ity ▁e qu ation LV ▁end - dia sto lic ▁volume ▁LV ▁end - sy sto lic ▁volume ▁mit ral _ ▁fill ing _ ▁flow ▁m va ▁veloci ty _ ▁time ▁mit ral _ ▁fill ing _ ▁flow ▁continuo us _ ▁wa ve ▁do pp ler _ ▁e cho card i ography ▁MR ▁mit ral ▁val ve ▁plast y
D-345	-0.709500253200531	mva continuity equationLV end-diastolic volume LV end-systolic volume mitral_ filling_ flow mva velocity_ time mitral_ filling_ flow continuous_ wave doppler_ echocardiography MR mitral valve plasty
P-345	-2.4928 -0.2065 -0.4130 -0.0317 -1.5551 -0.0789 -0.0178 -1.4329 -1.2160 -0.0152 -4.7473 -0.7653 -1.6055 -1.3632 -0.6186 -0.8820 -0.0124 -1.1828 -0.4393 -0.8838 -1.3848 -0.4122 -0.0108 -1.5240 -0.8656 -0.0170 -1.1001 -0.6519 -0.8551 -0.7798 -0.4187 -0.0966 -0.6132 -1.8254 -1.7486 -0.0068 -1.1186 -0.5293 -0.0168 -0.5692 -0.4123 -2.3481 -0.1628 -1.3814 -0.7187 -0.0051 -0.8350 -0.0333 -0.1725 -1.0118 -0.2546 -0.0503 -0.0986 -0.2118 -0.1855 -0.0245 -1.1898 -0.0043 -1.0727 -0.0208 -0.0688 -0.2593 -0.2411 -0.1405
S-157	Compared with usual care, although not reaching statitistical significance, RM trended to reduce all-cause mortality for STS HH (HR: 0.77, 95% credible interval (CrI): 0.55, 1.08), TM during office hours (HR: 0.76, 95% CrI: 0.49, 1.18) and TM24/7 (HR: 0.49, 95% CrI: 0.20, 1.18).<unk>
T-157	significance rm all-cause_mortality sts hh cri cri cri
H-157	-2.0143227577209473	▁stati tis tical _ ▁significa nce ▁RM ▁s ts _ h ▁h ▁h ▁h ▁h ▁h ▁office _ ▁hours ▁h ▁h ▁h ▁h ▁h ▁h
D-157	-2.0143227577209473	statitistical_ significance RM sts_h h h h h h office_ hours h h h h h h
P-157	-1.4204 -0.5433 -1.8646 -4.2471 -0.2234 -0.0415 -2.2500 -4.8830 -1.4841 -1.4935 -2.5195 -2.1653 -2.0635 -2.0997 -2.0635 -2.1279 -3.3745 -1.9180 -1.6062 -2.0085 -2.3841 -2.0560 -1.9690 -2.0034 -2.0301 -3.4484 -0.0983
S-381	We externally validated the HFPSI in the Ann Arbor Veterans' Affairs HF clinic (VA cohort, n = 445; 106 outcomes) and explored "real-time" HFPSI use (VA-RT cohort, n = 486; 141 outcomes) by tracking VA patients for 6 months from their most recently calculated HFPSI, rather than using an arbitrary start date for the cohort.<unk>
T-381	hfpsi hf clinic outcomes hfpsi outcomes tracking patients hfpsi
H-381	-1.3910061120986938	▁ HF PSI ▁Ann ▁Ar bor ▁Veteran s _ ▁Affairs ▁ HF ▁clinic VA - RT ▁co hor t ▁VA _ RT ▁ HF PSI ▁ HF PSI
D-381	-1.3910061120986938	HFPSI Ann Arbor Veterans_ Affairs HF clinicVA-RT cohort VA_RT HFPSI HFPSI
P-381	-0.2129 -0.9049 -1.9535 -0.3493 -0.0257 -0.0087 -0.0941 -0.0364 -0.3621 -0.1775 -0.4428 -0.1629 -5.3050 -1.2632 -0.2596 -0.0658 -4.1183 -0.0606 -0.0256 -2.7858 -2.4674 -1.8885 -0.9637 -1.1902 -4.1389 -2.0423 -1.6405 -4.5234 -4.1228 -0.1380
S-1706	Compared with AAs, non-AAs were more likely to attain maximal spironolactone dose (13.9% versus 5.8%; P=0.04) and had higher rates of hyperkalemia (potassium>5.5 mmol/L; 9.7% versus 4.2%; P<0.046), as well as lower rates of hypokalemia (potassium<3.5 mmol/L; 5.6% versus 17.9%; P<0.001).<unk>
T-1706	aas spironolactone hyperkalemia potassium hypokalemia potassium
H-1706	-0.633340060710907	▁AA s ▁spi rono lac tone ▁dose ▁hyper kal emia ▁po tas s ium
D-1706	-0.633340060710907	AAs spironolactone dose hyperkalemia potassium
P-1706	-0.2455 -0.2855 -0.8242 -0.0246 -0.6600 -0.2525 -1.7924 -0.8807 -0.4792 -0.2640 -1.1088 -0.2180 -0.0473 -0.1064 -2.8638 -0.0806
S-115	Multivariate analysis showed that patients with preserved LVEF had a similar risk of long-term mortality as patients with mild or moderate reduction in LVEF (hazard ratio [HR] 0.92 [p = 0.40] and 1.01 [p = 0.90], respectively) while severely reduced LVEF conferred increased increase rate compared with preserved LVEF (HR 1.20, p = 0.04).<unk>
T-115	multivariate_analysis patients preserved_lvef mortality patients lvef hazard_ratio lvef preserved_lvef
H-115	-1.1829904317855835	▁risk _ de _ long - term _ ▁mortal ity ▁LV EF haz ard ▁ratio
D-115	-1.1829904317855835	risk_de_long-term_ mortality LVEFhazard ratio
P-115	-6.4026 -2.4246 -1.5479 -0.3551 -0.1357 -0.2543 -1.0935 -0.4420 -0.6660 -0.2909 -1.5372 -0.3899 -0.2243 -0.0069 -1.2343 -2.9689 -0.1368
S-242	In patients having HFpEF, predictors of primary outcome were male gender (odds ratio [OR] 3.45, p = 0.004), NYHA class III (OR 3.05, p = 0.008), distance covered on a 6-minute walk test (6-MWT) of <620 feet (OR 2.81, p = 0.013), and <80% adherence to prescribed medications (OR 2.61, p = 0.018).<unk>
T-242	patients hfpef primary_outcome odds_ratio nyha_class_iii 6-minute_walk_test 6-mwt feet prescribed medications
H-242	-1.7678223848342896	▁ HF p EF ▁ HF p f ▁h p f ▁h p f ▁h p f ▁h p f ▁h p f ▁h p f ▁h p f ▁h p f ▁NY ha _ ▁class _ ▁III ▁distance _ ▁covered ▁m t ▁m t
D-242	-1.7678223848342896	HFpEF HFpf hpf hpf hpf hpf hpf hpf hpf hpf NYha_ class_ III distance_ covered mt mt
P-242	-0.7669 -0.0576 -0.0849 -0.6709 -2.9133 -0.5379 -0.3158 -1.3278 -4.5304 -0.8188 -0.4906 -4.3840 -0.5232 -0.5083 -4.2715 -0.7984 -0.6260 -4.1947 -1.0979 -0.7470 -4.1080 -1.4199 -0.9590 -4.0414 -1.7382 -1.1393 -3.9344 -2.0279 -1.3964 -3.8672 -2.2811 -1.6590 -5.1100 -0.8271 -3.8869 -0.5818 -0.6917 -1.1010 -1.1586 -3.7867 -0.9124 -2.6827 -0.0341 -2.1559 -0.0554 -1.7040 -0.1615
S-492	Abstract Echo-derived pulmonary arterial systolic pressure (PASP) and right ventricular (RV) tricuspid annular plane systolic excursion (TAPSE; from the end of diastole to end-systole) are of basic relevance in the clinical follow-up of heart failure (HF) patients, carrying two- to threefold increase in cardiac risk when increased and reduced, respectively.<unk>
T-492	echo-derived_pulmonary_arterial_systolic_pressure pasp right_ventricular rv tricuspid_annular_plane_systolic_excursion tapse diastole end-systole clinical follow-up heart_failure hf patients cardiac
H-492	-0.9473242163658142	▁e cho - der i ved ▁pulmonar y _ ▁arterial _ tension PAS p ▁right ▁vent ri cular ▁ RV _ ▁ann ular _ ▁plane _ syn sto lic ▁ excursion ▁dia stol e ▁end - sy stol e
D-492	-0.9473242163658142	echo-derived pulmonary_ arterial_tensionPASp right ventricular RV_ annular_ plane_synstolic excursion diastole end-systole
P-492	-1.7307 -0.0176 -0.0502 -0.0985 -0.1034 -0.0610 -0.0027 -0.0318 -1.0518 -1.0693 -0.2831 -3.3348 -0.5922 -0.9240 -2.5075 -0.3059 -0.1820 -0.1164 -1.9770 -0.0944 -5.1067 -0.8687 -0.0022 -0.6417 -0.6357 -0.1421 -0.9082 -2.0908 -1.7381 -2.3725 -0.0020 -5.1652 -0.0061 -0.1523 -0.5978 -0.0820 -0.6332 -0.0041 -0.0498 -2.9988 -0.1081
S-1190	The independent predictors of severe CAD included diabetes (odds ratio 5.1, p = 0.005), electrocardiographic Q waves or left bundle branch block (odds ratio 3.8, p = 0.02), and ≥2 nondiabetes risk factors: age (men ≥55 or women ≥65 years), dyslipidemia, hypertension, and tobacco use (odds ratio 4.8, p = 0.02).<unk>
T-1190	cad diabetes odds_ratio electrocardiographic_q_waves left_bundle_branch_block odds_ratio nondiabetes dyslipidemia hypertension odds_ratio
H-1190	-0.6822904944419861	▁severe ▁CAD ▁electro car dio graphic ▁Q ▁wa ves ▁left ▁bund le _ ▁bran ch _ ▁block ▁non dia bete s ▁dys li pide mia ▁hyper tension ▁to ba cco
D-1190	-0.6822904944419861	severe CAD electrocardiographic Q waves left bundle_ branch_ block nondiabetes dyslipidemia hypertension tobacco
P-1190	-3.7139 -0.2290 -0.7142 -0.0064 -0.0730 -0.2299 -0.9658 -1.8000 -0.0334 -1.0544 -0.0937 -0.2104 -0.4452 -1.2415 -0.0502 -1.2837 -0.5419 -1.3327 -0.8520 -0.0122 -0.0125 -3.8617 -0.0282 -0.0208 -0.4985 -0.0081 -0.0003 -0.0340 -0.0326 -0.2993 -2.0368 -0.1171
S-485	The area under the receiver operating characteristic curve (AUC) of E/e' ratios for PCWP estimation was 0.79 (95% confidence interval [CI] 0.70 to 0.87) for E/e'septal, 0.72 (95% CI 0.63 to 0.82) for E/elateral, and 0.79 (95% CI 0.70 to 0.87) for E/emean (all p values <0.0001).<unk>
T-485	area_under_the_receiver_operating_characteristic_curve auc pcwp confidence_interval septal p_values
H-485	-1.3562464714050293	▁receive r _ ▁operating _ ▁character istic _ cur ve ▁u e ▁ratio s ▁PC WP
D-485	-1.3562464714050293	receiver_ operating_ characteristic_curve ue ratios PCWP
P-485	-4.3793 -0.0080 -0.5745 -1.9778 -0.6136 -2.0610 -0.1460 -1.7816 -0.3849 -0.0221 -3.0677 -1.5117 -2.6472 -0.0182 -0.3874 -0.7252 -3.9096 -0.1966
S-680	Among trastuzumab-treated patients, older age (age > 80 years; HR, 1.53; 95% CI, 1.16 to 2.10), coronary artery disease (HR, 1.82; 95% CI, 1.34 to 2.48), hypertension (HR, 1.24; 95% CI, 1.02 to 1.50), and weekly trastuzumab administration (HR, 1.33; 95% CI, 1.05 to 1.68) increased the risk of CHF.<unk>
T-680	patients coronary_artery_disease hypertension trastuzumab administration chf
H-680	-0.8740975856781006	▁tras tuz um ab - tre ated ▁patients ▁corona ry ▁arter y ▁disease ▁hyper tension
D-680	-0.8740975856781006	trastuzumab-treated patients coronary artery disease hypertension
P-680	-0.6609 -0.0088 -0.1164 -1.1941 -0.9269 -0.0771 -1.9116 -1.4775 -2.0161 -0.1544 -0.3883 -0.2658 -1.7400 -0.5494 -0.0010 -3.2750 -0.0965
S-754	In the LVEF >30% subgroup, there was a trend for improvement in the clinical composite response with CRT ON versus CRT OFF (P=0.06) and significant reductions in LV end systolic volume index (-6.7 ± 21.1 versus 2.1 ± 17.6 mL/m(2); P=0.01) and LV mass (-20.6 ± 50.5 versus 5.0 ± 42.4 g; P=0.04) after 12 months.<unk>
T-754	lvef clinical crt crt systolic_volume_index lv_mass
H-754	-0.900538444519043	▁LV EF ▁clinic al ▁com posit e ▁response ▁c RT _ on ▁c RT _ ▁OFF ▁LV _ ▁end _ ▁sy sto lic ▁volume _ ▁index
D-754	-0.900538444519043	LVEF clinical composite response cRT_on cRT_ OFF LV_ end_ systolic volume_ index
P-754	-0.3810 -0.3093 -1.1683 -0.0120 -0.6487 -0.0048 -0.0191 -1.0279 -0.3067 -0.0500 -2.8444 -1.6374 -0.2392 -0.1616 -1.1166 -0.7161 -0.4773 -2.7419 -1.3681 -0.1110 -2.3447 -0.2368 -2.3171 -0.8451 -1.6250 -0.4773 -1.9351 -0.0928
S-1343	We show that intervention with TGF-β signaling by inhibiting TGF-β receptor type I or Smad 2/3 using small-molecule inhibitors improved c-Kit+ cell yield, attenuated epithelial to mesenchymal transition markers, stimulated the pluripotency marker Nanog, and improved efficiency of c-Kit+ cell differentiation toward cardiomyocyte-like cells in vitro.<unk>
T-1343	tgf-β_signaling tgf-β_receptor_type_i cell yield epithelial mesenchymal transition pluripotency_marker nanog cell cells in_vitro
H-1343	-0.4849697947502136	▁T GF - β ▁signal ing ▁T GF - β ▁receptor ▁s mad ▁small - mo le cule ▁inhibi tors ▁c - K it _ cell ▁yi eld ▁epi the li al ▁mes en chy mal ▁transition ▁marker s ▁pluri pote ncy _ ▁marker ▁c - K it _ cell ▁differenti ation ▁cardio my o cy te - like ▁cell s
D-1343	-0.4849697947502136	TGF-β signaling TGF-β receptor smad small-molecule inhibitors c-Kit_cell yield epithelial mesenchymal transition markers pluripotency_ marker c-Kit_cell differentiation cardiomyocyte-like cells
P-1343	-0.7003 -0.0416 -0.2457 -0.0976 -1.1155 -0.1699 -0.4917 -0.1077 -0.3903 -0.3587 -2.2087 -2.6818 -0.0031 -2.8967 -0.0106 -0.0280 -0.1131 -0.1424 -1.4656 -0.8411 -0.0054 -0.0492 -0.4611 -0.0209 -1.4249 -1.5763 -1.3971 -0.0008 -0.0532 -0.0314 -0.0240 -0.0251 -0.0121 -0.1128 -0.0630 -0.0597 -0.0085 -0.1758 -0.0844 -0.0016 -0.0534 -0.0055 -1.5359 -0.3011 -0.4560 -0.0144 -1.1133 -0.0606 -0.5870 -0.9149 -1.8614 -0.0075 -0.0342 -0.4487 -0.3862 -0.0741 -0.1850 -1.3363 -0.2583 -0.0956 -0.0044 -1.0790 -0.0428
S-243	In patients having HFrEF, the predictors were being on diuretics (OR 3.06, p = 0.001), having ≥3 co-morbidities (OR 2.11, p = 0.0001), distance covered on a 6-MWT of <620 feet (OR 1.94, p = 0.001), NYHA class III (OR 1.90, p = 0.001), and age >65 years (OR 1.63, p = 0.01).<unk>
T-243	patients hfref diuretics co-morbidities 6-mwt feet nyha_class_iii
H-243	-0.8950077891349792	▁h Fr f ▁di ure tics ▁co - mor bid ities ▁mw t ▁NY HA
D-243	-0.8950077891349792	hFrf diuretics co-morbidities mwt NYHA
P-243	-0.2295 -1.9919 -0.7481 -1.0856 -1.2417 -2.4531 -0.2246 -0.0136 -0.0253 -0.0075 -0.5364 -2.8791 -0.6069 -0.5161 -0.2682 -2.3173 -0.0699
S-344	After the surgery, HF disappeared and postoperative echocardiography confirmed a normal sized LV with an end-diastolic volume index of 71 mL/m2, normal LV ejection fraction of 0.70, no MR and preserved mitral valve opening with a mitral valve area (MVA) of 1.8 cm2, and a mean pressure gradient of 4.4 mm Hg (Fig 1A).<unk>
T-344	surgery hf postoperative echocardiography end-diastolic_volume_index lv_ejection_fraction mitral_valve_opening mitral_valve_area mva
H-344	-1.0125770568847656	▁ HF ▁implant ation ▁e cho card i ography ▁LV ▁end - dia sto lic ▁volume _ ▁index ▁LV ▁e je ction ▁MR ▁mit ral ▁val ve _ ▁opening ▁m va ▁mean _ tension ▁h g
D-344	-1.0125770568847656	HF implantation echocardiography LV end-diastolic volume_ index LV ejection MR mitral valve_ opening mva mean_tension hg
P-344	-1.5563 -0.0468 -1.7850 -3.6531 -1.4012 -0.1904 -0.2285 -0.4545 -0.2089 -3.4562 -0.3639 -0.0218 -2.0622 -0.3440 -1.5875 -0.1901 -2.4696 -0.2938 -3.3240 -1.4590 -0.2588 -0.0132 -0.7821 -1.2848 -0.0171 -1.0083 -0.0699 -2.2472 -0.7896 -0.4213 -0.9371 -1.5430 -0.6106 -0.4968 -2.3158 -0.0160 -0.5002 -0.0694
S-519	METHODS: Among the patients with systolic heart failure (ejection fraction ≤35%) randomized to either placebo or ivabradine in the SHIFT (Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial), 275 patients (n = 132, placebo; n = 143, ivabradine 7.5 mg twice a day) were included in the echocardiographic substudy.<unk>
T-519	patients systolic_heart_failure ejection_fraction randomized placebo ivabradine shift systolic_heart_failure_treatment_with_the_if_inhibitor_ivabradine_trial patients placebo ivabradine echocardiographic
H-519	-0.8211024403572083	▁implant ation ▁i va bra dine ▁SHI FT ▁Sy sto lic _ ▁Heart _ ▁Fail ure ▁in hib itor ▁i va bra dine _ tri al ▁i va bra dine ▁e cho car dio graphic
D-519	-0.8211024403572083	implantation ivabradine SHIFT Systolic_ Heart_ Failure inhibitor ivabradine_trial ivabradine echocardiographic
P-519	-3.2750 -1.5820 -1.4988 -0.0837 -1.1033 -0.0131 -0.3430 -1.0318 -1.5770 -0.0498 -2.8243 -0.7152 -0.3904 -0.5881 -0.0683 -0.0265 -3.2271 -0.5257 -0.0381 -1.2841 -0.0147 -0.2562 -0.0074 -1.7779 -0.4022 -0.0231 -0.7513 -0.0224 -0.4139 -0.0075 -3.6208 -0.1047 -0.0435 -0.3135 -1.4890 -0.8289 -0.0584
S-499	Hazard ratios for variables retained in the multivariate regression were as follows: TAPSE/PASP </≥ 0.36 mm/mmHg [hazard ratio (HR): 10.4, P < 0.001]; TAPSE </≥ 16 mm (HR: 5.1, P < 0.01); New York Heart Association functional class </≥ 3 (HR: 4.4, P < 0.001); E/e' (HR: 4.1, P < 0.001).<unk>
T-499	hazard_ratios multivariate_regression tapse pasp hazard_ratio tapse new_york_heart_association_functional_class
H-499	-2.1927030086517334	▁h ▁h ▁h g ▁h g ▁h z ▁h z ▁h z ▁h z ▁h z ▁h z
D-499	-2.1927030086517334	h h hg hg hz hz hz hz hz hz
P-499	-5.4269 -2.7315 -2.9272 -0.7412 -3.2252 -1.7892 -2.4949 -1.8805 -2.5309 -1.6545 -2.2564 -1.5089 -2.3296 -1.3797 -2.2156 -1.3562 -2.1602 -1.2867 -3.7290 -0.2299
S-390	Renal function was estimated by The Chronic Kidney Disease Epidemiology Collaboration equation and patients grouped by estimated glomerular filtration rate (eGFR)-group I: ≥60 mL/min per 1.73 m(2), group II: 30 to 59 mL/min per 1.73 m(2), group III: 15 to 29 mL/min per 1.73 m(2), group IV: <15 mL/min per 1.73 m(2).<unk>
T-390	renal_function the_chronic_kidney_disease_epidemiology_collaboration patients estimated_glomerular_filtration_rate egfr
H-390	-1.1307522058486938	▁Chro nic _ ▁Kid ney ▁Disease ▁Epidemi ology ▁figure ▁glo mer ular _ ▁filtr ation _ ▁rate ▁e G FR
D-390	-1.1307522058486938	Chronic_ Kidney Disease Epidemiology figure glomerular_ filtration_ rate eGFR
P-390	-2.0599 -1.3686 -0.9460 -0.2044 -0.1796 -0.8246 -0.4854 -1.4991 -4.1763 -0.8691 -0.0488 -0.1126 -1.4994 -1.1088 -0.0427 -1.8360 -1.8554 -0.1057 -1.1491 -1.7055 -2.4797 -0.3198
S-1968	Large-scale prospective randomized multicenter trial PARADIGM-HF with more than 8000 individuals with stabilized chronic heart failure with systolic dysfunction (LV EF 40%, later 35%), mostly in functional class NYHA II-III with elevated BNP/NT-pro BNP has shown 20% decrease in primary endpoint (cardiovascular death or hospitalization for heart failure) in a group treated by ARNI (LCZ696; sacubiltril - valsartan).<unk>
T-1968	prospective randomized paradigm-hf chronic_heart_failure systolic_dysfunction lv_ef functional_class nyha elevated bnp nt-pro_bnp primary_endpoint cardiovascular_death hospitalization heart_failure arni lcz696 sacubiltril valsartan
H-1968	-1.3391321897506714	▁para DIG m - HF ▁stabil ized ▁chronic _ heart _ ▁failure ▁sy sto lic _ ▁dys function LV ▁functional ▁class ▁NY HA _ ▁II - III ▁b NP ▁b NP ▁car dio vas cular _ ▁death ▁hospital ization _ ▁for _ heart _ ▁failure ▁AR NI ▁sa cubi lt ril ▁val sar tan
D-1968	-1.3391321897506714	paraDIGm-HF stabilized chronic_heart_ failure systolic_ dysfunctionLV functional class NYHA_ II-III bNP bNP cardiovascular_ death hospitalization_ for_heart_ failure ARNI sacubiltril valsartan
P-1968	-7.0016 -0.2032 -0.2368 -0.2691 -0.2321 -5.8059 -0.2643 -2.3891 -1.2521 -2.1777 -1.4913 -2.5309 -3.5212 -0.1760 -3.6762 -1.1432 -0.1350 -0.0523 -0.6393 -5.7064 -0.4253 -0.2555 -0.0674 -3.0727 -1.0137 -0.2059 -0.0280 -0.1532 -0.2737 -0.8785 -0.7745 -3.7718 -0.0638 -0.6395 -0.4157 -2.2045 -1.0603 -2.0564 -0.8614 -1.5664 -2.3154 -1.2518 -0.9806 -1.6471 -2.2946 -4.2613 -1.2749 -0.4110 -0.1030 -0.1994 -0.0344 -0.9614 -0.0284 -0.0078 -0.4698 -0.0586
S-1703	METHODS AND RESULTS: We assessed hyperkalemia and outcomes in African Americans (AAs; n=120) and non-AAs (n=1543; white 93%) with New York Heart Association (NYHA) class III or IV HF and left ventricular dysfunction who were randomized to spironolactone, titrated to 25 or 50 mg daily or placebo, in the Randomized Aldactone Evaluation Study (RALES).<unk>
T-1703	hyperkalemia outcomes african_americans aas new_york_heart_association nyha hf left_ventricular_dysfunction randomized spironolactone titrated placebo randomized_aldactone_evaluation_study rales
H-1703	-1.7740899324417114	▁hyper kal emia ▁African ▁American s ▁AA s ▁
D-1703	-1.7740899324417114	hyperkalemia African Americans AAs
P-1703	-0.4052 -0.1366 -0.1133 -3.6499 -1.6394 -0.0693 -1.9917 -0.0366 -4.6344 -5.0646
S-432	LV reverse remodeling (n=161; 48%) was associated with pre-CRT LV end-diastolic dimension index <3.1 cm/m(2), global longitudinal strain of left ventricle <-7%, left atrial area <26 cm(2), right ventricular end-diastolic area index <10.0 cm(2)/m(2), right atrial area <20 cm(2), and right ventricular fractional area change ≥35%.<unk>
T-432	lv_reverse_remodeling lv_end-diastolic_dimension longitudinal strain left_ventricle left_atrial_area right_ventricular_end-diastolic_area_index right_atrial right_ventricular_fractional_area change
H-432	-1.6751298904418945	▁rever se ▁remodel ing ▁pre - C RT ▁LV ▁vent ri cular ▁angle _ de _ vent ri cular ▁vent ri cular ▁angle _ de _ vent ri cular ▁vent ri cular
D-432	-1.6751298904418945	reverse remodeling pre-CRT LV ventricular angle_de_ventricular ventricular angle_de_ventricular ventricular
P-432	-0.0846 -0.0046 -0.5037 -0.0171 -0.8953 -0.0034 -0.7029 -0.0654 -2.8235 -3.5124 -0.2873 -0.3711 -5.3292 -1.5454 -3.1140 -0.2673 -2.2945 -3.5478 -1.0767 -4.2365 -1.2460 -1.2584 -4.4159 -1.1778 -1.9540 -0.3176 -3.2241 -2.6303 -1.0521 -3.4531 -0.6624 -0.9642 -3.7687 -0.1468
S-1364	B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide – Diagnostic role in stable coronary artery disease B-type natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP) are released from ventricular cardiomyocytes in response to an increase in ventricular wall stress and to myocardial ischemia.<unk>
T-1364	b-type_natriuretic_peptide n-terminal_pro-b-type_natriuretic_peptide diagnostic stable coronary_artery_disease b-type_natriuretic_peptide bnp nt-probnp ventricular_cardiomyocytes ventricular wall_stress myocardial_ischemia
H-1364	-1.0744987726211548	▁b - type _ ▁na tri ure tic _ pe pti de ▁b - type _ n - termin al _ pro - B - type _ ▁na tri ure tic _ pe pti de ▁ Diagnos tique ▁corona ry _ ▁arter y _ ▁disease ▁b - type _ ▁na tri ure tic _ pe pti de ▁b NP ▁vent ri cular _ ▁cardio my o cy tes ▁vent ri cular _ ▁wall _ ▁stress ▁my o card ial ▁ ische mia
D-1364	-1.0744987726211548	b-type_ natriuretic_peptide b-type_n-terminal_pro-B-type_ natriuretic_peptide Diagnostique coronary_ artery_ disease b-type_ natriuretic_peptide bNP ventricular_ cardiomyocytes ventricular_ wall_ stress myocardial ischemia
P-1364	-0.8631 -2.4653 -1.2613 -1.1064 -2.1402 -0.0536 -0.1190 -4.7364 -1.4090 -0.5788 -0.1840 -0.1867 -2.3768 -3.9317 -0.7314 -0.5016 -4.6904 -0.0829 -1.4120 -0.0069 -2.4108 -0.4459 -0.0350 -0.3896 -0.4960 -0.1547 -0.4984 -2.0360 -0.0455 -0.1362 -5.9596 -1.0250 -0.5621 -0.1645 -0.0611 -4.0220 -0.2843 -2.6431 -2.3426 -0.2787 -1.0141 -0.2958 -0.3346 -1.7528 -1.8344 -0.3063 -1.5397 -0.0372 -0.6554 -1.5788 -0.0266 -0.0832 -6.4948 -1.0091 -0.8754 -0.2065 -0.2600 -0.3993 -0.8943 -1.6435 -0.0639 -0.3761 -0.2373 -1.2267 -0.3873 -0.5811 -0.0632 -0.0562 -0.0088 -0.1052 -0.2840 -0.3623 -5.6944 -0.3713 -1.1383 -0.4997 -0.0962 -0.2183 -0.2263 -2.6408 -0.8733 -0.2879 -0.2313 -0.1572
S-654	To determine the role of IRS1 and IRS2 in the heart and examine whether hyperinsulinemia causes myocardial insulin resistance and cellular dysfunction via IRS1 and IRS2, we generated heart-specific IRS1 and IRS2 gene double-knockout (H-DKO) mice and liver-specific IRS1 and IRS2 double-knockout (L-DKO) mice.<unk>
T-654	irs1 irs2 heart hyperinsulinemia myocardial_insulin_resistance cellular_dysfunction irs1 irs2 heart-specific_irs1_and_irs2_gene_double-knockout h-dko liver-specific_irs1_and_irs2_double-knockout l-dko
H-654	-0.8687587976455688	▁i RS 2 ▁hyper insu line mia ▁my o card ial _ ▁insulin _ ▁resist ance ▁cel lular _ ▁dys function ▁i RS 2 ▁heart - specific ▁I RS 2 ▁double - k no ckou t ▁h - d KO ▁ liver - specific ▁I RS
D-654	-0.8687587976455688	iRS2 hyperinsulinemia myocardial_ insulin_ resistance cellular_ dysfunction iRS2 heart-specific IRS2 double-knockout h-dKO liver-specific IRS
P-654	-0.9162 -0.2870 -4.7579 -1.2558 -0.0421 -0.1751 -2.4491 -3.4302 -0.0621 -0.0922 -0.0308 -1.2986 -0.1330 -1.2767 -1.0621 -0.0105 -3.0348 -0.0067 -0.9929 -0.0989 -0.0962 -0.6322 -0.1145 -1.8779 -3.4757 -0.1384 -0.3404 -0.9680 -0.0805 -2.2518 -1.0945 -0.0125 -0.5707 -0.0473 -0.0309 -0.0098 -1.4498 -0.4358 -0.2521 -0.2420 -0.5868 -0.2087 -0.2113 -0.3011 -1.0681 -0.2045 -3.4760 -0.1102
S-665	The unadjusted practice-level prescription rates ranged from 44% to 100% for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (median, 85%; interquartile range, 75%-89%), from 49% to 100% for β-blockers (median, 92%; interquartile range, 83%-95%), and from 37% to 100% for optimal combined treatment (median, 79%; interquartile range, 66%-85%).<unk>
T-665	prescription angiotensin-converting_enzyme_inhibitors angiotensin_receptor_blockers interquartile_range β-blockers interquartile_range interquartile_range
H-665	-0.9371522068977356	▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors _ angi oten sin _ ▁receptor _ block ers ▁inter quart ile
D-665	-0.9371522068977356	angiotensin-converting enzyme inhibitors_angiotensin_ receptor_blockers interquartile
P-665	-3.4008 -1.4466 -0.3916 -1.2528 -0.9852 -0.0035 -0.0740 -1.5346 -0.6923 -0.0687 -0.6683 -1.0489 -1.7155 -0.6880 -0.0129 -0.4230 -1.5048 -0.7483 -2.1656 -0.4002 -0.0184 -2.6240 -0.0195 -0.0097 -2.3885 -0.0802
S-1177	Therapy with ivabradine (β = 0.34, p = 0.04) and change with treatment in exertional increase in the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity (β = -0.30, p = 0.02) were independent correlates of increase in exercise capacity, and therapy with ivabradine (β = 0.32, p = 0.007) was independently correlated with increase in peak oxygen uptake.<unk>
T-1177	therapy ivabradine change peak_early_diastolic_mitral_flow_velocity peak_early_diastolic_mitral_annular_velocity correlates exercise_capacity therapy ivabradine correlated peak_oxygen_uptake
H-1177	-1.1784979104995728	▁i va bra dine
D-1177	-1.1784979104995728	ivabradine
P-1177	-0.3287 -0.0245 -0.5745 -0.0068 -6.0244 -0.1120
S-45	Data Synthesis: Low-strength evidence from 6 trials and 26 observational studies suggests that liberal transfusion protocols do not improve short-term mortality rates compared with less aggressive protocols (combined relative risk among trials, 0.94 [95% CI, 0.61 to 1.42]; I2 = 16.8%), although decreased mortality rates occurred in a small trial of patients with the acute coronary syndrome (1.8% vs. 13.0%; P = 0.032).<unk>
T-45	evidence transfusion mortality relative_risk mortality patients acute_coronary_syndrome
H-45	-1.9836549758911133	▁liberal ▁trans fusion ▁protocol s
D-45	-1.9836549758911133	liberal transfusion protocols
P-45	-4.6960 -0.5285 -0.0944 -4.0508 -0.0262 -4.3996 -0.0899
S-1419	The risk of death or unplanned readmission during the 6-month observation period was lower among patients who saw a familiar physician (43.6%; adjusted hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.83-0.91) or an unfamiliar physician (43.6%; adjusted HR 0.90, 95% CI 0.83-0.97) for early follow-up visits, as compared with patients who had no follow-up visits (62.9%).<unk>
T-1419	death readmission patients physician hazard_ratio confidence_interval physician follow-up patients follow-up
H-1419	-1.0277973413467407	▁risk _ de _ ▁death ▁un plan ned _ ▁read mission
D-1419	-1.0277973413467407	risk_de_ death unplanned_ readmission
P-1419	-1.7678 -1.5349 -0.6841 -0.1295 -1.8128 -1.2092 -0.1487 -0.3087 -0.1094 -1.1354 -0.0233 -4.4047 -0.0928
S-1409	METHODS AND RESULTS: In HEK (human embryonic kidney) 293 cells overexpressing both β1AR and S1PR1, we demonstrated that β1AR downregulation can occur after stimulation with sphingosine-1-phosphate (an S1PR1 agonist), whereas S1PR1 downregulation can be triggered by isoproterenol (a β-adrenergic receptor agonist) treatment.<unk>
T-1409	hek human_embryonic_kidney cells β1ar s1pr1 β1ar downregulation sphingosine-1-phosphate s1pr1_agonist s1pr1 downregulation isoproterenol β-adrenergic_receptor_agonist
H-1409	-0.7369317412376404	▁h EK ▁em bry o nic _ ▁ki dne y ▁β 1 AR ▁down regul ation ▁sp hing os ine _ -1 - phos pha te ▁S 1 PR 1 ▁ago nist ▁iso prot eren ol ▁β - ad r energi c _ ▁receptor _ ▁ago nist
D-1409	-0.7369317412376404	hEK embryonic_ kidney β1AR downregulation sphingosine_-1-phosphate S1PR1 agonist isoproterenol β-adrenergic_ receptor_ agonist
P-1409	-0.2879 -0.6627 -1.3374 -0.0392 -0.0765 -1.0558 -0.4371 -1.0598 -0.0772 -0.0314 -2.5719 -0.1720 -0.6041 -4.2444 -0.8980 -0.0105 -0.1344 -0.1235 -0.2953 -0.1738 -1.1723 -3.2624 -0.0688 -0.0016 -0.0514 -0.0074 -1.5911 -0.0232 -0.0529 -1.8683 -1.8860 -0.1211 -2.6469 -0.0789 -2.4845 -0.0157 -0.0509 -0.0165 -0.0486 -0.1612 -1.8983 -0.2143 -1.3695 -0.3315 -0.7248 -0.9928 -0.0153 -0.6109 -0.0493
S-1330	Assessment was performed at baseline and after completion of training protocol and included 6-minute walked distance, quality of life (Kansas City Cardiomyopathy Questionnaire and Minnesota Living with Heart Failure Questionnaire), depressive symptoms (Beck Depression Inventory and Zung self-rated depression scores), B-type natriuretic peptide, endothelial function (flow-mediated dilatation), and left ventricular diastolic function.<unk>
T-1330	baseline training 6-minute_walked_distance quality_of_life kansas_city_cardiomyopathy_questionnaire minnesota_living_with_heart_failure_questionnaire symptoms beck_depression_inventory zung_self-rated_depression_scores b-type_natriuretic_peptide endothelial_function flow-mediated_dilatation left_ventricular_diastolic_function
H-1330	-0.8696149587631226	▁Kan sas ▁City ▁Card i om yo pathy ▁Minnesota ▁Heart _ ▁Fail ure ▁ depressiv e _ ▁symptoms ▁be ck _ de pression ▁in ven tory ▁depression ▁na tri ure tic ▁pe pti de ▁en dot heli al _ f ré la tation ▁vent ri cular _ ▁dia sto lic
D-1330	-0.8696149587631226	Kansas City Cardiomyopathy Minnesota Heart_ Failure depressive_ symptoms beck_depression inventory depression natriuretic peptide endothelial_frélatation ventricular_ diastolic
P-1330	-5.4366 -0.0026 -0.1892 -0.5458 -0.1240 -0.0237 -3.1438 -0.1396 -1.0398 -3.0902 -0.7409 -0.1500 -0.0943 -2.6667 -0.0019 -0.0088 -2.8934 -0.5062 -0.8102 -0.1676 -0.5132 -0.0455 -0.0573 -0.7194 -0.1501 -0.0113 -1.2043 -2.0852 -0.0024 -0.0279 -2.1789 -1.0518 -0.0426 -0.0521 -1.0431 -1.4698 -0.0379 -0.0081 -1.3934 -3.3184 -0.4699 -1.2505 -0.0024 -0.1884 -0.0536 -0.1432 -0.1184 -2.2103 -0.2490 -1.1515 -2.0939 -0.1008
S-976	Odds ratios with 95% confidence intervals for cardiovascular events after adjustment for age, gender, atrial fibrillation, left ventricular ejection fraction, diabetes mellitus, peripheral vascular disease, and history of myocardial infarction, heart failure, or stroke was 1.24 (1.06 to 1.45) in patients with an estimated glomerular filtration rate of 15 to 45 ml/min/1.73 m(2) but became nonsignificant after acute kidney injury was introduced into the statistical model.<unk>
T-976	odds_ratios confidence_intervals cardiovascular_events atrial_fibrillation left_ventricular_ejection_fraction diabetes_mellitus peripheral_vascular_disease myocardial_infarction heart_failure stroke patients estimated_glomerular_filtration_rate nonsignificant acute_kidney_injury
H-976	-0.44290539622306824	▁cardiovascular ▁events ▁at rial _ ▁fi bril lation ▁left ▁vent ri cular ▁e je ction _ fraction ▁diabetes ▁mell itus ▁per i pher al _ ▁vas cular ▁disease ▁my o card ial ▁in far ction ▁heart _ ▁failure
D-976	-0.44290539622306824	cardiovascular events atrial_ fibrillation left ventricular ejection_fraction diabetes mellitus peripheral_ vascular disease myocardial infarction heart_ failure
P-976	-2.3250 -1.7596 -0.3808 -0.0114 -1.4000 -0.6003 -0.0039 -0.0020 -0.0782 -0.2325 -0.0742 -0.2417 -1.1205 -0.2044 -0.0343 -1.2397 -0.0029 -0.0270 -0.1725 -0.0414 -0.1478 -0.1201 -0.2239 -0.0343 -0.2533 -0.6054 -0.0380 -1.9187 -0.0773 -0.0455 -0.0589 -0.0218 -0.1881 -0.2864 -0.0074 -0.0834 -1.0518 -0.1367 -2.3966 -0.0682
S-925	In conjunction, diastolic function improved (c=24.3 ± 5.3 to 22.7 ± 8.1 g/s; P=0.03; k=252 ± 115 to 170 ± 37 g/s(2); P=0.03), Ea decreased (2.0 ± 0.4 to 1.7 ± 0.4 mm Hg/mL; P=0.007), and ventricular-arterial coupling improved (Ees:Ea=1.5 ± 0.3 to 1.7 ± 0.4; P=0.04).<unk>
T-925	diastolic_function ea ventricular-arterial_coupling ees ea
H-925	-0.9685389399528503	▁con jun ction ▁dia sto lic ▁function ▁vent ri cular - arte rial ▁coup ling
D-925	-0.9685389399528503	conjunction diastolic function ventricular-arterial coupling
P-925	-2.6889 -0.1569 -0.0058 -0.5912 -0.2678 -2.0684 -3.6680 -1.6253 -0.0710 -0.1040 -0.4026 -0.1556 -0.0847 -0.2360 -2.4471 -1.7414 -0.1507
S-1835	The hazard ratios from the disease risk score (DRS)-stratified analyses were 0.83 (95% CI, 0.70 to 0.99) for saxagliptin versus sitagliptin, 0.63 (CI, 0.47 to 0.85) for saxagliptin versus pioglitazone, 0.69 (CI, 0.54 to 0.87) for saxagliptin versus sulfonylureas, and 0.61 (CI, 0.50 to 0.73) for saxagliptin versus insulin.<unk>
T-1835	hazard_ratios disease_risk_score drs saxagliptin sitagliptin saxagliptin pioglitazone saxagliptin sulfonylureas saxagliptin insulin
H-1835	-1.0144076347351074	▁disease _ risk ▁score ▁d RS ▁si tag lip tin ▁sax ag lip tin ▁pi og lita zone ▁sax ag lip tin ▁sul fon yl ure as
D-1835	-1.0144076347351074	disease_risk score dRS sitagliptin saxagliptin pioglitazone saxagliptin sulfonylureas
P-1835	-1.4518 -2.0630 -0.3632 -1.2356 -0.5528 -0.3103 -6.0427 -0.0064 -1.5694 -1.5607 -0.7563 -0.2892 -1.4228 -2.0645 -0.3997 -0.5977 -0.0683 -0.0635 -0.2983 -0.3091 -1.1012 -2.4373 -1.4785 -0.0045 -0.2428 -0.0834 -0.1590 -2.4121 -0.0735
S-106	Independent predictors for the development of IE among study patients included previous revascularization (coronary artery bypass surgery: hazard ratio [HR] 1.88, p = 0.003; percutaneous coronary intervention: HR 3.21, p <0.001) and increased systolic blood pressure (HR 1.67, p = 0.02), whereas a left bundle branch block pattern on the baseline electrocardiogram was associated with reduced risk for IE (HR 0.62, p = 0.02).<unk>
T-106	patients revascularization coronary_artery_bypass_surgery hazard_ratio percutaneous_coronary_intervention systolic_blood_pressure left_bundle_branch_block_pattern baseline electrocardiogram
H-106	-0.6319003105163574	▁re vas cular ization ▁co ron ary ▁arter y _ ▁by pass ▁surgery ▁hazard ▁ratio ▁per cuta ne ous ▁corona ry ▁intervention ▁sy sto lic ▁blood _ tension ▁left ▁bund le _ ▁bran ch _ ▁block ▁base line _ ▁electro card i ogram
D-106	-0.6319003105163574	revascularization coronary artery_ bypass surgery hazard ratio percutaneous coronary intervention systolic blood_tension left bundle_ branch_ block baseline_ electrocardiogram
P-106	-2.2789 -0.0385 -0.0800 -0.3918 -0.4164 -0.0971 -0.4084 -0.7186 -0.0670 -0.5593 -0.4055 -0.0065 -0.5231 -0.4509 -0.0423 -0.0520 -0.0009 -0.0154 -0.7788 -0.4264 -0.4776 -1.4916 -1.3432 -0.0194 -1.6868 -1.0683 -2.4341 -1.3493 -1.2729 -0.1266 -0.0715 -0.8287 -2.3022 -0.0329 -0.6543 -0.8555 -0.9066 -0.0227 -0.9921 -0.6336 -0.0264 -0.1737 -0.0201 -1.7093 -0.1785
S-1262	Compared with biomedical treatment alone, biomedical treatment plus CHM showed significant improvement in effective rate (relative risk, 1.26; 95% confidence interval [CI], 1.19-1.34), left ventricular ejection fraction (%) (mean difference, 5.88; 95% CI, 3.92-7.85), left ventricular diastolic end diameter (mm) (mean difference, -2.78; 95% CI, -5.15 to -0.42), and other outcome measures.<unk>
T-1262	biomedical biomedical relative_risk confidence_interval left_ventricular_ejection_fraction left_ventricular_diastolic_end_diameter outcome
H-1262	-1.2109432220458984	▁bio medic al ▁treatment ▁CH m ▁vent ri cular _ é je ction ▁ fraction ▁left ▁vent ri cular _ ▁dia sto lic _ ▁end
D-1262	-1.2109432220458984	biomedical treatment CHm ventricular_éjection fraction left ventricular_ diastolic_ end
P-1262	-0.0115 -0.0194 -0.0046 -2.9098 -3.4063 -0.1805 -3.7777 -0.0697 -0.3673 -1.2859 -3.1811 -1.1750 -0.0593 -2.8375 -0.0018 -1.2867 -0.2256 -0.1738 -0.5397 -0.4040 -3.8934 -0.2657 -2.0188 -1.7237 -0.1345 -2.6132 -0.1292
S-1114	METHODS: In this prospective, randomized, open-label crossover study with masked outcome assessments, stable heart failure patients (left ventricular ejection fraction < 40%) homozygous for the Arg16/Gln27 (n = 13) or Gly16/Glu27 haplotype (n = 8) of the β2-receptor were randomized to equipotent dosages of carvedilol or metoprolol for two 6-wk periods.<unk>
T-1114	prospective randomized crossover_study outcome stable_heart_failure patients left_ventricular_ejection_fraction homozygous haplotype β2-receptor randomized carvedilol metoprolol
H-1114	-0.9132009744644165	▁heart _ ▁failure ▁vent ri cular _ ▁e je ction ▁ fraction ▁β 2- recept or ▁car vedi lol ▁met o pro lol
D-1114	-0.9132009744644165	heart_ failure ventricular_ ejection fraction β2-receptor carvedilol metoprolol
P-1114	-5.1352 -0.9763 -2.4057 -1.0779 -0.1276 -0.2482 -1.4782 -0.8849 -0.8965 -0.0540 -3.0993 -0.0018 -3.0773 -0.9600 -0.0129 -0.1445 -0.9938 -0.1798 -0.1399 -0.4899 -0.0874 -0.0346 -0.1126 -0.1675 -0.0440
S-465	Of patients treated and released, low-volume ED cases exhibited higher risk of death/hospitalization/ED visit in the subsequent 7 (22.0%) and 30 days (44.9%) than medium (16.3%; aOR, 0.81 [95% CI, 0.73–0.90], and 35.3%; aOR, 0.79 [95% CI, 0.73–0.86]) or high-volume ED cases (13.0%; aOR, 0.69 [95% CI, 0.61–0.78], and 30.2%; aOR, 0.67 [95% CI, 0.61–0.74]).<unk>
T-465	patients death hospitalization aor aor aor aor
H-465	-1.4319045543670654	▁low - volu me ▁ED
D-465	-1.4319045543670654	low-volume ED
P-465	-2.9157 -0.0289 -0.0401 -0.0059 -1.1890 -5.6398 -0.2039
S-1625	RESULTS: At 2 years, participants offered the Health Buddy Program had 15% lower risk-adjusted all-cause mortality (hazard ratio (HR) = 0.85, 95% confidence interval (CI) = 0.74-0.98; P = .03) and had reductions in the number of quarterly inpatient admissions from baseline to the study period that were 18% greater than those of matched controls during this same time period (-0.035 vs -0.003; difference-in-differences = -0.032, 95% CI = -0.054 to -0.010, P = .005).<unk>
T-1625	health_buddy_program all-cause_mortality hazard_ratio confidence_interval inpatient admissions baseline
H-1625	-0.9551882147789001	▁health _ bud y _ program ▁risk - ad just ed ▁all - ca use _ ▁mortal ity haz ard ▁ratio ▁figure
D-1625	-0.9551882147789001	health_budy_program risk-adjusted all-cause_ mortalityhazard ratio figure
P-1625	-2.2579 -1.5053 -0.3802 -0.5760 -3.2067 -1.2855 -5.1606 -0.0607 -0.0038 -0.0004 -0.0246 -0.4347 -0.0120 -0.0007 -0.0183 -0.5325 -0.1047 -0.1181 -0.2609 -0.0037 -0.1190 -4.1867 -2.6015 -0.0700
S-691	Multivariable-adjusted hazard ratios were 1 (reference), 1.05 (95% CI, 0.89-1.24), 0.97 (95% CI, 0.81-1.17), and 0.85 (95% CI, 0.70-1.02) across quartiles of the Mediterranean diet score (P trend=0.08) and 1 (reference), 1.04 (95% CI, 0.89-1.21), 0.83 (95% CI, 0.70-0.98), and 0.84 (95% CI, 0.70-1.00) across quartiles of the DASH diet score (P trend=0.01).<unk>
T-691	multivariable-adjusted_hazard_ratios dash
H-691	-0.7702324390411377	▁multi vari able - ad just ed ▁hazard ▁ratio s ▁Mediterrane an _ die t _ ▁score
D-691	-0.7702324390411377	multivariable-adjusted hazard ratios Mediterranean_diet_ score
P-691	-0.7599 -0.0004 -0.0119 -0.5233 -0.0165 -0.0011 -0.1765 -1.3934 -1.0716 -0.0350 -3.9679 -0.5281 -1.9822 -0.3619 -0.1180 -2.6462 -0.5084 -0.3918 -0.1402
S-287	METHODS: Using sex-specific models, we added cTnT and NT-proBNP to age and race ("laboratory report" model) and to the ARIC HF model (includes age, race, systolic blood pressure, antihypertensive medication use, current/former smoking, diabetes, body mass index, prevalent coronary heart disease, and heart rate) in 9868 participants without prevalent HF; area under the receiver operating characteristic curve (AUC), integrated discrimination improvement, net reclassification improvement (NRI), and model fit were described.<unk>
T-287	ctnt nt-probnp report aric hf systolic_blood_pressure antihypertensive_medication diabetes body_mass_index coronary_heart_disease heart_rate hf area_under_the_receiver_operating_characteristic_curve auc integrated_discrimination_improvement net_reclassification_improvement nri
H-287	-1.0235614776611328	▁c t n t ▁NT - pro b NP ▁a RIC _ f ▁h f ▁sy sto lic ▁blood _ tension ▁anti hy per tensi ve ▁medication ▁smoking ▁corona ry _ ▁heart _ de _ f ré que nce ▁ HF ▁receive r _ ▁operating _ ▁character istic _ cur ve ▁discrimina tion ▁n RI
D-287	-1.0235614776611328	ctnt NT-probNP aRIC_f hf systolic blood_tension antihypertensive medication smoking coronary_ heart_de_fréquence HF receiver_ operating_ characteristic_curve discrimination nRI
P-287	-0.2169 -0.1295 -4.1123 -0.2766 -0.8825 -0.0258 -0.0103 -0.6658 -0.1008 -1.7275 -1.6485 -0.9997 -1.5407 -3.4953 -4.2365 -4.5613 -0.0716 -1.0250 -0.4153 -1.2919 -1.5653 -0.0263 -0.0153 -0.0061 -0.1515 -0.2676 -0.6028 -0.8858 -0.8951 -0.0439 -0.8174 -0.6769 -1.3053 -2.6881 -1.3730 -4.8657 -0.1593 -0.5629 -0.0236 -1.5888 -0.1844 -2.2819 -0.0024 -0.1690 -0.7895 -0.8895 -0.6882 -0.0112 -1.3900 -0.4420 -0.0075 -0.4760 -0.0047 -4.6110 -0.0976 -0.2999 -0.0439
S-1222	OBJECTIVES: The study sought to investigate the safety and efficacy of eplerenone in patients at high risk for hyperkalemia or worsening renal function (WRF) in EMPHASIS-HF, a trial that enrolled patients at least 55 years old with heart failure and reduced ejection fraction (HF-REF), in New York Heart Association (NYHA) functional class II and with an estimated glomerular filtration rate (eGFR) >30 ml/min/1.73 m(2) and serum potassium <5.0 mmol/l.<unk>
T-1222	eplerenone patients hyperkalemia renal_function emphasis-hf patients heart_failure_and_reduced_ejection_fraction hf-ref new_york_heart_association nyha functional_class estimated_glomerular_filtration_rate egfr serum_potassium
H-1222	-1.0544967651367188	▁ef fica cy ▁e pler en one ▁hyper kal emia ▁renal _ ▁function ▁EM PHA SIS - HF ▁heart _ organ isée ▁NY HA ▁glo mer ular ▁filtr ation _ ▁rate ▁e G FR ▁se rum _ po tas s ium
D-1222	-1.0544967651367188	efficacy eplerenone hyperkalemia renal_ function EMPHASIS-HF heart_organisée NYHA glomerular filtration_ rate eGFR serum_potassium
P-1222	-4.3113 -0.0361 -0.7592 -0.0541 -0.4635 -0.2757 -3.7443 -0.1572 -0.4514 -0.0224 -1.0612 -3.4582 -2.3286 -1.9100 -0.0116 -0.0924 -0.0187 -0.0147 -1.0987 -1.0011 -5.3758 -0.8810 -4.2039 -0.0912 -1.3704 -0.0262 -0.0716 -0.8841 -0.0092 -1.3445 -1.8805 -0.2721 -1.9169 -0.9828 -1.2952 -0.2769 -1.3571 -0.8525 -0.2199 -0.1157 -0.0120 -0.5607 -0.0727
S-81	Similarly, low-dose nesiritide had no significant effect on 72-hour cumulative urine volume (nesiritide, 8574 mL; 95% CI, 8014-9134 vs placebo, 8296 mL; 95% CI, 7762-8830; difference, 279 mL; 95% CI, -618 to 1176 mL; P = .49) or on the change in cystatin C level (nesiritide, 0.07 mg/L; 95% CI, 0.01-0.13 vs placebo, 0.11 mg/L; 95% CI, 0.06-0.16; difference, -0.04; 95% CI, -0.13 to 0.05; P = .36).<unk>
T-81	nesiritide nesiritide placebo change cystatin_c nesiritide placebo
H-81	-1.7315317392349243	▁low - dos e _ ▁nesi riti de ▁72 - ho ur ▁cum ul ative _ ▁urin e _ ▁volume nesi riti de ▁figure ▁cyst atin _ c
D-81	-1.7315317392349243	low-dose_ nesiritide 72-hour cumulative_ urine_ volumenesiritide figure cystatin_c
P-81	-3.9368 -0.1119 -2.5782 -0.3909 -4.4823 -2.6320 -0.2827 -0.1329 -6.6418 -0.0809 -0.0684 -0.0223 -2.5241 -0.0168 -0.0186 -1.5796 -3.0615 -0.3315 -4.0138 -0.4803 -4.0297 -0.4341 -0.1792 -5.6651 -1.9079 -0.3613 -2.0831 -0.6008 -3.1777 -0.1197
S-572	RESULTS: Compared with standard care, Nordic walking led to higher functional capacity (Δ 125.6 ± 59.4 m vs Δ 57.0 ± 71.3 m travelled during 6MWT; P = 0.001), greater self-reported physical activity (Δ 158.5 ± 118.5 minutes vs Δ 155.5 ± 125.6 minutes; P = 0.049), increased right grip strength (Δ 2.3 ± 3.5 kg vs Δ 0.3 ± 3.1 kg; P = 0.026), and fewer depressive symptoms (Hospital Anxiety and Depression Scale score = Δ -1.7 ± 2.4 vs Δ -0.8 ± 3.1; P = 0.014).<unk>
T-572	walking functional_capacity 6mwt physical activity symptoms hospital_anxiety_and_depression_scale
H-572	-1.9923033714294434	▁Nordic _ ▁walking _ de _ fon ction nel _ pu issa nce ▁m ▁m ▁m ▁m t ▁physical ▁activity
D-572	-1.9923033714294434	Nordic_ walking_de_fonctionnel_puissance m m m mt physical activity
P-572	-2.5077 -1.6294 -2.5947 -3.0126 -2.7958 -0.5378 -2.9744 -0.5954 -2.4414 -1.4372 -4.6018 -0.0490 -0.0047 -0.3561 -1.8238 -1.9599 -2.4103 -2.5507 -4.5977 -0.6926 -4.1452 -0.1125
S-1225	METHODS: This was a pre-specified analysis of subgroups of patients at high risk of hyperkalemia or WRF (patients ≥ 75 years of age, with diabetes, with eGFR <60 ml/min/1.73 m(2), and with systolic blood pressure < median of 123 mm Hg), examining the major safety measures (potassium >5.5, >6.0, and <3.5 mmol/l; hyperkalemia leading to study-drug discontinuation or hospitalization; and hospitalization for WRF) as well as the primary outcome (hospitalization for HF or cardiovascular mortality).<unk>
T-1225	patients hyperkalemia patients diabetes egfr systolic_blood_pressure potassium hyperkalemia leading hospitalization hospitalization primary_outcome hospitalization hf cardiovascular_mortality
H-1225	-0.9477288722991943	▁hyper kal emia ▁W RF ▁diabetes ▁e G FR ▁sy sto lic _ ▁blood _ tension ▁h g
D-1225	-0.9477288722991943	hyperkalemia WRF diabetes eGFR systolic_ blood_tension hg
P-1225	-2.1050 -0.5887 -0.1509 -2.9178 -0.3449 -0.2897 -0.0298 -1.2016 -0.8435 -1.0917 -0.1079 -2.4264 -1.4683 -0.2395 -0.9219 -1.4870 -0.2686 -0.0548 -2.3623 -0.0544
S-1268	The PAF, its key biosynthetic enzymes (lyso-PAF acetyltransferase [lyso-PAF-AT] and dithiothreitol [DTT]-insensitive CDP choline: 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase [PAF-CPT]), and its catabolic isoenzymes (PAF-acetylhydrolase [PAF-AH] and lipoprotein-associated phospholipase A2 [Lp-PLA2]) were measured in serum and leukocytes of participants.<unk>
T-1268	paf biosynthetic_enzymes lyso-paf_acetyltransferase lyso-paf-at 1-alkyl-2-acetyl-sn-glycerol_cholinephosphotransferase paf-cpt catabolic_isoenzymes paf-acetylhydrolase paf-ah lipoprotein-associated_phospholipase_a2 lp-pla2 leukocytes
H-1268	-0.7273277044296265	▁PA f ▁bio syn the tic ▁enzym es lys o - pa f ▁a ce tyl transfer ase lys o - pa f - AT ▁di thi oth rei tol ▁d t ▁CD p ▁cho line ▁al kyl -2 - ace tyl - s n - gly cer ol ▁cho line _ phos pho transfer ase ▁p f - c PT ▁cata bo lic ▁iso en zy mes PA f - ace tyl hydro lase ▁lipo prote in - as soci ated ▁ phos pho lipa se
D-1268	-0.7273277044296265	PAf biosynthetic enzymeslyso-paf acetyltransferaselyso-paf-AT dithiothreitol dt CDp choline alkyl-2-acetyl-sn-glycerol choline_phosphotransferase pf-cPT catabolic isoenzymesPAf-acetylhydrolase lipoprotein-associated phospholipase
P-1268	-0.3984 -0.2339 -1.1548 -0.0007 -0.2117 -1.0101 -0.2639 -0.0927 -2.1065 -0.0105 -0.0437 -1.3687 -0.1551 -0.8989 -0.3620 -0.9822 -0.7263 -1.0210 -3.7019 -0.0056 -0.0153 -0.5455 -0.1031 -2.4360 -0.7544 -0.0467 -0.0288 -0.4728 -0.1159 -0.1273 -2.8736 -0.2323 -1.0703 -0.1518 -4.9027 -0.0067 -4.1195 -0.0088 -1.1327 -0.1770 -0.3325 -0.0784 -0.0304 -0.1387 -0.0149 -0.0527 -0.0949 -0.3207 -0.0488 -2.7162 -0.0421 -1.4238 -0.2220 -1.3955 -3.2779 -0.9439 -2.4045 -0.1499 -0.3033 -0.2737 -1.7376 -1.1803 -0.0049 -0.4873 -0.7947 -0.1326 -0.0012 -0.1105 -1.6666 -0.2165 -0.1345 -0.5521 -0.1835 -0.8430 -0.0254 -0.3645 -0.7927 -0.2516 -1.1205 -0.1702 -0.0020 -0.1184 -0.4174 -0.3824 -0.3076 -0.2273 -0.5345 -3.5555 -0.0821
S-1175	RESULTS: The ivabradine group demonstrated significant improvement between baseline and follow-up exercise capacity (4.2 ± 1.8 METs vs. 5.7 ± 1.9 METs, p = 0.001) and peak oxygen uptake (14.0 ± 6.1 ml/min/kg vs. 17.0 ± 3.3 ml/min/kg, p = 0.001), with simultaneous reduction in exercise-induced increase in the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity (3.1 ± 2.7 vs. 1.3 ± 2.0, p = 0.004).<unk>
T-1175	ivabradine baseline follow-up exercise_capacity mets mets peak_oxygen_uptake peak_early_diastolic_mitral_flow_velocity peak_early_diastolic_mitral_annular_velocity
H-1175	-1.1852355003356934	▁i va bra dine _ group ▁base line _ ▁follow - up _ ▁exercise _ pu issa nce ▁ MET s ▁pe ak _ ▁oxygen _ up take
D-1175	-1.1852355003356934	ivabradine_group baseline_ follow-up_ exercise_puissance METs peak_ oxygen_uptake
P-1175	-0.0187 -0.0474 -0.3704 -0.0027 -5.4460 -1.0800 -2.1670 -0.1087 -1.8809 -2.8204 -0.0269 -0.0037 -1.3634 -1.5178 -0.6298 -3.5190 -0.0273 -0.0051 -3.6581 -1.0942 -0.0375 -0.6348 -0.0121 -0.2247 -2.3415 -1.8337 -0.4748 -0.3616 -3.7713 -0.0780
S-1455	Multivariate analysis revealed that the odds of CHF was higher in females [Odds Ratio (OR) = 2·9, P < 0·01], individuals with pre-HCT chest radiation (OR = 4·7, P = 0·05), hypertension (OR = 2·9, P = 0·01), and with variants of genes coding for the NAD(P)H-oxidase subunit RAC2 (rs13058338, 7508T→A; OR = 2·8, P < 0·01), HFE (rs1799945, 63C→G; OR = 2·5, P = 0·05) or the doxorubicin efflux transporter ABCC2 (rs8187710, 1515G→A; OR = 4·3, P < 0·01).<unk>
T-1455	multivariate_analysis chf odds_ratio chest hypertension genes rac2 doxorubicin_efflux_transporter abcc2
H-1455	-1.2909854650497437	▁CHF ▁h t ▁h t ▁h t ▁h t ▁hyper tension ▁ NAD _ h - oxid ase _ sub un it ▁ RAC 2 ▁do xor ubi cin _ eff lux _ ▁transporter
D-1455	-1.2909854650497437	CHF ht ht ht ht hypertension NAD_h-oxidase_subunit RAC2 doxorubicin_efflux_ transporter
P-1455	-1.3060 -3.6123 -3.6591 -0.4529 -2.1361 -0.8377 -2.0961 -1.3328 -2.7434 -1.8326 -0.0006 -2.1029 -0.6938 -3.4557 -0.7241 -0.7226 -0.0074 -4.1972 -4.0445 -0.7041 -0.1801 -0.0210 -1.3068 -0.0212 -0.4582 -0.5866 -0.7452 -0.0434 -0.0211 -0.7501 -0.6982 -0.4287 -1.6198 -0.7262 -2.0659 -0.1412
S-1958	From baseline to 3 month follow-up, we recorded improvements in NYHA classification (from class III to class II in seven [78%] of nine patients, from class III to class I in one [11%] patient, and no change in one [11%] patient; p=0·0004); quality of life, as assessed by the Duke Activity Status Index (from a mean score of 13 [SD 6·2] to 24·8 [12·9]; p=0·016) and the Kansas City Cardiomyopathy Questionnaire (from a mean score of 44·3 [SD 9·8] to 79·1 [13·0]; p=0·0001); and 6 min walk test distance (from a mean of 244 m [SD 112] to 318 m [134]; p=0·016).<unk>
T-1958	baseline follow-up nyha_classification patients patient change patient quality_of_life duke_activity_status_index kansas_city_cardiomyopathy_questionnaire 6_min_walk_test
H-1958	-1.3653159141540527	▁NY HA ▁classifica tion ▁class _ ▁II ▁class _ ▁III ▁figure ▁Duke _ ▁Activ ity _ ▁Status _ ▁Index ▁Kansas _ City _ ▁Card i om yo pathy
D-1958	-1.3653159141540527	NYHA classification class_ II class_ III figure Duke_ Activity_ Status_ Index Kansas_City_ Cardiomyopathy
P-1958	-2.5315 -0.4317 -1.1835 -0.0212 -1.0617 -1.3065 -1.4786 -3.0222 -1.3365 -0.8570 -3.4833 -3.6931 -0.7443 -0.5185 -0.0347 -0.1808 -1.5128 -1.1692 -1.6270 -2.6930 -1.2141 -1.9830 -0.6182 -2.2108 -0.2039 -0.0335 -2.5193 -0.2190 -2.9465 -0.1242
S-80	RESULTS: Compared with placebo, low-dose dopamine had no significant effect on 72-hour cumulative urine volume (dopamine, 8524 mL; 95% CI, 7917-9131 vs placebo, 8296 mL; 95% CI, 7762-8830 ; difference, 229 mL; 95% CI, -714 to 1171 mL; P = .59) or on the change in cystatin C level (dopamine, 0.12 mg/L; 95% CI, 0.06-0.18 vs placebo, 0.11 mg/L; 95% CI, 0.06-0.16; difference, 0.01; 95% CI, -0.08 to 0.10; P = .72).<unk>
T-80	placebo dopamine dopamine placebo change cystatin_c dopamine placebo
H-80	-1.5034351348876953	▁low - dos e ▁dop amine ▁72 - ho ur ▁cum ul ative ▁urin e _ ▁volume dop amine
D-80	-1.5034351348876953	low-dose dopamine 72-hour cumulative urine_ volumedopamine
P-80	-2.6614 -0.0706 -1.2269 -0.3605 -3.2452 -0.5729 -6.2436 -0.0947 -0.0603 -0.0199 -1.8235 -0.0330 -0.0278 -2.3920 -0.3735 -4.3788 -0.4440 -1.5223 -0.0302 -5.8545 -0.1366
S-66	High confidence in estimates was found for age (hazard ratio [HR], 1.45 for 10-year increase; 95% confidence interval [CI], 1.35-1.56), baseline glomerular filtration rate (HR, 1.25 for 15-mL/min decrease; 95% CI, 1.15-1.35), chronic obstructive pulmonary disease (HR, 1.54; 95% CI, 1.38-1.71), diabetes (HR, 1.56; 95% CI, 1.37-1.79), peripheral vascular disease (HR, 1.43; 95% CI, 1.2-1.72), left ventricular ejection fraction (HR, 0.77 for 10% increase; 95% CI, 0.73-0.83), and appropriate or inappropriate ICD shocks (HR, 2.34; 95% CI 1.59-3.44) New York Heart Association class, atrial fibrillation, and congestive HF were strongly associated with mortality but the confidence in estimates was low.<unk>
T-66	hazard_ratio confidence_interval baseline glomerular_filtration_rate chronic_obstructive_pulmonary_disease diabetes peripheral_vascular_disease left_ventricular_ejection_fraction icd_shocks new_york_heart_association_class atrial_fibrillation congestive_hf mortality
H-66	-1.4213945865631104	▁figure ▁h ard ▁ratio ▁h z ▁figure ▁figure ▁base line _ ▁glo mer ular ▁filtr ation _ ▁rate ▁h z ▁figure ▁chronic _ ▁ob struct ive _ ▁pulmonar y ▁disease ▁diabetes ▁vent ri cular _ ▁e je ction ▁ fraction
D-66	-1.4213945865631104	figure hard ratio hz figure figure baseline_ glomerular filtration_ rate hz figure chronic_ obstructive_ pulmonary disease diabetes ventricular_ ejection fraction
P-66	-2.9221 -4.4969 -1.0173 -2.2847 -3.5980 -1.9816 -1.7637 -3.3792 -2.6460 -0.1063 -1.8185 -0.7080 -0.0214 -0.0537 -0.7972 -0.0127 -3.3185 -1.3283 -3.4696 -1.4897 -4.5847 -3.5979 -0.2816 -1.6329 -0.0191 -0.0239 -0.3132 -0.2661 -0.1147 -1.6178 -0.2229 -2.4047 -0.0830 -0.2193 -0.7277 -0.9575 -0.1389 -0.0197 -1.3256 -0.0002 -3.8142 -0.1194
S-1761	At multivariable analysis, the following variables were significantly associated with primary study end point: peak oxygen uptake (% pred; P<0.001; hazard ratio [HR]=0.977; confidence interval [CI]=0.97-0.98), ventilatory efficiency slope (P=0.01; HR=1.02; CI=1.01-1.03), hemoglobin (P<0.05; HR=0.931; CI=0.87-1.00), left ventricular ejection fraction (P<0.001; HR=0.948; CI=0.94-0.96), renal function (modification of diet in renal disease; P<0.001; HR=0.990; CI=0.98-0.99), sodium (P<0.05; HR=0.967; CI=0.94-0.99), and AT nonidentification (P<0.05; HR=1.41; CI=1.06-1.89).<unk>
T-1761	multivariable_analysis end_point peak_oxygen_uptake hazard_ratio confidence_interval ventilatory_efficiency_slope hemoglobin left_ventricular_ejection_fraction renal_function renal_disease sodium
H-1761	-1.0227277278900146	▁pe ak _ ▁oxygen _ up take ▁hazard ▁ratio ▁figure ▁ventilator y _ ▁efficiency ▁s lope ▁hem o glob in ▁left ▁vent ri cular _ ▁e je ction _ fraction ▁renal
D-1761	-1.0227277278900146	peak_ oxygen_uptake hazard ratio figure ventilatory_ efficiency slope hemoglobin left ventricular_ ejection_fraction renal
P-1761	-5.6433 -0.0179 -1.5267 -1.2406 -1.6883 -0.3607 -0.1316 -0.0161 -0.2880 -3.1484 -1.1549 -0.1081 -0.3453 -1.1660 -1.4186 -0.0027 -1.8114 -0.0816 -0.0121 -0.4129 -2.6170 -0.5159 -0.1729 -0.5112 -0.6600 -1.0832 -0.3575 -0.0323 -1.2894 -0.0032 -0.1523 -5.6482 -0.1317
S-1331	RESULTS: A significant improvement in 6-minute walked distance (F = 21.61, P = .001), Kansas City Cardiomyopathy Questionnaire summary (F = 8.68, P = .006), Minnesota Living with Heart Failure Questionnaire (F = 6.43, P = .017), Beck Depression Inventory (F = 6.66, P = .015), Zung (F = 6.25, P = .019), and flow-mediated dilatation diameter (F = 11.98, P = .002) was observed in the FES group compared with placebo group; B-type natriuretic peptide also declined but not significantly (F = 0.249, P = .622), and there was a tendency toward lower mitral E/e' wave ratio (F = 3.066, P = .091).<unk>
T-1331	6-minute_walked_distance kansas_city_cardiomyopathy_questionnaire minnesota_living_with_heart_failure_questionnaire beck_depression_inventory flow-mediated_dilatation fes placebo b-type_natriuretic_peptide mitral
H-1331	-0.9347822070121765	▁Kansas ▁City _ car i om yo pathy ▁figure ▁Minnesota _ ▁Living _ ▁Heart _ ▁Fail ure ▁question naire ▁Beck _ de pression ▁in ven tory ▁z ung ▁flow - media ted _ di la tation _ ▁diameter ▁F es ▁place bo ▁b - type _ ▁na tri ure _ pe pti de
D-1331	-0.9347822070121765	Kansas City_cariomyopathy figure Minnesota_ Living_ Heart_ Failure questionnaire Beck_depression inventory zung flow-mediated_dilatation_ diameter Fes placebo b-type_ natriure_peptide
P-1331	-0.9565 -1.3442 -1.2258 -4.1556 -0.3164 -0.0359 -1.7455 -0.1917 -4.1180 -0.7597 -1.1843 -2.2017 -0.3146 -0.5168 -0.5325 -0.0566 -0.0516 -3.7988 -0.0023 -0.0405 -1.3352 -0.0223 -0.1027 -0.4802 -0.3525 -0.0170 -3.3613 -0.1316 -0.7020 -0.1157 -0.2003 -1.4320 -0.1642 -0.9703 -0.0513 -0.0036 -0.6867 -0.1131 -0.9381 -0.3192 -2.3831 -0.0194 -3.7114 -0.0355 -0.3635 -0.6907 -1.1705 -0.0052 -0.0928 -4.0389 -0.5562 -0.2638 -0.0519 -2.9149 -0.0670
2021-01-17 13:52:42 | INFO | fairseq_cli.generate | NOTE: hypothesis and token scores are output in base 2
2021-01-17 13:52:42 | INFO | fairseq_cli.generate | Translated 2,024 sentences (32,074 tokens) in 235.0s (8.61 sentences/s, 136.51 tokens/s)
2021-01-17 13:52:42 | WARNING | fairseq_cli.generate | If you are using BPE on the target side, the BLEU score is computed on BPE tokens, not on proper words.  Use --sacrebleu for standard 13a BLEU tokenization
Generate test with beam=5: BLEU4 = 21.75, 53.1/31.9/21.5/14.5 (BP=0.807, ratio=0.824, syslen=32074, reflen=38932)
